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Ageing,	   defined	   as	   the	   progressive	   deterioration	   of	  molecular,	   cellular,	   tissue	   and	  whole	   organism	  
function,	   is	   a	   primary	   risk	   factor	   for	   numerous	   diseases,	   such	   as	   cardiovasculature	   disease,	  
neurodegeneration	   and	   cancer.	   In	   recent	   years,	   advances	   in	   our	   knowledge	   of	   key	   determinant	  
mechanisms	  that	  underpin	  ageing	  decline,	  drives	   the	  notion	  that	   these	   features	  can	  be	  attenuated	  
and	   targeted	   therapeutically,	  enabling	  elderly	   individuals	   to	  experience	  an	  enhanced	  quality	  of	   life	  
into	   advanced	   old	   age.	   Sarcopenia	   comprises	   the	   age-­‐related	   loss	   of	   muscle	   mass,	   quality	   and	  
function	  and	  contributes	  to	  overall	  frailty,	  immobility	  and	  a	  greater	  risk	  of	  falls.	  The	  use	  of	  stem	  cell-­‐
derived	  conditioned	  media	  (CM)	  holds	  great	  clinical	  potential	  and	  recent	  studies	  have	  reported	  many	  
beneficial	  effects	   in	  a	  number	  of	   tissue	  models	  of	   injury	  and	  disease.	  We	  want	   to	  develop	  a	  novel	  
anti-­‐ageing	  therapy	  for	  the	  treatment	  of	  age-­‐associated	  declines	  in	  sarcopenia.	  First,	  we	  characterise	  
the	  skeletal	  muscle	  profile	  in	  a	  novel	  use	  of	  the	  Ercc1d/-­‐	  murine	  model	  of	  progeria	  and	  compare	  it	  to	  
the	   naturally-­‐aged	   phenotype.	   We	   examine	   the	   effects	   of	   CM,	   generated	   from	   adipose-­‐derived	  
mesenchymal	   stem	  cells	   (ADMSCs),	  on	   skeletal	  muscle	   composition,	   function	  and	   satellite	   cell	   (SC)	  
activity	   in	   sarcopenia	   and	   progeria.	   We	   show	   that	   CM	   has	   beneficial	   regulatory	   effects	   on	  
mechanisms	   underpinning	   the	   declines	   associated	   with	   the	   Hallmarks	   of	   Ageing,	   for	   example,	  
enhancing	  mitochondrial	   function	  and	   reducing	  oxidative	   stress.	   Importantly,	  we	  also	  demonstrate	  
that	   CM	   harbours	   pro-­‐angiogenic	   effects,	   which	   we	   hypothesise	   is	   unlikely	   to	   impact	   on	   skeletal	  
muscle	  alone.	  Remarkably,	  we	  report	   the	  Ercc1d/-­‐	  mice	  appear	   to	   launch	  a	  survival	  programme	  and	  
delay	  the	  progression	  of	  age-­‐related	  deterioration.	  A	  further	  feature	  associated	  with	  ageing	  skeletal	  
muscle	   is	   the	   impaired	  regenerative	   function	  and	  myofibre	   turnover	   following	   injury	  and	  daily	  use.	  
Key	   factors	   attributed	   to	   this	   decline	   in	   repair	   involve	   compromised	   SC	   activity	   as	   well	   as	   the	  
depletion	  of	  the	  stem	  cell	  pool,	  known	  to	  occur	  with	  age.	  We	  want	  to	  first,	  examine	  the	  influence	  of	  
the	  myofibre	  microenvironment	  on	  SC	  behaviour.	  Second,	  we	  investigate	  the	  use	  of	  non-­‐muscle	  cell	  
types	  as	  a	  source	  to	  generate	  muscle	  cells.	  We	  show	  that	  three	  stem	  cell	  types,	  ADMSC,	  dental	  pulp	  
stem	  cells	  (DP)	  and	  amniotic	  fluid	  stem	  cells	  (AFS)	  and	  one	  non-­‐stem	  cell	   line,	  MDA-­‐MB-­‐231	  (MDA)	  
breast	  cancer	  cells,	  adopted	  amoeboid-­‐based	  migration	  (blebbing)	  once	  seeded	  onto	  myofibres.	  We	  
also	  show	  that	  the	  regulation	  of	  the	  migratory	  mechanisms,	  known	  to	  be	  controlled	  by	  the	  Rac	  and	  
Rho	  signalling	  pathways,	  is	  conserved	  in	  each	  of	  these	  cell	  types.	  Remarkably,	  we	  also	  demonstrate	  
that	   a	   rapidly	   growing	   non-­‐muscle	   stem	   cell	   (AFS),	   as	   well	   as	   a	   non-­‐stem	   cell	   (MDA)	   initiate	  
expression	  of	  MyoD	  and	  furthermore,	  the	  AFS	  cells	  were	  directed,	  through	  exposure	  to	  the	  myofibre	  




3D	  -­‐	  Three	  Dimensions	  
4E-­‐BP	  -­‐	  4E	  binding	  proteins	  
ACh	  –	  Acetylcholine	  
ActRIIB	  –	  Activin	  type	  IIB	  receptor	  
ADMSC	  –	  Adipose	  derived	  mesenchymal	  stem	  cells	  	  
ADP	  –	  Adenosine	  diphosphate	  
AFS	  –	  Amniotic	  fluid-­‐derived	  stem	  cells	  
AGE	  -­‐	  Advanced	  glycation	  end-­‐products	  
AKT	  –	  Protein	  kinase	  B	  
ALK	  (1/2)	  -­‐	  Activin	  receptor-­‐like	  kinase	  (1/2)	  
AMP	  -­‐	  Adenosine	  monophosphate	  
AMPK	  –	  AMP-­‐activated	  protein	  kinase	  
ANOVA	  -­‐	  Analysis	  of	  Variance	  
ATP	  –	  Adenosine	  triphosphate	  
bFGF	  –	  Basic	  fibroblast	  growth	  factor	  
bHLH	  –	  Basic	  helix-­‐loop-­‐helix	  
BMC	  –	  Bone	  mineral	  content	  
BMD	  –	  Bone	  mineral	  density	  
BMSC	  –	  Bone	  marrow	  mesenchymal	  stem	  cells	  
°C	  -­‐	  Celsius	  
Ca2+	  -­‐	  Calcium	  ion(s)	  
CaMK	  –	  Ca2+/Calmodulin-­‐dependent	  protein	  kinase	  
CD31	  -­‐	  Cluster	  of	  differentiation	  31	  
CD34	  -­‐	  Cluster	  of	  differentiation	  34	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CD45	  –	  Cluster	  of	  differentiation	  45	  
Cdc42	  -­‐	  Cell	  division	  control	  protein	  42	  homolog	  
Cdkn2a/	  p16INK4a	  -­‐	  cyclin-­‐dependent	  kinase	  Inhibitor	  2A	  
CM	  –	  Conditioned	  media	  
cm	  -­‐	  Centimetres	  
CO2	  –	  Carbon	  dioxide	  	  
CSA	  –	  Cross-­‐sectional	  area	  
CTX	  -­‐	  Cardiotoxin	  
DAPI	  –	  4',6-­‐diamidino-­‐2-­‐phenylindole	  	  
dH2O	  –	  Deionised	  water	  (ultrapure)	  
DHE	  -­‐	  Dihydroethidium	  
DMD	  –	  Duchenne	  muscular	  dystrophy	  
DMEM	  –	  Dulbecco’s	  modified	  eagle	  medium	  	  
DMSO	  –	  Dimethyl	  sulfoxide	  
DNA	  -­‐	  Deoxyribonucleic	  acid	  
DP	  –	  Dental	  pulp	  stem	  cells	  	  
ECM	  –	  Extracellular	  matrix	  
EDL	  –	  Extensor	  digitorum	  longus	  	  
EDTA	  -­‐	  Ethylenediaminetetraacetic	  acid	  
EGF	  –	  Epidermal	  growth	  factor	  
eIF2	  -­‐	  Eukaryotic	  initiation	  factor	  2	  
ER	  –	  Endoplasmic	  reticulum	  
ERCC1	  –	  Excision	  repair	  cross-­‐complementary	  group	  1	  
Ercc1-­‐/-­‐	  	  -­‐	  Excision	  repair	  cross-­‐complementary	  group	  1	  null/knockout	  mouse	  
Ercc1d/-­‐	  	  -­‐	  Excision	  repair	  cross-­‐complementary	  group	  1	  mutant	  mouse	  (hybrid	  delta	  7	  (Δ7)/null)	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ETC	  –	  Electron	  transport	  chain	  
EV	  -­‐	  Extracellular	  vesicle	  
FAK	  -­‐	  Focal	  Adhesion	  Kinase	  
FBS	  –	  Fetal	  bovine	  serum	  	  
FG	  –	  Fast-­‐twitch	  glycolytic	  
FGF	  –	  Fibroblast	  growth	  factor	  
FOG	  –	  Fast-­‐twitch	  oxidative	  glycolytic	  
FOXO	  -­‐	  Fork-­‐head	  box	  O	  
g	  –	  Force	  of	  gravity	  (gravitational)	  
GAPs	  -­‐	  GTPase	  activating	  proteins	  
GDF-­‐8	  –	  Growth	  and	  differentiation	  factor	  8	  
GDF-­‐11	  –	  Growth	  and	  differentiation	  factor	  11	  
GDP	  -­‐	  Guanosine	  diphosphate	  	  
GEFs	  -­‐	  Guanine	  nucleotide	  exchange	  factors	  
GF	  –	  Growth	  factor	  
GFP	  –	  Green	  fluorescent	  protein	  
GH	  –	  Growth	  hormone	  
GM	  –	  Growth	  media	  
GPX	  -­‐	  Glutathione	  peroxidase	  
GTP	  -­‐	  Guanosine	  triphosphate	  
H2O	  -­‐	  Water	  
H2O2	  –	  Hydrogen	  peroxide	  
HDAC	  -­‐	  Histone	  deacetylase	  
H&E	  -­‐	  Haemotoxylin	  and	  eosin	  
HGF	  –	  Hepatocyte	  growth	  factor	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HIF1a	  –	  Hypoxia	  induced	  factor	  1a	  	  
HPR	  –	  Hexazotized	  pararosaniline	  
HPRT	  -­‐	  Hypoxanthine-­‐guanine	  phosphoribosyltransferase	  
IGF	  –	  Insulin-­‐like	  growth	  factor	  	  
IL-­‐6	  –	  Interleukin	  6	  
IM	  –	  Intramuscular	  	  
IMF	  -­‐	  intermyofibrillar	  
IMR-­‐90	  –	  Lung	  fibroblast	  IMR-­‐90	  cell	  line	  	  
IP	  –	  Intraperitoneal	  	  	  
IV	  –	  Intravenous	  	  
kPa	  –	  Kilopascal	  
MAPK	  -­‐	  Mitogen-­‐activated	  protein	  kinase	  
µL	  –	  Microliters	  
µM	  -­‐	  Micromolar	  	  
µm	  –	  Micrometre	  	  
MDA	  -­‐	  MDA-­‐MB-­‐231	  human	  breast	  adenocarcinoma	  cell	  line	  
mdx	  –	  Mouse	  model	  (muscular	  dystrophy	  -­‐	  x-­‐linked)	  	  
MEF2	  -­‐	  Myocyte	  enhancer	  factor	  2	  
MHC	  –	  Myosin	  Heavy	  Chain	  	  
MHC	  I	  -­‐	  Myosin	  Heavy	  Chain	  type	  I	  
MHC	  IIA	  -­‐	  Myosin	  Heavy	  Chain	  type	  IIA	  
MHC	  IIX	  -­‐	  Myosin	  Heavy	  Chain	  type	  IIX	  
MHC	  IIB	  -­‐	  Myosin	  Heavy	  Chain	  type	  IIB	  
mg	  –	  Milligrams	  
MI	  –	  Myocardial	  infarction	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miRNA	  –	  MicroRNA	  
mL	  –	  Millilitres	  
mM	  –	  Millimolar	  	  	  
mm	  –	  Millimetres	  
MMP	  –	  Matrix	  metalloproteinase	  
MnSOD	  -­‐	  Manganese	  superoxide	  dismutase	  
MRF	  –	  Myogenic	  regulatory	  factor	  
mRNA	  –	  Messenger	  RNA	  
MSC	  –	  Mesenchymal	  stem	  cells	  
mTOR	  –	  Mammalian	  target	  of	  rapamycin	  
MuRF1	  –	  Muscle	  Ring-­‐Finger	  protein	  1	  
MVs	  -­‐	  Microvesicles	  
Myf5	  –	  Myogenic	  factor	  5	  
MyoD	  –	  Myogenic	  differentiation	  1	  
NAD+	  -­‐	  Nicotinamide	  adenine	  dinucleotide	  (oxidised)	  
NADH	  -­‐	  Nicotinamide	  adenine	  dinucleotide	  (reduced)	  
NBT	  –	  4-­‐nitro	  blue	  tetrazolium	  chloride	  	  
NCAM	  -­‐	  Neural	  cell	  adhesion	  molecule	  
NER	  –	  Nucleotide	  excision	  repair	  
NFAT	  –	  Nuclear	  factor	  of	  activated	  T-­‐cells	  
NF-­‐κB	  -­‐	  nuclear	  factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  cells	  
NICD	  –	  Notch	  intracellular	  domain	  
NO	  –	  Nitric	  oxide	  	  
O2-­‐	  -­‐	  Superoxide	  
O2	  –	  Oxygen	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p53	  –	  Tumor	  suppressor	  protein	  53	  
P70S6K1	  -­‐	  70kDa	  S6	  protein	  kinase	  
PARP1	  -­‐	  Poly(ADP-­‐ribose)	  polymerase	  1	  
Pax3	  -­‐	  Paired	  box	  protein	  3	  	  	  
Pax7	  –	  Paired	  box	  protein	  7	  	  
PBS	  –	  Phosphate	  buffered	  saline	  	  
PCR	  –	  Polymerase	  chain	  reaction	  	  
Penstrep	  –	  Penicillin-­‐Streptomycin	  	  
PFA	  –	  Paraformaldehyde	  
PGC-­‐1α	  -­‐	  Peroxisome	  proliferator-­‐activated	  receptor-­‐γ	  co-­‐activator	  1	  alpha	  
PI3K	  -­‐	  Phosphoinositide	  3-­‐kinase	  
qPCR	  –	  Quantitative	  (Real-­‐Time)	  polymerase	  chain	  reaction	  
RBP-­‐	  Jκ	  -­‐	  Recombining	  binding	  protein	  Jκ	  
RNA	  -­‐	  Ribonucleic	  acid	  
ROCK	  –	  Rho-­‐associated	  protein	  kinase	  
ROS	  –	  Reactive	  oxygen	  species	  
RyR	  –	  Ryanodine	  receptor	  
SA-­‐beta-­‐gal	  -­‐	  Senescence-­‐associated	  beta-­‐galactosidase	  
SC	  –	  Satellite	  cell	  
SDH	  -­‐	  Succinate	  dehydrogenase	  
SEM	  –	  Standard	  error	  of	  the	  mean	  	  
SEM	  –	  Scanning	  electron	  microscopy	  	  
SERCA	  –	  Sacro/endoplasmic	  reticulum	  Ca2+-­‐ATPase	  	  
SFCM	  –	  Single	  fibre	  culture	  medium	  
SIRT1	  –	  Sirtiun	  1	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SMA	  –	  Alpha	  smooth	  muscle	  actin	  
SO	  –	  Slow-­‐twitch	  oxidative	  
SOD	  -­‐	  Superoxide	  dismutase	  
SR	  -­‐	  Sarcoplasmic	  reticulum	  
SS	  -­‐	  Subsarcolemmal	  	  
STAT3	  –	  Signal	  Transducer	  and	  Activator	  of	  Transcription	  	  
T0	  –	  Time	  plus	  zero	  hours	  	  
T2	  –	  Time	  plus	  2	  hours	  
T14	  –	  Time	  plus	  14	  hours	  
T24	  –	  Time	  plus	  24	  hours	  	  
T48	  –	  Time	  plus	  48	  hours	  	  
T72	  –	  Time	  plus	  72	  hours	  	  
TA	  –	  Tibialis	  anterior	  
TF	  –	  Transcription	  factor	  
TFAM	  –	  Mitochondrial	  transcription	  factor	  A	  
TGF-­‐β	  -­‐	  Transforming	  growth	  factor	  beta	  
TH	  -­‐	  Thyroid	  hormone	  
TNF-­‐α	  -­‐	  Tumour	  necrosis	  factor	  alpha	  
TSC	  (1/2)	  -­‐	  Tuberous	  sclerosis	  complex	  (1/2)	  
UPS	  -­‐	  Ubiquitin-­‐proteosome	  system	  
VEGF	  –	  Vascular	  endothelial	  growth	  factor	  	  
v/v	  –	  Volume	  per	  volume	  
WT	  –	  Wild-­‐type	  
XPA	  -­‐	  Xeroderma	  pigmentosum	  
XPF	  -­‐	  Xeroderma	  pigmentosum	  group	  F	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The	  overall	  aim	  of	  this	  project	  is	  to	  investigate	  the	  therapeutic	  effects	  of	  stem	  cell	  secretory	  factors	  
on	   age-­‐related	   declines	   in	   skeletal	   muscle. Diseases	   associated	   with	   ageing	   are	   becoming	   more	  
prevalent	   and	   as	   a	   result	   of	   improved	   longevity,	   this	   raises	   questions,	   as	   to	   whether	   human	  
‘healthspan’,	  can	  keep	  up	  pace	  with	  increasing	  lifespans.	  There	  has	  been	  a	  rise	  in	  the	  proportion	  of	  
elderly	  individuals	  in	  the	  human	  population	  and	  caring	  for	  these	  individuals	  into	  their	  advanced	  old	  
age,	  causes	  a	  greater	  strain	  on	  the	  healthcare	  and	  economic	  systems	  (Suzman	  &	  Beard	  2011;	  Martin	  
&	  Sheaff	  2007).	  	  
In	   recent	   years,	   López-­‐Otín	   and	   colleagues	  have	  enumerated	  nine	   ‘Hallmarks	  of	  Ageing’	   and	   these	  
can	   be	   described	   as	   common	   biological	   ‘themes’	   that	   have	   been	   shown	   to	   deteriorate	   over	   time,	  
leading	  to	  age-­‐related	  declines	  in	  function	  (López-­‐otín	  et	  al.	  2013).	  The	  hallmarks	  include;	  ‘genomic	  
instability’,	   ‘loss	   of	   proteostasis’,	   ‘stem	   cell	   exhaustion’,	   ‘cellular	   senescence’,	   ‘telomere	   attrition’,	  
‘altered	   intercellular	   communication’,	   ‘mitochondrial	   dysfunction’,	   ‘deregulated	   nutrient-­‐sensing’	  
and	   ‘epigenetic	   alterations’.	   It	   has	   also	   been	   suggested	   that	   the	   overall	   ‘ageing’	   effect	   develops	  
through	  a	  combination	  of	   these	  hallmarks	   (López-­‐otín	  et	  al.	  2013).	  The	  perception	  of	  ageing	   in	   the	  
literature	  has	  altered	  in	  recent	  years,	  to	  consider	  ageing	  as	  more	  of	  a	  pathology	  in	  itself	  (Beckman	  &	  
Ames	   1998;	   Aiello	   et	   al.	   2017;	   Gladyshev	   &	   Gladyshev	   2016).	   Thus,	   further	   investigation	   and	   an	  
improved	   understanding	   of	   the	   underlying	  mechanisms	   that	   appear	   to	   become	   ‘faulty’	   over	   time,	  
could	  indicate	  possible	  therapeutic	  targets	  (Martin	  &	  Sheaff	  2007;	  Melis	  et	  al.	  2013).	  
Overall	   frailty,	   defined	   by	   declines	   in	   energy,	   physical	   ability,	   cognition,	   fitness	   and	   health	   in	   the	  
elderly	   population,	   has	   been	   highly	   associated	   with	   deterioration	   of	   the	   neuromuscular	   system	  
(Rockwood	  et	  al.	  2005;	  Cesari	  et	  al.	  2006).	  Skeletal	  muscle	  makes	  up	  approximately	  45-­‐50%	  of	  total	  
body	  mass	  (Seifter	  et	  al.	  2005).	  Sarcopenia	  is	  defined	  as	  the	  age-­‐related	  loss	  in	  muscle	  mass,	  quality	  
and	  function	  and	  population	  studies	  have	  reported	  estimations	  of	  approximately	  20%	  of	  people	  aged	  
60-­‐70	  years	  old	  are	  affected	  by	  sarcopenia	  and	  this	  rises	  once	  over	  the	  age	  of	  80	  (up	  to	  ~50%)	  (von	  
Haehling	   et	   al.	   2010;	   Baumgartner	   et	   al.	   1998;	   Paddon-­‐Jones	   &	   Rasmussen	   2009;	   Burton	   &	  
Sumukadas	  2010).	  Muscle	  mass	  has	  also	  been	  estimated	  to	  decrease	  by	  ~1-­‐3%	  after	  the	  age	  of	  50,	  
annually	   and	   contributes	   to	   overall	   frailty,	   linked	   directly	   to	   a	   greater	   risk	   of	   falls,	   fractures	   and	  
hospitalisation	   (Doherty	   2003;	   von	   Haehling	   et	   al.	   2010;	   Grounds	   2014;	   Cesari	   et	   al.	   2006).	   An	  
extensive	  study	  conducted	  by	  Janssen	  and	  colleagues,	  calculated	  the	  approximate	  healthcare	  cost	  of	  
sarcopenia	   in	  the	  United	  States	  of	  America	  (U.S.A)	  as	  $7.7bn	  for	  women	  and	  $10.8bn	  for	  men,	  per	  
year,	  accountable	  for	  ~1.5%	  of	  total	  healthcare	  expenditure	  (Janssen	  et	  al.	  2004).	  It	  should	  be	  noted	  
however,	  that	  this	  estimation	  was	  calculated	  in	  2004	  and	  is	  expected	  to	  be	  higher	  today.	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The	  changes	  that	  occur	   in	  skeletal	  muscle	  structure	  and	  stem	  cell	   function	  with	  age	  have	  been	  the	  
focus	  research	  area	  of	  studies,	  in	  a	  number	  of	  different	  model	  systems,	  in	  animals	  as	  well	  as	  humans	  
(Alnaqeeb	  &	  Goldspink	  1987;	  Ansved	  &	  Larsson	  1989;	  Degens,	  Turek,	  et	  al.	  1993;	  Baumgartner	  et	  al.	  
1998;	  Shake	  et	  al.	  2002;	  Frontera	  et	  al.	  2008;	  Faulkner	  &	  Brooks	  1995;	  Terman	  &	  Brunk	  2004;	  Shefer	  
et	   al.	   2006;	   Collins	   et	   al.	   2007;	  Orford	  &	   Scadden	  2008;	   Collins-­‐Hooper	   et	   al.	   2012;	   Lavasani	   et	   al.	  
2012;	  Cheung	  &	  Rando	  2013;	  Sousa-­‐Victor	  et	  al.	  2014).	  However,	   it	   is	  apparent	   from	  the	   literature	  
that	  there	  remains	  the	  need	  for	  a	  detailed,	  comprehensive	  ‘ageing	  skeletal	  muscle	  profile’,	  as	  well	  as	  
an	  appropriate	  experimental	  set-­‐up	  to	   identify,	  outline	  and	  potentially	  treat,	  delay	  or	  even	  prevent	  
associated	  age-­‐related	  symptoms	  (Demontis	  et	  al.	  2013).	  
Skeletal	  muscle	   provides	   a	  model	   tissue	   to	   investigate	   the	   changes	   in	   stem	   cell	  maintenance	   and	  
function	   with	   age	   and	   sarcopenia	   delivers	   a	   consistent,	   well-­‐defined	   experimental	   model	   of	  
‘pathology’,	   in	   order	   to	   explore	   stem	   cell	   secretory	   factors	   as	   an	   anti-­‐ageing	   therapy	   (in	   mice).	  
Collaborators	   have	   previously	   established	   regulatory	   approved,	   clinically	   compliant,	   standard	  
operating	   procedures	   for	   the	   generation	   of	   autologous	   stem	   cell	   conditioned	   media-­‐based	  
therapeutic	  treatments.	  The	  use	  of	  stem	  cell-­‐derived	  conditioned	  media	  holds	  great	  clinical	  potential	  
and	  recent	  studies	  have	  reported	  many	  beneficial	  effects,	  observed	  in	  a	  number	  of	  tissue	  models	  of	  
injury	  and	  disease	  (Kinnaird	  et	  al.	  2004;	  Cho	  et	  al.	  2012;	  Cantinieaux	  et	  al.	  2013;	  Lavasani	  et	  al.	  2012;	  
Inoue	  et	  al.	  2013;	  Pawitan	  2014).	  It	  is	  believed	  that	  the	  clinical	  use	  of	  conditioned	  media	  will	  provide	  
a	   less	   invasive,	   more	   successful,	   safer	   alternative	   to	   stem	   cell	   transplantation	   (by	   reducing	   the	  
likelihood	  of	  host	  rejection	  in	  an	  inflammatory	  response	  and	  the	  occurrence	  of	  neoplasia)	  and	  could	  
play	  essential	  roles	  in	  the	  amelioration	  of	  disease	  (Cho	  et	  al.	  2012;	  Kim	  et	  al.	  2010).	  
The	   aims	   of	   the	   current	   research	   project	   are	   firstly,	   to	   explore	   how	   the	  muscle	   tissue	   health	   and	  
architecture	   alters	   with	   the	   onset	   and	   progression	   of	   sarcopenia	   in	   naturally-­‐aged	   mice.	   This	   is	  
achieved	   using	   a	   range	   of	   experimental	   parameters	   conducted	   at	   molecular,	   cellular,	   tissue	   and	  
whole	  organism	   levels	   to	  develop	  a	  broad	  skeletal	  muscle	  profile,	  providing	  a	  basis	   for	  subsequent	  
experimentation.	  Secondly,	   features	  of	   skeletal	  muscle	  composition,	   function	  and	   regeneration	  are	  
characterised,	   in	   the	   novel	   use	   of	   a	   murine	   model	   of	   DNA	   damage	   accumulation,	   in	   a	   resultant	  
phenotype	  of	   accelerated	  ageing	   (progeria).	   The	  progeric	   skeletal	  muscle	  profile	   is	   assessed	   in	   the	  
capacity	   to	   mimic	   the	   aspects	   of	   decline	   observed	   in	   sarcopenia	   in	   natural	   ageing.	   Thirdly,	   the	  
potential	   therapeutic	   paracrine	   effects	   of	   conditioned	   media	   (CM)	   treatment,	   generated	   from	  
adipose-­‐derived	  mesenchymal	  stem	  cells	  (ADMSC),	   is	  examined	  in	  both	  naturally-­‐aged	  and	  progeric	  
skeletal	   muscle.	   Lastly,	   the	   importance	   of	   the	   skeletal	   muscle	   myofibre	   matrix	   in	   determining	  
satellite	  cell	   (SC)	  regenerative	  function,	  as	  well	  as	  the	  influence	  of	  the	  myogenic	  microenvironment	  




Myocytes	   are	   the	   cells	   that	   make	   up	  muscle	   and	   differences	   in	   the	   characteristics,	   structure	   and	  
arrangement	  of	  these	  cells	  determine	  the	  muscle	  type.	  There	  are	  three	  main	  types	  of	  muscle	  found	  
in	  the	  human	  body;	  smooth	  muscle,	  cardiac	  muscle	  and	  skeletal	  muscle	  (Clark	  2005).	  The	  latter	  two	  
forms	   are	   distinguishable	   from	   smooth	  muscle	   by	   the	   striations	   or	   regular	   stripes	   observed	   across	  
individual	  myofibres.	  Thus,	  cardiac	  and	  skeletal	  muscle	  are	  also	  referred	  to	  as	  ‘striated	  muscle’	  due	  
to	  their	  macroscopic	  appearance	  (Pocock	  &	  Richards	  2006).	  Cardiac	  muscle	   is	  that	  of	  the	  heart	  and	  
smooth	   muscle	   is	   located	   primarily	   in	   the	   walls	   of	   blood	   vessels	   and	   hollow	   organs	   of	   the	   body,	  
including	  the	  digestive	  tract	  (Campbell	  2008).	  Skeletal	  muscle	  is	  a	  component	  of	  large,	  multi-­‐cellular	  
animals	   that,	   as	   the	   name	   suggests,	   is	   attached	   to	   the	   bones	   via	   tendons	   and	   is	   responsible	   for	  
voluntary	  movement.	  However,	   it	  will	  be	  seen	  that	   this	   is	  not	   the	  only	   function	  of	  skeletal	  muscle.	  
The	   investigations	   conducted	   in	   the	   current	   research	   project	   will	   be	   focused	   on	   skeletal	   muscle,	  
specifically.	  
Skeletal	  muscle	  
Skeletal	  muscle	  in	  humans	  comprises	  approximately	  40%	  of	  total	  body	  weight	  and	  is	  a	  highly	  dynamic	  
and	  plastic	  tissue	  (Janssen	  et	  al.	  2000;	  Frontera	  &	  Ochala	  2015).	  There	  are	  over	  650	  muscles	   in	  the	  
human	  body	   and	   they	   vary	   greatly	   in	   size,	   shape,	   attachments	   and	   composition.	   For	   example,	   the	  
Stapedius	  of	  the	  inner	  ear	  is	  the	  smallest	  striated	  muscle	  in	  the	  human	  body	  and	  averages	  about	  6-­‐
7mm	  in	  adults	  (Clement	  et	  al.	  2002).	  In	  contrast,	  the	  Sartorius	  muscle	  extends	  the	  length	  of	  the	  thigh	  
bone	   and	   although	   it	   has	   a	   relatively	   thin	   diameter,	   it	   is	   also	   the	   longest	   muscle.	   Therefore,	  
characteristics	  are	  extremely	  variable	  between	  muscles,	  this	  can	  be	  directly	  linked	  to	  the	  tasks	  each	  
muscle	  has	  to	  perform	  and	  these	   include	  a	  wide	  range	  of	  different	   functions	  throughout	  the	  body.	  
The	  main	   functions	   of	   skeletal	  muscle	   include:	   1.	  Maintains	   posture	   and	  body	   position.	   2.	   Permits	  
movement	  through	  force	  generation.	  3.	  Provides	  support	  to	  the	  soft	  tissues	  for	  example,	  the	  muscles	  
of	  the	  abdominal	  wall	  and	  pelvic	  floor.	  4.	  Guards	  entrances	  and	  exits	  of	  the	  mammalian	  body	  orifices.	  
5.	   Functions	   as	   a	   vital	   amino	   acid	   store	   and	   maintains	   core	   body	   temperature	   through	   heat	  
production,	  via	  the	  important	  role	  played	  in	  metabolism	  (MacIntosh	  et	  al.	  2006).	  
Skeletal	  muscle	  is	  known	  to	  maintain	  body	  posture	  and	  balance	  (involuntary)	  through	  interactions	  via	  
the	   two	   sub-­‐pathways	   of	   the	   vestibulospinal	   tract,	   the	   medial	   and	   lateral	   vestibulospinal	   tracts	  
(Siegel	   &	   Sapru	   2010).	   These	   tracts	   are	   responsible	   for	   regulating	   motor-­‐neuronal	   innervation,	   in	  
response	   to	   sensing	   external	   stimuli,	   to	   initiate	   stabilization	   of	   the	   head	   (and	   neck)	   muscles	   and	  
upright	   posture	   through	   the	   extensor	  muscles	   in	   the	   leg,	   respectively	   (Brodal	   2010).	  Moreover,	   a	  
further	   function	  of	   skeletal	  muscle	   is	   that,	   the	  Gastrocnemius	   and	  Soleus	  muscles	  of	   the	   lower	   leg	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that	   constitute	   the	   calf,	   are	   involved	   in	   the	   ‘calf	  muscle	  pump’	  mechanism,	  which	   functions	   in	   the	  
return	   of	   venous	   blood	   flow	   to	   the	   upper	   body	   from	   the	   lower	   extremities,	   essential	   in	   the	  
prevention	  of	  lower	  leg	  ulceration	  and	  deep	  vein	  thrombosis	  (DVT)	  (Bryant	  &	  Nix	  2012;	  Christopoulos	  
et	  al.	  1989;	  Meissner	  et	  al.	  2012).	  
Macroscopic	  anatomy	  of	  skeletal	  muscle	  
Skeletal	  muscle	   is	   comprised	  of	   a	   variety	  of	   tissues	   including	  blood	   vessels,	   nerves	   and	   connective	  
tissue.	   Each	  muscle	   is	   served	  by	  one	  nerve,	   one	   artery	   and	   at	   least	   one	   vein.	  All	   of	  which	   tend	   to	  
enter	  at	  one	  central	  point	  and	  branch	  extensively	  throughout	  the	  connective	  tissue	  layers	  (MacIntosh	  
et	   al.	   2006).	   The	   entire	   skeletal	  muscle	   body	   is	   surrounded	   by	   a	   dense	   connective	   tissue	   layer,	   of	  
which	  collagenous	   fibres	  are	  a	  major	   constituent,	   termed	   the	  epimysium	   (Rowe	  1981).	  The	   role	  of	  
the	   epimysium	   is	   to	   keep	   the	  muscle	   separate,	   protecting	   against	   friction	   from	   other	   surrounding	  
tissues	   and	   bones	   (MacIntosh	   et	   al.	   2006).	   A	   further	   collagenous	   layer,	   the	   perimysium,	   encases	  
fascicles	  which	  are	  bundles	  of	  myofibres.	  Myofibres	  are	  a	  multi-­‐nucleated	  syncytium	  of	  myonuclei,	  
surrounded	   by	   a	   plasma	  membrane	   (sarcolemma)	   and	   a	   layer	   of	   connective	   tissue	   known	   as	   the	  
endomysium,	  of	  which	  collagen	  fibres,	  laminin	  and	  fibronectin	  are	  the	  main	  components	  (MacIntosh	  
et	   al.	   2006;	   Bertolotto	   et	   al.	   1983;	   Gulati	   et	   al.	   1982;	   Engvall	   et	   al.	   1990).	   Myofibres	   consist	   of	  
bundles	  of	  protein	  filaments	  (myofibrils),	  longitudinally	  arranged	  down	  the	  length	  of	  the	  fibre,	  and	  in	  
turn,	   actin	   (thin)	   and	   myosin	   (thick)	   myofilaments,	   making	   up	   the	   striated,	   contractile	   element	  
(sarcomere)	   of	   skeletal	   muscle	   (Campbell	   2008;	   Pocock	   &	   Richards	   2006)	   (Figure	   1.1).	   The	  
epimysium,	  perimysium	  and	  endomysium	  are	  continuous	  with	   tendons,	  which	  at	  each	  end	   link	   the	  
muscle	   body	   to	   the	   bone,	   which	   it	   serves	   to	   transmit	   the	  mechanical	   force	   generated	   by	  muscle	  
contraction,	   to	   the	   skeleton	   (Light	   &	   Champion	   1984;	   Pocock	   &	   Richards	   2006).	   Additionally,	   just	  
below	  the	  perimysium	  sheets,	  arterioles	  and	  venules	  as	  well	  as	  intramuscular	  nerves,	  enter	  and	  form	  
branching	   patterns	   within	   these	   regions,	   as	   well	   as	   serving	   the	   endomysium	   layers.	   Furthermore,	  
arterioles	  supply	  blood	  to	  the	  dense	  capillary	  networks	  that	  serve	  individual	  myofibres	  (MacIntosh	  et	  
al.	  2006).	  
Microscopic	  anatomy	  of	  skeletal	  muscle	  
Skeletal	  muscle	  myofibres,	  depending	  on	  muscle	   length,	  can	  vary	  from	  a	  few	  millimetres	  to	  several	  
centimetres	   and	   range	   from	   50	   to	   100µm	   in	   diameter	   (Pocock	   &	   Richards	   2006).	   Myonuclei	   are	  
organised	   peripherally	   within	   the	   myofibre,	   beneath	   the	   sarcolemma	   and	   there	   are	   two	   distinct	  
subpopulations	   of	   mitochondria,	   the	   subsarcolemmal	   (SS)	   and	   the	   intermyofibrillar	   (IMF)	  
mitochondria	   (Bruusgaard	   et	   al.	   2006;	   Ferreira	   et	   al.	   2010;	   Leeuwenburgh	   et	   al.	   2005).	   	   The	  
contractile	  unit	   of	   skeletal	  muscle,	   the	   sarcomere,	   is	   repeated	  as	   a	   chain	   along	   the	   length	  of	   each	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myofibril	  and	   it	   is	   the	  alignment	  of	   these	  units,	   that	  creates	   the	  characteristic	   striations	  of	   skeletal	  
muscle	  (Pocock	  &	  Richards	  2006).	  When	  viewed	  using	  polarised	  light,	  there	  are	  two	  distinct	  regions	  
visible,	  a	  dark	  region,	  known	  as	  an	  A	  band	  (anisotrophy),	  composed	  of	  thick	  (myosin)	  filaments	  and	  a	  
light	   region,	   termed	   the	   I	  band	   (isotrophy),	  which	   is	  made	  up	  of	   thin	   filaments	   (actin)	   (Figure	  1.1).	  
Each	  I	  band	  is	  divided	  by	  a	  characteristic	   line,	  termed	  the	  Z	  line,	  which	  contains	  numerous	  proteins	  
including	  α-­‐actinin	  (binds	  actin	  filaments)	  and	  desmin	  (links	  adjacent	  Z	  lines	  for	  alignment),	  and	  the	  
region	   between	   two	   Z	   lines	   is	   the	   sarcomere	   unit.	   In	   the	   centre	   of	   the	   dark	   A	   band	   is	   a	   region	   in	  
which	   thick	   and	   thin	   filaments	   do	   not	   overlap	   and	   this	   results	   in	   a	   zone	  with	   a	   pale	   appearance,	  
known	  as	  the	  H	  zone.	  In	  the	  centre	  of	  the	  H	  zone,	  adjacent	  thick	  filaments	  form	  links	  to	  create	  the	  M	  
line	  (MacIntosh	  et	  al.	  2006).	  The	  myofibre	  sarcolemma	  contains	  a	  transverse	  tubule	  (T	  tubule)	  system	  
which	   comprises	   narrow	   tubules	   that	   project	   transversely	   from	   the	   sarcolemma	   across	   each	  
myofibre	  at	  the	  junctions	  between	  A	  and	  I	  bands.	  Each	  myofibril	   is	  surrounded	  by	  the	  sarcoplasmic	  
reticulum	   (SR),	   which	   is	   the	   endoplasmic	   reticulum	   of	   skeletal	   muscle.	   Where	   the	   SR	   and	   the	   T	  
tubules	  make	  contact,	  the	  SR	  enlarges	  to	  form	  terminal	  cisternae.	  The	  SR	  stores	  and	  releases	  calcium	  
and	   along	   with	   regulatory	   activity	   of	   actin	   filament	   proteins,	   troponin	   and	   tropomyosin,	   helps	   to	  
regulate	  muscle	  contraction	  (Pocock	  &	  Richards	  2006).	  
Muscle	  contraction	  
The	  sliding	  filament	  model	  of	  muscle	  contraction	  is	  dependent	  on	  the	  interactions	  between	  the	  thick	  
(myosin)	  and	   thin	   (actin)	   filaments.	  Each	  myosin	  molecule	  contains	  a	   rod-­‐like	   tail	  and	   two	  globular	  
head	  regions,	  which	  contain	  the	  ATP	  binding	  site	  and	  ATPase,	  where	  ATP	   is	  hydrolysed	  to	  ADP	  and	  
inorganic	  phosphate.	  The	  hydrolysis	  of	  ATP	  converts	  the	  myosin	  head	  region	  to	  a	  high	  energy	  state	  
that	  subsequently	  binds	  actin,	  forming	  a	  cross-­‐bridge,	  the	  actin	  filament	   is	  then	  pulled	  towards	  the	  
centre	   of	   the	   sarcomere.	   It	   is	   this	  movement	   that	   causes	   a	   shortening	   of	   the	   sarcomere	   and	   the	  
filaments	  slide	   longitudinally,	   increasing	  the	  overlap	  between	  the	  two	  types	  of	   filament.	  The	  cross-­‐
bridge	   is	  detached	  when	  a	  new	  ATP	  molecule	  binds	  the	  myosin	  head.	   In	  a	  repeated	  cycle,	   the	   free	  
myosin	   head	   cleaves	   the	   new	   ATP	   and	   attaches	   to	   a	   binding	   site	   further	   along	   the	   actin	   filament	  
(Campbell	  2008).	  
The	  arrival	  of	  an	  action	  potential	  at	   the	  pre-­‐synaptic	   terminal	  of	  a	  neuromuscular	   junction	   triggers	  
the	   release	   of	   the	   neurotransmitter	   acetylcholine	   (ACh).	   Subsequent	   binding	   of	   ACh	   to	   the	  
sarcolemmal	   nicotinic	   receptors	   on	   the	   myofibre	   leads	   to	   depolarisation,	   thereby	   generating	   an	  
action	  potential.	  The	  action	  potential	  spreads	  along	  the	  length	  of	  the	  myofibre	  via	  the	  T	  tubules	  and	  
triggers	  the	  release	  of	  calcium	  ions	  (Ca2+)	  from	  the	  terminal	  cisternae	  (Campbell	  2008).	  The	  Ca2+	  ions	  
bind	  the	  troponin	  complex,	  displacing	  tropomyosin,	  changing	  its	  position	  on	  the	  actin	  molecule.	  This	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in	   turn,	   exposes	   the	  myosin	   binding	   sites	   on	   the	   actin	   filament,	   allowing	  myosin/actin	   coupling	   to	  
take	  place,	   initiating	  muscle	   contraction	   through	   the	   sliding	   filament	  process.	  When	  motor	  neuron	  
stimulation	  ceases,	  the	  myofibre	  relaxes	  and	  the	  filaments	  slide	  back	  to	  their	  original	  positions	  and	  
the	  Ca2+	  ions	  are	  pumped	  out	  of	  the	  cytosol	  back	  into	  the	  SR.	  Low	  Ca2+	  ion	  levels	  cause	  troponin	  and	  
tropomyosin	   to	   return	   to	   their	   starting	  positions	  and	   therefore,	   inhibits	  myosin/actin	  binding	  once	  
more	  (Pocock	  &	  Richards	  2006).	  
	  
Figure	  1.1	  Microscopic	  structure	  of	  skeletal	  muscle.	  (A)	  Whole	  muscle.	  (B)	  A	  muscle	  fascicule	  (C)	  An	  
individual	  muscle	  fibre	  (D)	  Myofibril	  structure.	  (E,	  F)	  Myofilament	  structure	  and	  the	  arrangement	  of	  
thick	  and	  thin	  filaments	  (Pocock	  &	  Richards	  2006).	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Skeletal	  muscle	  myofibre	  classification,	  functional	  diversity	  and	  plasticity	  
A	  single	  motor	  neuron	  supplies	  one	  or	  more	  myofibres	  and	  together	  this	  forms	  a	  single	  motor	  unit	  
(Burke	   et	   al.	   1971;	   Pette	   &	   Vrbova	   1985).	   When	   the	   neuron	   is	   activated,	   the	   action	   potential	   is	  
transmitted	   to	  each	  myofibre	   it	   serves,	  as	  per	   the	  mechanism	  previously	  described.	  Therefore,	   the	  
motor	   unit	   is	   the	   final	   functional	   element	   that	   generates	   movement	   (Pette	   &	   Vrbova	   1985).	  
Myofibres	  are	  highly	  organised	  and	  display	  a	  wide	  range	  of	  diversity,	  which	  is	  attributed	  to	  a	  variety	  
of	   functional	   capacities	   and	   plasticity	   in	   their	   adaptation	   to	   functional	   demand	   (Goldspink	   1999;	  
Degens	   et	   al.	   1992;	   Pette	   &	   Staron	   2000).	   There	   are	   a	   number	   of	   ways	   that	   myofibres	   can	   be	  
classified	   and	   these	   can	   be	   based	   on	   among	   others,	   physiological,	   histochemical,	   biochemical	   and	  
morphometrical	   properties,	   such	   as	   contractile	   capacity,	   myosin	   heavy	   chain	   (MHC)	   composition,	  
oxidative	  capacity	  and	  fatigability	   (Larsson	  et	  al.	  1991;	  Alnaqeeb	  &	  Goldspink	  1987;	  Pette	  &	  Staron	  
1990)	   (Figure	   1.2).	   The	   diversity	   presented	   by	   skeletal	   muscle	   myofibres	   was	   recognised	   in	   early	  
studies	  describing	  muscles	  as	  ‘white’	  or	  ‘red’	  which,	  through	  later	  research	  utilising	  a	  combination	  of	  
physiological	   and	   the	   advance	   in	   enzyme	   histochemical	   methods,	   further	   elucidated	   these	   broad	  
differences	   in	  appearance,	  to	  refer	  to	  more	  specific	  physical	  properties,	  such	  as	  myoglobin	  content	  
and	  oxidative	  capacity	  (Pette	  &	  Staron	  1990).	  Burke	  and	  colleagues	  were	  among	  the	  first	  to	  classify	  
three	  distinct	  myofibre	  types	  in	  the	  Gastrocnemius	  muscle	  of	  cats,	  based	  on	  their	  physiological	  and	  
histochemical	  characteristics,	  identifying	  that	  myofibres	  within	  the	  same	  motor	  unit	  were	  uniform	  in	  
type	   (Burke	   et	   al.	   1971;	   Burke	   et	   al.	   1973).	   Additionally,	   Peter	   and	   colleagues	   utilised	   NADH	  
tetrazolium	   reductase	   and	   succinate	   dehydrogenase	   enzymes	   to	   study	   the	   glycolytic	   and	  oxidative	  
capacity	  of	  guinea	  pig	  and	  rabbit	  myofibres	  with	  low	  or	  high	  ATPase	  activity	  (Peter	  et	  al.	  1972).	  These	  
early	   classifications	   included	   (fatigue-­‐resistant)	   slow-­‐twitch	   oxidative	   (SO),	   (fatigue-­‐resistant)	   fast-­‐
twitch	  oxidative	  glycolytic	  (FOG)	  and	  (fast-­‐fatigable)	  fast-­‐twitch	  glycolytic	  (FG)	  myofibres	  (Burke	  et	  al.	  
1971;	   Peter	   et	   al.	   1972).	   This	   thereby,	   added	   a	   further	   dimension	   to	   classifications,	   where	  
relationships	  were	  made	  between	  metabolic	  properties	   (oxidation)	  and	   fatigability	   and	  established	  
that	  ‘red’	  muscle	  myofibres	  may	  be	  fast	  or	  slow	  (Burke	  et	  al.	  1971;	  Burke	  et	  al.	  1973;	  Pette	  &	  Staron	  
1990).	   The	  vast	  number	  of	  different	  ways	   that	  myofibres	   can	  be	  physiologically,	  histologically,	   and	  
biochemically	   identified	   and	   categorised	   therefore,	   can	   make	   general	   myofibre	   classification	   a	  
challenge	   (Larsson	   et	   al.	   1991).	   However,	   despite	   the	   numerous	   methods	   of	   classifying	   myofibre	  
types	   histologically,	   few	   have	   prevailed	   as	   universally-­‐used,	   ‘industry-­‐standard’	   protocols	   (Pette	   &	  
Staron	  1990;	  Pette	  &	  Staron	  2000).	  One	  method	  commonly	  used	  to	  identify	  different	  myofibre	  types	  
is	   by	  MHC	   isoform	   profile,	  where	   distributions	  within	   a	  muscle,	   between	  muscle	   types,	   as	  well	   as	  
across	   strains	   and	   species	   are	   extremely	   varied,	   further	   establishing	   skeletal	   muscle	   as	   a	   diverse,	  
heterogeneous	  tissue	  (Pette	  &	  Staron	  2000).	  MHC	  isoforms	  are	  accountable	  for	  the	  myosin	  ATPase	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activity	  and	  contractile	  rate	  of	  myofibres	  and	  have	  since,	  been	  categorised	  into	  type	  I	  (slow	  twitch)	  
and	  type	  II	  (fast	  twitch)	  groups	  (DeNardi	  1993).	  Schiaffino	  and	  colleagues	  used	  anti-­‐MHC	  isoform	  rat	  
monoclonal	  antibodies	  and	  immunoblotting	  analysis	  to	  identify	  the	  myofibre	  types	  and	  importantly,	  
described	   three	   distinct	   type	   II	   sub-­‐populations,	   including	   IIA,	   IIB	   and	   intermediate	   IIX/IID	   fibres	  
(Schiaffino	  et	  al.	  1989;	  DeNardi	  1993).	  Due	  to	  the	  many	  possible	  combinations	  in	  myosin	  heavy	  and	  
light	  chain	  isoforms,	  multiple	  hybrid	  myofibre	  types	  can	  be	  formed	  (Lowey	  et	  al.	  1993).	  This	  feature,	  
as	  well	   as	   the	   different	   classes	   of	  motor	   neurons	   that	   serve	   those	  myofibres,	   results	   in	   numerous	  
variations	   in	   the	  morphological,	   biochemical	   and	   contractile	   abilities	   of	   the	  myofibres	   in	   a	  muscle.	  
These	  features	  are	  highly	  dependent	  on	  specific	  muscle	  function.	  For	  example,	  muscles	  required	  to	  
maintain	  posture	  (postural),	  predominantly	  consist	  of	  slow-­‐twitch	  myofibres	  with	  high	  resistance	  to	  
fatigue.	  Whereas,	  phasic	  muscles	  contain	  a	  high	  proportion	  of	  fast-­‐twitch	  motor	  units	  for	  more	  rapid	  
movements	   (Pette	   &	   Vrbova	   1985).	   Moreover,	   the	   succinate	   dehydrogenase	   histochemical	   stain	  
remains	   a	   commonly	   used	  qualitative	   assessment	   of	   oxidative	   capacity	   in	  muscle	   (Takemura	   et	   al.	  
2017;	  Barnouin	  et	  al.	  2017;	  Pette	  &	  Staron	  2000).	  The	  metabolic	  requirement	  of	  each	  MHC	  isoform	  
varies	  significantly	   for	  example,	  slow	  twitch	  type	   I	  myofibres	  are	  generally	  characterised	  by	  a	  small	  
cross-­‐sectional	  area	  (CSA),	  an	  abundance	  of	  mitochondria,	  myoglobin	  and	  a	  greater	  capillary	  density	  
(Figure	  1.2).	  Fast	  twitch	  myofibres	  such	  as	  type	  IIB	  typically	  have	  a	  large	  CSA,	  few	  mitochondria,	  little	  
myoglobin	   and	   a	   rich	   in	   glycogen	   (Figure	   1.2).	   Type	   IIA	   and	   IIX	   myofibres	   have	   intermediate	  
properties	  (Gundersen	  2011;	  Yan	  et	  al.	  2011;	  Duan	  et	  al.	  2017)	  (Figure	  1.2).	  Furthermore,	  Type	  I	  and	  
IIA	  myofibres	   are	  more	   oxidative	   in	   their	  metabolism	  whereas,	   type	   IIX	   and	   IIB	   are	   predominantly	  
glyocolytic	   (Schiaffino	   &	   Reggiani	   1996;	   Pette	   &	   Staron	   2000)	   (Figure	   1.2).	   A	   range	   of	   fibre	   type-­‐
specific	   isoforms	   of	   other	   muscle	   proteins	   also	   determine	   differences	   between	   myofibre	   types.	  
Notably,	   the	   sarcoplasmic-­‐endoplasmic	   reticulum	   Ca2+-­‐ATPase	   (SERCA)	   isoforms	   vary	   between	  
myofibre	  type,	  with	  SERCA1a	  highly	  expressed	  in	  types	  IIX	  and	  IIB	  whereas,	  SERCA2a	  is	  expressed	  in	  
slow	   type	   I	   and	   IIA	  myofibres	   (Salvatore	  et	   al.	   2013;	   Schiaffino	  &	  Reggiani	   2011).	   Faster	  myofibres	  
also	  maintain	  a	  greater	  abundance	  of	  both	   ryanodine	   receptor	   (RyR)	   calcium	   release	   channels	  and	  
SERCA	  pumps	  which,	   together,	   regulate	   the	   release	  and	  ATP-­‐dependent	   re-­‐uptake	  of	   calcium	   from	  
the	  cytosol.	  Therefore,	  differing	  abundances	  of	   these	  proteins	  and	  SERCA	   isoform	  expressions,	   can	  









Figure	  1.2	  Myofibre	   isoforms	  and	  their	  physiological	  performance,	  adapted	  from	  (Duan	  et	  al.	  2017;	  
Gundersen	  2011).	  
Distribution	  of	  myofibres	  
Distribution	   of	   myofibre	   types	   varies	   within	   muscles	   and	   across	   muscle	   types	   and	   species.	   For	  
example,	  examination	  of	  the	  myofibre	  composition	  profiles	  of	  a	  large	  variety	  of	  different	  rat	  muscles	  
demonstrated	  that	  type	  IIB	  myofibres	  comprised	  the	  largest	  proportion	  of	  rat	  musculature,	  however	  
there	  were	  some	  muscles,	  such	  as	  the	  Soleus,	  that	  contained	  very	  few,	  if	  any	  type	  IIB	  myofibres	  (Delp	  
&	   Duan	   1996).	   Furthermore,	   Armstrong	   and	   colleagues	   have	   previously	   shown	   that	   the	   deep	  
extensor	  and	  flexor	  muscles	  of	  the	  limbs	  in	  a	  number	  of	  mammals,	  including	  rats,	  pigs,	  dogs	  and	  cats,	  
contain	  the	  highest	  proportion	  of	  type	  I	  myofibres,	  whereas	  the	  superficial	  muscles	  are	  comprised	  of	  
a	  large	  percentage	  of	  type	  IIB	  (Ariano	  et	  al.	  1973;	  Armstrong	  &	  Phelps	  1984;	  Armstrong	  et	  al.	  1987;	  
Armstrong	  et	  al.	  1982).	  Similarly,	   this	   is	  also	   the	  case	  when	  analysing	   the	  distribution	  of	  myofibres	  
within	   a	   single	   limb	   muscle.	   For	   example,	   the	   deep	   region	   contains	   the	   majority	   of	   the	   type	   I	  
myofibres,	  in	  contrast	  very	  few	  are	  located	  superficially,	  instead	  in	  this	  peripheral	  region	  there	  is	  an	  
abundance	  of	   type	   IIB	  myofibres	   (Armstrong	  &	  Phelps	   1984;	   Fuentes	   et	   al.	   1998).	   The	  distribution	  
and	  composition	  of	  myofibre	  types	  are	  vastly	  different	  in	  the	  rabbit	  Extensor	  digitorum	  longus	  (EDL),	  
Psoas	  and	  Tibialis	  anterior	  (TA)	  muscles,	  compared	  to	  the	  mouse	  and	  rat,	  as	  it	  has	  been	  shown	  that	  
the	  predominant	  myofibre	  is	  the	  type	  IIX	  and	  these	  muscles	  do	  not	  contain	  pure	  type	  IIB	  myofibres	  
(Hämäläinen	  &	  Pette	  1993).	   The	   type	   I	   distribution	  however,	   showed	  proximo-­‐distal	   differences	   in	  
the	  regionalisation	  across	  the	  hindlimb	  muscles	  of	  these	  three	  species.	  Furthermore,	  the	  muscles	  of	  
the	   rat	   hindlimb	   were	   all	   described	   as	   ‘fast’	   muscles,	   with	   the	   exception	   of	   the	   Soleus,	   and	   the	  
patterning	   of	   type	   I	   distribution	   was	   reported	   to	   be	   highly	   reproducible,	   with	   similar	   trends	   of	  
declining	   proximo-­‐distal	   type	   I	   myofibre	   densities	   (Wang	   &	   Kernell	   2001).	   The	   composition	   and	  
distribution	  of	  myofibres	  is	  known	  to	  be	  directly	  linked	  with	  the	  functional	  demand	  and	  specific	  role	  
of	  a	  given	  muscle.	  For	  example,	  anti-­‐gravity	  or	  postural	  muscles,	  such	  as	  the	  Soleus,	  contain	  a	  larger	  
proportion	   of	   slow	  oxidative	   (type	   I)	  myofibres	  whereas,	   locomotory	  muscles	   are	   comprised	   of	   an	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abundance	   of	   fast	   glycolytic	   (type	   II)	   myofibres	   (Suzuki	   1995).	   Significantly	   greater	   proportions	   of	  
type	   IIB	   myofibres	   comprised	   the	   muscles	   analysed	   in	   the	   rat	   and	   mouse,	   relative	   to	   the	   rabbit.	  
Additionally,	   studies	   in	   larger	   mammals	   and	   man	   have	   revealed	   a	   greater	   abundance	   of	   type	   I	  
myofibres,	  when	  compared	   to	   small	   animals	   (Delp	  &	  Duan	  1996;	  Prince	  et	  al.	  1976;	   Johnson	  et	  al.	  
1973).	   It	   was	   proposed	   that	   smaller	   animals	   have	   a	   greater	   requirement	   for	   the	   use	   of	   type	   IIB	  
myofibres	   due	   to	   their	   reliance	   of	   significantly	   faster	   contraction	   velocities	   for	   movement	  
(Hämäläinen	   &	   Pette	   1993;	   Suzuki	   1995;	   Delp	   &	   Duan	   1996).	   Studies	   examining	   myofibre	  
composition	   in	  human	  muscles	  however,	   are	   considerably	   less	   abundant	   than	   those	   carried	  out	   in	  
animals,	  particularly	  those	  conducted	   in	  small	  rodents	  (Smerdu	  et	  al.	  1994).	  Humans	  are	  suggested	  
to	   have	   only	   three	   (pure)	   myofibre	   types	   (I,	   IIA	   and	   IIX),	   as	   very	   few	   myofibres,	   located	   in	   the	  
masseter	   muscles	   and	   external	   oblique	   were	   demonstrated	   to	   contain	   type	   IIB	   RNA,	   but	   not	   IIB	  
protein	   (Yan	   et	   al.	   2011;	   Smerdu	   et	   al.	   1994;	   Horton	   et	   al.	   2001).	   In-­‐situ	   hybridisation	   analysis,	  
showed	   that	  MHC	   IIX-­‐specific	   mRNA	   probes	   hybridised	   with	   those	  myofibres	   that	   histochemically	  
expressed	   IIB,	  however	   the	   IIB-­‐specific	  probe	  only	  hybridised	  with	  a	   few	  myofibres	  histochemically	  
defined	   as	   type	   I	   in	   the	   external	   oblique	   muscle,	   but	   not	   with	   any	   IIB	   myofibres	   in	   any	   other	  
examined	  muscles	  (Horton	  et	  al.	  2001).	  
Transitions	  in	  myofibre	  type	  
The	  heterogeneity	  of	  myofibres	   in	   their	  physiological,	  biochemical	  and	  metabolic	   features,	   is	  a	  key	  
determinant	   of	   differences	   in	   contraction	   speed	   and	   fatigue	   resistance,	   enabling	   diverse	   muscle	  
groups	   to	   carry	   out	   a	   variety	   of	   functions	   and	   movements.	   A	   fundamental	   and	   remarkable	  
characteristic	  of	  myofibres	  is	  their	  adaptability	  to	  changing	  environmental,	  metabolic	  and	  functional	  
demands	   controlled	   by	   numerous	   intrinsic	   signalling	   pathways	   (Bassel-­‐Duby	   &	   Olson	   2006).	   The	  
adaptability	   of	   skeletal	   muscle	   was	   demonstrated	   using	   cross-­‐innervation	   of	   slow	   twitch	   Soleus	  
muscle	  with	  nerve	  fibres	  that	  normally	  supply	  the	  fast	  twitch	  Flexor	  digitorum	  longus,	  resulting	  in	  an	  
increased	   contractile	   speed.	   Additionally,	   a	   corresponding,	   slower	   contraction	   was	   observed	   with	  
cross-­‐innervation	   in	   the	   reverse,	   in	   fast	   twitch	   muscle	   (Buller	   et	   al.	   1960).	   Studies	   conducted	   to	  
examine	   the	   genetic	   regulation	   of	   these	  myofibre	   transitions,	   have	   been	   achieved	   using	   exercise,	  
transgenic	  animal	  models,	  electrical	  stimulation,	  disease	  states	  as	  well	  as	  microgravity.	  For	  example,	  
studies	   conducted	   in	   denervated	   rat,	   rabbit	   and	   cat	  muscles	   show	   that	   electrical	   stimulation	   that	  
mimics	  patterns	  of	  high	  (intermittent	  short	  bursts)	  and	  low	  (prolonged)	  frequency	  activities	  influence	  
the	  contractile	  properties	  of	  fast	  and	  slow	  muscles,	  respectively	  (Lomo	  et	  al.	  1974;	  Salmons	  &	  Vrbová	  
1969).	   A	   slow	   to	   fast	   switch	   in	   myofibre	   type	   can	   be	   induced,	   not	   only	   through	   high	   frequency	  
electrical	  stimulation,	  but	  also	  by	  muscle	  unloading,	  for	  example	  during	  hindlimb	  suspension,	  as	  well	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as	  hyperthyroidism	  (Caiozzo	  et	  al.	  1998).	  Alternatively,	  a	  switch	  in	  the	  opposing	  direction,	  from	  fast	  
to	   slow	   types,	   is	   induced,	   along	   with	   low	   frequency	   electrical	   stimulation,	   through	   muscle	  
overloading,	   as	   well	   as	   hypothyroidism	   (Nwoye	  &	  Mommaerts	   1981;	   Schiaffino	   &	   Reggiani	   2011).	  
Interestingly,	  the	  slow	  gene	  programme	  is	  difficult	  to	  reverse	  in	  adult	  myofibres	  and	  tends	  to	  persist	  
for	  a	   long	  duration,	  even	   in	  denervated	  muscle.	  Therefore,	  a	  myofibre	  transition	  from	  slow	  to	  fast,	  
which	  may	  can	  result	  in	  the	  disappearance	  of	  the	  slow	  myofibres,	  can	  only	  be	  induced	  by	  long-­‐term	  
complete	   inactivity.	   For	   example	   following	   spinal	   cord	   damage	   in	   mice	   or	   spinal	   cord	   injury	   in	  
humans	  (Schiaffino	  &	  Reggiani	  2011).	  In	  general,	  however,	  the	  development	  and	  maintenance	  of	  the	  
slow	   myofibre	   phenotype	   is	   dependent	   on	   innervation	   by	   a	   slow	   motor	   neuron.	   Whereas,	   the	  
development	  of	  fast	  characteristics	  is	  believed	  to	  be	  regulated	  by	  thyroid	  hormone	  (TH),	  as	  well	  as	  a	  
high	  frequency	  innervation	  pattern	  (Pette	  &	  Staron	  1997;	  Pette	  &	  Staron	  2000;	  Salvatore	  et	  al.	  2013).	  
Furthermore,	  it	  is	  well-­‐established	  that	  skeletal	  muscle	  myofibres	  undergo	  phenotypic	  transitions	  in	  
chronic	  disease,	  such	  as	  obesity,	  ageing,	  as	  well	  as	  in	  response	  to	  physical	  activity	  (Hickey	  et	  al.	  1995;	  
Inbar	   et	   al.	   1981;	   Yan	   et	   al.	   2011).	   Specifically,	   endurance	   exercise	   induces	   a	   transformation	   of	  
myofibres	  from	  those	  more	  glycolytic	  to	  an	  oxidative	  phenotype	  within	  faster	  type	  II	  myofibres,	  from	  
IIX	   to	   IIA,	   to	   I	   in	   humans	   and	   IIB	   to	   IIX,	   to	   IIA	   in	   rats	   and	   mice	   (Green	   et	   al.	   1979;	   Andersen	   &	  
Henriksson	  1977;	  Allen	  et	  al.	  2001;	  Schiaffino	  &	  Reggiani	  2011).	  Correspondingly,	  a	  higher	  proportion	  
of	   type	   IIA	   and	   IIX	   are	   observed	   in	   more	   sedentary	   humans	   (Klitgaard,	   Bergman,	   et	   al.	   1990).	  
Molecular	   genetics-­‐based	   research	   has	   allowed	   for	   a	   more	   detailed	   analysis	   of	   the	   underlying	  
regulation	  of	  exercise-­‐induced	  myofibre	  transitions.	  Subsequently,	  studies	  have	  established	  that	  the	  
activation	   of	   the	   calcineurin/NFAT	   (nuclear	   factor	   of	   activated	   T-­‐cells)	   signalling	   pathway,	   is	   a	   key	  
determinant	   for	   the	   expression	   of	   slow	   twitch	   muscle	   genes,	   through	   numerous	   loss	   and	   gain	   of	  
function,	   as	   well	   as	   transgenic	   animal	   studies	   (Chin	   et	   al.	   1998;	   Yan	   et	   al.	   2011).	   Additionally,	  
Ca2+/calmodulin-­‐dependent	  protein	   kinase	   (CaMK)	  activation	  of	  myocyte	  enhancer	   factor	  2	   (MEF2)	  
and	  the	  successive	  derepression	  of	  class	  II	  histone	  deacetylases,	  such	  as	  HDAC	  proteins	  (4,	  5	  and	  9)	  is	  
also	  involved	  in	  the	  transformation	  of	  myofibres	  to	  those	  more	  oxidative	  (Potthoff	  et	  al.	  2007;	  Yan	  et	  
al.	   2011).	   Furthermore,	   the	   AMP-­‐activated	   protein	   kinase	   (AMPK)	   and	   peroxisome	   proliferator-­‐
activated	  receptor	  gamma	  coactivator	  1-­‐alpha	  (PGC-­‐1α)	  interactions	  (AMPK/	  PGC-­‐1α),	  as	  well	  as	  the	  
p38γ3	  mitogen-­‐activated	  protein	  kinase	  (MAPK)/PGC-­‐1α	  signalling	  pathways,	  have	  been	  established	  
as	   functionally	   important	   in	   the	   response	   to	   metabolic	   stress	   and	   energy	   deprivation,	   through	  
increased	   contractile	   activity,	   by	   segmentally	   initiating	   exercise-­‐induced	   myofibre	   transitions	   and	  
mitochondrial	   biogenesis,	   respectively	   (Röckl	   et	   al.	   2007;	  Garcia-­‐Roves	   et	   al.	   2008;	   Lin	   et	   al.	   2002;	  




In	  general,	  muscle	  mass	  is	  dependent	  on	  the	  balance	  between	  protein	  synthesis	  and	  degradation	  and	  
mechanisms	  of	  both	  processes	  are	   sensitive	   to,	  among	  others,	  physical	   activity/exercise,	  hormonal	  
regulation,	   nutritional	   status,	   ageing	   and	   injury	   and	   disease	   (Frontera	   &	   Ochala	   2015;	   Goldspink	  
1999;	  Yang	  et	  al.	  1997;	  Cartee	  et	  al.	  1996;	  Degens	  &	  Alway	  2003).	  Increases	  in	  adult	  skeletal	  muscle	  
mass	   is	   believed	   to	   be	   as	   a	   result	   of	   increases	   in	   size	   (hypertrophy),	   in	   response	   to	   the	   greater	  
demand	   with	   growth,	   rather	   than	   increased	   myofibre	   number	   (hyperplasia)	   (Rowe	   &	   Goldspink	  
1969).	   Myofibre	   number	   is	   believed	   to	   reach	   maximum	   value	   at	   birth	   and	   remains	   unchanged	  
throughout	  development	  into	  adulthood	  (Glass	  2005;	  Alnaqeeb	  &	  Goldspink	  1987;	  Rowe	  &	  Goldspink	  
1969).	   Adaptation	   of	   muscle	   mass	   to	   changing	   functional	   demands	   is	   a	   further	   fundamental	  
characteristic	  of	  skeletal	  muscle	  plasticity	  and	  as	  such,	  is	  of	  interest	  where	  research	  into	  preventing	  
muscle	  wasting	   is	   a	   priority.	   For	   example,	   further	   understanding	   of	   the	  mechanisms	   underpinning	  
muscle	   hypertrophy	   and	   atrophy	   is	   critical	   in	   cases	   of	   myopathology	   and	   other	   diseases,	   cancer,	  
sepsis,	  HIV/AIDS	  and	  prolonged	  inactivity,	  as	  a	  result	  of	  injury	  and	  ageing.	  	  
Increased	   muscle	   loading,	   for	   example	   through	   resistance	   training	   exercise,	   results	   in	   muscle	  
(compensatory)	  hypertrophy	  whereas,	  unloading	  or	  prolonged	  disuse	   leads	  to	  a	  decreased	  mass	  or	  
atrophy.	   Importantly,	   these	   increases	   in	   muscle	   mass	   can	   be	   attributed	   to	   increases	   in	   myofibril	  
number	  and	  size	  and	  are	  therefore,	  typically	  accompanied	  by	  a	  greater	  contractile,	  force-­‐generating	  
capacity	   and	   overall	   strength	   (Alnaqeeb	   &	   Goldspink	   1987;	   Degens	   &	   Alway	   2003).	   Muscle	  
hypertrophy	   has	   been	   studied	   extensively	   and	   can	   be	   achieved	   through	   surgical	   denervation	   of	  
surrounding	   muscle	   synergists	   (in	   small	   animals),	   as	   well	   as	   through	   resistance	   training	   exercise	  
(small	  animals	  and	  humans),	  among	  others	  (Degens	  et	  al.	  1992;	  Degens,	  Turek,	  et	  al.	  1993;	  Lowe	  &	  
Alway	  2002;	  Roman	  et	  al.	  1993;	  Welle	  et	  al.	  1996).	  Importantly,	  there	  are	  key	  differences	  in	  the	  type	  
of	   exercise	   and	   the	   resultant	   effects	   on	   the	   response	   and	   adaptability	   of	   skeletal	   muscle.	   For	  
example,	  resistance	  training	  brings	  about	  changes	  relating	  predominantly	  to	  increased	  muscle	  mass	  
through	  greatly	   increased	   levels	  of	   rapid	  protein	   synthesis.	  Whereas,	  endurance	  exercise	   results	   in	  
more	  long-­‐term	  adaptations,	  including	  myofibre	  type	  transitions	  from	  more	  glycolytic	  to	  those	  more	  
oxidative	   and	  mitochondrial	  mass	   increases	   (Baar	   2006).	   Thus	   in	   humans,	   high	   resistance	   training	  
through	  weight-­‐lifting	  exercise	  results	  in	  increases	  in	  the	  size	  of	  FOG	  (IIA)	  and	  FG	  (IIX/IIB)	  myofibres	  
(Prince	  et	  al.	  1976;	  Staron	  et	  al.	  1984).	  Contrastingly	  in	  the	  rat,	  intensive	  forelimb	  exercise,	  has	  been	  
shown	  to	  increase	  the	  proportion	  and	  hypertrophy	  of	  SO	  myofibres	  (Jaweed	  et	  al.	  1977).	  Insulin-­‐like	  
growth	   factor-­‐1	   (IGF-­‐1)	  mRNA	  expression	  has	  been	  shown	  to	   increase	   in	   response	   to	  overload	  and	  
stretch,	   resulting	   in	   hypertrophy	   (Yang	   et	   al.	   1997).	   Furthermore,	   the	   underlying	   regulation	   of	  
signalling	   mechanisms,	   modulated	   by	   resistance	   exercise,	   implicates	   the	   activity	   of	   insulin	   and	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GH/IGF-­‐1	   in	   stimulating	   the	   PI3K/AKT/mTORC2	   pathway	   in	   resistance	   training-­‐induced	   protein	  
synthesis,	   through	   downstream	   components	   including,	   4E	   binding	   proteins	   (4E-­‐BP),	   eukaryotic	  
initiation	  factor	  2	  (eIF2)	  and	  70kDa	  S6	  protein	  kinase	  (P70S6K1),	  believed	  to	  be	  the	  primary	  controls	  
of	   initiation	   (Glass	   2005;	   Baar	   2006)	   (Figure	   1.3).	   The	   PI3K/AKT/mTORC2	   pathway	   simultaneously,	  
inhibits	   protein	   degradation	   and	   autophagy	   signalling	   through	   the	   fork-­‐head	   box	  O	   (FOXO),	  whilst	  
promoting	   synthesis	   (Velloso	   2008).	   Moreover,	   the	   CaMK/MEF2	   and	   AMPK/PGC1α	   signalling	  
pathways	   are	   initiated	   through	   endurance	   exercise	   and	   are	   responsible	   for	   characteristic	   activity-­‐
induced	   myofibre	   transitions	   (from	   IIX	   to	   IIA	   and	   I)	   (Klitgaard,	   Bergman,	   et	   al.	   1990;	   Andersen	   &	  
Henriksson	  1977;	  Baar	  2006).	  	  
	  





Skeletal	  muscle	  is	  a	  highly	  adaptive	  tissue	  with	  very	  plastic	  cells	  regarding	  their	  size,	  where	  myofibres	  
can	   undergo	   hypertrophy	   in	   response	   to	   increased	   demand	   (Schwartz	   2008;	   Rowe	   &	   Goldspink	  
1969).	   Contrastingly,	   myofibres	   also	   undergo	   atrophy	   in	   response	   to	   stimuli	   such	   as	   during	  
sarcopenia,	   denervation,	   cachexia	   (cancer),	   sepsis,	   muscular	   diseases	   and	   alternatively,	   prolonged	  
disuse	  or	  inactivity	  (Lynch	  et	  al.	  2007).	  The	  mechanisms	  that	  control	  the	  balance	  between	  anabolism	  
and	   catabolism	   are	   those	   that	   regulate	   protein	   synthesis	   and	   degradation.	   A	   functional	   shift	   or	  
dysregulation	   in	   either	   direction	   can	   drive	   the	   counteracting	   pathway	   more	   strongly,	   to	   induce	  
overall	   outcomes	   of	   extensive	   hypertrophy	   or	   atrophy	   (Lynch	   et	   al.	   2007).	   A	   gross	   loss	   of	  muscle	  
mass	   is	  regulated	  by	  the	  following	  mechanisms,	  the	  first	   is	   the	  ubiquitin-­‐proteasome	  system	  (UPS),	  
which	   mediates	   signalling	   of	   ubiquitin	   ligases	   MuRF1	   and	   atrogin-­‐1,	   further	   regulated	   by	   the	  
PI3K/AKT	  pathway	  via	  FOXO,	  as	  well	  as	  the	  NF-­‐κB	  pathway	  (Glass	  2005;	  Schwartz	  2008).	  The	  second	  
is	   the	   autophagy/lysosome	   pathway,	   also	   coordinated	   by	   FOXO	   signalling	   (Bechet	   et	   al.	   2005;	  
Schwartz	   2008).	   Thirdly,	   the	  Ca2+-­‐dependent	   cysteine	  protease,	   calpain	  pathway	   (Bartoli	  &	  Richard	  
2005;	  Lynch	  et	  al.	  2007).	  Furthermore,	  TGF-­‐β	  family	  member,	  Myostatin	  is	  a	  key	  negative	  regulator	  of	  
muscle	   hypertrophy.	   Myostatin	   initiates	   cellular	   signalling	   by	   binding	   either	   of	   the	   type	   II	   activin	  
receptors	   (IIa	   or	   IIb),	   activating	   type	   I	   receptors	  ALK4	  or	  ALK5,	   formation	  of	   this	   receptor	   complex	  
results	  in	  phosphorylation	  of	  transcription	  factors,	  SMAD2	  and	  SMAD3,	  which	  in	  turn,	  translocate	  to	  
the	   nucleus,	   bringing	   about	   a	   reduction	   in	   protein	   synthesis	   and	   upregulation	   of	   degradation	  
(Egerman	  et	  al.	  2015).	  
Additionally,	  apoptosis	  is	  believed	  to	  play	  an	  important	  role	  in	  muscle	  atrophy	  and	  has	  been	  shown	  
to	   occur	   in	   the	   myonuclei,	   stromal	   cells	   as	   well	   as	   the	   satellite	   stem	   cell	   populations	   of	   skeletal	  
muscle	   (Schwartz	   2008;	   Wang	   et	   al.	   2014).	   However,	   there	   is	   evidence	   of	   a	   relatively	   consistent	  
myonuclear	   domain,	   a	   strictly	   regulated	   theoretical	   amount	   of	   cytoplasm	   supported	   by	   a	   single	  
myonucleus	   (optimum	   myonuclei	   to	   cytoplasm,	   DNA	   to	   protein	   ratio),	   despite	   fluctuations	   in	  
myofibre	  size	  (Dupont-­‐Versteegden	  2006).	  The	  mechanism	  that	  governs	  the	  reduction	  of	  myonuclei	  
during	  atrophy	  has	  been	  shown	  to	  resemble	  that	  of	  apoptosis,	  including	  characteristics	  of	  chromatin	  
condensation	   and	   DNA	   fragmentation.	   However,	   it	   is	   also	   believed	   that	   alternatively,	   this	   process	  
should	   be	   described	   as	   ‘apoptotic	   nuclear	   death’,	   as	   unlike	  mono-­‐nucleated	   cells,	  multi-­‐nucleated	  
myofibres	   do	   not	   appear	   to	   completely	   package	   up	   and	   clear	   all	   cellular	   contents	   (nuclear	   and	  
cytoplasmic)	  (Dupont-­‐Versteegden	  2005).	  This	  therefore	  suggests	  that	  unlike	  traditionally-­‐described	  
apoptosis,	  there	  appears	  to	  be	  a	  subset	  of	  myonuclei	  that	  are	  more	  susceptible	  to	  apoptotic	  stimuli	  
to	  reduce	  overall	  total	  myonuclei	  numbers	  per	  myofibre	  (Schwartz	  2008;	  Dupont-­‐Versteegden	  2005).	  
Apoptosis	  has	  been	  shown	  to	  be	  higher	  in	  Soleus	  muscles	  of	  aged	  rats,	  compared	  to	  young,	  indicated	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by	   TUNEL	   assays	   as	  well	   as	   increased	   caspase	   activity	   (Leeuwenburgh	  et	   al.	   2005).	   Furthermore,	   a	  
study	  conducted	   in	  mice	  also	   showed	   that	   there	  was	  a	  distinct	   rise	   in	  apoptosis	   in	  aged	  muscle.	  A	  
small	  proportion	  was	  identified	  as	  the	  myonuclei	  however,	  apoptosis	  appeared	  to	  be	  concentrated	  in	  
the	   stromal	   cells,	   endothelial	   cells	   of	   the	   capillary	   network,	   as	   well	   as	   the	   satellite	   stem	   cell	  
population	  (Wang	  et	  al.	  2014).	  
Collagen	  synthesis	  and	  degradation	  
Like	   the	  myofibres	   themselves,	   the	  surrounding	  ECM	   is	  highly	  complex	  and	  can	  adapt	  according	   to	  
mechanical	  and	  reparative	  demands.	  Mechanical	  loading	  begins	  a	  signalling	  cascade	  from	  molecular	  
gene	  expression,	  transcription,	  translation,	  as	  well	  as	  post-­‐translational	  modifications,	  to	  bring	  about	  
collagen	   synthesis	   and	   degradation	   (Yasuda	   et	   al.	   1996).	   TGF-­‐β	   and	   IGF-­‐1	   are	   among	   the	   growth	  
factors	  released	  during	  exercise	  and	  this	  is	  accompanied	  by	  an	  increased	  procollagen	  expression	  and	  
collagen	   synthesis	   (Yang	   et	   al.	   1997;	   Kjær	   et	   al.	   2009).	   Collagen	   is	   produced	   as	   a	   triple	   helical	  
polypeptide	   chain	   of	   procollagen	   by	   the	   fibroblasts	   (as	   well	   as	   SCs)	   in	   the	   ECM,	   where	   the	  
procollagens	   are	   cleaved	   by	   proteases	   and	   assembled	   into	   collagen	   fibrils.	   Post-­‐translational	  
modifications	   include	   enzymatic	   cross-­‐linking,	   known	   to	   be	   increased	   in	   ageing	   (Zimmerman	   et	   al.	  
1993;	   Haus	   et	   al.	   2007;	  Wood	   et	   al.	   2014).	   ECM	   component	   remodelling	   and	   degradation	   in	   both	  
physiological	   and	   pathological	   conditions	   is	   dependent	   on	   key	   matrix	   metalloproteinase	   (MMP)	  
activity.	  In	  the	  mdx	  mouse,	  MMP-­‐2,	  MMP-­‐9	  as	  well	  as	  tumour	  necrosis	  factor	  (TNF-­‐α)	  activities	  were	  
increased	  during	  degeneration-­‐associated	  ECM	  remodelling	  (Bani	  et	  al.	  2008).	  Additionally,	  increases	  
in	  Wnt	  signalling	  has	  been	  implicated	  in	  the	  increased	  proliferation	  of	  muscle	  resident	  stromal	  cells	  




Essential	  to	  life	  is	  the	  ability	  for	  tissues	  to	  undergo	  repair	  following	  damage,	  caused	  through	  injury,	  
disease	   or	   normal	   cellular	   turn-­‐over,	   with	   age.	   Regeneration	   typically	   involves	   the	   activation	   and	  
proliferation	   of	   quiescent	   stem	   cells	   located	   within	   their	   tissue-­‐specific	   stem	   cell	   niche,	   through	  
various	   extrinsic	   factors	   and	   intrinsic	   signalling	   pathways.	   A	   stem	   cell	   can	   be	   described	   as	   an	  
unspecialized	  cell,	  that	  retains	  the	  ability	  to	  divide	  indefinitely	  producing	  two	  daughter	  cells;	  with	  the	  
capability	  of	  remaining	  quiescent	  and	  thereby,	  contributing	  back	  to	  the	  stem	  cell	  pool	  in	  a	  process	  of	  
self-­‐renewal,	   or	   initiating	   differentiation	   towards	   a	   specific	   cellular	   lineage,	   regulated	   by	   certain	  
external	  signalling	  molecules	  (Weissman	  2000).	  
Mammalian	   skeletal	  muscle	   during	   adulthood,	   is	   a	   stable	   post-­‐mitotic	   tissue	  which,	   under	   normal	  
conditions,	  requires	  only	  periodic	  fusion	  of	  the	  resident	  stem	  cells,	  satellite	  cells	  (SCs),	  in	  response	  to	  
daily	   wear	   and	   tear,	   to	   compensate	   for	   overall	   muscle	   turnover.	   However,	   upon	   injury	   skeletal	  
muscle	   maintains	   a	   remarkable	   ability	   to	   regenerate	   damaged	   myofibres.	   The	   degeneration	   and	  
subsequent	   regeneration	   process	   is	   highly	   regulated	   at	   molecular,	   cellular	   and	   tissue	   levels	   and	  
results	   in	   renewal	   of	   contractile	   units,	   that	   are	   fully	   innervated	   and	   vascularised.	   This	   process	   is	  
highly	   reliant	   on	   SCs	   and	   the	   intrinsic	   factors	   that	   govern	   the	   underlying	   mechanisms	   of	   their	  
regenerative	  function,	  as	  well	  as	  the	  interactions	  with	  the	  muscle	  stem	  cell	  microenvironment	  (niche)	  
through	  extrinsic	  factors.	  The	  resident	  stem	  cell	  population	  of	  skeletal	  muscle,	  first	  termed	  ‘satellite	  
cells’	   by	   Alexander	  Mauro	   in	   1961,	   remain	   quiescent	   beneath	   the	   basal	   lamina	   until	   activated	   by	  
external	   cues,	   through	  muscle	   damage	   or	   stress	   conditions	   (Mauro	   1961;	   Beauchamp	   et	   al.	   2000;	  
Bischoff	  2004).	  Once	  activated,	  satellite	  cells	  then	  enter	  the	  cell	  cycle,	  proliferate,	  migrate	  and	  form	  
progenitor	   (myoblast)	   cells,	   that	  differentiate	   into	  myotubes	   then	   fuse,	   replace	  and	   incorporate	  or	  
support	   damaged	   muscle	   (Collins-­‐Hooper	   et	   al.	   2012;	   Yin	   et	   al.	   2013).	   SC	   proliferation	   and	  
differentiation	  during	  regeneration	  is	  also	  believed	  to	  be	  influenced	  by	  innervation,	  therefore	  activity	  
and	   exercise,	   the	   vasculature,	   hormones	   including	   testosterone	   and	   thyroid	   hormone,	   nutrition	   as	  
well	  as	  the	  tissue	  lesion	  following	  damage	  (Yin	  et	  al.	  2013).	  
Identification	  of	  the	  satellite	  cell	  as	  the	  regenerative	  component	  of	  skeletal	  
muscle	  
Importantly,	   it	   was	   Snow	   and	   colleagues	   that	   demonstrated	   that	   SCs	   contributed	   nuclei	   to	  
regenerating	  skeletal	  muscle	  and	  this	  was	  not	  carried	  out	  by	  the	  myofibres	  themselves	  (Snow	  1977;	  
Snow	  1977a).	  Development	  of	  an	   in	  vitro	   suspension	  culture	  system	  of	   individually	  dissected	  single	  
myofibres	   from	  rat	  hindlimb	  muscles,	  enabled	   the	  study	  of	   the	  origin	  and	  behaviour	  of	  SCs.	   It	  was	  
shown	   that	   SCs	   were	   induced	   to	   divide	   following	   myofibre	   dispersal	   and	   subsequently,	   SCs	   were	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identified	   as	   a	   viable	   highly	   proliferative	   cell	   population	   with	   the	   potential	   to	   be	   utilised	   in	  
regeneration	   in	  myopathologies,	   such	   as	  muscular	   dystrophies	   (Bischoff	   1975).	   It	  was	   later	   shown	  
that	  freshly	  isolated	  SCs	  expressed	  CD34	  and	  Myf5	  and	  it	  was	  suggested	  that	  these	  markers	  could	  be	  
responsible	  for	  maintaining	  SC	  quiescence	  (Beauchamp	  et	  al.	  2000).	  Although,	  more	  recently,	  Notch	  
signalling,	   through	   the	   SC-­‐specific	   deletion	   of	   recombining	   binding	   protein	   Jκ	   (RBP-­‐	   Jκ),	   has	   been	  
demonstrated	   as	   having	   an	   essential	   role	   in	  maintenance	   of	   quiescence	   in	   SCs	   and	   therefore,	   the	  
stem	   cell	   pool	   (Bjornson	   et	   al.	   2012).	   A	   further	   study	   showed	   that	  microRNA-­‐489	   suppressed	   the	  
oncogene,	  DEK,	  post-­‐transcriptionally,	  which	  similarly	   implicated	  microRNA-­‐489	   in	   the	  preservation	  
of	  SC	  quiescence	  (Cheung	  et	  al.	  2012).	  Moreover,	  manipulation	  of	  culture	  conditions,	  including	  serum	  
and	  growth	  factor	  deprivation,	  loss	  of	  cell	  adhesion	  and	  contact	  inhibition	  have	  been	  shown	  to	  drive	  
cells	   into	   quiescence,	   by	   arresting	   cell	   cycle	   progression	   in	   G1	   phase.	   These	   findings	   therefore,	  
indicate	  that	  SC	  quiescence	  is	  not	  only	  regulated	  by	  intrinsic	  mechanisms	  but	  also	  by	  the	  extracellular	  
microenvironment.	  
Satellite	  cell	  activation	  
Studies	   into	   the	   activation	  of	   SCs	   revealed	   that	   the	  external	   stimuli	   (mitogens),	  were	   shown	   to	  be	  
released	  from	  crushed	  skeletal	  muscles	  and	  subsequently	  were	  identified	  as	  growth	  factors,	  including	  
transforming	  growth	  factor	  beta	  (TGF-­‐β),	  fibroblast	  growth	  factor	  (FGF),	   insulin-­‐like	  growth	  factor-­‐1	  
(IGF-­‐1)	  and	  hepatocyte	  growth	  factor	  (HGF)	  (Bischoff	  1986a;	  Allen	  &	  Boxhorn	  1989;	  Allen	  et	  al.	  1995).	  
It	   was	   established	   that	   IGF-­‐1	   increases	   SC	   proliferation	   and	   differentiation	   through	   the	   myogenic	  
lineage,	   FGF	   additionally,	   increased	   proliferation	   and	   similarly	   to	   TGF-­‐	   β,	   was	   also	   shown	   to	   have	  
inhibitory	   effects	   of	   SC	   differentiation.	   The	   influence	   of	   the	   myofibre	   microenvironment	   and	   SC	  
niche,	  on	  SC	  activation,	  was	  first	  reported	  by	  Bischoff	  and	  colleagues,	  who	  observed	  that	  SCs	  on	  the	  
myofibre	  surface	  had	  a	  reduced	  mitogenic	  response	  compared	  to	  isolated	  cells	  (Bischoff	  1990).	  
Satellite	  cell	  origin	  and	  function	  in	  myogenesis	  
It	  is	  well-­‐known	  that	  the	  ‘Paired	  Box’	  (Pax),	  family	  of	  transcription	  factors	  play	  essential	  roles	  during	  
myogenesis	  (Treisman	  et	  al.	  1991;	  Mansouri	  et	  al.	  1996).	  Importantly,	  structurally	  homologous	  Pax3	  
and	  Pax7	  have	  differing	  functions	  during	  embryonic	  development.	  In	  the	  mouse	  and	  chick,	  both	  Pax3	  
and	  Pax7	  are	  expressed	   in	   the	  neural	   crest	   cells	  and	   throughout	   the	  embryonic	  dorsal	  neural	   tube	  
(Goulding	  et	  al.	  1991;	  Mansouri	  et	  al.	  1996).	  However,	  one	  key	  role	  of	  Pax3	  and	  Pax7	  genes	   is	   the	  
specification	  of	  myogenic	   stem	   cells,	  which	   enter	   the	  myogenic	   programme	  during	   embryogenesis	  
and	  foetal	  development	  (Relaix	  et	  al.	  2005).	  Pax3	  and	  Pax7-­‐positive	  skeletal	  muscle	  progenitor	  cells,	  
derived	  from	  the	  central	  dermomyotome	  region	  of	  somites,	  activate	  myogenic	  regulatory	  genes	  and	  
differentiate	   into	   skeletal	  muscle	  myofibres	   or	   form	   the	   proliferating	   cell	   population,	   that	   in	   late-­‐
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stage	   foetal	  muscle,	   are	   believed	   to	   adopt	   a	   SC	   position	   (Ben-­‐Yair	   2005;	   Gros	   et	   al.	   2005;	   Kassar-­‐
Duchossoy	   et	   al.	   2005;	   Relaix	   et	   al.	   2005).	   This	   therefore,	   suggests	   that	   this	   population	  of	   somite-­‐
derived	  cells	  also	  provides	  the	  SCs	  of	  postnatal	  skeletal	  muscle	  (Gros	  et	  al.	  2005).	  Pax3	  is	  crucial	  for	  
the	   survival	  of	   the	  progenitor	   cells,	   located	  at	   the	  edges	  of	   the	  dermomyotome	   (particularly	   those	  
positioned	   hypaxially),	   where	   Pax3	   is	   required	   for	   delamination	   and	   subsequent	   migration	   of	  
progenitor	   cells	   to	   sites	   of	   skeletal	   muscle	   formation,	   for	   example	   the	   limbs	   (Franz	   et	   al.	   1993;	  
Goulding	   et	   al.	   1994).	   Furthermore,	   Pax3,	   together	   with	   Myf5	   has	   been	   shown	   to	   regulate	   the	  
activation	  of	  MyoD	  (Tajbakhsh	  et	  al.	  1997).	  However,	  Pax7	  is	  the	  predominant	  paralogue	  expressed	  
in	  adult	  human	  primary	  myoblasts,	  suggesting	  that	  despite	  structural	  similarities	  between	  Pax3	  and	  
Pax7	   proteins,	   the	   differential	   spatial-­‐temporal	   patterns	   of	   expression	   indicates	   that	   they	   regulate	  
myogenesis	  in	  distinctly	  different	  cell	  types	  during	  development.	  Moreover,	  Seale	  and	  colleagues	  did	  
not	  detect	  SCs	  in	  Pax7-­‐null	  mice,	  thereby	  suggesting	  that	  Pax7	  plays	  a	  crucial	  role	  in	  specification	  of	  
the	  SC	  lineage	  in	  vertebrates	  (Seale	  et	  al.	  2000).	  Pax3	  is	  shown	  to	  be	  expressed	  in	  a	  small	  subset	  of	  
the	  adult	  SC	  population,	  which	  includes	  the	  diaphragm	  and	  50%	  of	  the	  forelimb	  muscles.	  However,	  
the	  majority	  of	  the	  hindlimb	  musculature	  is	  negative	  for	  Pax3	  and	  a	  downregulation	  of	  Pax3	  has	  been	  
noted	  in	  the	  hindlimb	  during	  foetal	  development	  (Otto	  et	  al.	  2006;	  Relaix	  et	  al.	  2006).	  
Throughout	   the	   myogenesis	   process,	   in	   adult	   skeletal	   muscle	   regeneration,	   markers	   of	   myogenic	  
lineage	  are	  expressed	  in	  a	  step-­‐wise	  fashion	  during	  cell	  differentiation,	  beginning	  with	  the	  expression	  
of	  Pax7,	  a	  marker	  of	  satellite	  stem	  cell	  quiescence	  (Seale	  et	  al.	  2000;	  Zammit,	  Relaix,	  et	  al.	  2006).	  Co-­‐
expressed	   is	   Myf5	   (myogenic	   factor	   5)	   and	   following	   SC	   activation	   and	   determination	   towards	   a	  
myogenic	   lineage,	   sequential	   expression	   of	   other	   muscle-­‐specific	   basic	   helix-­‐loop-­‐helix	   (bHLH)	  
transcription	   factor	   (TF)	   proteins,	   belonging	   to	   the	   myogenic	   regulatory	   factor	   (MRF)	   family,	   is	  
initiated	   (Beauchamp	   et	   al.	   2000;	   Funk	   et	   al.	   1991).	   These	   factors	   include	   the	   ‘master	   regulatory	  
gene’,	   MyoD	   (myogenic	   differentiation	   protein	   1)	   and	   Myogenin	   and	   expression	   leads	   to	   the	  
formation	  of	  mature	  muscle	  cells	  (Funk	  et	  al.	  1991;	  Tapscott	  2005;	  Weintraub	  et	  al.	  1989;	  Grounds	  et	  
al.	  1992)	   (Figure	  1.4).	  However,	   it	  has	  also	  been	  shown	  that	   the	  SC	  population	   is	  heterogenous,	  as	  
subsets	   of	   SCs	   are	   known	   to	   divide	   asymmetrically	   and	   adopt	   divergent	   fates.	   SCs	   that	   co-­‐express	  
Pax7	  and	  MyoD,	  downregulate	  Pax7	  move	  towards	  terminal	  differentiation.	  However,	  other	  subsets	  
appear	   to	   alternatively,	   downregulate	  MyoD	   expression,	  maintaining	   Pax7	   and	  withdraw	   from	   cell	  
cycle,	   retaining	   a	   state	   of	   quiescence	   and	   thereby,	   replenishing	   the	   stem	   cell	   pool	   (Zammit	   et	   al.	  
2004;	  Nagata	  et	  al.	  2006).	  
The	  Wnt/β-­‐catenin	   signalling	   pathway	  has	   been	  established	   as	   a	   key	   regulator	   of	   cell	   proliferation	  
and	   lineage	  specification.	  Exogenous	  Wnt	   ligands,	  particularly	  Wnt1,	  Wnt3a	  and	  Wnt5a,	  have	  been	  
shown	   to	  be	  expressed	   in	  both	   the	   regenerating	  myofibre	  and	  SC	  population	  and	   therefore,	   it	  has	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been	   proposed	   that	   this	   signalling	   is	   important	   for	   SC	   proliferation	   during	   muscle	   regeneration	  
processes	  (Otto	  et	  al.	  2008).	  Additionally,	  Notch	  signalling	  is	  known	  to	  be	  important	  in	  the	  control	  of	  
cell	  proliferation,	  differentiation	  and	  cell	  fate	  determination	  (Artavanis-­‐Tsakonas	  et	  al.	  1999).	  Notch	  
signalling	   is	   initiated	   by	   the	   binding	   of	   Delta	   and	   Jagged	   ligands	   to	   the	   Notch	   transmembrane	  
receptors,	  which	   through	  a	   subsequent	  enzymatic	   receptor	   cleavage,	   forms	   the	  Notch	   intracellular	  
domain	   (NICD)	   and	   activation	   leads	   to	   NICD	   translocation	   to	   the	   nucleus,	   for	   targeted	   gene	  
expression	   (Artavanis-­‐Tsakonas	   et	   al.	   1999).	   Notch	   regulation	   in	   skeletal	   muscle	   regeneration	  
functions	  as	  a	   response	  to	  muscle	   injury,	  where	  the	  Delta	   ligand	   is	   rapidly	  upregulated	   in	  both	  the	  
myofibres	   and	   activated	   SCs,	   resulting	   in	   the	   initiation	   of	   SC	   proliferation.	   Subsequent	   Notch	  
inactivation,	   through	   the	   upregulation	   of	   the	   antagonist,	   Numb,	   enables	   differentiated	   myoblast	  
fusion,	  as	  the	  final	  step	  in	  myofibre	  repair.	  Interestingly,	  as	  SCs	  are	  known	  to	  divide	  asymmetrically,	  
producing	  two	  daughter	  cells	  with	  divergent	  fates,	  Numb	  was	  also	  localised	  asymmetrically,	  resulting	  
in	  daughter	  cells	  with	  different	  levels	  of	  Numb.	  Therefore,	  it	  is	  postulated	  that	  this	  feature	  supports	  
regulation	  of	  divergent	  SC	   fates	   (Conboy	  &	  Rando	  2002).	  Moreover,	  activation	  of	  Wnt	   signalling	   in	  
differentiating	   myoblasts	   antagonises	   Notch	   signalling	   and	   supports	   terminal	   differentiation,	  
indicating	   a	   large	   degree	   of	   cross-­‐talk	   interactions	   between	   these	   two	   well-­‐defined	   regulatory	  
mechanisms	  (Yin	  et	  al.	  2013).	  
	  
Figure	  1.4	  Satellite	  cell	  markers	  expressed	  during	  myogenesis	  (Zammit,	  Partridge,	  et	  al.	  2006).	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Studies	   investigating	   the	   differentiation	   capacity	   of	   SCs	   by	   induction	   towards	   other	   lineages,	  
alternative	   to	   myogenic	   specification	   (including	   adipogenic	   and	   osteogenic	   pathways),	   have	  
suggested	   that	   SCs	   share	   multipotential	   mesenchymal	   stem	   cell	   activity	   (Asakura	   et	   al.	   2001;	   De	  
Coppi	  et	  al.	  2006).	  Furthermore,	   it	  was	  shown	  that	   the	  potential	   therapeutic	  effects	  of	   the	   in	  vitro	  
culture	  and	  transplantation	  of	  isolated	  skeletal	  muscle-­‐derived	  (CD34+/45-­‐)	  stem	  cells	  (Sk-­‐34),	  in	  the	  
rejuvenation	  of	  damaged	  vascular,	  muscular	  and	  peripheral	  nervous	  systems,	  was	  due	  to	  their	  vast	  
differentiation	  capacity	  (Tamaki	  et	  al.	  2005;	  Tamaki	  et	  al.	  2007).	  Furthermore,	  the	  use	  of	  SCs/primary	  
myoblasts	   in	   transplantation	   experiments	   to	   supplement,	   support	   or	   alleviate	   degeneration	   in	  
skeletal	  muscle	  in	  disease	  (such	  as	  Duchenne	  Muscular	  Dystrophy,	  DMD	  or	  ischaemic	  heart	  disease),	  
following	   a	   myocardial	   infarction,	   or	   muscular	   injury,	   remains	   a	   potential	   candidate	   in	   cell-­‐based	  
therapy	   (Partridge	   2000;	   Hagege	   et	   al.	   2001;	   LaFramboise	   et	   al.	   2003).	   This	   is	   despite	   relatively	  
limited	  success	   thus	   far,	  due	   to	  a	   large	  proportion	  of	   transplanted	  cells	  dying	   in	   the	   first	  3	  days	  of	  
introduction	   into	  the	  host	   tissue,	  surviving	  myoblasts	  are	  rejected	  through	  an	   immune	  response	  or	  
do	  not	  migrate	  further	  than	  200µm	  away	  from	  the	  site	  of	   injection	  (Siegel	  et	  al.	  2009;	  Péault	  et	  al.	  
2007).	   However,	   it	   is	   in	   general	   agreement	   that	   for	  more	   successful	   cell-­‐based	   therapy,	   there	   is	   a	  
requirement	  for	  more	  effective	  dispersal	  and	  engraftment	  of	  injected	  cells	  (Siegel	  et	  al.	  2009).	  
The	  underlying	  mechanisms	  of	  satellite	  cell	  migration	  
The	   traditionally-­‐defined	   mechanism	   of	   cell	   migration	   is	   the	   lamellipodia-­‐based	   method,	   usually	  
described	   as	   the	   ‘crawling’	   of	   cells	   through	   the	   extracellular	   matrix	   (ECM).	   This	   process	   occurs	  
through	  the	  actin-­‐polymerization-­‐driven	  extension	  and	  branching	  of	  plasma	  membrane	  protrusions	  
(lamellipodia)	   from	   the	   leading	   edge	   of	   a	   migrating	   cell	   and	   the	   myosin	   II-­‐mediated	   contraction	  
behind	   the	   cell	   body,	   at	   the	   ‘lagging’	   end	   (Small	   et	   al.	   2002;	   Tyson	   et	   al.	   2014;	   Yoshida	  &	   Soldati	  
2006).	   In	   order	   to	   aid	   the	   ‘traction’	  movement	   generated	   by	   the	   cell,	   focal	   adhesion	   contacts	   are	  
made	  with	  the	  substratum/ECM	  as	  lamellipodia	  extend	  from	  the	  leading	  edge	  and	  these	  are	  broken	  
down	   at	   the	   back	   as	   the	   cell	   progresses	   forward	   (Alberts	   et	   al.	   2008).	   Recently	   however,	   an	  
alternative,	  ‘novel’	  mechanism	  for	  migration	  has	  been	  described	  in	  satellite	  cells	  and	  this	  is	  mediated	  
via	  plasma	  membrane,	  vesicle-­‐like	  ‘blebs’	  contributing	  visually	  to	  ‘amoeboid-­‐like’	  behaviour	  (Otto	  et	  
al.	   2011).	   The	   bleb-­‐based	   mechanism	   is	   initiated	   through	   local	   hydrodynamic	   modifications	   in	  
cytosolic	   pressure,	   simultaneous	   weakening	   of	   the	   cortex	   and	   subsequent	   detachment	   from	   the	  
plasma	  membrane.	   Localized	   ruptures	   of	   the	   cortex	   are	   created	   and	   expansion	   of	   the	  membrane	  
results	  in	  the	  protrusion	  of	  spherical	  ‘bleb’	  structures	  and	  migration	  has	  been	  shown	  to	  be	  affected	  
by	  the	  age	  of	  the	  satellite	  cell	  (Charras	  et	  al.	  2005;	  Charras	  &	  Paluch	  2008;	  Collins-­‐Hooper	  et	  al.	  2012;	  
Bergert	  et	   al.	   2012).	   The	  blebbing	  process	  or	   ‘lifespan’	   can	  be	   subdivided	   into	   three	  main	   ‘phases’	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including	   bleb	   initiation,	   stabilization	   and	   retraction	   (Tinevez	   et	   al.	   2009).	   Both	  mechanisms	   have	  
been	   shown	   to	   be	   implemented	   by	   the	   satellite	   cell	   and	   there	   is	   variation	   in	   migration	   speeds	  
dependent	  on	  which	  method	  is	  adopted,	  with	  the	  lamellipodia-­‐based	  motility	  occurring	  at	  a	  reduced	  
rate	   compared	   to	   blebbing	   (Otto	   et	   al.	   2011).	   As	   well	   as	   this,	   activated	   satellite	   cells	   have	   been	  
observed	   traveling	   beneath	   the	   surface	   laminin	   layer	   of	  myofibres	   via	   the	   traditional	   lamellipodia-­‐
driven	  form	  but	  tend	  to	  assume	  the	  faster	  blebbing	  method,	  once	  having	  emerged	  through	  this	  layer,	  
to	  migrate	  along	  the	  surface	  of	  myofibres	  (Otto	  et	  al.	  2011).	  
It	   is	   now	   widely	   believed	   that	   the	   Rac	   and	   Rho	   small	   GTPase	   signalling	   pathways	   function	  
antagonistically	   and	   are	   responsible	   for	   the	   regulation	   of	   cellular	   migration	   mechanisms	   (Sanz-­‐
Moreno	  et	  al.	  2011).	  Herein,	  Rac	  initiates	  extension	  of	  lamellipodia	  protrusions	  from	  the	  leading	  edge	  
of	  a	  migrating	  cell	  and	  therefore	  inhibition	  of	  Rac	  activity	  prevents	  this	  form	  of	  movement,	  whereas	  
Rho	  and	  associated	  Cdc42	  pathway	  interactions	  regulate	  amoeboid/bleb-­‐based	  motility	  (Calvo	  et	  al.	  
2011;	   Charras	   &	   Paluch	   2008;	   Nelson	   2008;	   Sanz-­‐Moreno	   et	   al.	   2011).	   Rac	   and	   Rho	   proteins	   are	  
constituents	  of	  subfamilies	  within	  the	  larger	  Ras	  superfamily	  of	  GTP	  hydrolases	  (Nelson	  2008;	  Ridley	  
&	  Hall	  1992;	  Ridley	  &	  Hall	  1994).	  GTPases	  have	  been	  described	  as	  ‘molecular	  switches’	  and	  function	  
through	   the	   binding	   of	   guanosine	   diphosphate	   (GDP)	   or	   guanosine	   triphosphate	   (GTP)	   resulting	   in	  
conformational	   changes	   in	   shape	   to	   alternate	   between	   an	   inactive	   and	   active	   state	   (Bustelo	   et	   al.	  
2007;	   Jaffe	   &	   Hall	   2005;	   Pollard	   et	   al.	   2007).	   Regulation	   of	   GTPase	   activity	   is	   controlled	   by	   GEFs	  
(guanine	  nucleotide	  exchange	   factors)	   and	  GAPs	   (GTPase	  activating	  proteins);	   the	   former	  activates	  
GTPases	   by	   exchange	  of	  GDP	   for	  GTP	   and	   the	   latter	   (GAPs),	   initiate	   breakdown	  of	   the	   bound	  GTP	  
molecule	  through	  hydrolysis	  and	  thereby	  reverts	  the	  protein	  back	  to	  its	  inactive	  state	  (Alberts	  et	  al.	  
2008;	  Bustelo	   et	   al.	   2007).	  On	  activation,	   interactions	  with	  other	  downstream	   signalling	  molecules	  
through	   particular	   signalling	   cascades	   and	   effector	   proteins	   are	   initiated	   in	   response.	   These	   bring	  
about	   regulation	   of	   specific	   cellular	   events	   including	   cell	   polarity,	   cytoskeleton	   organization,	   cell	  
migration,	  progression	  and	  regulation	  of	  the	  cell	  cycle	  and	  transcription	  (Bustelo	  et	  al.	  2007).	  
Three	   human	   isoforms	   of	   Rho	   (RhoA,	   B	   and	   C),	   two	   Rac	   isoforms	   (Rac1	   and	   2)	   and	   Cdc42	   were	  
identified	  as	  distinct	  branches	  of	  the	  Ras	  superfamily	  and	  studies	  began	  into	  the	  apparent	  differences	  
in	  function	  between	  the	  members,	  despite	  sharing	  a	  large	  amount	  of	  homology	  in	  their	  GTP	  binding	  
sites	  (Chardin	  1988;	  Madaule	  &	  Axel	  1985).	  In	  the	  early	  1990s,	  recombinant	  RhoA	  studies	  resulted	  in	  
alterations	   in	  fibroblast	  cell	  morphology	  and	  speculation	  as	  to	  the	  function	  of	  Rho	  in	  actin	  filament	  
organization	   and	   formation	   of	   stress	   fibres	   and	   focal	   adhesions	   was	   investigated	   (Paterson	   et	   al.	  
1990;	   Ridley	   &	   Hall	   1992).	   Similar	   experiments	   involving	   Rac1	   were	   then	   conducted	   and	   these	  
suggested	  that	  Rac	  plays	  a	  role	  in	  plasma	  membrane	  ‘ruffling’,	  as	  well	  as	  lengthening	  of	  lamellipodia	  
protrusions	  from	  the	  cell	  surface	  (Ridley	  et	  al.	  1992).	  Further	  investigation	  revealed	  that	  interactions	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between	  the	  Rac	  and	  Rho	  GTPase	  signalling	  pathways	  were	  common	  and	  ‘cross-­‐talk’	  at	  many	  levels,	  
between	   multiple	   downstream	   proteins,	   also	   occurred	   frequently	   (Ridley	   2001).	   A	   number	   of	  
chemical	  inhibitors	  have	  been	  developed	  to	  target	  particular	  members	  of	  the	  Rho	  family	  GTPases	  and	  
associated	  downstream	  effector	  proteins.	  Inhibition	  is	  a	  useful	  tool	  in	  cell	  signalling	  investigation,	  as	  
roles	  of	  specific	  target	  proteins	  and	  their	  interactions	  within	  a	  pathway,	  can	  be	  determined	  through	  
experimentation	   where	   the	   function	   is	   hindered	   or	   prohibited.	   This	   is	   achieved	   by	   observing	   the	  
effect	  on	  particular	  cellular	  processes,	  through	  the	  blocking	  or	   ‘knocking-­‐down’	  of	  constituents	   in	  a	  
pathway,	  in	  order	  to	  effectively	  observe	  what	  function	  is	  ‘missing’	  or	  impaired.	  For	  example,	  studies	  
currently	   being	   carried	   out	   by	   Marshall	   et	   al.	   involve	   in	   vivo	   experimentation	   and	   tissue	   culture	  
assays,	  to	  observe	  the	  two	  mechanisms	  of	  migration	  in	  tumour	  cells,	   in	  order	  to	  better	  understand	  
cancer	   cell	   invasion	   and	   metastasis	   (Ahn	   et	   al.	   2012;	   Sanz-­‐Moreno	   et	   al.	   2011).	   Similarly,	   in	  
understanding	  how	  these	  signalling	  pathways	  function,	  it	  is	  possible	  to	  manipulate	  the	  cell	  migration	  
mechanisms	   utilised	   by	   a	   particular	   cell	   type	   in	   vitro.	   Importantly,	   this	   in	   turn,	   enables	   the	  
observation	  of	  the	  effects	  that	  this	  has	  on	  cell	  speed,	  overall	  movement,	  directionality,	  morphology	  
and	   importantly,	  as	  with	  SCs,	  how	  these	   impact	  on	  muscle	  regeneration	   in	  general.	   In	  recent	  years	  
however,	   it	   is	   evident	   from	   the	   literature,	   that	   there	   has	   been	   a	   switch	   in	   focus	   towards	   studies	  
involving	   the	   investigation	   into	   properties	   of	   the	   stem	   cell	   microenvironment	   or	   ‘niche’	   and	  
extracellular	  matrix	  (ECM),	  in	  order	  to	  better	  understand	  their	  impacts	  on	  cell	  behaviour	  (migration,	  
morphology,	   differentiation	   and	   proliferation).	   Thus,	   it	   is	   postulated	   that	   different	   cell	   types	   are	  
governed	   by	   the	   same	   molecular	   regulation,	   regarding	   their	   adaptability	   and	   response	   to	   the	  
microenvironment,	  to	  facilitate	  different	  methods	  of	  motility.	  
The	  satellite	  cell	  extracellular	  matrix	  
In	  direct	  contact	  with	   the	  SCs,	   is	  a	  network	  of	  ECM	  components,	  such	  as	   type	   IV	  collagen,	   laminin,	  
fibronectin	   and	   glycoproteins,	   that	   constitute	   the	   myofibre	   basal	   lamina,	   separating	   the	   SC	  
population	   from	   the	   muscle	   interstitium	   (Sanes	   2003).	   These	   molecules	   are	   predominantly	  
synthesised	  and	  secreted	  by	  interstitial	  fibroblasts,	  but	  SCs	  and	  myoblasts	  are	  also	  known	  to	  produce	  
and	   remodel	   these	  components	  during	   regeneration	   (Kovanen	  2002).	  SCs	  are	   located	  between	   the	  
basal	   lamina,	   which	   comprises	   a	   network	   of	   collagen	   IV	   and	   the	   sarcolemma	   (apical),	   covered	   in	  
laminin	   (Woodley	   et	   al.	   1983;	   Collins	   et	   al.	   2007).	   The	   ECM	   network	   provides	   the	   myofibre	   with	  
mechanical	  support,	  physical	  strength	  and	  elasticity,	  as	  well	  as	   importantly,	  enabling	  binding	  of	  SCs	  
and	  other	  interstitial	  cells,	  for	  cell	  to	  cell	  and	  cell	  to	  ECM	  communication,	  for	  mechano-­‐sensing	  and	  
internal	   signal	   transduction.	   For	   example,	   α7/β1-­‐integrin	   binding	   sites	   are	   presented	   by	   the	   basal	  
lamina,	   for	   the	   physical	   tethering	   of	   the	   internal	   actin	   cytoskeleton	   of	   SCs,	   to	   the	   ECM	   for	   the	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molecular	   communication	   (Song	   et	   al.	   1992;	   Burkin	   &	   Kaufman	   1999;	   Mayer	   2003).	   Additionally,	  
muscle-­‐specific	  laminins	  (laminin-­‐2	  and	  -­‐4),	  interact	  with	  the	  myofibre	  surface	  through	  integrins	  and	  
dystroglycan	   (Gullberg	   et	   al.	   1999;	   Sanes	   2003).	   Moreover,	   essential	   for	   the	   initiation	   of	   a	   rapid	  
response	   to	   muscle	   injury,	   proteoglycans	   situated	   on	   the	   surface	   of	   SCs,	   act	   as	   receptors	   in	   the	  
binding	  of	  inactive	  growth	  factor	  precursors	  in	  resting,	  undamaged	  muscle.	  These	  precursors	  include	  
hepatocyte	   growth	   factor	   (HGF),	   basic	   fibroblast	   growth	   factor	   (bFGF),	   epidermal	   growth	   factor	  
(EGF),	   insulin-­‐like	   growth	   factor	   isoforms	   (IGF-­‐I	   and	   IGF-­‐II),	   as	   well	   as	   Wnt	   glycoproteins	   and	   are	  
believed	  to	  be	  sequestered	  from	  SCs,	  myofibres,	  interstitial	  cells	  or	  serum	  (Yin	  et	  al.	  2013;	  Tatsumi	  et	  
al.	   1998;	   Golding	   et	   al.	   2007;	  Machida	  &	   Booth	   2004;	   Brack	   et	   al.	   2008).	   Upon	   injury,	   proteolytic	  
enzymes,	   such	   as	   thrombin,	   serine	   proteases	   and	   matrix	   metalloproteinases	   (MMPs),	   present	   in	  
serum	   or	   the	   interstitium,	   rapidly	   activate	   the	   growth	   factor	   precursors.	   HGF	   functions	   during	   SC	  
activation,	  migration	  and	  proliferation	  (Allen	  et	  al.	  1995;	  Tatsumi	  et	  al.	  1998;	  Miller	  et	  al.	  2000).	  For	  
example,	   HGF	   has	   been	   shown	   to	   increase	   aged	   SC	   migration	   speeds	   along	   myofibres	   in	   culture	  
(Collins-­‐Hooper	  et	  al.	  2012).	  FGFs	  found	  in	  skeletal	  muscle	  have	  been	  associated	  with	  the	  stimulation	  
of	  myoblast	  proliferation	  and	  myogenic	  lineage	  progression	  and	  are	  also	  known	  to	  contribute	  to	  the	  
regeneration	   process	   through	   their	   well-­‐defined	   roles	   in	   angiogenesis	   (Allen	   &	   Boxhorn	   1989;	  
Kästner	   et	   al.	   2000;	   Floss	   et	   al.	   1997;	   Lefaucheur	   et	   al.	   1996).	   IGF	   signalling	   is	   highly	   linked	   with	  
protein	   synthesis	   and	   myofibre	   hypertrophy	   and	   therefore,	   as	   hypertrophy	   involves	   the	  
supplementation	  of	  myonuclei	  as	  the	  muscle	  grows,	  SCs	  are	  also	  activated	  by	  IGF	  signalling	  (Bark	  et	  
al.	   1998;	   Barton-­‐Davis	   et	   al.	   1999;	  Musarò	   et	   al.	   1999;	   Philippou	   et	   al.	   2007).	  MMPs,	   comprise	   a	  
family	  of	  zinc-­‐dependent	  enzymes	  responsible	  for	  the	  degradation	  of	  ECM	  components	  that	  function	  
in	   both	   the	   degenerative	   and	   subsequent	   regenerative	   phases	   in	   damaged	   muscle	   (in	   particular	  
MMP-­‐2	   and	  MMP-­‐9)	   (Carmeli	   et	   al.	   2004;	   Kherif	   et	   al.	   1999).	   Additionally,	   activated	  MMP-­‐2	   and	  
MMP-­‐9	  are	  known	  to	  degrade	  collagen	   IV	   in	  the	  muscle	  ECM,	  enabling	  SCs	  to	  emerge	  and	  migrate	  
across	  the	  basement	  membrane	  to	  the	  lesion	  site	  (Nishimura	  et	  al.	  2008).	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Hallmarks	  of	  ageing	  
The	   Oxford	   English	   Dictionary	   definition	   of	   ageing	   describes	   this	   as	   ‘the	   process	   of	   growing	   old’	  
however	   from	  a	  biological	   standpoint,	   the	   following	  definition	  was	  proposed	   in	  1991:	   ‘a	  persistent	  
decline	   in	   the	   age-­‐specific	   fitness	   components	   of	   an	   organism	   due	   to	   internal	   physiological	  
deterioration’	  (Rose	  1991).	  The	  phrase	  ‘internal	  physiological	  deterioration’	  has	  been	  used	  extremely	  
broadly	  here	  and	  importantly,	  it	  is	  what	  drives	  this	  process	  that	  is	  yet	  unknown	  and	  has	  the	  attention	  
of	  a	  large	  proportion	  of	  the	  regenerative	  medicine	  research	  field.	  It	  is	  well	  documented	  that	  there	  is	  
an	   age-­‐related	   degeneration	   in	   satellite	   stem	   cell	   number	   and	   function	   with	   the	   mechanisms	  
underpinning	   these	   declines	   remaining	   an	   area	   still	   poorly	   understood.	   It	   is	   apparent	   from	   the	  
literature	   that	   ageing	   is	   almost	   considered	   a	   pathology	   in	   itself	   and	   therefore	   something	   that	   is	  
potentially	   treatable.	   In	  2013,	   Lopéz-­‐Otín	  and	  colleagues	  published	  a	   review	  enumerating	   the	  nine	  
hallmarks	  of	  ageing,	  taking	  a	  similar	  format	  to	  the	  2000	  review	  entitled	  ‘The	  Hallmarks	  of	  Cancer’	  by	  
Hanahan	  and	  Weinberg	   (López-­‐otín	  et	  al.	  2013;	  Hanahan	  &	  Weinberg	  2000)	   (Figure	  1.5).	  Hallmarks	  
discussed	   in	   the	   2013	   review	   included	   ‘stem	   cell	   exhaustion’,	   ‘genomic	   instability’,	   ‘cellular	  
senescence’	  and	   ‘telomere	  attrition’	  and	   therefore	  describes	  how	  ageing	   is	  appreciated	  as	  a	  multi-­‐
stage	   pathology	   that	   can	   be	   potentially	   measured	   and	   assayed	   in	   vitro,	   as	   well	   as	   within	   animal	  
models	   at	   various	   levels,	   for	   example,	   this	   study	   provides	   a	   wide	   spectrum	   of	   characteristics	   for	  
detailed	  analysis	  at	  the	  molecular	  and	  cellular	  levels,	  where	  the	  effects	  of	  ageing	  begin	  (López-­‐otín	  et	  
al.	  2013).	  
	  




Modern	  biological	  theories	  of	  ageing	  
Modern	  biological	   theories	  of	  ageing	  broadly	   fall	   into	  two	  main	  categories:	  1.	  Programmed	  (death)	  
theory	  and	  2.	  Damage	  or	  error	  (error	  accumulation)	  theories	  and	  these	  discuss	  where	  ageing	  begins	  
at	  the	  core,	  on	  a	  molecular	  level.	  
The	   programmed	   theory	   contains	   three	   sub-­‐categories	   that	   includes	   ‘programmed	   longevity’	  
whereby	  ageing	  is	  the	  result	  of	  sequential	  switching	  on	  and	  off	  of	  certain	  genes,	  defining	  senescence	  
(organism)	   as	   the	   point	   where	   age-­‐related	   degeneration	   arises.	   This	   theory	   encompasses	   genetic	  
instability	   as	   a	   hallmark	   of	   ageing	   discussed	   in	   the	   review	   by	   Lopéz-­‐Otín	   and	   colleagues	   in	   2013.	  
Secondly,	   the	   ‘endocrine	   theory’	   describes	   how	   hormones	   control	   ageing	   progression	   through	   the	  
idea	  of	  a	  ‘biological	  clock’.	  For	  example	  the	  IGF-­‐1/insulin	  signalling	  (IIS)	  pathway	  has	  been	  implicated	  
in	  the	  hormonal	  monitoring	  of	  the	  ageing	  process.	  Thirdly,	  the	  ‘immunological	  theory’	  indicates	  that	  
the	   gradual	   weakening	   of	   the	   immune	   system	   with	   age	   increases	   susceptibility	   to	   infection	   and	  
disease,	  ageing	  and	  death.	  
The	  damage/error	  theory	  can	  be	  sub-­‐divided	  into	  five	  categories	  beginning	  with	  the	  ‘wear	  and	  tear	  
theory’	  first	  described	  by	  Weismann	  in	  1882	  (reviewed	  by	  Rose	  1991)	  as	  the	  process	  of	  cellular	  and	  
tissue	   components	   gradually	   wearing	   with	   time	   through	   their	   repeated	   use.	   The	   ‘(Pearl’s)	   rate	   of	  
living	   theory’	   suggests	   that	   the	   quicker	   the	   rate	   of	   an	   organism’s	   oxygen	   basal	   metabolism,	   the	  
shorter	  the	   lifespan	  and	  therefore	  provides	   initial	   foundations	  to	  the	  oxidative	  stress	  theory	  that	   is	  
widely	   accepted	   as	   a	   major	   contributing	   factor	   to	   the	   overall	   ageing	   process	   and	   is	   considered	   a	  
further	  hallmark	  of	  ageing.	  However,	   some	  argue	  this	  does	  not	   fully	  explain	   the	  maximum	   lifespan	  
and	  has	  since	  been	  altered	  to	  take	  into	  account	  features	  including	  the	  variation	  of	  fatty	  acid	  content	  
of	  cell	  membranes	  between	  species	  and	  some	  show	  how	  rapamycin	  (TOR)	  and	  forkhead	  transcription	  
factors	   (FOXO)	   could	   be	   implicated	   in	   promoting	   longevity	   through	   growth	   and	   stress	   resistance	  
pathways	  (Hulbert	  et	  al.	  2007;	  Rollo	  2010).	  
The	  rate	  of	  living	  theory	  along	  with	  the	  ‘free	  radical	  theory’	  similarly,	  depend	  on	  the	  oxidative	  stress	  
theory	  as	  a	  basis.	  The	  free	  radical	  theory	  specifically,	  includes	  damage	  to	  cellular	  components	  such	  as	  
nucleic	  acids,	  proteins,	  sugars	  and	  lipids	  caused	  by	  superoxide	  and	  other	  free	  radicals	  (Harman	  1956).	  
Single-­‐	   and	   double-­‐strand	   breaks	   can	   occur	   through	   such	   damage	   and	   these	   can	   accumulate	  with	  
age.	  Some	  natural	  antioxidants	  in	  the	  form	  of	  enzymes,	  exist	  in	  the	  body	  and	  without	  these,	  damage	  
and	   cell	   death	  would	   be	   greatly	   increased.	   Experiments	   involving	   the	   use	   of	   antioxidant	   agents	   in	  
rodents	  to	  prolong	  longevity,	  fuel	  this	  theory.	  More	  recently	  reactive	  oxygen	  species	  (ROS)	  signaling	  
has	  been	  highlighted	  as	  an	  important	  pathway	  contributing	  to	  cellular	  senescence	  and	  overall	  ageing,	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as	  an	  extension	   to	   the	   free	   radical	   theory	   (Afanas’ev	  2010).	  DNA	  damage	  occurs	  at	  high	   frequency	  
(>60,000	   times,	   per	   mammalian	   cell,	   per	   day),	   but	   is	   rapidly	   repaired	   through	   a	   number	   of	   DNA	  
damage	  repair	  mechanisms,	  dependent	  on	  the	  nature	  of	  the	  break	  (Bernstein	  et	  al.	  2013).	  However,	  
faults	  in	  these	  repair	  processes	  can	  lead	  to	  an	  accumulation	  of	  un-­‐repaired	  regions	  of	  DNA	  in	  somatic	  
cells,	   over	   time	   and	   can	   cause	   mutation	   and	   malfunction	   (Bernstein	   et	   al.	   2013).	   In	   particular,	  
damage	  to	  mitochondrial	  DNA	  can	   lead	  to	  mitochondrial	  dysfunction.	   It	   is	  this	  build-­‐up	  of	  naturally	  
occurring	  DNA	  damage	  that	  results	  in	  reduced	  genetic	  stability	  over	  time	  and	  is	  considered	  a	  major	  
contributing	  characteristic	  of	  the	  ageing	  process.	  Furthermore,	  the	  ‘cross-­‐linking	  theory’,	  introduced	  
in	  1942	  by	  Johan	  Bjorksten	  refers	   to	  an	  accumulation	  of	  cross-­‐linked	  proteins	  with	  time,	  which	  are	  
believed	   to	   damage	   cells	   and	   is	   therefore	   an	   underpinning	   feature	   of	   the	   ‘loss	   of	   proteostasis’	  
hallmark	  of	  ageing	  commonly	  discussed	  in	  the	  anti-­‐ageing	  research	  field	  (Bjorksten	  &	  Tenhu	  1990).	  
All	  of	  the	  above	  are	  examples	  of	  damage	  occurring	  randomly	  at	  a	  molecular	  level	  and	  are	  believed	  to	  
contribute	   to	   and	   constitute	   the	   overall	   effect	   of	   ageing.	   It	   is	   postulated	   that	   faults	   occurring	   at	  
molecular	  and	  cellular	  (as	  well	  as	  extracellular)	  levels,	  with	  DNA	  damage	  accumulation	  and	  oxidative	  
stress,	  among	  multiple	  others,	  leads	  to	  cellular	  senescence	  and	  therefore,	  impaired	  regeneration	  and	  
cellular	   turnover.	   In	   turn,	   these	   effects	   then	   impact	   on	   overall	   tissue	   health	   and	   architecture,	  
strength,	  mobility	  and	  other	  age-­‐related	  symptoms	  that	  can	  be	  observed	  at	  whole	  organism	  levels.	  
Although	   these	  molecular	  alterations	  arise	   randomly	  on	  a	   tissue-­‐wide	  basis,	   leading	   to	  widespread	  
ageing	   of	   the	   organism,	   the	   main	   focus	   tissue	   of	   the	   current	   project,	   skeletal	   muscle,	   provides	   a	  
useful,	  model	   tissue	   as	   a	   basis	   for	   ageing	   research.	   Skeletal	  muscle	   regeneration	   is	   a	   process	   that	  
occurs	  throughout	  adult	   life,	   it	  provides	  a	  variable	  to	  be	  measured	  during	  the	  ageing	  process,	  at	  all	  





Sarcopenia	   is	   termed	   as	   the	   degenerative	   loss	   of	   muscle	   mass,	   quality	   and	   function	   with	   age.	  
Numerous	   characteristic	   age-­‐related	   changes	   have	   been	   previously	   observed	   in	   myogenic	   ageing	  
studies,	  conducted	  at	  whole	  tissue,	  cellular	  and	  molecular	  levels.	  These	  include,	  among	  many	  others,	  
myofibre	   atrophy,	   decreased	   muscle	   weight,	   variations	   in	   muscle	   diameter,	   motor	   neuron	  
denervation,	   reduced	   contractile	   and	   force-­‐generating	   capacity,	   increased	   myofibre	   fibrosis,	   a	  
reduction	   in	   skeletal	  muscle	   satellite	   stem	  cell	  number	  and	   function	  and	   increased	  oxidative	   stress	  
(Shefer	  et	  al.	  2006;	  Collins	  et	  al.	  2007;	  Faulkner	  &	  Brooks	  1995;	  Alnaqeeb	  &	  Goldspink	  1987;	  Wang	  et	  
al.	  2014;	  Chai	  et	  al.	  2011).	  Many	  of	  these	  observations	  in	  ageing	  muscle	  can	  be	  explained,	  at	  least	  in	  
part,	   by	   some	  of	   the	  previously	   discussed	  hallmarks	  of	   ageing,	   as	   the	  underlying	  mechanisms	   that	  
decline	  and	  become	  apparently	  ‘faulty’	  with	  age.	  For	  example,	  features	  of	  mitochondrial	  dysfunction	  
are	   known	   to	   cause	   increased	   oxidative	   stress	   and	   reactive	   oxygen	   species	   (ROS)	   production.	  
Additionally,	   decreased	   regenerative	   capacity	   of	   satellite	   cells	   with	   age,	   has	   been	   shown	   to	   be	  
implicated	   at	   a	   molecular	   level,	   by	   loss	   of	   reversible	   stem	   cell	   quiescence	   and	   instead,	   causes	  
inappropriate	  progression	  through	  the	  cell	  cycle.	  This	  in	  turn,	  leads	  to	  an	  imbalance	  in	  the	  number	  of	  
progenitor	  cells	  produced	  and	  ultimately,	  a	  depletion	  in	  the	  number	  of	  stem	  cells	  that	  constitute	  the	  
stem	  cell	  pool	  (Orford	  &	  Scadden	  2008).	  
Sarcopenia	  progression	  measured	  at	  a	   tissue	   level,	  enables	   the	  examination	  of	  parameters	   such	  as	  
myofibre	  numbers,	   cross-­‐sectional	  area,	  proportion	  of	   regenerating	  myofibres,	  myosin	  heavy	  chain	  
(MHC)	   isoform	  myofibre	   typing	   and	   general	   tissue	   architecture,	   which	   are	   frequently	   analysed	   to	  
monitor	   the	   changes	   that	  occur	   to	  muscle	  health	  with	  age.	   Studies	   conducted	   in	  black	  6	  wild-­‐type	  
mice	   (C57BL/6),	   indicated	  an	  overall	   loss	  of	  muscle	  mass	   in	   the	  Gastrocnemius	  muscle	   (from	  0.6g-­‐
0.34g)	  with	  age	  (from	  20-­‐25	  months)	   (Wang	  et	  al.	  2014).	  Gastrocnemius	  growth	   initially	   followed	  a	  
similar	  trend	  to	  that	  of	  the	  recorded	  body	  weights,	  with	  an	  increase	  in	  weight	  with	  growth	  (between	  
2	  and	  11	  months)	  until	  maturation.	  However,	  unlike	  that	  of	  the	  muscle	  mass,	  body	  weight	  stabilized	  
and	  did	  not	  show	  the	  same	  decrease	  with	  old	  age	   (25	  months)	   (Wang	  et	  al.	  2014).	  A	  similar,	  early	  
investigation	  carried	  out	   in	  rats,	  showed	  that	  EDL	  (Extensor	  digitorum	  longus),	  TA	  (Tibialis	  anterior)	  
and	  Soleus	  muscle	  weights	  decreased	   in	  aged	   (≥22	  months)	  animals	   (Alnaqeeb	  &	  Goldspink	  1987).	  
Along	  with	  myofibre	  atrophy,	  observed	  changes	  to	  myofibre	  morphology	  through	  analysis	  of	  muscle	  
cross-­‐sections	   from	   adult	   to	   old	   ages,	   indicated	   that	   aged	   myofibres	   changed	   shape,	   were	   less	  
uniform	  and	  therefore,	  bordered	  fewer	  direct	  ‘neighbour’	  myofibres	  (Wang	  et	  al.	  2014).	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Effect	  of	  ageing	  on	  myofibre	  composition	  and	  size	  
Skeletal	   muscle	   is	   known	   to	   undergo	   a	   well-­‐defined	   shift	   of	   myofibre	   composition	   with	   age,	   to	  
comprise	  larger	  proportions	  of	  those	  with	  a	  higher	  oxidative	  capacity,	  for	  example	  type	  I	  myofibres	  
(Larsson	  &	  Edström	  1986;	  Alnaqeeb	  &	  Goldspink	  1987;	  Chai	  et	  al.	  2011;	  Rowan	  et	  al.	  2011).	  It	  is	  also	  
reported	  that	  ageing	   is	  associated	  with	   the	  progressive	   loss	  of	  motor	  neurons.	  Fast	  motor	  neurons	  
are	   preferentially	   lost,	   leading	   to	   the	   subsequent	   loss	   of	   type	   II	   myofibres.	   The	   switch	   to	   a	  more	  
oxidative	   phenotype	   therefore,	   has	   been	   linked	   to	   denervation	   of	   faster	   type	   II	   myofibres	   and	   a	  
corresponding	  re-­‐innervation	  by	  surviving	  slow	  twitch	  motor	  neurons	  (Lexell	  et	  al.	  1988;	  Lexell	  1997;	  
Degens	  2007).	  This	  re-­‐innervation	  is	  also	  believed	  to	  be	  the	  result	  of	  motor	  neuronal	  axon	  splitting,	  
however,	  there	  is	  some	  evidence	  that	  this	  ability	  is	  hindered	  in	  advanced	  old	  age	  (Faulkner	  &	  Brooks	  
1995;	   Larsson	   &	   Ansved	   1995;	   Demontis	   et	   al.	   2013).	   Furthermore,	   denervation/re-­‐innervation	  
events	  have	  also	  been	  implicated	  in	  reduced	  contractile	  capacity	  and	  the	  rearrangement	  of	  myofibre	  
types	  and	  it	  is	  proposed	  that	  type	  IIX	  myofibres	  are	  an	  intermediate	  form	  displayed	  during	  a	  slow	  to	  
fast	   or	   a	   fast	   to	   slow	   shift	   (Larsson	   et	   al.	   1991;	   Pette	   &	   Staron	   2000;	   Larsson	   &	   Ansved	   1995).	  
Myofibres	   that	  do	  not	  undergo	   successful	   re-­‐innervation	   following	  motor	  neuron	  atrophy,	  become	  
atrophic	   themselves.	  Myofibre	   atrophy	   is	   a	   key	   determinant	   in	   the	   loss	   of	   muscle	  mass	   with	   age	  
(Lexell	   et	   al.	   1988;	   Rowan	   et	   al.	   2012;	   Chai	   et	   al.	   2011).	   Chai	   and	   colleagues	   reported	   that	   the	  
characteristic	   increased	  myofibre	  atrophy	  and	  MHC	  phenotype	  switch	  to	  those	  more	  oxidative	  was	  
more	  noticeable	  in	  the	  Soleus	  muscle	  of	  geriatric	  mice	  (29	  month-­‐old),	  compared	  to	  the	  EDL	  (Chai	  et	  
al.	  2011).	  However,	   it	   is	  argued	  that	   the	  myofibre	  type	  transition	  to	  a	  slow	  oxidative	  phenotype,	   is	  
more	  achievable	  in	  a	  muscle	  that	  is	  defined	  as	  a	  slow	  muscle	  (Soleus),	  from	  IIA	  to	  I,	  compared	  to	  the	  
faster	  more	  glycolytic	   EDL,	   step-­‐wise	   from	   IIB	   to	   IIX	   to	   IIA	   (to	   I,	   rare)	   (Schiaffino	  &	  Reggiani	  2011).	  
Additionally,	   atrophic	  myofibres	  were	  observed	   to	  have	  a	   smaller	  CSA,	  were	  non-­‐uniform	   in	   shape	  
and	  myofibres	  exhibited	  centrally-­‐located	  nuclei,	  a	  described	  hallmark	  of	  degeneration/regeneration	  
events,	  in	  aged	  and	  geriatric	  muscle	  (Sousa-­‐Victor	  et	  al.	  2014;	  Barns	  et	  al.	  2014).	  
It	  has	  been	  established	  that	  there	   is	  a	  significant	  degree	  of	  muscle	   loss	  experienced	  with	  advanced	  
age,	   as	   by	  definition,	   sarcopenia	   encompasses	   a	   decline	   in	  muscle	  mass	   and	   function.	  Degens	   and	  
colleagues	  investigated	  these	  features	  in	  aged	  rat	  Plantaris	  muscles	  and	  observed	  that	  mass,	  overall	  
strength	  as	  a	  measurement	  of	  maximal	   tetanic	   force	   (P0),	   as	  well	   as	   resistance	   to	   fatigue	   (through	  
intermittent	  isometric	  contractions),	  were	  all	  significantly	  reduced	  in	  old	  age.	  It	  was	  concluded	  that	  
both	   skeletal	  muscle	  mass	  and	   function	  were	   therefore	  diminished	   in	  old	  age	   (Degens	  et	   al.	   1993;	  
Degens	   &	   Alway	   2003).	   Thus,	   Degens	   and	   colleagues,	   examined	   the	   capacity	   to	   which	   muscles	  
elicited	   a	   hypertrophic	   response	   during	   old	   age.	   Denervation	   techniques	   carried	   out	   in	   aged	   rat	  
Plantaris	  muscles,	   saw	   a	   similar	   response	   of	   compensatory	   hypertrophy	   to	   functional	   demands,	   in	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absence	  of	   the	  activity	  of	   its	  hindlimb	   synergists,	   suggesting	   that	   this	   feature	   is	  not	   limited	  by	  age	  
(Degens	  et	  al.	  1993).	  
Despite	   an	   accompanying	   increased	   connective	   tissue	   content	  with	   growth,	   noted	   during	   the	   first	  
year	  of	   life	  (in	  rats),	  the	  decline	  in	  force-­‐generation	  with	  age,	  could	  not	  be	  attributed	  to	  changes	  in	  
connective	   tissue	   content	   (Degens,	   Turek,	   et	   al.	   1993).	   It	   was	   reasoned	   that	   denervation/re-­‐
innervation	  events,	  loss	  of	  myofibrillar	  proteins	  and	  structural	  modifications	  in	  the	  myosin	  molecule	  
could	  all	  impact	  on	  overall	  contractile	  strength	  in	  ageing.	  Moreover,	  age-­‐dependent	  mutations	  in	  the	  
four-­‐and-­‐a-­‐half	  LIM	  domain	  protein	  1	  (FHL1),	   located	   in	  the	  sarcomeric	   I	  band	  and	  focal	  adhesions,	  
has	  been	   implicated	   in	  age-­‐associated	  myopathy,	  accompanied	  by	  myofibrillar	  and	   intermyofibrillar	  
(mitochondrial	  and	  SR)	  disorganisation,	  as	  well	  as	  impaired	  muscle	  oxidative,	  contractile	  and	  exercise	  
capacities,	  increased	  autophagy	  and	  subsequent	  decreased	  survival	  rates	  (Domenighetti	  et	  al.	  2014).	  
Additionally,	   the	   slowing	   of	  myosin	  maximum	   shortening-­‐velocity	   (V0),	   has	   been	   observed	   in	   vitro	  
with	  myosin	  extracted	  from	  the	  aged	  Soleus	  (rat),	  relative	  to	  young	  which	  therefore,	  impairs	  overall	  
contractile	  potential	  in	  aged	  muscle	  (Höök	  et	  al.	  1999).	  Furthermore,	  alterations	  in	  myosin	  structure	  
is	   believed	   to	   further	   impair	  myosin	   head	   binding	   strength	   and	   therefore	   force-­‐generation,	   during	  
maximal	  isometric	  contraction	  (Lowe	  et	  al.	  2001).	  Frequent	  degeneration	  and	  following	  regeneration	  
in	  muscle	  has	  been	  shown	  to	  alter	  the	  extracellular	  matrix	  (ECM)	  and	  connective	  tissue	  architecture	  
in	   both	  dystrophic	   and	   aged	  muscle	   (Kragstrup	  et	   al.	   2011;	   P.	  A.	  Marshall	   et	   al.	   1989).	   Changes	   in	  
features	   other	   than	   collagen	   thickness	   or	   abundance,	   such	   as	   increased	   cross-­‐linking	   of	   collagen,	  
advanced	   glycation	   end-­‐products	   (AGE),	   leads	   to	   increased	   myofibre	   stiffness	   and	   a	   reduction	   in	  
force-­‐generating	  ability	  (Haus	  et	  al.	  2007;	  Lacraz	  et	  al.	  2015;	  Kragstrup	  et	  al.	  2011;	  Wood	  et	  al.	  2014).	  
It	   has	   previously	   been	   suggested	   that	   increased	   physical	   activity	   and	   exercise	   training	   in	   aged	  
individuals,	  can	  counteract	  age-­‐related	  changes	   in	  morphology	  and	  function	  (Klitgaard,	  Mantoni,	  et	  
al.	  1990;	  Roman	  et	  al.	  1993;	  Welle	  et	  al.	  1996;	  Alway	  et	  al.	  1996).	  Fatigue	  resistance	  increased	  with	  
muscle	  overload	  (compensatory	  hypertrophy)	  in	  rats,	  at	  both	  a	  young	  and	  old	  age	  and	  tetanic	  force	  
was	   increased	   in	   trained	   and	   hypertrophic	  muscles	   (Degens,	   Veerkamp,	   et	   al.	   1993;	   Degens	   et	   al.	  
1993).	   Unlike	   in	   ageing	   humans	   however,	   force-­‐generating	   capacity	   and	   specific	   tension	   (force	  
generated	  by	  myofibres	  per	  unit	  of	  cross-­‐sectional	  area),	  were	  not	  increased	  during	  muscle	  overload	  
in	   rats	   of	   advanced	   age,	   instead	   these	   features	   declined	   (Degens	   &	   Alway	   2003).	   Moreover,	   a	  
prolonged	  decrease	   in	  muscle	   contractile	   activity	   (for	  example,	   sedentary	   lifestyle,	  bed	   rest,	   spinal	  
cord	  injury,	  limb	  immobilisation),	  is	  associated	  with	  disuse-­‐induced	  decreased	  myofibre	  CSA,	  muscle	  
mass	   and	   force	   generation,	   as	  well	   as	   a	   shift	   towards	   a	   fast	  myofibre	  phenotype	   (Stevenson	  et	   al.	  
2003).	   Furthermore,	   these	   inactivity-­‐associated	  muscle	   atrophy	   is	   reportedly,	   mediated	   through	   a	  
decrease	   in	   protein	   synthesis	   (decreased	   AKT	   and	   P70S6K	   expression	   and	   inhibition	   of	   eIF4E)	   and	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increased	  protein	  degradation	  (increase	  UPS,	  atrogin-­‐1	  and	  MuRF	  signalling)	  (Stevenson	  et	  al.	  2003).	  
Thus,	   training	   and	   physical	   activity	   carried	   out	   during	   adult	   life	   and	   extended	   into	   advanced	   age,	  
remains	   a	   valid,	   recommended	   intervention	   in	   the	   prevention	   of	   human	   sarcopenia-­‐related	  
deterioration	  (Lynch	  et	  al.	  2007).	  
Taken	  with	  what	  is	  known	  about	  the	  underlying	  mechanisms	  of	  hypertrophy	  and	  protein	  synthesis,	  it	  
is	   reasoned	   that	   the	   alterations	   to	   the	   regulation	   underpinning	   the	   ageing	   process,	   are	  mimicking	  
those	  associated	  with	  endurance	  exercise.	  Regulation	  of	  these	  mechanisms	  are	  therefore,	  concerned	  
with	  initiating	  a	  survival	  response,	  encompassing	  characteristics	  of	  cellular	  maintenance,	  as	  a	  priority	  
over	   growth,	   of	   which,	   mTOR	   signalling	   has	   a	   central	   role	   (Glass	   2005;	   Baar	   2006).	   Similarly,	   an	  
unbalanced	   nutrient	   intake,	   such	   as	   during	   starvation,	   combined	   with	   increased	   energy	  
requirements,	  promotes	  catabolism	  resulting	  in	  myofibre	  atrophy	  and	  loss	  of	  muscle	  mass	  (Koskelo	  
et	  al.	  1990;	  Elashry	  et	  al.	  2017).	  Characteristics	  of	  ageing	  are	  believed	  to	  arise	  through	  features	  that	  
can	  be	  described	  as	  stochastic,	  or	  alternatively,	  genetic	  in	  nature	  (Garinis	  et	  al.	  2008;	  Niedernhofer	  et	  
al.	   2006).	   Stochastic	   or	   spontaneously-­‐occurring	   events,	   refer	   to	   those	   arising	   as	   a	   result	   of	  
exogenous	   biological,	   physical	   or	   chemical	   factors,	   or	   endogenous	   features	   such	   as,	   replication	  
errors,	   hydrolytic	   reactions	   or	   reactive	   oxygen	   species	   (ROS),	   leading	   to	   an	   accumulation	   of	   DNA	  
damage	  and	  overall	  decline	   (Garinis	  et	  al.	  2008;	  Hoeijmakers	  2009).	  The	  genetic	  element	  however,	  
has	  been	  associated	  with	  the	  rate	  of	  decline	  and	  has	  been	   linked	  with	  the	  GH/IGF-­‐1	  signalling	  axis,	  
for	   example,	   which	   is	   a	   well-­‐defined	   regulatory	   pathway	   involved	   in	   maintaining	   the	   balance	  
between	   cellular	   growth/protein	   synthesis	   and	   cellular	   death/protein	   degradation	   (Garinis	   et	   al.	  
2008;	  Niedernhofer	  et	  al.	  2006;	  Glass	  2005;	  Velloso	  2008).	  Moreover,	  studies	  have	  utilised	  declining	  
GH/IGF-­‐1	   levels	  to	  predict	   longevity	   in	  the	  human	  population	  and	  consequently,	  these	  mechanisms	  
have	  been	  manipulated	  and	  utilised	   in	  numerous	  ageing	   intervention	  approaches,	  with	  the	   interest	  
of	  promoting	  overall	  longevity	  (Dollé	  et	  al.	  2006;	  Spindler	  2005;	  Bartke	  2005;	  Milman	  et	  al.	  2014).	  
It	  is	  proposed	  that,	  endurance	  exercise,	  starvation	  and	  ageing	  survival	  responses,	  elicit	  the	  activation	  
of	  AMPK,	  which	  is	  sensitive	  to	  metabolic	  stress	  and	  energy	  deprivation	  (low	  ATP).	  This	  subsequently,	  
regulates	  inhibition,	  through	  tuberous	  sclerosis	  complex-­‐1	  and	  -­‐2	  proteins	  (TSC1	  and	  TSC2),	  of	  mTOR	  
(mTORC1)	   and	   downstream	   initiators	   (4E-­‐BP2,	   eIF2	   and	   P70S6K1)	   of	   protein	   synthesis	   (Baar	   2006)	  
(Figure	  1.6).	  Meanwhile,	   low	   levels	  of	  GH/IGF-­‐1	  have	  been	  associated	  with	   increased	   longevity	  and	  
therefore,	   corresponding	   downregulation	   of	   IGF-­‐1	   activity	   during	   the	   age-­‐associated	   survival	  
response,	  further	  limits	  protein	  synthesis	  (Milman	  et	  al.	  2014;	  Bartke	  2005;	  Niedernhofer	  et	  al.	  2006;	  
Garinis	  et	  al.	  2008).	  Instead,	  this	  activity	  also	  results	  in	  the	  inhibition	  of	  downstream	  mTOR	  (mTORC2)	  
and	   AKT,	   in	   turn,	   activating	   FOXO	   (FOXO	   1	   and	   3),	   Atrogin-­‐1	   and	   MuRF1-­‐mediated	   protein	  
degradation,	   driving	   autophagy	   and	   the	   sequestering	   of	   amino	   acids,	   to	   be	   recycled	   for	   cellular	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turnover	  (Sandri	  et	  al.	  2004;	  Lee	  et	  al.	  2004;	  Mammucari	  et	  al.	  2007).	  FOXO	  is	  known	  to	  interact	  with	  
sirtuin	   1	   (SIRT1),	   activating	   both	   mitochondrial	   transcription	   factor	   A	   (TFAM)	   and	   peroxisome	  
proliferator-­‐activated	  receptor-­‐γ	  co-­‐activator	  1	  alpha	  (PGC1α),	  among	  multiple	  other	  coactivators,	  to	  
bring	  about	  changes	  in	  mitochondrial	  abundance	  and	  function,	  as	  well	  as	  driving	  myofibres	  to	  a	  more	  
oxidative	   phenotype.	   PGC1α	   is	   a	   critical	   metabolic	   sensor	   of	   calcium	   signalling	   induced	   by	   motor	  
neuron	   activity	   both	  by	   short	   term	  and	   chronic	   exercise	   in	   rodents	   and	  humans	   (Baar	   et	   al.	   2002;	  
Russell	  et	  al.	  2003).	  Furthermore,	  transgenic	  expression	  of	  PGC1α	  initiates	  mitochondrial	  biogenesis	  
and	  a	  switch	  to	  a	  more	  oxidative	  phenotype	  in	  more	  glycolytic	  muscles	  (Lin	  et	  al.	  2002).	  Therefore,	  
mitochondrial	  biogenesis	   is	   increased	   in	   response	   to	  exercise-­‐induced	  muscle	  contraction	   (Holloszy	  
1967;	  Baar	  et	  al.	  2002).	  SIRT1	  activity	  is	  reported	  to	  enhance	  the	  transcription	  of	  antioxidant	  genes,	  
including	   manganese	   superoxide	   dismutase	   (SOD2)	   and	   thus,	   functions	   in	   the	   elimination	   of	   ROS	  
superoxide	   (O2-­‐),	   produced	   by	   increased	   oxidative	   metabolism,	   from	   the	   electron	   transport	   chain	  
(ETC).	   However,	   SIRT1	   functions	   as	   a	   NAD+-­‐dependent	   histone/protein	   deacetylase	   and	   an	   age-­‐
related	   depletion	   in	   NAD+	   contributes	   to	   the	   potential	   limitation	   of	   SIRT1	   activity	   in	   aged	  muscle	  
(Fang	  et	  al.	  2016).	  Additionally,	  while	  the	  upregulation	  of	  SIRT1	  expression	  has	  been	  documented	  in	  
numerous	  pathological	   situations,	   levels	  are	  believed	   to	  be	  downregulated	  under	  chronic	  oxidative	  
stress	  conditions	  (Li	  2014).	  Thus,	  the	  beneficial	  antioxidant	  activity	  of	  SIRT1	  is	  potentially	  perturbed	  
in	  age-­‐related	  dysregulation.	  




Figure	  1.6	  Effects	  of	  ageing,	  starvation	  and	  exercise	  on	  the	  regulatory	  pathways	   involved	  in	  protein	  
synthesis,	  degradation,	  autophagy	  and	  mitochondrial	  function.	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Age-­‐related	  declines	  in	  satellite	  cell	  number	  and	  function	  
Importantly,	  effects	  of	  the	  ageing	  process	  can	  be	  observed	  at	  the	  cellular	  level	  during	  skeletal	  muscle	  
regeneration,	   performed	  by	   the	   resident	   stem	   cell	   population,	   satellite	   cells	   (SC).	   Culture	  of	   single	  
myofibres	  isolated	  from	  the	  murine	  Extensor	  digitorum	  longus	  (EDL)	  muscle	  at	  various	  ages,	  enables	  
the	  analysis	  of	  the	  effects	  of	  ageing	  on	  the	  underlying	  mechanisms	  of	  SC	  function,	  on	  the	  myofibre	  
matrix.	  It	  has	  been	  previously	  shown	  that	  fewer	  SCs	  are	  present	  on	  the	  myofibres	  isolated	  from	  aged	  
animals	   compared	   to	   young	   and	   that	   activated	   cells	   emerged	   through	   the	   basal	   lamina	   of	   the	  
myofibre	   in	  a	  delayed	  manner	  and	  migrated	  slower	   (Collins	  et	  al.	  2007;	  Shefer	  et	  al.	  2006;	  Collins-­‐
Hooper	   et	   al.	   2012).	   These	   age-­‐related	   declines	   have	   been	   attributed	   to	   changes	   in	   the	  myofibre	  
niche	  observed	  with	  age	  (Shefer	  et	  al.	  2006;	  Brack	  et	  al.	  2007;	  Collins	  et	  al.	  2007).	  These	  observations	  
are	   in	   keeping	   with	   some	   of	   the	   molecular	   declines	   outlined	   as	   typical	   hallmarks	   of	   ageing,	   for	  
example	   SCs	   experience	   cellular	   senescence	   and	   stem	   cell	   exhaustion	  with	   age,	   resulting	   in	   fewer	  
cells	  present	  in	  the	  stem	  cell	  pool.	  Delays	  in	  activation	  and	  emergence	  could	  be	  due	  to	  a	  previously	  
reported	  reduction	   in	  metabolic	  activity	   (particularly	   for	  protein	  synthesis	  and	  folding),	  of	  aged	  SCs	  
and	  an	  increased	  accumulation	  of	  collagen,	  resulting	  in	  a	  more	  dense,	  thicker	  endomysium	  that	  the	  
SC	  is	  required	  to	  remodel	  in	  order	  to	  emerge,	  respectively	  (Snow	  1977b;	  Marshall	  et	  al.	  1989).	  
Reduced	  SC	  migration	  speeds	  have	  been	  previously	  attributed	  to	  altered	  integrin	  expression	  (α6β1,	  
α7β1)	  and	  as	  integrins	  are	  known	  to	  have	  a	  high	  affinity	  for	  laminins	  present	  as	  a	  component	  of	  the	  
myofibre	   basal	   lamina,	   changes	   in	   integrin	   abundance	   or	   affinity,	   could	   lead	   to	   altered	  migration.	  
Notably,	  however	  both	  young	  and	  old	  satellite	  cells	  migrate	  via	  the	  bleb-­‐based,	  ‘amoeboid’	  method	  
of	  migration,	  which	  implies	  that	  there	  are	  fundamental	  differences	  in	  the	  bleb	  dynamics	  with	  age,	  for	  
example,	  the	  prolonged	  extension	  and	  retraction	  times	  of	  individual	  blebs	  (Siegel	  et	  al.	  2009;	  Collins-­‐
Hooper	  et	  al.	  2012).	  
Alternatively,	   stem	  cells	  enter	  an	   irreversible	  G0	  state	  of	  cellular	   senescence	  where	  proliferation	   is	  
permanently	  ceased	  and	  thereby	  cells	  no	  longer	  retain	  the	  ability	  to	  be	  activated	  for	  use	  in	  a	  process	  
of	   repair	   and	   regeneration	   (Cheung	  &	  Rando	  2013).	   Cellular	   senescence	   is	   commonly	  measured	   in	  
cell	   culture	   using	   a	   senescence-­‐associated	   beta-­‐galactosidase	   (SA-­‐beta-­‐gal)	   assay	   that	   detects	   a	  
cellular	  senescent	  phenotype	  through	  histochemical	  staining	  using	  an	  artificial	  substrate,	  X-­‐gal,	  first	  
used	  to	  measure	  accumulation	  of	  senescent	  cells	  with	  age	  and	  reported	  by	  Dimri	  and	  colleagues	  in	  
1995	   (Dimri	   et	   al.	   1995;	   Itahana	   et	   al.	   2007).	   A	   recent	   study	   conducted	   by	   Sousa-­‐Victor	   and	  
colleagues	   in	   young	   (2-­‐3	   months),	   adult	   (5-­‐6	   months),	   old	   (20-­‐24	   months)	   and	   geriatric	   (28-­‐32	  
months	   -­‐	   advanced	   aged)	   mice	   using	   comparative	   genetic	   profiling	   techniques	   revealed	   that	  
maintenance	   of	   quiescence	   into	   old	   age	   and	   therefore	   the	   prolonged	   regenerative	   capability	   of	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muscle	  is	  dependent	  on	  the	  active	  repression	  of	  senescence	  pathways	  (Sousa-­‐Victor	  et	  al.	  2014).	   In	  
geriatric	  ‘resting’	  (quiescent)	  satellite	  cells,	  the	  derepression	  of	  p16INK4a	  (Cdkn2a),	  a	  cyclin	  4	  inhibitor	  
and	  also	  a	  tumour	  suppressor	  protein	  that	  functions	  in	  checkpoint	  regulation	  of	  the	  cell	  cycle,	  causes	  
entry	   of	   the	   stem	   cell	   into	   a	   senescent	   state	   (geroconversion)	   therefore	   is	   rendered	   incapable	   of	  
activation	   for	   roles	   in	   repair	   responses.	   The	   research	   group	   carried	   out	   ectopic	   overexpression	   of	  
p16INK4a	  as	  well	  as	  silencing	  studies	   to	  observe	  the	  effects	   in	  young	  and	  geriatric	  cells,	   respectively.	  
The	   results	   were	   that	   silencing	   p16INK4a	   expression	   in	   aged	   cells	   caused	   restoration	   of	   quiescence	  
whereas	  overexpression	  in	  young	  satellite	  cells	  prohibited	  their	  activation	  (Sousa-­‐Victor	  et	  al.	  2014).	  
This	  study	  highlights	  the	  potential	  for	  regeneration	  that	  aged	  stem	  cells	  maintain	  throughout	  life	  but	  
apparently	  ‘lose’	  with	  altered	  gene	  expression	  and	  signalling	  over	  time.	  Also	  this	  was	  one	  of	  the	  first	  
studies	   to	   use	   and	   report	   on	   changes	   that	   occur	   in	  muscle	   ageing	   and	   sarcopenia	   in	   an	   advanced	  
aged	  or	   ‘geriatric’	  animals	  and	   that	  perhaps	   research	  using	   ‘young’,	   ‘adult’	  and	   ‘old’	  animals	  are	   in	  
fact,	   using	   animals	   where	   ‘old’	   (<28	   months	   of	   age),	   is	   not	   old	   enough	   and	   therefore,	   the	   vast	  
changes	  in	  tissues	  reported	  during	  advanced	  ageing	  are	  not	  being	  exhibited	  and	  thoroughly	  explored.	  
Conboy	   and	   colleagues	   have	   conducted	   a	   series	   of	   investigations	   over	   recent	   years	   and	   together	  
these	   studies	   evaluate	   the	   effects	   of	   intrinsic	   signalling	   and	   extrinsic	   factors	   on	   stem	   cell	   function	  
with	   age.	   With	   relevance	   to	   skeletal	   muscle,	   Conboy	   et	   al.	   demonstrated	   the	   importance	   of	   the	  
Notch	   signalling	   pathway	   in	   satellite	   cell	   activation,	   proliferation	   and	   ultimately	   the	   initiation	   of	  
regenerative	  processes	   (Conboy	  &	  Rando	  2002).	  Although,	   they	   showed	   that	  artificial	   activation	  of	  
the	  Notch	  signalling	  pathway	  can	   in	   turn,	   restore	   the	  activation	  of	  aged	  satellite	  cells	  and	  enhance	  
regenerative	  capability.	  These	  results	  suggest	  that	  the	   intrinsic	  regenerative	  potential	   is	  retained	   in	  
aged	   satellite	   cells	   and	   that	   it	   is	   the	   declining	   extrinsic	   factors/conditions	   of	   the	   aged	  
microenvironment	   causing	   the	   symptoms	   of	   sarcopenia	   and	   reduced	   repair	   (Conboy	   et	   al.	   2003;	  
Conboy	  et	  al.	  2005).	  
Studies	   carried	   out	   in	   rats	   showed	   that	   advanced	   aged	  muscle,	   once	   grafted	   into	   young	   hosts,	   is	  
regenerated	  to	  an	  equal	  degree	  as	   that	   in	  auto-­‐transplanted	  control	  animals	  however	  when	  young	  
muscle	   is	   grafted	   into	   old	   hosts,	   regeneration	   is	   significantly	   impaired	   (Carlson	   &	   Faulkner	   1989;	  
Carlson	  et	  al.	  2001).	  Conboy	  and	  colleagues	  used	  these	  findings	  to	  form	  a	  hypothesis	  to	  explore	  the	  
apparently	   different	   array	   of	   systemic	   factors	   between	   young	   and	   old	   animals	   causing	   these	  
differences	   in	   repair	   capability.	   They	   developed	   a	   series	   of	   heterochronic	   parabiosis	   experiments	  
where	  pairings	  between	  young	   (2-­‐3	  months)	  and	  old	   (19-­‐26	  months)	  mice	  are	  made,	  whereby	  two	  
animals	  share	  a	  circulatory	  system	  and	  therefore,	  factors	  present	  in	  the	  young	  animal	  are	  exposed	  to	  
the	  old	   animal	   and	  vice	   versa.	   This	   provides	   an	   alternative	  experimental	   procedure,	   contrasting	   to	  
tissue	  transplanting	  and	  grafting.	  Isochronic	  parabiosis	  pairings	  were	  also	  generated	  to	  use	  as	  control	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systems.	  Five	  days	  post-­‐injury,	  hindlimb	  muscles	  were	  examined	  using	  both	  haemotoxylin	  and	  eosin	  
(H&E)	  histological	  staining,	  as	  well	  as	  immunohistological	  protocols	  to	  study	  the	  degree	  of	  myofibre	  
regeneration	   and	   repair	   in	   all	   parabiosis	   conditions.	   This	   resulted	   in	   young	   conditions	   (both	  
isochronic	   and	   heterochronic	   parabioses)	   repairing	   well	   however,	   the	   isochronic	   pairing	   of	   old	  
animals	  repaired	  poorly	  in	  comparison,	  a	  well-­‐established	  characteristic	  of	  aged	  muscle	  tissue.	  
The	  repair	  of	  the	  heterochronic	  parabiosis	  in	  old	  partners	  conversely,	  improved	  regeneration	  to	  the	  
level	  of	  the	  young	  muscle	  therefore,	  indicating	  the	  defective	  regenerative	  potential	  of	  aged	  satellite	  
stem	  cells	  can	  be	  restored	  by	  the	  systemic	  factors	  produced	  and	  circulating	   in	  serum	  from	  a	  young	  
mouse,	  either	  increasing	  upregulatory	  factors	  or	  reducing	  inhibitory	  regulators,	  or	  a	  combination	  of	  
the	  two.	  The	  authors	  also	  comment	  on	  these	  effects	  being	  caused	  by	  the	  systemic	  factors	  produced	  
and	   circulating	   in	   the	   young	   serum,	   rather	   than	   the	   grafting	   of	   young	   satellite	   cells	   into	   the	   old	  
animals,	   having	   a	   reparative	   impact.	   This	   was	   tested	   in	   that	   the	   young	   partners	   were	   GFP+	  
(expressing	   green	   fluorescent	   protein)	   and	   on	   analysis,	   it	   was	   observed	   that	   less	   than	   0.1%	   of	  
repaired	   myotubes	   in	   the	   aged	   partner	   were	   GFP+.	   Conboy	   and	   colleagues	   suggested	   that	   this	  
impaired	   regeneration	   in	   aged	   muscle	   could	   be	   reversed	   by	   appropriate	   activation	   of	   the	   Notch	  
signaling	  pathway,	  previously	  reported	  to	  become	  defective	  with	  age,	  in	  particular	  the	  upregulation	  
of	  Notch	  ligand,	  Delta.	  Induction	  of	  Delta	  was	  reduced	  in	  the	  isochronic	  aged	  animals	  however,	  the	  
heterochronic	  parabiosis	  resulted	  in	  activation	  of	  Notch	  through	  Delta,	   in	  aged	  animals	  comparable	  
to	  levels	  of	  the	  young	  animals.	  Together	  these	  results	  conclude	  that	  the	  systemic	  regulatory	  factors	  
produced	  in	  young	  animals,	  are	  able	  to	  restore	  the	  defective	  regenerative	  potential	  of	  aged	  animals,	  
through	   processes	   that	   both	   increase	   satellite	   cell	   proliferation	   as	   well	   as	   function	   (Conboy	   et	   al.	  
2005).	  
Interestingly,	   other	   research	   groups	   have	   also	   seen	   rejuvenating	   effects	   through	   the	   youthful	  
systemic	   interactions	   created	   through	   the	   use	   of	   heterochronic	   parabiosis	   experimental	   set-­‐ups	  
(Murphy	  &	  Thuret	  2015).	  For	  example,	  in	  cardiac	  ageing	  studies,	  a	  factor	  that	  is	  frequently	  linked	  to	  
heart	  failure	  is	  cardiac	  hypertrophy.	  Using	  an	  old/young	  parabiosis	  pairing,	  regression	  of	  the	  cardiac	  
hypertrophy	  in	  old	  animals	  was	  observed	  and	  it	  was	  concluded	  that	  the	  TGF-­‐β	  (transforming	  growth	  
factor	  beta)	  superfamily	  member,	  GDF11	  (growth	  differentiation	  factor	  11),	  identified	  as	  a	  circulating	  
factor	   in	   the	   young	   animals,	   declined	   with	   age	   (Loffredo	   et	   al.	   2013).	   Furthermore,	   restoring	   the	  
GDF11	  levels	  in	  old	  animals,	  back	  to	  those	  measured	  in	  young	  animals,	  echoed	  the	  results	  seen	  in	  the	  
parabiosis	   and	   reversed	   the	   atrophy	   associated	   with	   ageing.	   Similarly,	   Sinha	   and	   colleagues	   used	  
parabiosis	  pairings	  with	  young	  animals	  and	  observed	   improved	   satellite	   cell	   function	   in	  aged	  mice,	  
also	   implicating	   the	   decline	   in	   circulating	   protein	   GDF11	   in	   old	   animals,	   as	   supplementation	   with	  
youthful	   levels	   of	   GDF11	   had	   the	   same	   beneficial	   effect	   (Sinha	   et	   al.	   2014).	   However,	   GDF8	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(Myostatin),	  also	  a	  TGF-­‐β	  family	  member,	   is	  highly	  homologous	  with	  GDF11	  and	  a	  recent	  study	  has	  
pointed	  out	   a	   large	   amount	   of	   antibody	   cross-­‐reaction	   between	  GDF11	   and	  Myostatin	   in	   previous	  
research	  (Egerman	  et	  al.	  2015).	  Subsequently,	  this	  has	  resulted	  in	  controversy	  and	  a	  large	  amount	  of	  
disparity	  in	  the	  field	  regarding	  the	  identity	  of	  the	  blood-­‐borne	  rejuvenation	  factor	  (Garber	  2016).	  
Effects	  of	  ageing	  on	  the	  skeletal	  muscle	  extracellular	  matrix	  
The	  myofibre	  ECM	  is	  known	  to	  be	  comprised	  of	  numerous	  components,	  such	  as	  collagen	  IV,	  laminins,	  
fibronectin	   and	   glycoproteins,	   that	   function	   critically,	   in	   the	   force	   transmission	   and	   providing	  
structure	   to	   the	   muscle,	   as	   well	   as	   the	   anchorage	   of	   cells	   to	   the	   basal	   lamina	   and	   cell	   to	   ECM	  
communication	   (Sanes	   2003).	   Structural,	   biochemical,	   cellular	   and	   functional	   alterations	   in	   the	  
skeletal	  muscle	  ECM,	  contribute	  to	  the	  declines	  in	  mechanical	  characteristics	  in	  ageing.	  
One	   of	   the	   main	   structural	   changes	   known	   to	   occur	   in	   skeletal	   muscle	   with	   age,	   is	   an	   observed	  
increased	   collagen	   content.	   Studies	   conducted	   in	   both	   humans	   and	   rodents	   overall,	   have	   shown	  
increases	  in	  collagen	  thickness	  and	  content	  with	  age,	  at	  a	  histological	  level	  through	  examining	  muscle	  
cross-­‐sections	   (Kragstrup	   et	   al.	   2011;	   Marshall	   et	   al.	   1989;	   Alnaqeeb	   et	   al.	   1984).	   Furthermore,	  
animal	  studies	   indicated	  that	  enzymatically	   facilitated	  collagen	  cross-­‐linking	   increased	  with	  age	  and	  
that	  physical	  exercise	  was	  observed	  to	  reduce	  cross-­‐link	  accumulation	  in	  aged	  animals	  (Zimmerman	  
et	   al.	   1993;	   Gosselin	   et	   al.	   1998).	   In	   contrast,	   ageing	   studies	   investigating	   the	   properties	   of	  
intramuscular	  endomysial	  collagen	  in	  human	  muscle	  biopsies	  (from	  Vastus	  lateralis),	   indicated	  that,	  
although	   there	   was	   no	   significant	   change	   in	   collagen	   cross-­‐linking	   levels	   with	   age,	   the	   advanced	  
glycation	  end-­‐product	   (AGE),	   pentosidine	  was	   increased	  by	   approximately	   200%	   (Haus	   et	   al.	   2007;	  
Takahashi	  et	  al.	  1995).	  Pentosidine,	  a	  derivative	  of	   ribose,	   forms	   fluorescent	  cross-­‐links	   in	   collagen	  
and	  could	  potentially,	  therefore,	  disrupt	  skeletal	  muscle	  contractibility,	  contributed	  by	  the	  ‘stiffening’	  
of	  tissues	  associated	  with	  ageing	  (Sell	  &	  Monnier	  1989).	  
An	   infiltration	   of	   adipocytes	   into	   the	   intermuscular	   compartments	   between	   muscle	   fascicles	   is	  
another	  observation	  noted	   in	  both	   sarcopenia,	   as	  well	   as	   some	  metabolic	  diseases,	   such	  as	   type	  2	  
diabetes	  and	   familial	  partial	   lipodystrophy	   (Dunnigan	  variety)	   (Vettor	  et	  al.	   2009;	  Garg	  et	  al.	   1999;	  
Gallagher	  et	  al.	  2009).	  Vettor	  and	  colleagues	  through	  a	  series	  of	   in	  vitro	  experiments,	  hypothesised	  
that	   the	   adipogenic	   potential	   of	   SCs	   could	   account	   for	   the	   presence	   of	   adipocytes	   within	   skeletal	  
muscle	  and	  that	  an	  understanding	  of	  the	  molecular	  signalling	  pathways	  underlying	  the	  muscle	  to	  fat	  
conversion	  could	  aid	  in	  explaining	  the	  increase	  noted	  in	  sarcopenia	  (Vettor	  et	  al.	  2009).	  
Additionally,	  cellular	  changes	  encompass	  characteristically	  altered	  mechanotransduction,	  reduced	  SC	  
activation	  and	  therefore,	  perturbed	  regeneration,	  among	  others.	  Changes	  to	  the	  ECM	  that	  impact	  on	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cellular	   function	   are	   associated	   with	   impaired	   cell	   to	   cell,	   or	   cell	   to	   ECM	   communication	   and	  
perturbed	   external	   to	   internal	   signal	   transduction.	   For	   example,	   the	   focal	   adhesion	   kinase	   (FAK)	  
pathway	  is	  known	  to	  interact	  with	  integrins	  and	  transduce	  intracellular	  signalling	  cascades	  in	  order	  to	  
direct	   alterations	   in	   motility	   via	   cytoskeletal	   actin	   organisation	   (Mehlen	   &	   Puisieux	   2006).	  
Additionally,	   load-­‐induced	   FAK	  mechanotransduction	   activity	   has	   been	   shown	   to	   be	   altered	   in	   the	  
aged	  smooth	  muscle	  of	   the	  rat	  aorta,	  where	  FAK	  content	  and	  basal	  phosphorylation	  were	  reduced	  
(Rice	  et	  al.	  2007).	  Moreover,	  aged	  Achilles	  tendon	  fibroblasts	  were	  shown	  to	  have	  reduced	  motility	  
and	  proliferation,	  as	  well	  as	  poor	  actin	  organisation	  and	  these	  altered	  cell	  to	  ECM	  interactions	  could	  
be	   largely	   attributed	   to	   changes	   in	   focal	   adhesion	   protein	   localisation	   (Arnesen	   &	   Lawson	   2006).	  
These	  findings,	  although	  evident	  in	  studies	  focusing	  on	  smooth	  muscle	  and	  connective	  tissue,	  could	  
indicate	   similar	   dysregulation	   associated	  with	   ageing	   skeletal	  muscle.	   Taken	  with	   the	   reduction	   in	  
integrin	  expression	  in	  SCs	  also	  known	  to	  occur	  with	  age,	  could	  indicate	  that	  key	  pathways	  involved	  in	  
mechanosensing,	   ECM	   interaction	   and	   intracellular	   regulation	   of	   cell	   migration,	   among	   other	  
mechanisms,	  are	  compromised	  with	  age	  (Collins-­‐Hooper	  et	  al.	  2012;	  Siegel	  et	  al.	  2009;	  Mayer	  2003).	  
Naturally-­‐aged	  skeletal	  muscle	  profiling	  and	  the	  requirement	  for	  a	  suitable	  
mammalian	  model	  
Although	   the	  wild-­‐type	  C57Bl/6	  muscle	  analysis	  will	   allow	   for	  a	  natural-­‐aged	   ‘muscle	  profile’	   to	  be	  
generated,	  there	  is	  an	  established	  requirement	  for	  an	  alternative	  in	  vivo	  experimental	  set-­‐up,	  to	  fully	  
investigate	   the	   progression	   or	   accumulation	   of	   damage	   with	   advancing	   age	   and	   this	   has	   become	  
more	  evident	   in	  recent	  years.	  Currently,	   there	  are	   limitations	  to	  waiting	  the	  ~2.5	  years	  to	  naturally	  
age	   mice,	   the	   heterochronic	   parabiosis	   systems	   (such	   as	   mortality	   risks,	   technical	   difficulties	  
regarding	  the	  maintenance	  of	  parabiont	  pairings	  over	  long	  periods	  of	  time),	  or	  young-­‐to-­‐old,	  old-­‐to-­‐
young	  transplantation	  techniques	  (Conboy	  et	  al.	  2013;	  Dollé	  et	  al.	  2011).	  A	  review	  by	  Demontis	  and	  
colleagues,	  discusses	  both	  extrinsic	   and	   intrinsic	   factors/defects	   that	  occur	   in	  muscle	  during	  aging,	  
including	  changes	   in	  physical	  exercise	  and	  hormone	   levels	   in	  aged	  animals	  as	  well	  as	  alterations	   in	  
neuromuscular	   junctions	   and	   denervation.	   Importantly	   however,	   the	   review	   uses	   the	   Drosophila	  
‘fruit	  fly’	  as	  a	  particular	  focus	  model	  and	  the	  authors	  indicate	  the	  need	  for	  more	  in-­‐depth	  studies	  of	  
sarcopenia,	   in	   a	  more	   suitable	  model	   for	   ageing	   (Demontis	  et	   al.	   2013).	  Demontis	  highlighted	   that	  
fruit	  fly	  muscles	  are	  small	  and	  difficult	  to	  compare	  to	  sarcopenia	  in	  mammals.	  It	  was	  suggested	  that	  
this	  is	  due	  to	  differences	  in	  the	  rate	  of	  muscle	  degeneration,	  attributed	  to	  the	  lack	  of	  satellite	  stem	  
cells	   in	   members	   of	   the	   Drosophilidae	   family.	   The	   author	   also	   states	   that	   mice	   however,	   are	  
expensive	  to	  keep	  for	  their	  greater	  life-­‐span	  (2-­‐3	  years)	  and	  therefore,	  are	  not	  economically	  viable	  or	  
practical	  for	  more	  long-­‐term	  geriatric	  animal	  studies	  (Demontis	  et	  al.	  2013).	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The	  Ercc1	  murine	  model	  of	  progeria	  
The	   development	   of	   a	   progeroid	   animal	  model	  which	   undergoes	   advanced	   ageing,	   living	   its	   entire	  
lifespan	  in	  a	  shortened	  period	  of	  time,	  thus	  allows	  for	  the	  analysis	  of	  the	  changes	  that	  occur	  with	  age	  
on	  a	  tissue-­‐wide	  basis,	  at	  a	  more	  efficient	  rate.	  Although	  with	  any	  progeria	  model	  developed	  for	  this	  
purpose,	  it	  would	  become	  of	  high	  importance	  to	  determine	  if	  such	  a	  model	  is	  suitable	  in	  mimicking	  
changes	   associated	   with	   natural	   ageing.	   Therefore,	   investigation	   into	   the	   advancement	   of	   age-­‐
related	   symptoms,	   relative	   to	   the	   rate	   typically	   noted	   in	   natural	   ageing,	  would	   allow	   for	   the	  most	  
accurate	  comparisons	  to	  be	  drawn	  during	  experimentation.	  
The	  Ercc1	  knockout	  murine	  progeroid	  model	  is	  suggested	  to	  effectively	  mimic	  alterations	  occurring	  in	  
the	  natural	  ageing	  process	  (Weeda	  et	  al.	  1997;	  Dollé	  et	  al.	  2011).	  The	  model	  is	  a	  genetic	  knockout	  of	  
the	   Ercc1	   (Excision	   repair	   cross	   complementation	   group	   1)	   gene	   encoding	   the	   Ercc1	   protein	   that	  
functions	   alongside	   its	   essential	   binding	   partner,	   XPF	   (Xeroderma	   pigmentosum	   group	   F),	   which	  
together,	  form	  an	  endonuclease	  complex	  that	  participates	  in	  excision	  DNA	  repair	  mechanisms.	  
DNA	  damage	  can	  occur	   through	  endogenous	   cellular	  processes	   including	  DNA	   replication	  errors	  or	  
reactive	   oxygen	   species	   (ROS)	   or	   caused	   by	   exogenous	   physical,	   biological	   or	   chemical	   agents	  
(Hoeijmakers	  2009).	  Naturally	  occurring	  DNA	  damage	  arises	  more	  than	  60,000	  times	  per	  mammalian	  
cell	   per	   day	   (Bernstein	   et	   al.	   2013).	   There	   are	   a	   number	   of	   different	  DNA	   repair	  mechanisms	   that	  
have	   evolved	   and	   are	   implemented,	   dependent	   on	   the	   nature	   of	   the	   damage,	   to	   cope	   with	   the	  
majority	   of	   these	   errors	   including	   both	   single-­‐stranded	   and	   double-­‐stranded	   breaks	   (Lord	   &	  
Ashworth	   2012).	   A	   form	   of	   single-­‐stranded	   repair,	   nucleotide	   excision	   repair	   (NER),	   is	   the	   process	  
implicated	  in	  the	  Ercc1	  mutant,	  which	  causes	  the	  advanced	  ageing	  and	  shortened	  lifespan.	  This	  is	  due	  
to	   the	   increased,	   rapid	  accumulation	  of	  DNA	  damage	   that	  has	  been	  previously	  associated	  with	   the	  
onset	   of	   age-­‐related	   symptoms	   and	   progeroid	   disorders	   and	   is	   frequently	   considered	   a	   major	  
contributing	   factor	   to	   genomic	   instability,	   a	   characteristic	   hallmark	   of	   ageing	   (Burtner	   &	   Kennedy	  
2010).	   The	   mutated	   mouse	   model	   shares	   the	   characteristic	   NER-­‐deficiency	   with	   human	   progeria	  
syndromes,	   xeroderma	  pigmentosum	  (XP),	  Cockayne	  syndrome	   (CS)	  and	   trichothiodystrophy	   (Dollé	  
et	   al.	   2011).	   Melton,	   McWhir	   and	   colleagues	   previously	   reported	   liver	   abnormalities,	   irregular	  
growth,	  reduced	  lifespan	  and	  a	  high	  mortality	  rate	  prior	  to	  weaning	  age	  (~3	  weeks)	  in	  a	  severe	  Ercc1	  
mutant	  murine	  model	  in	  1993	  (McWhir	  et	  al.	  1993;	  Weeda	  et	  al.	  1997).	  Hoeijmakers	  and	  colleagues	  
describe	   two	  Ercc1	  mouse	  mutants	   created	   through	   specific	  Ercc1	   gene	  disruptions	  by	  a	  neomycin	  
marker	  and	  restriction	  site	   insertions,	  one	   is	   the	  complete	   ‘knockout’,	   ‘Ercc1-­‐/-­‐’	   (disrupting	  exon	  7),	  
whereas	  the	  second	  is	  a	  seven	  amino-­‐acid	  carboxy-­‐terminal	  truncation	  at	  the	  C-­‐terminus	  of	  the	  wild-­‐
type	  Ercc1	  protein,	  hybrid	  genotype	  with	  the	  null,	  which	  results	  in	  a	  ‘knocked	  down’,	  ‘Ercc1	  delta	  (d/-­‐
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)’	   mutation	   (disrupted	   exon	   10),	   expressing	   10%	   of	   the	   normal	   level	   of	   ERCC1-­‐XPF.	   The	   Ercc1	  
knockout	  is	  therefore	  the	  more	  severe	  progeroid	  form	  with	  a	  maximal	  lifespan	  reported	  at	  ~30	  days	  
while	  the	  Ercc1d/-­‐	  mutation	  lives	  to	  ~30	  weeks.	  
The	  ERCC1	  model	   is	  not	  the	  only	  murine	  model	  of	  advanced	  age	  that	   is	  currently	  being	  explored	  in	  
the	   ageing	   research	   field.	   The	   Hutchinson-­‐Gilford	   progeria	   syndrome	   Zmpste24-­‐deficient	   mouse	  
(Zmpste24-­‐/-­‐)	   is	  a	  model	   for	   impaired	  DNA	  repair	  and	  accelerated	  cell	  senescence.	  Animals	  typically	  
show	   symptoms	   such	   as	   slow	   growth,	   abnormal	   gait,	   kyphosis,	   alopecia,	   osteoporosis	   and	   bone	  
abnormalities,	  causing	  bones	  to	  be	  prone	  to	  breakage	  (Butala	  et	  al.	  2012;	  Liu	  et	  al.	  2013;	  Young	  et	  al.	  
2005).	  As	  this	  progeroid	  model	  is	  that	  of	  early	  senescence,	  it	  could	  be	  used	  experimentally,	  to	  answer	  
specific	  questions	  regarding	  the	  accumulation,	  clearance	  and	  prevention	  of	  senescent	  cells	  with	  age.	  
Although	   the	   Zmpste24-­‐/-­‐	   model	   exhibits	   overall	   age-­‐associated	   symptoms,	   it	   is	   believed	   that	   the	  
Ercc1	  mouse	   can	   be	   utilized	   in	   the	   current	   research	   project,	   to	   aid	   in	   answering	   a	   broader,	  more	  
extensive	  range	  of	  hypotheses	  relating	  to	  more	  tissue	  types,	  but	  particularly,	  detailing	  changes	  that	  
occur	   in	   sarcopenia	   (Young	  et	  al.	  2005;	  Dollé	  et	  al.	  2011).	   For	  example,	  more	   recently,	   the	  Ercc1d/-­‐	  
mutation	   was	   reported	   to	   show	   reduced	   lifespan	   and	   survival	   as	   well	   as	   whole	   body	   and	   organ	  
weight	  declines	  with	  advanced	  age	  (Dollé	  et	  al.	  2011).	  The	  weights	  recorded	  for	  six	  organs	  including	  
the	  heart,	   liver,	  brain,	   spleen,	  kidney	  and	  thymus,	  showed	  overall	  declining	   trends	   in	  weight	  and	   it	  
was	   concluded,	   that	   the	   Ercc1d/-­‐	   	   model	   exemplifies	   a	   ‘segmental	   progeroid	   phenotype’	   and	   this	  
refers	   to	   the	   extent	   and	   severity	   of	   reported	   age-­‐related	   symptoms	   that	   were	   shown	   to	   vary	  
between	  particular	  organs	  and	  tissues	  (Dollé	  et	  al.	  2011).	  
Effect	  of	  ageing/progeria	  on	  mitochondrial	  function	  and	  oxidative	  stress	  
Nuclear	   DNA	   repair	   proteins	   have	   been	   linked	   to	   regulation	   of	   mitochondrial	   homeostasis.	  
Coordination	  of	  this	  process	  is	  reportedly	  controlled	  by	  nuclear	  transcription	  regulators,	  such	  as	  p53,	  
peroxisome	   proliferator-­‐activated	   receptor-­‐γ	   co-­‐activator	   1α	   (PGC1α),	   hypoxia	   inducible	   factor	   1α	  
(HIF1α),	   the	   fork-­‐head	   box	   O	   (FOXO)	   and	   sirtuin	   members	   (SIRT1,	   SIRT6	   and	   SIRT7)	   and	   NAD+	  
availability,	  as	  NAD+	  is	  depleted	  in	  ageing.	  SIRT1	  activity	  is	  NAD+-­‐dependant	  and	  among	  other	  roles,	  
deacetylates	   PGC1α,	   a	   key	   positive	   regulator	   of	   mitochondrial	   biogenesis.	   Additionally,	   another	  
NAD+-­‐dependant	   process	   implicated	   in	   the	   detection	   of	   DNA	   damage	   is	   PARylation,	   whereby	  
poly(ADP-­‐ribose)	   polymerase	   1	   (PARP1),	   a	   DNA	   break	   sensor,	   generates	   PAR	   in	   order	   to	   initiate	  
signalling	  involved	  in	  the	  recruitment	  of	  PAR-­‐binding	  DNA	  repair	  proteins	  (Gibson	  &	  Kraus	  2012;	  Fang	  
et	   al.	   2016).	   Imbalances	   in	   SIRT1	   and	   PARP1	   activity	   have	   been	   linked	   with	   ageing	   and	   other	  
pathologies	   and	   further	   implicated	   in	   Xeroderma	   pigmentosum	   (XPA)	   and	   Cockayne’s	   syndromes	  
(mutations	  in	  genes	  that	  encode	  CSA	  or	  CSB	  proteins)	  of	  premature	  ageing	  (Mouchiroud	  et	  al.	  2013;	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Scheibye-­‐Knudsen	  et	  al.	  2014;	  Gibson	  &	  Kraus	  2012).	  Studies	   investigating	  XPA	  or	  CSB	  patients	  and	  
cells,	   showed	   evidence	   of	   altered	   mitochondrial	   metabolism	   and	   accumulation	   of	   damaged	  
mitochondria.	   The	   findings	   of	   these	   studies	   observed	   reduced	   SIRT1	   activity,	   attributed	   to	  
constitutive	  PARP1	  DNA	  damage	  detection	  and	  this	  was	  reversed	  with	   inhibition	  of	  PARP1	  or	  NAD+	  
precursor	  supplementation	  which	  balanced	  SIRT1	  activity	  and	  mitochondrial	  homeostasis	  (Fang	  et	  al.	  
2014;	  Fang	  et	  al.	  2016;	  Scheibye-­‐Knudsen	  et	  al.	  2014).	  
Early	  work	  carried	  out	  examining	   the	   severity	  of	   the	   full	   knockout	  variant	  of	   the	   ERCC1-­‐deficiency,	  
revealed	  the	  postulated	  role	  of	  p53	  as	  a	  monitor	  of	  DNA	  damage	  (McWhir	  et	  al.	  1993).	  McWhir	  and	  
colleagues	   surmised	   that	   tissues	   under	   increased	   levels	   of	   oxidative	   stress,	   such	   as	   the	   highly	  
metabolically	   active	   liver,	   brain	   and	   kidney	   showed	   raised	   levels	   of	   p53	   (McWhir	   et	   al.	   1993).	  
Moreover,	   the	   brain	   is	   believed	   to	   be	   more	   prone	   to	   oxidative	   injury,	   due	   to	   relatively	   deficient	  
alternative	  antioxidant	  mechanisms	  (little	  catalase,	  glutathione	  peroxidase,	  glutathione	  and	  vitamin	  
E),	   compared	   to	   other	   tissues	   such	   as	   the	   liver	   (Olanow	   1992).	   Therefore,	   this	   is	   consistent	   with	  
greater	  p53	  levels	  occurring	  in	  tissues	  of	  increased	  oxidative	  stress	  (McWhir	  et	  al.	  1993).	  Additionally,	  
Borgesius	   and	   colleagues	   showed	   increased	   levels	   of	   p53	   and	   caspase-­‐3	   in	   cortical	   cells	   of	   Ercc1	  
mutant	   mice	   and	   that	   the	   neuronal	   DNA	   damage	   shared	   characteristics	   of	   brain	   pathology	   with	  
normal	  ageing	  (Borgesius	  et	  al.	  2011).	  Tumour	  suppressor	  p53,	  also	  known	  a	  master	  transcriptional	  
regulator,	   interacts	  with	  numerous	  effector	  genes	   involved	   in	  a	  variety	  of	  major	  cellular	  pathways,	  
including	   among	   others,	   cell	   cycle	   progression,	   apoptosis,	   autophagy,	   as	  well	   as	   ROS	   defence	   and	  
DNA	  repair	  mechanisms	  (Millau	  et	  al.	  2009).	  Thus,	  p53	  activity	   is	   implicated	   in	  at	   least	   two	  distinct	  
modes	   of	   action	   in	   roles	   combating	   increased	   levels	   of	   oxidative	   stress,	   firstly,	   monitoring	   the	  
increase	  and	  secondly,	  modulating	  SOD2	  antioxidant	  activity	  (Hussain	  et	  al.	  2004).	  Furthermore,	  Feng	  
and	   colleagues	   defined	   the	   cross-­‐talk	   between	   the	   p53	   and	   mTOR	   pathways,	   demonstrating	   p53	  
regulation	  of	  mTOR	  activity,	   including	   the	  downstream	   targets,	   such	  as	   components	  of	   autophagy,	  
through	  activation	  of	  AMPK	  and	  the	  TSC1/TSC2	  complex	  (Feng	  et	  al.	  2005).	  Upon	  detection	  of	  DNA	  
damage	   or	   following	   genotoxic	   stress,	   p53	   is	   activated,	   initiating	   starvation/energy	   depletion-­‐like	  
responses,	   inhibiting	  mTOR,	  protein	  translation	  and	  ribosome	  biogenesis	  is	  halted	  and	  autophagy	  is	  
induced	  (Feng	  et	  al.	  2005).	  Therefore,	  p53/mTOR	  activity	  is	  shown	  to	  be	  a	  key	  regulator	  in	  the	  shift	  
from	   cell	   proliferation	   and	   growth,	   to	   a	   survival	   response	   for	   cellular	  maintenance,	   as	  well	   as	   the	  
response	  to	  increased	  oxidative	  stress	  and	  ROS	  levels.	  
Ercc1d/-­‐	  and	  skeletal	  muscle	  
A	  handful	  of	  studies	  have	  so	  far	  started	  investigations	  into	  the	  age-­‐related	  changes	  that	  occur	  in	  the	  
Ercc1-­‐/-­‐	  knockout	  and	  Ercc1d/-­‐	   	  mutation,	  however	  it	   is	  currently	  believed	  that	  there	  has	  so	  far,	  been	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only	  one	  study	  published	  related	  to	  the	  focus	  tissue	  of	  the	  current	  research	  project,	  skeletal	  muscle.	  
This	  landmark	  study	  was	  conducted	  by	  Lavasani,	  Huard	  and	  colleagues	  and	  aimed	  to	  investigate	  the	  
role	   of	   stem	   cell	   function	   in	   age	   and	   therefore	   decreased	   regenerative	   capacity,	   as	   a	   hallmark	   of	  
ageing,	   using	   muscle-­‐derived	   stem/progenitor	   cells	   (MDSPCs)	   (Lavasani	   et	   al.	   2012).	   The	   MDSPC	  
populations	  were	  isolated	  from	  the	  following	  test	  groups:	  young	  (3	  weeks)	  and	  old	  wild-­‐type	  mice	  (2	  
years),	   progeroid	   Ercc1-­‐/-­‐	   (2-­‐3	   weeks)	   and	   Ercc1d/-­‐	   	   (5	   months),	   as	   well	   as	   age-­‐matched	   wild-­‐type	  
littermates	   and	   Xpa	   -­‐/-­‐	   (xeroderma	   pigmentosum	   complementation	   group	   A)	  mice	   (3	   weeks),	   that	  
present	  faulty	  NER,	  but	  do	  not	  experience	  the	  shortened	  lifespan	  that	  the	  Ercc1-­‐deficient	  mice	  do,	  as	  
controls	   and	   these	  were	   examined	   in	   vitro.	   Results	   showed	   among	   others,	   a	   significantly	   reduced	  
proliferation	   rate,	   MDSPC	   number	   and	   prolonged	   population	   doubling	   times	   in	   both	   the	   old	   and	  
progeroid	   MDSPCs.	   The	   differentiation	   capacity	   was	   also	   shown	   to	   be	   compromised	   in	   aged	   and	  
progeroid	   cells,	   through	   the	   formation	   of	   significantly	   fewer	   and	   smaller	   myotubes.	   This	   was	  
confirmed	  by	  a	  reduced	  expression	  of	  myogenic	  differentiation	  markers	  MHC,	  desmin	  and	  myogenin,	  
as	   well	   as	   decreased	   osteogenic	   and	   chondrogenic	   differentiation	   potential,	   compared	   to	   that	   of	  
young	  wild-­‐type	  MDSPCs	  (Lavasani	  et	  al.	  2012).	  To	  investigate	  whether	  this	  transplantation	  of	  young	  
MDSPCs	  would	  affect	  the	  onset	  of	  age-­‐related	  symptoms	  such	  as	  dystonia,	  ataxia	  and	  loss	  of	  vision	  in	  
ageing	  animals,	  the	  delta	  ‘knocked	  down’	  variant	  of	  the	  progeroid	  model	  (Ercc1d/-­‐)	  was	  used,	  in	  order	  
to	  be	  able	  to	  allow	  time	  for	  these	  symptoms	  to	  occur,	  as	  these	  are	  not	  singularly	  discernible	   in	  the	  
~30	  days	  lifespan	  of	  the	  full	  knockout	  Ercc1-­‐/-­‐	  mice	  (Lavasani	  et	  al.	  2012).	  The	  age	  of	  onset	  (weeks)	  of	  
symptoms	  including	  sarcopenia,	  incontinence,	  trembling,	  ataxia,	  lethargy,	  kyphosis	  and	  dystonia	  was	  
recorded	   and	   an	   ageing	   score	  was	   determined	   as	   the	   fraction	   of	   symptoms	   delayed	   between	   the	  
young	  MDSPC	  treatment	  and	  PBS	   injection	  controls	   (Lavasani	  et	  al.	  2012).	  This	   indicates	  the	  young	  
MDSPCs	  delayed	  the	  onset	  of	  age-­‐associated	  symptoms	  and	  therefore,	  highlights	  the	  causal	  role	  of	  
impaired	  stem	  cell	  function	  on	  the	  overall	  global	  degeneration	  that	  occurs	  with	  ageing.	  Furthermore,	  
using	  a	  MDSPC	  co-­‐culture	  transwell	  system,	  Lavasani	  et	  al.	  concluded	  that	  the	  beneficial	  effects	  the	  
young	  MDSPCs	  in	  Ercc1d/-­‐	  animals,	  could	  be	  attributed	  to	  paracrine	  ‘secreted	  factors’	  released	  from	  
these	   cells	   impacting	   on	   the	   implicated	   host	   cells,	   as	   engraftment	   and	   subsequent	   population	  
expansion	  of	   the	   transplanted	  cells	  was	   limited	   (Lavasani	  et	  al.	  2012).	  This	  observation	  holds	  great	  
significance	   considering	   the	   large	   volume	   of	   work	   currently	   being	   carried	   out	   into	   the	   release	   of	  
paracrine	   factors,	   microvesicle	   (MV)	   particles	   and	   the	   overall	   effects	   of	   a	   cell’s	   ‘secretome’	   on	   a	  
neighbouring	   cell	   or	   tissue.	   Future	   experimentation	   utilizing	   the	   Ercc1	   progeroid	   mouse	   in	   the	  
current	   research	   project,	   will	   explore	   the	   potential	   ‘anti-­‐ageing’	   effects	   of	   MV	   (stem	   cell-­‐derived	  
conditioned	  media)	  treatment	  in	  the	  onset	  and	  progression	  of	  sarcopenia.	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The	  secretome,	  microvesicles	  and	  conditioned	  media	  
Microvesicles	   (MVs)	   are	   fragments	   of	   plasma	   membrane	   that	   are	   secreted	   into	   the	   extracellular	  
space	   from	   cells	   either	   by	   exocytosis	   from	   the	   endosome	   compartment,	   or	   direct	   budding	   and	  
shedding	   of	   the	   surface	  membrane	   (Le	   Bihan	   et	   al.	   2012).	   It	   is	   now	  widely	   believed	   that	  MVs	   are	  
implicated	   in	   roles	   of	   cell-­‐cell	   communication,	   bringing	   about	   receptor-­‐mediated	   alterations	   to	  
neighbouring	   cells	   or	   the	   delivery	   of	   biochemical	   molecules	   as	   cargo	   that	   goes	   on	   to	   be	   used	   by	  
receiving	  cells	  (Camussi	  et	  al.	  2010).	  Vesicles	  were	  first	  reported	  in	  1983	  by	  Pan	  and	  Johnstone	  whilst	  
they	  examined	  sheep	  reticulocyte	  maturation	  and	  since,	  there	  has	  been	  a	  large	  amount	  of	  research	  
carried	  out	  into	  the	  different	  types	  of	  vesicle	  secreted	  from	  cells	  as	  part	  of	  their	  paracrine	  signalling	  
processes	   (Pan	  &	   Johnstone	   1983).	  Many	   studies	   refer	   to	   these	   vesicles	   differently	   and	   categorize	  
them	  based	  on	  a	  variety	  of	  biochemical	  properties	  and	  this	  has	  led	  to	  a	  large	  degree	  of	  confusion	  in	  
the	   literature	  when	   referring	   to	   the	   type	  of	   vesicle.	   For	   example,	   different	  nomencultures	  used	   to	  
name	   secreted	   vesicles	   have	   included	   exosomes,	   shedding	   microvesicles,	   nanoparticles,	  
microparticles,	   ectosomes,	   apoptotic	   blebs,	   exosome-­‐like	   vesicles	   and	   others	   (Mathivanan	   et	   al.	  
2010).	  It	  has	  been	  discussed	  recently	  how	  the	  classification	  of	  types	  of	  vesicle	  requires	  specification	  
however,	   Camussi	   et	   al.	   use	   the	   broader	   term	   microvesicles	   which	   is	   then	   sub-­‐categorized	   into	  
exosomes	  and	  shedding	  vesicles	  (Camussi	  et	  al.	  2010).	  
Exosomes	   are	  membranous	   vesicles	   of	   endosome	   origin,	   ranging	   in	   size	   typically	   from	   30-­‐120nm.	  
They	   are	   stored	   as	   large	   multivesiclar	   bodies	   of	   the	   late	   exosome	   and	   fuse	   with	   the	   plasma	  
membrane	   for	   release	   (exocytosis).	   Shedding	  microvesicles	  are	   larger	   than	  exosomes	   ranging	   from	  
100nm	  to	  1µm	  and	  form	  through	  the	  budding	  of	  the	  plasma	  membrane	  and	  cytoplasmic	  protrusions	  
and	   contents	   can	   vary	   greatly,	   due	   to	   the	  encompassing	  of	  membrane-­‐bound	   receptors	   and	  other	  
proteins,	  mRNA,	  miRNA	  and	   lipids,	  as	  well	  as	  the	  engulfing	  of	  cytoplasmic	  components	  as	  buds	  are	  
formed	  (Camussi	  et	  al.	  2010).	  Mathivanan	  and	  colleagues	  also	  agree	  that	  shedding	  microvesicles	  are	  
larger	  than	  exosomes	  and	  also	  categorize	  apoptotic	  blebs	  (plasma	  membrane	  bodies	  released	  from	  
apoptotic	   or	   dying	   cells),	   as	   vesicles	   to	   be	   considered	   separately	   when	   using	   ‘microvesicles’	   or	  
‘exosomes’	  as	  a	  broad	  term	  (Mathivanan	  et	  al.	  2010).	  
In	  a	  vast	  proteomics	  analysis	  study	  conducted	  by	  Le	  Bihan	  and	  colleagues,	  the	  exosome	  and	  shedding	  
vesicle	  (microparticle)	  subtypes	  were	  isolated	  from	  the	  conditioned	  media	  collected	  from	  culturing	  a	  
primary	   human	   skeletal	  muscle	   satellite	   cell	   line	   (Le	   Bihan	   et	   al.	   2012).	   The	   analysis	   revealed	   that	  
shedding	   vesicles	   contained	   proteins	   associated	   within	   the	   endoplasmic	   reticulum	   (ER),	  
mitochondria,	   Golgi,	   cytoskeleton	   and	   cytosol.	   Proteins	   identified	   included,	   among	   others,	   ER	  
resident	  proteins	  CALU	  and	  HSPA5,	  actin	  and	  tubulins	  (ACTB	  and	  TUBA1B)	  ribosomal	  subunits	  (RPL4	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and	  RPL10)	  and	  poly(A)	  binding	  protein	  (PABPC1).	  Contrastingly,	  exosomes	  contained	  proteins	  from	  
the	   plasma	  membrane,	   such	   as	   integrins	   (ITGA4,	   ITGA6	   and	   ITGA7),	   tetraspanins	   (CD9,	   CD81	   and	  
CD82)	   as	   well	   as	   those	   from	   the	   sub-­‐plasma	   membrane	   (flotillin-­‐1),	   endosomes	   (PDCD6IP)	   and	  
lysosomes	  (CD63	  and	  LAMP2)	  (Le	  Bihan	  et	  al.	  2012).	  
Most	   cell	   types	   secrete	  MVs	   and	   their	   roles	   in	   cell-­‐cell	   interactions	   and	  how	   they	   function	   remain	  
poorly	  understood.	  Multiple	  studies	  have	  shown	  that	  MVs	  are	  released	  from	  a	  variety	  of	  cell	  types,	  
with	  their	  ability	  to	  interact	  with	  many	  different	  receptor	  targets	  (Le	  Bihan	  et	  al.	  2012;	  Pawitan	  2014;	  
Kim	   et	   al.	   2014).	   As	  well	   as	   this,	   their	   apparent	   ‘non-­‐specific’	   uptake	   by	  many	   other	   nearby	   cells,	  
could	  indicate	  a	  beneficial	  method	  of	  biochemical	  molecule/	  component	  delivery	  and	  overall	  therapy	  
(Camussi	   et	   al.	   2010).	   For	   example,	   studies	   examining	  MVs	   released	   from	   a	   platelet,	   leukocyte	   or	  
endothelial	   origin	   may	   contain	   different	   pro-­‐inflammatory	   and	   anti-­‐inflammatory	   factors	   and	  
circulate	  in	  the	  blood,	  highlighting	  a	  potential	  therapeutic	  strategy	  to	  treat	  atherosclerosis	  (Ardoin	  et	  
al.	  2007).	  Furthermore,	  reports	  have	  analysed	  the	  array	  of	  ‘secretome’	  cytokines	  and	  growth	  factors,	  
released	   from	   stem	  cells	   and	   the	  postulated	  uptake	  and	   subsequent	  horizontal	   transfer	  of	   protein	  
and	   RNA	   cargo,	   results	   in	   the	   translation	   into	   functional	   proteins	   (Kim	   et	   al.	   2010;	   Kinnaird	   et	   al.	  
2004;	   Le	   Bihan	   et	   al.	   2012;	   Pawitan	   2014).	   Vascular	   endothelial	   growth	   factor	   (VEGF),	   fibroblast	  
growth	   factor-­‐2	   (FGF-­‐2)	   and	   Interleukin	   6	   (Il-­‐6)	   were	   just	   three	   of	   the	   identified	   cytokines	   to	   be	  
released	   from	   cultured	   human	   bone	   marrow	   stromal	   cells	   (mesenchymal	   stem	   cells),	   in	   a	   study	  
focused	  on	  a	  murine	  hindlimb	  ischaemia	  model	  (Kinnaird	  et	  al.	  2004).	  Interestingly,	  local	  injection	  of	  
the	   conditioned	   media	   collected	   from	   these	   human	   bone	   marrow	   mesenchymal	   cells	   (BMSC),	  
resulted	   in	   improved	   limb	   function,	   reduced	   tissue	   damage	   and	   atrophy	   (Kinnaird	   et	   al.	   2004).	  
Similarly,	   Cantinieaux	   and	   colleagues	  observed	   improved	  motor	   recovery	  with	  BMSC	  CM	   following	  
induced	  spinal	  cord	   injuries	   in	   rats	   (Cantinieaux	  et	  al.	  2013).	  Mellows	  and	  colleagues	  have	  recently	  
examined	  the	  therapeutic	  potential	  of	  CM,	  generated	  under	  stress	  conditions	  and	  free	  from	  all	  other	  
exogenous	   molecules,	   from	   amniotic	   fluid-­‐derived	   stem	   cells	   (AFS)	   (Mellows	   et	   al.	   2017).	   It	   was	  
demonstrated	   that	   the	   AFS	   secretome	   promoted	   stem	   cell	   proliferation,	   migration,	   as	   well	   as	  
protection	  against	  cellular	  senescence,	  in	  an	  acute	  model	  of	  skeletal	  muscle	  injury	  using	  cardiotoxin	  
(CTX).	  The	  biological	  molecules	  identified	  were	  shown	  to	  influence	  the	  regulation	  of	  a	  wide-­‐range	  of	  
cellular	   processes,	   such	   as	   cell	   cycle	   progression,	   cell	   to	   cell	   communication,	   cytoskeletal	  
organisation,	   cell	  motility,	  adherence	  and	  division,	  among	  numerous	  others.	  Although	   isolating	   the	  
EV	  fraction	  from	  the	  whole	  conditioned	  media	  content	  for	  separate	  treatment	  saw	  major	  beneficial	  
regenerative	  effects	  from	  both	  fractions,	  EVs	  were	  shown	  to	  harbour	  a	  large	  majority,	  but	  not	  all	  of	  
the	   therapeutic	   regulatory	   content.	   Therefore,	   AFS	   conditioned	   media	   was	   reported	   to	   maintain	  
numerous	   key	   regulatory	   properties,	   specific	   to	   each	   fraction.	   As	   well	   as	   this,	   importantly,	   it	   was	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established	   that	   conditioned	  media	   treatment	   facilitates	  effective	   tissue	   regeneration,	   through	   the	  
modification	  of	  existing,	  instead	  of	  the	  development	  of	  new,	  signalling	  mechanisms	  in	  the	  host.	  This	  
was	  evident	  from	  a	  large	  proportion	  of	  the	  EV	  content	  comprising	  miRNA	  and	  not	  mRNA	  (Mellows	  et	  
al.	  2017).	  These	  are	  just	  a	  selection	  of	  recent	  studies	  that	  have	  reported	  beneficial	  effects	  with	  the	  
use	  of	  stem	  cell-­‐generated	  conditioned	  media	  and	  the	  secreted	  paracrine	  factor	  contents,	  in	  a	  variety	  
of	   tissue	  models	   of	   injury	   and	   disease.	   However,	   on-­‐going	   research	   into	   the	   exact	   properties	   and	  
mechanisms	   by	   which	   conditioned	   media,	   paracrine-­‐driven	   cell-­‐cell	   interaction	   brings	   about	   the	  
reparative	   effects	   observed,	   remains	   an	   area	   still	   poorly	   understood.	   Although,	   the	   most	   recent	  
breakthroughs,	  regarding	  the	  numerous	  cellular	  processes	  targeted	  by	  conditioned	  media	  contents,	  
are	  beginning	  to	  clarify	  some	  of	  the	  specific	  regulatory	  mechanisms	  involved.	  
ADMSCs	  were	  the	  chosen	  cell	  type	  in	  the	  current	  study,	  for	  CM	  generation,	  this	  is	  due	  to	  a	  wealth	  of	  
promising	   data,	   reporting	   amelioration	   of	   pathologies,	   resulting	   from	   a	  wide	   variety	   of	   injury	   and	  
disease	  models,	  either	  using	  ADMSCs	  in	  whole	  cell-­‐based	  or	  CM	  approaches.	  For	  example,	  similarly,	  
to	  BMSC	  CM	  regenerative	  effects,	  ADMSC	  CM	  has	  been	  shown	  to	  contain	  pro-­‐angiogenic	  and	  anti-­‐
apoptotic	   growth	   factors,	   such	   as	   VEGF,	   FGF-­‐2	   and	   HGF	  which	   resulted	   in	   enhanced	   blood	   vessel	  
density,	  blood	  perfusion	  and	  limb	  salvage	  in	  a	  mouse	  hindlimb	  ischaemia	  model	  (Bhang	  et	  al.	  2014).	  
Furthermore,	   the	   role	   of	   ADMSC	   CM	   in	   dermal	   wound	   healing,	   found	   that	   paracrine	   factors	   up-­‐
regulated	  human	  dermal	  fibroblast	  synthesis	  of	  ECM	  proteins,	  type	  I	  and	  II	  collagens	  and	  fibronectin	  
(Kim	   et	   al.	   2007).	   Importantly,	   it	   was	   shown	   that	   CM	   generated	   from	   bone	   marrow-­‐derived	  
mesenchymal	   stem	   cells	   (BMSC)	   under	   hypoxic	   conditions,	   showed	   overall	   increased	   secretion	   of	  
HGF	  and	  VEGF	  which	   improved	  neurogenesis,	  motor	   function	   and	   cognition,	   following	   a	   traumatic	  
brain	  injury	  in	  rats	  (Chang	  et	  al.	  2013).	  As	  opposed	  to	  the	  isolation	  of	  MSCs	  isolated	  from	  the	  bone	  
marrow,	   dental	   pulp,	   umbilical	   cord	   or	   amniotic	   fluid,	   ADMSCs	   are	   comparatively	   more	   easily	  
extracted	   and	   minimally	   invasive,	   for	   culture	   for	   example,	   via	   liposuction.	   Moreover,	   previous	  
collaborators	  have	  developed	  a	  clinically-­‐compliant	  procedure	  for	  the	  isolation	  and	  expansion	  of	  CM	  
from	  autologous	  ADMSCs.	  CM	  is	   reported	  to	  be	  a	  safer	   form	  of	  cell-­‐free	  therapy,	  without	   the	  risks	  
associated	   with	   raising	   an	   immune	   response,	   or	   the	   development	   of	   neoplasia	   and	   other	  
inappropriate	   differentiation	   events.	   These	   collaborators	   are	   currently	   utilising	   these	   methods	   to	  
treat	  numerous	  pathologies	  and	  disease,	  as	  well	  as	  to	  enhance	  tissue	  regeneration	  following	  injury	  or	  




Importance	  of	  tissue	  microenvironment	  matrix	  components	  and	  substrate	  
elasticity	  
Recent	  studies	  have	  aimed	  to	  explore	  the	  effect	  of	  tissue	  microenvironments	  and	   in	  particular,	   the	  
rigidity	  or	  elasticity	  of	   the	  matrix	   substrate,	  on	   lineage	  specification	  of	   stem	  cells.	   In	  2006,	  a	   study	  
conducted	  by	   Engler	   and	   colleagues	   altered	   the	   stem	   cell	   research	   field	   and	   the	  way	   in	  which	   the	  
cellular	  differentiation	  process	  is	  now	  considered	  (Engler	  et	  al.	  2006).	  It	  was	  shown	  that	  by	  mimicking	  
the	  rigidity	  of	  an	   in	  vivo	  extracellular	  matrix	   (ECM)	  of	  a	  specific	  tissue	   in	  experiments	  performed	   in	  
vitro,	  naïve	  mesenchymal	  stem	  cells	   (MSCs)	  could	  be	  directed	  towards	  specific	   tissue	   lineages.	  This	  
was	  investigated	  through	  varying	  the	  concentration	  of	  bis-­‐acrylamide	  cross-­‐linking	  in	  polyacrylamide	  
gels	  coated	  with	  collagen	  I	  to	  support	  cellular	  adhesion	  and	  culturing	  MSC	  populations	  on	  these	  gels	  
of	  varying	  stiffness.	  For	  example,	  the	  softer	  matrices,	  measured	  using	  the	  Young’s	  (elastic)	  modulus	  
(0.1-­‐1	   kPa),	   best	   mimic	   the	   stiffness	   of	   the	   brain	   microenvironment	   and	   resulted	   in	   the	   MSC	  
specification	  towards	  a	  neurogenic	  pathway,	  indicated	  by	  cells	  adopting	  associated	  morphologies	  as	  
well	   as	   RNA	  microarray	   analysis	   revealing	   increased	   expression	   of	   neurogenic	   markers	   of	   mature	  
neurons,	   such	   as	   neurofilament	   light	   chain	   (NFL)	   and	   NCAM,	   signified	   to	   play	   important	   roles	   in	  
neural	   development	   (Lariviere	   &	   Julien	   2004;	   Rutishauser	   1984).	   More	   rigid	   substrates	   (11	   kPa)	  
however,	  that	  are	  physiologically	  relevant	  to	  muscle	  matrix	  rigidity,	  indicated	  increased	  upregulation	  
of	  a	  range	  of	  early	  to	   late	  myogenic	  markers	   including	  transcription	  factors	  (TF)	  Pax	  3	  and	  7,	  MyoD	  
and	   myogenin	   and	   therefore	   illustrates	   programming	   towards	   the	   muscle	   lineage.	   Matrices	  
engineered	   to	  mimic	   the	  microenvironment	   rigidity	   of	   collagenous	   bone	   (34	   kPa),	   showed	   greater	  
expression	   of	   osteogenic	   regulators	   including	   a	   TF	   associated	  with	   early	   osteoblast	   differentiation,	  
CBFα1	   (RUNX2)	   and	   osteocalcin	   a	   vitamin	   K-­‐dependent	   calcium-­‐binding	   protein	   vital	   for	   bone	  
formation	  (Gilbert	  et	  al.	  2002;	  Hauschka	  1986).	  
Understanding	   how	   the	   ECM	   impacts	   on	   the	   processes	   of	   stem	   cell	   differentiation	   and	   lineage	  
programming,	  will	   provide	  more	   appropriate	   approaches	   and	   increase	   the	   overall	   success	   of	   stem	  
cell	   therapy	   techniques,	   with	   particular	   relevance	   to	   tissue	   regeneration	   post-­‐injury,	   in	   disease	   as	  
well	   as	   with	   ageing.	   Use	   of	   more	   physiologically	   relevant	   culture	   matrices	   (with	   adjusted	   rigidity,	  
matrix	   thickness	   etc.)	   for	   in	   vitro	   studies,	   compared	   to	   the	  widely	   used	   ‘un-­‐natural’	   tissue	   culture	  
plastic-­‐based	   conditions,	   will	   provide	  more	   appropriate	   conditions	   to	   draw	   overall	   more	   accurate	  
conclusions	   regarding	  cell	  migration,	  differentiation	  and	  behaviour	   in	  vivo.	  Another	   research	  group	  
for	   example,	   investigated	   the	   influence	   of	  matrix	   stiffness,	  mimicking	   both	   healthy	   cardiac	  muscle	  
compared	   to	   damaged	   tissue	   post-­‐myocardial	   infarction	   (MI),	   on	   the	   specification	   of	   transplanted	  
MSCs	   (Sullivan	   et	   al.	   2014).	   In	   the	   field	   of	   tissue-­‐engineering	   for	   example,	   whereby	   organic,	   in-­‐
organic	  or	  synthetic	  materials	  are	  utilized	  in	  in	  vivo	  or	  ex	  vivo	  biological	  tissue	  scaffolds	  or	  constructs,	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as	  a	  method	  of	  aiding	  tissue	  transplants	  and	  restoring	  function	  after	  injury	  or	  disease	  (Caplan	  2007;	  
Jenkins	  et	  al.	  2003;	  Totonelli	  et	  al.	  2012).	  As	  such,	  tissue-­‐engineering	  is	  now	  considered	  a	  branch	  of	  
regenerative	  medicine	  (Jenkins	  et	  al.	  2003).	  A	  study	  conducted	  in	  2012,	  used	  a	  process	  of	  detergent-­‐
enzymatic	   decellularisation	   of	   rat	   small	   intestine,	   to	   form	   a	   connective	   tissue	   scaffold,	   to	   act	   as	   a	  
matrix	   to	   encourage	   cell	   re-­‐population	   after	   transplantation	   (Totonelli	   et	   al.	   2012).	   Importantly,	   in	  
addition	  to	  providing	  a	  great	  scope	  for	  exploration	  in	  the	  wider	  regenerative	  medicine	  research	  field,	  
the	   findings	   of	   the	   Engler	   et	   al.	   study	   informs	   and	   provides	   a	   basis	   for	   the	   experimentation	  





Hypotheses,	  aims	  and	  objectives	  
Project	  aim	  	  
The	  main	  aim	  of	   the	  current	   research	  project	   is	   to	  assess	   the	  potential	   therapeutic	  effects	  of	   stem	  
cell-­‐derived	   conditioned	   media,	   on	   age-­‐related	   deterioration,	   associated	   with	   the	   onset	   and	  
progression	  of	  sarcopenia,	  in	  skeletal	  muscle.	  
	  
Hypothesis	  1	  	  
Conditioned	  media	   generated	   from	   adipose-­‐derived	  mesenchymal	   stem	   cells,	   harbours	   regulatory	  
properties	   that	  attenuate,	  or	  even	  prevent	  characteristic	  age-­‐associated	  changes	   in	  skeletal	  muscle	  
composition	  and	  function.	  
Objectives	  
1. To	   develop	   a	   broad	   skeletal	   muscle	   profile	   in	   naturally-­‐aged	   C57BL/6	   mice,	   examining	  
characteristics	   of	   sarcopenia	   measured	   at	   molecular,	   cellular,	   tissue	   and	   whole	   organism	  
levels.	  
Although	  characteristics	  of	  age-­‐related	  decline	  in	  skeletal	  muscle,	  associated	  with	  the	  onset	  
and	  progression	  of	  sarcopenia,	  have	  been	  studied	  extensively	  in	  numerous	  muscle	  types	  and	  
across	   species,	   I	   aimed	   to	   analyse	   key	   physiological,	   histochemical,	   morphometric	   and	  
biochemical	   characteristics	   of	   the	   Soleus	   and	   Extensor	   digitorum	   longus	   (EDL)	   hindlimb	  
muscles,	   of	   young	   (3	   months),	   adult	   (6	   months),	   old	   (24	   months)	   and	   geriatric	   (27-­‐30	  
months)	   mice,	   in	   order	   to	   examine	   how	   muscle	   structure	   and	   function	   alter	   with	   age.	  
Features	  examined	   included,	  among	  others,	  muscle	  mass,	  myofibre	  number,	  myosin	  heavy	  
chain	   myofibre	   type	   composition,	   myofibre	   cross-­‐sectional	   area,	   oxidative	   capacity,	  
superoxide	   reactive	   oxygen	   species	   production,	   as	   well	   as	   capillary	   density	   and	   collagen	  
thickness.	  
	  	  
2. To	   isolate	   the	   secretome	   from	   adipose-­‐derived	   mesenchymal	   stem	   cells,	   under	   stressed	  
culture	  conditions.	  
Although	   numerous	   studies	   have	   shown	   the	   beneficial	   effects	   of	   stem/progenitor	   cell	  
transplantation	   in	  models	  of	   skeletal	  muscle	   injury	  and	  disease,	   these	  approaches	   typically	  
result	   in	  poor	  migration	  and	  engraftment	  of	   injected	  cells,	  suggesting	  that	  it	   is	  the	  secreted	  
factors	   originating	   from	   the	   donor	   cells	   that	   bring	   about	   observed	   regenerative	   effects	  
(Partridge	  2000;	  LaFramboise	  et	  al.	  2003;	  Lavasani	  et	  al.	  2012).	  Therefore,	  I	  have	  generated	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conditioned	   media	   (CM)	   from	   adipose-­‐derived	   mesenchymal	   stem	   cells	   (ADMSC)	   under	  
stressed	  culture	  conditions,	  tested	  in	  its	  protective	  effect	  against	  H2O2	  stress-­‐induced	  cellular	  
senescence	  in	  vitro.	  	  
	  
3. To	   utilise	   the	   naturally-­‐aged	   skeletal	   muscle	   profile	   to	   provide	   a	   basis	   for	   examining	   the	  
therapeutic	  effects	  of	  stem	  cell-­‐derived	  conditioned	  media.	  
Studies	  have	  established	  that	   the	  secretome	  released	   in	  young	  serum,	  as	  well	  as	   that	   from	  
cultured	   stem/progenitor	   cells	   had	   rejuvenating	   effects	   in	   the	   skeletal	  muscle	   of	   aged	   and	  
progeric	  mice	   (Conboy	  et	  al.	  2005;	  Lavasani	  et	  al.	  2012).	  Thus,	   the	  Soleus	   and	  EDL	  muscles	  
were	  analysed,	  using	  the	  series	  of	  molecular,	  cellular,	  tissue	  and	  whole	  organism	  parameters	  
utilised	   previously,	   to	   examine	   the	   paracrine	   effects	   in	   naturally-­‐aged	   (20	   month-­‐old)	  
C57BL/6	  mice	  treated	  with	  ADMSC	  CM.	  
	  
Hypothesis	  2	  	  
Conditioned	  media	   generated	   from	  adipose-­‐derived	  mesenchymal	   stem	   cells,	   provides	   therapeutic	  
effects	   that	  attenuate	   features	  of	  skeletal	  muscle	  composition	  and	  function,	   in	   the	  novel	  use	  of	  an	  
Ercc1d/-­‐	  mutant	  murine	  model	  of	  progeria.	  
Objectives	  
1. To	  characterise	  the	  skeletal	  muscle	  phenotype	  in	  the	  Soleus	  muscle	  of	  the	  Ercc1d/-­‐	  model	  of	  
progeria.	  
	  
Although	  a	  large	  proportion	  of	  ageing	  studies	  utilise	  laboratory	  rodents	  in	  order	  to	  examine	  
the	   changes	   that	   occur	   in	   sarcopenia,	   there	   is	   an	   increasing	   requirement	   for	   a	   suitable	  
mammalian	  model	  of	  accelerated	  ageing	  to	  maximise	  time	  and	  economic	  efficiency	  of	  data	  
delivery	  in	  ageing	  intervention	  research	  (Demontis	  et	  al.	  2013).	  Studies	  have	  established	  that	  
the	  Ercc1d/-­‐	  model	  displays	  systemic	  age-­‐associated	  degeneration,	  exhibits	  hallmark	  features	  
of	  ageing,	  including	  increased	  oxidative	  stress	  and	  cellular	  senescence	  and	  histopathological	  
characteristics	  have	  been	  extensively	  studies	  in	  the	  liver,	  kidney	  and	  spinal	  cord	  (Dollé	  et	  al.	  
2006;	  McWhir	  et	  al.	  1993;	  De	  Waard	  et	  al.	  2010).	  Therefore,	  using	  the	  series	  of	  parameters	  
used	  to	  develop	  the	  naturally-­‐aged	  skeletal	  muscle	  profile,	  I	  characterised	  the	  Soleus	  muscle	  




2. To	   determine	   the	   suitability	   of	   the	   Ercc1d/-­‐	   mouse	   in	   mimicking	   well-­‐defined	   aspects	   of	  
sarcopenia,	  as	  a	  model	  of	  natural	  ageing.	  
	  
Studies	   exploring	   the	   wide-­‐spread	   deterioration	   in	   the	   Ercc1d/-­‐	   model,	   have	   established	  
compartment-­‐specific	   features	   that	   mimic	   ‘normal’,	   ‘accelerated’	   and	   ‘extreme’	   ageing	  
progression	  (Dollé	  et	  al.	  2006).	  It	  is	  well	  known	  that	  the	  decline	  in	  overall	  fitness	  associated	  
with	   the	   ageing	   process	   comprises	   both	   stochastic	   and	   genetic	   components	   and	   this	   has	  
been	   linked	  with	  a	   shift	   in	  energy	   consumption,	   away	   from	  synthesis	   and	  growth,	   towards	  
molecular	   and	   cellular	  maintenance	   (Hoeijmakers	   2009;	   Garinis	   et	   al.	   2008).	   This	   shift	   has	  
been	  reported	  to	  be	  a	  prevalent	  feature	  in	  the	  Ercc1d/-­‐	  mouse	  (Dollé	  et	  al.	  2006).	  Therefore,	  it	  
was	   postulated	   that	   evidence	   for	   this	   shift	   would	   also	   be	   observed	   in	   the	   naturally-­‐aged	  
muscles,	   where	   myofibre	   atrophy	   and	   a	   reduction	   in	   myofibre	   cross-­‐sectional	   area	   are	  
reported	   (Degens,	  Turek,	  et	  al.	   1993;	  Klitgaard	  et	  al.	   1989;	   Sousa-­‐Victor	  et	  al.	   2014).	  Using	  
the	  naturally-­‐aged	  and	  Ercc1d/-­‐	  Soleus	  muscle	  profiles,	   detailed	   in	   the	  previous	  aims,	  direct	  
comparisons	  were	  drawn	  between	  muscle	  mass,	  myofibre	  number,	  cross-­‐sectional	  area	  and	  
composition,	  among	  others.	  	  
	  
3. To	  examine	  the	  potential	  beneficial	  paracrine	  effects	  of	  stem-­‐cell	  derived	  conditioned	  media	  
on	  phenotypical	  aspects	  of	  the	  Ercc1d/-­‐	  Soleus.	  
	  
As	   the	  Ercc1d/-­‐	  mutant	   is	   one	  of	   rapidly	   accumulating	  DNA	  damage,	   it	  was	   postulated	   that	  
features	   of	   decline	   associated	  with	   those	  well-­‐defined	   in	   natural	   ageing,	   particularly	   those	  
relating	   to	   metabolism	   and	   oxidative	   stress,	   would	   be	   more	   predominant	   in	   the	   Ercc1d/-­‐	  
Soleus,	  compared	  to	  naturally-­‐aged	  muscles.	  Following	  similar	  examination	  methods	  as	  in	  the	  
naturally-­‐aged	   aims,	   the	   paracrine	   effect	   of	   ADMSC	   CM	   was	   investigated	   in	   the	   Ercc1d/-­‐	  
Soleus,	  using	  the	  developed	  array	  of	  analyses.	  	  
	  	  
Hypothesis	  3	  	  
Conditioned	   media	   generated	   from	   adipose-­‐derived	   mesenchymal	   stem	   cells,	   increases	   skeletal	  
muscle	  satellite	  cell	  number	  and	  regenerative	   function	   in	  natural	  ageing	  and	   in	   the	  Ercc1d/-­‐	  mutant	  




1. To	  examine	  the	  impact	  of	  natural	  ageing	  on	  the	  underlying	  mechanisms	  of	  satellite	  cell	  (SC)	  
function.	  
	  
It	   is	  well	  known	  that	  SCs	  exhibit	  delayed	  activation	  and	  emergence,	  reductions	  in	  migration	  
velocity,	   a	   lock	   into	   premature	   cellular	   senescence,	   proliferation	   and	   differentiation	  
potential,	  with	  age	  (Collins-­‐Hooper	  et	  al.	  2012;	  Sousa-­‐Victor	  et	  al.	  2014;	  Collins	  et	  al.	  2007).	  
All	   are	   essential	   steps	   underpinning	   the	   process	   of	   skeletal	  muscle	   regeneration,	  myofibre	  
turnover	  and	  the	  supply	  of	  new	  myonuclei	  with	  muscle	  hypertrophy	  (Zammit	  2002;	  Snijders	  
et	   al.	   2009).	   Thus,	   in	   order	   to	   provide	   a	   basis	   for	   subsequent	   experimentation,	   these	  
mechanisms	  of	  SC	  activity,	  were	  analysed	  on	  isolated	  single	  myofibre	  cultures	  from	  the	  EDL	  
muscle	   of	   young	   (3	   months)	   and	   aged	   (24	   months)	   C57BL/6	   mice.	   Immunocytochemical	  
protocols	  for	  Paired	  box	  protein	  7	  (Pax7)	  and	  Myogenic	  differentiation	  1	  (MyoD)	  were	  used	  
to	  identify	  satellite	  cells,	  laminin	  to	  visualise	  the	  myofibre	  basal	  lamina	  and	  α-­‐smooth	  muscle	  
actin	   to	   examine	   cell	   morphology.	   Time-­‐lapse	   microscopy	   allowed	   SCs	   to	   be	   tracked	   and	  
migration	  speeds	  to	  be	  calculated.	  
	  
2. To	  characterise	  the	  underlying	  mechanisms	  of	  Ercc1d/-­‐	  satellite	  cell	  function.	  
	  
Although,	   it	   has	   been	   established	   that	   isolated	   and	   cultured	   Ercc1d/-­‐	   muscle-­‐derived	  
progenitor	   cells	   exhibited	   defective	   proliferation	   and	   differentiation	   capacities,	   the	   other	  
vital	   aspects	   of	   SC	   activity	   had	   yet	   to	   be	   fully	   characterised,	   within	   the	   single	   myofibre	  
microenvironment	   (Lavasani	   et	   al.	   2012).	   Thus,	   the	   investigation	   was	   conducted	   as	   in	   the	  
previous	   aim,	   using	   single	   myofibres	   isolated	   from	   Ercc1d/-­‐	   EDL	   muscles	   to	   analyse	   SC	  
emergence,	  migration	  speed,	  morphology,	  proliferation	  and	  differentiation.	  
	  
3. To	   assess	   the	   suitability	   of	   the	   Ercc1d/-­‐	   progeric	  mouse,	   as	   a	  model	   of	   accelerated	   natural	  
muscle	  ageing,	  at	  a	  cellular	  level.	  
	  
It	  has	  been	  widely	  accepted	  that	  the	  ageing	  skeletal	  muscle	  myofibre	  and	  stem	  cell	  ‘niche’	  is	  
also	   affected	   by	   the	   ageing	   process	   and	   is	   a	   key	   determinant	   in	   SC	   function	   (Collins	   2006;	  
Grounds	  2014).	  This	   is	  as	  opposed	   to	   the	  earlier	   conclusions	   suggesting	   that	  declines	  were	  
solely	   due	   to	   a	   loss	   of	   intrinsic	   potential.	   The	   need	   for	   an	   appropriate	   accelerated	   ageing	  
model	  is	  also	  evident	  at	  a	  cellular	  level	  and	  would	  benefit	  areas	  of	  research	  concerned	  with	  
enhancing	   regenerative	   capacity	   in	   aged	   skeletal	  muscle,	  where	   the	   interplay	  between	   the	  
74	  
Taryn	  Morash	  
aged	  SC	  and	  its	  local	  microenvironment	  can	  be	  examined,	  for	  example	  during	  manipulations	  
of	  the	  endogenous	  milieu	  (Conboy	  et	  al.	  2003).	  	  As	  with	  previous	  aims,	  results	  can	  be	  directly	  
compared	  between	  the	  naturally-­‐aged	  and	  Ercc1d/-­‐	  satellite	  cell	  mechanisms	  of	  function.	  
	  
4. To	   examine	   the	   therapeutic	   potential	   of	   stem-­‐cell	   derived	   conditioned	   media	   in	   vivo	  
treatment	  on	  the	  underlying	  aspects	  of	  naturally-­‐aged	  and	  Ercc1d/-­‐	  satellite	  cell	  function.	  
	  
It	  has	  been	  shown	  that	  the	  ability	  of	  young	  stem/progenitor	  cells	  to	  restore	  the	  proliferative	  
and	   differentiation	   dysfunction	   demonstrated	   by	   aged	   and	   progeric	   stem	   cells	   which	   was	  
attributed	   to	   the	   secretome	   (Lavasani	   et	   al.	   2012).	   Thus,	   as	   with	   the	   previous	   aim,	  
mechanisms	   of	   SC	   regenerative	   activity	   were	   examined	   on	   isolated	   single	  myofibres	   from	  
naturally-­‐aged	  and	  progeric	  EDL	  muscles.	  
	  
Hypothesis	  4	  	  
Skeletal	   muscle	  myofibres	   promote	   non-­‐muscle	   stem	   cells	   and	   non-­‐stem	   cells	   to	   adopt	  myogenic	  
characteristics.	  
Objectives	  
1. To	  determine	  that	  the	  amoeboid-­‐based	  migratory	  feature	  demonstrated	  by	  satellite	  cells,	  is	  
directed	  predominantly	  by	  the	  myofibre	  surface.	  
	  
It	   has	   been	   established	   that	   SCs	   migrate	   on	   myofibres	   using	   an	   amoeboid/bleb-­‐based	  
mechanism	   (Collins-­‐Hooper	   et	   al.	   2012;	   Otto	   et	   al.	   2011).	   It	   is	   unknown	   whether	   the	  
myofibre	   matrix	   could	   induce	   the	   bleb-­‐based	   form	   of	   migration	   in	   non-­‐muscle	   cells.	  
Therefore,	   this	   was	   tested	   by	   co-­‐culturing	   myofibres	   with	   transplanted	   adipose-­‐derived	  
mesenchymal	  stem	  cells,	  amniotic	  fluid	  stem	  cells,	  dental	  pulp	  stem	  cells	  and	  a	  breast	  cancer	  
cell	   line,	   MDA-­‐MB-­‐231	   cells	   and	   analysing	   the	   mode	   of	   migration	   using	   time-­‐lapse	  
microscopy.	  
	  
2. To	   examine	   the	   impact	   of	   the	   aged	   myofibre	   microenvironment	   on	   the	   migratory	   and	  
morphological	  characteristics	  of	  resident	  satellite	  cells	  and	  non-­‐muscle	  cells.	  
	  
It	  was	  shown	  that	  SC	  migration	  speed	  was	  reduced	  on	  aged	  myofibres	  (Collins-­‐Hooper	  et	  al.	  
2012).	   It	   is	  unclear	  whether	  this	   feature	   is	  determined	  by	  a	  decline	   in	  function	   intrinsic	  the	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aged	  SC,	  or	  directed	  by	  the	  physical	  properties	  of	  the	  myofibre	  surface.	  Thus,	  the	  same	  non-­‐
muscle	   cell	   types	   used	   in	   the	   previous	   aim,	   were	   transplanted	   and	   co-­‐cultured	   with	  
myofibres	   and	   morphology	   was	   analysed	   using	   an	   immunocytochemical	   protocol	   for	   α-­‐
smooth	  muscle	  actin	  and	  migration	  examined	  using	  time-­‐lapse	  microscopy.	  	  
	  
3. To	  assess	  the	  in	  vitro	  effects	  of	  stem-­‐cell	  derived	  conditioned	  media	  on	  the	  morphology	  and	  
migration	   speeds	   of	   resident	   satellite	   cells	   and	   non-­‐muscle	   cells	   co-­‐cultured	   with	   aged	  
myofibres.	  
	  
It	   has	   been	   shown	   that	   conditioned	  media	   treatment	   enhances	   the	   closure	   of	   an	   artificial	  
‘wound’,	  as	  a	  migration	  assay	  in	  vitro	  (Mellows	  et	  al.	  2017).	  Therefore,	  the	  effects	  of	  in	  vitro	  
administration	   of	   conditioned	  media	   on	   the	  migration	   of	   resident	   SCs	   as	  well	   as	   the	   non-­‐
muscle	   cells	   on	   both	   young	   and	   aged	   myofibres.	   Furthermore,	   in	   vivo	   and	   in	   vitro	  
administration	  of	  conditioned	  media	  was	  compared.	  
	  
4. To	  determine	  whether	  the	  molecular	  mechanisms	  that	  underpin	  the	  regulation	  of	  amoeboid-­‐
based	  migration	  were	  the	  same	  in	  each	  cell	  type.	  
	  
It	  is	  well	  known	  that	  Rac	  and	  Rho	  GTPase	  signalling	  pathways	  are	  central	  to	  the	  regulation	  of	  
cell	  morphology	  and	  mode	  of	  migration,	  where	  Rac	  drives	  actin	  filament	  formation	  and	  Rho	  
is	  responsible	  for	  bleb-­‐mediated	  motility	  (Sanz-­‐Moreno	  et	  al.	  2008;	  Sanz-­‐Moreno	  &	  Marshall	  
2009).	  Thus,	  the	  use	  of	  Y-­‐27632	  and	  CK666	  (ROCK	  and	  Arp2/3)	  inhibitors	  were	  used	  to	  block	  
Rho	  and	  Rac	  signalling	  and	  examine	  the	  impact	  on	  the	  morphological	  and	  migratory	  features	  
of	  each	  cell	  type.	  
	  
5. To	   establish	   the	   influence	   of	   the	  myofibre	   surface	   on	   non-­‐muscle	   stem	   and	   non-­‐stem	   cell	  
fate.	  
	  
It	  has	  been	  shown	  that	  the	  elasticity	  or	  rigidity	  of	  a	  matrix	  has	  profound	  effects	  of	  the	  fate	  of	  
stem	  cells	  (Engler	  et	  al.	  2006).	  Thus,	  the	  transplanted	  cell	  types	  were	  examined	  for	  myogenic	  
markers	  after	  10	  days	  co-­‐culture	  on	  myofibres	  and	  subsequently	  dissociated	  and	  examined	  
for	  myosin	  heavy	  chain	  expression	  and	  myotube	  formation.	  












Thawing	  of	  cells	  
All	   cell	   culture	  protocols	   including	   the	  preparation	  of	   fresh,	   cell-­‐specific	   culture	  media	  prior	   to	   the	  
thawing	  of	   cells,	  were	   carried	  out	  under	  a	   laminar	   flow	  hood,	   following	  a	  high	   standard	  of	  aseptic	  
tissue	  culture	   technique.	  Aliquots	  of	  media	   (9mL)	  were	  pipetted	   into	  sterile	  15mL	  centrifuge	   tubes	  
and	  pre-­‐warmed	  to	  37°C	  in	  a	  water	  bath	  (e.g.	  one	  per	  cell	  type).	  Cells	  were	  stored	  in	  1.8mL	  cryovials	  
at	  approximately	  -­‐200°C	  within	  a	  liquid	  nitrogen	  dewar	  and	  to	  thaw,	  vials	  were	  removed	  from	  liquid	  
nitrogen	  storage	  and	  placed	  directly	  into	  a	  37°C	  water	  bath	  and	  agitated	  gently	  to	  speed	  up	  the	  rate	  
of	   thawing.	   Under	   aseptic	   conditions,	   the	   contents	   (1mL	   thawed	   media	   cell	   suspension),	   was	  
pipetted	   into	   the	  15mL	  centrifuge	   tubes	  of	  pre-­‐warmed	   (37°C),	   fresh,	  cell-­‐specific	  culture	  medium.	  
Cells	  were	  then	  centrifuged	  at	  400g	  for	  5	  minutes	  to	  form	  a	  pellet	  which	  was	  then	  re-­‐suspended	  in	  a	  
further	  volume	  of	  warmed	  (37°C),	  fresh	  media	  (for	  example,	  1mL)	  for	  accurate,	  manual	  cell	  counting	  
using	  a	  haemocytometer.	  After	   counting,	   cells	  were	   seeded	   into	  appropriately-­‐sized	   tissue	  culture-­‐
treated	  flasks	  at	  an	  appropriate	  seeding	  density	  for	  that	  cell	  type	  with	  fresh	  media	  warmed	  to	  37°C.	  
Any	   non-­‐adherent	   cells	   present	   24	   hours	   after	   thawing	   and	   seeding	   were	   removed	   through	  
aspiration	   of	   the	  media	   and	   fresh	  media	  was	   added.	  During	   cell	   expansion,	  media	  was	   exchanged	  
every	   3	   days.	   Cells	   were	   grown	   to	   appropriate	   numbers	   for	   experimentation	   (2.5x105)	   or	   to	   70%	  
confluency	  in	  order	  to	  maintain	  stem	  cell	  properties.	  	  
Passaging	  of	  cells	  
Once	   cells	   had	   expanded	   in	   culture	   to	   reach	   the	   appropriate	   number	   or	   confluency,	   cells	   were	  
dissociated	   from	   the	   culture	   surface	   using	   trypsin	   (1x	   TrypLE™	   Select	   12563-­‐011).	   Media	   was	  
removed	  and	  replaced	  with	  1x	  TrypLE™	  Select,	  incubated	  at	  37°C	  and	  5%	  CO2	  for	  5	  minutes	  to	  allow	  
for	  complete	  dissociation.	  As	  previously	  described	  in	  the	  ‘Thawing	  of	  cells’	  protocol,	  cell	  suspensions	  
were	   collected	   into	   sterile	   15mL	   centrifuge	   tubes	   and	   centrifuged	   at	   1,200	   rpm	   for	   5	  minutes,	   re-­‐
suspended	   in	   1mL	   of	   warmed	   (37°C),	   fresh	   media	   for	   accurate,	   manual	   cell	   counting	   using	   a	  
haemocytometer.	   2.5x105	   cells	   of	   each	   type	   were	   required	   for	   use	   in	   cell	   transplantation	  
experiments	   and	   were	   pipetted	   into	   sterile	   35mm	   culture	   petri	   dishes	   (Sarstedt	   82.1135.500) 
containing	   1mL	   of	   Single	   Fibre	   Culture	   Medium	   (SFCM)	   and	   intact	   isolated	   single	   myofibres	  
(approximately	  700	  per	  hindlimb	  muscle)	   and	   left	   to	  adhere	   for	  2	  hours.	  Cells	   required	   for	   further	  
expansion	   in	  culture	  were	  passaged	  and	  counted	  as	  described	  and	  seeded	  at	  appropriate	  densities	  
with	  media	  changes	  every	  3	  days.	  Alternatively,	  cells	  no	   longer	  required	  for	  expansion	  were	  frozen	  
down	  for	  long-­‐term	  storage.	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Freezing	  cells	  for	  long-­‐term	  storage	  
Dissociated	  cells,	  as	  previously	  described	   in	   the	  protocol	   for	   ‘Passaging	  of	  cells’,	  were	  counted	  and	  
centrifuged	  for	  5	  minutes	  at	  400g	  and	  instead,	  were	  re-­‐suspended	  in	  warmed	  (37°C)	  freezing	  media	  
and	  pipetted	  into	  1.8mL	  cryovials	  (5x105	  or	  1x106	  cells	  per	  1mL	  freezing	  media	  per	  cryovial).	  Cryovials	  
were	   cooled	   at	   a	   slow	   rate	   of	   1°C	   per	  minute	   in	   a	  Mr	   Frosty™	   freezing	   container	   (Thermo	   Fisher	  
Scientific	   5100-­‐0001)	   stored	   at	   -­‐80°C	   overnight.	   Cryovials	   were	   then	   transferred	   from	   -­‐80°C	   to	   a	  
liquid	  nitrogen	  dewar	  for	  long-­‐term	  storage	  at	  approximately	  -­‐200°C.	  
Preparation	  of	  nitric	  acid-­‐treated	  cover	  slips	  for	  cell	  culture	  
Round	   cover	   slips	  were	  washed	   in	   65%	   (v/v)	   nitric	   acid	   (previously	   prepared	   under	   a	   fume	   hood)	  
overnight	   with	   gentle	   agitation.	   Cover	   slips	   were	   then	   washed	   3	   times	   with	   distilled	   H2O	   for	   30	  
minutes	  each	  with	  gentle	  agitation	  and	  washed	  a	  further	  time	  in	  70%	  ethanol	  in	  a	  new	  glass	  beaker.	  
Under	  aseptic	  conditions,	  cover	  slips	  were	  carefully	  laid	  out	  to	  air	  dry	  on	  a	  layer	  of	  clean	  tissue	  and	  
once	  dry,	  cover	  slips	  were	  autoclaved.	  Nitric	  acid	  cover	  slips	  were	  used	  to	  analyse	  the	  differentiation	  
of	  dissociated	  AFS,	  MDA	  and	  SCs	   from	  myofibres	  and	   the	  potential	   to	   form	  of	  myotubes	  using	   the	  
MHC+	  immunocytochemical	  protocol	  (discussed	  later	  in	  ‘Myotube	  formation	  culture’	  section).	  	  	  
Collagenase	  solution	  preparation	  	  
For	  two	  EDL	  muscles	   (one	  mouse	  dissection),	  a	  1mL	  aliquot	  of	  2mg/mL	  type-­‐1	  collagenase	  solution	  
was	  prepared	  in	  DMEM.	  
Preparation	  of	  culture	  plates	  	  
Following	  sterile	  tissue	  culture	  conditions,	  1mL	  of	  SFCM	  was	  added	  to	  each	  required	  well	  of	  12-­‐well	  
culture	  plates	  (Greiner	  665180).	  Where	  inhibitor	  was	  used,	  the	  required	  inhibitor	  was	  added	  to	  SFCM	  
at	  the	  required	  concentration	  and	  made	  up	  to	  a	  total	  volume	  of	  1mL	  in	  each	  well.	  The	  plates	  were	  
placed	  in	  an	  incubator	  at	  37°C	  and	  5%	  CO2	  for	  the	  required	  period	  of	  time.	  
Cytoskeletal	  inhibitor	  preparation	  
The	   ROCK	   inhibitor	   (Y-­‐27632	   dihydrochloride,	   Abcam	   ab120129)	   was	   used	   at	   a	   concentration	   of	  
10µg/mL.	  The	  Arp2/3	  inhibitor	  (CK666,	  Abcam	  ab141231)	  was	  used	  at	  a	  concentration	  of	  150µM.	  The	  
required	  concentrations	  of	   inhibitors	  were	  made	  up	   in	  SFCM	  to	  a	   total	   volume	  of	  1mL	  per	   culture	  
plate	  well.	   Cells	  were	   added	   to	   the	   culture	  wells	   of	   isolated	   single	  myofibres	   and	   after	   allowing	   2	  
hours	   for	   cell	   adherence,	   myofibres	   (with	   transplanted	   cells)	   were	   transferred	   to	   wells	   of	   a	   new	  
culture	  plate	  and	  incubated	  with	  1mL	  SFCM	  (control)	  plus	  inhibitor	  treatments.	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Conditioned	  media	  generation	  
Phosphate	  buffered	  saline	  (PBS)	  preparation	  for	  conditioned	  media	  (CM)	  
generation	  
CM	  was	  generated	   in	  1x	  PBS	   that	  was	  prepared	   in-­‐house	  and	   sterilised	   through	  autoclaving	   for	  20	  
minutes	  at	  approximately	  120°C.	  Aliquots	  of	  PBS	  were	  prepared	  in	  8.9mL	  OptiSeal™	  ultracentrifuge	  
tubes	  (Beckman	  Coulter	  361623)	  and	  centrifuged	  using	  an	  Optima	  XPN-­‐80	  ultracentrifuge	  at	  70,000g	  
for	   120	   minutes.	   Under	   aseptic	   conditions,	   care	   was	   taken	   to	   avoid	   disruption	   of	   any	   pelleted	  
material,	  whilst	  the	  ultracentrifuged	  supernatant	  from	  each	  tube	  was	  removed,	  combined	  and	  stored	  
at	  room	  temperature.	  
Generation	  of	  conditioned	  media	  (CM)	  from	  hADMSCs	  
Dissociated	  hADMSCs	  in	  suspension	  were	  aliquoted	  into	  sterile	  1.5mL	  micro-­‐centrifuge	  tubes	  (1x106	  
cells	   per	   tube)	   and	   washed	   in	   1mL	   previously	   prepared	   sterile	   ultracentrifuged	   PBS.	   Cells	   were	  
pelleted	   through	   centrifugation	   at	   400g	   for	   5	   minutes	   and	   re-­‐suspended	   in	   a	   further	   1mL	  
ultracentrifuged	   PBS.	   The	   wash	   step	   was	   repeated	   a	   further	   2	   times.	   A	   final	   volume	   of	   400µL	  
ultracentrifuged	   PBS	   was	   added	   to	   the	   cell	   pellet	   and	   centrifuged	   a	   further	   time	   at	   400g	   for	   5	  
minutes.	  Pellet	  cultures	  were	  incubated	  at	  room	  temperature	  for	  24	  hours,	  re-­‐pelleted	  at	  400g	  for	  5	  
minutes	  prior	  to	  the	  careful	  aspiration	  of	  the	  (T24	  CM)	  supernatant,	  avoiding	  any	  disturbance	  to	  the	  
pellet.	  The	  CM	  aspirations	  were	  combined	  and	  centrifuged	  at	  4,000g	  for	  20	  minutes	  to	  pellet	  any	  cell	  
debris,	  then	  separated	  into	  500µL	  aliquots	  and	  stored	  at	  -­‐20°C	  to	  ensure	  one	  single	  freeze-­‐thaw	  cycle	  
in	  preparation	  for	  use	  in	  each	  experiment.	  Pellet	  cultures	  were	  incubated	  an	  additional	  24	  hours	  at	  
room	  temperature	  in	  a	  further	  400µL	  of	  fresh	  ultracentrifuged	  PBS	  prior	  to	  the	  aspiration	  of	  the	  (T48	  
CM)	   supernatant,	   following	   the	   previously	   outlined	   protocol	   for	   the	   collection	   of	   T24	   CM	   and	   the	  
process	  was	  repeated	  for	  the	  generation	  of	  T72	  CM.	  
Post-­‐CM	  generation	  hADMSC	  differentiation	  to	  adipogenic	  lineage	  
Expanded	  hADMSCs	  following	  CM	  generation	  were	  prepared	  for	  adipogenic	  differentiation	  in	  4-­‐well	  
dishes	   (surface	   area	   of	   1.9cm2)	   at	   a	   seeding	   density	   of	   4,000	   cells	   per	   cm2	   and	   were	   cultured	   in	  
standard	  conditions	  (37°C	  and	  5%	  CO2)	  in	  hADMSC-­‐specific	  media	  until	  90%	  confluent.	  Growth	  media	  
in	   the	   ‘test’	   wells	   was	   replaced	   with	   StemPro®	   Adipogenesis	   basal	   medium	   (Life	   Technologies	  
A10410-­‐01),	   StemPro®	   Adipogenesis	   Supplement	   (Life	   Technologies,	   Thermo	   Fisher	   Scientific	  
A10065-­‐01),	   as	   per	   the	   manufacturer’s	   instructions	   whereas,	   the	   ‘control’	   wells	   continued	   to	   be	  
cultured	   in	  growth	  media.	  Cells	  were	   cultured	   for	  21	  days	  with	   fresh	  media	   changes	  every	  3	  days.	  
After	   21	   days,	   cells	  were	   gently	  washed	   in	   PBS	   following	   careful	   aspiration	   of	   the	  media	   to	   avoid	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disruption	  to	  the	  very	  confluent	  cell	  layer.	  Cells	  were	  then	  fixed	  in	  4%	  (w/v)	  PFA/PBS	  for	  15	  minutes,	  
washed	  3	  times	  with	  ultrapure	  deionised	  water	  (dH2O)	  and	  washed	  with	  60%	  (v/v)	  isopropanol	  for	  5	  
minutes.	  Cells	  were	  then	  air-­‐dried	  and	   incubated	  at	   room	  temperature	   in	  a	  working	  solution	  of	  Oil	  
Red	  O	  stain	   (see	   ‘Appendix	  1	   -­‐	  Materials’)	   for	  30	  minutes	  with	  gentle	  agitation.	  Following	   staining,	  
any	   excess	   dye	  was	   removed	  with	   4	   consecutive	   dH2O	  washes	   for	   5	  minutes	   each	   and	   cells	  were	  
allowed	   to	   air	   dry.	   Cells	   were	   visualised	   and	   imaged	   using	   a	   brightfield	   microscope	   at	   low	  
magnifications	   (for	   example,	   10	   or	   20x).	   Successful	   differentiation	   of	   mesenchymal	   stem	   cells	  
towards	  an	  adipogenic	  lineage	  was	  identified	  by	  positive	  Oil	  Red	  O	  staining	  of	  oil	  droplets	  within	  the	  
cells.	  
Post-­‐CM	  generation	  hADMSC	  differentiation	  to	  osteogenic	  lineage	  
Expanded	  hADMSCs	  following	  CM	  generation	  for	  osteogenic	  differentiation	  were	  prepared	  using	  the	  
protocol	  as	  followed	  with	  adipogenic	  differentiation.	  Cells	  in	  ‘test’	  wells	  were	  cultured	  with	  StemPro®	  
Osteocyte/Chondrocyte	   basal	   medium	   (Life	   Technologies,	   Thermo	   Fisher	   Scientific	   A10069-­‐01),	  
StemPro®	  Osteogenesis	  Supplement	   (Life	  Technologies,	  Thermo	  Fisher	  Scientific	  A10066-­‐01)	  as	  per	  
the	   manufacturer’s	   instructions.	   Cells	   were	   subsequently	   fixed	   in	   4%	   PFA/PBS	   for	   15	   minutes,	  
washed	  3	  times	  with	  dH2O	  and	  incubated	  at	  room	  temperature	  in	  a	  working	  solution	  of	  Alizarin	  Red	  S	  
stain	   for	  30	  minutes	  with	  gentle	  agitation.	  Following	  staining,	  as	  per	   the	  adipogenic	  differentiation	  
protocol,	   cells	   were	   washed	   with	   dH2O,	   air	   dried	   and	   imaged	   using	   a	   brightfield	   microscope	   (for	  
example,	   10	   or	   20x).	   Successful	   differentiation	   of	  mesenchymal	   stem	   cells	   towards	   an	   osteogenic	  
lineage	  was	  identified	  by	  positive	  Alizarin	  Red	  S	  staining	  of	  calcium	  deposits	  within	  cells.	  
Post-­‐CM	  generation	  hADMSC	  differentiation	  to	  chondrogenic	  lineage	  
For	  chondrogenic	  differentiation,	  hADMSCs,	  (post-­‐CM	  generation)	  were	  cultured	  at	  very	  high	  density	  
(1x106	  cells	  per	  15mL	  centrifuge	  tube)	  as	  pellet	  cultures,	  centrifuged	  at	  400g	  for	  5	  minutes,	  to	  allow	  
for	   the	   formation	   of	   cellular	   spheroids.	   ‘Test’	   pellet	   cultures	   were	   cultured	   with	   StemPro®	  
Osteocyte/Chondrocyte	   basal	   medium	   (Life	   Technologies,	   Thermo	   Fisher	   Scientific	   A10069-­‐01),	  
StemPro®	   Chondrogenesis	   Supplement	   (Life	   Technologies,	   Thermo	   Fisher	   Scientific	   A10064-­‐01),	   in	  
standard	  conditions	  (37°C	  and	  5%	  CO2)	  for	  21	  days.	  Media	  was	  changed	  every	  3	  days	  with	  care	  taken	  
to	  avoid	  disturbance	  to	  the	  spheroids.	  After	  21	  days,	  cells	  were	  gently	  washed	  and	  fixed	  as	  per	  the	  
adipogenic	  differentiation	  protocol	  and	  were	  incubated	  at	  room	  temperature	  in	  a	  working	  solution	  of	  
Alcian	   Blue	   stain	   overnight,	   in	   the	   dark.	   Following	   staining,	   any	   excess	   dye	   was	   removed	   with	   2	  
consecutive	   washes	   with	   the	   destaining	   solution	   for	   20	   minutes	   each.	   Cells	   were	   visualised	   and	  
imaged	   using	   a	   brightfield	   microscope	   at	   low	   magnifications	   (for	   example,	   10	   or	   20x).	   Successful	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differentiation	  of	  mesenchymal	  stem	  cells	  towards	  a	  chondrogenic	  lineage	  was	  identified	  by	  positive	  
Alcian	  Blue	  staining	  of	  acidic	  polysaccharides	  (for	  example	  glycosaminoglycans)	  in	  cartilage	  deposits	  
within	  cells.	  
Cellular	  senescence	  assay	  
Cells	  that	  have	  entered	  replicative	  senescence,	  a	  feature	  associated	  with	  ageing	  and	  the	  reduced	  rate	  
of	  stem	  cell-­‐mediated	  repair,	  are	  frequently	  observed	  using	  the	  X-­‐gal	  staining	  protocol.	  This	  method	  
was	  first	  reported	  by	  Dimri	  and	  colleagues	  to	  quantify	  the	  number	  of	  cells	  expressing	  β-­‐galactosidase	  
following	  initiation	  of	  cellular	  senescence,	  histochemically	  identifiable	  at	  pH	  6,	   in	  vitro	  (Dimri	  1995).	  
IMR-­‐90	  lung	  fibroblast	  cells	  were	  expanded	  in	  culture	  to	  70%	  confluency	  and	  passaged	  following	  the	  
previously	  detailed	  cell	  culture	  protocols,	  into	  the	  wells	  of	  2	  separate	  12-­‐well	  plates	  (surface	  area	  of	  
3.5cm2)	   at	   a	   seeding	   density	   of	   50,000	   cells	   per	  well.	   Cells	  were	   cultured	  until	   70%	   confluent,	   the	  
media	  was	   aspirated	   from	   each	  well	   and	   cells	  were	  washed	   in	   sterile	   PBS.	   900µL	   of	   fresh	   growth	  
media	   was	   added	   to	   each	   well	   and	   for	   the	   ‘PBS	   control’	   wells	   100µL	   previously	   prepared	   sterile	  
ultracentrifuged	   PBS	   was	   added	   to	   make	   a	   1mL	   final	   volume.	   For	   the	   ‘test’	   wells	   however,	   the	  
required	   concentrations	   of	   conditioned	  media	   previously	   generated	   from	   hADMSCs	  was	   added	   to	  
each	  well	  and	  made	  up	  to	  a	  final	  volume	  of	  1mL	  ultracentrifuged	  PBS.	  For	  example,	  1%	  CM	  required	  
900µL	  of	  fresh	  growth	  media,	  10µL	  CM	  and	  90µL	  PBS.	  Cells	  were	  cultured	  for	  24	  hours	  after	  which	  
the	  media	  was	  aspirated	   from	  each	  well	  and	  replaced	  with	  1mL	  100µM	  H2O2	   in	  growth	  media	  and	  
incubated	   for	   2	   hours,	   in	   order	   to	   initiate	   cellular	   senescence.	   The	   cells	   were	   then	   washed	   with	  
sterile	  PBS	  twice	  prior	  to	  48	  hours	  incubation	  in	  1mL	  fresh	  growth	  media	  in	  standard	  conditions	  (37°C	  
and	   5%	   CO2).	   After	   48	   hours,	   cells	   were	   passaged	   from	   the	   12-­‐well	   plates	   and	   each	   well	   was	   re-­‐
seeded	  into	  3	  wells	  of	  a	  24-­‐well	  plate	  (surface	  area	  of	  1.8cm2)	  at	  a	  density	  of	  800	  cells	  per	  well	  and	  
cultured	  for	  a	  further	  24	  hours	  to	  adhere.	  Cells	  were	  then	  fixed	  with	  0.2%	  glutaraldehyde,	  2%	  PFA	  for	  
5	  minutes,	  rinsed	  twice	  with	  sterile	  PBS	  and	  incubated	  for	  18	  hours	  at	  37°C	  in	  the	  dark	  with	  250µL	  
per	  well	  senescence	  staining	  solution.	  Following	  staining,	  the	  cells	  were	  washed	  twice	  with	  PBS	  and	  
twice	  with	  methanol	  and	  then	  air-­‐dried	  prior	  to	  analysis.	  Cells	  were	  visualised	  and	  counted	  manually	  
using	   an	   inverted	  microscope	   (Zeiss	  A1	   Inverted	  Epifluorescent	  Microscope)	   and	   the	  proportion	  of	  
positively-­‐stained	   (blue)	   senescent	   cells	   were	   recorded	   for	   each	   condition.	   For	   example	   ‘stressed’	  
and	   ‘unstressed’	   controls	   cultured	   in	   the	   presence	   and	   absence	   of	   H2O2,	   respectively	   and	   those	  
conditions	  pre-­‐treated	  with	  CM	  at	  various	  concentrations.	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Animal	  maintenance	  and	  use	  
Ethical	  approval	  
The	  experiments	  were	  performed	  under	  a	  project	   license	  from	  the	  United	  Kingdom	  Home	  Office	   in	  
agreement	  with	  the	  Animals	  (Scientific	  Procedures)	  Act	  1986.	  Healthy	  animals	  were	  maintained	  and	  
housed	   in	   accordance	   to	   the	   Animals	   (Scientific	   Procedures)	   Act	   1986	   (UK)	   within	   the	   Biological	  
Resource	  Unit	   at	   the	  University	  of	  Reading	  under	   standard	  environmental	   conditions	   (20-­‐22°C,	  12-­‐
hour	  light-­‐dark	  cycle)	  and	  provided	  food	  (standard	  pelleted	  diet)	  and	  water	  ad	  libitum.	  	  
Maintenance	  of	  heterozygous	  ERCC1	  mutant	  mouse	  populations	  
To	   maintain	   sufficient	   young	   and	   healthy	   experimental	   mouse	   populations	   within	   the	   Biological	  
Resources	   Unit,	   regular	   breeding	   pairs	   were	   set	   up	   and	   monitored.	   The	   ERCC1	   mutants	   were	  
reported	   to	   be	   embryonically	   lethal	   on	   a	   single	   inbred	   laboratory	   mouse	   strain	   by	   the	   research	  
groups	   that	   developed	   the	   ERCC1	  mouse	  model	   (Weeda,	   et	   al.	   1997).	   This	   feature	   resulted	   in	   the	  
requirement	  to	  breed	  and	  maintain	  populations	  of	   two	  separate	  mouse	  strains	   (C57BL/6	  and	  FVB),	  
both	   heterozygous	   for	   the	   ERCC1	   mutation	   for	   the	   knockout	   (+/-­‐)	   as	   well	   as	   the	   knocked-­‐down,	  
‘delta’	  mutant	  (d/+),	  giving	  rise	  to	  a	  total	  of	  four	  heterozygous	  breeding	  populations	  (+/-­‐	  C57BL/6,	  +/-­‐	  
FVB,	   d/+	   C57BL/6	   and	   d/+	   FVB).	   Regular	   breeding	   of	   animals	   from	   each	   of	   these	   heterozygous	  
populations	   with	   a	   wild-­‐type	   mouse	   of	   the	   same	   inbred	   strain,	   continuously	   maintained	   healthy	  
cohorts.	  All	  of	  the	  heterozygous	  breeding	  animals	  live	  the	  full,	  expected	  lifespan	  of	  non-­‐mutant,	  wild-­‐
type	  mice	  and	  do	  not	  experience	  any	  of	  the	   impairments	  or	  health	   issues	  associated	  with	  progeric,	  
full	   knockout	   (-­‐/-­‐)	  or	  delta	  mutant	   (d/-­‐)	  animals.	  However,	   to	  give	   rise	   to	   the	  progeric	  ERCC1	  delta	  
mice	   used	   in	   experiments	   for	   the	   present	   study,	   heterozygous	   +/-­‐	   animals	   from	   one	  
strain/background	   were	   bred	   with	   heterozygous	   d/+	   animals	   on	   the	   other	   strain/background.	   For	  
example,	   as	   FVB	   females	   were	   found	   to	   breed	   more	   successfully	   and	   produced	   larger	   litter	   sizes	  
(average	   8-­‐10	   pups	   each	   compared	   to	   5-­‐7	   pups	   per	   C57BL/6	   litter),	   an	   example	   breeding	   pair	  
comprised	  of	  a	  female	  FVB	  (+/-­‐)	  and	  a	  male	  C57BL/6	  (d/+).	  
Isolation	  of	  genomic	  DNA	  for	  genotyping	  of	  ERCC1	  litters	  
Ear	   clip	   samples	   were	   collected	   into	   1.5mL	   micro-­‐centrifuge	   tubes	   and	   placed	   on	   ice.	   Chemical	  
digestion	  of	  the	  ear	  tissue	  was	  initiated	  by	  adding	  100µL	  of	  50mM	  sodium	  hydroxide	  (NaOH)	  to	  each	  
sample	  followed	  by	  brief	  vortexing.	  Samples	  were	  incubated	  at	  95°C	  on	  a	  heat	  block	  for	  1	  hour	  with	  
gentle	  shaking.	  The	  chemical	  digestion	  was	  stopped	  by	  neutralisation	  with	  10µL	  of	  1.5M	  Tris	  buffer	  
(pH	  7.4)	  and	  samples	  were	  centrifuged	  at	  13,000	  rpm	  for	  1	  minute.	  The	  solutions	  of	  crudely	  isolated	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genomic	  DNA	  were	  then	  used	  in	  a	  genotyping	  polymerase	  chain	  reaction	  (PCR)	  protocol	  or	  stored	  at	  -­‐
20°C.	  
Polymerase	  chain	  reaction	  (PCR)	  protocol	  for	  the	  genotyping	  of	  ERCC1	  litters	  
ERCC1	  primers	  (listed	  in	  ‘Appendix	  3’)	  were	  used	  in	  a	  primer	  ‘cocktail’	  solution	  and	  were	  combined	  
with	  other	  essential	  PCR	  components	  including	  taq	  polymerase,	  a	  deoxynucleotide	  (dNTP)	  mix	  and	  a	  
buffer	  solution	  containing	  magnesium	  chloride	  (MgCl2)	  to	  formulate	  a	  ‘master	  mix’,	  made	  in-­‐house.	  
Aliquots	  of	  the	  ‘master	  mix’	  were	  then	  added	  to	  5µL	  volumes	  of	  the	  isolated	  DNA	  solutions	  in	  0.2mL	  
PCR	  tubes	  (Eppendorf	  0030	  123.332)	  and	  run	  on	  the	  following	  cycle	  programme	  on	  a	  Bio-­‐Rad	  T100	  
Thermal	  Cycler:	  
1.	  Incubate	  at	  95°C	  for	  5	  minutes	  
2.	  Incubate	  at	  92°C	  for	  30	  seconds	  
3.	  Incubate	  at	  59°C	  for	  30	  seconds	  
4.	  Incubate	  at	  72°C	  for	  50	  seconds	  	  	  
5.	  Cycle	  steps	  2-­‐4	  for	  32	  times	  
6.	  Incubate	  at	  72°C	  for	  5	  minutes	  
7.	  Cool	  to	  18°C	  
8.	  End	  and	  store	  at	  4°C	  
Gel	  electrophoresis	  for	  the	  genotyping	  of	  ERCC1	  litters	  
Agarose	  was	  dissolved	  in	  1x	  Tris-­‐acetate-­‐EDTA	  (TAE)	  to	  make	  a	  2%	  (mini)gel	  containing	  5%	  SYBR	  safe	  
DNA	  gel	  stain	  (Thermo	  Fisher	  Scientific	  S33102),	  with	  care	  taken	  to	  avoid	  creating	  air	  bubbles.	  Once	  
set,	  the	  gel	  was	  submerged	  in	  TAE	  buffer	  in	  the	  electrophoresis	  chamber,	  the	  combs	  were	  removed	  
and	   samples	  were	   loaded	   into	  wells	   along	  with	  Orange	  G	   loading	   buffer	   (Thermo	   Fisher	   Scientific	  
R0631)	  (for	  example	  5µL	  Orange	  G	  added	  to	  15µL	  PCR	  reaction	  product).	  The	  first	  well	  of	  each	  row	  
however,	   was	   loaded	   with	   5µL	   100bp	   DNA	   ladder	   (Promega	   G2101)	   and	   following	   a	   40-­‐minute	  
electrophoresis	  run	  at	  70V,	  the	  resulting	  presence	  and	  sizes	  of	  bands,	  visualised	  and	  imaged	  using	  an	  
ultraviolet	  (UV)	  transilluminator	  system,	  were	  used	  to	  determine	  the	  genotypes	  of	  ERCC1	  mice.	  Band	  
sizes	  of	  246bp,	  390bp	  and	  500bp	   indicated	   the	  presence	  of	   a	  wild-­‐type,	  ERCC1	  mutant	  and	  ERCC1	  
delta	  allele,	  respectively.	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In	  vivo	  experimentation	  
Intraperitoneal	  (IP)	  injection	  of	  CM	  for	  in	  vivo	  experimentation	  
Under	  aseptic	  conditions,	  sterile	  PBS	  was	  added	  to	   individual	  conditioned	  media	  aliquots	   (in	  sterile	  
1.5mL	   micro-­‐centrifuge	   tubes),	   calculated	   based	   on	   animal	   body	   weight,	   consistent	   between	   all	  
treated	  animals	  in	  each	  cohort,	  as	  per	  the	  doses	  described	  below.	  Vehicle-­‐treated	  control	  doses	  were	  
prepared	   using	   comparable	   volumes	   of	   sterile	   PBS.	   The	   doses	   of	   solution	   to	   be	   injected	   were	  
prepared	   in	   1mL	   insulin	   syringes	   (31G	  needle).	   Animals	  were	   restrained	   by	   the	   scruff	   of	   the	   neck,	  
following	   good	   animal	   handling	   technique.	   Briefly,	   the	   scruff	   was	   grasped	   with	   the	   thumb	   and	  
forefinger	  and	  the	  tail	  tucked	  away	  by	  the	  little	  finger.	  Whilst	  restraining	  the	  mouse	  in	  a	  horizontal	  
position	   in	   one	   hand,	   the	   other	   hand	   is	   free	   to	   inject	   the	   doses	   intraperitoneally.	   The	   needle	  was	  
inserted	  into	  the	  posterior	  quadrant	  of	  the	  abdomen,	  a	  small	  distance	  away	  from	  the	  midline	  (right-­‐	  
side	  of	  the	  animal,	  between	  the	  midline	  and	  the	  hind-­‐limb)	  at	  a	  45°	  angle	  pointed	  upwards	  and	  away	  
to	  avoid	  the	  bladder.	  Following	  injection,	  animals	  were	  returned	  to	  their	  cages	  and	  monitored	  at	  30-­‐
minute	  intervals	  for	  up	  to	  2	  hours	  to	  ensure	  animals	  remained	  healthy	  and	  in	  a	  good	  condition.	  Mice	  
were	  weighed	  weekly	  to	  ensure	  accurate	  dose	  calculation	  and	  to	  further	  monitor	  the	  health	  of	  the	  
animals.	  
CM/PBS	  I.P	  injection	  schedules	  for	  in	  vivo	  experimentation	  
The	   CM	   used	   in	   all	   experiments	   (both	   in	   vivo	   and	   in	   vitro)	   was	   collected	   in	   the	   same	   batch	   for	  
consistency	  and	  was	  tested	  for	  protection	  against	  H2O2	  stress-­‐induced	  cellular	  senescence	  as	  well	  as	  
post-­‐CM	  cell	  differentiation	   in	  vitro	  assays,	  using	  the	  protocols	  previously	  described.	  Naturally-­‐aged	  
20-­‐month-­‐old	  mice	   (C57BL/6)	  were	   injected	   (I.P)	  with	  15µL/g	  doses	  of	  CM,	   (or	  PBS	  vehicle	  control)	  
every	  2	  weeks,	  over	  a	  time	  period	  of	  4	  months	  (until	  24	  months	  of	  age),	  resulting	   in	  8	   injections	   in	  
total.	  Animals	  were	  euthanised	  and	  tissues	  harvested	  2	  weeks	  after	  the	  final	  I.P	  injection.	  
ERCC1	   delta	  mice	   (and	  wild-­‐type	   littermate	   controls)	  were	   injected	   (I.P)	  with	   30µL/g	   doses	   of	   the	  
same	  batch	  of	   tested	  CM	  as	  used	   in	  the	  naturally-­‐aged	   in	  vivo	  experiment,	   (or	  PBS	  vehicle	  control)	  
every	   2	   weeks	   over	   a	   time	   period	   of	   6	   weeks	   (from	   9	   weeks	   to	   13	   weeks	   of	   age),	   resulting	   in	   3	  
injections	  in	  total.	  Animals	  were	  euthanised	  and	  tissues	  harvested	  2	  weeks	  after	  the	  final	  I.P	  injection	  
at	  16	  weeks	  of	  age.	  
Measurement	  of	  mouse	  forelimb	  grip	  strength	  
Forelimb	  grip	  strength	  measurements	  were	  made	  using	  a	  digital	  force	  gauge	  (Chatillon	  DFM-­‐2).	  The	  
force	  gauge	  was	  fixed	  firmly	  to	  the	  bench	  with	  the	  metal	  grip	  bar	  extruding	  from	  the	  bench	  surface.	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The	  force	  meter	  was	  tared	  to	  zero	  and	  the	  mouse	  was	  gently	  lifted	  by	  the	  tail	  and	  held	  at	  a	  height	  in	  
which	  the	  mouse	  could	  firmly	  grasp	  the	  bar.	  The	  grip	  was	  inspected	  to	  confirm	  that	  the	  mouse	  had	  a	  
good,	   symmetrical	   grasp	  with	  both	   front	  paws.	  At	  a	   slow,	   consistent	   speed,	   the	  mouse	  was	  pulled	  
back,	  away	  from	  the	  grip	  strength	  meter,	  until	  the	  grasp	  was	  broken.	  At	  this	  point,	  the	  force	  gauge	  
measured	  the	  peak/maximal	  force	  in	  grams	  and	  the	  value	  was	  recorded.	  The	  process	  was	  repeated	  3	  
times	  per	  animal	  with	  at	  least	  1-­‐minute	  intervals	  between	  testing	  to	  allow	  the	  mouse	  to	  rest	  and	  to	  
avoid	  habit	  formation.	  Peak	  values	  as	  well	  as	  average	  force	  were	  used	  during	  analysis,	  normalised	  to	  
body	  weight.	  
Measurement	  of	  motor	  coordination	  and	  balance	  through	  rotarod	  
performance	  testing	  
Motor	   coordination	   was	   measured	   through	   performance	   testing	   using	   an	   accelerating	   rotarod	  
system	  (Panlab/Harvard	  Apparatus	  LE	  8500).	  Mice	  were	  acclimatised	  to	  the	  rotarod	  system	  set	  to	  a	  
start	   speed	   of	   4	   rpm.	   The	   mouse	   was	   gently	   placed	   on	   the	   rotating	   rod,	   facing	   away	   from	   the	  
direction	  of	   rotation	   to	  ensure	   the	  mouse	  walked	   forward	   for	  a	  1-­‐minute	  duration.	  The	  mice	  were	  
monitored	  to	  ensure	  they	  did	  not	  attempt	  to	  turn	  in	  their	  lane	  or	  grasp	  onto	  the	  rotating	  rod	  to	  avoid	  
walking.	   Between	   1-­‐minute	   trial	   runs,	   animals	   were	   returned	   to	   their	   cages	   for	   10-­‐minute	   rest	  
intervals	   and	   the	   apparatus	   was	   cleaned	   with	   a	   mild,	   animal-­‐safe	   cleanser.	   The	   procedure	   was	  
repeated	  for	  a	  total	  of	  3	  times.	  Following	  adequate	  acclimatization	  and	  rest	  period,	  the	  mouse	  was	  
placed	   on	   the	   rotating	   rod	   as	   previously	   described	   and	   after	   10	   seconds	   of	   steady	   walking,	   the	  
acceleration	   programme	   was	   initiated	   until	   the	   mouse	   fell	   and	   triggered	   the	  measurement	   to	   be	  
recorded	  on	   the	   system.	  Apparatus	  was	  cleaned	  with	  a	  mild,	  animal-­‐safe	  cleanser	  and	   the	  process	  
was	  repeated	  3	  times	  separated	  by	  15-­‐minute	  rest	   intervals.	  A	  note	  of	  the	   latency	  to	  fall	   (seconds)	  
and	   the	   rotating	   speed	   at	   fall	   (rpm)	   were	   made	   and	   these	   parameters	   analysed	   between	  
treatment/genotype/age	  groups.	  
Euthanasia	  procedure	  
Mice	  were	  humanely	  euthanised	  using	  Schedule	  1	  killing	  through	  carbon	  dioxide	  (CO2)	  asphyxiation	  
and	  death	  was	  confirmed	  by	  cervical	  dislocation.	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  at	  whole	  muscle	  level	  
Extensor	  Digitorum	  Longus	  (EDL)	  muscle	  dissection	  from	  mouse	  	  
Myofibres	  were	  isolated	  from	  the	  Extensor	  digitorum	  longus	  (EDL)	  muscle	  of	  the	  hindlimb.	  The	  mice	  
were	   euthanised	   using	   schedule	   1	   killing	   by	   carbon	   dioxide	   (CO2)	   asphyxiation	   and	   EDL	   muscle	  
dissection	  occurred	   immediately	   following	  death	  was	  confirmed.	  A	  70%	  ethanol	   spray	  was	  used	   to	  
sterilise	  the	  hind	  leg	  fur	  and	  surrounding	  area.	  A	  scalpel	  blade	  was	  used	  to	  make	  incisions	  in	  the	  skin	  
around	   the	   thigh	   (proximal	   to	   the	   EDL	   or	   TA	   muscles	   to	   avoid	   damage),	   pulling	   distally	   with	   the	  
thumb	  and	  forefinger,	  over	  and	  away	  from	  the	  footpad	  the	  skin	  is	  carefully	  removed.	  An	  incision	  was	  
made	  and	  using	   the	   same	  distal	  pulling	  action,	   the	   remaining	   skin	  on	   the	   footpad	  was	   removed	   in	  
order	  to	  reveal	  the	  distal	  tendons	  attached	  to	  the	  digits.	  Grade	  4	  forceps	  were	  used	  to	  remove	  the	  
connective	  tissue	  (fascia)	  layer	  covering	  the	  TA	  and	  EDL	  muscles.	  The	  distal	  tendon	  of	  the	  TA	  muscle	  
was	   located	   and	   incised	  using	   curved	  microscissors	   approximately	   1cm	  below	   the	   TA	  muscle	   body	  
and	   using	   grade	   4	   forceps,	   pulled	   proximally	   towards	   the	   knee,	   revealing	   the	   extent	   of	   the	   EDL	  
muscle	   beneath.	   The	   forceps	  were	   used	   to	   locate	   the	   four	   distal	   tendons	   of	   the	   EDL	   raising	   each	  
superior	  to	  the	  footplate	  and	  freeing	  the	  tendons	  from	  the	  ankle	  cartilage	  by	  gently	  pulling	  posterior	  
to	  the	  muscle	  body.	  The	  two	  proximal	  tendons	  of	  the	  EDL	  were	  incised	  using	  microscissors	  furthest	  
from	   the	  muscle	   body	   as	   possible,	   leaving	   the	  majority	   of	   the	   tendons	   intact	   and	   freeing	   the	   EDL	  
muscle,	  whilst	  the	  muscle	  was	  kept	  taut	  using	  forceps	  to	  pull	  proximally	  to	  the	  knee.	  The	  muscle	  was	  
removed	  from	  the	  limb	  and	  incubated	  at	  37°C	  and	  5%	  CO2	  in	  the	  previously	  prepared	  1mL	  aliquot	  of	  
2mg/mL	  type-­‐1	  collagenase	  solution	  for	  single	  myofibre	  digestion	  or	  frozen	  for	  histological	  analyses.	  
Dissection	  of	  the	  Tibialis	  Anterior	  and	  Soleus	  muscle	  from	  mouse	  
The	  Tibialis	  Anterior	  (TA)	  muscle	   lies	  superior	  to	  the	  EDL	  in	  the	  hindlimb	  and	  in	  order	  to	  access	  the	  
EDL,	   the	  distal	   tendon	  of	  the	  TA	  was	   incised	  using	  microscissors	  and	  the	  muscle	   lifted	  anteriorly	  to	  
reveal	   the	  extent	  of	   the	  EDL	  beneath.	   It	   is	   at	   this	  point	   in	   the	  procedure	   therefore	   that	   the	  TA	  be	  
dissected	  from	  the	  hindlimb	  if	  required.	  Careful	  incision	  of	  the	  proximal-­‐most	  region	  of	  the	  TA	  where	  
it	   arises	   from	   the	   lateral	   condyle	   of	   the	   tibia	   allowed	   for	  muscle	   removal.	   The	   Soleus	   however	   is	  
located	  in	  the	  posterior	  compartment	  of	  the	  hindlimb	  with	  the	  Gastrocnemius	  lying	  superficial	  to	  the	  
Soleus	   and	   arises	   from	   the	   fibula	   (and	   some	   fibres	   from	   the	   medial	   border	   of	   the	   tibia)	   running	  
posterior	   to	   insert	   (along	  with	   the	  Gastrocnemius)	   into	   the	   calcaneus	   (heel	   bone)	   via	   the	   Achilles	  
tendon.	  The	  Gastrocnemius	  was	  required	  to	  be	  gently	  dissected	  away	  and	  removed	  from	  the	  Soleus	  
muscle	  body,	  leaving	  the	  Achilles	  tendon	  intact.	  As	  well	  as	  this,	  the	  Soleus	  required	  careful	  removal	  
from	   the	  muscles	   beneath	   (for	   example	   the	   Flexor	   digitorum	   longus).	   The	   proximal	   tendon	   of	   the	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Soleus	  was	   lifted	  with	   forceps	  and	   incised	  using	  microscissors	   followed	  by	  the	   lifting	  and	  cutting	  of	  
the	  distal	  (Achilles)	  tendon	  to	  complete	  dissection.	  
Snap-­‐freezing	  of	  tissue	  
In	   preparation	   for	   the	   euthanisation,	   dissection	   and	   subsequent	   snap-­‐freezing	   of	   mouse	   tissue,	   a	  
beaker	  of	  200mL	  iso-­‐pentane	  was	  frozen	  following	  immersion	  into	  a	  dewar	  of	  liquid	  nitrogen.	  Freshly	  
dissected	   tissue	   (after	   fresh	  weight	  was	  measured)	  was	   then	  positioned	  appropriately	   (muscle	   laid	  
straight)	   on	   a	   small,	   2cm2	   piece	   of	   aluminium	   foil	   and	   lowered	   onto	   the	   frozen	   iso-­‐pentane.	   The	  
freezing	   of	   the	   tissue	   occurred	   rapidly	   (snap-­‐frozen)	   indicated	   by	   the	   muscle	   appearing	   whiter	   in	  
colour.	  Once	   completely	   frozen,	   the	   tissue	  was	   carefully	   removed	   from	   the	   foil	   strip	   using	   forceps	  
and	  quickly	  placed	  into	  labelled	  microfuge	  tubes	  on	  dry	  ice	  (forceps	  and	  tubes	  were	  pre-­‐cooled	  in	  dry	  
ice	   before	   use	   to	   minimise	   tissue	   thawing).	   Eppendorfs	   were	   transferred	   from	   dry	   ice	   to	   -­‐80°C	  
freezers	  for	  storage.	  
Preparation	  of	  muscle	  tissue	  for	  cryosectioning	  
Prior	   to	   the	   removal	   of	   frozen	   tissue	   from	   -­‐80°C	   storage,	   a	   glass	   beaker	   ethanol	   bath	  was	   super-­‐
cooled	   on	   dry	   ice.	   1cm2	   aluminium	   foil	   cubes	   were	   prepared	   and	   filled	   with	   O.C.T	   embedding	  
medium	  (TAAB	  O023)	  and	  the	  snap-­‐frozen	  tissue	  mounted	  into	  the	  O.C.T	  cube	  and	  rapid	  freezing	  was	  
enabled	   by	   plunging	   into	   the	   super-­‐cooled	   ethanol	   bath	   to	   avoid	   thawing.	   The	  muscle	   tissue	  was	  
cryosectioned	  transversely	  at	  a	  10µm	  section	  thickness	  using	  a	  Bright	  OTF	  cryostat	  (OTF/AS-­‐001/HS).	  
Serial	  muscle	  sections	  (approximately	  12	  sections,	  therefore	  equivalent	  to	  ~120µm	  per	  muscle	  mid-­‐
belly	   region)	   were	   mounted	   onto	   glass	   slides	   (Menzel-­‐Glaser	   J2800AMNZ),	   air-­‐dried	   at	   room	  
temperature	  for	  30	  minutes	  and	  stored	  at	  -­‐80°C	  for	  future	  processing.	  
Haematoxylin	  and	  eosin	  (H&E)	  histological	  staining	  protocol	  
Glass	   slides	   with	   mounted	   tissue	   sections	   were	   removed	   from	   -­‐80°C	   storage,	   incubated	   at	   room	  
temperature	   for	  30	  minutes	  to	  dry	  and	  washed	   in	  1	  x	  PBS	  for	  2	  minutes	   followed	  by	  an	  18-­‐minute	  
incubation	   in	   Mayer’s	   haematoxylin	   to	   stain	   the	   nucleic	   material.	   The	   haematoxylin	   stain	   was	  
removed	   using	   a	   2-­‐minute	  wash	   in	   distilled	  water	   and	   2	   dips	   in	   acidic	   alcohol	   (see	   ‘Appendix	   1	   –	  
Materials’).	   The	   slides	   were	   immersed	   in	   running	   water	   for	   5	   minutes	   and	   then	   washed	   in	   70%	  
ethanol	  for	  1	  minute.	  Next,	  the	  protein	  material	  was	  stained	  by	  a	  1%	  eosin	  solution	  for	  2-­‐3	  minutes	  
and	  to	  finish,	  underwent	  a	  series	  of	  ethanol	  washes	  (90%,	  100%,	  100%,	  100%)	  to	  dehydrate	  before	  
clearing	   the	  samples	  with	  xylene	   (2	  washes,	  3	  minutes	  each).	  Cover	  slips	  were	  mounted	  using	  DPX	  
mounting	  medium	  (Fisher	  Scientific	  10050080).	  Slides	  were	  allowed	  to	  air	  dry	  and	  sections	  were	  then	  
visualised	  and	  imaged	  using	  a	  brightfield	  microscope	  at	  low	  magnifications	  (for	  example,	  5	  or	  10x).	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Succinate	  dehydrogenase	  (SDH)	  histological	  staining	  protocol	  to	  determine	  
muscle	  oxidative	  capacity	  
As	  per	  the	  H&E	  staining	  protocol,	   frozen	  tissue	  sections	  were	  air-­‐dried	  at	  room	  temperature	  for	  30	  
minutes.	  A	  border	  surrounding	  the	  sections	  was	  drawn	  using	  an	  ‘ImmEdge’	  hydrophobic	  barrier	  pen	  
(Vector	   Laboratories	   H-­‐4000).	   The	   NBT	   and	   succinate	   stocks	   were	   mixed	   with	   phenazine	  
methosulphate	   to	   form	   the	   incubation	  medium,	   just	  prior	   to	  use	  and	  was	  kept	  out	  of	   strong	   light.	  
The	  incubation	  medium	  was	  added	  directly	  to	  samples	  at	  room	  temperature	  and	  allowed	  to	  develop	  
for	   approximately	  2-­‐4	  minutes	   (for	  Soleus	   and	  EDL	  muscles)	  until	   a	  blue/purple	   colour	  was	   visible.	  
Samples	  were	  washed	  in	  distilled	  water	  for	  1	  minute	  to	  stop	  the	  staining	  reaction	  and	  fixed	  in	  formol	  
calcium	   for	   15	   minutes	   before	   mounting	   glass	   cover	   slips	   using	   ‘Hydromount’,	   a	   water-­‐based	  
mounting	  medium	  (National	  Diagnostics	  HS-­‐106).	  Sections	  were	  then	  visualised	  and	  imaged	  using	  a	  
brightfield	  microscope	  at	  low	  magnifications	  (for	  example,	  5	  or	  10x).	  
Endothelial	  marker	  CD31	  histological	  staining	  protocol	  to	  identify	  vasculature	  
Tissue	   sections	   were	   air-­‐dried	   and	   prepared	   with	   a	   hydrophobic	   border,	   as	   per	   the	   SDH	   staining	  
protocol.	  Once	  dry,	  the	  sections	  were	  washed	  with	  PBS	  for	  5	  minutes	  and	  incubated	  sequentially,	  for	  
15	  minutes	   each,	   with	   the	   Avidin	   and	   Biotin	   components	   of	   an	   Avidin/Biotin	   Blocking	   Kit	   (Vector	  
Laboratories	  SP-­‐2001).	  Sections	  were	  then	  washed	  in	  0.05%	  Tween	  20	  (Sigma-­‐Aldrich	  P9416)	  in	  PBS	  
(PBS-­‐T)	   for	   5	  minutes	   and	   incubated	   in	  wash	  buffer	   for	   30	  minutes	   as	   an	   antigen	   blocking	   step	   to	  
avoid	   any	  non-­‐specific	   antibody	  binding.	   Following	   this,	   the	  wash	  buffer	  was	   removed	   and	   the	   rat	  
anti-­‐mouse	  CD31	  primary	  antibody	   (Bio-­‐Rad	  MCA2388)	   (pre-­‐diluted	  at	  1:150	   in	  wash	  buffer	   for	  30	  
minutes)	  was	  added	  to	  the	  sections	  and	  incubated	  for	  1	  hour	  at	  room	  temperature.	  To	  remove	  any	  
un-­‐bound	  antibody,	  sections	  were	  then	  washed	  3	  times	  in	  PBS-­‐T	  for	  5	  minutes	  each.	  The	  rabbit	  anti-­‐
rat	  HRP	  secondary	  antibody	  (Abcam	  ab6734)	  (pre-­‐diluted	  at	  1:200	  in	  wash	  buffer	  for	  30	  minutes)	  was	  
added	   to	   the	   sections	   and	   incubated	   for	   1	   hour	   at	   room	   temperature.	   To	   remove	   any	   un-­‐bound	  
antibody,	   sections	  were	   then	  washed	  a	   further	  3	   times	   in	  PBS-­‐T	   for	  5	  minutes	  each.	   Following	   the	  
manufacturer’s	   instructions,	   sections	  were	   then	   incubated	   for	   10	  minutes	   in	   Vectastain	   Elite	   ABC-­‐
HRP	   solution	   (Vector	   Laboratories	   PK-­‐6100)	   and	  washed	   a	   further	   3	   times	   in	   PBS-­‐T	   for	   5	  minutes	  
each.	   Following	   the	  manufacturer’s	   instructions,	   sections	   were	   then	   incubated	   in	   DAB	   Peroxidase	  
(HRP)	   Substrate	   solution	   for	   approximately	   4-­‐5	   minutes	   until	   sections	   had	   stained	   a	   grey	   colour.	  
Staining	  development	  was	  stopped	  with	  a	  1-­‐minute	  wash	  in	  distilled	  H2O.	  Slides	  were	  then	  incubated	  
in	  a	  series	  of	  100%	  ethanol	  dehydration	  steps	   (3	  times,	  1	  minute	  each)	  and	  a	   further	   incubation	   in	  
xylene	   for	   1	   minute,	   before	   glass	   cover	   slips	   were	   mounted	   on	   each	   slide	   using	   DPX	   mounting	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medium	  (Fisher	  Scientific	  10050080).	  Slides	  were	  allowed	  to	  air	  dry	  and	  sections	  were	  then	  visualised	  
and	  imaged	  using	  a	  brightfield	  microscope	  at	  low	  magnifications	  (for	  example,	  5	  or	  10x).	  
Immunohistochemistry	  
Glass	   slides	   were	   removed	   from	   -­‐80°C	   storage	   and	   prepared	   as	   per	   the	   SDH	   histological	   staining	  
protocol.	   Samples	   were	   washed	   twice	   in	   PBS	   and	   care	   was	   taken	   to	   avoid	   disrupting	   the	   section	  
adherence.	   PBS	  was	   replaced	  with	   permeability	   buffer	   and	   incubated	   at	   room	   temperature	   for	   15	  
minutes,	  followed	  by	  further	  washing	  stages,	  three	  times	  with	  PBS,	  then	  once	  with	  wash	  buffer	  as	  a	  
blocking	  step	  to	  avoid	  any	  non-­‐specific-­‐binding,	  for	  30	  minutes.	  The	  wash	  buffer	  was	  removed	  from	  
the	  sample	  and	  primary	  antibody	  (pre-­‐diluted	   in	  wash	  buffer	  at	  room	  temperature	  for	  30	  minutes)	  
was	  added	  and	  incubated	  for	  1	  hour	  at	  room	  temperature.	  The	  sample	  was	  washed	  5	  times	  in	  wash	  
buffer	   to	   remove	   any	   unbound	   primary	   antibody	   and	   the	   first	   secondary	   antibody	   (pre-­‐diluted	   in	  
wash	  buffer	  at	  room	  temperature	  for	  30	  minutes	  in	  the	  dark)	  was	  added	  and	  incubated	  for	  1	  hour	  at	  
room	   temperature	   in	   the	   dark.	   The	   sample	   was	   washed	   3	   times	   in	   wash	   buffer	   to	   remove	   any	  
unbound	  secondary	  antibody.	  Finally,	  samples	  were	  covered	  with	  a	  cover	  slip	  affixed	  with	  mounting	  
medium	  and	  DAPI,	  for	  analysis.	  With	  the	  Myosin	  Heavy	  Chain	  (MHC)	  isoform	  protocol,	  primary	  and	  
secondary	   antibodies	   were	   added	   sequentially	   and	   pairs	   of	   slides	   (serial	   sections)	   were	   divided	  
accordingly	  between	  alternative	  pairings	  of	  the	  three	  MHC	  isoforms	  (i.e.	  slide	  1:	  Type	  IIA	  and	  type	  I,	  
slide	  2:	  type	  IIA	  and	  type	  IIB)	  to	  avoid	  cross-­‐reactivity	  (IgG	  targets).	  
Imaging	  of	  muscle	  sections	  and	  data	  analysis	  
Muscle	   sections	   were	   processed	   for	   immunohistochemical	   or	   histological	   staining	   protocols	   and	  
viewed	  using	  the	  Zeiss	  AxioImager	  or	  Zeiss	  AxioSkop	  microscope	  systems,	  AxioCam	  MRm	  camera	  and	  
AxioVision	   software	   (version	   4.9.1)	   5x	   magnification	   images	   were	   captured	   and	   stitched/merged	  
together	   using	   Adobe	   Photoshop	   CS4	   image	   manipulation	   software	   to	   form	   photographs	   of	   the	  
overall	  muscle	  section.	  Myonuclei,	  SDH	  positive	  myofibres	  and	  total	  myofibre/	  myofibre	  typing	  (ratio	  
of	  type	  I,	  type	  IIA	  and	  type	  IIb	  myofibres)	  counts	  were	  carried	  out	  on	  stitched	  whole	  muscle	  section	  
5x	  images.	  CD31	  positive	  capillary	  counts	  were	  carried	  out	  on	  20x	  magnification	  images	  within	  1mm2.	  
The	   ‘ImageJ’	   software	   ‘Cell	   Counter’	   plug-­‐in	   analysis	   tool	   was	   used	   to	   count	  
myofibres/cells/capillaries.	   10x	   magnification	   images	   were	   captured	   (representative,	   comparable	  
locations	   in	  muscle)	   in	   order	   to	  perform	   cross-­‐sectional	   area	   (CSA)	   analysis	   of	  myofibres	  using	   the	  
‘Outline’	  measurement	  tool	  in	  the	  AxioVision	  (version	  4.9.1)	  software.	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Quantitative	  real-­‐time	  polymerase	  chain	  reaction	  (qPCR)	  
Muscles	  were	  wrapped	  in	  aluminium	  foil	  and	  submerged	  into	  liquid	  nitrogen,	  following	  this,	  muscles	  
were	  pulverised	  into	  a	  powder	  and	  transferred	  to	  1.5mL	  microfuge	  tubes	  with	  a	  flat	  base.	  500µL	  of	  
TRIzol	   reagent	   (Invitrogen	   15596-­‐018)	  was	   added	   to	   each	   tube	   and	   the	   sample	   solubilised	   using	   a	  
tissue	   homogeniser.	   Total	   RNA	   was	   prepared	   from	   muscle	   samples	   using	   the	   RNeasy®	   Mini	   Kit	  
(Qiagen	   74104)	   and	   RNase-­‐Free	   DNase	   Set	   (Qiagen	   79254),	   according	   to	   the	   manufacturer’s	  
instructions.	   According	   to	   the	   RNA	   concentrations,	   measured	   using	   the	   Nanodrop	   2000	   (Thermo	  
Fisher	  Scientific),	  0.5µg	  of	  total	  RNA	  was	  reverse	  transcribed	  using	  the	  RevertAid	  H	  Minus	  First	  Strand	  
cDNA	  Synthesis	  Kit	  (Thermo	  Fisher	  Scientific	  K1631),	  following	  the	  manufacturer’s	  instructions.	  From	  
each	  sample	  5µL	  was	  used	  to	  prepare	  arbitrary	  dilutions	  of	  5	  standards.	  The	  optimal	  efficiencies	  of	  
each	  primer	   (housekeeping	  gene	  and	  genes	  of	   interest)	   fall	  between	  90	  and	  110%.	  Relative	  mRNA	  
levels	  were	  analysed	  by	  quantitative	   real-­‐time	  PCR	   (qPCR),	  using	   the	   following	  cycling	  protocol:	  15	  
seconds	  at	  95°C,	  60	  seconds	  at	  60°C,	  on	  a	  StepOnePlus™	  Real	  Time	  PCR	  system,	  using	   the	  Applied	  
Biosystems	  SYBR	  Green	  PCR	  Master	  Mix	   (Thermo	  Fisher	   Scientific	  4309155)	  and	  StepOne	   software	  
v.2.1.	   Primers	   were	   designed	   using	   the	   primer	   designing	   tool	   on	   the	   NCBI	   Blast	   website	   and	   the	  
primers	   listed	   in	   Appendix	   3.	   All	   data	   were	   normalised	   to	   the	   housekeeping	   gene,	   hypoxanthine-­‐




Skeletal	  muscle	  analyses	  at	  cellular	  level	  
Mouse	  EDL	  single	  myofibre	  isolation	  	  
The	  rate	  of	  enzymatic	  digestion	  and	  separation	  of	  the	  EDL	  myofibres	  in	  the	  1mL	  aliquot	  of	  2mg/mL	  
type-­‐1	  collagenase	  solution	  was	  increased	  through	  regular	  agitation	  and	  swirling,	  every	  15	  minutes.	  
After	   monitoring	   for	   1.5-­‐2	   hours,	   the	   majority	   of	   the	   myofibres	   were	   observed	   as	   separated,	  
individual	  myofibres	  in	  suspension.	  Using	  a	  sterile,	  tapered	  glass	  pipette	  the	  fibres	  were	  transferred	  
to	  a	  washing	  dish	  and	  viewed	  under	  a	   stereomicroscope.	   In	  order	   to	   isolate	  as	  many	  myofibres	  as	  
possible,	   any	  bundles	  of	   fibres	  were	   carefully	   aspirated	   and	  washed	   twice	   in	  DMEM	   (incubated	   to	  
37°C)	  to	  remove	  residual	  collagenase	  and	  then	  washed	  twice	  in	  SFCM	  (incubated	  to	  37°C)	  to	  replace	  
the	  DMEM.	  At	  this	  stage,	  fibres	  were	  either	  cultured	  or	  fixed	  at	  time-­‐zero	  (T0).	  
Single	  myofibre	  culture	  	  
The	  desired	  number	  of	  myofibres	   (for	  example	  10	  per	  well	   for	   time-­‐lapse,	  ~50	   for	   later	   fixing	  etc.)	  
were	   transferred	   from	   the	   wash	   dish	   after	   isolation	   to	   previously	   prepared	   wells	   containing	   1mL	  
SFCM	  (incubated	  to	  37°C)	   in	  a	  12-­‐well	  plate.	  For	  the	  cell	   transplantation	  experiments,	  2.5x105	  AFS,	  
ADMSC,	  DP	  or	  MDA	  cells	  were	  divided	  between	  culture	  dish	  wells,	  added	  and	  allowed	  to	  adhere	  for	  2	  
hours.	  After	  2	  hours,	  fibres	  (and	  therefore	  attached	  cells)	  were	  transferred	  to	  a	  new	  dish	  containing	  
warmed	  (37°C),	  fresh	  SFCM	  (or	  adapted	  LT-­‐SFCM	  for	  long-­‐term	  culture	  of	  myofibres,	  T120	  and	  T240)	  
and	  incubated	  at	  37°C	  and	  5%	  CO2	  for	  the	  required	  culture	  period.	  Alternatively,	  12-­‐well	  plates	  were	  
placed	   within	   a	   time-­‐lapse	   microscopy	   system	   surrounded	   by	   a	   temperature-­‐	   and	   CO2-­‐controlled	  
chamber	   for	   the	   generation	   of	   time-­‐lapse	   cell	   migration	   data.	   Myofibres	   were	   fixed	   at	   various	  
relevant	  time-­‐points	  for	  further	  analysis	  (for	  example	  immunocytochemistry).	  
Myotube	  formation	  culture	  
Incubation	   of	   isolated	   myofibres	   with	   single	   fibre	   culture	   media	   (SFCM)	   enriched	   with	   a	   higher	  
concentration	  (5%)	  of	  chick	  embryo	  extract	  (LT-­‐SFCM),	  allowed	  for	  a	  prolonged	  culture	  period	  of	  10	  
days	  (T240).	  Transplanted	  AFS	  and	  MDA	  cell/myofibre	  co-­‐cultures	  were	  set-­‐up	  as	  per	  the	  previously	  
outlined	  protocol	  and	  following	  10	  days	  culture,	  were	  incubated	  in	  1x	  TrypLE™	  Select	  for	  10	  minutes	  
at	   37°C	   to	   dissociate	   the	   cells	   from	   the	   myofibres.	   The	   cell/myofibre	   suspensions	   were	   filtered	  
through	  70µm	  cell	   strainers	   to	   remove	  whole	  myofibres	  and	  hyper-­‐contracted	  debris,	   isolating	   the	  
remaining	  dissociated	  cell	  fraction.	  The	  isolated	  cells	  were	  then	  seeded	  into	  wells	  of	  a	  12-­‐well	  plate	  
lined	  with	  sterile	  nitric	  acid-­‐treated	  cover	  slips	  and	  cultured	  in	  fresh	  cell-­‐specific	  growth	  media	  under	  
standard	  conditions	  (37°C	  and	  5%	  CO2),	  until	  a	  95%	  confluency	  level	  was	  reached.	  Additionally,	  AFS	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and	   MDA	   cells	   expanded	   in	   the	   absence	   of	   myofibres,	   were	   also	   seeded	   and	   grown	   to	   95%	  
confluency	   in	   normal	   growth	   media	   or	   LT-­‐SFCM	   as	   ‘control’	   cultures.	   Once	   95%	   confluency	   was	  
reached,	   growth	   media	   was	   aspirated	   and	   replaced	   with	   myogenic	   differentiation	   media	   in	   all	  
conditions	   with	   the	   exception	   of	   the	   ‘growth	   media	   control’	   treatments.	   Cells	   were	   incubated	   in	  
standard	  conditions	  (37°C	  and	  5%	  CO2),	  with	  media	  changes	  every	  3	  days	  and	  cell	  morphology	  was	  
monitored	  daily	  for	  the	  formation	  of	  myotubes	  using	  a	  brightfield	  microscope.	  After	  7	  days,	  myotube	  
formation	   was	   evident	   and	   cell	   cultures	   were	   fixed	   in	   4%	   PFA/PBS	   and	   washed,	   prior	   to	   further	  
processing	  for	  analysis,	  for	  example	  immunocytochemical	  protocols.	  
Fixing	  isolated	  myofibres	  	  
Myofibres	  were	  fixed	  by	  adding	  4%	  paraformaldehyde/phosphate	  buffered	  saline	  (PFA/PBS)	  solution	  
to	   the	  wash	  dish	   containing	   the	   fibres	   (after	   isolation)	   at	   a	   volume	   ratio	  of	  1:1,	   resulting	   in	   a	   final	  
concentration	  of	  2%	  PFA/PBS	  and	  left	  for	  15	  minutes	  at	  room	  temperature	  then	  washed	  3	  times	  in	  
PBS	   to	   replace	   the	   PFA/PBS	   fixative.	   Stored	   in	   phosphate	   buffered	   saline	   (PBS)	   at	   4°C,	   for	   later	  
analysis	  in	  transparent	  1.5mL	  microfuge	  tubes	  (Axygen	  MCT-­‐150).	  
Immunocytochemistry	  	  
This	   protocol	   was	   carried	   out	   as	   per	   previously	   described	   with	   the	   whole	   muscle	  
‘Immunohistochemistry’	   protocol	   and	   differs	   only	   in	   that	   the	   following	   details	   the	   treatment	   of	  
cells/myofibres	  instead	  of	  whole	  muscle	  sections,	  as	  well	  as	  differences	  in	  the	  antibodies	  used.	  The	  
fixed	  myofibres,	  stored	  at	  4°C	  were	  washed	  twice	  in	  PBS	  and	  care	  was	  taken	  to	  avoid	  removing	  the	  
myofibres	  from	  the	  microfuge	  tube	  during	  washing.	  PBS	  was	  replaced	  with	  permeability	  buffer	  and	  
incubated	  at	  room	  temperature	  for	  15	  minutes,	  followed	  by	  further	  washing	  stages,	  three	  times	  with	  
PBS,	  then	  once	  with	  wash	  buffer	  as	  a	  blocking	  step,	   for	  30	  minutes.	  The	  wash	  buffer	  was	  removed	  
from	   the	   sample	   (myofibres)	   and	   the	   primary	   antibody	   (pre-­‐diluted	   in	   wash	   buffer	   at	   room	  
temperature	  for	  30	  minutes)	  was	  added	  and	  incubated	  for	  1	  hour	  at	  room	  temperature.	  The	  sample	  
was	  washed	  5	  times	  in	  wash	  buffer	  to	  remove	  any	  unbound	  primary	  antibody	  and	  the	  first	  secondary	  
antibody	  (pre-­‐diluted	  in	  wash	  buffer	  at	  room	  temperature	  for	  30	  minutes	  in	  the	  dark)	  was	  added	  and	  
incubated	   for	   1	   hour	   at	   room	   temperature	   in	   the	   dark.	   The	   sample	  was	  washed	   3	   times	   in	   wash	  
buffer	   to	   remove	  any	  unbound	   secondary	   antibody.	   Finally,	  myofibres	  were	  mounted	  onto	   a	   glass	  
microscope	  slide	  and	  covered	  with	  a	  cover	  slip	  affixed	  with	  mounting	  medium	  and	  DAPI,	  for	  analysis.	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Time-­‐lapse	  microscopy	  and	  imaging	  of	  satellite	  stem	  cell	  migration	  	  
Myofibres	  both	  treated	  with	  inhibitor	  and	  untreated	  (control)	  were	  viewed	  in	  culture	  plates	  under	  a	  
time-­‐lapse	   microscope	   (Nikon	   Eclipse	   TE200)	   over	   a	   time	   period	   of	   12	   hours.	   Points	   along	   single	  
myofibres	  were	  located	  using	  the	  microscope	  at	  20X	  magnification	  and	  were	  photographed	  every	  15	  
minutes	  for	  a	  total	  time	  period	  of	  12	  hours.	  
Biological	  sample	  preparation	  for	  critical	  point	  drying	  and	  scanning	  electron	  
microscopy	  (SEM)	  EMLAB	  (Electron	  Microscopy	  Laboratory)	  protocol	  
Myofibres	  were	  fixed	  with	  the	  4%	  PFA/PBS	  solution	  using	  the	  previously	  described	  method,	  washed	  
three	   times	   in	   PBS	   and	   then	   washed	   in	   distilled	   water	   for	   15	  minutes.	   Samples	   were	   dehydrated	  
through	  an	  acetone	  series	  (30%,	  50%,	  70%,	  80%,	  90%	  and	  three	  times	  at	  100%)	  at	  room	  temperature	  
and	  were	  left	  for	  15	  minutes	  at	  each	  step	  in	  the	  series.	  (Solvent/distilled	  water	  solutions	  each	  made	  
up	   to	   10mL	   in	   total).	   Samples	   were	   placed	   in	   a	   sample	   holder,	   covered	   with	   fresh	   dry	   solvent	  
(acetone)	  and	  dried	  in	  the	  critical	  point	  dryer	  (Balzers	  CPD	  030	  –	  using	  liquid	  CO2).	  The	  dehydration	  
method	  was	  repeated	  ten	  times	  to	  ensure	  all	  acetone	  had	  been	  replaced	  by	  liquid	  CO2.	  Sample	  stubs	  
were	   prepared	   with	   carbon	   disc	   covers.	   The	   gaseous	   CO2	   was	   vented	   off	   and	   immediately	   the	  
dehydrated	  myofibre	   samples	  were	  mounted	  onto	   the	   prepared	   stubs	   and	   coated	  with	   gold	   in	   an	  
Edwards	  S150B	  sputter	  coater	  for	  3	  minutes.	  A	  dessicator	  was	  used	  to	  store	  the	  samples	  for	  future	  
imaging	  and	  analysis	  using	  the	  SEM	  (FEI	  600F).	  
Proliferation	  	  
Myofibres	   were	   cultured	   for	   48	   hours	   in	   total	   and	   fibres	   were	   fixed	   at	   T14,	   T24	   and	   T48.	  
Immunocytochemistry	  was	  carried	  out	  following	  the	  previously	  described	  protocols	  using	  antibodies	  
against	  Pax7	  and	  MyoD	  and	  myofibres	  were	  mounted	  onto	  glass	  microscope	   slides	  with	  mounting	  
media	   and	   DAPI	   for	   analysis.	   The	   myofibres	   were	   viewed	   under	   a	   Zeiss	   AxioImager	   fluorescence	  
microscope	   using	   three	   fluorescent	   filters	   and	   cells	   were	   counted	   based	   on	   whether	   they	   were	  
observed	  as	  positive	  for	  Pax7,	  MyoD	  or	  both.	  Proliferation	  was	  calculated	  as	  number	  of	  cell	  per	  fibre,	  
number	  of	  cell	  clusters	  per	  fibre	  and	  separately,	  cluster	  size	  (cells	  per	  cluster).	  
Myofibre	  image	  and	  movie	  analysis	  	  
All	  movie	  analysis	  was	   carried	  out	  using	   the	   freeware	  analysis	  programme,	   ‘ImageJ’	   (version	  1.46).	  
Time-­‐lapse	   movies	   were	   first	   registered	   to	   allow	   for	   the	   movement	   of	   the	   myofibre	   that	   would	  
otherwise	   contribute	   inaccurately	   to	   the	   distance	   travelled	   by	   the	   satellite	   cell	   using	   the	   sister	  
freeware	   programme	  of	   ImageJ,	   ‘Fiji’	   (version	   1.0).	   Individual	   satellite	   cells	  were	  manually	   tracked	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using	  the	  plug-­‐in	  ‘MTrackJ’.	  Bleb	  dynamics	  were	  quantified	  manually	  using	  ImageJ.	  Different	  stages	  of	  
cell	   emergence	   and	   proliferation	   of	   individual	   satellite	   cells	   were	   manually	   assessed	   using	  
quantification	   of	   live	   images	   through	   the	   Zeiss	   AxioImager,	   AxioCam	  MRm	   camera	   and	   AxioVision	  
software	  (version	  4.9.1)	  system.	  
Statistical	  analysis	  	  
Calculations	   carried	   out	   were	   to	   determine	   that	   the	   data	   was	   normally	   distributed	   as	   well	   as	   to	  
ascertain	   the	   mean,	   standard	   deviation	   (SD)	   and	   standard	   error	   of	   the	   mean	   (SEM),	   followed	   by	  
statistical	  analysis.	  Student’s	  t-­‐tests	  or,	  where	  applicable,	  one-­‐way	  analysis	  of	  variance	  (ANOVA)	  tests	  
among	   groups	   of	   data	   were	   used	   with	   post-­‐hoc	   Tukey	   multiple	   comparison	   tests	   (also	   known	   as	  
Tukey’s	   range	   test	   or	   Tukey-­‐Kramer	   test)	   between	   treatments	   to	   determine	   significance.	   Where	  
appropriate,	   two-­‐way	  ANOVA	   tests	  were	   conducted	   to	   assess	   the	   interaction	  between	  groups	   and	  
treatments.	   A	   level	   of	   95%	   significance	   is	   represented	   by	   a	   P-­‐value	   (p)	   <0.05,	   99%	   significance	   (p	  
<0.01)	   and	   99.9%	   significance	   (p	   <0.001).	   Error	   bars	   represent	   standard	   error	   of	   the	  mean	   (SEM).	  
Statistical	   analysis	   was	   performed	   using	   ‘GraphPad	   Prism’	   statistical	   software	   (version	   6).	   The	  
following	  animal	  numbers	  were	  as	  follows	  for	  histological	  analyses:	  Young	  (3),	  Adult	  (6),	  Old	  (5),	  Old	  
CM	   (5)	   and	  Geriatric	   (3).	   qPCR	   analyses	   comprised	   of	   3	   samples	   per	   age	   group/treatment	   cohort.	  
Isolated	  single	  myofibre	  analyses	  were	  conducted	  on	  ≥15	  healthy	  myofibres	  from	  3	  animals	  per	  age	  
group/condition	  at	  all	  times.	  
	  
	  








Development	  of	  an	  ageing	  skeletal	  muscle	  	  
profile	  and	  the	  therapeutic	  effects	  	  




The	  following	  series	  of	  in	  vivo	  experiments	  investigated	  the	  hypothesis	  that	  conditioned	  media	  (CM)	  
generated	  from	  adipose-­‐derived	  mesenchymal	  stem	  cells	   (ADMSC),	  maintains	  regulatory	  properties	  
that	   attenuate,	   delay	   or	   even	   prevent	   characteristic	   age-­‐associated	   alterations	   in	   skeletal	   muscle	  
composition	  and	  function.	  Numerous	  characteristic	  alterations	  have	  been	  previously	  observed	  with	  
the	  onset	   and	  progression	  of	   sarcopenia	   in	  human	  and	  animal	   studies,	   conducted	  at	  whole	   tissue,	  
cellular	   and	   molecular	   levels.	   These	   features	   include,	   among	   many	   others,	   myofibre	   atrophy,	  
decreased	   muscle	   weight,	   variations	   in	   muscle	   diameter,	   motor	   neuron	   denervation,	   reduced	  
contractile	  and	  force-­‐generating	  capacity,	  increased	  myofibre	  fibrosis,	  a	  reduction	  in	  skeletal	  muscle	  
satellite	  stem	  cell	  number	  and	  function	  and	  increased	  oxidative	  stress	  (Shefer	  et	  al.	  2006;	  Collins	  et	  
al.	  2007;	  Faulkner	  &	  Brooks	  1995;	  Alnaqeeb	  &	  Goldspink	  1987;	  Wang	  et	  al.	  2014;	  Chai	  et	  al.	  2011).	  
Development	  of	  a	  broad	  skeletal	  muscle	  profile	   in	  naturally-­‐aged	  C57BL/6	  mice	  provides	  a	  basis	   to	  
test	  the	  potential	  anti-­‐ageing,	  therapeutic	  effects	  of	  ADMSC	  CM	  treatment.	  	  
Using	   a	   protocol	   established	   by	   a	   collaborator,	   CM	   was	   generated	   from	   ADMSCs	   under	   hypoxic-­‐
stressed	  and	  nutrient	  deprived	  conditions,	  in	  order	  to	  induce	  the	  stem	  cells	  to	  produce	  and	  secrete	  
survival	   factors.	   A	   study	   has	   shown	   that	   the	   total	   protein	   secreted	   by	   MSCs	   was	   greater	   under	  
hypoxic	  compared	  to	  normoxic	  conditions	  (Kinnaird	  et	  al.	  2004).	  Additionally,	  the	  factors	  that	  were	  
demonstrated	  to	  be	  up-­‐regulated	  included	  FGF-­‐2,	  IL-­‐6,	  TGF-­‐β,	  TNF-­‐α	  and	  VEGFa,	  key	  to	  angiogenesis	  
and	  regulation	  of	  inflammation,	  for	  example.	  Briefly,	  ADMSCs	  were	  expanded	  under	  normal	  growth	  
conditions	   to	   the	   required	   number	   of	   cells,	   washed	   to	   remove	   any	   exogenous	   growth	   factors	  
originating	   from	   the	   growth	  media,	   and	   pelleted	   in	   separate	   1x106	   PBS	   cell	   cultures.	   Conditioned	  
media	  was	  collected	  at	  T24,	  48	  and	  72	  (hours)	  time-­‐points	  with	  fresh	  PBS	  replaced	  at	  each,	  however,	  
the	  T24	  fraction	  was	  utilised	  in	  the	  present	  study.	  Colleagues	  have	  shown	  that	  protein	  concentration	  
and	  nucleic	  acid	  content	  of	   the	  T24	  and	  48	   fractions	   released	  by	  ADMSCs,	  under	   these	  conditions,	  
are	   similar	   and	   in	   the	   third	   time-­‐point	   (T72),	   this	   content	   is	   decreased	   (In	   press,	   Frontiers	   in	  
Immunology).	  The	  development	  of	  an	  in	  vitro	  senescence	  assay	  to	  test	  the	  efficacy	  of	  ADMSC	  CM	  has	  
been	   developed	   and	   proven	   to	   be	   robust	   among	   colleagues	   (Mellows	   et	   al.	   2017).	   Properties	  
maintained	  by	  CM	  have	  therefore,	  been	  shown	  to	  protect	  against	  cellular	  senescence	  and	  this	  assay	  
was	  used	  in	  the	  same	  way	  in	  the	  current	  study,	  to	  indicate	  CM	  efficacy	  prior	  to	  the	  novel	  treatment	  
to	  study	  ageing	  skeletal	  muscle.	  Following	  testing,	  animals	  were	  injected	  intraperitoneally	  (I.P)	  with	  





Conditioned	  media	  from	  adipose-­‐derived	  mesenchymal	  stem	  cells	  
demonstrated	  protective	  effects	  against	  cellular	  senescence	  
Firstly,	   the	   efficacy	   of	   ADMSC	  CM	  as	   a	   regulator	   of	   cellular	   senescence	  was	   assessed.	   CM	  used	   at	  
concentrations	  of	  1%	  and	  10%,	  reduced	  the	  proportion	  of	  positively-­‐stained	  senescence-­‐associated	  
β-­‐gal	   cells,	   following	  H2O2	   treatment,	   to	   the	   levels	  of	   the	  unstressed	   control	   (p	  =	  <0.05	  and	  <0.01,	  
respectively)	   (Figure	  3.1	  A).	   Secondly,	   the	  ADMSCs	  were	  demonstrated	   to	   retain	  multipotency	  and	  
differentiated	  towards,	  chondrogenic,	  osteogenic	  and	  adipogenic	  lineages,	  following	  the	  collection	  of	  
CM	  (Figure	  3.1	  B,	  C,	  D,	  E,	  F).	  
	  
Figure	   3.1	   ADMSC-­‐derived	   CM	   protects	   against	   cellular	   senescence	   and	   differentiation	   assays	  
indicate	   post-­‐CM	  generation	   stemness.	   (A)	  Senescence	   assay	   showing	   that	   CM	   (1%,	   10%)	   protects	  
against	   cellular	   senescence	   (SA-­‐B-­‐gal)	   in	   a	   cultured	   IMR90	   lung	   fibroblast	   cell	   line	   (B)	   Post-­‐CM	  
ADMSCs	   in	   pellet	   culture	   (21	   days),	   were	   induced	   towards	   a	   chondrogenic	   lineage	   before	   being	  
stained	  with	  Alcian	  Blue	  stain.	  A	  positive	  result	  would	  be	  the	  cellular	  spheroid	  staining	  blue.	  Of	  note,	  
growth	   media	   pellet	   cultures	   also	   stained	   positively	   and	   appeared	   as	   shown	   here.	   (C)	  
Undifferentiated	  ADMSC	  growth	  media	  control	   for	  osteogenesis.	   (D)	  Post-­‐CM	  ADMSCs	  cultured	   for	  
21	  days	  towards	  osteogenic	  lineage	  prior	  to	  Alizarin	  Red	  S	  staining.	  Positive	  differentiation	  results	  in	  
mineralisation	   staining	   red.	   (E)	   ADMSC	   growth	   media	   control	   for	   adipogenesis,	   starting	   to	  
differentiate	   towards	   adipogeneic	   lineage.	   (F)	   Post-­‐CM	   ADMSCs	   cultured	   for	   21	   days	   towards	  
adipogeneic	  lineage	  prior	  to	  Oil	  Red	  O	  staining,	  with	  internal	  fat	  droplets	  staining	  deep	  red	  in	  colour.	  
Scale	  bar	  100µm.	  *p<0.05,	  **p<0.01,	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	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Body	  weight	  changes	  in	  natural	  ageing	  
Body	   weights	   for	   the	   four	   age	   groups,	   young	   (3	   months),	   adult	   (6	   months),	   old	   (24	  months)	   and	  
geriatric	  (27-­‐30	  months),	  were	  recorded	  to	  provide	  information	  about	  the	  growth	  of	  wild-­‐type	  (WT),	  
female	  C57BL/6	  mice	  during	  the	  progression	  of	  natural	  ageing	  (Figure	  3.2	  A).	  The	  initial	  growth	  phase	  
from	  young	   to	  adult	  ages	  was	  observed	  with	  an	   increase	   in	  body	  weight	   from	  an	  average	  of	  18	   to	  
42g.	  Mass	  further	  increased	  during	  old	  and	  geriatric	  ages	  to	  43	  and	  45g,	  respectively,	  however	  when	  
tested,	  these	  differences	  were	  statistically	  non-­‐significant.	  
Additionally,	  weights	  were	  recorded	  weekly	  to	  monitor	  animals	  regularly	  throughout	  the	  in	  vivo	  CM	  
IP	   experimental	   time-­‐periods.	   Firstly,	   body	  weights	   for	   the	  Old	  CM-­‐treated	   cohort	   appeared	   lower	  
than	   the	   PBS	   vehicle	   control	   animals	   however,	   this	   difference	   was	   not	   statistically	   significantly	  
different	   and	   indicated	   a	   large	   amount	   of	   variation	   in	   weight	   within	   each	   cohort	   (Figure	   3.2	   B).	  
Secondly,	   percentage	  weight	   change	   relative	   to	   the	   starting	  weight	  was	   calculated	   and	  where	   the	  
reduction	  in	  the	  body	  mass	  of	  the	  animals	  treated	  with	  CM	  was	  significantly	  different	  at	  week	  90	  (p	  =	  
<0.05)	   (Figure	   3.2	  C).	   Percentage	  weight	   change	  during	   the	   latter	  weeks	   then	  became	   increasingly	  
variable,	  particularly	  within	  the	  Old	  CM	  cohort.	  
Strength	  and	  activity	  assessment	  shows	  a	  decline	  in	  grip	  strength	  with	  age	  
Animal	  functional	  studies	  were	  conducted	  to	  examine	  the	  maximum	  force	  exerted	  in	  the	  aged	  animal	  
cohorts	  (CM	  or	  PBS	  vehicle),	  as	  assessed	  using	  a	  grip	  strength	  monitor,	  as	  well	  as	  motor	  coordination	  
measured	   using	   rotarod	   performance	   testing.	   Average	   grip	   strength	   decreased	   incrementally	   with	  
age,	  where	  forces	  normalised	  to	  body	  weight,	  measured	  in	  all	  latter	  months	  tested	  (21	  to	  24),	  were	  
all	  significantly	  reduced	  when	  compared	  to	  that	  at	  20	  months	  old	  (p	  =	  <0.05	  and	  <0.01)	  (Figure	  3.2	  
D).	   Further	  declines	   in	  maximum	   force	  were	  observed	  after	  21	  months	   (p	  =	  <0.05	  and	  <0.01),	   in	  a	  
step-­‐wise	   fashion,	  which	  decreased	   again	   from	  22	   to	   23	  months	  of	   age	   (p	  =	  <0.01).	   Subsequently,	  
grip	   strength	   remained	   consistent	   and	   did	   not	   alter	   significantly	   between	   23	   and	   24	   months.	  
Moreover,	  average	  force	  exerted	  by	  animals	  treated	  with	  CM,	  followed	  a	  similar	  declining	  trend	  with	  
age	   as	   those	  measured	   in	   the	   PBS	   vehicle	   control	   cohort	   (Figure	   3.2	   E).	   However,	   the	   CM-­‐treated	  
animals	   measured	   a	   greater	   average	   grip	   strength	   in	   the	   latter	   weeks	   of	   the	   experiment,	   when	  
compared	  to	  the	  PBS	  controls,	  to	  a	  statistically	  significant	  degree	  at	  23	  months	  (100	  weeks)	  old	  (p	  =	  
<0.05).	  Thereafter,	  force	  between	  the	  two	  treatment	  groups	  remained	  consistent.	  
Rotarod	   performance	   assessment	   indicated	   a	   large	   degree	   of	   variation	   in	   organismal	   motor	  
coordination	  from	  20	  to	  24	  months	  of	  age	  (Figure	  3.2	  F).	  Initially,	  activity	  increased	  from	  20	  months	  
to	  a	  peak	  performance	  measured	  at	  21	  months	  (p	  =	  <0.05).	  Following	  this,	  rotarod	  activity	  returned	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to	  similar	   levels	  measured	  at	  the	  start	  of	  the	  experiment	  (20	  months).	  Furthermore,	  CM	  treatment	  
had	   no	   additional	   effects	   on	  motor	   coordination	  measurements	   during	   the	   progression	   of	   natural	  
ageing	  from	  20	  to	  24	  months	  (Figure	  3.2	  G).	  
	  
Figure	   3.2	   Investigating	   the	   effect	   of	   ADMSC	   CM	   (CM)	   on	   body	   mass,	   grip	   strength	   and	   rotarod	  
performance	  with	  age.	  (A)	  Body	  weights	  of	  young	  (3	  months),	  adult	  (6	  months),	  old	  (24	  months)	  and	  
geriatric	  (27-­‐30	  months)	  C57BL/6	  mice.	  (B-­‐C)	  CM	  does	  not	  significantly	  impact	  on	  the	  body	  weights	  of	  
old	  mice.	   (D)	   Functional	   assessment	   of	   the	   average	   grip	   strength	   of	   old	  mice,	   force	   normalised	   to	  
body	   weight	   showed	   a	   decline	   in	   force	   exerted	   with	   increasing	   age.	   Significance	   indicated	   by	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sequential	   letter	  pairings,	   from	  left	   to	  right	   (p	  =	  <0.05).	   (E)	  Grip	  strength	  was	   largely	  unaffected	  by	  
CM	   in	   old	  mice,	   differing	   at	   100	  weeks	   of	   age	   only.	   (F)	   Rotarod	   activity	   in	   old	  mice	  was	   variable.	  
Significance	   indicated	   by	   letter	   pairings	   (p	   =	   <0.05).	   (G)	   Rotarod	   activity	   in	   old	   mice	   was	   not	  
influenced	   by	   CM	   treatment.	   The	   initiation	   of	   the	   CM/PBS	   treatment	   programme	   (blue	   arrows).	  
*p<0.05,	  **p<0.01,	  ***p<0.001,	  (A,	  D,	  F)	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing,	  (B,	  C,	  E,	  G)	  
Individual	  student’s	  t-­‐tests.	  	  
	  
Increased	  fresh	  skeletal	  muscle	  weight	  with	  initial	  growth	  and	  declines	  with	  age	  
evident	  in	  most	  hindlimb	  muscles	  analysed	  
Fresh	   hind-­‐limb	   muscle	   weights	   were	   recorded	   at	   the	   time	   of	   dissection,	   prior	   to	   freezing	   and	  
processing.	  All	  muscles	  analysed	  increased	  in	  weight	  from	  young	  ages	  and	  peaked	  at	  either	  adult	  or	  
old	  ages,	  during	  the	  initial	  growth	  phase	  of	  the	  animals	  (p	  =	  <0.05).	  Soleus	  and	  EDL	  muscles	  increased	  
from	  approximately	  9mg	  at	  young	  ages	  to	  13	  -­‐	  14mg	  at	  old	  age	  (p	  =	  <0.05)	  (Figure	  3.3	  A,	  B).	  The	  TA	  
increased	  from	  38	  to	  48mg	  from	  young	  to	  adult	  ages	  (p	  =	  <0.001)	  (Figure	  3.3	  C).	  The	  Gastrocnemius	  
peaked	   at	   approximately	   140mg	   from	   95mg	   between	   young	   and	   adult	   ages	   (p	   =	   <0.001)	   and	   the	  
Plantaris	  increased	  from	  14	  to	  22mg	  (p	  =	  <0.001)	  (Figure	  3.3	  D,	  E).	  Both	  the	  EDL	  and	  Gastrocnemius	  
muscles	  remained	  at	  weights	  similar	  to	  those	  recorded	  at	  peak	  growth	  into	  advanced	  ageing	  and	  any	  
changes	   shown	   were	   not	   statistically	   significant.	   The	   Soleus	   and	   TA	   muscles	   however,	   showed	  
statistically	   significant	   decreases	   in	  weight	   during	   advanced	   ageing,	   after	   peaking	   during	   initial	   old	  
ages	  (p	  =	  <0.05).	  Whereas,	  the	  Plantaris	  peaked	  at	  an	  adult	  age	  and	  decreased	  earlier	  in	  the	  ageing	  
process	  (p	  =	  <0.001).	  CM	  treatment	  did	  not	  significantly	  affect	  the	  muscle	  weights	  in	  old	  age	  in	  the	  
EDL,	  TA,	  Gastrocnemius	   or	  Plantaris.	   In	   the	  Soleus	   however,	  CM	  reduced	   the	  muscle	  weight	  at	  old	  




Figure	  3.3	  Fresh	  hindlimb	  muscle	  weights	  of	  young	   (3	  months),	  adult	   (6	  months),	  old	   (24	  months),	  
geriatric	  (27-­‐30	  months)	  and	  old	  CM-­‐treated	  C57BL/6	  mice.	  (A)	  Soleus	  weight.	  (B)	  EDL	  weight.	  (C)	  TA	  
weight.	   (D)	   Gastrocnemius	   weight.	   (E)	   Plantaris	   weight	   (Geriatric	   data	   not	   available).	   *p<0.05,	  
**p<0.01,	  ***p<0.001,	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  
	  
MHC	  isoform	  myofibre	  composition	  shift	  to	  a	  slower	  phenotype	  in	  the	  ageing	  
Soleus	  muscle	  
The	  myofibre	  type	  (for	  example	  slow-­‐twitch	  type	  I,	   fast-­‐twitch	  type	  IIA,	   IIX	  and	  IIB)	  differs	  between	  
muscle	   type,	   depending	   on	   function	   and	   has	   been	   shown	   to	   alter	   with	   age	   and	   the	   onset	   of	  
sarcopenia	   (Alnaqeeb	   &	   Goldspink	   1987;	   Chai	   et	   al.	   2011;	   Rowan	   et	   al.	   2011;	   Larsson	   &	   Edström	  
1986).	  The	  Soleus	  muscle	  consists	  of	  a	  higher	  proportion	  of	  type	  I,	  slow-­‐twitch	  myofibres,	  has	  a	  high	  
capillary	  density,	  high	  resistance	  to	  fatigue	  and	  high	  oxidative	  capacity	  (Alnaqeeb	  &	  Goldspink	  1987;	  
Omairi	  et	  al.	  2016).	  	  
To	   ascertain	   an	   indication	   of	   how	   contractile,	   motor	   neuron	   innervation	   and	   metabolic	   functions	  
might	   be	   changing	   during	   ageing,	   the	   myosin	   heavy	   chain	   (MHC)	   myofibre	   composition	   was	  
examined.	  MHC	  was	  visualised	  and	  analysed	  using	  immunohistochemical	  staining	  of	  transverse	  cross-­‐
sections	   of	   the	   maximal,	   ‘mid-­‐belly’	   region	   of	   frozen	   Soleus	   muscles.	   Positive	   expression	   of	   the	  
different	  MHC	  isoforms,	  types	  I,	  IIA	  and	  IIB	  (and	  negative	  IIX	  myofibres),	  as	  well	  as	  the	  total	  myofibre	  
number	  were	  quantified	   for	   all	   four	   age	  groups,	   young,	   adult,	   old	   and	  geriatric,	   as	  well	   as	  old	   age	  
with	  CM	  treatment.	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Total	   myofibre	   numbers	   in	   the	   Soleus	   remained	   relatively	   consistent,	   approximately	   850	   -­‐	   950	  
myofibres,	  during	  young,	  adult	   and	  old	   ages	   (Figure	  3.4	  A).	   In	  advanced	  ageing	  however,	  myofibre	  
numbers	   were	   significantly	   decreased	   to	   an	   average	   of	   770	   (p	   =	   <0.05).	   CM	   did	   not	   significantly	  
increase	  the	  average	  number	  of	  myofibres	  in	  old	  age.	  
Regarding	  the	  MHC	  myofibre	  typing,	  it	  was	  shown	  that	  during	  the	  growth	  phase	  between	  young	  and	  
adult,	   the	  percentage	  of	   type	   I	  myofibres	   increased	   significantly	   from	  35	   to	   48%,	   respectively	   (p	  =	  
<0.05)	  and	  to	  56%	  at	  old	  and	  geriatric	  ages	   (p	  =	  <0.001,	   respectively)	   (Figure	  3.4	  B,	  C).	  Meanwhile,	  
concordantly,	   the	   percentage	   of	   type	   IIA	  myofibres	   reduced	   from	   54	   to	   44%	   during	   the	   young	   to	  
adult	  growth	  phase,	  respectively	  (p	  =	  <0.01)	  (Figure	  3.4	  B,	  D).	  Percentages	  of	  type	  I	  and	  IIA	  after	  this	  
age	  (adult),	  did	  not	  vary	  significantly	  and	  the	  Soleus,	  a	  predominately	  oxidative	  muscle,	  continued	  to	  
remain	  approximately	  60%	  type	   I	   into	  geriatric	  ages.	   IIX	  and	   IIB	  myofibre	   types	   represented	  only	  a	  
small	   percentage	   (less	   than	   5%)	   of	   the	   myofibres	   comprising	   the	   slow	   twitch	   Soleus	   muscle	   and	  
shows	   a	   further	   switching	   of	   the	   fastest	   type	   IIB	   myofibres	   to	   slower	   types	   (for	   example	   type	   I),	  
where	   there	  were	  no	   IIB	   observed	   at	   old	   and	   geriatric	   ages,	   relative	   to	   young	   and	   adult	   ages	   (p	  =	  
<0.01	  and	  <0.001,	  respectively)	  (Figure	  3.4	  B,	  E).	  CM	  treatment	  in	  old	  age	  had	  no	  significant	  effects	  




Figure	  3.4	  The	  effect	  of	  ADMSC	  CM	  (CM)	  and	  ageing	  on	  Myosin	  heavy	  chain	  (MHC)	  isoform	  myofibre	  
composition	  of	  the	  Soleus	  muscle.	  (A)	  Quantification	  of	  the	  total	  myofibre	  number	  in	  the	  Soleus,	  saw	  
a	  reduction	  at	  a	  geriatric	  age.	  (B)	  Overall	  MHC	  myofibre	  type	  composition	  shows	  a	  switch	  to	  a	  slower	  
phenotype	   with	   increasing	   age.	   (C)	   Proportion	   of	   MHC	   type	   I	   myofibres	   increases	   with	   age.	   (D)	  
Proportion	  of	  MHC	  type	  IIA	  myofibres	  decreases	  with	  age.	  (E)	  Proportion	  of	  MHC	  type	  IIX	  myofibres	  
remains	   unchanged.	   (F)	   Proportion	   of	   MHC	   type	   IIB	   myofibres	   decreases	   with	   age.	   *p<0.05,	  
**p<0.01,	  ***p<0.001,	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  
	  
Changes	  in	  myofibre	  cross-­‐sectional	  area	  (CSA)	  in	  the	  ageing	  Soleus	  muscle	  
In	   analysing	   the	   myofibre	   cross-­‐sectional	   area	   (CSA),	   it	   can	   be	   determined	   what	   morphometric	  
changes	  occur	  in	  ageing	  myofibres,	  which	  has	  been	  shown	  to	  be	  a	  key	  determinant	  of	  muscle	  force-­‐
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generating	   capacity	   and	   contributes	   to	   the	   overall	   effects	   or	   symptoms	   of	   sarcopenia	   (Degens	   &	  
Alway	   2003;	   Larsson	   &	   Edström	   1986;	   Ansved	   &	   Larsson	   1989).	   CSA	   analysis	   was	   performed	   and	  
recorded	  by	  MHC	  myofibre	  type	  in	  order	  to	  establish	  any	  fibre	  type-­‐specific	  trends.	  
Cross-­‐sectional	  area	  of	  type	  I	  myofibres	  did	  not	  change	  dramatically	  between	  the	  four	  age	  groups	  or	  
with	  CM	  treatment	  in	  the	  Soleus	  (Figure	  3.5	  A).	  Type	  IIA	  myofibres	  showed	  an	  increased	  CSA,	  peaking	  
at	  old	  age	  (1800µm2)	  when	  compared	  to	  young	  (~1000µm2,	  p	  =	  <0.01)	  and	  maintaining	  this	   level	  of	  
hypertrophy	   into	   advanced	   ageing	   (Figure	   3.5	   B).	   The	   CSA	   of	   type	   IIX	   myofibres	   however,	   was	  
extremely	   variable	   due	   to	   the	   low	   number	   of	   IIX	   myofibres	   that	   represented	   only	   a	   very	   small	  
proportion	  (less	  than	  5%)	  of	  the	  Soleus,	  as	  previously	  discussed	  (Figure	  3.5	  C).	  Similarly,	  the	  observed	  
increase	  in	  the	  IIB	  CSA	  between	  young	  and	  adult	  ages	  was	  not	  statistically	  different	  due	  to	  the	  large	  
range	  in	  size	  of	  the	  small	  proportion	  of	  IIB	  myofibres,	  leading	  to	  variability	  in	  the	  data	  (Figure	  3.5	  D).	  
There	  was	  no	  significant	  difference	   in	  CSA	   in	  any	  of	  the	  myofibre	  types	   in	  old	  age	  treated	  with	  CM	  
(Figure	  3.5	  A,	  B,	  C).	  
	  
Figure	  3.5	  Determining	  the	  influence	  of	  ADMSC	  CM	  (CM)	  and	  ageing	  on	  Myosin	  heavy	  chain	  (MHC)	  
isoform	  myofibre	  cross-­‐sectional	  area	  (CSA)	  of	  the	  Soleus	  muscle.	  (A)	  MHC	  type	  I	  myofibre	  CSA.	  (B)	  
MHC	  type	  IIA	  myofibre	  CSA.	  (C)	  MHC	  type	  IIX	  myofibre	  CSA.	  (D)	  MHC	  type	  IIB	  myofibre	  CSA.	  *p<0.05,	  
**p<0.01,	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	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Oxidative	  capacity	  is	  reduced	  in	  the	  ageing	  Soleus	  	  
It	   is	   reported	   in	   the	   literature	   that	   there	   is	  a	   switch	   from	   faster,	   glycolytic	  myofibres	   to	   those	  of	  a	  
slower,	  more	  oxidative	  nature	  in	  the	  ageing	  Soleus	  (Alnaqeeb	  &	  Goldspink	  1987;	  Rowan	  et	  al.	  2011;	  
Larsson	  &	  Edström	  1986).	  Along	  with	  accumulation	  of	  DNA	  damage	  and	   loss	  of	  proteostasis	  during	  
ageing,	   mitochondrial	   dysfunction	   and	   increased	   oxidative	   stress	   are	   also	   key	   factors	   that	   can	  
exacerbate	  overall	  functional	  decline	  (López-­‐otín	  et	  al.	  2013;	  Pieczenik	  &	  Neustadt	  2007).	  Therefore,	  
importantly,	  parameters	  that	  indicate	  the	  degree	  that	  metabolic	  function	  and	  some	  of	  these	  aspects	  
of	  the	  ‘hallmarks	  of	  ageing’	  were	  altered	  in	  the	  naturally	  aged	  Soleus	  muscles,	  were	  investigated	  in	  
the	  current	  study.	  
The	  histological	  succinate	  dehydrogenase	  (SDH)	  staining	  protocol	  was	  carried	  out	  on	  Soleus	  muscle	  
transverse	   cross-­‐sections	   to	   analyse	   the	   metabolic	   status	   of	   myofibres.	   SDH-­‐positive	   oxidative	  
myofibres	   formed	  approximately	  55	  –	  60%	  of	   the	  total	  myofibres	  during	  young,	  adult	  and	  old	  ages	  
(Figure	  3.6	  A).	  Although,	  at	  geriatric	  ages,	  the	  percentage	  oxidative	  myofibres	  decreased	  to	  45%	  (p	  =	  
<0.05).	  	  
Despite	   the	   proportion	   of	   oxidative	   myofibres	   at	   old	   age	   being	   maintained	   at	   levels	   observed	   at	  
young	  and	  adult	  ages,	  CM	  treatment	  significantly	  increased	  the	  average	  oxidative	  myofibres	  to	  69%	  
of	  the	  total	  (p	  =	  <0.01).	  The	  increase	  observed	  with	  CM	  treatment	  in	  old	  animals	  was	  also	  statistically	  
significant	  when	  compared	  to	  both	  young	  and	  adult	  age	  groups	  (p	  =	  <0.05).	  
Vasculature	  organisation	  of	  the	  Soleus	  remains	  constant	  during	  ageing	  but	  CM	  
treatment	  increases	  myofibre	  capillary	  density	  
In	   order	   to	   further	   investigate	   the	   mechanisms	   underpinning	   the	   changes	   observed	   in	   metabolic	  
function	  in	  advanced	  ageing	  as	  well	  as	  CM	  treatment,	  vasculature	  organisation	  was	  explored.	  Firstly,	  
the	  number	  of	  capillaries	  was	  measured	  through	  the	  quantification	  of	  CD31+	  cells	  per	  myofibre.	  	  
The	  number	  of	  capillaries	  serving	  each	  fibre	  was	  shown	  to	  increase	  during	  the	  initial	  young	  to	  adult	  
growth	   phase	   (2.5	   to	   3.8,	   respectively,	  p	   =	   <0.05)	   (Figure	   3.6	   B).	   This	   capillary	   density	   profile	  was	  
seemingly	   maintained	   in	   the	   ageing	   Soleus	   at	   old	   and	   geriatric	   ages.	   As	   with	   the	   trend	   observed	  
previously	  with	   the	   percentage	   oxidative	  myofibres	   and	   furthermore,	   despite	   the	   capillary	   density	  
profile	   being	   maintained	   at	   adult	   levels	   into	   old	   age,	   treatment	   with	   CM	   further	   increased	   the	  
number	  of	  capillaries	  per	  fibre	  to	  4.3	  (p	  =	  <0.05).	  
Secondly,	   qPCR	   analysis	   of	   a	   member	   of	   the	   vascular	   endothelial	   growth	   factor	   (VEGF)	   family	   of	  
genes	  responsible	  for	  roles	  in	  regulating	  angiogenesis	  and	  vasculogenesis	  was	  analysed	  in	  the	  ageing	  
Soleus	   and	   indicated	   that	   relative	   levels	  of	  mRNA	  expression	  between	   the	   four	  age	  groups	   (young,	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adult,	   old	   and	   geriatric)	   were	   not	   significantly	   different	   (Figure	   3.6	   C).	   The	   CM	   group	   showed	  
increased	   levels	   of	  VEGFα	  165	  when	   compared	   to	   the	   geriatric	   age	   group	   (p	   =	   <0.05)	   but	  was	  not	  
significantly	  different	  to	  the	  old	  control	  or	  any	  other	  group.	  
Reactive	  oxygen	  species	  (ROS)	  production	  is	  greater	  in	  the	  ageing	  Soleus	  and	  
CM	  harbours	  apparent	  antioxidant	  properties	  
It	   is	  well	  established	  in	  the	  literature	  that	  mitochondrial	  dysfunction	  is	  highly	  implicated	  in	  multiple	  
pathological	   and	   toxicological	   conditions	   as	  well	   as	   age-­‐related	   degeneration,	   including	   sarcopenia	  
(Pieczenik	  &	  Neustadt	   2007).	  As	  well	   as	   this,	  DNA,	  but	   particularly	  mitochondrial	  DNA	   (mtDNA),	   is	  
extremely	  susceptible	  to	  damage	  and	  one	  of	  the	  sources	  of	  damage	  is	  reactive	  oxygen	  species	  (ROS)	  
produced	  by	  the	  mitochondria	  themselves	  (Pieczenik	  &	  Neustadt	  2007).	  Therefore,	  as	  a	  measure	  of	  
oxidative	  stress	  in	  the	  ageing	  muscles	  in	  current	  study,	  the	  ROS,	  superoxide	  (O2-­‐)	  was	  detected	  using	  
a	  small-­‐molecule	   fluorescent	  dye	  known	  as	  dihydroethidium	  (DHE).	  DHE	  fluorescence	   intensity	  was	  
measured	  within	  small	  and	  large	  myofibres	  of	  Soleus	  muscles	  for	  each	  age	  group,	  as	  well	  as	  with	  CM	  
treatment	   in	  old	  age.	  Firstly,	   it	  was	  observed	  that	  there	  was	  a	  higher	   intensity	  of	  DHE	  fluorescence	  
within	   the	   centre	   of	   smaller	   myofibres	   than	   larger-­‐sized	   myofibres	   however	   this	   difference	   was	  
statistically	  significant	  in	  geriatric	  age	  group	  only	  (p	  =	  <0.01)	  (Figure	  3.6	  D).	  When	  analysing	  the	  small	  
myofibres	   only,	   it	   appeared	   that	   superoxide	   production	   increased	   slightly	   with	   age	   with	   levels	  
peaking	   at	   geriatric	   age	   (with	   a	   relative	   intensity	   of	   approximately	   9	   to	   13.3a.u.)	   (Figure	   3.6	   E).	  
Although	  due	  to	  a	  large	  amount	  of	  variation,	  the	  increase	  observed	  was	  not	  statistically	  different	  to	  
younger	  age	  groups.	  Interestingly,	  a	  decreased	  DHE	  fluorescence	  intensity	  was	  measured	  in	  old	  age	  
when	  treated	  with	  CM	  when	  compared	  to	  the	  ‘old’	  control	  and	  geriatric	  groups	  (p	  =	  <0.01	  and	  <0.05,	  
respectively).	   A	   statistically	   significant	   increase	   in	   DHE	   intensity	   was	   noted	   in	   the	   large	  myofibres	  
between	  young	  and	  old	  age	  groups	  (p	  =	  <0.05)	  and	  the	  reduction	  seen	  with	  CM	  treatment	  in	  old	  age	  
was	  not	  statistically	  different	  from	  the	  aged	  control	  (Figure	  3.6	  F).	  
Mitochondrial	   superoxide	   dismutase	   (SOD2)	   is	   a	   manganese	   superoxide	   dismutase	   (MnSOD)	   that	  
catalyses	  the	  mutating	  of	  O2-­‐	  into	  hydrogen	  peroxide	  (H2O2)	  which	  in	  turn,	  is	  transformed	  into	  H2O	  by	  
catalase,	   glutathione	   peroxidase	   (GPX)	   or	   peroxidredoxin	   III	   (PRX	   III)	   (Pieczenik	   &	   Neustadt	   2007;	  
Green	  et	  al.	  2004).	  Therefore,	  SOD2	  is	  an	  enzyme	  responsible	  for	  mitochondrial	  antioxidant	  activity	  
and	  as	  previously	  shown	  with	  DHE	  analysis,	  an	  increase	  in	  superoxide	  levels	  within	  myofibres	  could	  
indicate	  dysfunctional	  antioxidant	  regulation.	  Next,	  qPCR	  analysis	  was	  carried	  out	  to	  investigate	  any	  
observed	   changes	  with	   age	   in	   SOD2	   gene	   expression.	   It	  was	   shown	   that	   SOD2	   levels	   did	   not	   alter	  
significantly	   from	   young	   to	   advanced	   old	   ages	   and	   remained	   consistent	   throughout	   the	   murine	  




Figure	   3.6	   The	   effect	   of	   ADMSC	   CM	   (CM)	   and	   ageing	   on	   the	   metabolic	   status,	   vasculature	  
organisation	   and	   mitochondrial	   function	   of	   the	   Soleus.	   (A)	   Proportion	   of	   myofibres	   positive	   for	  
succinate	  dehydrogenase	  (SDH)	  staining	  to	  assess	  the	  oxidative	  capacity.	  (B)	  Capillary	  density	  (CD31+	  
cells	  per	   fibre).	   (C)	  VEGFa	  165	  mRNA	  expression.	   (D)	  Dihydroethidium	   (DHE)	   fluorescence	   intensity	  
indicating	  ROS	  production	  is	  greater	  in	  small	  myofibres	  (E)	  Quantification	  of	  ROS	  production	  in	  small	  
myofibres.	   (F)	   Quantification	   of	   ROS	   production	   in	   large	   myofibres.	   (G)	   Antioxidant	   superoxide	  
dismutase	  2	  (SOD2)	  mRNA	  expression.	  *p<0.05,	  **p<0.01,	  ***p<0.001,	   (A-­‐C,	  E-­‐G)	  One-­‐way	  ANOVA	  
with	  Tukey	  post	  hoc	  testing.	  (D)	  Individual	  student’s	  t-­‐tests.	  
	  
Changes	  in	  collagen	  IV	  density	  and	  dystrophin	  glycoprotein	  complex	  (DGC)	  
components	  of	  the	  ageing	  Soleus	  extracellular	  matrix	  (ECM)	  and	  CM	  modifies	  
connective	  tissue	  content	  
Collagen	   is	   a	   key	   component,	   along	  with	   other	   proteins	   and	   lipids,	   of	   the	   basal	   lamina	   of	   skeletal	  
muscle	  and	  it	  is	  has	  been	  previously	  reported	  in	  the	  literature	  that	  collagens	  become	  more	  dense	  and	  





components	   impact	   on	   the	   muscle’s	   overall	   contractility,	   as	   well	   as	   on	   the	   essential	   mechanisms	  
underpinning	  satellite	  cell	  regeneration	  following	  damage	  or	  injury,	  such	  as	  emergence	  through	  the	  
basal	  lamina	  and	  migration.	  
Collagen	   IV,	  a	  basement	  membrane	  component	  surrounding	  each	  myofibre,	  was	  analysed	  using	  an	  
immunofluorescence	  protocol	  of	   transverse	   cross-­‐sections	  of	   the	   ageing	  Soleus.	   Collagen	   thickness	  
was	   measured	   and	   categorised	   based	   on	   border	   type,	   dependent	   on	   MHC	   myofibre	   types.	   For	  
example,	  borders	  between	  type	  I	  myofibres	  and	  those	  between	  non-­‐type	  I	  myofibres.	  	  
Firstly,	   there	   was	   a	   notable	   difference	   between	   the	   two	   types	   of	   border	   with	   non-­‐type	   I	   borders	  
having	  a	  thicker	  collagen	  layer	  than	  type	  I	  in	  adult	  and	  old	  ages,	  with	  and	  without	  CM	  treatment	  (p	  =	  
<0.05	   and	   <0.01)	   (Figure	   3.7	   A).	   Secondly,	   with	   age,	   collagen	   thicknesses	   increased	   incrementally	  
with	  the	  growth	  of	  the	  animal	  from	  young	  to	  adult	  (p	  =	  <0.001)	  and	  again	  into	  old	  age	  (p	  =	  <0.05)	  in	  
borders	   between	   type	   I	   myofibres	   (Figure	   3.7	   B).	   Thickness	   subsequently	   decreased	   from	   a	   peak	  
thickness	   of	   2.9µm	   at	   old	   age	   to	   2.4µm	   at	   geriatric	   ages	   (p	   =	   <0.01)	   but	   did	   not	   reduce	   to	   levels	  
previously	   measured	   at	   young	   ages,	   1.7µm	   (p	   =	   <0.001).	   Interestingly,	   CM	   treatment	   reduced	  
collagen	  thickness	  in	  old	  age	  from	  2.9µm	  to	  2.3µm	  (p	  =	  <0.001).	  	  
Collagen	   thickness	   of	   borders	   between	   non-­‐type	   I	   myofibres	   also	   showed	   similar	   trends	   as	   those	  
observed	  with	   type	   I.	   A	   steady	   increase	   in	   collagen	  width	  was	  measured	   during	   the	   initial	   growth	  
phase	  from	  young	  to	  adult	  and	  further	  still	   from	  adult	  to	  old	  age	  to	  a	  peak	  thickness	  of	  3.5µm	  (p	  =	  
<0.05,	   respectively)	   (Figure	  3.7	  C).	  As	  before,	  CM	  attenuated	   the	  collagen	   thickness	   (2.8µm)	   in	   the	  
basement	  membrane	  of	  myofibres	  in	  Soleus	  muscles	  from	  old-­‐aged	  mice	  (p	  =	  <0.05).	  
Moreover,	   collagen	   content	   within	   ageing	   Soleus	   muscles	   was	   further	   investigated	   using	   qPCR	  
analysis	  to	  determine	  the	  relative	  expression	  levels	  of	  genes	  coding	  for	  components	  of	  collagen	  I	  and	  
collagen	  IV	  (Col1A1	  and	  Col4A1,	  respectively).	  Collagen	  I	  is	  a	  highly	  abundant,	  key	  structural	  protein	  
of	   skin,	   bone,	   dentin,	   tendons	   and	   the	   endomysium	   of	  myofibrils	   as	  well	   as	   in	   fibrous	   scar	   tissue	  
following	  repair	  (Light	  &	  Champion	  1984;	  Orgel	  et	  al.	  2006).	  	  
Collagen	   I	   analysis	   indicated	   an	   evidently	   large	   degree	   of	   variation,	   therefore	   any	   observed	  
differences	   were	   not	   statistically	   significant	   (Figure	   3.7	   D).	   Although,	   there	   was	   a	   statistically	  
significant	  decrease	  in	  collagen	  IV	  expression	  in	  geriatric	  Soleus	  muscles	  when	  compared	  to	  all	  other	  
age	  groups	   (p	  =	  <0.05)	   (Figure	  3.7	  E).	  Additionally,	   treatment	  with	  CM	  had	  no	  effect	  on	   the	  mRNA	  
level	  of	  collagen	  IV	  at	  old	  age.	  
Two	  further	  genes	  that	  code	  for	  essential	  components	  of	  the	  dystrophin	  glycoprotein	  complex	  (DGC),	  
responsible	   for	   linking	   the	  myofibre	   cytoskeleton	   to	   the	  extracellular	  matrix,	  were	  examined	  using	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qPCR	   analysis.	   Dystrophin	   is	   located	   on	   the	   inside	   surface	   of	   the	   myofibre	   sarcolemma	   (plasma	  
membrane)	  and	  has	  the	  primary	  role	  of	  connecting	  actin	  filaments	  with	  other	  supporting	  signalling	  
and	   adaptor	   proteins	   to	   the	   endomysium	   for	   the	   structural	   and	  mechanical	   stability	   of	  myofibres	  
during	   muscle	   contraction.	   Sarcoglycans,	   although	   constitute	   a	   sub-­‐set	   of	   the	   DGC	   bound	   to	  
dystrophin,	  are	  the	  transmembrane	  protein	  component	  of	  the	  complex.	  Components	  of	  the	  DGC	  are	  
believed	   to	   have	   essential	   sensing	   and	   signalling	   roles	   in	   mechanotransduction,	   in	   response	   to	  
myofibre	   loading.	   Along	   with	   the	   lack	   of	   dystrophin	   in	   Duchenne	  muscular	   dystrophy	   (DMD),	   the	  
structural	   integrity	   of	   the	   myofibre	   basal	   lamina,	   extracellular	   matrix	   interactions,	   as	   well	   as	   this	  
mechanosensing	   response,	   are	   all	   implicated	   (Goldspink	   1999).	   Dystrophin	   and	   beta-­‐sarcoglycan,	  
members	  of	   the	  DGC,	  were	  examined	   in	   the	  present	  study	  to	   investigate	   the	  possible	  shared	  myo-­‐
pathological	  dysfunction	  demonstrated	  in	  DMD,	  in	  ageing.	  Furthermore,	  changes	  in	  DGC	  components	  
could	  indicate	  a	  source	  of	  muscle	  weakness	  and	  declined	  force-­‐generating	  capacity	  in	  ageing.	  
The	  relative	  mRNA	  of	  both	  dystrophin	  (coded	  by	  the	  DMD	  gene)	  and	  beta-­‐sarcoglycan	  (sgcb)	  during	  
ageing	   showed	   a	   similar	   trend	   of	   increased	   expression	   between	   adult	   and	   old	   age	   (p	   =	   <0.05	   and	  
<0.01,	  respectively)	  (Figure	  3.7	  F,	  G).	  There	  were	  no	  significant	  differences	  in	  the	  expression	  of	  these	  




Figure	   3.7	   Investigating	   the	   influence	   of	   ADMSC	   CM	   (CM)	   and	   ageing	   on	   collagen	   content	   and	  
structural	   components	  of	   the	  dystrophin	  glycoprotein	  complex	   (DGC)	   in	   the	  Soleus.	   (A)	  Collagen	   IV	  
thickness	   between	   MHC	   myofibres,	   type	   I	   border	   with	   another	   type	   I.	   Non-­‐type	   I	   border	   with	   a	  
second	   non-­‐type	   I	   myofibre	   (B)	   Collagen	   IV	   thickness	   in	   type	   I	   myofibre	   borders	   (C)	   Collagen	   IV	  
thickness	   in	   non-­‐type	   I	   myofibre	   borders	   (D)	   Collagen	   I	   mRNA	   expression	   (E)	   Collagen	   IV	   mRNA	  
expression	   (F)	   Dystrophin	   mRNA	   expression.	   (G)	   Beta-­‐sarcoglycan	   mRNA	   expression.	   *p<0.05,	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**p<0.01,	  ***p<0.001,	  (B-­‐G)	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  (A)	  Individual	  student’s	  t-­‐
tests.	  
MHC	  isoform	  myofibre	  composition	  shift	  to	  an	  even	  faster	  phenotype	  in	  the	  
ageing	  EDL	  muscle	  
The	  ageing	  profile	  of	  the	  Soleus,	  a	  muscle	  more	  oxidative	  in	  nature,	  was	  then	  compared	  to	  that	  of	  the	  
EDL,	   a	   faster,	   more	   glycolytic	   muscle	   type.	   This	   aimed	   to	   establish	   the	   extent	   of	   the	   impact	   of	  
observed	   changes	   associated	   with	   the	   onset	   of	   sarcopenia	   in	   two	   distinct,	   metabolically	   diverse	  
hindlimb	  muscles.	   As	  with	   the	  Soleus,	   transverse	   cross-­‐sections	   of	   the	   EDL	  muscle	  were	   examined	  
using	   an	   immunohistochemical	   protocol	   for	   the	   visualisation	   and	   analysis	   of	   the	   MHC	   isoform	  
content	   of	   individual	   myofibres.	   MHC	   fibre	   types	   (I,	   IIA,	   IIX	   and	   IIB)	   were	   quantified	   across	   the	  
maximal,	  mid-­‐belly	   region	  of	   each	  EDL	   at	   young,	   adult,	   old	   and	   geriatric	   ages	   including	   an	  old	   age	  
cohort	  treated	  with	  CM.	  
Firstly,	  total	  myofibre	  number	  indicated	  a	  reduction	  with	  age	  from	  approximately	  1100	  myofibres	  at	  
young	  and	  adult	  ages	  to	  840	  at	  old-­‐age	  (p	  =	  <0.05	  and	  <0.001,	  respectively)	  (Figure	  3.8	  A).	  Myofibre	  
number	  at	  geriatric	  age	  however,	  was	  not	   significantly	  different	   from	  that	  at	  any	  other	  age	  group.	  
There	  was	  also	  no	  statistically	  significant	  difference	  in	  the	  total	  number	  of	  myofibres	  in	  old	  age	  with	  
CM	  when	  compared	  to	  the	  control	  old-­‐aged	  group.	  
Secondly,	  MHC	  myofibre	   typing	   analysis	   showed	   less	   than	   1%	   of	   the	   total	   fibres	   in	   all	   age	   groups	  
were	   slow-­‐twitch	   type	   I	   (Figure	   3.8	   B,	   C).	   Additionally,	   between	   10	   -­‐	   17%	   of	   total	   myofibres,	  
consistently	   across	   all	   four	   age	   groups	   as	   well	   as	   CM	   treatment,	   were	   type	   IIA	   (Figure	   3.8	   B,	   D).	  
However,	  there	  was	  an	  observed	  reduction	  in	  the	  percentage	  of	  IIX	  myofibres	  with	  age	  (Figure	  3.8	  B,	  
E).	   From	   adult	   to	   old	   age,	   the	   percentage	   of	   IIX	   fibres	   decreased	   from	   14.5	   to	   8.4%	   (p	   =	   <0.001).	  
Moreover,	   geriatric	   EDLs	   contained	   the	   smallest	   proportion	   of	   IIX	   fibres	   (4.9%),	   significantly	   fewer	  
than	  at	  young	  (12.7%)	  and	  adult	   (14.5%)	  ages	  (p	  =	  <0.05	  and	  <0.001,	  respectively)	  as	  well	  as	  at	  old	  
age	  with	  CM,	  10.5%	  (p	  =	  <0.05).	  CM	  treatment	  did	  not	  significantly	  affect	  the	  percentage	  of	  IIX	  fibres	  
at	  old	  age.	  Furthermore,	  an	  observed	  switch	  to	  an	  even	  faster	  phenotype	  with	  age	  was	  noted,	  with	  
an	  increased	  proportion	  of	  total	  myofibres	  identified	  as	  type	  IIB	  from	  adult	  (68%)	  to	  old	  (78%)	  ages	  (p	  
=	  <0.001)	  (Figure	  3.8	  F).	  Although	  significantly	  greater	  than	  the	  proportion	  measured	  in	  adulthood	  (p	  





Figure	  3.8	  Examining	  the	  effect	  of	  ADMSC	  CM	  (CM)	  and	  ageing	  on	  Myosin	  heavy	  chain	  (MHC)	  isoform	  
myofibre	  composition	  of	  the	  EDL	  muscle.	  (A)	  Quantification	  of	  the	  total	  myofibre	  number.	  (B)	  Overall	  
MHC	  myofibre	   type	   composition.	   (C)	   Proportion	   of	  MHC	   type	   I	  myofibres.	   (D)	  Proportion	   of	  MHC	  
type	   IIA	   myofibres.	   (E)	   Proportion	   of	   MHC	   type	   IIX	   myofibres.	   (F)	   Proportion	   of	   MHC	   type	   IIB	  
myofibres.	  *p<0.05,	  ***p<0.001,	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  
	  
Changes	  in	  myofibre	  cross-­‐sectional	  area	  (CSA)	  in	  the	  ageing	  EDL	  muscle	  
As	   in	   the	   Soleus,	   Myofibre	   CSA	   was	   measured	   by	   MHC	   isoform	   in	   order	   to	   further	   examine	   any	  
myofibre	  morphometric	   changes	   in	   the	  ageing	  EDL.	  Average	   type	   I	  myofibre	  CSA	  did	  not	  vary	  with	  
age,	   unlike	   those	   measured	   in	   type	   IIA	   fibres	   that	   indicated	   an	   age-­‐related	   increase,	   peaking	   at	  
geriatric	  age	  (~630µm2),	  statistically	  significant	  when	  compared	  to	  the	  young	  (~440µm2)	  age	  group	  (p	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=	  <0.05)	  (Figure	  3.9	  A,	  B).	  Type	  IIX	  and	  IIB	  myofibres,	  like	  type	  I,	  appeared	  to	  exhibit	  a	  reduced	  degree	  
of	   variation	   with	   age	   progression,	   regarding	   relatively	   consistent	   average	   CSAs	   between	   all	   age	  
groups	   (650	   –	   800µm2,	   1300	   –	   1400µm2	   and	   400	   -­‐	   500µm2	   approximate	   size	   ranges,	   respectively)	  
(Figure	  3.9	  C,	  D).	  CM	  treatment	  showed	  a	  decreased	  CSA	  in	  type	  IIB	  myofibres	  when	  compared	  to	  the	  
adult	  age	  group	  (p	  =	  <0.05)	  however,	  CM	  did	  not	  affect	  myofibre	  size	  in	  old	  age.	  
	  
Figure	  3.9	  The	  effect	  of	  ADMSC	  CM	  (CM)	  and	  ageing	  on	  Myosin	  heavy	  chain	  (MHC)	  isoform	  myofibre	  
cross-­‐sectional	   area	   (CSA)	   of	   the	   EDL	   muscle.	   (A)	   MHC	   type	   I	   myofibre	   CSA.	   (B)	   MHC	   type	   IIA	  
myofibre	   CSA.	   (C)	  MHC	   type	   IIX	  myofibre	   CSA.	   (D)	  MHC	   type	   IIB	  myofibre	   CSA.	   *p<0.05,	  One-­‐way	  
ANOVA	  with	  Tukey	  post	  hoc	  testing.	  
	  
Oxidative	  capacity	  remains	  unchanged	  in	  the	  ageing	  EDL	  	  
As	  previously	  discussed,	  unlike	  the	  Soleus,	  the	  EDL	  is	  a	  predominantly	  glycolytic	  muscle	  with	  distinctly	  
diverse	  metabolic	  characteristics.	  In	  order	  to	  better	  understand	  some	  of	  the	  changes	  observed	  in	  the	  
more	  glycolytic	  muscle	  with	  age	  as	  well	  as	  those	  reported	  in	  the	  literature,	  metabolic	  function	  in	  the	  
ageing	  EDL	  was	  investigated.	  	  
To	   examine	   the	   metabolic	   status	   of	   myofibres,	   the	   histological	   succinate	   dehydrogenase	   (SDH)	  
staining	  protocol	  was	  carried	  out	  on	  transverse	  cross-­‐sections	  of	  the	  EDL	  muscle	  from	  5	  cohorts,	  at	  
young,	  adult,	  old	  and	  geriatric	  ages	  as	  well	  as	  with	  CM	  treatment	  during	  old	  age.	  It	  was	  observed	  that	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approximately	  45	  -­‐	  49%	  of	  total	  myofibres	  were	  SDH-­‐positive	  during	  young,	  adult,	  old	  and	  geriatric	  
ages	   (Figure	  3.10	  A).	  CM	   treatment	  during	  old	  age	  did	  not	   significantly	   increase	   the	  percentage	  of	  
SDH-­‐positive	  myofibres	  compared	  to	  any	  other	  age	  or	  treatment	  group.	  
Vasculature	  organisation	  is	  not	  altered	  by	  CM	  treatment	  in	  the	  ageing	  EDL	  
As	  discussed,	  a	  key	  component	  of	  metabolic	  function	  is	  oxygen	  delivery	  and	  as	  previously	  shown	  with	  
the	  SDH	  analysis,	   there	  were	  no	  observed	   changes	   in	   the	  proportion	  of	  oxidative	  myofibres	   in	   the	  
ageing	  EDL	  muscle	  and	  CM	  treatment	  during	  old	  age	  did	  not	  have	  any	  significant	  effects.	  Vasculature	  
organisation	   was	   investigated	   in	   order	   to	   further	   understand	   the	   features	   under-­‐lying	   metabolic	  
regulation	   and	   how	   these	   are	   affected	   during	   ageing	   of	   a	   primarily	   glycolytic	  muscle.	   As	  with	   the	  
Soleus,	  CD31+	  cells	  were	  quantified	  per	  myofibre	  to	  examine	  the	  effect	  of	  CM	  during	  old	  age	  on	  the	  
number	  of	  capillaries.	  However,	  unlike	  in	  the	  Soleus,	  CM	  had	  no	  effect	  on	  the	  number	  of	  CD31+	  cells	  
at	  old	  age	  in	  the	  EDL.	  (Figure	  3.10	  B).	  
Reactive	  oxygen	  species	  (ROS)	  production	  increases	  in	  the	  large	  myofibres	  of	  
the	  ageing	  EDL	  and	  CM	  displays	  antioxidant	  potential	  
ROS	   production	   and	   oxidative	   stress,	   as	   previously	   discussed,	   are	   believed	   to	   have	   key	   negative	  
impacts	   on	   mitochondrial	   function	   and	   the	   onset	   and	   progression	   of	   age-­‐related	   degeneration	  
(Pieczenik	   &	   Neustadt	   2007;	   López-­‐otín	   et	   al.	   2013).	   Therefore,	   as	   before	   with	   the	   Soleus,	  
dihydroethidium	   (DHE)	   fluorescence	   intensity	   within	   myofibres	   was	   measured	   to	   detect	  
mitochondrial	   superoxide	   (O2-­‐)	   ROS	   production.	   DHE	   fluorescence	   intensity	  was	   compared	   in	   both	  
small	  and	  large	  myofibres	  of	  muscles	  from	  animals	  treated	  with	  CM	  during	  old	  age	  and	  compared	  to	  
that	   in	   adult	   EDLs.	   As	   seen	   in	   the	  Soleus	  muscle,	   there	  was	   a	   statistically	   greater	   intensity	   of	  DHE	  
fluorescence	  within	  the	  centre	  of	  smaller	  myofibres	  compared	  to	  larger-­‐sized	  myofibres	  in	  both	  adult	  
and	  old	  ages	  as	  well	  as	  with	  CM	  treatment	  (p	  =	  <0.05	  and	  <0.001,	  respectively)	  (Figure	  3.10	  C).	  DHE	  
intensity	  did	  not	  significantly	  differ	  in	  the	  smaller	  myofibres	  with	  age	  nor	  with	  CM	  treatment	  (Figure	  
3.10	   D).	   However,	   the	   increase	   in	   fluorescence	   intensity	   between	   adult	   and	   old	   age	   and	   the	  
subsequent	   reduction	   with	   CM	   treatment,	   were	   statistically	   significant	   (p	   =	   <0.05	   and	   <0.01,	  
respectively)	  (Figure	  3.10	  E).	  	  
Myofibre	  collagen	  IV	  density	  increases	  with	  age	  in	  the	  EDL	  
As	  collagen	  thickness	   is	  believed	  to	  be	  a	  key	  component	   implicated	   in	  reduced	  contractile	  ability	   in	  
disease	   as	   well	   as	   in	   sarcopenia	   as	   previously	   discussed,	   additionally	   in	   the	   current	   study,	   the	  
collagen	   IV	   thickness	  was	  measured	   in	   the	   EDL.	   As	   carried	   out	   previously	  with	   the	   Soleus	  muscle,	  
collagen	   IV	  was	   visualised	   using	   an	   immunofluorescence	   protocol	   of	   transverse	   cross-­‐sections	   and	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thickness	   was	   measured	   by	   MHC	   myofibre	   border	   type.	   For	   example,	   borders	   between	   type	   IIB	  
myofibres	  and	  those	  between	  non-­‐type	  IIB	  myofibres.	  	  
An	  observed	  difference	  in	  collagen	  IV	  thickness	  between	  MHC	  border	  type	  was	   indicated.	  A	  thicker	  
layer	   of	   collagen	   in	   non-­‐type	   IIB	   borders	  was	  measured	  when	   compared	   to	   that	   between	   type	   IIB	  
myofibres,	   this	   difference	   however	   was	   statistically	   significant	   in	   old-­‐age	   only,	   2.6	   and	   2.2µm,	  
respectively	  (p	  =	  <0.05)	  (Figure	  3.10	  F).	  When	  analysing	  the	  thickness	  of	  collagen	  in	  type	  IIB	  borders	  
alone,	   an	   incremental	   increase	  with	   age	  was	   noted,	  with	   a	   thickness	   of	   1.7	   -­‐	   1.8µm	  at	   young	   and	  
adult	   ages,	   peaking	   at	   2.5µm	   at	   a	   geriatric	   age	   (p	   =	   <0.05)	   (Figure	   3.10	   G).	   Similar	   trends	   were	  
observed	  when	  analysing	  the	  thickness	  of	  collagen	  IV	  between	  non-­‐type	  IIB	  myofibres.	  For	  example,	  
a	  peak	  thickness	  was	  also	  measured	  at	  a	  geriatric	  age,	  which	  showed	  a	  significant	  increase	  from	  2µm	  
at	  adult	  ages	  to	  2.8µm	  at	  geriatric	  age	  (p	  =	  <0.05)	  (Figure	  3.10	  H).	  The	  collagen	  thickness	  in	  both	  type	  
IIB	   and	   non-­‐type	   IIB	   borders,	   between	   adult	   and	   old	   age,	   was	   statistically	   non-­‐significant.	  
Furthermore,	  CM	   treatment	  did	  not	   significantly	   affect	   type	   IIB	   collagen	   IV	   thickness	   in	  old	  age,	   in	  




Figure	   3.10	   The	   effect	   of	   ADMSC	   CM	   (CM)	   on	   the	   metabolic	   status,	   vasculature	   organisation,	  
mitochondrial	  function	  and	  collagen	  content	  of	  the	  ageing	  EDL.	  (A)	  Proportion	  of	  myofibres	  positive	  
for	   succinate	   dehydrogenase	   (SDH)	   staining	   to	   assess	   the	   oxidative	   capacity.	   (B)	   Capillary	   density	  
(CD31+	  per	  myofibre).	  (C)	  Dihydroethidium	  (DHE)	  fluorescence	  intensity	  indicating	  ROS	  production	  is	  
greater	   in	   small	   myofibres	   (D)	   ROS	   production	   in	   small	   myofibres.	   (E)	   ROS	   production	   in	   large	  
myofibres.	  (F)	  Collagen	  IV	  thickness	  between	  MHC	  myofibres,	  type	  IIB	  border	  with	  another	  type	  IIB.	  
Non-­‐type	  IIB	  border	  with	  a	  second	  non-­‐type	  IIB	  myofibre	  (G)	  Collagen	  IV	  thickness	  type	  IIB/	  type	  IIB	  
myofibre	   border	   (H)	   Collagen	   IV	   thickness	   non-­‐type	   IIB/	   non-­‐type	   IIB	   myofibre	   border	   *p<0.05,	  
**p<0.01,	   ***p<0.001,	   (A,	   D,	   E,	   G,	   H)	   One-­‐way	   ANOVA	   with	   Tukey	   post	   hoc	   testing.	   (B,	   C,	   F)	  
Individual	  student’s	  t-­‐tests.	  
	  




The	   hADMSCs	   that	   were	   used	   to	   generate	   the	   CM	   in	   the	   present	   study,	   were	   a	   commercially	  
available	   cell	   line	   that	   have	   been	   fully	   characterised	   in	   their	   expression	   of	   numerous	   stem	   cell	  
markers	  of	  multipotency,	  including	  CD29,	  CD44,	  CD73,	  CD90,	  CD105	  and	  CD166	  while	  being	  negative	  
for	  CD14,	  CD31,	  CD45	  and	  Lin1.	  It	  is	  well-­‐established	  that	  ADMSC	  multipotency	  can	  be	  demonstrated	  
by	   the	  ability	   to	  differentiate	   towards	  not	  only	  an	  adipogenic	   lineage,	  but	  also	   towards	  osteogenic	  
and	   chondrogenic	   specifications	   (Baglio	   et	   al.	   2012;	   Condé-­‐Green	   et	   al.	   2016).	   Importantly,	   this	  
feature	  was	   retained	   following	   CM	  generation	   in	   the	   present	   study,	   indicating	   that	   the	   secretome	  
collected	  was	  indeed	  that	  produced	  by	  stem	  cells.	  Additionally,	  it	  was	  observed	  that	  ADMSC	  growth	  
media	  control	   cells	  also	   initiated	  progression	  down	   their	   typical	  adipogenic	   lineage,	  evident	  by	   the	  
formation	  of	  lipid	  droplets	  in	  the	  adipogenesis	  control	  cultures.	  Furthermore,	  it	  was	  noted	  that	  under	  
pellet	  culture	  conditions,	  to	  facilitate	  the	  differentiation	  towards	  a	  chondrogenic	  lineage,	  the	  growth	  
media	  control	  ADMSCs	  were	  also	  observed	  as	  positively-­‐stained	  for	  Alcian	  blue,	  visibly	  no	  different	  to	  
the	   positive	   differentiation	  media	   culture.	   This	   indicates	   that	   the	   pellet	   culture	   system	   alone	  was	  
sufficient	  in	  directing	  ADMSCs	  to	  a	  chondrogenic	  lineage.	  Therefore,	  this	  indicates	  the	  importance	  of	  
growth	   factor	   influences	   and	   those	   directed	   by	   culture	   and	   ECM	   conditions	   in	   directing	   ADMSC	  
lineage	   specification.	  Nevertheless,	   these	   findings	   demonstrate	   the	   differentiation	   potential	   of	   the	  
ADMSCs	   following	  CM	  generation.	  CM	  was	  also	  tested	  using	  a	  robust	  assay	  and	  a	  protective	  effect	  
against	   H2O2	   stress-­‐induced	   cellular	   senescence,	   was	   observed.	   CM	   treatment	   tested	   at	  
concentrations	  of	  both	  1	  and	  10%	  resulted	   in	  a	   reduction	   in	  positively-­‐stained	  SA-­‐β-­‐gal	  cells	   to	   the	  
level	  of	  the	  unstressed	  control.	  However,	  it	  should	  be	  noted	  that	  the	  unstressed	  control	  displayed	  an	  
unexpectedly	   high	   proportion	   of	   senescent	   cells,	   nevertheless,	   the	   efficacy	   of	   CM	   treatment	   in	  
providing	   protection	   despite	   this,	   was	   evident.	   This	   finding	   indicates	   that	   importantly,	   properties	  
maintained	   by	   the	   CM	   in	   the	   present	   study	   demonstrate	   regulatory	   effects	   involved	   with	   the	  
mechanisms	  of	  senescence,	  cell	  cycle	  arrest	  and	  survival.	  Of	  which,	  these	  are	  key	  mechanisms	  known	  
to	  become	  dysregulated	  with	  age,	   leading	  to	  decreased	  proliferation	  and	  differentiation	  capacities,	  
for	  example.	  
The	  design	  of	  the	  naturally-­‐aged	  in	  vivo	  CM	  series	  of	  experiments	  has	  enabled	  the	  investigation	  of	  a	  
variety	  of	  research	  parameters	  at	  a	  range	  of	  tissue	  levels,	  in	  order	  to	  develop	  a	  broad	  murine	  ageing	  
profile	  of	  multiple	  aspects,	   in	  order	   to	  assess	   the	  potential	   therapeutic	  effect	  of	  ADMSC	  CM.	   (A)	   It	  
was	  determined	  that	  sarcopenia	  was	   indeed	  evident	  by	   the	   loss	  of	  muscle	  mass,	  however	   this	  was	  
primarily	  observed	  at	   a	   geriatric	   age.	   (B)	   Key	  phenotypical	   features	  were	  explored	  and	   indicated	  a	  
reduced	  total	  myofibre	  number,	  an	  increase	  in	  metabolic	  dysfunction,	  increased	  ROS	  production	  and	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evidence	   of	   a	   fast	   to	   slow	  MHC	   switch	   of	   myofibres	   in	   the	   ageing	   Soleus.	   There	   was	   however,	   a	  
switch	   in	   the	   reverse	   direction,	   from	   fast	   to	   an	   even	   faster	   phenotype	   in	   the	   EDL.	   (C)	   ADMSC	  CM	  
treatment	  in	  aged	  animals	  did	  not	  appear	  to	  influence	  features	  such	  as	  the	  overall	  myofibre	  number,	  
size	   or	   type,	   although	   there	   is	   some	   evidence	   for	   potential	   modification	   of	   signalling	   pathways	  
involved	   in	   angiogenesis,	   oxidative	   metabolism,	   reduced	   ROS	   production/increased	   antioxidant	  
activity,	  as	  well	  as	  collagen	  organisation.	  	  
Measurements	   recorded	   at	   a	   whole	   organism	   level	   indicated	   that	   with	   an	   initial	   growth	   phase	   in	  
young	   female	   C57BL/6	   mice,	   body	   mass	   dramatically	   increased	   between	   3	   and	   6	   months	   of	   age.	  
Hereafter,	  weight	  appeared	  to	  plateau,	  into	  old	  and	  advanced	  old	  age.	  This	  finding	  is	  consistent	  with	  
those	   in	  other	   studies,	   although	   some	  also	  describe	   that	   the	   increase	   in	  weight	   continues	  until	   12	  
months,	  at	  which	  point	  thereafter,	  remains	  constant	  or	  in	  some	  cases,	  declines	  into	  advanced	  old	  age	  
(Glatt	  et	  al.	  2007;	  Halloran	  et	  al.	  2002;	  Lessard-­‐Beaudoin	  et	  al.	  2015;	  Marino	  2012;	  Fahlstrom	  et	  al.	  
2011).	  Mice	  are	   reported	   to	  undergo	  a	   rapid	   increase	   in	  body	  mass	  with	   initial	   growth,	  during	   the	  
first	   4	  weeks	   and	   continue	   to	   grow	   and	   gain	  weight	   over	   a	   considerable	   portion	   of	   their	   life-­‐span	  
(Fahlstrom	  et	  al.	  2011;	  Turturro	  et	  al.	  1999;	  Glatt	  et	  al.	  2007).	  Changes	  in	  body	  mass	  with	  age	  have	  
been	   attributed	   to,	   among	   others,	   alterations	   in	   features	   of	   body	   composition.	   For	   example,	   one	  
study	  conducted	  in	  mice	  up	  to	  20	  months	  of	  age,	  described	  steady	  increases	  in	  body	  mass	  and	  total	  
body	  bone	  mineral	  density	   (BMD),	  as	  well	   as	  a	  distinct	   increase	   in	  percentage	  body	   fat	  between	  6	  
and	  12	  months	   (Glatt	  et	  al.	  2007).	   In	  humans,	  peak	  bone	  mineral	  density	   is	  achieved	  between	   the	  
ages	  of	  10	  and	  19	  years	  and	  bone	  mineral	  content	   (BMC)	  however,	   this	  continues	  to	   increase	  until	  
approximately	   35	   years	   of	   age	   (Halloran	   et	   al.	   2002).	   Additionally,	   in	   human	   ageing	   studies,	   body	  
compositional	  parameters	  such	  as	  lean	  mass,	  BMD	  and	  BMC	  were	  all	  significantly	  reduced	  in	  old	  age	  
(Halloran	  et	  al.	  2002;	  Jiang	  et	  al.	  2015;	  Riggs	  et	  al.	  1981).	  Moreover,	  it	  has	  been	  suggested	  that	  age-­‐
related	  changes	  in	  bone	  architecture	  and	  mass	  in	  mice	  were	  remarkably	  similar	  to	  those	  observed	  in	  
human	   ageing	   (Halloran	   et	   al.	   2002).	   Interestingly	   however,	   the	   old	   and	   geriatric	   animals	   in	   the	  
current	  study	  did	  not	  experience	  this	  decline	  in	  body	  mass,	  which	  has	  been	  reported	  by	  some	  others	  
in	  advanced	  old	  age,	  despite	  the	  geriatric	  animals	  having	  a	  particularly	  frail	  appearance	  and	  structure	  
at	   the	   experimental	   end-­‐point.	   The	   old	   animals,	   contrastingly,	   had	   a	   reasonable	   amount	   of	   white	  
adipose	  tissue	  visible	  upon	  tissue	  harvesting	  at	  the	  experimental	  end-­‐point.	  This	  potentially	  indicates	  
a	   certain	   level	   of	   inactivity	   in	   old	   age.	   As	   it	   is	   also	   well-­‐known	   in	   the	   literature,	   that	   actively	  
contracting	   muscle,	   during	   exercise	   for	   example,	   releases	   myokines	   which,	   among	   other	  
characteristics,	  modifies	   the	  metabolic	  phenotype	  of	  adipose	   tissue,	  enhancing	  browning	  and	   fatty	  
acid	  oxidation	  (Boa	  et	  al.	  2017;	  Pedersen	  2009).	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Functional	   tests	   have	   been	   used	   as	   assessments	   of	   motor	   function	   and	   strength	   and	   reportedly,	  
young	   C57BL/6	   mice	   improve	   rotarod	   performance	   remarkably	   between	   1	   and	   3	   months	   of	   age.	  
However,	  this	  parameter	  as	  well	  as	  grip	  strength	  measurements	  are	  both	  shown	  to	  decline	  with	  age	  
(Fahlstrom	  et	  al.	  2011;	  Serradj	  &	  Jamon	  2007).	  Therefore,	  the	  decreasing	  average	  grip	  strength	  in	  the	  
relatively	   short	   experimental	   duration	   in	   the	   current	   study,	   from	   20	   to	   24	   months	   of	   age,	   is	   in	  
keeping	  with	   the	  declining	   trends	  described	   in	   the	   literature,	   however,	   this	  was	  not	   the	   case	  with	  
rotarod	  testing.	  Studies	  utilising	  extracted	  slow	  (β)	  myosin,	  in	  an	  in	  vitro	  motility	  assay,	  showed	  that	  
the	   changes	   to	   myosin	   with	   age	   contributed	   to	   slowed	   actomyosin	   interaction,	   effecting	   overall	  
force-­‐generating	  capacity	  (Höök	  et	  al.	  1999).	  
Characterisation	  of	  the	  skeletal	  muscle	  phenotype	  in	  natural	  ageing	  
With	  an	  observed	  decline	  in	  grip	  strength	  exerted	  by	  aged	  animals,	   it	  can	  be	  reasonably	  postulated	  
that	   aspects	   associated	   with	   the	   onset	   and	   progression	   of	   sarcopenia	   in	   the	   current	   study,	   are	  
evident.	  By	  definition,	  sarcopenia	  has	  been	  attributed	  to	  a	  loss	  of	  muscle	  mass	  with	  age.	  Additionally,	  
this	   is	   also	   accompanied	   by	   a	   reduction	   in	   contractile	   force-­‐generating	   capacity	   associated	  with	   a	  
certain	   degree	   of	   dysregulation	   and	   dysfunction	   of	   the	  musculature	   in	   ageing	   human	   and	   animal	  
studies	   (Brooks	  &	  Faulkner	  1991;	  Degens	  &	  Alway	  2003;	  Klitgaard,	  Mantoni,	  et	  al.	  1990;	  Larsson	  &	  
Edström	   1986;	   Rittweger	   et	   al.	   2004).	   Initially	   increasing	  muscle	  mass	   with	   the	   normal	   post-­‐natal	  
growth	   phase	   of	   the	   animal,	   has	   been	   attributed	   to	   compensatory	   hypertrophy	   in	   response	   to	   a	  
greater	  demand	  and	  load	  from	  initial	  increases	  in	  body	  weight	  and	  that	  fibre	  number	  usually	  remains	  
constant	  during	  this	  phase	  (hypertrophy	  over	  hyperplasia)	  (Rowe	  &	  Goldspink	  1969).	  The	  findings	  in	  
the	  current	  study	  appear	  to	  be	  consistent	  therefore,	  with	  what	  has	  previously	  been	  reported	  in	  the	  
literature,	   regarding	   the	  evidence	   for	  normal	  growth-­‐related	  compensatory	  hypertrophy.	  Following	  
this,	   weight	   subsequently	   decreased	   in	   most	   hind-­‐limb	   muscles	   into	   old	   or	   geriatric	   ages.	   Thus,	  
providing	  further	  indication	  of	  the	  onset	  and	  development	  of	  sarcopenia	  in	  the	  animals	  studied	  in	  the	  
described	  series	  of	  experiments.	  
Despite	  the	  grip	  strength	  analysis	  being	  used	  to	  measure	  the	  force	  exerted	  by	  the	  forelimb	  muscles,	  
we	  can	  postulate	  that	  declines	  in	  function,	  although	  differing	  between	  muscle	  types,	  are	  universal	  in	  
the	  ageing	  muscle	  compartment.	  The	  Soleus	  muscle	  was	  selected	  for	  investigation,	  at	  a	  tissue	  level,	  
into	  the	  changes	  that	  occur	  with	  age,	  due	  to	  the	  metabolic	  status	  being	  typically	  more	  oxidative	   in	  
nature,	  primarily	   consisting	  of	   type	   I	   and	   IIA	  myofibres.	   In	   contrast,	   the	  EDL,	  was	  used	  not	  only	   to	  
explore	   the	   effects	   of	   ageing	   on	   single	   myofibre	   cultures,	   but	   was	   examined	   and	   compared	  
histologically	   at	   a	   whole	   muscle	   level,	   to	   the	   Soleus,	   as	   a	   representative	   muscle	   with	   relatively	  
greater	  numbers	  of	  more	  glycolytic	  myofibres.	  A	  key	   feature	  of	   sarcopenia	   is	  myofibre	  atrophy,	  as	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well	   as	   this,	   there	   is	   a	   well-­‐established	   switch	   to	   those	   with	   a	   higher	   oxidative	   capacity	   with	   age	  
(Alnaqeeb	  &	  Goldspink	   1987;	   Chai	   et	   al.	   2011;	   Rowan	   et	   al.	   2011;	   Larsson	  &	   Edström	  1986).	   Both	  
were	   characteristics	   evident	   in	   the	   Soleus	   muscle	   of	   the	   current	   study,	   with	   distinctly	   fewer	  
myofibres	  present	  at	  a	  geriatric	  age.	  As	  well	  as	  an	  apparent	  increase	  in	  slower	  MHC	  type	  I	  myofibres	  
compared	   to	  young,	  with	  a	  corresponding	  decrease	   in	   faster	   type	   IIA.	  This	   switch	   in	  myofibre	   type	  
has	  been	  associated	  with	  denervation	  of	  faster	  type	  II	  (IIX	  and	  IIB)	  and	  subsequent	  re-­‐innervation	  of	  
neighbouring	  slow-­‐twitch	  myofibres,	  also	  believed	  to	  be	  the	  result	  of	  motor	  neuronal	  axon	  splitting	  
(Faulkner	  &	  Brooks	  1995;	  Demontis	  et	  al.	  2013;	  Larsson	  &	  Ansved	  1995).	  It	  has	  also	  been	  suggested	  
that	  denervation/re-­‐innervation	  processes	  resulted	   in	  rearrangement	  of	  myofibre	  types,	  namely	   IIX	  
as	   an	   intermediate	   form	   assumed	   by	  myofibres	   under-­‐going	   a	   slow	   to	   fast	   or	   a	   fast	   to	   slow	   shift	  
(Larsson	  et	  al.	  1991;	  Pette	  &	  Staron	  2000).	  Further	  evidence	  of	  denervation/re-­‐innervation	  with	  age,	  
reported	  in	  the	  literature,	  is	  the	  presence	  of	  larger	  motor	  units,	  occupying	  a	  larger	  territory	  evident	  
by	  MHC	  IIX	  grouping	  (Larsson	  et	  al.	  1991).	  Alternatively,	  endocrine	  influences	  have	  been	  investigated	  
regarding	  their	  effects	  on	  myofibre	  type	  composition.	  Thyroid	  hormones	  have	  been	  shown	  to	  be	  the	  
hormones	   with	   the	   most	   substantial	   effect	   on	   changes	   in	   myofibre	   types,	   in	   particular,	  
hypothyroidism	  initiates	  fast	  to	  slow	  transitions,	  whereas,	  hyperthyroidism	  causes	  transitions	  in	  the	  
reverse	  direction,	  from	  slow	  to	  fast	  (Nwoye	  &	  Mommaerts	  1981;	  Caiozzo	  et	  al.	  1998;	  Li	  et	  al.	  1996;	  
Pette	  &	  Staron	  2000).	  Therefore,	  changes	  in	  thyroid	  hormones	  with	  age	  may	  contribute,	  along	  with	  
changing	  demand	  and	  load	  as	  well	  as	  selective	  motor	  neuron	  denervation	  and	  re-­‐innervation	  to	  the	  
overall	   changes	   seen	   in	   myofibre	   phenotype	   and	   alteration	   to	   force-­‐generating	   capacity	   (Pette	   &	  
Staron	   2000).	   Additionally,	   denervation	   has	   been	   attributed	   to	   the	   majority	   of	   myofibre	   atrophy	  
observed	  in	  aged	  rats	  (Rowan	  et	  al.	  2012).	  It	  was	  also	  shown	  that	  type	  IIA	  myofibres	  appeared	  to	  be	  
eliminated	   at	   a	  more	   advanced	   rate	   compared	   to	   faster	   types	   in	   the	   ageing	   rat	  Soleus	   and	   slower	  
types	   seem	   to	   be	   less	   susceptible	   to	   atrophy	   (Larsson	   &	   Edström	   1986;	   Rowan	   et	   al.	   2011).	  
Furthermore,	  a	   study	  conducted	   in	  human	  vastus	   lateralis	  muscles	   saw	  that	   type	   IIB	  myofibres	  are	  
most	   susceptible	   to	   atrophy	   in	   ageing	   (Lexell	   et	   al.	   1988).	   The	   findings	   of	   the	   current	   study	   are	  
therefore,	   also	   in	   agreement	  with	   aspects	   of	  myofibre	   atrophy	   and	   the	   reported	   changes	   to	  MHC	  
myofibre	  phenotype	  in	  the	  ageing	  Soleus.	  
The	  opposite	   trend	  however,	  was	  evident	   in	   the	  EDL,	  where	  an	  apparent	   switch	   from	   fast	   type	   IIX	  
myofibres	   to	  an	  even	   faster	  phenotype	  was	  observed,	  with	  an	   increase	   in	   type	   IIB	  myofibres	   from	  
adult	  to	  old	  age.	  Other	  than	  hyperthyroidism,	  a	  shift	  in	  this	  direction	  is	  typically	  the	  result	  of	  disuse,	  
suggesting	  that	  the	  animals	  in	  the	  present	  study	  may	  have	  been	  experiencing	  a	  degree	  of	  inactivity,	  
sufficient	  to	  elicit	  a	  phenotype	  change	  in	  the	  EDL	  but	  not	  in	  the	  Soleus.	  However,	  this	  type	  of	  slow	  to	  
fast	  shift	   is	  more	  frequently	   linked	  to	  more	  complete	  disuse,	  for	  example	  from	  limb	  immobilisation	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(Leeuwenburgh	  et	   al.	   2005;	   Schwartz	   2008;	   Schiaffino	  &	  Reggiani	   2011).	   Reasons	   for	   the	   EDL	   shift	  
discrepancy	   could	   also	   indicate	   that	   the	   characteristically	   slower	   Soleus	   muscle,	   could	   be	   more	  
susceptible	  to	  influences	  towards	  an	  even	  slower	  phenotype	  (switch	  from	  IIA	  to	  I)	  and	  has	  a	  shorter	  
transition	   ‘journey’	   to	   travel	   in	   comparison	   to	   the	   faster	   EDL	   (IIB	   to	   IIX	   to	   IIA	   to	   I)	   (Schiaffino	   &	  
Reggiani	  2011).	  Otherwise,	  however,	  the	  reasons	  for	  this	  discrepancy	  with	  those	  previously	  reported	  
are	  not	  clear.	  Although,	  despite	  the	  general	  agreement	  of	  a	  fast	  to	  slow	  shift,	  some	  other	  (human)	  
studies,	  have	  alternatively,	  shown	  unchanged	  myofibre	  type	  proportions	  in	  ageing	  (Lexell	  et	  al.	  1986;	  
Lexell	  et	  al.	  1988;	  Grimby	  et	  al.	  1984;	  Kosek	  2006).	  	  
Myofibre	  loss	  during	  old	  age	  was	  also	  apparent	  in	  the	  EDL,	  indicated	  by	  the	  considerable	  reduction	  in	  
myofibre	  numbers	  compared	   to	  younger	  ages.	  Myofibre	  numbers	  observed	  at	  a	  geriatric	  age	  were	  
slightly	  greater	  than	  those	  seen	  in	  old	  age.	  An	  explanation	  for	  this	  trend	  could	  be	  that	  frail	  myofibres,	  
or	   those	   undergoing	   atrophy	   or	   degradation,	   split	   longitudinally	   giving	   the	   impression	   of	   greater	  
numbers	  present	  (Alnaqeeb	  &	  Goldspink	  1987).	  Suggesting	  that	  sarcopenia	  shows	  similar	  attributes	  
to	   myo-­‐pathological	   conditions,	   such	   as	   observed	   myofibre	   branching	   instead	   of	   supposed	  
hyperplasia	   in	   Duchenne	   muscular	   dystrophy	   (DMD)	   (Faber	   et	   al.	   2014).	   Although,	   it	   would	   be	  
expected	  that	  in	  this	  case,	  there	  would	  be	  myofibres	  with	  greatly	  variable	  and	  reduced	  CSAs	  present	  
(Alnaqeeb	  &	  Goldspink	  1987).	  This	  trend	  was	  somewhat	  evident	   in	  the	  variation	  of	  type	   IIX	  and	   IIB	  
CSA	   at	   geriatric	   ages.	   Analysis	   of	   serial	   sections	   spanning	   the	   entire	   length	   of	   the	   muscle	   would	  
however,	  give	  a	  greater	  understanding	  of	  this	  phenomenon	  (Alnaqeeb	  &	  Goldspink	  1987).	  As	  in	  the	  
Soleus,	  CSA	  of	  the	  relatively	  small	  proportion	  of	  type	  IIA	  myofibres	  in	  the	  EDL,	  presented	  a	  degree	  of	  
hypertrophy	   at	   a	   geriatric	   age.	   However,	   the	   number	   of	   IIA	   myofibres	   as	   well	   as	   total	   oxidative	  
capacity	   remained	   comparatively	   unchanged.	   Aside	   from	   potential	   explanations	   of	   hypertrophy	   in	  
old	  and	  advanced	  old	  ages	  relating	  to	  those	  of	  compensatory	  growth,	  in	  response	  to	  other	  aspects	  of	  
loss	  of	  function	  or	  force-­‐generating	  inefficiencies	  in	  aged	  muscle,	  or	  due	  to	  an	  increasing	  demand	  or	  
load	  with	  increased	  body	  mass,	  underlying	  causes	  of	  this	  observed	  feature	  are	  largely	  unknown.	  As	  
declines	   in	  muscle	  mass	  with	  age	  are	  usually	   attributed	   to	  a	   loss	   in	  myofibre	  number,	   a	   change	   in	  
myofibre	  type	  or	  a	  reduction	  in	  myofibre	  size	  or	  a	  combination	  of	  the	  three	  (Alnaqeeb	  &	  Goldspink	  
1987).	   The	  apparent	   loss	  of	   larger	   fast-­‐twitch	   type	   II	  myofibres	   in	   the	   current	   study,	  despite	   some	  
evidence	   of	   hypertrophy,	   was	   sufficient	   to	   equal	   an	   overall	   net	   decline	   in	   ageing	   Soleus	   mass.	  
Contrastingly,	   in	   the	  EDL,	  a	  decline	   in	  muscle	  mass	  was	  not	  evident,	  despite	  a	  distinct	   reduction	   in	  
myofibre	  numbers	  at	  old	  age.	  However,	  a	  combination	  of	  an	  increased	  proportion	  of	  IIB	  (largest	  CSA)	  
and	   slight	   hypertrophy	   in	   IIA	   appears	   to	   be	   sufficient	   to	   combat	   any	   potential	   reductions	   in	  mass	  
attributed	   to	   the	   myofibre	   loss.	   However,	   increased	   ECM	   deposition	   and	   thickening	   may	   also	  
contribute	  to	  this.	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The	  switch	  to	  an	  overall	  slower	  myofibre	  phenotype,	  observed	  in	  the	  Soleus,	  could	  indicate	  a	  number	  
of	   abnormalities	   in	   regulation	   and	   function	   with	   age.	   Some	   of	   these	   aspects	   were	   thereby	  
investigated	  further	  in	  this	  series	  of	  analyses.	  Firstly,	  it	  can	  be	  hypothesised	  that	  the	  fast	  to	  slow	  shift	  
is	  compensating	  in	  regards	  to	  impaired	  oxygen	  delivery.	  For	  example,	  decreased	  vascular	  density	  and	  
blood	   flow	   has	   been	   reported	   in	   the	   literature,	   in	   the	   brain	   as	  well	   as	   in	   skeletal	  muscle,	   in	   both	  
humans	  and	  rodents	  (Groen	  et	  al.	  2014;	  Bell	  &	  Ball	  1990;	  Sonntag	  et	  al.	  1997;	  Degens,	  Turek,	  et	  al.	  
1993).	  Degens	  and	  colleagues	  in	  particular,	  report	  overall	  capillary	  loss	  with	  age	  (Degens,	  Turek,	  et	  al.	  
1993).	  However,	  this	  was	  not	  the	  case	  in	  the	  present	  study,	  as	  the	  number	  of	  capillaries	  per	  myofibre	  
in	  the	  Soleus,	  did	  not	  undergo	  the	  loss	  reported	  during	  old	  age	  and	  this	  was	  further	  backed	  up	  by	  the	  
consistent	  VEGFa165	  expression	  also	  observed.	  Additionally,	  capillary	  proliferation	  was	  found,	  along	  
with	  compensatory	  myofibre	  hypertrophy,	  in	  the	  Plantaris	  and	  that	  this	  feature	  was	  not	  lost	  in	  aged	  
rats,	  only	  delayed	  in	  response	  to	  demand	  and	  CSA	  increases	  (Degens	  et	  al.	  1992;	  Degens,	  Turek,	  et	  al.	  
1993).	  The	  type	  IIA	  myofibres	  in	  the	  aged	  and	  geriatric	  Soleus	  muscles	  in	  the	  present	  study,	  indicated	  
significant	   hypertrophy,	   which	   could	   also	   be	   described	   as	   ‘compensatory’.	   This	   term	   however,	   is	  
being	   used	   in	   regards	   to	   the	   potential	   need	   to	   combat	   the	   loss	   of	   force-­‐generating	   units	  with	   the	  
simultaneous	   decreases	   in	   number	   of	   type	   IIA	   myofibres	   also	   seen,	   rather	   than	   compensatory	  
relative	  to	  increased	  demand	  in	  response	  to	  exercise	  training.	  
As	  features	  of	   impaired	  oxygen	  delivery	  were	  not	  evident,	  compensatory	  hypertrophy	  and	  a	  switch	  
to	   those	  myofibres	  with	  a	  higher	  oxidative	  capacity	   could	  also	   suggest	  dysfunctional	  mitochondrial	  
activity,	   highlighting	   that	   there	   may	   be	   a	   change	   in	   how	   the	   oxygen	   is	   being	   used	   to	   make	   ATP.	  
Analysis	  of	  SDH	  activity	  in	  the	  Soleus	  further	  indicates	  that	  this	  may	  be	  the	  case.	  Despite	  an	  increase	  
in	  the	  proportion	  of	  type	  I	  myofibres,	  but	  consistent	  with	  the	  reduction	  in	  type	  IIA	  (also	  known	  to	  be	  
fast	  oxidative;	  FO),	  SDH	  activity	  reveals	  an	  overall	  decline	  in	  oxidative	  capacity	  in	  advanced	  old	  age.	  
Moreover,	  mitochondrial	  dysfunction	  is	  shown	  to	  be	  highly	  implicated	  in	  numerous	  pathological	  and	  
toxicological	  conditions,	  including	  sarcopenia	  (Pieczenik	  &	  Neustadt	  2007;	  Bua	  et	  al.	  2002;	  Wei	  et	  al.	  
1998).	   In	   fact,	   increased	  oxidative	   stress,	   being	  one	  of	   the	  nine	   ‘Hallmarks	  of	  Ageing’,	   is	   therefore	  
believed	  to	  be	  a	  main	  contributing	  factor	  to	  organismal	  senescence	  (López-­‐otín	  et	  al.	  2013).	  Harmful	  
accumulation	   of	   reactive	   oxygen	   species	   (ROS),	   superoxide	   (O2-­‐),	   is	   known	   to	   exacerbate	   the	  
problem,	   further	   damaging	  mtDNA	   (Pieczenik	   &	   Neustadt	   2007;	  Wei	   et	   al.	   1998).	   Additionally,	   as	  
skeletal	  muscle	  is	  a	  tissue	  that	  consumes	  high	  amounts	  of	  oxygen,	  consequently	  this	  results	  in	  higher	  
concentrations	  of	  accumulated	  ROS.	  Levels	  of	  O2-­‐	  ROS	  production	  in	  the	  current	  project,	  were	  higher	  
in	   the	   smaller	   myofibres,	   in	   both	   the	   Soleus	   and	   EDL,	   compared	   to	   large	   myofibres.	   This	   finding	  
correlates	  to	  those	  myofibres	  with	  a	  smaller	  CSA	  typically	  being	  type	  I	  (and	  a	  small	  proportion	  of	  type	  
IIA)	   and	   traditionally,	   are	   more	   mitochondria-­‐rich	   and	   concordantly,	   more	   oxidative	   in	   nature	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(Alnaqeeb	   &	   Goldspink	   1987;	   Degens	   et	   al.	   1992;	   Omairi	   et	   al.	   2016).	   O2-­‐	   ROS	   production	   was	  
subsequently	  shown	  to	  increase	  in	  both	  small	  and	  large	  myofibres	  in	  the	  ageing	  EDL	  and	  Soleus,	  to	  a	  
significant	   degree	   however,	   in	   the	   large	   myofibres	   of	   both	   muscles.	   This	   is	   consistent	   with	   the	  
previously	  described	  fast	  to	  slow	  shift	   in	  the	  Soleus,	  suggesting	  that	  larger	  (typically	  more	  glycolytic	  
fast	  twitch)	  myofibres	  such	  as	  type	  II,	  during	  the	  switch	  to	  slower	  type	  I,	  were	  reprogrammed	  to	  have	  
a	  higher	  capacity	  for	  oxidative	  metabolism,	  thereby	  producing	  more	  ROS.	  Whereas,	   in	  the	  EDL,	  the	  
fast	   to	   an	   even	   faster	   shift	   in	   myofibre	   type,	   suggests	   that	   a	   greater	   amount	   of	   dysfunctional	  
oxidative	  metabolism,	   leading	   to	  O2-­‐	   production,	  may	   be	   occurring	   in	   a	   proportion	   of	   these	   larger	  
myofibres,	  despite	  typically	  being	  more	  glycolytic	  in	  nature.	  Moreover,	  it	  is	  very	  unlikely	  that	  smaller	  
more	  oxidative	  myofibres	   (type	   I	   and	   IIA),	   that	  were	  measured	   to	  have	   average	  CSAs	  of	   <500µm2,	  
were	  analysed	  as	  part	  of	  the	  ‘large’	  myofibre	  category	  in	  the	  DHE	  ROS	  analysis.	  Further	  signifying	  that	  
it	   was	   indeed	   type	   IIX	   and	   IIB	   myofibres	   that	   showed	   this	   increased	   O2-­‐	   production	   in	   old	   age.	  
Therefore,	   these	   findings,	   taken	   together,	   are	   in	   agreement	   with	   what	   is	   known	   regarding	  
accumulated	  ROS	  and	  increased	  oxidative	  stress	  in	  ageing	  muscle.	  	  
The	   factors	   most	   likely	   resulting	   in	   increased	   ROS	   production	   during	   ageing	   include	   abnormal	  
oxidative	   phosphorylation	   (ox-­‐phos)	   respiratory	   function	   and	   deficiencies	   in	   antioxidant	   defence	  
mechanisms.	   The	   latter	   was	   investigated	   and	   it	   was	   hypothesised	   that	   impaired	   or	   deficient	  
mitochondrial	   antioxidant	   activity	   is	   a	   main	   factor	   contributing	   to	   the	   observed	   increased	   ROS	  
production	   in	   ageing.	   Alternatively,	   increased	   antioxidant	   activity	   with	   age	   would	   suggest	   a	  
functional	  response	  to	  a	  detection	  of	  greater	  oxidative	  stress.	  Mitochondrial	  superoxide	  dismutase	  2	  
(SOD2),	  an	  antioxidant	  enzyme	  known	  to	  catalyse	  the	  transformation	  of	  O2-­‐	  into	  H2O2,	  is	  known	  to	  be	  
up-­‐regulated	  following	  exercise-­‐induced	  oxidative	  stress	  and	  ROS	  production	  (Pieczenik	  &	  Neustadt	  
2007;	   Davies	   et	   al.	   1982;	   Karnati	   et	   al.	   2013).	   This	   is	   believed	   to	   be	  mediated	   by	   redox-­‐sensitive	  
transcription	   factor	   nuclear	   factor	   κB	   (NF-­‐κB),	   which	   once	   activated	   and	   following	   nuclear	  
translocation,	   binds	   to	   target	   DNA	   sequences	   including	   mtSOD	   (SOD2),	   resulting	   in	   SOD2	   up-­‐
regulation	   (Ryan	   et	   al.	   2008;	   Gomez-­‐Cabrera	   et	   al.	   2005;	   Ji	   et	   al.	   2004).	   Studies	   conducted	   in	   rat	  
muscles	   also	   indicated	   that	   while	   training-­‐induced	   increases	   in	   SOD2	   were	   observed	   in	   young	  
animals,	   training	  was	   insufficient	   in	   providing	   any	   additional	   protection	   against	   oxidative	   stress	   in	  
aged	   animals	   (Leeuwenburgh	   et	   al.	   1994).	   SOD2	   mRNA	   expression	   levels	   however,	   remained	  
constant	   with	   age	   in	   the	   Soleus	   muscles	   of	   the	   current	   study.	   Firstly,	   this	   could	   indicate	   that	  
antioxidant	  activity	  is	  not	  affected	  in	  the	  aged	  murine	  Soleus	  muscle	  and	  that	  the	  ROS	  production	  is	  
occurring	   at	   such	   an	   increased	   rate	   that	   SOD2	   cannot	   keep	   pace.	   Secondly,	   another	   explanation	  
could	  be	  that,	  although	  SOD2	  is	  known	  to	  be	  up-­‐regulated	  by	  oxidative	  stress,	  it	  also	  requires	  various	  
stages	  of	  post-­‐translational	  modification	  to	  be	  catalytically	  active	   (Ryan	  et	  al.	  2008).	  Additionally,	  a	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number	  of	  proteins	  (such	  as	  cyclins,	  cyclin-­‐dependent	  kinases	  as	  well	  as	  p53)	  interact	  with	  and	  alter	  
SOD2	  activity	  via	  various	  post-­‐translational	  modifications	  (Candas	  &	  Li	  2014).	  Therefore,	  as	  it	  was	  the	  
mRNA	  levels	  that	  were	  analysed	  in	  this	  series	  of	  experiments,	  a	  constant	  expression	  at	  a	  molecular	  
level	  may	  have	  been	  all	  that	  was	  required	  and	  regulatory	  fluctuations	  in	  the	  enzyme	  may	  have	  been	  
evident	  when	   exploring	   at	   the	   protein	   level	   instead.	   Suggesting	   that	   there	  may	  have	   been	   altered	  
transcription	   of	   SOD2	  mRNA	   initially,	   subsequently	   resulting	   in	   changes	   in	   protein	   levels	   which	   in	  
turn,	   acted	   as	   a	   feedback	   mechanism,	   further	   regulating	   transcription	   of	   SOD2	   mRNA.	   Or	   more	  
essentially,	  post-­‐translational	  modification	  is	  responsible	  for	  a	  large	  proportion	  of	  SOD2	  activity	  and	  
response	  to	  oxidative	  stress.	  Furthermore,	  investigation	  for	  example,	  into	  the	  levels	  of	  activated	  NF-­‐
κB,	  as	  well	  as	  western	  blot	  analysis	  of	  the	  NF-­‐κB	  and	  SOD2	  translated	  proteins,	  would	  be	  of	  particular	  
interest	   to	   the	  present	  body	  of	   research,	   in	  order	   to	  give	  a	  better	  understanding	  of	   this	  process	   in	  
ageing.	  
Collagen	   is	   the	   main	   supporting	   component	   of	   skeletal	   muscle	   and	   comprises	   the	   majority	   of	  
connective	   tissue.	   There	   are	   three	  main	   distinct	   collagens	   characterised	   in	   skeletal	  muscle,	   type	   I	  
collagen	  of	  the	  epimysium,	  perimysium	  and	  tendon.	  Type	  III	   is	  a	  component	  of	  the	  perimysium	  and	  
type	   IV	   is	   located	   in	   the	   basement	   membrane	   of	   myofibres	   therefore,	   endomysium	   (Light	   &	  
Champion	   1984).	   Collagen	   has	   been	   shown	   to	   become	   denser	   with	   age	   (Alnaqeeb	   et	   al.	   1984;	  
Marshall	  et	  al.	  1989).	   It	  has	  also	  been	  shown	  that	  an	   increased	  amount	  of	  cross-­‐linking	  of	  collagen	  
fibrils	  with	  age	   results	   in	   the	  overall	   stiffening	  of	   connective	   tissue	   layers	   (Zimmerman	  et	  al.	  1993;	  
Kragstrup	  et	  al.	  2011).	  Furthermore,	  characteristically	  altered	  features	  such	  as	  these	  are	  believed	  to	  
impact	  on	  skeletal	  muscle	  contractility,	  force-­‐generating	  capacity	  and	  interfere	  with	  myofibre	  signal	  
transduction	   and	   mechanosensing	   ability.	   Examination	   of	   the	   myofibre	   extracellular	   matrix	   and	  
connective	   tissue	   components	   in	   this	   series	  of	  experiments	   indicated	   that,	   in	   keeping	  with	  what	   is	  
reported	  in	  the	  literature,	  collagen	  thickness	  increased	  in	  old	  age	  in	  the	  Soleus	  muscle	  and	  at	  geriatric	  
ages	   in	   the	  EDL.	  However,	   in	  geriatric	  ages	   in	   the	  Soleus,	   collagen	  thickness	  subsequently	   reduced,	  
suggesting	  potential	  connective	  tissue	  loss	  into	  advanced	  old	  ages.	  However,	  the	  diminished	  collagen	  
mRNA	  expression	   levels	   in	   the	  Soleus,	   at	   a	   geriatric	   age,	   appear	   to	   support	   the	   finding	  of	   reduced	  
collagen	  content	  and	  suggests	  that	  this	  was	  achieved	  through	  gene	  down-­‐regulation.	  Key	  structural	  
dystrophin	   glycoprotein	   complex	   (DGC)	   components,	   dystrophin	   and	   beta-­‐sarcoglycan,	   both	  
appeared	  to	  be	  up-­‐regulated	  between	  adult	  and	  old	  ages	  in	  the	  Soleus.	  An	  explanation	  for	  this	  could	  
be	  compensatory	   in	  response	  to	  potential	   reductions	   in	  structural	   integrity	  of	   the	  ageing	  myofibre,	  
perhaps	  in	  the	  degradation	  of	  collagenous	  fibril	  content	  or	  indeed	  that	  of	  other	  basal	  lamina	  or	  DGC	  
components.	  Moreover,	  the	  importance	  of	  the	  DGC	  and	  surrounding	  extracellular	  matrix	  anchor	  and	  
signalling	  proteins	  to	  mechanotransduction,	  in	  response	  to	  myofibre	  stretch	  and	  overload,	  have	  been	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implicated	   in	  Duchenne	  muscular	  dystrophy	   (Goldspink	  1999).	  Suggesting	   that	   the	  up-­‐regulation	  of	  
dystrophin	   and	   beta-­‐sarcoglycan	   in	   old	   age,	   is	   avoiding	   similar	   myo-­‐pathological	   dysfunction	  
associated	  with	  DMD,	  regarding	  how	  a	  muscle	  signals	  and	  responds	  appropriately	  to	  loading.	  	  
The	  effects	  of	  CM	  generated	  from	  ADMSCs	  on	  naturally-­‐aged	  skeletal	  muscle	  
phenotype	  
In	  recent	  decades,	  the	  therapeutic	  effects	  of	  adult	  stem	  cells	  and	  their	  self-­‐renewal	  and	  multipotent	  
capabilities	  have	  dominated	  the	  research	  field	  of	  regenerative	  medicine.	  Numerous	  studies	  involving	  
the	   introduction	  of	  a	  variety	  of	  different	  stem	  cell	   types	   into	  sites	  of	   tissue	  damage	  or	   injury,	  have	  
been	   conducted,	   in	   order	   to	   examine	   the	   regenerative	   capabilities.	   Stem	   cells	   are	   proposed	   to	  
proliferate	  and	  differentiate,	  overall	  contributing	  to	  the	  host	  tissue.	  However,	  despite	  varying	  success	  
of	   engraftment	   and	   even	   in	   sites	   where	   injected	   or	   introduced	   stem	   cells	   are	   no	   longer	   present,	  
therapeutic	  effects	  have	  continued	  to	  be	  observed	  in	  the	  host	  tissue.	  Such	  findings	  fuel	  the	  notion	  of	  
a	  paracrine	  effect	  whereby,	  stem	  cells	  have	  been	  shown	  to	  secrete	  an	  array	  of	  regulatory	  molecules,	  
as	  a	  form	  of	  cell	  to	  cell	  communication.	  Key	  to	  the	  current	  study,	  this	  concept	  has	  sparked	  numerous	  
investigations	  into	  the	  beneficial	  effects	  of	  a	  young	  secretome	  in	  an	  aged	  host	  or	  environment.	  	  
Work	   carried	   out	   by	   colleagues,	   analysed	   the	   CM	   isolated	   from	   amniotic	   fluid	   stem	   (AFS)	   cells	  
(Mellows	   et	   al.	   2017).	   Two	   separate	   compartments,	   the	   extracellular	   vesicle	   (EV)	   and	   the	   free	  
secretome	  fractions	  were	  shown	  to	  contain	  an	  abundance	  of	  molecules	  specific	  to	  each	  fraction,	  that	  
were	   shown	   to	  promote	   regeneration	   in	   a	   cardiotoxin-­‐induced	   injury	  model	   in	  mouse	  TA	  muscles.	  
Further	   analysis	   of	   the	   EV	   fraction	   revealed	   that	   it	  was	   rich	   in	  miRNA,	   rather	   than	  mRNA	  and	   it	   is	  
suggested	   that	   this	   is	   the	   key	   regulatory	   mechanism	   under-­‐lying	   therapeutic	   paracrine	   activity.	  
Importantly,	  miRNA	  known	  to	  target	  specific	  signalling	  pathways	  in	  areas	  key	  to	  the	  current	  project	  
include,	  metabolic	  process,	  response	  to	  stress,	  mitochondrion	  organisation	  and	  ageing.	  The	  AFS	  CM	  
was	  isolated	  in	  the	  same	  way,	  utilising	  the	  same	  protocol,	  as	  the	  ADMSC-­‐derived	  CM	  in	  the	  current	  
study,	  free	  of	  exogenous	  molecules.	  
The	  measurements	  carried	  out	  at	  a	  whole	  organism	  level,	  showed	  that	  old	  animals	  treated	  with	  CM,	  
initially	  appeared	  to	  have	  a	  slightly	  reduced	  body	  weight	  during	  the	  4-­‐month	  in	  vivo	  CM	  study.	  With	  a	  
significant	  decrease	  noted	  after	  the	  first	  CM	  injection	  in	  percentage	  weight	  change.	  A	  large	  amount	  
of	   variation	   in	   the	   animal	   weights	   was	   also	   noted	   and	   resulted	   in	   albeit	   minimal	   differences.	  
However,	   this	   could	   suggest	   that	   CM	   had	   impacts	   on	   the	   features	   of	   lipid	   metabolism,	   body	  
composition	   and	   body	   fat	   previously	  mentioned.	  Mellows	   and	   colleagues	   showed	   that	   one	   of	   the	  
biological	  processes	   targeted	  by	   the	  miRNA	  present	   in	   the	  secreted	  EV	  CM	  fraction	   from	  AFS	  cells,	  
was	   lipid	  metabolism	  (Mellows	  et	  al.	  2017).	  Further	  analysis	  of	  the	  ADMSC-­‐derived	  CM	  used	  in	  this	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project	  is	  required	  in	  order	  to	  elucidate	  key	  determinant	  molecules	  present	  that	  could	  contribute	  to	  
the	  changes	  observed.	  
Grip	  strength	  measurements	   in	  the	  aged	  animals	  decline	  to	  the	  same	  degree	  with	  and	  without	  CM	  
treatment,	   indicating	   that	  CM	  did	  not	  alter	   the	   force-­‐generating	  ability	   in	  aged	  animals.	  Moreover,	  
CM	  treatment	   in	  old	  age	   resulted	   in	  a	   reduction	   in	  Soleus	  weight,	  despite	   the	  key	  determinants	  of	  
muscle	  weight	  regarding	  myofibre	  number	  and	  size,	  were	  seemingly	  unchanged	  with	  CM.	  A	  further	  
component	  capable	  of	  altering	  muscle	  weight	  is	  connective	  tissue	  content.	  However,	  discordantly,	  a	  
decreased	  collagen	  IV	  (basement	  membrane)	  thickness	  and	  mRNA	  expression	  was	  observed	  with	  CM	  
treatment	   in	   old	   age	   and	   collagen	   I	   (a	  more	   structural	   collagen	   type	   and	   a	   constituent	   of	   tendon)	  
levels	   were	   not	   affected.	   In	   the	   EDL,	   there	   were	   no	   apparent	   changes	   to	   muscle	   weight,	   total	  
myofibre	   number	   or	   size	   with	   CM	   treatment	   in	   old	   age	   and	   additionally,	   collagen	   IV	   thicknesses	  
remained	  constant.	  These	  results	  together	   indicate	  that	  CM	  treatment	  does	  not	  harbour	  the	  ability	  
to	   significantly	   alter	   features	   underlying	   overall	   hyperplasia	   or	   hypertrophy	   in	   the	   naturally	   aged	  
Soleus	  or	  EDL	  muscles.	  
However,	  Soleus	  muscles	  from	  aged	  CM-­‐treated	  mice	  showed	  an	  increased	  number	  of	  capillaries	  per	  
myofibre,	  which	   is	   in	  keeping	  with	  some	  of	   the	   reported	   findings	   in	   the	   literature,	   implicating	  pro-­‐
angiogenic	  paracrine	  signalling	  in	  neovascularisation	  following	  tissue	  damage.	  One	  study	  investigated	  
the	  therapeutic	  effects	  of	  the	  exosome	  fraction	  CM	  from	  CD34+	  cells	   isolated	  and	  purified	  from	  the	  
peripheral	  blood	   in	  an	   ischaemic	  hindlimb	   injury	  model	  (Mathiyalagan	  et	  al.	  2017).	  The	  EV	  CM	  was	  
shown	  to	  be	  rich	   in	  pro-­‐angiogenic	  miRNA	  such	  as	  endothelial	   cell	  miR-­‐126-­‐3p	  which	  subsequently	  
regulated	  genes	   associated	  with	   angiogenesis	   including,	   vascular	   endothelial	   growth	   factor	   (VEGF),	  
angiopoietin	  1	  and	  2	  (ANG1	  and	  ANG2),	  matrix	  metallopeptidase	  9	  (MMP9)	  and	  thrombospondin	  1	  
(TSP1).	  Results	  suggested	  that	  treatment	  with	  the	  EV	  CM	  mediated	  tissue	  repair	  in	  the	  hindlimb,	  via	  
pro-­‐angiogenic	   paracrine	   signalling.	   Moreover,	   the	   colleagues	   investigating	   AFS	   CM	   alongside	   this	  
project,	   revealed	   in	   the	   hindlimb	   cardiotoxin	   (CTX)	   injury	   model	   that	   more	   efficient	   tissue	  
regeneration	   was	   promoted	   with	   AFS	   CM	   treatment	   and	   this	   was	   associated	   with	   an	   increase	   in	  
vascularisation.	   Analysis	   of	   the	   miRNA	   target	   processes	   showed	   that	   AFS	   CM	   contained	   those	  
involved	  in	  angiogenesis	  and	  the	  circulatory	  system.	  Despite,	  alternative	  cell	  types	  used	  to	  create	  the	  
CM	   in	   the	   studies	   previously	   described,	   the	   results	   of	   the	   present	   study	   would	   support	   the	  
hypothesis	   that	   the	   ADMSC	   CM	   also	   contains	   pro-­‐angiogenic	   regulatory	   factors	   or	   molecules.	  
However,	  further	  analysis	  of	  the	  ADMSC	  CM	  is	  required	  in	  order	  to	  investigate	  this	  further.	  
In	   the	   naturally-­‐aged	   EDL	   however,	   unlike	   the	   Soleus,	   capillary	   density	   was	   not	   altered	   by	   CM	  
treatment.	  An	  explanation	  for	  this	  difference	  is	  that	  the	  Soleus	  muscle	  is	  a	  highly-­‐vascularised	  muscle	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relative	   to	   the	  EDL,	   therefore	   it	   requires	  an	   increased	  rate	  of	  oxygen	  delivery	   in	  order	   to	  carry	  out	  
oxidative	   metabolism.	   Remarkably,	   CM	   treatment	   in	   the	   aged	   Soleus,	   appears	   to	   have	   also	  
significantly	   improved	   the	   oxidative	   capacity	   and	   this	   seems	   to	   have	   been	   accompanied	   by	   the	  
increased	   capillary	   density.	   Therefore,	   it	   can	   be	   postulated	   that	   key	   therapeutic	   targets	   of	   the	  
ADMSC-­‐derived	  CM	  content	   includes	  mechanisms	  of	  not	  only	  angiogenesis	  but	  also	  components	  of	  
oxidative	  metabolism.	  As	  previously	  mentioned,	  AFS-­‐derived	  CM	  has	  been	  shown	  to	  possess	  miRNA	  
that	   target	   genes	   associated	   with	   mechanisms	   of	   metabolism,	   stress	   response	   and	   mitochondrial	  
organisation,	   among	   many	   others	   (Mellows	   et	   al.	   2017).	   Furthermore,	   in	   vitro	   studies,	   from	   the	  
research	   prospective	   of	   radiotherapy	   treatment	   in	   obese	  melanoma	   patients,	   reported	   protective	  
effects	   of	   adipocyte-­‐derived	   CM,	   through	   reduced	   oxidative	   stress	   and	   improved	   cell	   survival,	   in	  
malignant	   melanocytes	   (Coelho	   et	   al.	   2017).	   Moreover,	   CM	   treatment	   drastically	   reduced	   the	  
amount	  of	  O2-­‐	  ROS	  detected,	   to	   those	   levels	  observed	   in	  small,	   juvenile	  and	  adult	  myofibres	   in	   the	  
Soleus.	   This	   finding	   is	   in	   agreement	   with	   that	   of	   both	   improved	   oxygen	   delivery	   and	   oxidative	  
capacity,	  to	  levels	  significantly	  more	  than	  those	  observed	  in	  juvenile	  mice.	  Decreased	  amounts	  of	  O2-­‐	  
ROS	  were	  also	  observed	  in	  the	  large	  myofibres	  of	  the	  EDL,	  in	  the	  absence	  of	  any	  changes	  in	  capillary	  
density	  or	  oxidative	  capacity.	  Taken	  together,	  the	  findings	  of	  this	  series	  of	  experiments	  suggest	  that	  
CM	  generated	  from	  ADMSCs	  not	  only	  retains	  the	  potential	  to	  modify	  signalling	  pathways	  associated	  
with	   angiogenesis	   and	   metabolism,	   but	   additionally	   harbours	   possible	   therapeutic,	   antioxidant	  
properties.	  More	  research	  however,	  is	  required	  in	  order	  to	  define	  the	  miRNA	  content	  of	  the	  ADMSC-­‐
derived	  CM	  used	  in	  the	  present	  study.	  
In	   conclusion,	   this	   series	   of	   experiments	   developed	   a	   natural	   ageing	   skeletal	  muscle	   profile	   giving	  
insights	   into	   a	   variety	   of	   physiological,	   immunohistological	   and	   biochemical	   parameters	   in	   two	  
distinctly	   different	   hindlimb	  muscles	   of	   mice,	   the	   Soleus	   and	   EDL.	   Additionally,	   this	   body	   of	   work	  
investigates	   a	   novel	   approach	   of	   utilising	   conditioned	   media	   (CM)	   generated	   from	   a	   fully-­‐
characterised	  human	  adipose-­‐derived	  mesenchymal	  stem	  cell	  (ADMSC)	  line,	  under	  stressed	  (hypoxic	  
and	  nutrient-­‐free)	   culture	  conditions,	  as	  a	  potential	   therapeutic	   treatment	  of	  well-­‐established	  age-­‐
associated	   declines,	   in	   the	   onset	   and	   development	   of	   sarcopenia,	   in	   naturally-­‐aged	   mice.	   After	  
establishing	  that	  sarcopenia	  was	  indeed	  evident	  by	  the	  observed	  loss	  of	  muscle	  mass	  in	  the	  geriatric	  
muscles	  examined,	  other	  key	  phenotypical	  features	  were	  explored.	  Features	  in	  keeping	  with	  what	  is	  
established	   in	   the	   literature	   include	   reduced	   total	   myofibre	   number,	   an	   increase	   in	   metabolic	  
dysfunction,	   resulting	   in	  greater	  ROS	  production	  and	  evidence	  of	  a	   fast	   to	   slow	  MHC	  switch	   in	   the	  
ageing	  Soleus.	  In	  contrast,	  a	  switch	  in	  the	  reverse	  direction,	  from	  fast	  to	  even	  faster	  type,	  was	  seen	  in	  
the	  ageing	  EDL	  and	  the	  reasons	  underlying	  this	  shift	  remain	  unclear.	  CM	  treatment	  in	  aged	  animals	  
did	   not	   appear	   to	   influence	   features	   such	   as	   the	   overall	  myofibre	   number,	   size	   or	   type.	  However,	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there	  is	  evidence	  for	  potential	  modification	  of	  signalling	  pathways	  involved	  in	  angiogenesis,	  oxidative	  
metabolism,	   reduced	   ROS	   production/antioxidant	   activity,	   as	  well	   as	   collagen	   organisation.	   Future	  
work	  continuing	  this	  area	  of	  research	  will	  benefit	  from	  examination	  of	  CM	  effects	  in	  geriatric	  animals,	  
due	   to	   the	   observation	   of	   the	  majority	   of	   characterisitics	   associated	  with	   sarcopenia	   at	   a	   geriatric	  
rather	  than	  old	  age,	  in	  the	  current	  project.	  Additionally,	  it	  would	  also	  be	  essential	  to	  administer	  CM	  
treatment	   in	   young	   control	   animals	   in	   order	   to	   determine	   any	   effect	   CM	   properties	   have	   on	   the	  
maturation	  and	  early	  growth	  phase	  of	  skeletal	  muscle.	  
Furthermore,	   the	  more	   oxidative	   Soleus	  muscle	   appears	   to	   have	   been	   affected	   to	   a	   larger	   degree	  
than	  the	  typically	  more	  glycolytic	  EDL,	  in	  the	  characteristics	  of	  natural	  ageing	  noted	  in	  this	  series	  of	  
experiments.	   In	   addition,	   this	   series	   of	   results	   further	   highlights	   the	   importance	   of	   murine	  
experiments	  in	  the	  field	  of	  ageing	  research.	  The	  mouse	  is	  an	  effective	  ageing	  mammalian	  model,	  as	  
evident	   from	   the	   relatively	   consistent	   changes	   established	   in	   the	   literature,	   in	   numerous	   species	  
including	  humans,	  as	  well	  as	  the	  ability	  for	  effective	  analysis	  in	  a	  relatively	  short	  period	  of	  time	  (for	  
example	   the	   lifespan	   of	   2-­‐2.5	   years).	   Moreover,	   this	   natural	   ageing	   skeletal	   muscle	   profile	   has	  
provided	  a	  basis	  for	  comparison	  of	  the	  changes	  that	  occur	  in	  the	  progeric	  ERCC1	  delta	  murine	  model	  
in	   the	   following	  chapter	  of	   results.	   Importantly,	   this	  will	   investigate	   the	  hypothesis	   that	   the	  ERCC1	  
delta	  mutant	  mouse	  is	  a	  good	  model	  of	  ageing	  skeletal	  muscle	  and	  mimics	  those	  changes	  reported	  in	  
natural	  ageing.	  
	  








Characterisation	  of	  the	  skeletal	  	  
muscle	  phenotype	  in	  the	  Ercc1d/-­‐	  	  




A	   large	  proportion	  of	   the	   studies	   conducted	   in	  order	   to	  establish	   the	  changes	   that	  occur	   in	  ageing	  
skeletal	  muscle,	   as	  well	   as	  multiple	  other	   tissues	   and	  organ	   systems,	  utilise	   the	   laboratory	  mouse.	  
Moreover,	   numerous	   parallels	   can	   be	   drawn	   between	   the	   murine	   and	   human	   ageing	   processes,	  
making	  the	  mouse	  a	  beneficial	  and	  universal	  model	  of	  natural	  ageing.	  However,	   there	   is	  a	  growing	  
need	  for	  a	  suitable	  mammalian	  model	  of	  accelerated	  ageing.	  This	  is	  due	  to	  the	  high	  costs	  associated	  
with	  housing	  mice	  for	  their	  2	  –	  3	  year	   lifespan,	  which	  in	  turn,	   impacts	  on	  experimental	  cohort	  size.	  
Additionally,	   intervention	  approaches	  designed	  to	  study	  and	  potentially	   treat	  symptoms	  associated	  
with	  natural	  ageing	  ultimately,	  often	  extend	  over	  the	  full	   lifespan	  of	   the	  animal,	   thus	  resulting	   in	  a	  
reduced	  efficiency	  of	  data	  delivery.	  	  
The	  creation	  of	  nucleotide	  excision	  repair	  (NER)-­‐	  and	  DNA	  interstrand	  cross-­‐link	  repair-­‐compromised	  
ERCC1-­‐mutant	  mouse	  models,	   that	   exhibited	   remarkably	   reduced	   lifespans	   and	   premature	   cellular	  
senescence,	   allows	   for	   a	   relatively	   short-­‐term	   experimental	   model	   of	   accelerated	   ageing.	   These	  
progeroid	   models	   exhibit	   components	   of	   both	   stochastic	   and	   genetic	   age-­‐associated	   decline	   in	  
fitness.	  Additionally,	  they	  have	  also	  been	  reported	  to	  display	  a	  shift	  in	  energy	  consumption	  towards	  a	  
survival	   response	   of	   molecular	   and	   cellular	   maintenance,	   over	   that	   dedicated	   to	   proliferation,	  
synthesis	   and	   overall	   growth	   (Niedernhofer	   et	   al.	   2006).	   The	   more	   severe	   ERCC1	   knockout	   (-­‐/-­‐)	  
mouse	  lives	  a	  full	  lifespan	  within	  approximately	  30	  -­‐	  40	  days	  whereas,	  the	  truncated	  ERCC1	  delta	  (d/-­‐)	  
mutant,	   which	   functions	   at	   only	   10%	   of	   normal	   NER	   activity	   has	   been	   shown	   to	   live	   up	   to	  
approximately	   6	   months	   (Weeda	   et	   al.	   1997).	   The	   Ercc1d/-­‐	   mutant	   has	   been	   reported	   to	   display	  
systemic	   age-­‐associated	   degeneration	   with	   compartment-­‐specific	   features	   that	   mimic	   ‘normal’,	  
‘accelerated’	   and	   ‘extreme’	   ageing	   progression	   (Dollé	   et	   al.	   2011).	   The	   histopathological	  
characteristics	  of	  the	  Ercc1d/-­‐	  mouse	  have	  been	  extensively	  studied	  in	  liver	  and	  kidney,	  as	  well	  as	  the	  
neurodegenerative	  abnormalities	  in	  the	  spinal	  cord	  (Weeda	  et	  al.	  1997;	  Dollé	  et	  al.	  2011;	  De	  Waard	  
et	   al.	   2010).	   The	   potential	   of	   the	   Ercc1d/-­‐	   mouse	   therefore,	   to	   be	   used	   as	   an	   effective	   model	   of	  
sarcopenia	  in	  skeletal	  muscle,	  remains	  to	  be	  explored.	  
The	  utilisation	  of	  the	  Ercc1d/-­‐	  progeroid	  mouse	  in	  this	  series	  of	  experiments,	  allows	  for	  development	  
of	  a	   skeletal	  muscle	  profile	   in	  a	  model	  of	  accelerated	  ageing.	  The	  Ercc1d/-­‐	  model	   is	  associated	  with	  
hallmark	  features	  of	  ageing,	   including	   increased	  oxidative	  stress	  and	  cellular	  senescence.	  Therefore	  
the	  paracrine	  effects	  of	  ADMSC-­‐derived	  CM	  will	  be	   tested	  as	  a	  potential	   therapy	   for	  any	  observed	  
myo-­‐pathological	   qualities.	   Characteristics	   of	   the	   progeric	   skeletal	   muscle	   phenotype	   can	   be	  
subsequently	   compared	   to	   those	   associated	   with	   onset	   and	   progression	   of	   sarcopenia	   in	   natural	  
ageing.	   Firstly,	   as	   in	   the	   naturally-­‐aged	   series	   of	   experiments,	   analysis	  was	   carried	   out	   at	   a	  whole	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organism	  and	  tissue	   level.	  Animal	  cohorts	   included	  the	  Ercc1d/-­‐	   (d/-­‐)	  mice	  and	  their	   (+/+)	   littermate	  
controls,	  treatments	  comprised	  of	  ADMSC-­‐derived	  CM	  or	  PBS-­‐vehicle,	  +/+	  PBS,	  +/+	  CM,	  Ercc1d/-­‐	  (d/-­‐)	  
PBS	   and	  Ercc1d/-­‐	   CM.	   Treatments	  were	   injected	   intraperitoneally	   (I.P)	   at	   two	  week	   intervals,	  when	  




Significantly	  reduced	  body	  weight	  in	  the	  Ercc1d/-­‐	  progeroid	  mice	  
Body	  weight	   and	   overall	   animal	   health	  were	  monitored	   daily	   throughout	   the	   in	   vivo	  experimental	  
time-­‐period	   due	   to	   the	   severe	   nature	   and	   rate	   of	   degeneration	   in	   the	   Ercc1d/-­‐	   mice,	   particularly	  
during	  the	  latter	  days	  of	  the	  8-­‐week	  study.	  Body	  weight	  was	  measured	  in	  grams	  (g)	  and	  most	  striking	  
was	   the	   drastically	   reduced	   weight	   of	   the	   Ercc1d/-­‐	   progeric	  mice	   (d/-­‐)	   compared	   to	   the	   littermate	  
controls	  (+/+),	  evident	  at	  each	  weekly	  interval	  throughout	  the	  experiment	  (p	  =	  <0.001)	  (Figure	  4.1	  A).	  
At	  week	  9,	  the	  first	  week	  of	  the	  experiment,	  the	  average	  starting	  body	  weight	  of	  the	  control	  animals	  
was	  32.4g	  whereas,	  the	  progeric	  animals	  weighed	  15.9g.	  The	  control	  animals	  subsequently	  continued	  
to	  grow	  and	  increase	  in	  body	  mass,	  peaking	  at	  week	  16,	  the	  final	  week	  of	  the	  study,	  at	  an	  average	  of	  
41.6g.	   Contrastingly,	   the	   Ercc1d/-­‐	   animals	   remained	   at	   a	   constant	   average	   weight	   throughout	   the	  
experiment,	  dropping	  to	  15g	  at	  the	  lowest	  at	  week	  11,	  peaking	  at	  16.3g	  during	  week	  14	  and	  ending	  
at	  a	  final	  weight	  of	  15.9g,	  the	  same	  as	  the	  average	  weight	  when	  the	  study	  commenced.	  
Furthermore,	   the	   previously	   discussed	   trends	   in	   body	  weight	   were	   supported	  when	   analysing	   the	  
percentage	   change	   in	   body	  weight.	   These	   results	   indicated	   that	   by	  week	   11,	   the	   degree	   by	  which	  
body	  weight	  changed	  from	  that	  recorded	  at	  the	  start	  of	  the	  study,	  between	  +/+	  (12.1%	  increase)	  and	  
Ercc1d/-­‐	  (5.1%	  decrease)	  animals,	  was	  significantly	  different	  (p	  =	  <0.05)	  (Figure	  4.1	  B).	  This	  difference	  
was	  maintained	   throughout	   the	   experiment	   as	   the	   control	   animals	   continued	   to	   increase	   in	   body	  
mass,	  gaining	  28.8%	  of	  the	  starting	  weight	  at	  week	  16	  (p	  =	  <0.001).	  Ercc1d/-­‐	  percentage	  weight	  change	  
fluctuated	  between	  the	  lowest	  (5.1%	  decrease)	  and	  peak	  weight	  at	  week	  14	  (3%	  increase).	  
CM	  treatment	  did	  not	  affect	  progeric	  Ercc1d/-­‐	  body	  weight	  
Moreover,	  with	  such	  a	  dramatically	  reduced	  body	  weight	  in	  the	  Ercc1d/-­‐	  mutant	  mouse,	  the	  following	  
step	  was	  to	  establish	  if	  there	  were	  any	  effects	  of	  CM	  treatment	  on	  overall	  body	  weight.	  Firstly,	  body	  
weights	   fluctuated	   within	   a	   1g	   range	   throughout	   the	   experiment	   (15.9	   –	   16.8g)	   (Figure	   4.1	   C).	  
However,	   these	   differences	   were	   not	   statistically	   significant	   at	   any	   of	   the	   weekly	   intervals.	  
Percentage	  change	  in	  body	  weight	  analysis	  were	  also	  not	  statistically	  different	  at	  any	  of	  the	  weekly	  
intervals	   (Figure	   4.1	   D).	   Interestingly,	   both	   cohorts	   ended	   the	   study	   at	   week	   16	   with	   an	   average	  
percentage	  change	  of	  0%.	  Therefore,	  CM	  treatment	  had	  no	  effect	  on	  body	  weight	  and	  weight	  did	  not	  
change	  significantly	  from	  the	  start	  to	  the	  end	  of	  the	  study.	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CM	  treatment	  initially	  appeared	  to	  reduce	  control	  body	  weight	  
The	  effects	  of	  CM	  treatment	  on	  control	  littermates	  was	  investigated	  by	  also	  injecting	  a	  control	  cohort	  
intraperitoneally	  (I.P)	  with	  the	  same	  batch	  of	  CM	  as	  the	  progeric	  Ercc1d/-­‐animals,	  following	  the	  same	  
I.P	   injection	  schedule.	  Similarly	  to	  the	  other	  experimental	  cohorts,	  body	  weight	  was	  monitored	  and	  
recorded	  as	  an	  indication	  of	  overall	  animal	  health	  and	  growth,	  with	  and	  without	  CM	  treatment.	  	  
Weight	  gain	  patterns	   in	  both	   the	  control	   (+/+)	  PBS-­‐vehicle	  and	  control	  CM	  appeared	   to	  be	   similar,	  
both	  gaining	  weight	  at	  a	  linear	  rate	  (Figure	  4.1	  E).	  The	  average	  weight	  of	  the	  control	  PBS	  cohort	  was	  
greater	  than	  that	  of	  the	  control	  CM	  group	  at	  all	  of	  the	  weekly	  intervals	  throughout	  the	  8-­‐week	  study.	  
However,	   it	  was	  noted	  that	  average	  starting	  weights	  between	  the	  cohorts	  varied	  by	  approximately	  
3g,	  with	  control	  PBS	  weighing	  more	  than	  the	  CM	  group,	  prior	  to	  the	  first	  I.P	  injection,	  although	  the	  
difference	  was	   statistically	   non-­‐significant.	   Average	   body	  weight	   recorded	   at	   the	   end	   of	   the	   study	  
were	   also	   not	   statistically	   different	   between	   the	   two	   cohorts.	   Percentage	   change	   in	   body	   weight	  
removed	  any	  misleading	  effect	  the	  slight	  differences	  in	  average	  starting	  weight	  may	  have	  had	  on	  the	  
overall	   results.	  However,	  any	  observed	  differences	   in	  percentage	   increase	   in	  body	  weight	  were	  not	  
statistically	  significant,	  at	  any	  of	  the	  weeks	  measured	  throughout	  the	  experiment	  (Figure	  4.1	  F).	  
Strength	  and	  activity	  assessment	  indicates	  a	  functional	  deficit	  in	  the	  Ercc1d/-­‐	  
mice	  
Functional	  studies	  assessed	  the	  force	  exerted,	  using	  a	  grip	  strength	  monitor,	  by	  the	  Ercc1d/-­‐	  mice	  in	  
comparison	   to	   the	   littermate	   controls,	   with	   and	   without	   CM	   treatment.	   Additionally,	   motor	  
coordination	   was	   examined	   using	   rotarod	   performance	   testing.	   Normalised	   grip	   strength	   was	   not	  
statistically	   different	   between	   the	   control	   and	   Ercc1d/-­‐	   mice,	   despite	   the	   overall	   greater	   average	  
control	  normalised	  force	  compared	  to	  Ercc1d/-­‐	  (Figure	  4.1	  G).	  Furthermore,	  CM	  treatment	  in	  controls	  
did	   not	   significantly	   alter	   grip	   strength	   relative	   to	   the	   control	   PBS-­‐vehicle	   cohort.	   The	   control	   CM	  
cohort	  was	  distinctly	  greater	  than	  those	  measured	   in	  the	  Ercc1d/-­‐	  mice	  (PBS	  and	  CM,	  p	  =	  <0.01	  and	  
0.05,	   respectively).	   CM	   treatment	   in	   the	   Ercc1d/-­‐	   however,	   did	   not	   have	   any	   additional	   effects	  
compared	  to	  the	  Ercc1d/-­‐	  PBS.	  Moreover,	  control	  rotarod	  performance	  was	  visibly	  greater	  than	  in	  the	  
Ercc1d/-­‐	  animals,	  despite	  this,	  statistically	  the	  difference	  between	  +/+	  (PBS)	  and	  Ercc1d/-­‐	  (PBS)	  controls	  
was	   non-­‐significant	   (Figure	   4.1	  H).	   Both	   control	   PBS	   and	   control	   CM	   animals	   exhibited	   double	   the	  
rotarod	  activity	  compared	  to	  Ercc1d/-­‐	  treated	  with	  CM	  (p	  =	  <0.05,	  respectively).	  When	  the	  genotypes	  




Figure	  4.1	  Determining	   the	   effects	   of	  ADMSC	  CM	   (CM)	  on	  body	  weight,	   grip	   strength	   and	   rotarod	  
performance	  in	  Ercc1d/-­‐	  progeric	  mice.	  (A)	  Drastically	  reduced	  body	  weights	  of	  the	  Ercc1d/-­‐	  (d/-­‐)	  mice	  
compared	   to	   (+/+)	   littermate	   controls.	   (B)	   The	   percentage	   change	   in	   body	   weight	   of	   Ercc1d/-­‐	   and	  
control	  mice.	  (C)	  CM	  does	  not	  impact	  on	  the	  body	  weights	  of	  Ercc1d/-­‐	  mice.	  (D)	  Percentage	  change	  in	  
body	  weight	  of	  Ercc1d/-­‐	  mice.	  (E)	  The	  effect	  of	  CM	  on	  the	  body	  weights	  of	  control	  mice.	  (F)	  CM	  does	  
not	   alter	   the	   body	   weight	   of	   control	   mice.	   (G)	   Functional	   assessment	   of	   average	   grip	   strength	   of	  
Ercc1d/-­‐	  and	  control	  mice,	  force	  normalised	  to	  body	  weight.	  (H)	  The	  effect	  of	  CM	  on	  rotarod	  activity	  in	  
Ercc1d/-­‐	  and	  control	  mice.	  The	  administration	  of	  CM/PBS	  treatment	  (blue	  arrows).	  *p<0.05,	  **p<0.01,	  
***p<0.001,	  (A-­‐F)	  Two-­‐way	  ANOVA	  (repeated	  measures)	  with	  Tukey	  post	  hoc	  testing.	  (G-­‐H)	  One-­‐way	  
ANOVA	  with	  Tukey	  post	  hoc	  testing.	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Fresh	  skeletal	  muscle	  weight	  revealed	  distinctly	  smaller	  hindlimb	  muscles	  in	  the	  
Ercc1d/-­‐	  mouse	  
A	   greatly	   reduced	   weight	   was	   observed	   in	   all	   hind-­‐limb	   skeletal	   muscles	   (Soleus,	   EDL,	   TA,	  
Gastrocnemius	  and	  Plantaris)	  of	  the	  Ercc1d/-­‐	  mice,	  compared	  to	  those	  of	  the	  littermate	  controls	  (p	  =	  
<0.01	   and	   <0.001)	   (Figure	   4.2	   A,	   B,	   C,	   D,	   E).	   Additionally,	   there	  were	   no	   discernible	   differences	   in	  
muscle	  weight	  in	  Ercc1d/-­‐	  or	  control	  animals	  treated	  with	  CM	  in	  any	  of	  the	  hind-­‐limb	  muscles	  (Figure	  
4.2	  F).	  
	  
Figure	   4.2	   Ercc1d/-­‐	   fresh	   hindlimb	   muscle	   weights	   are	   half	   that	   of	   the	   control.	   (d/-­‐	   PBS),	   Ercc1d/-­‐	  
ADMSC	  CM-­‐treated	  (d/-­‐	  CM),	   (+/+	  PBS)	  and	  (+/+	  CM)	   littermate	  controls.	  (A)	  Soleus	  weight	  (B)	  EDL	  
weight	  (C)	  TA	  weight	  (D)	  Gastrocnemius	  weight	  (E)	  Plantaris	  weight.	  (F)	  The	  effect	  of	  CM	  treatment	  
on	   control	   muscle	   weights.	   **p<0.01,	   ***p<0.001,	   (A-­‐E)	   One-­‐way	   ANOVA	   with	   Tukey	   post	   hoc	  
testing.	  (F)	  Individual	  student’s	  t-­‐tests.	  	  
	  
MHC	  isoform	  myofibre	  composition	  is	  unchanged	  in	  the	  Ercc1d/-­‐	  Soleus	  muscle	  
compared	  to	  control	  
MHC	   myofibre	   composition	   was	   investigated	   using	   immunohistochemical	   staining	   of	   transverse	  
cross-­‐sections	  of	  the	  ‘mid-­‐belly’	  region	  of	  frozen	  Soleus	  muscles.	  A	  well-­‐established	  shift	  to	  a	  slower	  
MHC	  phenotype	  is	  reported	  in	  natural	  ageing	  therefore	  importantly,	  analysis	  of	  MHC	  content	  in	  the	  
Ercc1d/-­‐	   Soleus	   was	   carried	   out	   to	   give	   an	   indication	   of	   any	   potential	   changes	   to	   physiology	   and	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function	  in	  the	  model	  of	  progeria.	  Positive	  expression	  of	  the	  different	  MHC	  isoforms,	  types	  I,	  IIA	  and	  
IIB	   (very	   few	   in	   Soleus)	   (and	   negative	   IIX	  myofibres),	   as	   well	   as	   the	   total	   myofibre	   number,	   were	  
quantified	  for	  all	  four	  cohorts,	  control	  and	  Ercc1d/-­‐	  animals,	  with	  and	  without	  CM	  treatment.	  
The	  average	  total	  number	  of	  myofibres	  in	  the	  control	  Soleus	  was	  approximately	  840,	  indicating	  that	  
CM	  had	  no	  effect	  on	  this	  parameter	  in	  the	  controls	  (Figure	  4.3	  A).	  The	  total	  myofibres	  was	  reduced	  to	  
an	  average	  of	  704	   in	  the	  Ercc1d/-­‐	  animals,	  significantly	   lower	  than	  the	  control	  CM	  group	  (p	  =	  <0.05)	  
but	  this	  reduction	  was	  not	  statistically	  significant	  when	  compared	  to	  that	  of	  the	  control	  PBS	  (Figure	  
4.3	  A).	  CM	  treatment	  did	  not	  have	  any	  discernible	  effect	  on	  total	  myofibre	  number	  (Figure	  4.3	  A).	  
When	  analysing	  the	  MHC	  myofibre	  types,	   it	  was	  noted	  that,	  despite	  the	  Soleus	  muscle	  traditionally	  
being	  comprised	  of	  a	  higher	  percentage	  of	  type	  I,	  slow-­‐twitch	  myofibres	  as	  a	  majority,	  this	  was	  not	  
the	   case	   with	   the	   littermate	   control	   animals	   (Figure	   4.3	   B).	   The	   myofibre	   type	   representing	   the	  
largest	  proportion	  of	  the	  Soleus	  muscle	  in	  the	  controls	  was	  type	  IIA	  (approximately	  51%),	  with	  37%	  of	  
the	   muscle	   formed	   of	   type	   I	   myofibres.	   In	   the	   Ercc1d/-­‐	   Soleus	   however,	   42%	   of	   the	   muscle	   was	  
represented	  by	   type	   I	  myofibres	   as	   a	  majority	   although	   this	  was	  not	   statistically	   significantly	  more	  
than	   the	   percentage	   of	   type	   I	  myofibres	   in	   the	   control	   (Figure	   4.3	   C).	   The	   percentage	   of	   type	   IIA	  
myofibres	  observed	  was	   slightly	  decreased	   in	   the	  Ercc1d/-­‐	  muscles	  when	  compared	   to	   the	  controls,	  
from	  51%	  to	  39%,	  however	   this	  difference	  was	  not	   statistically	  significant	   (Figure	  4.3	  D).	  Although,	  
the	   type	   IIA	  percentage	  was	   significantly	   increased	  with	  CM	   treatment	   in	   the	  Ercc1d/-­‐	  muscles	   (p	   =	  
<0.05).	   Percentages	   of	   all	   other	   MHC	   myofibre	   types	   (IIX,	   IIB	   as	   well	   as	   hybrid	   I	   /	   IIA)	   remained	  
consistent	  between	  control	  and	  Ercc1d/	  cohorts,	  as	  well	  as	  with	  CM	  treatment,	  with	  no	  other	  changes	  
observed	  (Figure	  4.3	  E,	  F,	  G).	  Additionally,	  MHC	  myofibre	  typing	  analysis	  was	  carried	  out	  in	  the	  Soleus	  
muscles	   from	   the	   control	   CM	   and	   compared	   to	   that	   of	   the	   control	   PBS.	   It	   was	   noted	   that	   the	  
percentage	  of	  type	  I	  myofibres	  increased	  from	  37%	  to	  40%	  in	  the	  control	  cohort	  treated	  with	  CM	  (p	  =	  




Figure	   4.3	   Investigating	   the	   effect	   of	   ADMSC	   CM	   (CM)	   on	   Myosin	   heavy	   chain	   (MHC)	   isoform	  
myofibre	  composition	  of	  the	  Ercc1d/-­‐	  Soleus.	  Ercc1d/-­‐	  (d/-­‐	  PBS),	  Ercc1d/-­‐	  CM-­‐treated	  (d/-­‐	  CM),	  (+/+	  PBS)	  
and	   (+/+	   CM).	   (A)	   Quantification	   of	   total	   myofibre	   number.	   (B)	   Overall	   MHC	   myofibre	   type	  
composition.	  (C)	  Proportion	  of	  MHC	  type	  I	  myofibres.	  (D)	  Proportion	  of	  MHC	  type	  IIA	  myofibres.	  (E)	  
Proportion	  of	  MHC	  type	   IIX	  myofibres.	   (F)	  Proportion	  of	  MHC	  type	   IIB	  myofibres.	   (G)	  Proportion	  of	  
MHC	   hybrid	   type	   I	   /IIA	  myofibres.	   (H)	   The	   effect	   of	   CM	   treatment	   on	   control	   Soleus	   composition.	  
*p<0.05,	  (A,	  C-­‐G)	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  (H)	  Individual	  student’s	  t-­‐tests.	  	  
	  
Ercc1d/-­‐	  myofibre	  cross-­‐sectional	  areas	  (CSAs)	  were	  similar	  to	  control	  
One	  of	   the	  key	   components	   that	   can	  determine	   force-­‐generating	   capacity	   is	  myofibre	   size.	  Muscle	  
growth	  usually	  comprises	  an	  increase	  in	  myofibre	  number	  (hyperplasia),	  and/or	  increases	  in	  myofibre	  
size	  (hypertrophy).	  As	  the	  Ercc1d/-­‐	  model	  has	  been	  reported	  to	  shift	  resources	  away	  from	  growth	  to	  
focus	  on	  genomic	  preservation	  and	  lifespan	  extension,	  it	  is	  of	  interest	  to	  investigate	  possible	  effects	  
of	  this	   in	  skeletal	  muscle	  and	  to	  relate	  this	  feature	  to	  function.	  As	  with	  the	  naturally-­‐aged	  muscles,	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myofibre	  CSA	  was	  analysed	  by	  MHC	  myofibre	  type	  in	  the	  progeric	  Soleus.	  Overall,	  CSA	  between	  the	  
myofibres	  of	  the	  control,	  Ercc1d/	  -­‐and	  Ercc1d/-­‐	  CM	  cohorts	  was	  highly	  consistent	  in	  each	  MHC	  myofibre	  
type.	  Type	  I	  myofibres	  observed,	  had	  a	  reduced	  area	  when	  treated	  with	  CM	  in	  the	  progeric	  muscles	  
(1330µm2)	  when	  compared	  with	   the	  Ercc1d/-­‐	  PBS	   (1510µm2)	  and	  control	  PBS	   (1540µm2)	   (Figure	  4.4	  
A).	  There	  was	  a	  similar	  trend	  shown	  in	  the	  type	  IIA	  myofibres,	  where	  CM	  appeared	  to	  decrease	  CSA	  
in	   the	  Ercc1d/-­‐muscles	   (1170µm2),	   compared	   to	   that	  of	   the	  progeric	   control	   (1220µm2)	   and	   control	  
CSA	   (1300µm2)	   (Figure	   4.4	   B).	   However,	   these	   differences	   were	   statistically	   non-­‐significant.	  
Additionally,	  despite	   the	   control	   cohort	   appearing	   to	  have	   larger	  CSA	   in	   type	   IIX	  and	   IIB	  myofibres	  
and	  CM	  seeming	  to	  have	  decreased	  the	  CSA	  of	  IIB	  myofibres,	  these	  differences	  were	  not	  statistically	  
significant	   (Figure	   4.4	   C,	   D).	   Therefore,	   control	   and	   Ercc1d/-­‐myofibres	   were	   similar	   in	   size	   and	   CM	  
treatment	   had	   no	   additional	   effects	   on	   this	   parameter.	   Furthermore,	   CM	   treatment	   had	   no	  
significant	  effect	  on	  myofibre	  CSA	  in	  the	  littermate	  controls	  (Figure	  4.4	  E).	  
	  
Figure	  4.4	  Examining	  the	  effect	  of	  ADMSC	  CM	  (CM)	  on	  Myosin	  heavy	  chain	  (MHC)	  isoform	  myofibre	  
cross-­‐sectional	  area	  (CSA)	  in	  the	  Ercc1d/-­‐	  Soleus.	  Ercc1d/-­‐	  (d/-­‐	  PBS),	  Ercc1d/-­‐	  CM-­‐treated	  (d/-­‐	  CM),	  (+/+	  
PBS)	  and	  (+/+	  CM).	  (A)	  MHC	  type	  I	  myofibre	  CSA.	  (B)	  MHC	  type	  IIA	  myofibre	  CSA.	  (C)	  MHC	  type	  IIX	  
myofibre	  CSA.	   (D)	  MHC	   type	   IIB	  myofibre	  CSA.	   (E)	   CM	   treatment	  does	  not	   impact	  on	   control	   fibre	  




Oxidative	  capacity	  is	  consistent	  in	  the	  Ercc1d/-­‐	  Soleus	  relative	  to	  control	  
Further	  to	   investigating	  the	  changes	  to	  metabolic	   function	  and	  oxidative	  capacity	  that	  occur	  during	  
the	   onset	   and	   progression	   of	   natural	   ageing,	   these	   characteristics	  were	   subsequently	   examined	   in	  
the	   progeric	   Ercc1d/-­‐	   model.	   As	   before,	   to	   analyse	   the	   myofibres	   more	   oxidative	   in	   nature	   as	   a	  
percentage	  of	  the	  total,	  the	  histological	  succinate	  dehydrogenase	  (SDH)	  staining	  protocol	  was	  carried	  
out	   on	   Soleus	   muscle	   transverse	   cross-­‐sections.	   These	   results	   indicated	   that	   the	   percentage	   of	  
oxidative	   myofibres	   in	   the	   Ercc1d/-­‐	   Soleus	   muscles	   (52%)	   was	   not	   statistically	   different	   from	   the	  
average	   observed	   in	   the	   control	   (57%)	   (Figure	   4.5	   A).	  Moreover,	   CM	   treatment	   had	   no	   additional	  
effect	   on	   the	   oxidative	   capacity	   in	   the	   progeric	   Soleus	   nor	   on	   that	   seen	   in	   the	   littermate	   control	  
(Figure	  4.5	  B).	  
Capillary	  density	  is	  reduced	  in	  the	  Ercc1d/-­‐	  Soleus	  and	  CM	  may	  harbour	  pro-­‐
angiogenic	  properties	  
As	  previously	  discussed,	  oxygen	  delivery	  and	  therefore	  vasculature	  organisation	  can	  give	  key	  insights	  
into	   any	   changes	   to	   the	  metabolic	   regulation	   of	   muscle	   during	   ageing.	   To	   further	   assess	   this	   key	  
aspect	  as	  part	  of	  the	  development	  of	  a	  skeletal	  muscle	  profile	  for	  the	  Ercc1d/-­‐	  mutant	  mouse	  model	  
of	   progeria,	   CD31+	   cells	   were	   analysed	   and	   quantified	   using	   an	   immunohistochemical	   protocol	   to	  
examine	  capillary	  density.	  
It	   was	   observed	   that	   the	   average	   number	   of	   CD31+	   cells	   was	   2	   cells	   per	   myofibre	   in	   the	   Ercc1d/-­‐	  
progeric	  Soleus,	  which	  was	  notably	  fewer	  when	  compared	  to	  the	  control	  where	  2.5	  cells	  served	  each	  
myofibre	   (p	   =	   <0.05)	   (Figure	   4.5	   C).	   Furthermore,	   CM	   treatment	   increased	   the	   capillary	   density	   to	  
that	   observed	   in	   the	   control	   (2.5	   cells	   per	   myofibre),	   however	   this	   increase	   was	   not	   statistically	  
significant	  when	   compared	   to	   the	  Ercc1d/-­‐	   PBS	   nor	   the	   control	   cohorts.	  Despite,	   a	   further	   increase	  
seen	   in	   the	   capillary	   density	   in	   the	   control	   with	   CM	   treatment,	   to	   2.8	   cells	   per	   myofibre,	   this	  
difference	  was	  also	  proved	  to	  be	  statistically	  non-­‐significant	  (Figure	  4.5	  D).	  
A	  similar	  trend	  was	  noted	  when	  examining	  the	  relative	  mRNA	  expression	  of	  VEGFa	  165	  through	  qPCR	  
analysis.	   The	   expression	   level	   of	   VEGFa	   165	   was	   lowest	   in	   the	   Ercc1d/-­‐	   PBS	   cohort	   however	   any	  
differences	  observed	  were	  statistically	  not	  significant	  (Figure	  4.5	  E).	  
Reactive	  oxygen	  species	  (ROS)	  production	  is	  increased	  with	  CM	  treatment	  in	  
the	  Ercc1d/-­‐	  Soleus	  
As	  previously	  discussed,	  one	  of	  the	  sources	  of	  DNA	  damage	  is	  through	  excessive	  production	  of	  ROS	  
such	   as	   superoxide	   (O2-­‐)	   and	   is	   also	   a	   hallmark	   characteristic	   of	   mitochondrial	   dysfunction	   during	  
ageing.	   As	   the	   Ercc1d/-­‐	   mutant	   mouse	   is	   that	   which	   mimics	   progeria	   and	   is	   itself	   a	   consequential	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model	   resulting	   from	   insufficient	   nucleotide	   excision	   repair	   (NER)	   mechanisms	   and	   therefore	  
accumulated	   DNA	   damage,	   the	   degree	   that	   ROS	   production	   contributed	   to	   the	   development	   of	  
sarcopenia	   in	   this	   model	   were	   examined.	   As	   before,	   O2-­‐	   was	   identified	   using	   the	   DHE	  
immunohistochemical	  fluorescence	  protocol	  and	  the	  intensity	  was	  analysed	  within	  myofibres	  of	  both	  
small	  and	  large	  CSAs	  of	  Ercc1d/-­‐	  and	  control	   littermate	  Soleus	  muscles,	  with	  and	  without	   in	  vivo	  CM	  
treatment.	  	  
Firstly,	   relative	   DHE	   intensity	   was	   higher	   in	   the	   small	   myofibres	   of	   the	   Ercc1d/-­‐	   Soleus	   (11.6)	   in	  
comparison	  to	  the	  control	  (8.5),	  although	  this	  increase	  was	  not	  statistically	  significant	  (Figure	  4.5	  F).	  
ROS	  production	  in	  small	  myofibres	  in	  the	  Soleus	  from	  Ercc1d/-­‐	  CM-­‐treated	  animals	  however	  was	  the	  
highest	  (13.2)	  and	  was	  statistically	  increased	  from	  that	  of	  the	  control	  (p	  =	  <0.05)	  but	  not	  significantly	  
different	  from	  that	  of	  the	  Ercc1d/-­‐	  PBS	  cohort.	   In	  contrast,	  CM	  treatment	   in	  the	  control	  animals	  had	  
no	  effect	  on	  DHE	  intensity	  measured	  in	  the	  small	  myofibres	  (Figure	  4.5	  G).	  As	  previously	  observed	  in	  
the	   naturally	   aged	   Soleus	   data,	   DHE	   fluorescence	   intensity	  was	   greater	   in	   the	   centre	   of	  myofibres	  
with	  a	  smaller	  CSA	  in	  both	  Ercc1d/-­‐	  PBS	  and	  CM	  (p	  =	  <0.05	  and	  <0.001,	  respectively)	  as	  well	  as	  control	  
PBS	  and	  CM	  conditions	  (p	  =	  <0.05	  and	  <0.01,	  respectively)	  (Figure	  4.5	  H).	  Furthermore,	  the	  increase	  
in	  ROS	  production	  was	  also	  observed	  in	  the	  large	  myofibres	  of	  progeric	  Soleus	  muscles	  but	  notably	  so	  
in	  the	  CM-­‐treated	  cohort	  when	  compared	  to	  the	  control	  (p	  =	  <0.01)	  (Figure	  4.5	  I).	  As	  observed	  with	  
the	  smaller	  myofibres,	  CM	  treatment	  in	  the	  control	  animals	  did	  not	  affect	  DHE	  intensity	  in	  the	  larger	  
myofibres	   (Figure	   4.5	   J).	   Finally,	   as	   in	   the	   natural	   ageing	   experiment,	   SOD2	   gene	   expression	   was	  
analysed	   in	   the	   progeric	   study	   to	   provide	   insights	   into	   mitochondrial	   antioxidant	   activity.	  
Quantitative	  PCR	  analysis	  indicated	  a	  slightly	  increased	  level	  of	  SOD2	  (0.9	  relative	  gene	  expression)	  in	  
the	   control	   PBS	   Soleus	   muscles,	   compared	   to	   all	   other	   cohorts	   (approximately	   0.5)	   however	   the	  




Figure	   4.5	   Investigating	   the	   influence	   of	   ADMSC	   CM	   (CM)	   on	   the	   metabolic	   status,	   vasculature	  
organisation	  and	  mitochondrial	  function	  of	  the	  Ercc1d/-­‐	  Soleus.	  Ercc1d/-­‐	  (d/-­‐	  PBS),	  Ercc1d/-­‐	  CM-­‐treated	  
(d/-­‐	  CM),	  (+/+	  PBS)	  and	  (+/+	  CM).	  (A)	  Proportion	  of	  myofibres	  positive	  for	  succinate	  dehydrogenase	  
(SDH)	   staining	   to	  assess	   the	  oxidative	  capacity.	   (B)	  CM	  treatment	  does	  not	  affect	   control	  oxidative	  
capacity.	   (C)	   Capillary	   density	   (CD31+	   cells	   per	   myofibre).	   (D)	   CM	   treatment	   does	   not	   impact	   on	  
control	  capillary	  density.	  (E)	  VEGFa	  165	  mRNA	  expression.	  (F)	  ROS	  production	  in	  small	  myofibres.	  (G)	  
CM	  treatment	  does	  not	   influence	  ROS	  production	   in	   littermate	  controls	   (small	  myofibres).	   (H)	  ROS	  
production	   is	   greater	   in	   small	  myofibres.	   (I)	  ROS	   production	   in	   large	  myofibres.	   (J)	  CM	   treatment	  
does	   not	   influence	   ROS	   production	   in	   littermate	   controls	   (large	   myofibres).	   (K)	   Antioxidant	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superoxide	  dismutase	  2	   (SOD2)	  mRNA	  expression.	  *p<0.05,	  **p<0.01,	  ***p<0.001,	   (A,	  C,	  E,	  F,	   I,	  K)	  
One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  (B,	  D,	  G,	  H,	  J)	  Individual	  student’s	  t-­‐tests.	  
	  
Changes	  in	  the	  extracellular	  matrix	  (ECM)	  of	  the	  progeric	  Soleus	  muscle	  
Increases	   in	   collagen	   layer	   thickness	   are	  well	   established	   in	   the	   process	   of	   natural	   ageing	   and	   is	   a	  
feature	   that	   is	   implicated	   in	   overall	   muscle	   signalling	   and	   contractile	   function	   in	   old	   and	   geriatric	  
ages.	   In	  the	  present	  study,	  collagen	  thickness	  analysis	  was	  also	  carried	  out	   in	  Soleus	  muscles	  of	  the	  
Ercc1d/-­‐	   mouse.	   Collagen	   IV	   thickness	   analysis	   was	   conducted	   as	   before,	   by	  MHC	  myofibre	   border	  
type	  of	  transverse	  Soleus	  cross-­‐sections	  visualised	  using	  immunofluorescence.	  	  
Initially,	   collagen	   appeared	   to	   be	   thicker	   in	   non-­‐type	   I	   borders	  when	   compared	   to	   those	   of	   type	   I	  
myofibres	   in	   all	   control	   and	   Ercc1d/-­‐	   conditions	   however	   these	   increases	   were	   statistically	   non-­‐
significant	  (Figure	  4.6	  A).	  Furthermore,	  when	  analysing	  the	  two	  border	  types	  individually,	  despite	  an	  
observed	   slight	   increase	   in	   thickness	   in	  progeric	  borders	   (both	   type	   I	   and	  non-­‐type	   I)	   compared	   to	  
control,	  there	  were	  no	  significant	  changes	  in	  collagen	  IV	  content	  in	  the	  Ercc1d/-­‐	  Soleus	  and	  CM	  had	  no	  
additional	  effect	   (Figure	  4.6	  B,	  C).	   In	   the	   littermate	  controls,	  CM	  treatment	  also	  had	  no	  discernible	  
effect	   on	   collagen	   thickness	   (Figure	   4.6	   D).	   Furthermore,	   qPCR	   analysis	   carried	   out	   indicated	   no	  
notable	   variation	   in	   ECM	   content	   regarding	   collagen	   I	   and	   IV,	   dystrophin	   and	   beta-­‐sarcoglycan	  
relative	  mRNA	  expression,	  in	  the	  Ercc1d/-­‐	  Soleus	  muscle	  compared	  to	  that	  of	  the	  control,	  nor	  with	  CM	  




Figure	   4.6	   Examining	   the	   influence	   of	   ADMSC	   CM	   (CM)	   on	   collagen	   thickness	   and	   structural	  
components	   of	   the	   dystrophin	   glycoprotein	   complex	   (DGC)	   in	   the	   Ercc1d/-­‐	   Soleus.	   (A)	   Collagen	   IV	  
thickness	   between	   MHC	   myofibres,	   type	   I	   border	   with	   another	   type	   I.	   Non-­‐type	   I	   border	   with	   a	  
second	   non-­‐type	   I	   myofibre	   (B)	   Collagen	   IV	   thickness	   between	   type	   I	   myofibres	   (C)	   Collagen	   IV	  
thickness	  between	  non-­‐type	   I	  myofibres	   (D)	  CM	  treatment	  does	  not	  affect	   collagen	   IV	   thickness	   in	  
either	   border	   type	   in	   littermate	   controls	   (E)	   Collagen	   I	   mRNA	   expression	   (F)	   Collagen	   IV	   mRNA	  
expression	  (G)	  Dystrophin	  mRNA	  expression.	  (H)	  Beta-­‐sarcoglycan	  mRNA	  expression.	  (B,	  C,	  E-­‐H)	  One-­‐
way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  (A,	  D)	  Individual	  student’s	  t-­‐tests.	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Numerous	  characteristics	  of	  Ercc1d/-­‐	  skeletal	  muscle	  reflect	  sarcopenia	  in	  
natural	  ageing	  while	  others	  appear	  amplified	  
A	   further	   hypothesis	   to	   be	   investigated	   was	   that	   the	   Ercc1d/-­‐	   mutant	   mouse	   provided	   a	   good	  
mammalian	   model	   of	   progeria	   and	   mimicked	   characteristics	   of	   degeneration	   associated	   with	   the	  
onset	  and	  progression	  of	  sarcopenia	  in	  natural	  ageing.	  To	  that	  end,	  parameters	  investigated	  as	  part	  
of	  developing	  a	  muscle	  profile	   for	   the	  Ercc1d/-­‐	  animals	  were	  compared	  to	  that	   formed	  for	  naturally	  
ageing	  muscle,	   in	   the	  previously	  reported	  experiments	  of	   the	  current	  project.	  For	  example,	  Ercc1d/-­‐	  
hind-­‐limb	   muscles	   were	   shown	   to	   have	   substantially	   reduced	   muscle	   weight	   in	   all	   muscle	   types,	  
when	   compared	   to	   those	   of	   old,	   naturally-­‐aged	   animals	   (p	   =	   <0.001)	   (Figure	   4.7	   A,	   B,	   C	   ,	   D,	   E).	  
Furthermore,	   the	   observed	   significant	   reduction	   in	   progeric	   muscle	   mass	   was	   also	   evident	   when	  
compared	   to	   weights	   recorded	   at	   a	   geriatric	   age	   in	   the	   EDL	   (p	   =	   <0.05),	   TA	   (p	   =	   <0.001)	   and	  
Gastrocnemius	  (p	  =	  <0.001)	  muscles	  (Figure	  4.7	  B,	  D).	  
	  
Figure	  4.7	  Substantially	  reduced	  Ercc1d/-­‐	  fresh	  hindlimb	  muscle	  weights	  compared	  to	  natural	  ageing.	  
(A)	   Soleus	   weight	   (B)	   EDL	   weight	   (C)	   TA	   weight	   (D)	   Gastrocnemius	   weight	   (E)	   Plantaris	   weight.	  
*p<0.05,	   **p<0.01,	   ***p<0.001,	   (A-­‐D)	  One-­‐way	  ANOVA	  with	   Tukey	  post	   hoc	   testing.	   (E)	   Individual	  





Furthermore,	  myofibre	  type	  analysis	  indicated	  that	  Ercc1d/-­‐	  Soleus	  muscles	  had	  remarkably	  different	  
MHC	   composition	   to	   that	   of	   naturally-­‐aged	   animals.	   Firstly,	   the	   Ercc1d/-­‐	   cohort	   showed	   a	   greatly	  
reduced	  proportion	  of	  type	  I	  myofibres,	  42%	  compared	  to	  56%	  at	  old	  age	  and	  60%	  at	  geriatric	  age	  (p	  
=	   <0.05	   and	   <0.01,	   respectively)	   (Figure	   4.8	   A).	   However,	   type	   IIA	   proportions	   were	   no	   different	  
between	   the	   Ercc1d/-­‐	   and	   naturally-­‐aged	   Soleus	   (Figure	   4.8	   B).	  Moreover,	   as	   the	   amount	   of	   type	   I	  
myofibres	   decreased,	   the	   proportional	   deficit	   shifted	   to	   the	   fastest	   phenotypes	   as	   percentages	   of	  
type	   IIX	   (p	  =	  <0.01),	   IIB	   (p	  =	  <0.05)	  and	  hybrid	  type	   I	  /	   IIA	  (p	  =	  <0.01)	   increased	  when	  compared	  to	  
those	  analysed	  at	  old	  age	   (Figure	  4.8	  C,	  D).	   The	   same	   trend	  was	   seen	  when	  compared	   to	  geriatric	  
ages	  (p	  =	  <0.05,	  <0.05	  and	  0.01,	  respectively).	  
CSAs	  of	  myofibres	  analysed	  between	  naturally	  aged	  and	  Ercc1d/-­‐	  Soleus	  muscles	  was	  not	  statistically	  
different	   in	   type	   I	   myofibres,	   however	   type	   IIA	  myofibre	   size	   was	   significantly	   reduced	   in	   Ercc1d/-­‐	  
muscles,	  compared	  to	  old	  age	  (p	  =	  <0.05)	  (Figure	  4.8	  E,	  F).	  Type	  IIX	  CSA	  was	  also	  smaller,	  ~1100µm2,	  
in	  Ercc1d/-­‐	  myofibres	  compared	  to	  geriatric	  ages,	  ~1900µm2	  (p	  =	  <0.001),	  therefore	  this	  indicated	  that	  
Ercc1d/-­‐	  IIX	  myofibres	  were	  more	  similar	  in	  size	  to	  those	  measured	  at	  old	  age	  1400µm2	  (Figure	  4.8	  G).	  




Figure	  4.8	  Myosin	  heavy	  chain	  (MHC)	  isoform	  myofibre	  composition	  and	  size	  indicates	  an	  alternative	  
myofibre	  phenotype	  in	  the	  Ercc1d/-­‐	  Soleus	  compared	  to	  natural	  ageing.	  (A)	  Proportion	  of	  MHC	  type	  I	  
myofibres	  (B)	  Proportion	  of	  MHC	  type	   IIA	  myofibres.	  (C)	  Proportion	  of	  MHC	  type	   IIX	  myofibres.	  (D)	  
Proportion	  of	  MHC	  type	  IIB	  myofibres.	  (E)	  MHC	  type	  I	  myofibre	  CSA.	  (F)	  MHC	  type	  IIA	  myofibre	  CSA.	  
(G)	   MHC	   type	   IIX	  myofibre	   CSA.	   (H)	   MHC	   type	   IIB	  myofibre	   CSA.	   *p<0.05,	   **p<0.01,	   ***p<0.001,	  




Regarding	  the	  parameters	  analysed	  to	  determine	  potential	  changes	  in	  metabolic	  status	  and	  function,	  
such	  as	  the	  percentage	  oxidative	  myofibres	  (SDH),	  ROS	  production	  (DHE)	  and	  SOD2	  gene	  expression,	  
the	   differences	   noted	   in	   old	   and	   geriatric	   ageing	   and	   in	   the	   Ercc1d/-­‐	   Soleus	   were	   not	   statistically	  
significant,	  indicating	  a	  degree	  of	  consistency	  (Figure	  4.9	  A,	  D,	  E,	  F).	  
Contrastingly,	   the	   capillary	   density	   in	   the	   Ercc1d/-­‐	   muscle	   demonstrated	   an	   extremely	   reduced	  
number	   of	   CD31+	   cells	   (2	   cells	   per	   myofibre)	   compared	   to	   the	   old	   and	   geriatric	   Soleus	   with	   an	  
average	   of	   3.6	   cells	   each	   (p	   =	   <0.01)	   (Figure	   4.9	   B).	   At	   a	   molecular	   level	   however,	   qPCR	   analysis	  
indicated	   that	   there	  was	   statistically	   no	   variation	   in	  mRNA	   expression	   of	   VEGFa	   165	   between	   the	  
Ercc1d/-­‐progeric	  model	  and	  that	  in	  old	  and	  geriatric	  ages	  (Figure	  4.9	  C).	  
Similarly,	  the	  collagen	  IV	  borders	  between	  both	  MHC	  type	  I	  and	  non-­‐type	  I	  myofibres	  were	  found	  to	  
be	  thinner	  in	  the	  Ercc1d/-­‐	  Soleus,	  significantly	  so	  (type	  I),	  when	  compared	  to	  the	  collagen	  thickness	  in	  
old	   age	   (p	   =	   <0.05)	   but	   interestingly,	   statistically	   no	   different	   to	   those	  measured	   at	   geriatric	   ages	  
(Figure	   4.9	   G,	   H).	   Quantative	   PCR	   analysis	   of	   collagen	   mRNA	   expression	   it	   was	   seen	   that	   both	  
collagen	   I	   and	   IV	   levels	   were	   consistent	   between	   naturally	   aged	   old	   and	   geriatric	   groups	   when	  
compared	  to	  that	  of	  the	  Ercc1d/-­‐	  Soleus	  (Figure	  4.9	  I,	  J).	  Expression	  of	  DGC	  component,	  dystrophin,	  in	  
Ercc1d/-­‐	  muscles	  however,	  was	  significantly	  lower	  than	  old	  age	  (Figure	  4.9	  K).	  Beta-­‐sarcoglycan	  mRNA	  




Figure	  4.9	  Assessing	  the	  suitability	  of	  the	  Ercc1d/-­‐	  model	  of	  progeria	  in	  mimicking	  natural	  ageing.	  The	  
following	   characteristics	   of	  metabolic	   status,	   vasculature	   organisation,	  mitochondrial	   function	   and	  
structural	   and	   ECM	   components	   are	   compared	   in	   the	   Soleus.	   (A)	  Oxidative	   capacity.	   (B)	   Capillary	  
density	   (CD31+	   cells	   per	  myofibre).	   (C)	   VEGFa	   165	  mRNA	   expression.	   (D)	   ROS	   production	   in	   small	  
myofibres.	   (E)	   ROS	   production	   in	   large	   myofibres.	   (F)	   Antioxidant	   superoxide	   dismutase	   2	   (SOD2)	  
mRNA	  expression.	  (G)	  Collagen	  IV	  thickness	  in	  type	  I	  myofibre	  borders	  (H)	  Collagen	  IV	  thickness	  non-­‐
type	   I	   myofibre	   borders	   (I)	   Collagen	   IV	   mRNA	   expression	   (J)	   Collagen	   I	   mRNA	   expression	   (K)	  
Dystrophin	  mRNA	   expression.	   (L)	  Beta-­‐sarcoglycan	  mRNA	   expression.	  *p<0.05,	   **p<0.01,	  One-­‐way	  




Characterisation	  of	  the	  skeletal	  muscle	  phenotype	  in	  the	  Ercc1d/-­‐	  murine	  model	  
of	  progeria	  
The	   first	  objective	  of	   this	  current	  series	  of	  experiments	  was	   to	  characterise	   features	  of	   the	  Ercc1d/-­‐	  
skeletal	   muscle	   phenotype.	   Secondly,	   as	   with	   the	   naturally-­‐aged	   study,	   the	   experiments	   were	  
designed	  in	  order	  to	  additionally	  determine	  the	  effects	  of	  ADMSC-­‐derived	  CM	  as	  a	  potential	  therapy.	  
The	  CM	  treatment	  was	  assessed	  in	  its	  capability	  to	  impact	  on	  hallmark	  components	  such	  as	  increased	  
oxidative	   stress,	   associated	   with	   the	   Ercc1d/-­‐	   model,	   or	   any	   age-­‐related,	   myo-­‐pathological	   traits,	  
utilising	   the	   parameters	   employed	   previously	   for	   analysis	   at	   a	   whole	   organism	   and	   muscle	   level.	  
Thirdly,	  comparisons	  were	  made	   in	  order	   to	  establish	  how	  reliably	  or	  accurately	   the	  Ercc1d/-­‐	  model	  
displays	  and	  mimics	  characteristics	  associated	  with	  sarcopenia	  in	  natural	  ageing.	  
This	   series	   of	   experiments	   has	   enabled	   the	   development	   of	   a	   progeric	   skeletal	   muscle	   profile,	  
detailing	   the	   observed	   differences	   in	   physiological,	   immunohistological	   and	   biochemical	  
characteristics	   of	   the	   naturally-­‐aged	   and	  Ercc1d/-­‐	   Soleus	  muscle.	   As	  with	   the	   naturally-­‐aged	   animal	  
experimentation,	  parameters	  were	  measured	  at	  whole	  organism,	  tissue,	  cellular	  and	  molecular	  levels	  
and	   the	   effect	   of	   CM	   treatment	   on	   these	   features	   were	   recorded.	   Firstly,	   observations	   and	  
measurements	  recorded	  at	  a	  whole	  organism	  level	  included	  regular	  body	  weight	  and	  health	  checks.	  
Dramatic	  reduction	  in	  body	  weight	  (>15%	  within	  2	  weeks),	  along	  with	  the	  development	  of	  features	  
such	  as	  prominent	  spine	  or	   ribs,	   sunken	  hips,	  hunched	  body	  position,	  matted	   fur,	   slow	  respiration,	  
not	  responsive	  to	  touch	  stimuli,	  rectal	  or	  uterine	  prolapse,	  skin	  lesions	  or	  visible	  tumours	  would	  have	  
been	   of	   sufficient	   health	   concern	   for	   that	   animal	   to	   be	   sacrificed	   via	   a	   Schedule	   1	   method.	  
Fortunately,	  body	  condition	  did	  not	  decline	  to	  this	  severe	  extent	  in	  any	  of	  the	  progeric	  animals	  and	  
although	  body	  weight	  fluctuated	  slightly,	   it	  did	  not	  deteriorate	  anywhere	  near	  to	  this	  degree.	  Body	  
weights	   of	   the	   Ercc1d/-­‐	   animals	   were	   remarkably	   reduced	   compared	   to	   their	   control	   littermates	  
throughout	   the	   experimental	   duration.	   This	   is	   in	   keeping	   with	   findings	   reported	   in	   the	   literature,	  
where	   it	   is	   reasoned	   that	   the	   additional	   conclusion	   that	   Ercc1d/-­‐	   cells	   enter	   premature	   replicative	  
senescence,	   could	   be	   an	   underlying	   cause	   of	   the	   stunted	   growth,	   very	   small	   phenotype	   and	  
drastically	  reduced	  lifespan	  of	  the	  Ercc1d/-­‐	  mice	  (Weeda	  et	  al.	  1997;	  De	  Waard	  et	  al.	  2010;	  Dollé	  et	  al.	  
2011).	   Additionally,	   it	   was	   noted	   that	   at	   the	   experimental	   end-­‐point,	   when	   the	   animals	   were	   16	  
weeks	   old,	   the	   Ercc1d/-­‐	  mice	   displayed	   a	   number	   of	   the	   previously	   reported	   age-­‐related	   signs	   and	  
symptoms,	  such	  as	  tremors,	  incontinence,	  kyphosis,	  ataxia,	  dystonia,	  forelimb	  and	  hindlimb	  clasping	  
as	  well	   as	   having	   an	   overall	   frail	   appearance	   (Lavasani	   et	   al.	   2012).	   Although	   a	   certain	   amount	   of	  
weight	  gained	  during	  the	  early	  growth	  phase	  can	  be	  attributed	  to	  fat,	  percentage	  body	  fat	  has	  been	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shown	  instead	  to	  increase	  rapidly	  after	  6	  months	  of	  age	  (Glatt	  et	  al.	  2007).	  Skeletal	  muscle	  however,	  
develops	   rapidly	   during	   post-­‐natal	   growth,	   between	   the	   initial	   3	   –	   4	   weeks	   and	   continues	   into	  
adulthood.	  In	  studies	  conducted	  in	  rodents,	  whole-­‐body	  muscle	  mass	  is	  reported	  to	  increase	  50-­‐fold	  
during	   the	   initial	   growth	   phase	   and	   of	   the	   total	   gained	   mass	   of	   the	   growing	   animal,	   muscle	  
contributes	  50%	  of	  the	  overall	  increase	  (Gokhin	  et	  al.	  2008).	  Muscle	  growth	  is	  the	  result	  of	  increases	  
in	  myofibre	   number	   (hyperplasia)	   or	   increases	   in	  myofibre	   size	   (hypertrophy).	   As	  mouse	   EDLs	   are	  
believed	   to	   have	   the	   entire	   complement	   of	  myofibres	   at	   birth,	   remaining	   unchanged	   in	   studies	   of	  
myofibre	   number	   between	   1	   –	   8	   weeks	   of	   age,	   muscle	   mass	   increases	   are	   therefore	   attributed	  
primarily	   to	   myofibre	   hypertrophy	   (White	   et	   al.	   2010;	   Gokhin	   et	   al.	   2008;	   Stickland	   1981).	  
Furthermore,	  the	  animals	  in	  the	  current	  study	  were	  9	  weeks	  old	  at	  the	  start	  of	  the	  experiment	  and	  
muscle	  hypertrophy	  is	  likely	  to	  be	  the	  main	  contributing	  factor	  in	  control	  body	  weight	  increases.	  The	  
Ercc1d/-­‐	  animals	  however,	  are	  reported	  to	  experience	  stunted	  growth	  and	  visibly	  this	  was	  evident	  at	  
the	   start	   of	   the	   study	  by	   animal	   size	   alone	   (Weeda	  et	   al.	   1997;	  Dollé	   et	   al.	   2011;	  De	  Waard	   et	   al.	  
2010).	  	  
Strength	  and	  activity	  testing	  revealed	  that	  there	  was	  a	  large	  degree	  of	  variation	  in	  the	  data,	  however	  
despite	   this,	  very	  strong	   trends	   indicated	  overall	  decreased	  grip	  strength	  and	  rotarod	  performance	  
displayed	  by	  the	  Ercc1d/-­‐	  animals.	  Functional	  tests	  such	  as	  these	  are	  used	  universally	  in	  the	  research	  
field	  to	  give	  an	  indication	  of	  functionality.	  A	  decreased	  functionality	  therefore	  could	  be	  expected	  in	  
the	   Ercc1d/-­‐	   mice	   given	   their	   overall	   reduced	   body	   size	   however,	   this	   may	   also	   provide	   an	   initial	  
indication	  of	  muscular	  deficits	  and	  decreased	  force-­‐generating	  capacity.	  This	  reduction	  is	  consistent	  
with	  a	  reduced	  force	  measurement	  previously	  observed	  in	  natural	  ageing.	  	  
In	   the	   Ercc1d/-­‐	   animals	   however,	   along	   with	   reduced	   body	   mass,	   muscle	   weights	   were	   also	  
significantly	  reduced	  when	  compared	  to	  those	  in	  control	   littermates.	  This	   is	   in	  keeping	  with	  muscle	  
mass	  declines	  reported	  in	  natural	  ageing,	  in	  the	  literature,	  as	  well	  as	  in	  the	  majority	  of	  the	  naturally-­‐
aged	  hindlimb	  muscles	  of	  the	  previous	  series	  of	  experiments	  discussed	  (Rogers	  &	  Evans	  1993).	  Taken	  
with	  what	   is	   known	   regarding	   the	   key	   determinants	   behind	  muscle	   growth,	   this	   finding	   therefore	  
indicates	  potential	  impairments	  in	  cell	  proliferation	  or	  the	  underlying	  mechanisms	  of	  hypertrophy	  or	  
both.	  This	  was	   further	   investigated	  and	   total	  myofibre	  number	  did	  appear	   to	  be	   fewer	   than	   in	   the	  
control	   (significantly	   so	   when	   compared	   to	   control	   CM	   cohort).	   It	   should	   be	   noted	   that	   initial	  
development	   of	   Ercc1d/-­‐	   is	   reportedly	   normal	   and	   it	   is	   after	   this	   time	   that	   rapid	   mutation	  
accumulation	  occurs,	  along	  with	  the	  appearance	  of	  characteristics	  associated	  with	  premature	  ageing	  
(Dollé	  et	   al.	   2006).	   This	   therefore	   suggests	   that	   cell	   proliferation	  during	  early	  muscle	  development	  
was	   not	   affected	   and	   instead,	   directs	   thinking	   towards	   myofibre	   loss	   as	   the	   explanation	   behind	  
reduced	  myofibre	  number.	  This	  is	  in	  keeping	  with	  the	  previously	  reported	  entry	  of	  Ercc1d/-­‐	  cells	  into	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premature	  cellular	   senescence	   (Weeda	  et	  al.	  1997).	  Work	  carried	  out	  by	  De	  Waard	  and	  colleagues	  
revealed	  increased	  motor	  neuron	  loss	  and	  denervation	  of	  skeletal	  myofibres	  in	  the	  Ercc1d/-­‐	  mice	  (De	  
Waard	  et	  al.	  2010).	  Additionally,	  as	  apoptosis	  has	  been	  linked	  to	  myofibre	  atrophy	  in	  sarcopenia,	  it	  is	  
postulated	  that	  among	  others,	  caspase	  levels	  for	  example,	  will	  indicate	  a	  higher	  instance	  of	  apoptosis	  
occurring	   in	   the	   Ercc1d/-­‐	  muscles	   (Dupont-­‐Versteegden	   2005;	  Wang	   et	   al.	   2014).	   However,	   further	  
exploration	  into	  apoptotic	  signalling	  pathways	  is	  required	  in	  order	  to	  provide	  a	  better	  understanding	  
of	  this	  activity	  in	  the	  surmised	  myofibre	  atrophy	  in	  the	  Ercc1d/-­‐	  mouse.	  Moreover,	  while	  investigating	  
qualitative	   features	  of	  hypertrophy,	   the	  Ercc1d/-­‐	  myofibres	  appeared	  to	  maintain	  a	   trend	  towards	  a	  
reduced	  cross-­‐sectional	  area	  compared	  to	  controls,	  particularly	  in	  the	  faster	  myofibres	  types	  (type	  IIX	  
and	   IIB).	   These	   results	   are	   overall	   in-­‐keeping	   with	   what	   is	   already	   well-­‐established,	   regarding	   a	  
metabolic	   shift	   towards	   maintenance	   and	   away	   from	   proliferation	   and	   growth,	   in	   the	   interest	   of	  
extending	   longevity	   (Garinis	   et	   al.	   2008;	  Niedernhofer	   et	   al.	   2006).	   Furthermore,	   it	  would	   indicate	  
that	  the	  mechanisms	  regulating	  muscle	  growth	  are	  also	  somewhat	  dampened	  in	  the	  Ercc1d/-­‐	  Soleus,	  
as	  a	  survival	  response.	  It	  should	  be	  noted	  that	  these	  faster	  myofibre	  types	  are	  less	  abundant	  in	  the	  
Soleus,	  which	   subsequently	   resulted	   in	   small	   degrees	   of	   variation	   becoming	   amplified	   in	   the	   data,	  
equalling	  overall	  statistical	  non-­‐significance.	  Therefore,	  it	  would	  be	  of	  interest	  to	  further	  investigate	  
the	   underlying	   mechanisms	   of	   both	   protein	   synthesis	   and	   protein	   degradation,	   hypertrophy	   and	  
atrophy,	   in	   Ercc1d/-­‐	   muscle.	   For	   example,	   western	   blot	   analysis	   of	   IGF-­‐1	   and	   PI3K/AKT	   signalling	  
pathway,	   responsible	   for	   the	   balance	   between	   protein	   catabolism	   and	   anabolism,	   would	   aid	   in	  
elucidating	   the	  details	  of	   this	   shift	   in	  muscle.	  Examination	  of	   the	  molecular	  activity	  of	  downstream	  
components	   of	   AKT	   such	   as	   mTORC1,	   4E-­‐BP2	   and	   e1F4E,	   associated	   with	   protein	   synthesis	   or	  
FOXO1/3,	   Atrogin-­‐1	   and	   MuRF1,	   connected	   to	   the	   regulation	   of	   degradation,	   could	   be	   used	   to	  
provide	  further	  understanding	  of	  the	  trend	  observed.	  	  
Further	   qualitative	   analysis	   revealed	  no	  discernible	   differences	   in	  MHC	  myofibre	  phenotype	   in	   the	  
Ercc1d/-­‐	   Soleus	   compared	   to	   control.	   This	   finding	   is	   therefore	   unlike	   the	   shift	   to	   a	   slower,	   more	  
oxidative	  phenotype	  observed	  in	  natural	  ageing.	  This	  seems	  to	  be	  a	  surprising	  result,	  when	  the	  loss	  
of	   motor	   neurons	   and	   increased	   denervation	   through	   associated	   degeneration,	   are	   a	   previously	  
reported	  phenomenon	  in	  the	  Ercc1d/-­‐	  animals	  (De	  Waard	  et	  al.	  2010).	  The	  process	  of	  denervation/re-­‐
innervation	   is	  believed	   to	  be	  a	  main	   cause	  of	  myofibre	   typing	   transitions	   (Larsson	  &	  Ansved	  1995;	  
Larsson	   et	   al.	   1991;	   Faulkner	  &	   Brooks	   1995).	   However,	   this	   could	   suggest	   that	  myofibre	   atrophy,	  
resultant	  of	  extensive	  motor	  neuron	  degeneration,	  may	  have	  been	  too	  detrimental	  to	  any	  potential	  
for	   re-­‐innervation.	   Additionally,	   this	   suggests	   that	   also	   unlike	   natural	   ageing,	   the	   faster	   myofibre	  
types	  do	  not	   seem	   the	  most	   susceptible	   to	  atrophy	   (Larsson	  &	  Edström	  1986;	  Rowan	  et	   al.	   2011).	  
Indicating	   that	   more	   wide-­‐spread	   atrophy	   occurred	   in	   Ercc1d/-­‐,	   which	   lead	   to	   an	   overall	   reduced	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myofibre	  number,	  however	  this	  was	  not	  type-­‐specific.	  Furthermore,	  contrastingly	  to	  natural	  ageing,	  
but	   in	   keeping	   with	   the	   consistent	   MHC	   phenotypes,	   there	   was	   no	   evidence	   of	   a	   change	   in	   the	  
percentage	   oxidative	   myofibres	   in	   the	   Ercc1d/-­‐	   Soleus	   muscle.	   However,	   there	   was	   evidence	   of	  
reduced	  capillary	  density,	  suggesting	  that	  oxygen	  delivery	  may	  not	  be	  as	  efficient	  in	  Ercc1d/-­‐	  muscle.	  
This	  therefore,	  is	  in-­‐keeping	  with	  findings	  of	  capillary	  loss	  associated	  with	  natural	  ageing	  (Degens	  et	  
al.	  1993).	  	  
Moreover,	   ROS	   production,	   although	   showing	   slightly	   increased	   levels	   above	   the	   control	   in	   the	  
Ercc1d/-­‐	  mice,	  was	  not	  statistically	  significant.	  An	  explanation	  for	  this	  trend	  could	  suggest	  that	  at	  the	  
rate	  O2-­‐	  ROS	  was	  being	  generated	  as	  a	  by-­‐product	  of	  dysfunctional	  oxidation,	  it	  could	  also	  have	  been	  
sequestered	  at	  a	  reasonably	  equivalent	  efficiency	  by	  antioxidants.	  However,	  further	  analysis	  revealed	  
that	  SOD2	  expression	  levels	  in	  the	  Ercc1d/-­‐	  Soleus,	  were	  unchanged	  compared	  to	  that	  of	  the	  control.	  
As	   it	   is	  known	  that	  SOD2	  expression	   increases	   in	  response	  to	  oxidative	  stress,	   it	  could	  be	  reasoned	  
that	   the	  albeit	  slight	   increases	   in	  O2-­‐	  ROS,	  were	  not	  sufficiently	  detected	   in	  the	  Ercc1d/-­‐,	   in	  order	  to	  
induce	   an	   increase	   in	   SOD2	   expression.	   Moreover,	   SOD2	   requires	   a	   number	   of	   post-­‐translational	  
modifications	  to	  become	  catalytically	  active	  and	  function	  is	  also	  regulated	  further	  at	  a	  protein	  level,	  
for	   example	   by	   cyclins	   and	   p53	   (Ryan	   et	   al.	   2008;	   Candas	   &	   Li	   2014).	   Therefore,	   it	   would	   be	   of	  
interest	  to	  measure	  SOD2	  protein	  levels	  to	  further	  understand	  SOD2	  function	  in	  the	  Ercc1d/-­‐	  as,	  with	  
an	   absence	   of	   regulation	   at	   a	   gene	   expression	   level,	   the	   protein	   level	   may	   provide	   a	   better	  
understanding	  of	  its	  activity.	  Additionally,	  as	  superoxide	  is	  just	  one	  of	  the	  ROS	  that	  can	  play	  a	  role	  in	  
overall	   damage	   of	   DNA,	  mtDNA,	   lipids,	   proteins,	   oxidative	   phosphorylation	   enzymes	   for	   example,	  
there	  are	  also	  many	  other	  free	  radicals	  that	  can	  do	  just	  as	  much	  damage	  if	  levels	  are	  not	  maintained	  
by	  the	  range	  of	  antioxidant	  mechanisms.	  For	  example,	  glutathione	  peroxidase	  (GPX),	  is	  downstream	  
from	   SOD2,	   that	   functions	   in	   the	   detoxification	   of	   H2O2	   to	   water	   (Pieczenik	   &	   Neustadt	   2007).	  
Therefore,	   as	  Ercc1d/-­‐	  has	  been	  previously	   linked	  with	  high	   levels	  of	   oxidative	   stress,	   other	   sources	  
would	  merit	  further	  investigations.	  
The	  effects	  of	  CM	  generated	  from	  ADMSCs	  on	  Ercc1d/-­‐	  Soleus	  muscle	  
phenotype	  	  
Research	  carried	  out	  by	  Lavasani	  and	  colleagues	  in	  2012	  provided	  the	  basis	  for	  the	  hypothesis	  that	  in	  
vivo	  CM	  treatment	  will	  have	  beneficial	  therapeutic	  effects	  in	  the	  skeletal	  muscle	  of	  Ercc1d/-­‐	  mice.	  This	  
landmark	  study	  reported	  that	   in	  vivo	  administration	  of	  young	  muscle	  progenitor/stem	  cells	  into	  the	  
Ercc1d/-­‐	   progeroid	   mice	   resulted	   in	   extended	   lifespan	   and	   ‘healthspan’.	   Furthermore,	   improved	  
characteristics	   of	   regeneration,	   including	   proliferation,	   differentiation	   as	   well	   as	   tissue	  
vascularisation,	  were	  evident	  even	  in	  the	  absence	  of	  transplanted	  donor	  cells	  (Lavasani	  et	  al.	  2012).	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This	  essential	   finding	   therefore	   infers	   rejuvenation	  potential	   released	  by	  young/healthy	  cells	  acting	  
through	   a	   paracrine	   effect	   via	   ‘secreted	   factors’.	   	   Using	   the	   previously	   established	   series	   of	  
parameters,	  investigating	  at	  whole	  organism	  and	  tissue	  levels,	  the	  potential	  therapeutic	  properties	  of	  
ADMSC	  CM	  is	  assessed	  in	  the	  Soleus	  muscle	  of	  Ercc1d/-­‐	  mice.	  
Ercc1d/-­‐	  body	  weight	  appeared	   to	  be	  unaffected	  by	  CM	  treatment.	  However,	   in	   the	  control,	  weight	  
was	   reduced	   compared	   to	   the	   PBS-­‐vehicle	   controls,	   after	   the	   second	   and	   third	   IP	   injections.	   An	  
explanation	   for	   this	   could	   be	   that	   previously	   mentioned	   in	   the	   naturally-­‐aged	   experimentation,	  
where	  it	  was	  suggested	  that	  CM	  could	  modulate	  features	  of	  body	  composition	  and	  body	  fat	  through	  
signalling	   targets	   associated	   with	   lipid	   metabolism,	   as	   seen	   in	   the	   miRNA	   analysis	   of	   the	   CM	  
generated	  from	  AFS	  cells	  (Mellows	  et	  al.	  2017).	  Although,	  the	  control	   littermates	  had	  relatively	  less	  
visible	   fat	   than	  the	  old	  animals	  at	   the	  experimental	  end-­‐point	  and	  as	  previously	  discussed,	  skeletal	  
muscle	  mass	  increases	  are	  known	  to	  contribute	  to	  a	  large	  proportion	  of	  body	  weight	  gain,	  occurring	  
at	  a	  rapid	  pace	  during	  the	  early	  growth	  phase	  of	  mice	  (Gokhin	  et	  al.	  2008).	  It	  could	  be	  suggested	  that	  
CM	   treatment	   instead	   impacted	   on	   the	   rate	   of	   hypertrophy	   when	   compared	   to	   control	   PBS.	  
However,	   when	   this	   data	   was	   analysed	   as	   the	   percentage	   change	   in	   body	   weight,	   this	   previously	  
observed	  difference	  did	  not	  reach	  statistical	  significance.	  
As	  in	  the	  naturally-­‐aged	  series	  of	  experiments,	  CM	  appeared	  to	  have	  no	  additional	  effects	  in	  aspects	  
of	  grip	  strength	  and	  rotarod	  performance,	  muscle	  weight,	  myofibre	  number	  or	  myofibre	  size	   in	  the	  
Ercc1d/-­‐	  Soleus.	  CM	  treatment	  however	  did	  appear	  to	   increase	  the	  proportion	  of	  type	   IIA	  myofibres	  
from	  a	  slightly	  reduced	  percentage	  in	  the	  Ercc1d/-­‐	  muscles	  to	  a	  control	  level.	  This	  could	  suggest	  that	  
CM	  potentially	  prevented	   loss	  of	   the	   faster	   type	   IIA	  myofibres,	  which	   is	   the	   type	  that	   is	   reportedly	  
more	   susceptible	   to	  myofibre	   denervation	   and	   damage	   than	   slower	   types,	   as	   previously	   discussed	  
(Larsson	  &	  Edström	  1986;	  Rowan	  et	  al.	  2011).	  Alternatively,	  CM	  may	  have	  caused	  a	  myofibre	  switch	  
to	   a	   faster	   oxidative	   type	   IIA,	   indicating	   that	   where	   there	   was	   a	   large	   amount	   of	   myofibre	   loss	  
observed	   in	   the	   Ercc1d/-­‐	   Soleus,	   which	   is	   attributed	   to	   motor	   neuron	   degeneration,	   CM	   may	   be	  
assisting	   successful	   re-­‐innervation	   by	   surviving	   motor	   neurons.	   CM	   treatment	   in	   the	   control	   also	  
appeared	   to	  have	  no	   further	   impact	  on	   these	  aspects	  of	  muscle	  physiology	  and	  phenotype.	  Unlike	  
the	   previous	   findings	   in	   the	   naturally-­‐aged	   Soleus,	   the	   oxidative	   capacity	   and	   capillary	   density	  
parameters	  in	  both	  control	  and	  Ercc1d/-­‐,	  appeared	  relatively	  unaffected	  by	  CM	  treatment.	  There	  was	  
a	   slight,	   albeit	   non-­‐significant	   increase	   in	   the	  Ercc1d/-­‐	   capillary	   density	   to	   a	   level	  more	   akin	   to	   that	  
observed	  in	  the	  control,	  therefore	  suggesting	  as	  before,	  that	  CM	  may	  hold	  pro-­‐angiogenic	  potential.	  
This	   again	   would	   be	   in-­‐keeping	   with	   a	   pool	   of	   miRNA	   targets	   identified	   in	   the	   AFS-­‐derived	   CM	  
analysis	   (Mellows	   et	   al.	   2017).	   ROS	   production	   however	   in	   both	   large	   and	   small	   myofibres,	   was	  
remarkably	   greater	   in	  Ercc1d/-­‐	  muscles	  with	  CM	   treatment.	   This	   is	   seemingly	   counterintuitive	   for	   a	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potential	  therapy	  in	  a	  model	  of	  progeria,	  where	  oxidative	  stress	  and	  damage	  through	  ROS	  production	  
would	   only	   exacerbate	   the	   situation.	   A	   possible	   explanation	   for	   this	   could	   be	   that	   as	   O2-­‐	   ROS	  
generation	   is	   known	   to	   be	   a	   by-­‐product	   of	   ‘normal’,	   functional	   oxidative	   metabolism	   within	  
mitochondria,	   if	   in	   the	   instance	   that	   CM	   increased	   the	   rate	   of	   metabolism,	   utilising	   the	   ‘faulty’	  
machinery,	  O2-­‐	  ROS	  may	  have	  been	  produced	  at	  an	  advanced	   rate.	  Secondly,	  accumulated	  O2-­‐	  ROS	  
may	  also	  be	  due	   to	   inadequate	  antioxidant	   activity	  or	   regulation.	   Similar	   to	   the	   findings	   in	  natural	  
ageing,	   SOD2	  mRNA	   levels	   remained	  unchanged	  between	  control	  and	  Ercc1d/-­‐	   conditions,	  with	  and	  
without	   CM	   treatment.	   Therefore,	   it	   could	   be	   postulated	   that	   post-­‐translational	   modulation	   of	  
antioxidant	  activity	  was	   instead	  more	   regulated	   in	  a	  more	  negative	  direction	  with	  CM.	  Thirdly,	   the	  
damage	   caused	   through	   dysfunctional	  mitochondrial	   activity	   in	   the	   Ercc1d/-­‐,	  may	   have	   reached	   an	  
irreversible	   state,	   thus	   any	   potential	   beneficial	   impacts	   on	   metabolism	   and	   stress	   response,	  
maintained	  by	  the	  CM,	  now	  has	   little	  therapeutic	  effect.	  This	  additionally,	  could	  also	  be	  the	  reason	  
behind	   the	   relatively	   unchanged	   oxidative	   capacity	   and	   capillary	   density.	   Collagen	   IV	   thickness,	  
expression	   of	   collagen	   types	   I	   and	   IV	   as	   well	   as	   DGC	   complex	   components,	   dystrophin	   and	   beta-­‐
sarcoglycan	  also	  appeared	  to	  be	  unaltered	  with	  CM	  treatment.	  	  
In	  a	  model	  of	  such	  severe	  and	  rapid	  systemic	  DNA	  damage	  accumulation	  and	  subsequent,	  systematic	  
organ	   failure	   and	   despite	   stunted	   growth,	   the	   Soleus	   phenotype,	   in	   regards	   to	   some	   of	   the	  
physiological	   parameters	   analysed,	   was	   not	   as	   drastically	   altered	   as	   initially	   expected.	  With	   some	  
evidence	  of	  myofibre	  loss,	  surmised	  to	  be	  the	  outcome	  of	  the	  previously	  described	  shift	  to	  a	  survival	  
response.	  Where	  energy	  reserves	  are	  focused	  away	  from	  proliferation	  and	  synthesis	  and	  instead,	  are	  
directed	  towards	  pathways	  of	  genomic	  and	  cellular	  maintenance,	  autophagy	  and	  biological	  material	  
recycling.	  Taken	  together,	  this	  could	  potentially	  signify	  distinct	  differences	  in	  CM	  treatment	  efficacy,	  
in	   altering	   components	   of	   regulation	   to	   bring	   about	   seemingly	   beneficial,	   therapeutic	   (pro-­‐
angiogenic,	   antioxidant,	   ECM	   component)	   changes	   in	   naturally-­‐aged	   muscle,	   compared	   to	   seeing	  
relatively	  little	  impact	  in	  the	  severe	  model	  of	  premature	  ageing.	  As	  concluded	  in	  the	  natural	  ageing	  
series	  of	  experiments,	   the	   therapeutic	   value	  of	  CM	  seems	   to	  be	   the	  ability	   to	   regulate	   (potentially	  
through	  miRNA),	  the	  signalling	  and	  behaviour	  of	  resident	  stem	  and	  existing	  somatic	  cell	  populations,	  
to	   carry	   out	   regeneration	   or	   to	   combat	   age-­‐related	   decline.	   This	   therefore,	   may	   be	   possible	   in	   a	  
system	   where	   the	   survival	   response	   and	   shift	   towards	   maintenance	   may	   not	   be	   quite	   so	   strong.	  
Whereas	   it	   appears	   that	   CM	   treatment	   in	   the	   Ercc1d/-­‐	   model	   is	   not	   as	   capable	   of	   regulating	  
mechanisms	  of	  regeneration,	  to	  counter	  the	  rapid	  onset	  of	  wide-­‐spread	  decline.	  This	  suggests	  that,	  in	  
a	  model	  displaying	  such	  an	  extreme	  survival	  response	  and	  postulated	  systematic	  default	  to	  cellular	  
conservation,	  autophagy	  and	  death,	  the	  control	  of	  these	  mechanisms	  is	  not	  so	  easily	  overridden	  by	  
the	  therapeutic	  paracrine	  effect	  of	  CM.	  Overall,	  it	  could	  be	  hypothesised	  that	  CM	  has	  more	  beneficial	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therapeutic	  value	  in	  systems	  undergoing	  slower,	  more	  chronic	  features	  of	  decline	  and	  dysregulation.	  
Suggesting	   that	   there	   is	   perhaps	   a	   threshold	   at	   which	   point	   the	   paracrine	   effect	   of	   properties	  
harboured	   by	   CM,	   may	   no	   longer	   be	   able	   to	   aid	   in	   balancing	   features	   of	   such	   advanced	   and	  
somewhat	  over-­‐whelming	  signals	  of	  decline	  and	  dysregulation.	  
Numerous	  characteristics	  of	  Ercc1d/-­‐	  skeletal	  muscle	  reflect	  sarcopenia	  in	  
natural	  ageing	  while	  others	  appear	  amplified	  
A	   key	  objective	   of	   the	  project	  was	   to	   determine	   the	   extent	   that	   the	  Ercc1d/-­‐	  mouse	  model	  mimics	  
features	  of	  sarcopenia	  in	  natural	  ageing.	  The	  first	  main	  finding	  when	  comparing	  some	  of	  the	  aspects	  
of	  Soleus	  physiology	  and	  myofibre	  phenotype	  was	  that	  Ercc1d/-­‐	  muscle	  weights	  were	  all	  remarkably	  
lower	   than	   those	   measured	   in	   old	   and	   geriatric	   animals.	   This	   is	   not	   surprising	   when	   the	   well-­‐
documented	   runted	   phenotype	   of	   the	   Ercc1d/-­‐	   is	   considered	   (Weeda	   et	   al.	   1997;	   De	  Waard	   et	   al.	  
2010;	  Dollé	  et	  al.	  2011).	  This	  finding	  is	  even	  more	  remarkable	  as,	  despite	  the	  evidence	  of	  sarcopenia	  
in	  the	  old	  and	  geriatric	  animals,	  as	  well	  as	  the	  particularly	  frail	  appearance	  of	  the	  geriatric	  cohort	  at	  
the	   experimental	   end-­‐point,	   the	   Ercc1d/-­‐	   muscles	   were	   so	   strikingly	   smaller.	   Regarding	   MHC	  
composition,	  as	  previously	  mentioned,	  the	  naturally-­‐aged	  muscles	  exhibit	  an	  established	  switch	  to	  a	  
slower	   myofibre	   phenotype.	   Whereas,	   this	   shift	   was	   not	   observed	   in	   the	   Ercc1d/-­‐	   Soleus.	   This	  
therefore,	   is	   represented	   when	   the	   proportions	   are	   directly	   compared.	   Further	   indicating	   that	  
Ercc1d/-­‐	  Soleus	  muscles	  contain	  greater	  numbers	  of	  faster	  type	  IIX	  and	  IIB	  myofibres,	  whereas	  there	  
are	  very	  few	  present	   in	  old	  and	  geriatric	  muscle.	   It	   is	  surmised	  that	  this	  may	  be	  the	  result	  of	  more	  
wide-­‐spread	  motor	  neuron	  degeneration	  and	  atrophy	   in	   the	  Ercc1d/-­‐	  muscles.	   This	   is	   in	   contrast	   to	  
natural	   ageing	   where	   faster	   myofibre	   types	   are	   reportedly	   more	   susceptible	   to	   denervation	   and	  
damage	   (Larsson	  &	   Edström	  1986;	   Rowan	   et	   al.	   2011).	   Additionally,	  myofibre	   size	   appeared	   to	   be	  
reduced	   in	   the	  Ercc1d/-­‐	  Soleus	   compared	   to	   that	   in	  old	  and	  geriatric	   animals,	   significantly	   so	   in	   the	  
faster	  myofibre	   types.	   As	   hypertrophy	   is	   a	   key	   feature	   determining	  muscle	   growth,	   this	   finding	   is	  
consistent	   with	   the	   overall	   stunted	   size	   of	   Ercc1d/-­‐	   animals.	   Moreover,	   as	   previously	   discussed,	   it	  
could	  be	   suggested	   that	   the	  naturally-­‐aged	  animals	   are	   experiencing	   a	   shift	   towards	  maintenance,	  
away	  from	  growth,	  as	  a	  survival	  response	  with	  the	  onset	  and	  development	  of	  sarcopenia.	  However,	  
this	   survival	   response	   appears	   to	   be	   further	   amplified	   in	   the	   severe	   Ercc1d/-­‐	   model	   of	   premature	  
ageing.	  This	  could	   further	  suggest	  that	  the	  severity	  of	   the	  DNA	  damage	  accumulation	  has	  caused	  a	  
large	   majority	   of	   regulation	   of	   signalling	   pathways	   to	   default	   towards	   apoptosis,	   autophagy	   and	  
necrosis.	  	  
Out	   of	   the	   physiological	   parameters	   measured	   in	   the	   Ercc1d/-­‐	   Soleus,	   that	   arguably	   mimic	  
characteristics	  observed	  in	  natural	  ageing	  include	  oxidative	  capacity,	  ROS	  production	  and	  antioxidant	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activity.	  In	  contrast,	  features	  that	  appear	  to	  occur	  to	  a	  more	  extreme	  degree	  than	  in	  natural	  ageing,	  
include	   evidence	   of	  myofibre	   atrophy	   and	   greatly	   reduced	  muscle	  weight,	  myofibre	   CSA,	   capillary	  
density,	   collagen	   thickness	   and	   DGC	   component,	   dystrophin	   expression.	   Whereas,	   a	   feature	   that	  
seems	   to	   display	   an	   alternative	   trend	   to	   that	   noted	   in	   natural	   ageing	   was	   MHC	   composition,	  
exhibiting	  an	  overall	  faster	  phenotype	  in	  the	  Ercc1d/-­‐	  Soleus.	  Capillary	  density,	  collagen	  thickness	  and	  
also	   dystrophin	   levels	   were	   reduced	   in	   the	   Ercc1d/-­‐	   Soleus	   however,	   these	   are	   trends	   that	   are	  
arguably	   less	  surprising	  when	  the	  reduced	  myofibre	  size	   is	  also	  considered.	  This	  therefore	  suggests	  
that	   blood	   supply	   and	   basement	  membrane	   collagen	   IV	   and	   dystrophin	   content	   are	   ‘scaled-­‐down’	  
proportionately	   to	   serve	   the	   smaller	   Ercc1d/-­‐	   myofibre.	   In	   conclusion,	   the	   Soleus	   muscle	   profile	  
developed	   in	   the	   Ercc1d/-­‐	   progeric	   model,	   shares	   a	   number	   of	   characteristics	   with	   the	   onset	   and	  
progression	   of	   sarcopenia	   in	   natural	   ageing.	   In	   contrast,	   the	   severity	   of	   the	   DNA	   damage	  
accumulation	  ultimately	  results	  in	  some	  seemingly	  amplified	  features	  that	  far	  exceed	  those	  observed	  
in	  natural	  ageing.	  These	  would	  potentially	  continue	  to	  surpass	  those	  levels	  experienced	  by	  the	  most	  
moribund	  naturally-­‐aged	  animals,	   if	  allowed	  to	  survive	   to	  end-­‐of-­‐life.	   It	   can	  also	  be	  concluded	  that	  
the	   Ercc1d/-­‐	   mouse	   also	   demonstrated	   a	   distinct	   Soleus	  MHC	  myofibre	   composition	  which	   did	   not	  
mimic	  the	  phenotype	  shift	  that	  is	  well-­‐documented	  in	  natural	  ageing.	  Overall,	  these	  characteristics	  of	  
the	   Ercc1d/-­‐	   Soleus	   drive	   the	   notion	   that	   the	   Ercc1d/-­‐	   model	   is	   one	   displaying	   features	   of	   ‘super-­‐
ageing’,	  from	  a	  skeletal	  muscle	  aspect.	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It	   has	   been	   previously	   established	   in	   the	   literature	   that	   there	   are	   notable	   changes	   that	   occur	   to	  
satellite	   cell	   (SC)	   number	   and	   function	  with	   age.	   It	   is	  well-­‐reported	   that	   SCs	   exhibit	   a	   reduction	   in	  
proliferation	  and	  self-­‐renewal,	   thereby	   leading	  to	  a	  depleted	  stem	  cell	  pool,	  with	  age	  (Collins	  et	  al.	  
2007;	  Shefer	  et	  al.	  2006).	  Stem	  cell	  exhaustion	  is	  one	  of	  the	  hallmarks	  of	  ageing,	  along	  with	  increased	  
cellular	   senescence	   (López-­‐otín	   et	   al.	   2013).	   Studies	   have	   established	   that	   SCs	   experience	  
‘geroconversion’	   and	   enter	   an	   irreversible	   state	   of	   senescence,	   leading	   to	   these	   declines	   in	   SC	  
number	  attributed	  to	  a	  reduction	  in	  proliferative	  capacity	  (Sousa-­‐Victor	  et	  al.	  2014;	  García-­‐Prat	  et	  al.	  
2016).	  Colleagues	  have	  previously	   reported	  a	   reduction	   in	  aged	  SC	  migration	  speeds,	  alterations	   in	  
amoeboid-­‐based	   motility	   through	   abnormal	   bleb	   dynamics,	   as	   well	   as	   a	   delayed	   activation	   and	  
emergence	   of	   aged	   SCs	   (Collins-­‐Hooper	   et	   al.	   2012).	   SC	   activation	   and	   subsequent	   emergence,	   is	  
known	   to	   occur	   upon	   myofibre	   injury	   or	   damage,	   or	   induced	   in	   this	   study	   by	   isolating	   single	  
myofibres,	  within	  the	  initial	  24	  hours	  (Collins-­‐Hooper	  et	  al.	  2012;	  Zammit	  et	  al.	  2004).	  Hereafter,	  SCs	  
proliferate	   and	   migrate	   along	   myofibres,	   while	   MyoD	   and	   Myf5	   co-­‐expression	   demonstrates	  
commitment	  to	  a	  myogenic	  lineage	  by	  48	  hours	  (Zammit	  2002;	  Cornelison	  &	  Wold	  1997;	  Cooper	  et	  
al.	  1999).	  As	  important	  steps	  in	  the	  process	  of	  skeletal	  muscle	  myofibre	  regeneration,	  any	  declines	  in	  
the	   function	  of	   these	  underlying	   features,	   impact	  on	   the	  potential	   for	  efficient	  and	  effective	   repair	  
and	  have	  therefore,	  been	  implicated	  in	  muscular	  dystrophies	  as	  well	  as	  sarcopenia	  (Collins-­‐Hooper	  et	  
al.	  2012;	  Gutmann	  &	  Carlson	  1976;	  Schultz	  &	  Lipton	  1982;	  Yin	  et	  al.	  2013).	  To	  analyse	  and	  document	  
the	  characteristics	  of	  SC	  function,	  parameters	  were	  measured	  at	  a	  cellular	  level	  in	  order	  to	  develop	  a	  
more	  detailed	  skeletal	  muscle	  profile	  for	  both	  natural	  ageing	  and	  the	  Ercc1d/-­‐	  progeria	  model.	  
Importantly,	   findings	  reported	  by	  Johnny	  Huard	  and	  colleagues,	   indicated	  the	  therapeutic	  potential	  
of	   the	   secretome	   of	   young	   stem/progenitor	   cells,	   in	   the	   ability	   to	   restore	   the	   dysfunction	  
demonstrated	  by	  aged	  and	  progeric	  stem	  cells,	  regarding	  proliferation	  and	  differentiation	  processes	  
(Lavasani	  et	  al.	  2012).	  These	  findings	  are	  an	  extension	  to	  the	  landmark	  studies	  reported	  by	  Conboy	  
and	   colleagues	   that	   saw	   similar	   rejuvenating	   effects	   in	   aged	   SC	   proliferative	   and	   differentiation	  
potential,	   from	   circulating	   factors	   in	   young	   serum,	   using	   a	   heterochronic	   (young/old)	   parabiosis	  
system	  (Conboy	  et	  al.	  2003;	  Conboy	  et	  al.	  2005).	  Using	  these	  reported	  findings	  as	  a	  platform,	  a	  series	  
of	   experiments	   were	   conducted	   in	   order	   to	   investigate	   the	   effects	   of	   our	   human	   adipose-­‐derived	  
mesenchymal	   stem	   cell	   (hADMSC)	   conditioned	  media	   (CM)	   on	   key	  mechanisms	   of	   skeletal	  muscle	  
satellite	   cell	   regeneration	   in	   both	   natural	   ageing,	   as	   well	   as	   in	   the	   Ercc1d/-­‐	   progeria	   model.	   As	  
previously	   described,	   the	   Ercc1d/-­‐	   mouse	   has	   been	   reported	   to	   demonstrate	   segmental	   age-­‐
associated	  functional	  decline	  and	  some	  of	  these	  features	  have	  been	  classified	  based	  on	  the	  rate	  that	  
these	  symptoms	  are	  acquired,	  relative	  to	  natural	  ageing	  (Dollé	  et	  al.	  2011).	  Lavasani	  and	  colleagues	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reported	   defective	   proliferation	   and	   differentiation	   potential	   in	   Ercc1d/-­‐	   muscle-­‐derived	   progenitor	  
cells	  isolated	  and	  cultured	   in	  vitro	  (Lavasani	  et	  al.	  2012).	  However,	  these	  aspects	  of	  SC	  activity	  have	  
yet	  to	  be	  fully	  characterised,	  alongside	  the	  other	  vital	  mechanisms	  of	  SC	  function	  (such	  as	  emergence	  
and	  migration),	  within	  the	  single	  myofibre	  microenvironment.	  The	  aim	  of	  this	  series	  of	  experiments	  
was	  to	  investigate	  the	  mechanisms	  underpinning	  SC	  activity,	  which	  are	  well-­‐known	  to	  undergo	  age-­‐
associated	   deterioration	   during	   sarcopenia,	   in	   the	   Ercc1d/-­‐	   model	   of	   progeria.	   Additionally,	   the	  
suitability	   of	   the	   Ercc1d/-­‐	   progeric	   mouse,	   as	   a	   model	   of	   accelerated	   natural	   muscle	   ageing	   at	   a	  
cellular	   level,	   can	   be	   assessed.	   Lastly,	   as	  with	   the	   naturally-­‐aged	   experimentation,	   the	   therapeutic	  






Conditioned	  media	  reversed	  the	  abnormally	  advanced	  emergence	  trend	  
observed	  in	  naturally	  aged	  satellite	  cells	  
In	  order	  to	  visualise	  the	  locations	  of	  SCs	  during	  the	  process	  of	  emergence,	  an	  immunocytochemical	  
protocol	  was	  used	  to	  determine	  the	  positions	  of	  SCs	  (identified	  by	  Pax7	  expression),	  relative	  to	  the	  
basal	  lamina	  (indicated	  by	  laminin	  expression)	  (Collins-­‐Hooper	  et	  al.	  2012;	  Otto	  et	  al.	  2011).	  Initially,	  
it	  was	  observed	  that	  at	  T0,	   the	  point	  of	  single	  myofibre	   isolation,	  the	  majority	  of	  SCs	  were	  present	  
beneath	   the	   basal	   lamina	   layer	   (‘IN’),	   for	   the	   young	   (98.8%),	   old	   PBS	   (97.1%)	   and	   old	   CM	   (97.2%)	  
conditions,	   compared	   to	   those	  beginning	   to	   emerge	   (‘50%’	   or	   ‘partially	   emerged’)	   or	   those	  having	  
emerged,	  residing	  on	  the	  outside	  surface	  of	  single	  myofibres	  (‘OUT’)	  (p	  =	  <0.001,	  respectively)	  (Figure	  
5.1	  A,	  B,	  C,	  D)	  .	  There	  were	  no	  significant	  differences	  observed	  between	  cohorts	  in	  the	  percentage	  of	  
SCs	  ‘IN’,	  ‘50%’	  emerged	  or	  ‘OUT’	  at	  T0.	  By	  T24	  however,	  58.2%	  of	  young	  SCs	  remained	  in	  a	  sub-­‐basal	  
position,	   significantly	   more	   than	   those	   fully	   emerged	   (29.4%)	   and	   those	   that	   were	   undergoing	  
emergence	   (12.4%),	   at	   that	   time	   (p	   =	   <0.01	   and	   <0.001,	   respectively)	   (Figure	   5.1	   E,	   F,	   G,	   H).	  
Interestingly,	   in	   the	   old	   age	   cohort	   at	   T24,	   fewer	   SCs	   remained	   beneath	   the	   surface	   layer	   (18.1%)	  
compared	  to	  those	  that	  had	  emerged	  (51.3%)	  (p	  =	  <0.05)	  and	  the	  remaining	  30.6%	  of	  cells	  that	  were	  
in	  the	  process	  of	  emerging.	  Although,	  as	  observed	  with	  young	  control	  SCs,	  CM	  treatment	  in	  old	  age	  
resulted	   in	   a	   larger	   percentage	  of	   cells	   yet	   to	   emerge	   (51.4%)	   compared	   to	   the	   20.6%	  undergoing	  
emergence	   (p	   =	   <0.05),	   with	   the	   remaining	   28%	   of	   SCs	   having	   completely	   emerged.	   Moreover,	  
analysis	   between	   age	   and	   treatment	   groups	   further	   indicates	   these	   findings,	   that	   there	   was	   a	  
substantially	  smaller	  proportion	  of	  SCs	  under	  the	  basement	  membrane	  compared	  to	  young	  and	  Old	  
CM-­‐treated	  cultures	  (p	  =	  <0.01,	  respectively).	  The	  proportion	  of	  SCs	  50%	  and	  fully	  emerged	  were	  not	  




Figure	   5.1	   Conditioned	   media	   reversed	   the	   abnormally	   advanced	   emergence	   trend	   observed	   in	  
naturally	   aged	   satellite	   cells.	   (A-­‐D)	   The	   analysis	   of	   SCs	   positioning	   relative	   to	   the	   basal	   lamina,	   as	  
quantified	   by	   proportion	   of	   cells	   ‘IN’	   (inside/under),	   ‘50%’	   (in	   the	   process	   of	   emerging)	   and	   ‘OUT’	  
(outside/over),	  at	  T0,	  concomitant	  with	  SC	  activation	  and	  subsequent	  emergence.	  (E-­‐H)	  An	  abnormal	  
proportion	  of	  aged	  SCs	  were	  undergoing	  or	  has	  successfully	  emerged	  at	  T24.	  This	  pattern	  appeared	  
to	  be	  reversed	  by	  CM.	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	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Conditioned	  media	  greatly	  increased	  satellite	  cell	  migration	  speeds	  in	  old	  age	  
SC	  migration	  speeds	  have	  previously	  been	  shown	  to	  decrease	  with	  age	  (Collins-­‐Hooper	  et	  al.	  2012).	  
However,	   it	   is	  currently	  unknown	  whether	  the	  underlying	  mechanisms	  regulating	  cell	  migration	  can	  
be	   influenced	   by	   components	   maintained	   by	   CM	   treatment.	   Migrating	   SCs	   on	   myofibres	   were	  
monitored	   from	  T24	   to	  T48,	  at	  10x	  magnification	  using	   time-­‐lapse	  microscopy	  and	  average	   speeds	  
were	  calculated	   for	  each	  age	  and	  treatment	  group.	  Firstly,	   it	  was	  noted	  that	  cell	  migration	  speeds,	  
despite	  being	  slightly	  reduced	  from	  young	  (45.2µm/h)	  to	  adult	  (38.3µm/h)	  ages	  and	  then	  increasing	  
again	   in	   old	   (42.8µm/h)	   and	   geriatric	   (47.9µm/h)	   ages,	   these	   fluctuations	   were	   not	   statistically	  
significant	  (Figure	  5.2	  A).	  Remarkably	  however,	  despite	  SC	  migration	  speeds	  remaining	  constant	  with	  
age,	  CM	   treatment	   considerably	   increased	   the	   velocities	  of	   aged	  SCs,	  when	   compared	   to	  both	   the	  
adult	  and	  old	  age	  control	  groups	  (p	  =	  <0.05)	  (Figure	  5.2	  A).	  
Satellite	  cells	  adopt	  a	  rounded	  morphology	  on	  both	  adult	  and	  aged	  single	  
myofibres	  
Cellular	   characteristics	   such	   as	   the	   morphologies	   adopted	   by	   cells	   analysed	   can	   provide	   basic	  
indications	  as	  to	  which	  of	  the	  two	  methods	  of	  cell	  migration	  SCs	  were	  utilising	  at	  the	  point	  of	  single	  
myofibre	   fixation.	   These	   two	   mechanisms	   of	   motility	   include	   the	   more	   traditionally	   reported	  
lamellipodia-­‐mediated	  traction	  whereas	  the	  more	  recently	  established	  blebbing	  or	  amoeboid-­‐based	  
method,	   defined	   in	   SC	   movement	   during	   the	   process	   of	   muscle	   regeneration,	   is	   shown	   to	   be	  
associated	   with	   an	   increased	   velocity	   (Otto	   et	   al.	   2011).	   An	   elongated	   (mesenchymal)	   cellular	  
appearance,	   suggests	   migration	   via	   the	   former,	   lamellipodia-­‐driven	   mechanism	   and	   on	   the	   other	  
hand,	   a	  more	   rounded	  morphology,	   indicates	   that	   a	   SC	  may	   be	   utilising	   the	   latter,	   the	   amoeboid	  
bleb-­‐based	  mechanism.	   Single	  myofibres	   fixed	   and	   analysed	   at	   T48	   using	   an	   immunofluorescence	  
protocol	   to	   identify	   the	  organisation	  of	  alpha	  smooth	  muscle	  actin	   (SMA),	  paired	  with	  an	  antibody	  
against	   myogenic	   marker	   MyoD,	   to	   detect	   the	   SCs	   and	   classify	   the	   frequencies	   that	   ‘round’	   or	  
‘elongated’	  morphologies	  were	  adopted.	  It	  was	  noted	  that	  SCs	  at	  both	  young	  and	  old	  age	  (with	  and	  
without	  CM	  treatment),	  took	  on	  a	  more	  rounded	  morphology,	  compared	  to	  those	  more	  elongated	  (p	  
=	   <0.001,	   respectively)	   (Figure	   5.2	   B).	   However,	   there	   was	   a	   slightly	   reduced	   proportion	   of	   SCs	  
observed	   adopting	   a	   round	  morphology	   at	   old	   age	   (93.7%)	   and	   again	  with	   CM	   treatment	   (85.2%),	  
when	   compared	   to	   100%	   of	   young	   SCs	   (Figure	   5.2	   C).	   This	   was	   therefore	   accompanied	   by	   a	  
corresponding	  increased	  percentage	  of	  elongated	  cells	  (6.3	  and	  14.8%,	  respectively),	  although	  these	  
differences	   were	   statistically	   not	   significant	   (Figure	   5.2	   D).	   Thus,	   the	  majority	   of	   SCs	   observed	   on	  




Figure	   5.2	   Conditioned	   media	   greatly	   increased	   satellite	   cell	   migration	   speeds	   in	   old	   age.	   (A)	   SC	  
migration	  speeds	  determined	  for	  young	  (3	  months),	  adult	  (6	  months),	  old	  (24	  months),	  geriatric	  (27-­‐
30	  months)	   and	   old	   CM-­‐treated	  myofibre	   conditions.	   (B)	   The	  majority	   of	   young,	   old	   and	   old	   CM-­‐
treated	   SCs	   were	   observed	   adopting	   a	   round	   form.	   Significance	   indicated	   between	   round	   and	  
elongated	  morphologies	  ***p<0.001	   (C)	  The	  proportion	  of	  rounded	  cells	  was	  no	  different	  between	  
cohorts	   (D)	   The	   proportion	   of	   elongated	   cells	   was	   no	   different	   between	   cohorts.	   *p<0.05,	  
***p<0.001,	  (A,	  C,	  D)	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  (B)	  Individual	  student’s	  t-­‐tests.	  	  
	  
Conditioned	  media	  did	  not	  enhance	  the	  diminished	  proliferative	  potential	  of	  
aged	  satellite	  cells	  
SC	  proliferation	  has	  been	  shown	  to	  be	  diminished	  with	  increasing	  age	  and	  has	  also	  been	  associated	  
with	   increased	   cellular	   senescence	   and	   apoptosis	   and	   an	   overall	   depleted	   stem	   cell	   pool	   (Collins	  
2006;	  Collins	  et	  al.	  2007;	  Schultz	  &	  Lipton	  1982;	  Collins-­‐Hooper	  et	  al.	  2012;	  García-­‐Prat	  et	  al.	  2016;	  
Sousa-­‐Victor	   et	   al.	   2014;	   Wang	   et	   al.	   2014;	   Shefer	   et	   al.	   2006).	   The	   dysfunction	   underlying	   this	  
reduction	   in	   SC	   proliferative	   capacity	   in	   ageing	   however,	   was	   remarkably	   restored	   through	  
experimentation	  exploring	  rejuvenating	  properties	  as	  part	  of	  a	  paracrine	  effect	  (Conboy	  et	  al.	  2003;	  
Conboy	  et	  al.	  2005;	  Lavasani	  et	  al.	  2012).	  Thus,	  it	  remains	  to	  be	  seen	  whether	  the	  ADMSC	  CM	  used	  in	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the	   current	   study,	   contains	   similar	   regulatory	   potential	   in	   enhancing	   the	   proliferative	   capacity	   of	  
aged	  SCs.	  
Pax7,	   the	  SC	  marker	  of	  quiescence,	  was	  used	   in	   immunocytochemical	  protocols	  on	  single	  myofibre	  
cultures	   fixed	   at	   the	   earlier	   time-­‐points	   (T0	   and	   T24),	   whereas	   at	   T48,	  MyoD,	   a	  myogenic	  marker	  
expressed	   later	   in	   the	   SC	  differentiation	  pathway,	  was	  used	   to	   identify	   individual	   or	   groups	  of	   SCs	  
along	  myofibres	  over	   time	  to	  monitor	  proliferation.	  Average	  cells	  per	  myofibre	  were	  quantified,	  as	  
well	  as	  the	  number	  of	  sites	  or	  events	  (clusters),	  that	  cells	  appeared	  along	  myofibres.	  The	  size	  of	  these	  
clusters	  (number	  of	  cells	  per	  cluster)	  were	  additionally	  analysed.	  Firstly,	   it	  was	  noted	  that	  young	  SC	  
populations	  at	  T0	  had	  an	  average	  of	  2.1	   cells	  per	  myofibre	  which	   subsequently	  almost	  doubled	  by	  
T24	  to	  4.8	  cells	  (Figure	  5.3	  A).	  Following	  this,	  from	  T24	  to	  48,	  further	  proliferation	  resulted	  in	  more	  
than	  double	  the	  number	  of	  cells	  within	  this	   time	  to	  an	  average	  of	  11.6	   (p	  =	  <0.001).	  Secondly,	   this	  
was	   not	   the	   case	   in	   aged	   conditions	   (with	   and	   without	   CM	   treatment)	   (Figure	   5.3	   A).	   Despite	   a	  
consistent	  T0	  starting	  average	  number	  of	  cells	  to	  that	  of	  young	  myofibres,	  initial	  proliferation	  within	  
the	  first	  24	  hours	  was	  not	  evident.	  By	  T48,	  the	  average	  number	  of	  cells	  had	  risen	  to	  4.3,	  a	  significant	  
increase	   to	   those	   observed	   at	   T0	   (p	   =	   <0.05),	   but	   statistically	   no	   different	   to	   T24.	   Moreover,	   SC	  
numbers	  did	  not	  change	  significantly	  from	  those	  present	  at	  T0,	  in	  the	  48-­‐hour	  culture	  duration	  in	  old	  
age	  with	  CM	  treatment	  (Figure	  5.3	  A).	  	  
Analysis	  of	  SC	  clusters	  or	  events	  along	  the	  myofibres	  showed	  an	  increase	  in	  young	  SC	  clusters	  from	  
T0	  to	  24,	  from	  an	  average	  of	  1.8	  to	  4	  clusters	  and	  to	  5.5	  at	  T48	  (p	  =	  <0.05,	  respectively	  and	  p	  =	  <0.001	  
between	  T0	  and	  48)	  (Figure	  5.3	  B).	  In	  old	  age,	  the	  number	  of	  SC	  clusters	  did	  not	  change	  in	  the	  initial	  
24	   hours	   of	   culture,	   but	   subsequently,	   increased	   from	  1.8	   to	   3.3	   cell	   clusters	   from	  T24	   to	   48	   (p	   =	  
<0.05)	  (Figure	  5.3	  B).	  As	  observed	  previously	  with	  the	  average	  cells	  per	  myofibre	  in	  old	  age	  with	  CM	  
treatment,	   similarly,	   the	   number	   of	   clusters	   did	   not	   change	   during	   the	   48	   hours	   of	   culture.	  
Furthermore,	  the	  number	  of	  cells	  per	  cluster	  (cluster	  size)	  increased	  only	  in	  the	  young	  SC	  population,	  
doubling	   from	  single	   cell	   events	  at	  T0	  and	  24	   time-­‐points	   to	   clusters	   containing	  2	   cells	   at	  T48	   (p	   =	  
<0.001,	  respectively).	  In	  contrast,	  old	  SC	  populations	  (with	  or	  without	  CM	  treatment),	  were	  observed	  
as	  single	  cells	  throughout	  the	  48-­‐hour	  culture	  period	  (Figure	  5.3	  C).	  	  
When	   this	   data	  was	   analysed	   between	   age	   and	   treatment	   groups,	   it	  was	   noted	   that	   there	  were	   no	  
discernible	   differences	   in	   the	   number	   of	   cells	   or	   clusters	   per	   myofibre	   and	   cluster	   size	   remained	  
constant,	   at	   T0	   (Figure	   5.3	   D,	   E,	   F).	   By	   T24	   however,	   following	   the	   initial	   proliferation	   previously	  
described	   in	   young	   SC	   populations,	   the	   number	   of	   cells	   per	  myofibre	  was	   significantly	   greater	   than	  
those	  present	   in	  old	  PBS	  and	  CM	  conditions	   (p	   =	  <0.001	  and	  <0.05,	   respectively)	   (Figure	  5.3	  G).	  This	  
increase	  in	  the	  young	  SC	  population	  was	  also	  evident	  when	  the	  number	  of	  clusters	  per	  myofibre	  at	  T24	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were	  compared	  to	  those	  in	  the	  old	  PBS	  and	  CM	  cohorts	  (p	  =	  <0.001	  and	  <0.01,	  respectively)	  (Figure	  5.3	  
H).	   There	   were	   no	   observed	   differences	   in	   cluster	   size	   between	   age	   and	   treatment	   groups	   at	   T24	  
(Figure	  5.3	  I).	  Lastly,	  following	  the	  further	  population	  doubling	  seen	  from	  T24	  to	  48,	  the	  number	  of	  cells	  
per	   myofibre	   at	   T48	   were	   greatly	   increased	   in	   young	   SCs	   when	   compared	   to	   old	   PBS	   and	   old	   CM	  
conditions	  (p	  =	  <0.05	  and	  <0.01,	  respectively)	  (Figure	  5.3	  J).	  An	  observed	  decreased	  number	  of	  clusters	  
per	   myofibre	   between	   young	   and	   old	   age	   and	   again	   with	   CM	   treatment,	   were	   statistically	   not	  
significant	   (Figure	   5.3	   K).	   However,	   the	   cluster	   sizes	   quantified	   in	   old	   age	   (with	   and	   without	   CM	  
treatment)	  at	  T48	  were	  notably	  reduced	  when	  compared	  to	  those	  in	  young	  SCs	  (p	  =	  <0.05	  and	  <0.01,	  
respectively)	   (Figure	   5.3	   L).	   Therefore,	   the	   number	   of	   SCs	   and	   cell	   clusters	  were	   greatly	   reduced	   on	  





Figure	  5.3	  Conditioned	  media	  did	  not	  enhance	  the	  diminished	  proliferative	  potential	  of	  aged	  satellite	  
cells	  (A-­‐C)	  SC	  proliferation	  recorded	  as	  cells	  per	  myofibre,	  clusters	  per	  myofibre	  and	  cluster	  size.	  (D-­‐
F)	  Very	  few	  cells	  were	  present	  on	  myofibres	  at	  T0,	  in	  all	  three	  conditions,	  young,	  old	  and	  old	  CM	  (G-­‐I)	  
By	  T24,	  young	  SCs	  had	  proliferated,	  whereas	  old	  SCs	  had	  not.	  (J-­‐L)	  By	  48,	  young	  SCs	  had	  continued	  to	  
proliferate	   further,	  while	  old	  SCs	   increased	   in	  quantity	   slightly,	  CM	  treatment	  appeared	   to	  perturb	  
this,	  already	  diminished	  capacity.	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  One-­‐way	  ANOVA	  with	  Tukey	  post	  
hoc	  testing.	  
	  
Conditioned	  media	  advanced	  satellite	  cell	  emergence	  in	  the	  Ercc1d/-­‐	  model	  of	  
progeria	  
The	  essential	  underlying	  mechanisms	  of	  SC	  reparative	  function,	  emergence,	  migration,	  proliferation	  
and	  differentiation,	  were	  subsequently	  characterised	  in	  the	  progeric	  Ercc1d/-­‐	  murine	  model.	  As	  before	  
with	  the	  natural	  ageing	  experimentation,	  SCs,	  following	  activation	  through	  single	  myofibre	  isolation	  
at	  T0,	  emergence	   from	   the	  original	   sub-­‐basal	   location	  was	  analysed	  using	  an	   immunocytochemical	  
protocol	  for	  Pax7	  and	  laminin,	  between	  T20	  and	  24	  time-­‐points.	  At	  T20,	  the	  majority	  of	  SCs	  remained	  
inside	   the	   basal	   lamina	   layer	   in	   both	   the	   control	   (+/+)	   (78.5%)	   and	   Ercc1d/-­‐	   (d/-­‐)	   (86.5%)	   vehicle-­‐
treated	  (PBS)	  conditions,	  relative	  to	  both	  those	  cell	  populations	  50%	  and	  fully	  emerged	  (p	  =	  <0.001,	  
respectively)	   (Figure	   5.4	   A).	   Additionally,	   there	   was	   an	   increased	   proportion	   of	   cells	   undergoing	  
emergence	  (16.4%)	  in	  the	  control	  PBS	  condition,	  compared	  to	  those	  fully	  emerged	  (5.2%),	  at	  the	  T20	  
culture	  point	   (p	  =	  <0.05)	   (Figure	  5.4	  A).	  Examination	  of	   the	  Ercc1d/-­‐	  CM-­‐treated	  condition	  however,	  
showed	  no	  statistical	  differences	  and	  therefore	   indicated	  that	   there	  were	  equal	  proportions	  of	  SCs	  
that	  remained	  beneath	  the	  basal	   lamina	   layer,	   that	  had	  emerged	  half-­‐way	  and	  those	  that	  had	  fully	  
emerged	  by	  T20	  (Figure	  5.4	  A).	  	  
Moreover,	   when	   exploring	   this	   result	   further	   between	   cohorts,	   it	   was	   noted	   that	   there	   were	  
distinctly	  fewer	  SCs	  positioned	  at	  a	  sub-­‐basal	  location	  in	  the	  Ercc1d/-­‐	  CM	  condition	  (42.9%),	  compared	  
to	  the	  Ercc1d/-­‐	  PBS	  (86.5%)	  and	  control	  PBS	  (78.5%)	  (p	  =	  <0.001	  and	  <0.01,	  respectively)	  (Figure	  5.4	  B).	  
There	   were	   no	   statistical	   differences	   in	   the	   percentage	   of	   cells	   that	   were	   50%	   emerged	   at	   T20,	  
between	   the	   control	   PBS,	  Ercc1d/-­‐	   PBS	   and	  Ercc1d/-­‐	   CM	   cohorts,	   16.4,	   12.5	   and	   19.6%,	   respectively	  
(Figure	  5.4	  C).	  Consequently,	  the	  proportion	  of	  SCs	  of	  the	  Ercc1d/-­‐	  CM	  cohort	  (37.5%)	  were	  shown	  to	  
have	   fully	  emerged	  at	   this	  earlier	   time-­‐point,	   remarkably	   increased	   relative	   to	   the	  control	  PBS	  and	  
Ercc1d/-­‐	  PBS	  (p	  =	  <0.001,	  respectively)	  (Figure	  5.4	  D).	  
By	   T24,	   the	  majority	   of	   SCs	  were	   still	   yet	   to	   fully	   emerge	   in	  both	   the	   control	   PBS	   and	  Ercc1d/-­‐	   PBS	  
cultures	   (p	   =	   <0.001)	   (Figure	   5.4	   E).	   Whereas,	   the	   majority	   of	   Ercc1d/-­‐	   CM	   SCs	   had	   fully	   emerged	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(54.6%,	   p	   =	   <0.001,	   relative	   to	   those	   half-­‐way	   emerged),	   with	   only	   36.5%	   at	   a	   sub-­‐basal	   position	  
(Figure	  5.4	  E).	  This	  trend	  was	  further	  evident	  when	  comparing	  the	  positions	  of	  SCs	  between	  cohorts,	  
similarly	   to	   those	  described	   at	   T20.	   The	  proportion	  of	   SCs	   that	  were	   residing	   under	   the	  basement	  
membrane	   at	   T24	   were	   greatly	   reduced	   in	   the	   Ercc1d/-­‐	   CM	   condition,	   relative	   to	   control	   PBS	   and	  
Ercc1d/-­‐	   PBS	   (p	   =	   <0.01,	   respectively)	   (Figure	   5.4	   F).	   As	   with	   the	   earlier	   time-­‐point	   (T20),	   the	  
percentages	  of	  cells	  undergoing	  emergence	  were	  statistically	  no	  different	  between	  groups	  (Figure	  5.4	  
G).	  However,	  there	  was	  a	  greatly	  increased	  proportion	  of	  Ercc1d/-­‐	  CM	  SCs	  fully	  emerged	  by	  T24,	  when	  
compared	   to	   control	   PBS	   and	  Ercc1d/-­‐	   PBS	   (p	   =	   <0.001	   and	   <0.01,	   respectively)	   (Figure	   5.4	  H).	   The	  
effect	  of	  CM	  treatment	  in	  the	  control	  animals	  on	  SC	  emergence	  was	  investigated.	  At	  T20,	  the	  results	  
indicated	   no	   discernible	   differences	   in	   the	   proportions	   of	   SCs	   that	   were	   undergoing	   emergence,	  
those	   that	   had	   fully	   emerged	   or	   those	   residing	   interior	   to	   the	   basal	   lamina	   (Figure	   5.4	   i).	   CM	  
treatment	   in	   the	   controls	   by	   T24	   however,	   indicated	   a	   50%	   reduction	   in	   SCs	   yet	   to	   emerge	   and	   a	  
remarkable	  corresponding	  increase	  in	  the	  proportion	  of	  SCs	  fully	  emerged,	  relative	  to	  the	  control	  PBS	  




Figure	   5.4	  Conditioned	  media	   advanced	   satellite	   cell	   emergence	   in	   the	  Ercc1d/-­‐	  model	   of	   progeria.	  
The	  analysis	  of	  SCs	  positioning	  relative	  to	  the	  basal	   lamina,	  as	  quantified	  by	  proportion	  of	  cells	   ‘IN’	  
(inside/under),	   ‘50%’	   (in	   the	   process	   of	   emerging)	   and	   ‘OUT’	   (outside/over).	   (A-­‐D)	  By	   T20,	   a	   large	  
proportion	  of	  Ercc1d/-­‐	  SCs	   treated	  with	  CM	  had	  emerged	   in	  an	  advanced	  fashion.	   (E-­‐H)	  By	  T24,	   this	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advanced	  emergence	  trend	  had	  continued.	  (i)	  At	  T20,	  CM	  treatment	  did	  not	  influence	  emergence	  of	  
the	   control	   SCs.	   (ii)	  By	   T24,	   however,	   control	   CM	   SCs	   has	   also	   emerged	   at	   a	  more	   advanced	   rate	  
compared	   to	   control	   SCs.	   *p<0.05,	   **p<0.01,	   ***p<0.001,	   (A-­‐H)	  One-­‐way	  ANOVA	  with	   Tukey	   post	  
hoc	  testing.	  (i,	  ii)	  Individual	  student’s	  t-­‐tests.	  	  
	  
Increased	  Ercc1d/-­‐	  satellite	  cell	  migration	  speeds	  were	  returned	  to	  control	  
velocities	  with	  conditioned	  media	  treatment	  
SC	  migration	  speeds	  were	  also	  determined	  for	  each	  treatment	  group	  as	  part	  of	  the	  progeric	  Ercc1d/-­‐	  
investigation.	  Time-­‐lapse	  microscopy	  was	  used	  to	  capture	  SC	  movement	  and	  behaviour	  from	  T24	  and	  
48	   time-­‐points	   following	   SC	   activation,	   initiated	   at	   the	   point	   of	   single	  myofibre	   isolation	   (T0).	   The	  
results	   showed	   that	   while	   the	   average	   SC	   migration	   speed	   recorded	   in	   the	   control	   PBS	   was	  
48.3µm/h,	  the	  progeric	  Ercc1d/-­‐	  PBS	  SCs	  travelled	  at	  a	  remarkably	  faster	  rate	  of	  63.3µm/h	  (p	  =	  <0.01)	  
(Figure	  5.5	  A).	  Contrastingly,	  CM	  treatment	  reduced	  the	  average	  speed	  of	  motility	  of	  Ercc1d/-­‐	  SCs	  to	  
52.7µm/h	  (p	  =	  <0.05),	  therefore,	  returning	  to	  a	  rate,	  although	  slightly	  quicker	  than	  that	  of	  the	  control	  
PBS	  SCs,	  statistically	  no	  different	  to	  control	  PBS	  (Figure	  5.5	  A).	  CM	  treatment	  in	  the	  control	  animals	  
however,	  had	  no	  discernible	  effects	  on	  SC	  migration	  speed	  (Figure	  5.5	  B).	  	  
Ercc1d/-­‐	  satellite	  cells	  display	  the	  distinctive	  rounded	  morphology	  
Furthermore,	  information	  regarding	  morphology	  frequencies	  and	  basic	  indications	  as	  to	  the	  methods	  
of	  SC	  motility	  along	  myofibres	  in	  each	  condition,	  was	  gathered	  in	  the	  Ercc1d/-­‐	  experimentation,	  as	  per	  
the	   protocol	   carried	   out	   for	   the	   natural	   ageing	   series.	   For	   example,	   ‘round’	   or	   ‘elongated’	   SC	  
morphologies	  were	  visualised	  and	  classified	  using	  immunocytochemistry	  of	  single	  myofibres	  fixed	  at	  
T48	  to	  detect	  MyoD/SMA	  expression.	  As	  seen	   in	  the	  young	  and	  natural-­‐aged	  SCs,	  the	  predominant	  
morphologies	  adopted	  for	  migration	  along	  myofibres	  in	  each	  control	  and	  Ercc1d/-­‐	  condition	  (PBS	  and	  
CM)	   were	   those	   more	   rounded	   (p	   =	   <0.001,	   respectively)	   (Figure	   5.5	   C).	   The	   SC	   morphology	  
frequencies,	   when	   compared	   between	   cohorts,	   indicated	   a	   slight	   reduction	   in	   the	   proportion	   of	  
round	   cells,	   from	  98%	   in	   control	  PBS	  and	  Ercc1d/-­‐	   PBS	   to	  90%,	   in	   the	  Ercc1d/-­‐	   CM-­‐treated	   condition	  
(Figure	  5.5	  C,	  D).	  As	  well	  as	  a	  corresponding	  increase	  in	  those	  with	  an	  elongated	  form	  in	  Ercc1d/-­‐	  CM	  
SCs,	  however	  these	  observed	  differences	  were	  statistically	  not	  significant	  (Figure	  5.5	  C,	  E).	  Moreover,	  




Figure	  5.5	   Increased	  Ercc1d/-­‐	  satellite	  cell	  migration	  speeds	  were	  returned	  to	  control	  velocities	  with	  
conditioned	  media	  treatment	  (A)	  Ercc1d/-­‐	  SCs	  demonstrated	  a	  remarkably	  increased	  rate	  of	  migration	  
however,	   CM	   appeared	   to	   reverse	   this	   to	   a	   control	   SC	   speed	   (B)	   CM	   did	   not	   influence	   control	   SC	  
velocity.	   (C-­‐E)	  Ercc1d/-­‐	   SCs	   adopted	  a	   characteristic	   rounded	  morphology	  and	  CM	  did	  not	  have	  any	  
significant	   effect	   on	   cell	   shape.	   (C)	   Significance	   represented	   between	   round	   and	   elongated	  
morphologies	   ***p<0.001.	   (F)	   CM	   also	   did	   not	   influence	   the	   control	   SC	   morphology.*p<0.05,	  





The	  diminished	  Ercc1d/-­‐	  satellite	  cell	  number	  and	  proliferative	  capacity	  could	  
not	  be	  restored	  by	  conditioned	  media	  
As	  in	  the	  naturally-­‐aged	  series	  of	  experiments,	   immunofluorescent	  identification	  of	  Pax7	  and	  MyoD	  
was	   used	   at	   fixation	   points	   (T0,	   24	   and	   48)	   to	   monitor	   SC	   proliferation,	   another	   key	   component	  
process	  in	  muscle	  repair.	  In	  addition,	  during	  the	  series	  of	  analyses	  to	  investigate	  those	  differences	  in	  
the	  progeric	  model,	  myofibres	  were	  also	  fixed	  at	  a	  later	  time-­‐point	  after	  72	  hours	  culture	  following	  
myofibre	  isolation	  (T72)	  to	  extend	  the	  time	  frame	  in	  which	  proliferation	  could	  be	  examined.	  Firstly,	  
quantification	  of	   the	  number	  of	  cells	  per	  myofibre	  revealed	  that	   in	   the	  control	  SC	  populations,	   the	  
largest	   increases	   in	  SC	  numbers	  occurred	  after	  the	   initial	  24	  hours	  of	  culture,	   from	  4	  -­‐	  6	  cells	  at	  T0	  
and	  T24,	   to	  13	   -­‐	  14	  cells	  at	  T48	  and	  T72	   (p	   =	  <0.001,	   respectively)	   (Figure	  5.6	  A).	  CM	  treatment	   in	  
control	  animals	  showed	  a	  similar	  trend,	  with	  increased	  SC	  numbers	  from	  T0	  and	  24	  to	  48	  (p	  =	  <0.01)	  
and	  again	   to	  19	   cells	   at	   T72	   (p	   =	  <0.001)	   (Figure	  5.6	  A).	   SC	  numbers	   in	   the	  Ercc1d/-­‐	   conditions	  also	  
remained	  consistent	  in	  the	  first	  24	  hours	  of	  culture	  (T0	  -­‐	  24)	  however	  average	  number	  of	  2	  cells	  per	  
myofibre	  was	  observed	  at	  these	  early	  time	  points	  (Figure	  5.6	  A).	  Increased	  SC	  numbers	  were	  seen	  by	  
T48	  and	  72	  (4	  –	  4.5	  cells	  per	  myofibre,	  respectively)	  in	  the	  Ercc1d/-­‐	  PBS	  control	  cultures	  (statistically	  
significant	   at	   T72	   only,	  p	   =	   <0.05)	   (Figure	   5.6	   A).	   CM	   treatment	   in	   progeric	   animals	   resulted	   in	   SC	  
numbers	  peaking	  at	  T48,	  increasing	  from	  an	  average	  of	  less	  than	  2	  cells	  per	  myofibre	  at	  T0	  to	  4	  cells	  
at	  T48	  (p	  =	  <0.05)	  and	  remaining	  consistent	  with	  no	  further	  proliferation	  noted	  between	  T48	  and	  72	  
(Figure	  5.6	  A).	  Furthermore,	  the	  number	  of	  clusters	  per	  myofibre	  increased	  from	  T24	  (5.3	  clusters),	  
peaking	  at	  T48	  (9	  clusters)	  in	  the	  control	  groups	  (p	  =	  <0.01,	  respectively)	  (Figure	  5.6	  B).	  Subsequently,	  
cluster	  numbers	  were	  decreased	  in	  the	  control	  PBS	  between	  48	  and	  72	  hours	  culture	  to	  5.5	  clusters	  
(p	   =	   <0.01)	   (Figure	   5.6	   B).	   Meanwhile,	   with	   CM	   treatment	   control	   SC	   cluster	   numbers	   remained	  
consistent	  at	  T72	  with	  those	  counted	  at	  T48	  (8	  –	  9	  clusters),	  significantly	  more	  than	  T24	  (p	  =	  <0.05).	  
SC	  cluster	  numbers	  in	  the	  progeric	  myofibre	  cultures	  (with	  and	  without	  CM	  treatment)	  however,	  did	  
not	  change	  notably	  over	  the	  72-­‐hour	  culture	  period	  (approximately	  3	  clusters	  per	  myofibre)	  (Figure	  
5.6	  B).	  Moreover,	  average	  SC	  cluster	  sizes	   increased	  in	  control	  myofibre	  cultures	  (with	  and	  without	  
CM	  treatment)	  significantly	  from	  1	  –	  1.5	  cells	  per	  cluster,	  at	  the	  earlier	  time-­‐points	  (T24	  and	  T48),	  to	  
2.5	  cells	  at	  T72	  (p	  =	  <0.001,	  respectively)	  (Figure	  5.6	  C).	  Additionally,	  the	  number	  of	  cells	  per	  cluster	  
in	  the	  Ercc1d/-­‐	  PBS	  condition	  doubled	  from	  single	  cells	  to	  clusters	  of	  2	  cells	  between	  T24	  and	  72	  (p	  =	  
<0.01,	  respectively)	  (Figure	  5.6	  C).	  
Analysis	  of	  SC	  proliferation	  between	  cohorts	  showed	  that	  at	  each	  time-­‐point	  (T0,	  24,	  48	  and	  72)	  the	  
number	  of	  SCs	  per	  myofibre	  were	  significantly	  greater	   in	  the	  control	  PBS	  cultures	  compared	  to	  the	  
Ercc1d/-­‐	  PBS	  and	  Ercc1d/-­‐	  CM	  conditions	  (p	  =	  <0.001,	  respectively)	  (Figure	  5.6	  D-­‐G).	  A	  similar	  trend	  was	  
observed	  with	   an	   increased	  number	  of	   clusters	  per	  myofibre	   in	   the	   control	   PBS	  at	   T24,	   48	  and	  72	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culture	  points	  (p	  =	  <0.001,	  respectively)	  (Figure	  5.6	  H-­‐J).	  Contrastingly,	  cluster	  sizes	  were	  significantly	  
larger	  in	  Ercc1d/-­‐	  CM	  SC	  populations	  at	  T24,	  relative	  to	  those	  in	  the	  control	  and	  Ercc1d/-­‐	  PBS	  cultures	  (p	  
=	  <0.01,	  respectively)	  (Figure	  5.6	  K).	  By	  T48	  however,	  there	  were	  no	  statistical	  differences	  in	  cluster	  
size	  between	  the	  groups	  (Figure	  5.6	  L).	  Furthermore,	  Ercc1d/-­‐	  CM	  average	  cluster	  sizes	  were	  notably	  
reduced	  from	  2.5	  cells	  per	  cluster	  to	  1.7	  cells	  at	  T72	  (p	  =	  <0.05)	  (Figure	  5.6	  M).	  Lastly,	  CM	  treatment	  
in	   control	   animals	   resulted	   in	   no	   discernible	   differences	   in	   the	   number	   of	   SCs	   per	  myofibre	  when	  
compared	   to	   those	   without	   CM	   (Figure	   5.6	   i).	   Subsequently,	   CM	   however	   showed	   an	   increased	  
number	  of	  clusters	  per	  myofibre	  at	  T72	  compared	  to	  the	  control	  PBS	  (p	  =	  <0.05)	  but	  there	  were	  no	  




Figure	   5.6	   The	   diminished	   Ercc1d/-­‐	   satellite	   cell	   number	   and	   proliferative	   capacity	   could	   not	   be	  




Figure	  5.6	  Continued.	  The	  diminished	  Ercc1d/-­‐	   satellite	  cell	  number	  and	  proliferative	  capacity	  could	  
not	  be	  restored	  by	  conditioned	  media	  (A-­‐C)	  SC	  proliferation	  recorded	  as	  cells	  per	  myofibre,	  clusters	  
per	  myofibre	   and	   cluster	   size.	   (D-­‐G)	   Ercc1d/-­‐	   SCs	   demonstrated	   a	   severely	   diminished	   proliferative	  
capacity,	  the	  number	  of	  SCs	  per	  myofibre	  was	  unchanged	  during	  the	  72-­‐hour	  culture	  period.	  (H-­‐J)	  A	  
similar	  trend	  was	  noted	  with	  the	  number	  of	  clusters	  per	  myofibre.	  CM	  treatment	  did	  not	   influence	  
Ercc1d/-­‐	   SC	  proliferative	  potential.	   (K-­‐M)	  SCs	  were	  observed	  primarily	  as	   single	  cells	   in	  each	  culture	  
condition,	   CM	   treatment	   appeared	   to	   alter	  Ercc1d/-­‐	   cluster	   sizes	   (i,	   ii,	   iii)	   	   CM	   treatment	   showed	  a	  
slight	   increase	   in	   control	   SCs	   (non-­‐significant)	   and	   clusters	   (*p<0.05)	   per	   myofibre.	   *p<0.05,	  
**p<0.01,	   ***p<0.001,	   (A-­‐M)	   One-­‐way	   ANOVA	   with	   Tukey	   post	   hoc	   testing.	   (i,	   ii,	   iii)	   Individual	  
student’s	  t-­‐tests.	  
	  
Ercc1d/-­‐	  satellite	  cells	  exhibited	  a	  normal	  commitment	  to	  myogenic	  
differentiation	  and	  conditioned	  media	  delayed	  myogenin	  expression	  
To	  investigate	  the	  differentiation	  potential	  Ercc1d/-­‐	  SCs,	  myofibres	  were	  cultured	  and	  fixed	  at	  T24,	  48	  
and	  72	  following	  isolation	  and	  immunocytochemical	  protocols	  carried	  out	  to	  detect	  Pax7,	  MyoD	  (T24	  
and	  48)	  and	  myogenin	   (T72).	   In	  order	   to	  examine	  any	  differences	   in	  SC	  myogenic	  differentiation	   in	  
the	  Ercc1d/-­‐	  progeric	  model,	  as	  well	  as	  to	  determine	  the	  effects	  of	  CM	  treatment	  on	  this	  parameter,	  
the	   control	   and	   Ercc1d/-­‐	   SC	   populations	   (PBS-­‐	   and	   CM-­‐treated)	   were	   compared.	   Firstly,	   it	   was	  
observed	  that	  at	  T24	   the	  SC	  populations	  of	  all	   four	  cohorts	  predominantly	  co-­‐expressed	  both	  Pax7	  
and	  MyoD	  ‘double’	  (ranging	  from	  84	  to	  94%),	  significantly	  more	  than	  either	  marker	  expressed	  singly	  
(p	  =	  <0.001,	  respectively)	  (Figure	  5.7	  A).	  Additionally,	  Ercc1d/-­‐	  CM	  SCs	  showed	  increased	  expression	  of	  
Pax7	  individually	  (17%),	  relative	  to	  that	  of	  MyoD	  only	  (1%)	  (p	  =	  <0.05)	  (Figure	  5.7	  A).	  At	  T48,	  similarly,	  
the	  majority	  of	  SCs	  continued	  to	  co-­‐express	  Pax7	  and	  MyoD	  (86	  to	  99%),	  compared	  to	  either	  alone	  (p	  
=	   <0.001,	   respectively)	   (Figure	   5.7	   B).	   However	   by	   T72,	   when	   analysing	   Pax7	   and	   myogenin	  
expression,	   a	   greater	   proportion	   of	   SCs	   in	   the	   control	   PBS	   and	   Ercc1d/-­‐	   PBS	   conditions	   were	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myogenin-­‐positive	   only	   (69	   and	   84%,	   respectively),	   significantly	   more	   than	   those	   expressing	   Pax7	  
only	  or	  double	  (p	  =	  <0.001,	  respectively)	  (Figure	  5.7	  C).	  	  
With	   CM	   treatment,	   control	   SCs	   showed	   significantly	   greater	   expression	   of	   Pax7	   and	   myogenin	  
individually	  than	  combined	  (p	  =	  <0.001,	  respectively)	  (Figure	  5.7	  C).	  Statistical	  analysis	  of	  the	  Ercc1d/-­‐	  
CM	  SCs,	   indicated	  that	  neither	  Pax7,	  myogenin	  alone	  nor	  double	  expression,	  comprised	  the	   largest	  
proportion	   (Figure	   5.7	   C).	   Furthermore,	   when	   comparing	   the	   differences	   in	   myogenic	   marker	  
expression	   between	   groups	   at	   the	   three	   time-­‐points	   it	   was	   noted	   that	   there	   were	   no	   statistically	  
significant	  variations	   in	  Pax7,	  MyoD	  individual	  or	  double	  expression	  at	  T24	  (Figure	  5.7	  D,	  E,	  F).	  This	  
was	  also	   the	   trend	  observed	  at	  T48	  where	  proportions	  of	   SC	  populations	  expressing	   the	  myogenic	  
markers	  were	   consistent	   between	   cohorts	   (Figure	   5.7	  G,	   H,	   I).	   At	   T72,	   despite	   a	   slightly	   increased	  
proportion	  of	  Ercc1d/-­‐	  CM	  SCs	  recorded	  expressing	  Pax7,	  relative	  to	  the	  control	  PBS	  and	  Ercc1d/-­‐	  PBS,	  
these	  differences	  were	  statistically	  not	  significant	  (Figure	  5.7	  J).	  Double	  expression	  of	  both	  Pax7	  and	  
myogenin	   however	   in	   the	   CM-­‐treated	   Ercc1d/-­‐	   SCs,	   was	   notably	   greater	   when	   compared	   to	   the	  
Ercc1d/-­‐	  PBS	  (p	  =	  <0.05)	  (Figure	  5.7	  K).	  Additionally,	  myogenin	  expression	  alone	  in	  the	  Ercc1d/-­‐	  CM	  SC	  
population	  at	  T72	  was	  distinctly	  less	  than	  the	  Ercc1d/-­‐	  control	  (p	  =	  <0.01)	  (Figure	  5.7	  L).	  CM	  treatment	  
in	  control	  animals	  also	  indicated	  that	  at	  T24	  there	  were	  no	  discernible	  differences	  in	  the	  proportions	  
of	   SCs	  expressing	  Pax7,	  MyoD	  or	  both	   (Figure	  5.7	   i).	  At	   T48,	  CM	   increased	   the	  percentage	   SCs	   co-­‐
expressing	   both	   myogenic	   markers,	   from	   86	   to	   99%	   (p	   =	   <0.001)	   (Figure	   5.7	   ii).	   Moreover,	   CM	  
treatment	  showed	  that	  a	  greater	  proportion	  of	  SCs	  continued	  to	  express	  Pax7	  by	  T72,	  as	  well	  as	  a	  





Figure	   5.7	   Ercc1d/-­‐	   satellite	   cells	   exhibited	   a	   normal	   commitment	   to	   myogenic	   differentiation	   and	  





Figure	   5.7	   Continued.	   Ercc1d/-­‐	   satellite	   cells	   exhibited	   a	   normal	   commitment	   to	   myogenic	  
differentiation	  and	  conditioned	  media	  delayed	  myogenin	  expression.	  (A-­‐C)	  Myogenic	  differentiation	  
expression	   at	   T24,	   T48	   (Pax7,	   MyoD),	   and	   T72	   (Pax7,	   myogenin).	   (D-­‐F)	   T24	   expression	   of	   Pax7,	  
Double	   and	   MyoD	   between	   cohorts.	   (G-­‐I)	   T48	   expression	   of	   Pax7,	   Double	   and	   MyoD	   between	  
cohorts.	  (J-­‐L)	  T72	  expression	  of	  Pax7,	  Double	  and	  MyoD	  between	  cohorts.	  (i,	   ii,	   iii)	  Effect	  of	  CM	  on	  
control	   SC	   differentiation	   *p<0.05,	   **p<0.01,	   ***p<0.001,	   (A-­‐L)	  One-­‐way	   ANOVA	  with	   Tukey	   post	  
hoc	  testing.	  (i,	  ii,	  iii)	  Individual	  student’s	  t-­‐tests.	  
	  
Characteristics	  of	  Ercc1d/-­‐	  satellite	  cell	  function	  exhibit	  a	  ‘super	  ageing’	  
phenotype	  compared	  to	  natural	  ageing	  
Importantly,	  an	  objective	  of	  the	  current	  study	  is	  to	  establish	  the	  suitability	  of	  the	  Ercc1d/-­‐	  mouse	  as	  a	  
model	  of	  natural	  ageing,	  for	  use	   in	  potential	   future	  sarcopenia	   intervention	  approaches.	  Therefore,	  
the	   parameters	   measured	   at	   a	   cellular	   level,	   to	   characterise	   SC	   number	   and	   function,	   can	   be	  
compared	   to	   those	   findings	   reported	   in	   the	   natural	   ageing	   series	   of	   experiments.	   The	   first	   finding	  
indicated	   that	   a	   large	   proportion	   of	   Ercc1d/-­‐	   SCs,	   approximately	   70%,	   were	   delayed	   in	   their	  
emergence	  from	  their	  sub-­‐laminal	  position	  at	  T24	  compared	  to	  18%	  of	  old	  SCs	  (p	  =	  <0.001)	  (Figure	  
5.8	   A).	   Correspondingly,	   therefore,	   larger	   proportions	   of	   old	   SCs	   were	   either	   in	   the	   process	   of	  
emerging,	  or	  had	  fully	  emerged	  by	  T24,	  relative	  to	  Ercc1d/-­‐	  SCs	  (p	  =	  <0.05,	  respectively)	  (Figure	  5.8	  B,	  
C).	  In	  regards	  to	  the	  average	  speed	  of	  SC	  migration,	  it	  was	  observed	  that	  Ercc1d/-­‐	  SCs	  migrated	  faster	  
(63.3µm/h)	   than	   both	   old	   (42.8µm/h)	   and	   geriatric	   (47.9µm/h)	   SCs	   (Figure	   5.8	   D).	   However,	   this	  
increase	  was	  statistically	  significant	  relative	  to	  the	  old	  SC	  speeds	  only	  (p	  =	  <0.001).	  When	  comparing	  
the	  morphologies	  assumed	  by	  Ercc1d/-­‐	  SCs	  to	  those	  seen	   in	  old	  age,	  while	  the	  majority	  of	  SCs	  were	  
rounded	   in	   shape,	   98	   and	   94%	   respectively,	   statistically	   there	   were	   no	   differences	   between	   the	  
groups	  when	  the	  morphologies	  were	  analysed	  individually	  (Figure	  5.8	  E,	  F).	  Moreover,	  the	  number	  of	  
cells	   and	   clusters	   per	   myofibre	   were	   consistent	   between	   naturally-­‐aged	   and	   Ercc1d/-­‐	   myofibre	  
cultures.	  Old	  SC	  cluster	  sizes	  were	  slightly	  increased	  relative	  to	  Ercc1d/-­‐	  sizes	  at	  T24	  (p	  =	  <0.05)	  (Figure	  




Figure	   5.8	   Characteristics	   of	   Ercc1d/-­‐	   satellite	   cell	   function	   exhibit	   a	   ‘super	   ageing’	   phenotype	  
compared	  to	  natural	  ageing.	  (A-­‐C)	  Ercc1d/-­‐	  SC	  showed	  a	  delayed	  emergence	  compared	  to	  naturally-­‐
aged	  SCs.	  Indicated	  by	  the	  percentage	  of	  SCs	  observed	  inside/under	  the	  basal	  lamina	  (‘IN’),	  partially	  
emerged	   (‘50%’)	   and	   those	   positioned	   on	   the	   outer	   membrane	   of	   the	   basal	   lamina	   having	   fully	  
emerged	  (‘OUT’).	  (D)	  Ercc1d/-­‐	  SCs	  migrated	  at	  faster	  velocities	  compared	  to	  old	  and	  geriatric	  SCs.	  (E-­‐F)	  
Both	   aged	   and	   Ercc1d/-­‐	   SCs	   adopted	   a	   round	   morphology.	   (G-­‐I)	   Both	   aged	   and	   Ercc1d/-­‐	   SCs	  
demonstrated	   a	   diminished	   proliferative	   capacity	   *p<0.05,	   ***p<0.001,	   (D)	  One-­‐way	   ANOVA	  with	  





Mammalian	   skeletal	   muscle	   in	   adulthood	   is	   a	   stable	   postmitotic	   tissue,	   which	   under	   normal	  
conditions,	  requires	  only	  periodic	  fusion	  of	  the	  resident	  stem	  cells,	  satellite	  cells	  (SCs),	  in	  response	  to	  
daily	   wear	   and	   tear,	   to	   compensate	   for	   overall	   muscle	   turnover.	   However,	   upon	   injury	   skeletal	  
muscle	   maintains	   a	   remarkable	   ability	   to	   regenerate	   damaged	   myofibres.	   The	   degeneration	   and	  
subsequent	   regeneration	   process	   is	   highly	   regulated	   at	   molecular,	   cellular	   and	   tissue	   levels	   and	  
results	   in	   renewal	   of	   contractile	   units,	   that	   are	   fully	   innervated	   and	   vascularised.	   This	   process	   is	  
dependent	   on	   SCs	   and	   the	   intrinsic	   factors	   that	   govern	   the	   underlying	   mechanisms	   of	   their	  
regenerative	  function,	  as	  well	  as	  the	  interactions	  with	  the	  muscle	  stem	  cell	  microenvironment	  (niche)	  
through	  extrinsic	  factors.	  SCs	  remain	  quiescent	  beneath	  the	  basal	  lamina	  until	  activated	  in	  response	  
to	  damage	  or	  injury.	  Following	  activation,	  SCs	  proceed	  to	  emerge	  from	  their	  sub-­‐laminal	  position	  to	  
the	   myofibre	   surface,	   where	   they	   migrate,	   proliferate,	   differentiate	   and	   subsequently	   fuse	   to	  
maintain	   existing	  myofibres	   or	   comprise	   newly	   formed	  myofibres.	   The	   declines	   in	   skeletal	  muscle	  
regenerative	  potential	  with	  age	  are	  consistently	  attributed	  to	  reductions	  in	  SC	  number	  and	  function.	  
In	  1976,	  Gutmann	  and	  Carlson	  observed	  that	  aged	  skeletal	  muscle	  maintains	  the	  ability	  to	  regenerate	  
however,	  the	  rate	  of	  regeneration	  is	  reduced	  with	  age	  (Gutmann	  &	  Carlson	  1976).	  Research	  into	  this	  
notion	   has	   since	   continued	   and	   has	   revealed	   fewer	   SCs	   in	   aged	   muscle,	   reduced	   myogenic	  
progression	   and	   differentiation	   as	  well	   as	   increased	   SC	   apoptosis	   (Collins	   et	   al.	   2007).	   Schultz	   and	  
Lipton	  reported	  that	  SCs	  isolated	  from	  the	  EDL	  and	  Soleus	  muscles	  of	  aged	  rats,	  showed	  a	  diminished	  
capacity	   for	   generating	   progeny	   and	   that	   initiation	   of	   this	   activity	   was	   delayed,	   indicating	   overall	  
compromised	   SC	   activation	   and	   proliferation	   (Schultz	   &	   Lipton	   1982).	   However,	   Collins	   and	  
colleagues	   also	   reported	   that	   despite	   the	   overall	   SC	   depletion	   in	   old	   age,	   a	   minority	   of	   the	   SC	  
population	  generated	  large	  clusters	  of	  progeny	  as	  well	  as	  a	  distinct	  population	  of	  differentiated	  cells.	  
This	   finding	   indicated	   that	   this	   small	   proportion	  of	   the	   ageing	   SC	  pool	   could	   regenerate	  muscle	   as	  
effectively	  as	  observed	  in	  the	  larger	  SC	  populations	  of	  young	  myofibres,	  but	  could	  explain	  the	  overall	  
reduced	   rate	   of	   regenerative	   associated	  with	   old	   age	   (Collins	   et	   al.	   2007).	   Additionally,	   colleagues	  
have	  previously	  established	   that	  aged	  murine	  SCs	  demonstrate	  delayed	  activation,	  emergence	  and	  
differentiation,	  as	  well	  as	  a	  decreased	  rate	  of	  migration	  and	  alterations	  to	  the	  amoeboid-­‐based	  form	  
of	   motility	   associated	   with	   abnormal	   bleb	   dynamics	   (Collins-­‐Hooper	   et	   al.	   2012).	   Therefore,	   it	   is	  
evident	  that	  age-­‐related	  declines	  in	  regenerative	  function	  and	  regulation	  impacts	  each	  aspect	  of	  SC	  
activity.	  This	  suggests	  that	  research	  into	  potential	  therapeutic	  strategies	  may	  be	  required	  to	  analyse	  
and	  target	  each	  of	  the	  underlying	  mechanisms	  compromised	  during	  ageing.	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In	   recent	  decades,	   research	  has	   focused	  on	  SCs	  and	   their	  niche,	   in	  order	   to	  better	  understand	   the	  
interactions	  between	  them	  and	  to	  develop	  therapeutic	  approaches.	  These	  approaches	  aim	  to	  target	  
the	   dysregulation	   and	   dysfunction	   implicated	   in	   physiological	   and	   pathological	   conditions,	   such	   as	  
those	   reported	   in	   sarcopenia	   and	   muscular	   dystrophies,	   where	   regenerative	   capacity	   is	  
compromised.	   A	   number	   of	   strategies	   so	   far,	   have	   concentrated	   on	   stem	   or	   progenitor	   cell	  
transplantation	  and	  rely	  on	  donor	  cell	  integration,	  differentiation	  and	  engraftment	  into	  damaged	  or	  
impaired	   tissue	   (Péault	   et	   al.	   2007;	   Satoh	   et	   al.	   1993;	   Lafreniere	   et	   al.	   2004).	   Myoblasts,	   bone	  
marrow	   stem	   cells	   (BMSCs),	   mesangioblasts,	   pericytes,	   embryonic	   stem	   (ES)	   cells	   and	   induced	  
Pluripotent	  Stem	  (iPS)	  cells	  are	  among	  the	  cell	  types	  examined	  regarding	  their	  potential	  to	  carry	  out	  
myogenic	  regeneration	  as	  forms	  of	  cell-­‐based	  therapy	  (Yin	  et	  al.	  2013).	  However,	  these	  approaches	  
have	   resulted	   in	   limited	   success	   and	   although	   stem	   cells	   are	   often	   associated	   with	   measurable	  
features	  of	  amelioration	  in	  pathology,	  donor	  cells	  experience	  high	  levels	  of	  rapid	  cell	  death,	   initiate	  
an	   immune	   response	   and	   show	   minimal	   intramuscular	   migration	   and	   incorporation	   (Satoh	   et	   al.	  
1993;	   Lafreniere	  et	   al.	   2004;	  Péault	   et	   al.	   2007;	  Partridge	  2000;	  Briggs	  &	  Morgan	  2013).	   For	   these	  
reasons,	  alternative	  strategies	  have	  moved	  away	  from	  the	  concept	  of	  whole	  cell-­‐based	  approaches	  
and	  instead	  have	  fuelled	  research	  into	  the	  notion	  that	  stem	  cells	  mediate	  tissue	  renewal	  and	  overall	  
enhancement	   through	   factors	   released	   as	   a	   paracrine	   effect.	   In	   ageing	   muscle	   this	   concept	   was	  
developed	   further	   through	  a	  series	  of	  heterochronic	  parabiosis	  experiments	  conducted	  by	  Conboy,	  
Rando	   and	   colleagues.	   These	   experiments	   demonstrated	   that	   systemic	   factors	   circulating	   in	   the	  
vasculature	  of	  young	  mice	  had	  rejuvenating	  effects	  in	  aged	  mice	  (Conboy	  et	  al.	  2005).	  Notably,	  one	  
mechanism	  that	   this	  was	  believed	  to	  be	  achieved	  was	  through	  modification	  of	   the	  Notch	  signalling	  
pathway,	  up-­‐regulation	  of	  which	  is	  known	  to	  diminish	  with	  age	  (Conboy	  &	  Rando	  2002).	  Therefore,	  it	  
was	   concluded	   that	   factors	   present	   in	   the	   young	   serum	   enhanced	   the	   proliferative	   and	   overall	  
regenerative	   capacity	   of	   aged	   SCs	   (Conboy	   et	   al.	   2005).	   Additionally,	   in	   the	   Ercc1d/-­‐	   model	   of	  
premature	   ageing	   utilised	   in	   the	   present	   project,	   a	   landmark	   study	   conducted	   by	   Lavasani	   and	  
colleagues	   concluded	   similarly,	   that	   ‘secreted	   factors’	   from	   young	   control	  muscle	   stem/progenitor	  
cells	   introduced	   intraperitoneally	   into	   progeric	  mice	   extended	   lifespan	   and	   improved	   regenerative	  
function	   (Lavasani	   et	   al.	   2012).	   As	   before,	   limited	   engraftment	   into	   host	   muscles	   was	   noted	   and	  
beneficial	   effects	   such	   as	   improved	   proliferation,	   differentiation	   as	   well	   as	   indications	   of	   neo-­‐
vascularisation	   were	   evident	   even	   where	   transplanted	   donor	   cells	   were	   not	   detected,	   further	  
suggesting	  a	  paracrine	  effect.	  
These	   findings	   were	   used	   as	   a	   basis	   in	   the	   formation	   of	   the	   following	   hypotheses	   which	  
subsequently,	  directed	  investigation	  at	  a	  cellular	  level	  through	  the	  current	  series	  of	  experiments.	  The	  
first	   hypothesis	   builds	   on	   what	   is	   reported	   in	   the	   literature	   and	   investigates	   the	   notion	   that	   the	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decline	   in	   regenerative	   function	   observed	   in	   natural	   ageing,	   is	   attributed	   to	   deterioration	   of	  
mechanisms	   intrinsic	   to	   the	   ageing	   skeletal	  muscle	   satellite	   cell.	   Secondly,	   extending	   this	   body	   of	  
work	  into	  the	  Ercc1d/-­‐	  experimentation,	  similarly,	  the	  mechanisms	  of	  SC	  function	  were	  investigated	  in	  
order	  to	  document	  the	  characteristics	  of	  skeletal	  muscle	  regenerative	  function	  in	  the	  progeric	  model.	  
Importantly,	   this	  work	  aims	  to	   further	  our	  knowledge	  of	   these	  processes	   in	  a	  murine	  model	   that	   is	  
continuing	  to	  display	  features	  that	  could	  be	  described	  as	  ‘super-­‐ageing’.	  The	  third	  hypothesis	  is	  that	  
the	   regenerative	   capacity	   is	   enhanced	   in	   skeletal	   muscle	   of	   aged	   mice	   treated	   with	   ADMSC	   CM.	  
Finally,	   as	   in	   natural	   ageing,	   the	   hypothesis	   that	   ADMSC	   CM	   treatment	   harbours	   therapeutic	  
potential	   in	   the	  enhancement	  of	   SC	   regenerative	   function	   in	  Ercc1d/-­‐	  mice	  was	   also	  examined.	   The	  
platform	   therefore,	   for	   this	   work	   relies	   on	   the	   important	   landmark	   findings	   regarding	   the	  
rejuvenating	  potential	  of	  secreted	  factors	  from	  stem	  cells.	  These	  beneficial	  properties	  are	  believed	  to	  
function	  through	  therapeutic	  paracrine	  effects,	  rather	  than	  more	  traditional,	  whole	  stem	  cell-­‐based	  
approaches.	  	  
Characterisation	  of	  mechanisms	  of	  satellite	  cell	  numbers	  and	  function	  in	  
natural	  ageing	  
The	   essential	   first	   step	   in	   the	   regenerative	   process	   following	   injury-­‐induced	   activation	   is	   the	  
emergence	   of	   SCs	   from	   their	   sub-­‐laminal	   position	   to	   the	   myofibre	   surface.	   Otto	   and	   colleagues	  
reported	  that	  SCs	   immediately	  after	  myofibre	   isolation	  (T0),	  were	  uniformly	  covered	  in	  the	   layer	  of	  
laminin	  which	  constitutes	  a	  component	  of	  the	  plasma	  membrane	  (Otto	  et	  al.	  2011).	  This	  finding	  was	  
consistent	  with	  the	  emergence	  analysis	  carried	  out	  in	  the	  current	  study,	  where	  both	  young	  and	  old	  
SCs	   were	   observed	   in	   their	   original	   quiescent	   location	   at	   T0.	   Following	   this	   and	   prior	   to	   the	  
emergence	  of	  SCs,	  remodelling	  of	  the	  laminin	  layer	  takes	  place	  within	  the	  initial	  18	  hours	  of	  culture,	  
at	  which	   time	  holes	  become	  visible.	   By	  24	  hours,	   the	  majority	   of	   SCs	   reportedly	   emerge	   via	   these	  
holes	   and	   were	   observed	   positioned	   above	   intact	   laminin	   (Otto	   et	   al.	   2011;	   Collins-­‐Hooper	   et	   al.	  
2012).	  However,	   this	  characteristic	  was	  not	   the	  case	  with	   the	  young	  SCs	   in	   the	  present	  emergence	  
analysis,	  as	  more	  than	  50%	  of	  the	  total	  SCs	  remained	  beneath	  the	  basal	  lamina	  at	  T24.	  Whereas,	  the	  
majority	   of	   old	   SCs	   had	   either	   fully	   emerged	   or	   were	   partially	   emerged	   by	   this	   time,	   which	   is	  
therefore	   in	   keeping	   with	   what	   has	   been	   previously	   reported	   for	   young	   SCs,	   but	   does	   not	   follow	  
trends	  described	  in	  old	  SC	  populations.	  For	  example,	  colleagues	  showed	  overall	  delayed	  emergence	  
in	  aged	  SCs	  compared	  to	  young	  controls	  (Collins-­‐Hooper	  et	  al.	  2012).	  Reasons	  for	  these	  discrepancies	  
are	   however,	   currently	   unknown.	   One	   explanation	   could	   be	   that	   the	   myofibre	   connective	   tissue,	  
laminin,	  basal	  lamina	  and	  ECM	  components	  are	  more	  easily	  remodelled,	  allowing	  SCs	  to	  emerge	  at	  a	  
more	   advanced	   rate	   compared	   to	   young	   SCs.	   Collagen	   IV	   was	   previously	   examined	   at	   the	   whole-­‐
muscle	  level	  and	  this	  indicated	  that	  collagen	  IV,	  found	  in	  the	  basement	  membrane	  of	  myofibres,	  was	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thicker	  at	  older	  ages,	  significantly	  so	  at	  geriatric	  ages,	  for	  example.	  This	  therefore,	  would	  not	  support	  
this	   notion	   as	   denser,	   more	   tightly	   cross-­‐linked	   collagen	   associated	   with	   aged	   muscle,	   has	   been	  
shown	  to	  impair	  SC	  regenerative	  function	  and	  provides	  a	  greater	  challenge	  for	  SCs	  to	  create	  holes	  to	  
emerge	  through	  (Lacraz	  et	  al.	  2015;	  Collins-­‐Hooper	  et	  al.	  2012;	  Alnaqeeb	  et	  al.	  1984;	  Gao	  et	  al.	  2008).	  
A	   further	  explanation	  could	  be	   that	   slight	  growth	   factor	   fluctuations	  between	  batches	  of	   the	  chick	  
embryo	   extract	   supplement	   of	   single	   fibre	   culture	   media,	   could	   result	   in	   varied	   responses	   from	  
different	   cultures	   of	   single	  myofibres.	   As	   emergence	   is	   the	   first	   step	   of	   SC	   regenerative	   function,	  
following	   activation,	   it	   could	   be	   argued	   that	   an	   advanced	   rate	   of	   SC	   emergence	   could	   also	   be	  
indicative	  of	  an	  overall	  more	  efficient	  repair	  or	  myofibre	  turnover.	  However,	  this	  process	  of	  efficient	  
renewal	   is	   highly	   reliant	   on	   the	   subsequent	   steps	   of	   SC	   regeneration,	   for	   example,	   migration,	  
proliferation	  and	  differentiation.	  Thus,	  further	  mechanisms	  of	  SC	  function	  were	  also	  examined	  in	  the	  
current	  series	  of	  experiments.	  
Another	   essential	   aspect	   of	   SC	   activity	   that	   was	   a	   much	   neglected	   feature	   of	   regeneration	   until	  
relatively	   recently,	   is	   the	   necessity	   for	   SCs	   to	  migrate	   to	   the	   site	   of	   damage	   in	   order	   to	   carry	   out	  
cellular	   tissue	   repair	   (Otto	   et	   al.	   2011;	   Collins-­‐Hooper	   et	   al.	   2012).	   Therefore,	   SC	   migration	   was	  
analysed	  and	  unlike	  the	  trends	  previously	  documented	  by	  colleagues,	  old	  SCs	  did	  not	  demonstrate	  a	  
reduced	  migration	  speed	  compared	  to	  young	  controls	  (Collins-­‐Hooper	  et	  al.	  2012).	  Thus,	  this	  finding	  
is	  surprising	  but	  even	  more	  so,	  was	  that	  the	  velocity	  at	  which	  SCs	  travelled	  at	  a	  geriatric	  age,	  was	  also	  
statistically	   no	   different	   to	   those	   measured	   at	   all	   other	   ages.	   Marked	   declines	   at	   geriatric	   ages,	  
associated	   with	   the	   progression	   of	   sarcopenia,	   reduced	   intrinsic	   regenerative	   and	   self-­‐renewal	  
potential,	  have	  been	  reported	  by	  others	  and	  is	  starting	  to	  highlight	  the	  importance	  of	  the	  dramatic	  
deterioration	  that	  occurs	  between	  old	  and	  geriatric	  ages,	  in	  both	  animal	  and	  human	  subjects	  (Sousa-­‐
Victor	   et	   al.	   2014).	   Analysis	   of	   the	  morphologies	   adopted	   by	   SCs	   at	   both	   young	   and	   old	   ages	   also	  
indicated	  that	  90	  –	  100%	  of	  the	  SCs	  were	  more	  rounded	  in	  shape.	  A	  more	  spherical	  morphology	  was	  
noted	  to	  be	  positively	  correlated	  with	  the	  amoeboid/bleb-­‐based	  form	  of	  cellular	  motility.	  Therefore,	  
together	   the	   results	   suggest	   that	   the	   intrinsic	   regulatory	  mechanisms	   that	  mediate	   the	  migratory	  
aspects	  of	  SC	  function,	  were	  not	  substantially	  influenced	  by	  ageing	  progression	  in	  the	  current	  study.	  
Moreover,	   reductions	   in	   SC	   velocity	   in	   ageing,	   reported	   by	   Collins-­‐Hooper	   and	   colleagues,	   were	  
attributed	   to	   abnormal	   bleb	  dynamics,	   specifically	   evident	   from	  a	  prolonged	  bleb	   lifespan	   through	  
delayed	   bleb	   extension	   and	   retraction	   phases	   (Collins-­‐Hooper	   et	   al.	   2012).	   Additionally,	   aged	   SCs	  
were	  also	  shown	  to	  have	  reduced	  expression	  of	  cell-­‐extracellular	  adhesion	  components,	  integrin	  α6,	  
α7	   and	   β1	   (Collins-­‐Hooper	   et	   al.	   2012).	   These	   heterodimer	   glycoproteins	   are	   known	   to	   have	   high	  
affinities	   for	   laminin	   in	   skeletal	   muscle	   and	   disruption	   of	   integrin	   adhesion	   has	   been	   linked	   with	  
decreased	   SC	   migration	   speeds	   (Collins-­‐Hooper	   et	   al.	   2012;	   Siegel	   et	   al.	   2009;	   Mayer	   2003).	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Therefore,	   it	  would	   be	   of	   interest	   to	   the	   present	   series	   of	   experiments,	   to	   further	   investigate	   the	  
characteristics	   of	   old	   and	   geriatric	   SC	   bleb	   dynamics	   as	   well	   as	   integrin	   expression,	   to	   provide	   an	  
explanation	   for	   the	   alternative	   trends	   in	   migration	   speed	   observed,	   relative	   to	   those	   previously	  
stated	  in	  the	  literature.	  	  
Next,	   the	   proliferative	   capacity	   of	   aged	   SCs	   was	   analysed	   and	   in	   keeping	   with	   findings	   of	   others,	  
proliferation	   in	   aged	   SC	   populations	   was	   diminished	   (Schultz	   &	   Lipton	   1982;	   Collins	   et	   al.	   2007;	  
Collins-­‐Hooper	  et	  al.	  2012;	  Sousa-­‐Victor	  et	  al.	  2014;	  García-­‐Prat	  et	  al.	  2016).	  Although	  some	  evidence	  
of	   proliferation	   was	   observed	   over	   the	   48-­‐hour	   culture	   period	   in	   aged	   SC	   populations,	   the	   total	  
number	   of	   cells	   present	   at	   T24	   and	   48	   were	   remarkably	   reduced	   compared	   to	   young	   SCs.	  
Additionally,	  there	  is	  also	  indication	  of	  the	  delayed	  initiation	  of	  proliferation	  that	  Schultz	  and	  Lipton	  
previously	   described	   (Schultz	   &	   Lipton	   1982).	   This	   is	   evident	   by	   the	   apparent	   lag	   in	   increased	   SC	  
number	  per	  myofibre	  at	  T48,	  equalling	  the	  average	  observed	  at	  the	  earlier	  T24	  time-­‐point	  in	  young	  
populations.	  Moreover,	   it	  can	  potentially	  be	  surmised	  that	  the	  SCs	  initiating	  proliferation	  in	  old	  age	  
within	  the	  48-­‐hour	  culture	  period	  analysed,	  are	  the	  minority	  population	  that	  Collins	  and	  colleagues	  
described	  as	   the	  smaller	  proportion	  of	   total	  SCs	   that	   retain	   the	  proliferative	  capability	   into	  old	  age	  
(Collins	   et	   al.	   2007).	   Sousa-­‐Victor	   and	   colleagues	   reported	   at	   a	   geriatric	   age,	   that	   SCs	   had	   lost	   the	  
ability	  to	  maintain	  reversible	  quiescence	  and	  instead,	  entered	  an	  irreversible	  senescence,	  known	  as	  
geroconversion	  (Sousa-­‐Victor	  et	  al.	  2014).	  This	  has	  been	  shown	  to	  occur	  through	  the	  derepression	  of	  
p16INK4a,	  a	  tumour	  suppressor	  gene	  that	  stalls	  cell	  cycle	  progression	  from	  G1	  to	  S	  phase	  and	  therefore	  
is	   considered	   a	  master	   regulator	   of	   senescence	   (Sousa-­‐Victor	   et	   al.	   2014;	   García-­‐Prat	   et	   al.	   2016).	  
Regulatory	   mechanisms	   such	   as	   this	   function	   as	   DNA	   damage	   check-­‐points	   in	   normal	   stem	   cell	  
physiology	   to	   detect	   and	   initiate	   apoptotic	   clearance	   of	   damaged	   cells	   that	   exhibit	   features	   of	  
dysfunctional	   control	   that	   occur	   during	   natural	   ageing	   progression.	   Therefore	   these	   otherwise	  
protective	   mechanisms	   may	   be	   ‘hijacked’	   and	   become	   inappropriately	   regulated,	   exacerbating	  
further	   damage	   responses	   during	   age-­‐associated	   DNA	   damage	   accumulation,	   similarly	   to	  
dysregulation	   also	   observed	   in	   cancer	   (Sperka	   et	   al.	   2012;	   García-­‐Prat	   et	   al.	   2016).	   Although,	   this	  
feature	  was	  prominent	  at	  geriatric	  ages	  in	  the	  previously	  discussed	  study	  conducted	  by	  Sousa-­‐Victor	  
and	  colleagues,	  it	  would	  be	  of	  interest	  to	  the	  current	  project	  to	  investigate	  DNA	  damage	  check-­‐point	  
regulatory	   mechanisms,	   such	   as	   cell	   cycle	   arrest	   via	   p16INK4a	   or	   other	   indications	   of	   cellular	  
senescence,	   such	   as	   senescence-­‐associated	   beta	   galactosidase	   (SA-­‐β-­‐gal).	   This	   could	   be	   used	   to	  
establish	  if	  the	  reduction	  in	  proliferative	  potential	  observed	  in	  old	  SCs	  in	  the	  present	  study	  could	  be	  
attributed	  to	  premature	  geroconversion	  to	  a	  senescent	  state.	  Another	  explanation	  for	  decreased	  SC	  
number	   in	   old	   age	   could	   be	   the	   result	   of	   increased	   SC	   apoptosis	   reported	   by	   others	   in	   the	   field	  
(Collins	  et	  al.	  2007;	  Wang	  et	  al.	  2014).	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It	  should	  be	  noted	  that	  due	  to	  a	  lack	  of	  availability	  of	  aged	  myofibres	  during	  experimentation,	  it	  was	  
not	   possible	   to	   examine	   myogenic	   differentiation	   of	   aged	   SCs.	   However,	   it	   has	   been	   previously	  
reported	   that	   SCs	   demonstrate	   a	   delayed	   commitment	   to,	   as	   well	   as	   a	   reduced	   myogenic	  
differentiation.	   Furthermore,	   it	   could	   be	   argued	   that	   the	   underlying	   regulatory	  mechanisms	   of	   SC	  
proliferation	  were	  overall	  affected	  by	  ageing	  to	  a	  higher	  degree	  than	  the	  other	  aspects	  examined	  in	  
the	  current	  series	  of	  experiments	  (emergence	  and	  migration).	  This	  could	  be	  indicative	  of	  age-­‐related	  
dysregulation	   impacting	  more	  detrimentally	  on	  signalling	  pathways	  mediating	  the	  balance	  between	  
growth	   and	   maintenance,	   described	   previously	   as	   part	   of	   a	   survival	   response,	   evident	   in	   ageing	  
progression.	  This	   therefore,	  could	  suggest	  a	  potential	   trade-­‐off	   in	   the	  prioritisation	  of	  maintenance	  
over	  growth	  regarding	  a	  compromised	  SC	  regenerative	  capacity,	  as	   those	  mechanisms	  required	   for	  
proliferation	  would	  seemingly	  be	  dampened	  during	  this	  shift	  in	  resources	  with	  age.	  Despite	  observing	  
superficially	  positive	  findings	  for	  aspects	  of	  SC	  regenerative	  function	  in	  the	  aged	  myofibre	  condition,	  
such	   as	   advanced	   emergence	   and	   ‘normal’	   SC	   migration	   observed	   in	   the	   current	   study.	   These,	  
coupled	   with	   an	   observed	   reduction	   in	   SC	   number	   and	   progeny-­‐generating	   capacity,	   as	   well	   as	  
potentially	   impaired	   terminal	  myogenic	   differentiation	   (based	  on	   the	   findings	  of	   others),	   however,	  
would	  still	  result	   in	  an	  overall	  reduced	  regenerative	  capacity.	  Therefore,	  an	  advanced	  pattern	  of	  SC	  
emergence	  and	  maintenance	  of	  migration	  speed	  in	  old	  age,	  may	  serve	  as	  compensatory	  regulation	  in	  
order	   to	   limit	   the	   impact	   of	   reduced	   SC	   number,	   proliferative	   capacity	   and	   reportedly	   impaired	  
differentiation	   on	   the	   overall	   process	   of	   repair.	   Each	   aspect	   is	   essential	   in	   order	   to	   bring	   about	  
successful	  and	  efficient	  muscle	  repair	  and	  diminished	  function	  of	  any	  of	  these	  mechanisms,	  either	  as	  
a	  result	  of	  ageing	  or	  in	  disease,	  will	  have	  a	  detrimental	  effect.	  It	  is	  important	  that	  studies	  wishing	  to	  
examine	  the	  SC	  regeneration	  process,	  for	  example	  in	  disease	  or	  ageing	  intervention	  research,	  analyse	  
and	   target	  each	  aspect	  of	  SC	   function.	  As	  with	   the	  whole	  muscle	   studies,	  an	  appropriate	  model	  of	  
accelerated	   age-­‐related	   muscle	   decline	   is	   required,	   in	   order	   to	   conduct	   successful	   and	   efficient	  
intervention	  studies	  examining	  these	  features	  of	  SC	  regenerative	  capacity.	  
Characterisation	  of	  mechanisms	  of	  satellite	  cell	  number	  and	  function	  in	  the	  
Ercc1d/-­‐	  progeric	  model	  
As	   SCs	   are	   known	   to	   be	   quiescent	   at	   T0	   and	   emerge	   from	   their	   sub-­‐laminal	   position	   in	   the	   latter	  
hours	  of	  the	  initial	  24	  hours	  of	  single	  myofibre	  culture,	  this	  important	  window	  for	  emergence	  in	  early	  
SC	   activity	  was	  more	   closely	   studied	   in	   the	  Ercc1d/-­‐	   experimentation	   (Otto	   et	   al.	   2011).	   In	   keeping	  
with	  previous	  observations	   therefore,	  within	   this	   relatively	   short	  period	  of	   culture	   (4	  hours),	  more	  
SCs	   (control	   and	  Ercc1d/-­‐)	   had	  emerged.	  However,	   similarly	   to	   trends	   seen	   in	   the	  naturally-­‐aged	  SC	  
emergence	   analysis,	   these	   proportions	   were	   distinctly	   less	   than	   the	   control	   SCs	   reported	   to	   have	  
emerged	  by	  T24	  by	  colleagues	  previously	  (Otto	  et	  al.	  2011;	  Collins-­‐Hooper	  et	  al.	  2012).	  Reasons	  for	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these	  discrepancies,	  other	  than	  possible	  serum	  growth	  factor	  level	  variations,	  are	  currently	  unknown.	  
Although	   an	   unknown	   degree	   of	   variation,	   if	   any	   at	   all,	  may	   be	   introduced	  with	   the	   C57BL/6/FVB	  
hybrid	   genetic	  background	   the	  Ercc1d/-­‐	  mutant	   is	   generated	   in,	   as	   the	  naturally-­‐aged	  animals	  were	  
C57BL/6	   laboratory	   strains	   only.	   In	   addition,	   despite	   the	   aforementioned	   abnormally	   delayed	  
emergence	   noted	   in	   control	   conditions,	   the	   findings	   indicate	   that	   mechanisms	   underlying	   SC	  
emergence	   may	   not	   be	   profoundly	   affected	   in	   the	   Ercc1d/-­‐	   model.	   This	   is	   because	   observed	  
proportions	   of	   emerged	   SCs	   were	   not	   statistically	   different	   from	   those	   observed	   in	   the	   control	  
myofibre	  cultures.	  
In	   keeping	   with	   what	   others	   have	   previously	   reported,	   almost	   100%	   of	   the	   SCs	   analysed	   in	   both	  
control	  and	  Ercc1d/-­‐	  conditions,	  were	  observed	  with	  amoeboid/bleb	  characteristics	  (Otto	  et	  al.	  2011;	  
Collins-­‐Hooper	   et	   al.	   2012).	   Surprisingly,	   however,	   Ercc1d/-­‐	   SCs	   were	   found	   to	   migrate	   along	  
myofibres	   at	   a	   considerably	   faster	   rate	   compared	   to	   control	   cells.	   This	   finding	   is	   somewhat	  
unexpected	  in	  a	  model	  of	  such	  extreme	  dysregulation,	  as	  it	  could	  be	  argued	  that	  a	  faster	  migration	  
speed	  would	  also	  subsequently	  result	  in	  SCs	  reaching	  the	  lesion	  site	  faster,	  in	  order	  to	  carry	  out	  more	  
efficient	  repair.	  As	  discussed	  in	  previous	  chapters,	  multiple	  factors,	  other	  than	  migration	  method,	  can	  
influence	  cell	  motility	  and	  overall	  speed	  of	  movement.	  Characteristics	  both	  intrinsic	  and	  extrinsic	  to	  
the	  cell	  can	  influence	  motility	  and	  a	  number	  of	  these	  are	  reported	  to	  become	  altered	  with	  age.	  For	  
example,	  intrinsic	  regulation	  of	  well-­‐known	  mediators	  of	  migration	  such	  as	  the	  finding	  that	  artificially	  
inducing	   NO/HGF	   signalling	   in	   myofibre	   suspension	   cultures	   in	   vitro,	   has	   been	   associated	   with	  
increasing	  motility	  of	  aged	  SC	  populations	  (Otto	  et	  al.	  2011;	  Collins-­‐Hooper	  et	  al.	  2012).	  Additionally,	  
smooth	  muscle	  actin	  concentrated	  at	  the	  plasma	  membrane	  of	  a	  forming	  bleb	  during	  the	  amoeboid	  
method	  of	  migration	  indicates	  that	  changes	  in	  cytoskeletal	  organisation	  bring	  about	  bleb	  extensions	  
and	  retractions.	  It	  has	  been	  suggested	  that	  an	  increased	  rate	  of	  extension	  and	  retraction	  results	  in	  an	  
increased	   rate	  of	  movement	  and	   that	   this	  bleb	   lifespan	   is	  decreased	   in	  aged	  SCs	   (Otto	  et	  al.	  2011;	  
Collins-­‐Hooper	  et	  al.	  2012).	  External	  interactions	  via	  focal	  adhesion	  contacts,	  integrins	  and	  therefore,	  
both	   cell	   to	   cell,	   as	   well	   as	   cell	   to	   ECM	   communications,	   have	   also	   been	   implicated	   in	   ageing,	   as	  
discussed	   and	   like-­‐wise	   regarding	  both	   the	  naturally-­‐aged	   and	  Ercc1d/-­‐	   SC	   experimentation,	   further	  
analysis	  into	  these	  features	  is	  required.	  
Collagen,	   a	  major	   component	   of	   connective	   tissue,	   is	   shown	   to	   become	   thicker	   and	  more	   densely	  
cross-­‐linked	  with	  age,	  which	  not	  only	  impacts	  on	  overall	  muscle	  contractility	  but	  has	  been	  shown	  to	  
interfere	   with	   cellular	   signalling	   (Kragstrup	   et	   al.	   2011;	   Gao	   et	   al.	   2008;	   Alnaqeeb	   et	   al.	   1984).	  
Additionally,	  an	  important	  finding	  within	  the	  field	  of	  cell	  biology	  and	  tissue	  engineering,	  is	  that	  stem	  
cells	   respond	  to	   their	  microenvironment	  of	  niche	  by	   ‘feeling’	   the	  elasticity	  of	   their	  substrate	  which	  
then	   directs	   characteristics	   of	   cell	   behaviour	   including	   migration	   and	   differentiation	   (Engler	   et	   al.	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2004;	   Engler	   et	   al.	   2006).	   Although,	   when	   analysing	   the	   Ercc1d/-­‐	   Soleus	   at	   a	   whole	   tissue	   level,	  
discussed	  in	  the	  previous	  chapters,	  it	  was	  noted	  that	  collagen	  IV	  thickness	  surrounding	  each	  myofibre	  
was	   not	   statistically	   different	   between	   Ercc1d/-­‐	   and	   controls.	   However,	   this	   parameter	   does	   not	  
indicate	  how	  densely	  cross-­‐linked	  the	  collagen	  is	  and	  therefore	  cannot	  provide	  any	  insights	  into	  the	  
substrate	  elasticity	  in	  the	  Ercc1d/-­‐	  model.	  
The	  efficiency	  of	  the	  regeneration	  process,	  as	  previously	  discussed,	  is	  heavily	  influenced	  by	  the	  other	  
features	  of	  SC	  function,	  such	  as	  productive	  generation	  of	  progeny,	  as	  well	  as	  successful	  and	  efficient	  
myogenic	  differentiation.	  Thus,	  critically,	  it	  was	  established	  that,	  although	  there	  was	  some	  evidence	  
of	   proliferation	   during	   the	   72-­‐hour	   culture	   period,	   the	   number	   of	   Ercc1d/-­‐	   SCs	   per	   myofibre	   was	  
drastically	  depleted	  at	  each	  time-­‐point,	   including	  those	  quiescent	  at	  T0.	  This	   finding	   is	   therefore	   in	  
keeping	  with	  what	  is	  reported	  in	  the	  literature	  in	  naturally-­‐aged	  skeletal	  muscle,	  as	  well	  as	  what	  was	  
observed	  in	  the	  previous	  series	  of	  experiments.	  This	  suggests	  that	  a	  large	  proportion	  of	  Ercc1d/-­‐	  SCs	  
are	   failing	   to	   proliferate	   and	   instead	   are	   undergoing	   premature	   geroconversion.	   That	   is,	   cells	   are	  
entering	   an	   accelerated	   irreversible	   state	   of	   senescence,	   a	   process	   that	   has	   been	   associated	  with	  
naturally-­‐aged	  geriatric	  SCs	  (Sousa-­‐Victor	  et	  al.	  2014;	  García-­‐Prat	  et	  al.	  2016).	  As	  the	  Ercc1d/-­‐	  model	  is	  
one	   of	   accumulated	   DNA	   damage,	   it	   can	   be	   reasonably	   postulated	   that	   the	   cell	   cycle	   arrest	  
mechanisms	  and	   those	  driving	  SC	   senescence	  are	   functioning	  both	   in	   response	   to	   the	  detection	  of	  
high	   levels	   of	   DNA	   damage,	   but	   also	   to	   prevent	   any	   further	   damage	   as	   a	   protective	   mechanism.	  
Further	  experimentation	  using	  the	  SA-­‐β-­‐gal	  assay	  can	  be	  used	  to	  confirm	  the	  proportion	  of	  SCs	  that	  
have	  become	  senescent.	  Despite	  observing	  dramatically	  depleted	  Ercc1d/-­‐	   SC	  numbers	  and	  reduced	  
proliferation,	  those	  cells	  that	  remained	  functional	  and	  did	  not	  undergo	  geroconversion,	  appeared	  to	  
differentiate	  as	  successfully	  as	  the	  control	  SCs.	  This	  was	  evident	  by	  consistent	  proportions,	  relative	  to	  
the	  control,	  of	  Ercc1d/-­‐	  SC	  expression	  of	  myogenic	  markers,	  MyoD	  (T24	  and	  48)	  and	  myogenin	  (T72),	  
being	  observed.	  This	  is	  a	  somewhat	  unexpected	  finding	  as	  delayed	  lineage	  commitment	  and	  reduced	  
myogenic	  differentiation	  were	  features	  previously	  reported	  to	  occur	  in	  naturally-­‐aged	  SC	  populations	  
(Collins-­‐Hooper	  et	  al.	  2012;	  Collins	  et	  al.	  2007).	  
Importantly,	  as	  in	  the	  naturally-­‐aged	  SC	  populations,	  proliferation	  appears	  to	  be	  the	  mechanism	  that	  
is	   the	   most	   detrimentally	   affected	   in	   the	   regenerative	   process	   in	   Ercc1d/-­‐	   SC	   populations.	   It	   is	  
proposed	  therefore,	   that	  SCs	  have	  undergone	  geroconversion,	   transforming	   from	  a	  quiescent	  state	  
to	  senescence.	  In	  an	  otherwise	  depleted	  SC	  pool,	  the	  underlying	  regulation	  that	  normally	  promotes	  
growth	   has	   defaulted	   to	   conserve	   resources	   as	   a	   survival	   response	   and	   shifted	   towards	   cellular	  
maintenance.	   Thus,	   it	   would	   be	   of	   interest	   to	   better	   our	   understanding	   of	   this	   survival	   response	  
beginning	  with	  investigation	  into	  the	  regulatory	  pathways	  involved	  in	  apoptosis	  and	  autophagy.	  For	  
example,	   analysing	   components	   of	   these	   signalling	   pathways,	   could	   aid	   in	   determining	   the	   extent	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that	   the	   reduction	   in	   SC	   numbers	   can	   be	   attributed	   to	   cell	   death	   and	   to	   indicate	   how	   biological	  
materials	  are	  being	  recycled	  instead	  of	  newly	  synthesised.	  Other	  aspects	  of	  regenerative	  function	  in	  
Ercc1d/-­‐	   SCs	  however,	  were	  either	   consistent	  with	   control	   SCs,	   as	   in	   the	   case	  of	  differentiation	  and	  
emergence,	  or	  advanced	  as	  with	  speed	  of	  movement.	  Regulation	  of	  these	  features	  could	  therefore,	  
be	  the	  result	  of	  compensatory	  regulation	  in	  attempts	  to	  limit	  the	  impact	  of	  declines	  in	  regenerative	  
function	   caused	   primarily	   by	   a	   lack	   of	   SC	   progeny-­‐generation.	   Therefore,	   exhibiting	   characteristics	  
associated	   with	   altered	   mechanisms	   of	   skeletal	   muscle	   regenerative	   capacity,	   the	   Ercc1d/-­‐	   model	  
demonstrates	   parallels	   to	   those	   declines	   in	   SC	   number	   and	   function	   observed	   in	   natural	   ageing	  
progression.	  However,	  in	  a	  model	  of	  such	  severe	  dysfunction	  it	  is	  somewhat	  surprising	  that	  the	  other	  
underlying	  mechanisms	  of	  SC	  activity	  were	  not	  more	  drastically	  affected,	  particularly	  differentiation.	  
However,	   the	   Ercc1d/-­‐	   model	   of	   progeria	   has	   been	   described	   as	   ‘segmental’	   in	   its	   deterioration,	  
referring	   to	   some	   compartments,	   organs	   and	   tissues	   being	   more	   affected	   by	   the	   DNA	   damage	  
accumulation	   than	   others	   (Dollé	   et	   al.	   2011).	   These	   declines	  were	   then	   scored	   relative	   to	   natural	  
ageing	   as	   ‘normal’,	   ‘accelerated’	   or	   ‘extreme’.	   In	   conclusion	   therefore,	   it	   could	   be	   argued	   that	   SC	  
regenerative	   potential	   in	   Ercc1d/-­‐	   skeletal	   muscle	   mimics	   some	   features	   of	   natural	   ageing	   to	   a	  
‘normal’	   extent,	   for	   example,	   reduced	   proliferative	   potential.	   However,	   there	   is	   evidence	   of	  
dysregulation	  in	  the	  SC	  parameters	  discussed	  which	  show	  variability	  from	  aspects	  observed	  in	  natural	  
ageing.	   For	   example,	   a	   large	   degree	   of	   abnormality	   was	   noted	   in	   emergence	   and	   migration	  
characteristics	  in	  both	  Ercc1d/-­‐	  and	  aged	  SCs.	  
Investigating	  the	  effects	  of	  conditioned	  media	  treatment	  on	  satellite	  cell	  
activity	  in	  natural	  ageing	  
The	  hypothesis	  that	  ADMSC	  CM	  treatment	  will	  enhance	  the	  function	  of	  the	  underlying	  mechanisms	  
of	   SC	   regenerative	   activity	   in	   old	   age,	   was	   investigated.	   The	   initial	   finding	   indicated	   that	   CM	  
treatment	  appeared	  to	  reverse	  the	  advanced	  pattern	  of	  SC	  emergence	  seen	  in	  old	  age,	  to	  that	  of	  the	  
young	  control	  SCs.	  This	  therefore	  suggests	  that,	  despite	  emergence	  appearing	  abnormally	  delayed	  in	  
young	   SCs,	   relative	   to	   previously	   reported	   findings	   of	   others,	   the	   advanced	   emergence	   of	   old	   SCs	  
observed,	  may	  not	  necessarily	  be	  advantageous	  in	  the	  process	  of	  regeneration	  in	  aged	  SCs.	  However,	  
this	   seems	   somewhat	   counterintuitive,	   as	   it	   could	   be	   surmised	   that	   the	   earlier	   SCs	   emerge	   to	   the	  
myofibre	   surface,	   the	  earlier	   they	  are	  available	   to	  carry	  out	   cellular	   repair.	  Although,	  as	  previously	  
mentioned,	   this	   notion	   is	   highly	   reliant	   on	   the	   functionality	   of	   the	   other	   aspects	   of	   SC	   activity,	  
including	   migration,	   proliferation	   and	   differentiation.	   Nevertheless,	   this	   finding	   indicates	   that	   CM	  




Remarkably,	   CM	   treatment	   in	   old	   age	   also	   showed	   an	   increased	   SC	  migration	   speed	   compared	   to	  
both	   the	   old	   and	   adult	   control	   SCs.	   This	   suggests	   that	   regulatory	   properties	   maintained	   within	  
ADMSC	   CM	   can	   also	   mediate	   features	   of	   cell	   motility.	   Altered	   characteristics	   could	   include	   for	  
example,	   modified	   bleb	   dynamics	   such	   as	   bleb	   number,	   size	   or	   lifespan,	   or	   other	   membrane	  
adaptations,	   such	  as	   those	   regulating	   focal	  adhesion	  contacts	  or	  actin	  cytoskeletal	  organisation.	  As	  
before,	   utilising	   what	   has	   been	   reported	   regarding	   the	   cellular	   processes	   targeted	   by	   the	   miRNA	  
content	  of	  AFS	  CM,	   it	  could	  be	  reasonably	  postulated	  that	  broad	  signalling	  pathways	  such	  as	  those	  
regulating	  cell	  communication,	  ECM	  organisation,	  cell	  adherence	  and	  motility,	  may	  also	  be	  targets	  of	  
ADMSC	  content	  (Mellows	  et	  al.	  2017).	  Further	  investigation	  into	  establishing	  the	  properties	  specific	  
to	   CM	   generated	   from	   ADMSC	   is	   required.	   Importantly,	   CM	   treatment	   therefore,	   not	   only	   shows	  
potential	   for	  adapting	  the	  regulation	   intrinsic	  to	  the	  SC	  population	  but	   introduced	  systemically,	  CM	  
has	  adaptive	  regulatory	  effects	  universally	  within	  the	  local	  microenvironment,	  mediating	  somatic	  and	  
stem	  cell	  interactions	  (Mellows	  et	  al.	  2017).	  	  
Treatment	   with	   NO	   donors	   and	   HGF	   separately,	   has	   been	   shown	   to	   induce	   aged	   SCs	   to	   travel	   at	  
speeds	   associated	   with	   young	   SCs	   (Collins-­‐Hooper	   et	   al.	   2012).	   Despite	   SC	   migration	   speeds	  
remaining	  constant	  with	  age	  in	  the	  current	  study,	  CM	  treatment	  similarly	  enhanced	  migration	  speed	  
and	   therefore,	   this	   previously	   reported	   finding,	   could	   indicate	   key	   signalling	   components	   that	   are	  
regulated	  by	  factors	  within	  CM.	  Therefore,	  the	  NO/HGF	  signalling	  pathways	  would	  be	  an	  important	  
avenue	  for	  further	  investigation	  into	  elucidating	  more	  specific	  properties	  of	  ADMSC	  CM.	  Along	  with	  
analysis	  of	  SC	  migration	  speed	  in	  old	  age,	  colleagues	  have	  also	  previously	  used	  a	  mathematical	  model	  
approach	   to	   study	   SC	   migration	   trajectories	   (Collins-­‐Hooper	   et	   al.	   2012).	   The	   outcome	   saw	   that	  
young	  SCs	  adopt	  a	  migratory	  pattern	  that	   is	  described	  as	  a	   ‘memoryless’	  random	  walk	  method	  and	  
travel	   larger	   distances	   length-­‐wise	   along	   myofibres.	   This	   pattern	   indicates	   that	   a	   cell’s	   past	  
movement	  does	  not	  have	  any	  bearing	  on	  the	  future	  directionality	  and	  that	  there	  is	  equal	  chance	  of	  
taking	  a	  left	  or	  right	  turn.	  Whereas,	  this	  ‘memoryless’	  feature	  appeared	  to	  be	  lost	   in	  ageing,	  where	  
SCs	  were	  more	   likely	  to	  continue	  travelling	   in	  the	  direction	   it	  had	  been	  previously,	  whilst	  migrating	  
overall	   shorter	   distances	  within	   a	   time	   frame	   (Collins-­‐Hooper	   et	   al.	   2012).	   This	  model	  would	   infer	  
that	   older	   SCs	   would	   be	   less	   adaptable	   or	   plastic	   regarding	   their	   directionality	   in	   response	   to	   a	  
damage	   stimuli	   and	   additionally,	   would	   take	   longer	   to	   arrive	   at	   the	   lesion	   site.	   This	   finding	   is	  
important	   to	   take	   into	   consideration	   in	   the	   present	   study,	   as	   observed	   comparable	   velocities	   to	  
younger	   ages,	   as	   well	   as	   increased	   speeds	   with	   CM	   treatment,	   in	   aged	   conditions,	   might	   not	  
necessarily	  correlate	  with	  functional	  SC	  directionality.	  Indeed,	  an	  increased	  migration	  speed	  could	  be	  
described	  as	  compensatory	   if	   in	  the	   instance	  that	  aged	  SC	  directionality	   is	   impaired.	   It	  would	  be	  of	  
interest	   to	   mathematically	   model	   the	   migration	   of	   SCs	   treated	   with	   CM	   in	   old	   age	   in	   order	   to	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establish	  if	  the	  observed	  increase	  in	  velocity	  is	  coupled	  with	  correction	  of	  the	  ‘memoryless’	  feature	  
of	   young	   SC	   motility.	   It	   is	   therefore	   important	   to	   consider	   that	   cell	   migration	   comprises	   multiple	  
parameters	   beyond	   speed	   of	  movement,	   such	   as	   directionality,	   that	   can	   become	   altered	  with	   age	  
impacting	  on	  overall	  SC	  regenerative	  efficacy.	  
A	  further	  finding	  of	  the	  present	  study	  was	  that	  SC	  proliferation	  was	  not	  enhanced	  with	  CM	  treatment	  
in	  old	  age.	  Rather	  the	  opposing	  trend	  was	  observed	  at	  T48,	  where	  the	  number	  of	  SCs	  and	  cell	  clusters	  
per	   myofibre	   were	   statistically	   no	   different	   to	   those	   present	   at	   earlier	   time-­‐points	   with	   CM	  
treatment.	  Whereas,	   there	  was	   evidence	   of	   proliferation	   over	   the	   culture	   duration	   in	   the	   old	   age	  
control.	  This	  suggests	  that	  factors	  found	  in	  CM	  treatment	  may	  have	  negatively	  regulated	  proliferative	  
pathways	   (such	  as	  Notch-­‐mediated	   signalling)	   in	  old	   age,	   instead	  of	  having	  an	  overall	   rejuvenating	  
effect	  as	  reported	  by	  others	  previously	  (Conboy	  et	  al.	  2003;	  Conboy	  et	  al.	  2005;	  Lavasani	  et	  al.	  2012).	  
However,	   findings	   such	   as	   this	   require	   further	   investigation	   into	   the	   properties	   of	   ADMSC	   CM,	  
specifically.	  As	  any	  observed	  variation	   in	  effects	  could	  be	  attributed	  to	   the	  use	  of	  a	   therapeutically	  
viable	   mesenchymal	   stem	   cell,	   this	   is	   an	   alternate	   stem	   cell	   type	   to	   those	   myogenic	   and	  
haematopoietic	  in	  origin	  examined	  in	  the	  studies	  conducted	  by	  others	  (Conboy	  et	  al.	  2003;	  Conboy	  et	  
al.	  2005;	  Lavasani	  et	  al.	  2012).	  This	  is	  an	  important	  consideration	  as	  secreted	  factors	  are	  believed	  to	  
vary	   between	   cell	   types.	   Overall,	   however,	   these	   findings	   suggest	   that	   regulatory	   properties	  
harboured	   by	   CM	   could	   not	   enhance	   the	   proliferative	   potential	   of	   naturally-­‐aged	   SCs.	   This	   could	  
suggest	   that	   the	   proposed	   shift	   of	   resources	  with	   age,	   from	  mechanisms	   of	   growth	   to	   those	   that	  
prioritise	  maintenance,	  may	  not	  be	  overcome	  by	  CM	  treatment	  intervention	  approaches	  to	  improve	  
regenerative	   function	   (Garinis	   et	   al.	   2008;	   Niedernhofer	   et	   al.	   2006).	   Equally,	   the	   modulating	  
regulatory	  effect	  of	  CM	  was	  unable	  to	  sufficiently	  combat	  the	  reduction	  in	  SC	  numbers	  in	  old	  age,	  as	  
a	  result	  of	  increased	  apoptosis	  or	  geroconversion	  to	  a	  senescent	  state,	  for	  example.	  Interestingly,	  the	  
in	   vitro	   assay	   used	   to	   test	   the	   efficacy	   of	   the	   CM	   generated	   from	   ADMSC	   cells	   demonstrates	   the	  
protective	  effects	  of	  CM	  treatment	  against	  cellular	  senescence.	  This	  therefore	  could	  be	  explained	  by	  
a	   number	   of	   scenarios,	   including	   but	   not	   limited	   to,	   the	   possibility	   that	   the	   aged	   SCs	   were	   not	  
undergoing	   senescence.	   That,	   in	   vivo	   CM	   treatment	   in	   aged	   animals	   was	   unable	   to	   combat	   SC	  
senescence.	  Or	  alternatively,	  that	  aged	  SCs	  were	  already	  experiencing	  SC	  geroconversion	  prior	  to	  CM	  
administration	   beginning	   at	   20	   months	   of	   age.	   Hence,	   the	   equivalent	   ‘protective’	   effect	   may	   be	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Similarly	   to	   the	   naturally-­‐aged	   series	   of	   experiments,	   the	   effects	   of	   CM	   treatment	   were	   also	  
measured	   utilising	   the	   parameters	   underlying	   SC	   reparative	   function	   in	   Ercc1d/-­‐	   myofibre	   cultures.	  
Remarkably,	   CM	   treatment	   appeared	   to	   advance	   SC	   emergence	   compared	   to	   the	   control	   PBS	   and	  
Ercc1d/-­‐	  PBS	  at	  T20,	  which	  has	  resulted	   in	  the	  majority	  of	  SCs	  having	  become	  fully	  emerged	  by	  T24.	  
Moreover,	  CM	  treatment	  in	  the	  control	  PBS	  had	  no	  effect	  on	  SC	  emergence	  at	  T20	  however,	  as	  with	  
Ercc1d/-­‐	   PBS,	   by	   T24	   the	   majority	   of	   control	   CM	   cells	   had	   fully	   emerged.	   This	   indicates	   an	   overall	  
advanced	   rate	   of	   emergence	   compared	   to	   control,	   that	   was	   also	   somewhat	   delayed	   relative	   to	  
Ercc1d/-­‐	   CM	   SCs.	   Taken	  with	   what	   is	   already	   known	   about	   the	   emergence	   process,	   this	   therefore,	  
could	   suggest	   that	   CM	   maintains	   factors	   that	   potentially	   regulate	   features	   of	   SC	   activation	   and	  
response	   to	  damage	  stimuli,	  ECM	  and	   laminin	   remodelling	  and/or	  SC	  migration,	   in	  order	   to	  enable	  
overall	  increased	  emergence	  efficiency	  (Otto	  et	  al.	  2011;	  Collins-­‐Hooper	  et	  al.	  2012).	  Features	  such	  as	  
the	   response	   to	   stimuli,	   cell	   communication,	   ECM	   organisation	   and	   cell	   motility	   were	   identified	  
among	  the	  vast	  array	  of	  cellular	  processes	  that	  were	  targeted	  by	  miRNA	  present	  in	  AFS	  CM	  reported	  
by	  our	  colleagues	  (Mellows	  et	  al.	  2017).	  Despite	  utilising	  CM	  generated	  from	  an	  alternative	  stem	  cell	  
type	  in	  the	  current	  project,	  it	  can	  be	  reasonably	  postulated	  that	  factors	  targeting	  aspects	  of	  cellular	  
function	  similar	  to	  those	  identified	  in	  the	  AFS	  secretome,	  could	  also	  be	  released	  from	  ADMSCs.	  
Similarly	  to	  CM	  treatment	  in	  old	  age	  as	  previously	  discussed,	  CM	  also	  appeared	  to	  adapt	  regulation	  
that	  directed	   changes	   in	   SC	  motility	   in	  Ercc1d/-­‐	  myofibre	   cultures.	   In	   contrast	  however,	   rather	   than	  
increasing	  SC	  migration	  speeds	  as	  observed	  in	  naturally-­‐aged	  SCs,	  CM	  treatment	  reduced	  Ercc1d/-­‐	  SC	  
velocities	   to	   a	   control	   level.	   Furthermore,	   this	   could	   suggest	   that	   the	   greater	  Ercc1d/-­‐	   (PBS	   vehicle-­‐
treated	   control)	   SC	   migration	   speeds	   initially	   observed,	   were	   not	   beneficial	   or	   perhaps	   not	   fully	  
functional	   in	   the	  process	   of	  Ercc1d/-­‐	   SC	   repair,	   possibly	   due	   to	   the	   aforementioned	   impairments	   in	  
response	   to	   stimuli	   and	  directionality	   (Collins-­‐Hooper	   et	   al.	   2012).	  Additionally,	   as	  before	  with	   the	  
naturally-­‐aged	  experimentation,	  the	  regulatory	  mechanisms	  that	  underpin	  proliferation	  appear	  to	  be	  
those	  most	  affected	  by	  age-­‐related	  modifications	  and	  is	  a	  feature	  of	  SC	  function	  seemingly	  mimicked	  
in	   the	  Ercc1d/-­‐	  model	   of	   progeria.	  Moreover,	   CM	   treatment	   in	   the	  Ercc1d/-­‐	  model	  was	   also	   seen	   to	  
have	  the	  least	  influence	  on	  SC	  number	  and	  proliferative	  capacity.	  As	  before,	  this	  is	  believed	  to	  be	  due	  
to	   the	   shift	   away	   from	  mechanisms	   controlling	   growth,	  which	   further	   suggests	   that	   the	   regulatory	  
potential	  of	  CM	  is	  unable	  to	  impact	  on	  such	  as	  strong	  survival	  response.	  
Interestingly,	   regarding	   the	   final	   aspect	   of	   SC	   function	   analysed,	   CM	   appeared	   to	   perturb	   the	  
progression	  of	  myogenic	  differentiation	  in	  a	  substantial	  proportion	  of	  both	  control	  and	  Ercc1d/-­‐	  SCs	  at	  
T72.	  At	   this	   time-­‐point	   in	   young	  SCs,	   the	  majority	  of	   SCs	  are	   reported	   to	  express	  myogenin,	   a	   late	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myogenic	   marker	   indicating	   initiation	   of	   differentiation,	   which	   was	   consistent	   with	   the	   trends	  
observed	   in	  control	  PBS	  and	  Ercc1d/-­‐	  PBS	  SC	  populations	   in	   the	  present	  study	   (Grounds	  et	  al.	  1992;	  
Zammit	   et	   al.	   2004;	   Zammit,	   Partridge,	   et	   al.	   2006;	   Otto	   et	   al.	   2011;	   Collins-­‐Hooper	   et	   al.	   2012).	  
Importantly,	  it	  is	  known	  that	  SCs	  adopt	  divergent	  fates	  that	  is,	  once	  activated,	  SCs	  express	  both	  Pax7	  
and	  MyoD	  a	  transcription	  factor	  key	  to	  the	  initiation	  of	  myogenic	  commitment	  (Zammit	  et	  al.	  2004;	  
Grounds	   et	   al.	   1992;	   Rudnicki	   et	   al.	   1993).	   Hereafter,	   proliferating	   SCs	   downregulate	   Pax7	   and	  
continue	   along	   the	   myogenic	   lineage,	   subsequently	   expressing	   myogenin	   and	   differentiate	  
(Yablonka-­‐Reuveni	   &	   Rivera	   1994;	   Zammit	   et	   al.	   2004;	   Zammit,	   Relaix,	   et	   al.	   2006).	   Contrastingly,	  
other	   SCs	   seemingly	   withdraw	   from	   immediate	   myogenic	   differentiation	   and	   instead	   continue	   to	  
express	  Pax7	  but	  lose	  MyoD,	  entering	  a	  state	  of	  quiescence	  once	  more	  (Nagata	  et	  al.	  2006;	  Zammit	  
et	   al.	   2004;	   Yablonka-­‐Reuveni	  &	   Rivera	   1994).	   The	  majority	   of	   SCs	   in	   all	   conditions	   at	   T24	   and	   48	  
were	  observed	  co-­‐expressing	  both	  Pax7	  and	  MyoD.	  Interestingly,	  evident	  from	  the	  larger	  proportion	  
of	  cells	  still	  expressing	  Pax7	  only	  at	  T72	  however,	  it	  is	  difficult	  to	  say	  whether	  this	  subset	  is	  delayed	  in	  
their	   lineage	   progression	   from	  MyoD	   to	  myogenin	   expression,	   or	   these	   cells	   are	   in	   the	   process	   of	  
downregulating	   to	   a	   quiescent	   state.	   It	   would	   be	   important	   therefore	   to	   determine	   whether	   the	  
Pax7+	   proportion	   at	   T72	  were	   also	   co-­‐expressing	  MyoD.	   Nevertheless,	   these	   findings	   demonstrate	  
that	  CM	  contains	  properties	  that	  delayed	  the	  activity	  of	  the	  key	  components	  driving	  progression	  of	  
myogenic	   differentiation,	   in	   both	   the	   control	   and	   Ercc1d/-­‐	   SCs.	   Indeed,	   over	   20%	   of	   the	   miRNA	  
present	   in	  AFS	  CM	  was	   shown	   to	  be	   those	   that	   targeted	   cell	   differentiation	   (Mellows	  et	   al.	   2017).	  
Therefore,	  this	  result	   in	  the	  current	  study	  suggests	  that	  CM	  generated	  from	  ADMSCs	  could	  contain	  
similar	   regulatory	   potential,	   regarding	   the	   control	   of	   SC	   myogenic	   differentiation.	   However,	   this	  
could	   indicate	   a	   potentially	   negative	   effect	   of	   CM	   treatment	  whereby,	   SC	   regenerative	   capacity	   is	  
further	  compromised	   through	  delayed	  myogenic	  differentiation.	  Although,	   in	   the	   instance	   that	   this	  
subset	   of	   SCs	   were	   withdrawing	   from	  myogenic	   lineage	   progression,	   it	   could	   be	   argued	   that	   CM	  
treatment	  was	  acting	  on	  these	  regulatory	  mechanisms	  to	  promote	  conservation	  of	  the	  quiescent	  SC	  
pool.	   Further	   investigations	   into	   these	   trends	   however,	   are	   required	   in	   order	   to	   provide	   a	   better	  
understanding	  of	  this	  regulation.	  
CM	   treatment	   in	   the	   Ercc1d/-­‐	   model	   therefore,	   was	   shown	   to	   initiate	   an	   advanced	   rate	   of	   SC	  
emergence,	   normalise	   the	   accelerated	   SC	   migration	   speed	   observed	   in	   Ercc1d/-­‐	   control	   SCs	   and	  
surprisingly,	   delay	   myogenic	   lineage	   progression.	   Overall,	   these	   results	   suggest	   that	   ADMSC	   CM	  
harbours	  regulatory	  potential	  regarding	  the	  underlying	  mechanisms	  of	  these	  features	  of	  SC	  activity.	  
Moreover,	   it	   is	   unclear	   the	   extent	   of	   the	   CM	   therapeutic	   effects,	   as	   some	   of	   these	   altered	  
mechanisms	   appear	   to	   be	   unexpected	   and	   possibly	   counterintuitive.	   For	   example,	   the	   slowed	   SC	  
migration	   speed,	   although,	   as	   discussed,	   this	   could	   highlight	   further	   migratory	   defects,	   such	   as	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directionality	  and	  response	  to	  damage	  stimuli.	  Nevertheless,	  these	  findings	  seem	  to	  indicate	  a	  large	  
degree	   of	   dysregulation	   underpinning	   Ercc1d/-­‐	   SC	   function.	   As	   with	   the	   naturally-­‐aged	   SCs,	  
proliferative	  capacity	  is	  the	  characteristic	  most	  perturbed	  in	  the	  process	  of	  SC	  regeneration	  in	  Ercc1d/-­‐	  
skeletal	   muscle.	   As	   described	   previously	   therefore,	   this	   could	   further	   suggest	   that	   regulation	   and	  
resources	   have	   moved	   away	   from	   growth,	   in	   a	   shift	   concerned	   with	   cellular	   conservation	   and	  
survival.	   Additionally,	   in	   a	   model	   associated	   with	   high	   rates	   of	   DNA	   damage	   accumulation,	   it	   is	  
essential	  to	  protect	  genomic	  and	  cellular	  integrity.	  Thus,	  it	  can	  be	  reasoned	  that	  a	  mechanistic	  shut-­‐
down	   of	   proliferation,	   as	   well	   as	   a	   possible	   drive	   towards	   cellular	   senescence	   and	   apoptosis	  
exemplifies	   protective	   action	   to	   prevent	   further	   dysregulation.	   Further	   investigation	   into	   the	  
regulation	  of	   features	   such	   as	   senescence	   and	   apoptosis,	   is	   therefore,	   required	   to	  provide	   a	  more	  
detailed	  understanding	  of	  this	  survival	  response	  in	  the	  Ercc1d/-­‐	  model.	  
Overall,	   parallels	   can	   be	   drawn	   between	   the	   characteristic	   changes	   that	   occur	   in	   SC	   number	   and	  
function	   in	   natural	   ageing	   and	   the	   Ercc1d/-­‐	   progeric	   model.	   However,	   the	   concept	   of	   the	   Ercc1d/-­‐	  
mouse	   being	   a	   model	   of	   skeletal	   muscle	   ‘super-­‐ageing’	   is	   therefore,	   not	   only	   evident	   at	   a	   whole	  
muscle	  level,	  but	  also	  at	  a	  cellular	  level,	  when	  analysing	  both	  the	  myofibre	  and	  the	  resident	  stem	  cell	  
population.	  Therefore,	  the	  Ercc1d/-­‐	  model	  can	  be	  confidently	  taken	  forward	  for	  use	  in	  future	  skeletal	  
muscle	  ageing	  studies	  to	  research	  potential	  intervention	  approaches,	  wishing	  to	  better	  regenerative	  
function.	  However,	  as	  also	  discussed	  previously	  at	  a	  tissue	  level,	  old	  SCs	  may	  not	  be	  old	  enough	  and	  
it	  could	  be	  argued	  that	  those	  features	  observed	  at	  a	  geriatric	  age	  are	  more	  comparable	  and	  similar	  to	  
characteristics	  of	  SC	   function	  seen	   in	   the	  Ercc1d/-­‐	  progeric	  model.	  This	   further	   indicates	   that	   future	  
experimentation	  should	   focus	  on	  CM	  administration	   in	  geriatric	  animals	   to	  directly	  compare	  to	   the	  
effects	  of	  CM	  treatment	  in	  Ercc1d/-­‐	  muscle.	  
Remarkably,	  however,	  these	  findings	  demonstrate	  the	  regulatory	  potential	  of	  ADMSC	  CM	  treatment.	  
Moreover,	  this	  further	   indicates	  that,	  although	  properties	  harboured	  by	  CM	  altered	  mechanisms	  of	  
SC	   regeneration,	   those	   signalling	   pathways	   that	   suggested	   such	   a	   strong	   shift	   towards	   cellular	  
maintenance,	  were	   not	   additionally	   effected	   by	   CM.	   It	   could	   be	   subsequently	   postulated	   that	   CM	  
supported	  this	  shift.	  Further	   investigation	   into	   the	  properties	  maintained	  by	  ADMSC	  CM	  and	  detail	  
regarding	  the	  cellular	  processes	  and	  signalling	  pathways	  targeted	  by	  components	  of	  ADMSC	  CM,	   is	  
required.	   This	   subsequently,	   can	   also	   be	   studied	   in	   conjunction	   with	   the	   findings	   of	   altered	  
mechanisms	   of	   SC	   function	   presented	   in	   the	   current	   project,	   alongside	   additional	   aspects	   such	   as	  
senescence,	  apoptosis	  and	  autophagy,	  to	  further	  define	  the	  result	  of	  CM	  treatment	  and	  how	  it	  may	  
be	  having	  a	  regulatory	  effect.	  








Skeletal	  muscle	  myofibres	  promote	  	  
non-­‐muscle	  stem	  cells	  and	  non-­‐stem	  cells	  to	  




It	  has	  been	  established	  that	  skeletal	  muscle	  myofibres	  promote	  SCs	  to	  migrate	  utilising	  a	  distinctive	  
amoeboid-­‐based	   mechanism,	   which	   involves	   the	   frequent	   extension	   and	   retraction	   of	   membrane	  
protrusions	   or	   ‘blebs’	   (Otto	   et	   al.	   2011;	   Collins-­‐Hooper	   et	   al.	   2012).	   Amoeboid-­‐based	  migration	   is	  
believed	  to	  develop	  traction	  through	  numerous	  blebs	  forming	  simple	  focal	  adhesions	  with	  the	  ECM,	  
each	   creating	   small	   amounts	   of	   pull	   (Charras	   &	   Paluch	   2008;	   Tozluoğlu	   et	   al.	   2013).	   Bleb-­‐based	  
motility	   in	   SCs	   is	   shown	   to	  be	   the	   faster	   form	  of	  movement	  along	  myofibres,	   relative	   to	   the	  more	  
traditionally-­‐described	   lamellipodia-­‐based	   method	   (Otto	   et	   al.	   2011).	   However,	   until	   relatively	  
recently,	  cell	  migration	  was	  a	  much	  neglected	  although,	  essential	  characteristic	  of	  SC	  repair.	  
Regulation	   of	   the	   Rac	   and	   Rho	   GTPase	   signalling	   pathways,	   that	   function	   antagonistically	   to	   one	  
another,	   are	   known	   to	   mediate	   between	   the	   two	   mechanisms	   of	   migration	   (Sanz-­‐Moreno	   et	   al.	  
2011).	  Rac	  activity	  and	  its	  downstream	  components	  control	  lamellipodia	  extension,	  whereas	  the	  Rho	  
signalling	  pathway	  is	  responsible	  for	  plasma	  membrane	  blebbing	  and	  therefore,	  the	  amoeboid-­‐based	  
migration	   (Calvo	   et	   al.	   2011;	   Charras	   &	   Paluch	   2008;	   Sanz-­‐Moreno	   et	   al.	   2011).	   Importantly,	   it	   is	  
unknown	   whether	   the	   underlying	   mechanisms	   of	   bleb-­‐based	   motility	   are	   regulated	   by	   intrinsic	  
properties	   of	   SCs,	   or	   stimulated	   by	   characteristics	   of	   the	   myofibre	   surface.	   Indeed,	   the	   myofibre	  
matrix	  seemingly	   influences	  the	  mode	  of	  migration	  adopted	  by	  SCs,	  as	   it	  was	  previously	  noted	  that	  
on	  plastic	  surfaces	  in	  vitro,	  SCs	  formed	  lamellipodia	  (Otto	  et	  al.	  2011).	  	  
The	   physical	   properties	   of	   the	   microenvironment	   surface	   are	   not	   only	   believed	   to	   impact	   on	  
mechanisms	  of	  migration,	   but	   have	   also	  been	   shown	   to	  direct	   lineage	   specification	   and	   therefore,	  
the	   fate	   of	   stem	   cells.	   Engler	   and	   colleagues	   demonstrated	   that,	   by	  mimicking	   the	   physiologically-­‐
relevant	  matrix	   elasticities	  of	  brain,	  muscle	  or	  bone	   in	   vitro,	  human	  mesenchymal	   stem	  cells	  were	  
induced	   towards	   neuronal,	   myogenic	   or	   osteogenic	   lineages,	   respectively	   (Engler	   et	   al.	   2006).	  
Furthermore,	   Gilbert	   and	   colleagues	   reported	   that	   altered	   surface	   stiffness,	   for	   example	   through	  
fibrosis	  as	  a	  result	  of	  damage,	  dramatically	  perturbed	  the	  self-­‐renewing	  capacity	  of	  SCs	  (Gilbert	  et	  al.	  
2010).	   Therefore,	   these	   findings	  are	   vital	   to	   the	   fields	  of	   stem	  cell	   therapy	  and	   tissue	  engineering,	  
where	   culture	   conditions	   and	   tissue	   scaffolds	   can	   be	   tailored	   to	   the	   physiological	   elasticities,	  
improving	  overall	   therapeutic	   success.	  Consideration	  of	   the	  physiological	  matrix	  elasticity	   and	  how	  
these	   become	   altered	   in	   both	   ageing,	   injury	   and	   disease,	   can	   better	   optimise	   stem	   cell	   treatment	  
within	  a	  specific	  tissue.	  Moreover,	  the	  so	  far	  largely	  limited	  success	  reported	  with	  the	  use	  of	  whole	  
cell-­‐based	  therapies,	   in	  replenishing	  damaged	  tissue	  in	  cases	  of	   injury	  and	  disease,	  can	  therefore	  in	  
part,	   be	   attributed	   to	   a	   limited	   understanding	   or	   consideration	   of	   the	   tissue	   surface	   elasticity.	  
Additionally,	   alterations	   to	   the	   skeletal	  muscle	  myofibre	  microenvironment	   or	   niche	   are	   known	   to	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occur	  with	  increasing	  age	  which	  impact	  on	  overall	  contractility	  and	  force-­‐generating	  capacity,	  as	  well	  
as	  also	  reducing	  mechanotransduction	  signalling	  and	  SC	  regulation.	  For	  example,	  SC	  activity	  has	  been	  
shown	   to	   be	   impaired	   due	   to	   an	   increased	   microenvironment	   stiffness	   linked	   with	   subsequent	  
increases	   in	  ECM	  content	  and	  cross-­‐linking	  (Lacraz	  et	  al.	  2015;	  Kragstrup	  et	  al.	  2011).	  Deposition	  of	  
collagen,	  a	  main	   structural	  ECM	  component,	  as	  well	   as	   fat	   infiltration	  have	  also	  been	  shown	   to	  be	  
greater	   in	   ageing	   muscle	   (Alnaqeeb	   et	   al.	   1984;	   Lacraz	   et	   al.	   2015;	   Kent-­‐Braun	   et	   al.	   2000;	  
Baumgartner	  2000;	  Taaffe	  et	  al.	  2009).	  Other	  features	  such	  as	  collagen	  cross-­‐linking	  and	  a	  build-­‐up	  of	  
advanced	   glycation	   end-­‐product	   (AGE)	   cross-­‐links	   are	   also	   believed	   to	   contribute	   to	   increased	  
stiffness	  of	  myofibres	  observed	   in	  ageing	   (Zimmerman	  et	  al.	  1993;	  Gosselin	  et	  al.	  1998;	  Haus	  et	  al.	  
2007).	  
These	   findings	   taken	  together	   formed	  the	  knowledge	  basis	   for	   the	   following	  series	  of	  experiments.	  
Importantly,	   building	   on	   the	   results	   from	   the	   experiments	   conducted	   and	   discussed	   in	   previous	  
sections,	  the	  role	  of	  the	  myofibre	  microenvironment	   in	  directing	  SC	  activity	  was	   investigated.	   (A)	   It	  
was	   hypothesised	   that	   the	   amoeboid-­‐based	   migratory	   phenomenon	   demonstrated	   by	   skeletal	  
muscle	  SCs,	  is	  directed	  predominantly	  by	  the	  myofibre	  surface	  (Otto	  et	  al.	  2011;	  Collins-­‐Hooper	  et	  al.	  
2012).	  (B)	  It	  is	  unknown	  whether	  the	  myofibre	  matrix	  similarly,	  could	  induce	  the	  bleb-­‐based	  form	  of	  
migration	   in	  non-­‐muscle	  cells,	  as	  an	  alternative	  migratory	  option	  available	  to	  all	  stem	  cells.	   (C)	  The	  
impact	  of	  the	  ageing	  myofibre	  microenvironment	  on	  the	  migratory	  and	  morphological	  characteristics	  
of	  the	  non-­‐muscle	  cells	  was	  examined.	  (D)	  The	  extent	  that	  alterations	  to	  SC	  activity	  can	  be	  attributed	  
to	  physical	  features	  of	  the	  ageing	  myofibre,	  rather	  than	  changes	  intrinsic	  to	  the	  SC,	  was	  assessed.	  (E)	  
The	   in	   vitro	   effects	   of	   CM	   treatment	   in	   our	   single	  myofibre	   culture	   set-­‐up,	  were	   investigated	   and	  
comparisons	  drawn	  between	  in	  vitro	  and	  in	  vivo	  CM	  treatment	  of	  the	  previous	  experimentation.	  (F)	  It	  
was	  postulated	  that	  the	  same	  molecular	  mechanisms	  underpinned	  the	  regulation	  of	  amoeboid-­‐based	  
migration	  in	  each	  cell	  type	  examined.	  (G)	  It	  was	  proposed	  that	  the	  fate	  of,	  not	  only	  transplanted	  non-­‐
muscle	  stem	  cells,	  but	  also	  non-­‐stem	  cells	  could	  be	  influenced	  by	  the	  myofibre	  surface.	  
As	  before,	  single	  myofibres	  were	   isolated	   from	  the	  EDL	  muscle	  of	  mice	  and	  cultured.	  Alternatively,	  
however,	  myofibres	  were	  co-­‐cultured	  with	  transplanted	  non-­‐muscle	  stem	  and	  non-­‐stem	  cells.	  Three	  
well-­‐defined	   stem	   cell	   populations	   used	   included	   human	   adipose-­‐derived	  mesenchymal	   stem	   cells	  
(ADMSC),	  dental	  pulp	  stem	  cells	  (DP)	  and	  amniotic	  fluid	  stem	  cells	  (AFS).	  These	  stem	  cell	  types	  have	  
been	  extensively	  characterised	  for	  multipotency,	  are	  relatively	  easily	  cultured	  and	  are	  currently	  being	  
developed	   as	   stem	   cell	   therapies	   for	   human	  diseases	   (Bajek	   et	   al.	   2016;	   Condé-­‐Green	   et	   al.	   2016;	  
Mead	  et	  al.	  2016;	  Collart-­‐Dutilleul	  et	  al.	  2015;	  Zhang	  et	  al.	  2006;	  Tajiri	  et	  al.	  2014).	  The	  MDA-­‐MB-­‐231	  
breast	  cancer	  cell	  line	  (MDA)	  is	  a	  well-­‐defined,	  highly	  invasive	  epithelial	  cancer	  cell	  line,	  chosen	  in	  the	  
present	  study	  as	  a	  non-­‐stem	  cell	  source	  that	  is	  extremely	  easy	  to	  cultivate.	  The	  MDA	  cell	  line	  is	  also	  
196	  
Taryn	  Morash	  
studied	  extensively	  in	  cancer	  metastasis,	  characterised	  by	  an	  invasive	  endothelial-­‐like	  morphology	  in	  
three-­‐dimensional	   (3D)	  Matrigel	  culture	  (Chavez	  et	  al.	  2010;	  Kenny	  et	  al.	  2007;	  Harrell	  et	  al.	  2014).	  
AFS,	   DP	   and	  MDA	   cells	   were	   all	   GFP+	   cell	   lines	   and	   therefore,	   were	   identified	   using	   an	   anti-­‐GFP	  
antibody.	   The	   ADMSC	   cells	   however,	   were	   identified	   using	   PKH26	   membrane	   dye.	   Subsequently,	  
migration	  of	  these	  transplanted	  cell	  types	  along	  myofibres	  was	  analysed	  using	  time-­‐lapse	  microscopy	  
and	  morphological	  features	  were	  visualised	  using	  immunocytochemistry	  protocols	  for	  alpha	  smooth	  




The	  skeletal	  myofibre	  matrix	  influences	  non-­‐muscle	  cellular	  morphologies	  
Firstly,	   the	   influence	   of	   the	   myofibre	   surface	   on	   the	   mechanisms	   underlying	   cell	   migration	   was	  
characterised.	   Thus,	   cell	   morphologies	   of	   each	   cell	   type	   were	   compared	   on	   tissue	   culture	   plastic	  
versus	   on	   myofibres.	   It	   was	   noted	   that,	   like	   the	   majority	   of	   SCs,	   ADMSC,	   AFS	   and	   DP	   stem	   cells	  
cultured	   on	   plastic,	   displayed	   an	   elongated,	   flattened	   shape	   (p	   =	   <0.001)	   (Figure	   6.1	   A,	   C1-­‐4).	   In	  
contrast,	  approximately	  80%	  of	  MDA	  cells	  were	  more	  rounded	  than	  elongated	   (p	  =	  <0.001)	   (Figure	  
6.1	  A).	  These	  morphology	  profiles	  were	  subsequently	  compared	  to	  those	  displayed	  when	  the	  same	  
cell	  types	  were	  situated	  on	  the	  myofibres	  surface.	  As	  previously	  reported,	  it	  was	  observed	  that	  all	  SCs	  
assumed	  a	  rounded	  morphology	  (p	  =	  <0.001)	  (Figure	  6.1	  B).	  Once	  placed	  on	  myofibres,	  remarkably,	  
the	   proportion	   of	   rounded	   morphologies	   were	   significantly	   higher	   in	   all	   of	   the	   other	   cell	   types	  
examined	  (ADMSC,	  p	  =	  <0.01.	  AFS,	  DP,	  MDA,	  p	  =	  <0.001,	  respectively)	  (Figure	  6.1	  B,	  C5-­‐8).	  
	  
Figure	  6.1	  The	  skeletal	  myofibre	  matrix	  influences	  non-­‐muscle	  cellular	  morphologies.	  (A)	  Frequencies	  
of	  morphologies	  adopted	  by	  SCs,	  ADMSCs,	  AFS,	  DP,	  MDA	  on	  plastic.	  (B)	  Frequencies	  of	  morphologies	  
adopted	   by	   SCs,	   ADMSCs,	   AFS,	   DP,	   MDA	   on	   myofibres.	   Ercc1d/-­‐	   SCs	   migrated	   at	   faster	   velocities	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compared	  to	  old	  and	  geriatric	  SCs.	  (C)	  Representative	  morphologies	  of	  non-­‐muscle	  cells	  observed	  on	  
plastic	  (1-­‐4)	  and	  on	  myofibres	  (5-­‐8).	  	  **p<0.01,	  ***p<0.001,	  Individual	  student’s	  t-­‐tests.	  
	  
The	  skeletal	  muscle	  myofibre	  impacts	  on	  the	  migration	  speed	  of	  co-­‐cultured	  
non-­‐muscle	  cells	  
Next,	   the	   influence	   of	   the	   matrix	   substrate	   on	   cell	   migration	   speed	   was	   explored.	   Firstly,	   it	   was	  
observed	  that	  SCs	  travelled	  faster	  on	  myofibres,	  when	  compared	  to	  plastic	  (p	  =	  <0.001)	   (Figure	  6.2	  
A).	  In	  fact,	  the	  SC	  migration	  speed	  on	  myofibres	  was	  double	  that	  recorded	  on	  plastic	  (approximately	  
40	   and	  20µm/h,	   respectively).	   In	   addition,	   the	  myofibre	  matrix	   also	   supported	   faster	  motility	   than	  
that	   of	   a	   plastic	   surface,	   for	   both	   DP	   and	   MDA	   cells	   (p	   =	   <0.001)	   (Figure	   6.2	   A).	   In	   contrast,	   a	  
significantly	  decreased	  migration	  speed	  was	  observed	   in	  ADMSC	  and	  AFS	  cells,	  on	  myofibres	  when	  
compared	  to	  plastic	  (p	  =	  <0.01	  and	  <0.001,	  respectively)	  (Figure	  6.2	  A).	  The	  migration	  speeds	  of	  the	  
differing	   cell	   morphologies	   on	   myofibres,	   were	   compared.	   It	   was	   noted	   that	   migration	   speeds	   of	  
ADMSC,	   DP	   and	   MDA	   cells	   were	   not	   affected	   by	   the	   shape	   of	   the	   cell	   (round	   v	   elongated).	  
Surprisingly	   however,	   rounded	   AFS	   cells	   travelled	   at	   slower	   speeds	   on	   myofibres,	   (23µm/h),	  
compared	  to	  those	  with	  an	  elongated	  form	  (32µm/h,	  p	  =	  <0.01)	  (Figure	  6.2	  B).	  
	  
Figure	  6.2	  The	  skeletal	  muscle	  myofibre	   impacts	  on	  the	  migration	  speed	  of	  co-­‐cultured	  non-­‐muscle	  
cells.	   (A)	  Cell	  migration	   speed	   comparison	   between	   plastic	   and	  myofibre	   substrates.	   (B)	  Migration	  
speeds	   of	   differing	   morphologies	   of	   resident	   and	   non-­‐muscle	   cells	   on	   myofibres.	   **p<0.01,	  




The	  effect	  of	  the	  ageing	  skeletal	  myofibre	  matrix	  and	  in	  vitro	  conditioned	  
media	  treatment	  on	  non-­‐muscle	  cellular	  morphologies	  
After	   establishing	   that	   the	   myofibre	   surface	   influenced	   the	   cellular	   morphologies	   adopted	   by	  
transplanted	  non-­‐muscle	  cells	  on	  young	  myofibres,	  similar	  analyses	  were	  conducted	  using	  aged	  (24	  
month-­‐old)	  myofibres.	  Firstly,	  it	  was	  noted	  that,	  concurrent	  with	  the	  findings	  of	  young	  myofibres,	  for	  
each	   cell	   type	   examined,	   the	  majority	   of	   cells	   adopted	   a	   rounded	  morphology	   on	   aged	  myofibres	  
(ADMSC,	  p	  =	  <0.05.	  SC,	  AFS,	  DP,	  MDA	  p	  =	  <0.001,	  respectively)	  (Figure	  6.3	  A,	  B).	  CM	  treatment	  was	  
then	  used	  alternatively	   in	   vitro,	   at	   the	   chosen	   concentration	   (1%),	  which	  demonstrated	  protection	  
against	  cellular	  senescence	  during	  CM	  testing.	  Secondly,	  with	  CM	  treatment,	  as	  observed	  previously,	  
the	  majority	  of	  cells	  in	  each	  cell	  type,	  were	  more	  rounded	  in	  shape	  in	  young	  myofibre	  cultures	  (p	  =	  
<0.001)	  (Figure	  6.3	  C).	  Similarly,	  in	  aged	  myofibre	  cultures	  with	  CM	  treatment,	  the	  rounded	  form	  was	  
the	  most	  frequently	  adopted	  morphology	  in	  SC,	  ADMSC,	  DP	  and	  MDA	  cell	  types	  (ADMSC,	  p	  =	  <0.01.	  
SC,	  DP,	  MDA	  p	  =	  <0.001,	  respectively)	  (Figure	  6.3	  D).	  In	  contrast,	  for	  AFS	  cells,	  there	  was	  no	  statistical	  
difference	  between	  the	  proportions	  of	  cells	  that	  took	  on	  more	  rounded	  or	  more	  elongated	  forms,	  in	  
the	   aged	   CM-­‐treated	   condition	   (Figure	   6.3	   D).	   The	   proportions	   of	   round	   cells	   were	   subsequently	  
analysed	  in	  more	  detail	  between	  culture	  conditions,	  for	  each	  cell	  type	  examined	  (Figure	  6.3	  D).	  It	  was	  
noted	  that	  neither	  the	  aged	  myofibre	  surface	  nor	   in	  vitro	  CM	  treatment	   influenced	  SC	  morphology	  
(Figure	   6.3	   E).	   Additionally,	   there	   were	   no	   statistical	   differences	   in	   the	   proportion	   of	   rounded	  
ADMSCs	   observed	   between	   conditions	   (Figure	   6.3	   F).	   The	   aged	   myofibre	   surface	   alone	   did	   not	  
influence	   the	   shape	   of	   AFS	   cells	   (Figure	   6.3	   G).	   However,	   CM	   treatment	   in	   old	   myofibre	   cultures	  
drastically	   reduced	   the	   percentage	   of	   AFS	   cells	   that	   adopted	   a	   round	   form,	   relative	   to	   the	   other	  
conditions	  (p	  =	  <0.001	  and	  <0.01)	  (Figure	  6.3	  G).	  Remarkably,	  the	  proportions	  of	  both	  DP	  and	  MDA	  
cells	   that	   took	   on	   a	   rounded	   morphology	   were	   significantly	   decreased	   on	   aged	   myofibres,	   when	  
compared	  to	  young	  (p	  =	  <0.05	  and	  <0.001,	  respectively)	  (Figure	  6.3	  H,	  I).	  Moreover,	  CM	  treatment	  in	  
aged	   cultures,	   subsequently	   increased	   the	   percentage	   of	   round	  DP	   cells	   observed	   to	   a	   proportion	  




Figure	  6.3	  The	  effect	  of	  the	  ageing	  skeletal	  myofibre	  matrix	  and	  in	  vitro	  conditioned	  media	  treatment	  
on	  non-­‐muscle	   cellular	  morphologies.	   Frequencies	  of	  morphologies	   adopted	  by	   SCs,	  ADMSCs,	  AFS,	  
DP,	  MDA	  on:	  (A)	  Young	  myofibres.	  (B)	  Old	  myofibres.	  (C)	  Young	  myofibres	  with	   in	  vitro	  CM.	  (D)	  Old	  
myofibres	   with	   in	   vitro	   CM.	   Significance	   indicated	   between	   round	   and	   elongated	   forms.	   (E-­‐I)	  
Percentage	   of	   rounded	   cells	   observed	   of	   each	   cell	   type	   between	   culture	   conditions.	   *p<0.05,	  








































The	  effect	  of	  the	  ageing	  skeletal	  myofibre	  matrix	  and	  in	  vitro	  conditioned	  
media	  treatment	  on	  the	  migration	  speeds	  of	  non-­‐muscle	  cells	  
In	  the	  previous	  series	  of	  experiments,	  in	  vivo	  CM	  treatment	  resulted	  in	  altered	  cell	  migration	  speeds	  
(increased	   in	   natural	   ageing,	   decreased	   in	   Ercc1d/-­‐).	   Thus,	   the	   regulatory	   effects	   of	   in	   vitro	   CM	  
treatment	  on	  the	  speed	  of	  movement	   in	  the	  non-­‐muscle	  cells,	   in	  young	  and	  aged	  myofibre	  culture	  
conditions,	   was	   explored.	   Firstly,	   it	   was	   noted	   that,	   despite	   a	   slightly	   reduced	   average	   migration	  
speed	  observed	  on	  aged	  myofibres,	  there	  were	  no	  statistical	  differences	  in	  SC	  velocities	  in	  any	  of	  the	  
conditions	   (Figure	   6.4	   A).	   ADMSC	  migration	   speeds	   were	   significantly	   increased	   in	   aged	   myofibre	  
cultures	  when	  compared	  to	  young	  (p	  =	  <0.001)	   (Figure	  6.4	  B).	  Additionally,	  CM	  treatment	   in	  young	  
myofibre	  cultures	  also	  resulted	  in	  greater	  rates	  of	  ADMSC	  motility	  (p	  =	  <0.05)	  (Figure	  6.4	  B).	  Similarly	  
to	   SCs,	   variations	   in	   AFS	   migration	   speeds	   between	   culture	   conditions,	   were	   statistically	   not	  
significant	   (Figure	   6.4	   C).	   On	   the	   other	   hand,	   as	   observed	   with	   ADMSCs,	   CM	   treatment	   in	   young	  
myofibre	   cultures	   increased	   the	   rate	   of	   motility	   of	   DP	   cells	   (p	   =	   <0.05)	   (Figure	   6.4	   D).	  Moreover,	  
speed	  of	  movement	  was	   further	  drastically	   increased	   in	  DP	  cells	   co-­‐cultured	  on	   the	  aged	  myofibre	  
surface	   (p	   =	   <0.001).	   Strikingly	   however,	   CM	   treatment	   in	   aged	   myofibre	   cultures,	   returned	   DP	  
migration	   speeds	   to	   those	   recorded	  when	   travelling	  along	  young	  myofibres	   (p	   =	  <0.05).	   Lastly,	   the	  
age	  of	  the	  myofibre	  did	  not	  significantly	  influence	  the	  rate	  of	  motility	  of	  the	  transplanted	  MDA	  cells	  
(Figure	  6.4	  E).	  However,	  remarkably,	  CM	  treatment	  in	  the	  aged	  myofibre	  condition	  greatly	  enhanced	  




Figure	  6.4	  The	  effect	  of	  the	  ageing	  skeletal	  myofibre	  matrix	  and	  in	  vitro	  conditioned	  media	  treatment	  
on	  the	  migration	  speeds	  of	  non-­‐muscle	  cells.	  Cell	  migrations	  speeds	  of	  (A)	  SC,	  (B)	  ADMSC,	  (C)	  AFS,	  (D)	  
DP,	   (E)	  MDA	   in	  different	  age	  and	  CM	  culture	   conditions.	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  One-­‐way	  
ANOVA	  with	  Tukey	  post	  hoc	  testing.	  
	  
Examining	  the	  activity	  of	  ROCK	  and	  Arp2/3	  in	  the	  regulation	  of	  cell	  migration	  
and	  morphologies	  
Next,	   the	  molecular	  mechanisms	  underpinning	  cell	  migration	  and	  morphology	  were	   investigated.	   It	  
was	  proposed	   that	   the	   same	   regulatory	   signalling	  pathways	   that	   support	   efficient	   SC	  motility,	   also	  
drives	   the	   amoeboid-­‐based	  method	   of	  migration	   observed	   in	   all	   other	   cell	   types	   examined,	   when	  
placed	   on	  myofibres.	   Importantly,	   colleagues	   have	   previously	   shown	   that	   ROCK	   activity	  was	   a	   key	  
determinant	  of	  the	  rounded	  morphology	  and	  bleb-­‐based	  migration	  in	  SCs	  (Collins-­‐Hooper	  et	  al.	  2012;	  
Otto	  et	  al.	  2011).	  Contrastingly,	  studies	  have	  demonstrated	  that	  the	  activity	  of	  the	  Arp2/3	  complex	  is	  
required	   for	  actin	  branching	  and	  organisation	   in	   the	   formation	  of	   lamellipodia	  (Bergert	  et	  al.	  2012;	  
Wu	  et	  al.	  2012).	  Through	  the	  use	  of	  Y-­‐27632	  and	  CK666,	  well-­‐known	  inhibitors	  of	  ROCK	  and	  Arp2/3,	  
respectively,	  the	  effects	  of	  blocking	  the	  activity	  of	  each	  counter-­‐acting	  signalling	  pathway	  separately,	  
on	  cell	  migration	   speeds	  and	  morphology,	  were	  analysed	   (Krawetz	  et	  al.	  2011;	  Hetrick	  et	  al.	  2013;	  
Bergert	  et	  al.	  2012).	  As	  before,	  cell	  migration	  was	  analysed	  using	  time-­‐lapse	  microscopy.	  Additionally,	  
cell	  morphologies	  were	  visualised	  using	  an	  immunocytochemistry	  protocol	  to	  identify	  alpha	  smooth	  
muscle	  actin	  (SMA)	  organisation	  within	  transplanted	  cells	  on	  myofibres.	  Firstly,	  it	  was	  observed	  that	  
inhibiting	  ROCK	  did	  not	  affect	  SC	  migration	  speeds	  (Figure	  6.5	  A).	  Inhibiting	  ROCK	  decreased	  the	  rate	  
of	  motility	   in	  ADMSC,	  AFS	   and	  MDA	   cells,	  when	   compared	   to	   the	   control	   cells	   (mock-­‐treated	  with	  
solvent	  only)	  (p	  =	  <0.001)	  (Figure	  6.5	  B).	  Like	  with	  the	  SCs,	  DP	  cells	  treated	  with	  the	  ROCK	  inhibitor	  
however,	  showed	  no	  statistical	  difference	  in	  migration	  speeds,	  relative	  to	  control	  cells	  (Figure	  6.5	  B).	  
Furthermore,	   inhibition	   of	   Arp2/3	   activity	   significantly	   reduced	   the	   rate	   of	   motility	   of	   SCs	   and	  
ADMSCs	  only	  (p	  =	  <0.001	  and	  <0.05,	  respectively)	  (Figure	  6.5	  B).	  Following	  this,	  the	  influence	  of	  the	  
inhibitors	  on	  cell	  morphology	  was	  also	  investigated.	  For	  all	  cell	  types,	  inhibition	  of	  ROCK	  resulted	  in	  
the	  majority	  of	  cells	  adopting	  an	  elongated	  morphology	  (SC,	  ADMSC,	  DP,	  p	  =	  <0.001.	  MDA,	  p	  =	  <0.01.	  
AFS,	  p	  =	  <0.05)	  (Figure	  6.5	  C).	  Whereas,	  Arp2/3	  inhibition	  promoted	  almost	  100%	  of	  cells	  of	  each	  cell	  




Figure	  6.5	  Examining	  the	  activity	  of	  ROCK	  and	  Arp2/3	  in	  cell	  migration	  and	  morphologies.	  (A)	  Effect	  
of	   inhibiting	   ROCK	   (Y-­‐27632)	   and	   Arp2/3	   (CK666)	   on	   resident	   SC	  migration	   and	  morphologies.	   (B)	  
Effect	  of	   inhibiting	  ROCK	  (Y-­‐27632)	  and	  Arp2/3	  (CK666)	  on	  non-­‐muscle	  cell	  migration	  on	  myofibres.	  
(C)	   Effect	   of	   inhibiting	   ROCK	   (Y-­‐27632)	   and	   Arp2/3	   (CK666)	   on	   non-­‐muscle	   cell	   morphology	  
frequencies.	   Statistical	   differences	   indicated	   between	   proportion	   of	   rounded	   and	   elongated	   cell	  
numbers.	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  (A-­‐B)	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  (A,	  C)	  
Individual	  student’s	  t-­‐tests.	  	  
	  
Influence	  of	  ROCK	  and	  Arp2/3	  on	  cell	  surface	  characteristics	  of	  non-­‐muscle	  cells	  
on	  myofibres	  
It	   is	  well-­‐established	   that	   SCs	  utilise	   the	   amoeboid-­‐like	  mechanism	   for	  movement	   along	  myofibres	  
and	   characteristically,	   this	   form	   of	   motility	   employs	   an	   abundance	   of	   regular	   dynamic	   plasma	  
membrane	  vesicle-­‐like	  protrusions	  or	  blebs	   (Otto	  et	  al.	  2011;	  Collins-­‐Hooper	  et	  al.	  2012;	  Charras	  &	  
Paluch	  2008).	  Thus,	  the	  non-­‐muscle	  cells	  were	  examined	  for	  the	  presence	  of	  visible	  cell	  surface	  blebs	  
using	  scanning	  electron	  microscopy	  (SEM).	  As	  treatment	  with	  the	  Y-­‐27632	  (ROCK)	  inhibitor	  resulted	  
in	  an	  abundance	  of	  elongated	  cells	  on	  myofibres,	  as	  discussed,	  therefore	  there	  was	  an	  absence	  of	  cell	  
surface	  blebs	  with	  all	  cell	  types	  (ADMSC,	  DP,	  MDA,	  p	  =	  <0.001.,	  AFS,	  p	  =	  <0.01	  SC)	  (Figure	  6.6	  i,	  A).	  In	  
contrast,	  treatment	  with	  CK666	  indicated	  a	  significant	  increase	  in	  the	  number	  of	  blebs	  present	  on	  the	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surface	  of	  ADMSC,	  DP	  and	  MDA	  cells	  on	  myofibres,	  when	  compared	  to	  control	  cells	  (p	  =	  <0.05	  and	  
<0.001,	  SC	  CK666	  data	  missing)	  (Figure	  6.6	  i,	  A).	  Following	  this,	  examination	  of	  the	  bleb	  dimensions,	  
was	   subsequently	   conducted.	   It	   was	   noted	   that	   bleb	   dimensions	   were	   not	   affected	   to	   any	   great	  
degree,	   compared	   between	   control	   and	   Arp2/3-­‐inhibited	   cells,	   with	   the	   exception	   of	   an	   increase	  





Figure	   6.6	   Influence	   of	   ROCK	   and	   Arp2/3	   on	   cell	   surface	   characteristics	   of	   non-­‐muscle	   cells	   on	  
myofibres.	  Quantification	  of	  resident	  SC	  bleb	  numbers	   (i)	  Bleb	  dimensions	  (ii).	  (A)	  Quantification	  of	  
bleb	  numbers	  on	  non-­‐muscle	  cells	  following	  ROCK	  (Y-­‐27632)	  and	  Arp2/3	  (CK666)	  inhibition;	  (B)	  Bleb	  
dimensions.	   Scanning	   electron	   microscopy	   (SEM)	   images	   of	   transplanted	   cell	   types	   treated	   with	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solvent	   only	   (C-­‐F),	   ROCK	   inhibitor	   (G-­‐J)	   and	   Arp2/3	   inhibitor	   (K-­‐N).	   Scale	   5µm.	   *p<0.05,	   **p<0.01,	  
***p<0.001,	  (A)	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  (i-­‐ii,	  B)	  Individual	  student’s	  t-­‐tests.	  	  
	  
The	  effect	  of	  the	  skeletal	  myofibre	  matrix	  on	  the	  proliferative	  capacity	  of	  non-­‐
muscle	  cells	  
The	   influence	   of	   the	   extrinsic	   physical	   properties	   of	   the	   myofibre	   surface,	   on	   the	   underlying	  
mechanisms	  of	  proliferation	  remained	  to	  be	  examined.	  Young	  SCs	  following	  activation	  are	  shown	  to	  
initiate	   rounds	   of	   cell	   division	   at	   approximately	   24	   hours,	   hereafter	   total	   numbers	   of	   SCs	   per	  
myofibre	  are	  known	  to	  more	  than	  double	  by	  48	  hours	  of	  culture	  (Collins-­‐Hooper	  et	  al.	  2012;	  Zammit	  
2002).	   Proliferation	   of	   the	   transplanted	   ADMSC,	   AFS	   and	   MDA	   cells	   on	   the	   surface	   of	   single	  
myofibres,	  was	  monitored	  at	   T14,	   24	  and	  48	   (Figure	  6.7	  A,	  B,	   C).	  Most	  notably	  however,	   the	   total	  
number	  and	  cluster	   sizes	  of	  ADMSCs	  present	  on	  myofibres	  had	  significantly	  decreased	  by	  T48	   (p	   =	  
<0.05,	   respectively)	   (Figure	   6.7	   C).	   Additionally,	   proliferation	   was	   evident	   in	   the	  MDA	   population,	  
with	   an	   observed	   increase	   in	   total	   cells	   per	   myofibre	   by	   T48,	   however	   this	   difference	   was	   not	  
statistically	   significant	   (Figure	   6.7	   A).	   Although,	   contrastingly,	   the	   number	   of	   MDA	   clusters	   per	  
myofibre	  was	  reduced	  between	  T14	  and	  24	  (p	  =	  <0.05)	  (Figure	  6.7	  B).	  Moreover,	  the	  number	  of	  AFS	  
cells	  fluctuated	  slightly	  but	  differences	  observed	  were	  statistically	  not	  significant.	  	  
Induction	  of	  MyoD	  expression	  in	  AFS	  and	  MDA	  cells	  after	  prolonged	  culture	  on	  
myofibres	  
Myogenic	  lineage	  commitment	  and	  differentiation	  of	  SCs	  into	  myoblasts,	  the	  expression	  of	  MHC	  and	  
fusion	   into	  mature	  myotubes,	  marks	   the	  essential	   final	   step	   in	   the	  process	  of	  SC-­‐mediated	  skeletal	  
muscle	   repair,	   maintenance	   and	   growth.	   Lastly,	   therefore,	   the	   myofibre	   matrix	   was	   examined	  
regarding	  the	  potential	  to	  direct	  non-­‐muscle	  cells	  towards	  a	  myogenic	  fate.	  As	  before,	  the	  GFP+	  non-­‐
muscle	  cells	  were	  seeded	  onto	  freshly	  isolated	  myofibres	  in	  order	  to	  profile	  the	  expression	  of	  MyoD,	  
the	   marker	   of	   myogenic	   lineage	   commitment	   (Zammit	   et	   al.	   2004).	   Resident	   SCs	   are	   known	   to	  
express	   Pax7	   on	   freshly	   isolated	   myofibres,	   whereas	   MyoD	   expression	   becomes	   detectable	   at	  
approximately	  T24	  (Zammit	  et	  al.	  2004).	  Pax7	  is	  subsequently,	  gradually	  down-­‐regulated	  following	  48	  
hours	   of	   culture,	   where	   cells	   continue	   along	   the	  myogenic	   differentiation	   pathway	   (Zammit	   et	   al.	  
2004;	  Zammit,	  Relaix,	  et	  al.	  2006;	  Yablonka-­‐Reuveni	  &	  Rivera	  1994).	  None	  of	  the	  transplanted	  GFP+	  
non-­‐muscle	   cells	   examined	   (ADMSC,	   AFS	   and	  MDA),	   co-­‐expressed	   Pax7	   at	   the	   SC-­‐relevant	   culture	  
time-­‐points	   (T14,	  24	  and	  48),	  evident	  by	   the	   lack	  of	   ‘Double’	  expression	   (Figure	  6.7	  D,	  E,	  F).	  MyoD	  
expression	  was	  detected	  in	  more	  than	  80%	  of	  the	  resident	  SCs	  after	  24	  hours	  of	  culture	  (Figure	  6.8	  
A).	   Between	   48	   and	   120	   hours	   of	   culture,	   all	   SCs	   on	   myofibres	   expressed	   MyoD,	   which	   then	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diminished	   by	   T240	   (Figure	   6.8	   A).	   The	   non-­‐muscle	   cell	   types	   were	   observed	   initially	   adopting	  
rounded	  morphologies	   once	   transplanted	   onto	  myofibres,	   up	   until	   approximately	   T48,	  where	   cells	  
took	  on	  one	  of	  two	  forms.	  ADMSC	  and	  DP	  cells	  were	  observed	  gradually	  elongating	  and	  outstretching	  
lamellipodia	   protrusions,	   particularly	   around	   the	   myofibre	   circumference,	   resulting	   in	   myofibre	  
constrictions	  (Figure	  6.8	  B,	  C).	  By	  T72,	  it	  was	  observed	  that	  no	  normal,	  healthy	  myofibres	  remained	  in	  
the	   presence	   of	   both	  ADMSC	   and	  DP	   cells,	  with	   a	   large	  majority	   either	   curled	   into	   balls	   or	   hyper-­‐
contracted	   signifying	   myofibre	   damage.	   Contrastingly,	   AFS	   and	   MDA	   cells	   maintained	   a	   rounded	  
morphology	  and	  myofibres	   remained	  healthier	  during	  prolonged	  culture.	  Remarkably,	   it	  was	  noted	  
that	  by	  T240,	  approximately	  50%	  of	  AFS	  and	  MDA	  cells	  robustly	  expressed	  MyoD	  (Figure	  6.8	  A,	  D,	  E).	  
	  
Figure	  6.7	  The	  effect	  of	  the	  skeletal	  myofibre	  matrix	  on	  the	  proliferative	  capacity	  of	  non-­‐muscle	  cells.	  
(A)	  Proliferation	  analysed	  as	  cells	  per	  myofibre.	   (B)	  Proliferation	  analysed	  as	  clusters	  per	  myofibre.	  
(C)	  Proliferation	  analysed	  as	  cluster	  size.	  GFP+	  (D)	  ADMSC	  (E)	  AFS	  (F)	  MDA	  do	  not	  co-­‐express	  Pax7.	  
*p<0.05,	  (A-­‐F)	  One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  testing.	  
	  
Next,	   the	   myogenic	   differentiation	   potential	   of	   the	   non-­‐muscle	   cells	   was	   further	   investigated.	   As	  
observed	  with	  SC	  in	  previous	  studies,	  following	  enzymatic	  dissociation	  from	  myofibres,	  the	  ability	  of	  
cells	   to	   create	  myotube	   structures	   and	   therefore,	   myogenic	   differentiation,	   can	   be	   demonstrated	  
(Zammit	   et	   al.	   2004;	   Zammit,	   Relaix,	   et	   al.	   2006).	   Most	   remarkably,	   AFS	   cells	   that	   had	   been	  
dissociated	  from	  myofibres,	  fused	  to	  create	  elongated	  myotubes	  and	  this	  was	  further	  supported	  by	  
the	  co-­‐expression	  of	  GFP	  and	  MHC,	  a	  key	  component	  of	   the	  contractile	  property	  of	  muscle	   (Figure	  
6.8	  F).	  In	  contrast	  however,	  MDA	  cells	  that	  had	  also	  previously	  been	  co-­‐cultured	  for	  240	  hours	  on	  the	  
myofibre	   surface	   and	   subsequently	   dissociated,	   failed	   to	   fuse	   and	   form	   myotubes	   and	   did	   not	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express	  MHC	  (Figure	  6.8	  G).	  Alternatively,	  MDA	  cells	  proliferated	  profusely	  resulting	  in	  multiple	  cell	  
layers.	  Quantification	  of	  the	  AFS	  cells	  that	  expressed	  MHC	  showed	  that	  approximately	  8%	  of	  all	  AFS	  
cells	   cultured,	   were	   positive	   for	  MHC	   and	   fused	   to	   form	  myotubes	   with	   an	   average	   of	   1.5	   nuclei	  
(Figure	  6.8	  H,	  I).	   Importantly,	  characteristics	  of	  myogenic	  differentiation	  were	  not	  observed	  in	  MDA	  
or	   AFS	   cells	   that	   had	   not	   previously	   been	   in	   contact	   with	  myofibres	   (Figure	   6.9	   A,	   B).	   SC	   positive	  
controls	  expressed	  MHC	  and	  fused	  to	  form	  myotubes	  in	  culture	  (Figure	  6.9	  C).	  
	  
Figure	  6.8	  Induction	  of	  MyoD	  expression	  in	  AFS	  and	  MDA	  cells	  after	  prolonged	  culture	  on	  myofibres.	  
(A)	  Temporal	  profiling	  of	  non-­‐resident	  cells	  on	  myofibres	  for	  MyoD	  expression	  (B)	  ADMSC	  identified	  
by	  GFP	  expression,	  constricting	  myofibres	  at	  T24.	  (C)	  DP	  cell	  distorting	  myofibres	  at	  T24.	  (D)	  AFS	  cell	  
T240	  showing	  nuclear	  expression	  of	  MyoD	  co-­‐localising	  with	  DAPI	  (indicated	  by	  magenta	  arrow).	  (E)	  
MDA	  cell	  at	  T240	  showing	  nuclear	  expression	  of	  MyoD	  co-­‐localising	  with	  DAPI	  (indicated	  by	  magenta	  
arrow).	  (F)	  AFS	  cells,	  identified	  by	  GFP	  expression,	  co-­‐localising	  with	  myosin,	  fused	  to	  form	  elongated	  
myotube	  structures	  (arrowheads).	  (G)	  MDA	  cells	  co-­‐cultured	  with	  myofibres	  failed	  to	  initiate	  myosin	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expression.	   (H)	  Quantiﬁcation	   of	  GFP+	   cells	   expressing	  myosin.	   (I)	  Number	   of	   nuclei	   per	   cell	   GFP+	  
expressing	  myosin.	  Scale	  10µm	  (B–E),	  and	  100µm	  (F,	  G).	  *p<0.05,	  (H-­‐I)	  Individual	  student’s	  t-­‐tests.	  
	  
Figure	  6.9	  AFS	  and	  MDA	  cells	  that	  had	  not	  been	  in	  contact	  with	  the	  myofibre	  failed	  to	  express	  MHC	  
and	   did	   not	   fuse	   (A)	  MHC-­‐	  AFS	   cells,	   grown	   on	   glass	   cover	   slips	   in	   single	  myofibre	   culture	  media	  
(SFCM),	   that	   had	   not	   previously	   been	   co-­‐cultured	  with	  myofibres.	   (B)	  MHC-­‐	  MDA	   cells,	   grown	   on	  
glass	  cover	  slips	   in	  single	  myofibre	  culture	  media	  (SFCM),	  that	  had	  not	  previously	  been	  co-­‐cultured	  
with	  myofibres.	  (C)	  Dissociated	  SC	  positive	  control,	  cultured	  SCs	  on	  glass	  cover	  slips	  express	  MHC	  and	  
fuse	   (white	   arrowheads).	   MHC+	   SCs	   positioned	   side-­‐by-­‐side,	   aligning	   prior	   to	   fusion	   (yellow	  
arrowhead).	  Scale	  100µm.	  
	  




The	   importance	   of	   the	   physical	   properties	   of	   microenvironments	   is	   ever-­‐increasingly	   becoming	   a	  
focal	   point	   of	  much	   research.	   This	   is	   largely	   due	   to	   relatively	   unsuccessful	   use	   of	  whole	   stem	   cell	  
approaches	   to	   enhance	   tissue	   regeneration	   (Yin	   et	   al.	   2013).	   For	   example,	   including	   those	   that	  
employ	  the	  use	  of	  pre-­‐existing	  mechanisms	  of	  host	  tissues,	  through	  a	  paracrine	  effect	  such	  as	  stem	  
cell-­‐derived	   conditioned	  media	   (Conboy	  et	  al.	   2005;	  Mellows	  et	  al.	   2017).	  However,	   there	   remains	  
huge	  clinical	  benefit	  for	  successful	  whole	  stem	  cell-­‐based	  therapies.	  	  
Engler	  and	  colleagues	  altered	  the	  field	  of	  stem	  cell	  therapy,	  by	  showing	  that	  the	  elasticity	  or	  rigidity	  
of	  a	  matrix	  has	  profound	  effects	  on	  the	  fate	  of	  stem	  cells	  (Engler	  et	  al.	  2006).	   It	  was	  demonstrated	  
that	  by	  artificially	  mimicking	   the	  physiologically-­‐relevant	  matrix	  elasticities	  of	   the	  brain,	  muscle,	  or	  
bone	   in	   vitro,	   human	   mesenchymal	   stem	   cells	   were	   directed	   towards	   neuronal,	   myogenic	   or	  
osteogenic	  differentiation	  lineages,	  respectively	  (Engler	  et	  al.	  2006).	  Additionally,	  increased	  myofibre	  
stiffness	  with	  age	  and	  increased	  fibrosis	  following	  damage,	  has	  been	  shown	  to	  significantly	  impaired	  
SC	   regenerative	   potential	   and	   self-­‐renewing	   capacity	   (Gilbert	   et	   al.	   2010;	   Lacraz	   et	   al.	   2015).	  
Colleagues	  have	  also	  previously	  demonstrated	  that	  the	  skeletal	  muscle	  myofibre	  promotes	  resident	  
SCs	  to	  migrate	  utilising	  the	  distinctive	  amoeboid	  bleb-­‐based	  mechanism	  (Otto	  et	  al.	  2011).	  Therefore,	  
this	  further	  highlights	  the	   importance	  of	  the	  matrix	  elasticity	   in	  altering	  mechanisms	  of	  SC	  function	  
and	   further	   suggests	   how	   features	   such	   as	   cell	   migration,	   proliferation,	   self-­‐renewal	   and	  
differentiation	  are	  impacted	  in	  ageing,	  injury	  and	  disease.	  
It	   was	   established	   that	   all	   cell	   types,	   once	   introduced	   to	   the	   myofibre	   surface,	   similarly	   to	   the	  
resident	  SC	  population,	  adopted	  a	  rounded	  morphology	  and	  migrated	  by	  the	  amoeboid-­‐based	  form	  
of	  motility.	  Additionally,	  all	  cell	  types	  developed	  cell	  surface	  blebs,	  as	  observed	  during	  bleb-­‐mediated	  
movement	  of	  SCs.	  Therefore,	  these	  findings	  demonstrate	  that	  these	  features	  are	  not	  unique	  intrinsic	  
characteristics	  to	  SCs	  and	  instead,	  they	  are	  directed	  through	  contact	  with	  the	  myofibre	  (Morash	  et	  al.	  
2017).	  Others	  have	  previously	  reported	  that	  the	  amoeboid-­‐based	  migratory	  method	  was	  the	  faster	  of	  
the	  two	  forms	  of	  motility,	  demonstrated	  in	  SCs	  (Otto	  et	  al.	  2011).	  However,	  it	  should	  be	  noted	  that,	  
despite	   all	   non-­‐muscle	   cell	   types	   taking	   on	   the	   bleb-­‐mediated	   amoeboid	  mechanism,	   this	  was	   not	  
always	   accompanied	  by	  an	   increase	   in	   velocity.	  Rapid	   amoeboid	  movement	   is	   dependent	  on	   rapid	  
and	  frequent	  bleb	  extensions	  and	  retractions,	  whereby	  the	  full	  lifecycle	  of	  a	  bleb	  has	  been	  shown	  to	  
total	   approximately	   60	   seconds	   (Otto	   et	   al.	   2011).	   Furthermore,	   the	   bleb	   lifecycle	   is	   known	   to	   be	  
prolonged	   in	   aged	   SC	  motility	   which	   has	   been	   linked	   to	   an	   observed	   reduction	   in	   SC	   velocities	   in	  
ageing	  (Collins-­‐Hooper	  et	  al.	  2012).	  Therefore,	  one	  explanation	  for	  an	  apparent	  discordant	  finding	  of	  
bleb-­‐based	  migration,	  resulting	  in	  a	  slower	  rate	  of	  movement,	  in	  some	  of	  the	  non-­‐muscle	  cell	  types	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(ADMSC	   and	   AFS),	   could	   be	   that	   there	   is	   variation	   in	   the	   bleb	   dynamics	   between	   cell	   types.	  
Furthermore,	  upon	  closer	  investigation,	  it	  does	  seem	  that	  the	  number	  of	  blebs	  per	  DP	  and	  MDA	  cell	  
were	  slightly	  greater	   than	   those	  present	  on	   the	  surface	  on	  both	  ADMSCs	  and	  AFS	  cells.	  Moreover,	  
rapid	  assembly	  and	  disassembly	  of	  simple	  focal	  adhesion	  structures	  between	  the	  cell	  and	  the	  matrix,	  
has	  been	  proposed	   in	   the	   faster	  bleb-­‐mediated	  motility	   (Nagano	  et	  al.	  2012;	  Tozluoğlu	  et	  al.	  2013;	  
Charras	   &	   Paluch	   2008).	   Therefore,	   it	   could	   be	   postulated	   that	   the	   regulation	   of	   the	   molecules	  
required	   for	  efficient	   focal	  adhesion	   formation	  and	  deconstruction	  may	  be	  mismatched	   in	  some	  of	  
these	   cell	   types.	   It	   could	  be	   further	   suggested	   that	   the	   focal	   adhesions	  and	  other	   contacts	   formed	  
with	   the	   myofibre,	   vary	   between	   non-­‐muscle	   cells	   and	   SCs.	   For	   example,	   primary	   SCs	   have	   been	  
shown	   to	  express	  and	   interact	  with	  a	  wider	   range	  of	   integrins	   in	   the	  myofibre	  niche,	   compared	   to	  
C2C12	  and	  MM14	  murine	  satellite	  cell/myoblast	  cell	  lines	  (LaFramboise	  et	  al.	  2003).	  These	  cell	  lines	  
are	  extensively	  studied	  alongside	  mouse	  primary	  SCs	  similarly,	  to	  examine	  their	  capacities	  to	  express	  
MHC	  and	  differentiate	  to	  fuse	  and	  form	  myotubes	   in	  vitro	  (Yablonka-­‐Reuveni	  2011).	  However,	  even	  
in	   such	   similar	   myoblast	   cell	   types,	   variation	   in	   features	   of	   cell	   to	   ECM	   communication	   and	  
interaction	  have	  been	   identified.	  Thus,	   in	   four	  vastly	  different	  non-­‐muscle	  cell	   types	   (including	  one	  
non-­‐stem	  cell,	  MDA),	   in	   the	   current	   series	  of	   experiments,	   the	   concept	  of	  differing	  developmental	  
histories	  can	  be	  considered,	  regarding	  their	  altered	  interactions	  with	  the	  myofibre	  niche.	  Moreover,	  
in	  muscle,	  this	  notion	  of	  developmental	  history	  has	  been	  well-­‐defined,	  with	  respect	  to	  the	  divergent	  
properties	   and	   regulation	   of	  muscle	   stem	   cells,	   responsible	   for	  maintaining	  muscle	   growth	   during	  
late	  stages	  of	  embryogenesis	  and	  alternatively,	  carrying	  out	  post-­‐natal	  growth	  and	  repair	  (McKinnell	  
&	   Rudnicki	   2005;	   Relaix	   et	   al.	   2005).	   However,	   further	   analysis	   to	   determine	   whether	   these	  
differences	   in	   migration	   speed	   between	   cell	   types	   can	   be	   attributed	   to	   variations	   in	   the	   bleb	  
dynamics	   or	   focal	   adhesions,	   remains	   to	   be	   examined.	   It	   would	   be	   of	   interest	   to	   analyse	   FAK	  
signalling	   pathway,	   as	   well	   as	   focal	   adhesion	   protein	   localisation	   in	   these	   different	   cell	   types	   on	  
myofibres.	  Additionally,	   it	  could	  be	  hypothesised	  that	  differing	   integrin	   isoforms	  may	  be	  presented	  
on	  these	  different	  cell	  types	  which	  may	  have	  differing	  affinities	  for	  the	  myofibre	  ECM	  components,	  
therefore,	  integrin	  staining	  would	  aid	  in	  investigating	  these	  features.	  
A	   further	   finding	   of	   the	   current	   series	   of	   experiments	   was	   that,	   when	   comparing	   the	   cell	  
morphologies	   adopted	   on	   aged	   myofibres	   to	   those	   observed	   on	   young	   myofibres,	   all	   cell	   types	  
similarly	  took	  on	  a	  more	  rounded	  form.	  This	  result	  could	  therefore,	  suggest	  that	  despite	  the	  previous	  
reports	  of	  myofibre	  stiffening	  with	  age,	  any	  potential	  alterations	  in	  myofibre	  substrate	  elasticity	  did	  
not	  affect	  the	  cell	  morphologies	  observed	  in	  each	  cell	  type	  (Lacraz	  et	  al.	  2015).	  Following	  this,	  in	  vitro	  
CM	  treatment	   in	  both	  young	  and	  aged	  myofibre	  cultures	  was	  examined	   in	  each	  cell	   type.	  Firstly,	   it	  
was	  observed	  that	  resident	  SC	  morphologies	  were	  not	  affected	  by	  myofibre	  age	  nor	  CM	  treatment.	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This	  finding	  is	  therefore,	  in	  keeping	  with	  the	  previous	  series	  of	  naturally-­‐aged	  SC	  experiments,	  which	  
demonstrated	   that	   SC	   morphologies	   were	   unchanged	   in	   ageing	   and	   CM	   treatment	   in	   vivo	   was	  
observed	   to	   have	   no	   additional	   effects	   on	   this	   feature.	   Notably	   however,	   CM	   treatment	   in	   aged	  
myofibre	   cultures	   significantly	   reduced	   the	   proportion	   of	   round	   AFS	   cells.	   Additionally,	   the	   aged	  
myofibre	  decreased	   the	  proportion	  of	   round	  DP	  and	  MDA	  cells,	  which	  appeared	   to	  be	   restored	  by	  
CM	  treatment	  in	  the	  DP	  cells,	  but	  not	  in	  the	  MDA	  cells.	  This	  indicates	  that	  properties	  maintained	  by	  
CM,	   could	   be	   counteracting	   the	   influence	   of	   the	  myofibre,	   in	   directing	   the	   signalling	   implicated	   in	  
actin	  organisation	  and	  the	  overall	   structure	  of	   the	  cell,	   in	   the	  AFS	  and	  DP	  cell	   types.	  Subsequently,	  
cell	  migration	  speeds	  were	  compared	  between	  young	  and	  aged	  myofibres,	  with	  and	  without	   in	  vitro	  
CM	  treatment.	  Interestingly,	  despite	  in	  vivo	  CM	  treatment	  in	  the	  previous	  naturally-­‐aged	  SC	  series	  of	  
experiments,	   increasing	   aged	   SC	   migration	   speeds,	   this	   was	   not	   evident	   with	   in	   vitro	   CM.	   This	  
therefore,	  could	   indicate	  potentially	  more	  potent	  effects	  of	   in	  vivo	  administration	  of	  CM	  treatment	  
versus	  that	  added	  to	  myofibre	  cultures	  in	  vitro.	  Furthermore,	  ADMSC	  migration	  speeds	  appeared	  to	  
be	   increased	  by	  CM	  treatment	  as	  well	  as	  by	  an	  aged	  myofibre.	  This	  was	  also	  observed	   in	  DP	  cells,	  
with	  the	  exception	  that	  CM	  treatment	  in	  aged	  cultures	  reduced	  DP	  velocities	  to	  those	  comparable	  to	  
young	   control	   cultures.	   Contrastingly,	   CM	   treatment	   in	   aged	   cultures	   significantly	   increased	  MDA	  
migration	   speeds.	   These	   findings	   indicate	   that	   the	   aged	  myofibre	   surface	   induced	   a	   faster	   rate	   of	  
motility	  in	  ADMSC	  and	  DP	  cells.	  As	  previously	  discussed,	  this	  could	  suggest	  that	  features	  such	  as	  focal	  
adhesion	  contacts,	  as	  well	  as	  bleb	  dynamics	  were	  altered	  in	  these	  cell	  types	  whilst	  in	  contact	  with	  the	  
aged	  myofibre	  substrate.	  Additionally,	  CM	  also	  appeared	  to	  regulate	  components	  of	  the	  underlying	  
mechanisms	  regulating	  cell	  migration.	  Mellows	  and	  colleagues	  showed	  that	  a	  large	  proportion	  of	  the	  
AFS	   CM	   contents	   targeted	   regulation	   of	   cell	   motility	   and	   actin	   organisation.	   Therefore,	   ADMSC-­‐
derived	   CM	  used	   in	   the	   current	   study	   could	   potentially	   harbour	   similar	   properties	   to	   result	   in	   the	  
altered	   features	   of	   cell	   morphology	   and	  migration	   observed	   (Mellows	   et	   al.	   2017).	   Overall,	   these	  
findings	   indicate	  that	  alterations	   in	  the	  physical	  properties	  of	  aged	  myofibres,	  such	  as	  an	   increased	  
substrate	   elasticity	   as	   previously	   reported,	   appeared	   to	   be	   detected	   by	   the	   non-­‐muscle	   types	   and	  
resulted	   in	  variances	   in	  cell	  morphologies	  adopted	  and	  speed	  of	  movement.	   Interestingly	  however,	  
these	  alterations	   in	  cell	  behaviour	  were	  not	  elicited	   in	  resident	  SCs,	   to	  the	  degree	  that	  non-­‐muscle	  
cells	  were	  influenced.	  This	  therefore,	  could	  be	  explained	  by	  the	  previously	  mentioned	  concept	  of	  the	  
differing	  developmental	  histories	  between	  SCs	  and	  non-­‐muscle	  cells.	  Furthermore,	  this	  could	  indicate	  
that	  SCs	  are	  perhaps	  more	  plastic	   in	   their	  behaviour,	   in	  order	   to	  cope	  with	  physical	  adaptations	   to	  




Despite	  observing	  varying	  profiles	  of	  migration	  speeds,	  importantly,	  it	  was	  shown	  that	  regulation	  of	  
the	  same	  underlying	  molecular	  pathways	  are	  responsible	  for	  directing	  the	  cell	  morphologies	  of	  both	  
SCs	  and	  non-­‐muscle	  cells	  on	  myofibres	   (Morash	  et	  al.	  2017).	  Previous	  work	  conducted	  by	  Marshall	  
and	   colleagues	  has	   shown	   that	   the	  blebbing	   and	   lamellipodia-­‐driven	  mechanisms	  are	   regulated	  by	  
the	   antagonistic	   activity	   of	   Rho	   and	   Rac	   GTPase	   signalling,	   respectively	   (Sanz-­‐Moreno	   et	   al.	   2008;	  
Sanz-­‐Moreno	  &	  Marshall	  2009).	  Rho	  activity	  is	  supported	  by	  downstream	  ROCK	  function	  to	  promote	  
the	  formation	  of	  actin	  stress	  fibres	  and	  produce	  high	  levels	  of	  actomyosin	  contractility	  in	  amoeboid-­‐
based	  motility	  and	  simultaneously,	  inactivates	  Rac	  (Calvo	  et	  al.	  2011;	  Sanz-­‐Moreno	  et	  al.	  2011;	  Sanz-­‐
Moreno	  &	  Marshall	  2009).	  Rac	  alternatively,	  through	  downstream	  interactions	  with	  the	  WAVE2	  and	  
Arp2/3	   complexes,	   drives	   actin	   filament	   formation	   and	   ‘y-­‐branching’	   of	   lamellipodia	   protrusions	  
(Eden	   et	   al.	   2002;	   Goley	   et	   al.	   2004;	   Soderling	   &	   Scott	   2006;	   Sanz-­‐Moreno	   et	   al.	   2008;	  Wu	   et	   al.	  
2012).	   Therefore,	   in	   the	   current	   study,	   it	   was	   observed	   that	   the	   relationship	   between	   these	   two	  
counteracting	  pathways	   is	   conserved	   in	   the	   three	  different	   stem	  cells	   and	   the	  non-­‐stem	  cell	   types	  
examined.	  Moreover,	  physical	  contact	  with	  the	  myofibre	  surface	  therefore,	  appears	  to	  be	  detected	  
by	   the	   transplanted	   non-­‐muscle	   cells,	   which	   in	   turn,	   elicits	   an	   intracellular	   response,	   altering	   the	  
regulation	   of	   these	   intrinsic	   signalling	   mechanisms,	   resulting	   in	   the	   adoption	   of	   resident	   SC	  
behaviour.	   An	   understanding	   of	   this	   feature	   in	   young,	   healthy	   myofibre	   cultures	   can	   be	   used	   to	  
provide	   possible	   insights	   into	   the	   mechanisms	   and	   signalling	   components	   that	   may	   become	  
dysregulated	   with	   age	   or	   during	   disease.	   Examination	   of	   the	   intrinsic	   regulation	   of	   the	   Rac/Rho	  
pathways	  that	  determine	  cell	  morphology	  and	  migration	  in	  ageing	  SCs	  therefore,	  is	  required.	  
An	   additional	   finding	   of	   the	   present	   series	   of	   experiments	   was	   that	   proliferation,	   a	   further	   key	  
component	  of	  SC	  activity,	  was	  influenced	  by	  the	  myofibre	  surface	  (Morash	  et	  al.	  2017).	  Resident	  SCs	  
following	  activation,	  are	  known	  to	  proliferate	  on	  myofibres	  after	  approximately	  24	  hours	  of	  culture	  
and	   double	   in	   number	   by	   T48	   (Zammit	   2002;	   Collins-­‐Hooper	   et	   al.	   2012).	   This	  was	   somewhat	   the	  
trend	  observed	  with	  the	  transplanted	  MDA	  cells	  on	  myofibres,	  which	  is	  in	  keeping	  with	  the	  reported	  
population	  doubling	  time	  of	  MDA	  cells	  of	  approximately	  27	  hours	  (Limame	  et	  al.	  2012).	  MDA	  cells	  are	  
also	   well-­‐known	   for	   being	   a	   highly	   aggressive,	   invasive	   breast	   cancer	   cell	   and	   a	   key	   feature	  
underpinning	  cancer	  progression,	  is	  the	  ability	  to	  act	  outside	  normal	  control	  and	  ‘hijack’	  mechanisms	  
utilised	  in	  normal	  tissue	  homeostasis,	  in	  order	  to	  drive	  proliferation	  and	  growth	  (Chavez	  et	  al.	  2010;	  
Hanahan	  &	  Weinberg	  2000).	  Therefore,	  unsurprisingly,	  MDA	  cells	  demonstrated	  a	  high	  degree	  of	  cell	  
proliferation	   on	   myofibres,	   which	   may	   indeed	   occur	   regardless	   of	   physical	   microenvironmental	  
characteristics.	  Contrastingly,	  AFS	  cells,	  despite	  having	  a	  reported	  population	  doubling	  time	  of	  25-­‐30	  
hours	  in	  vitro,	  were	  not	  induced	  to	  proliferate	  by	  the	  myofibre	  surface	  (Cananzi	  et	  al.	  2009;	  Tsai	  et	  al.	  
2007).	  The	  number	  of	  ADMSCs	  on	  myofibres	  significantly	  declined	  over	  the	  48-­‐hour	  culture	  duration	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which	  could	  indicate	  a	  lack	  of	  proliferative	  activity	  on	  this	  ‘foreign’	  matrix.	  Furthermore,	  as	  previously	  
discussed,	   the	  morphology	   of	   ADMSCs	   notably	   changed	   following	   extended	   culture	   on	  myofibres,	  
gradually	   cells	   elongated	   and	   caused	   a	   large	   degree	   of	   myofibre	   constriction	   and	   overall	   death	  
(hypercontraction)	   through	   lamellipodia	   extensions.	   Therefore,	   this	   could	   indicate	   not	   only	   an	  
absence	  of	  ADMSC	  proliferation,	  but	  also	   increased	  myofibre	   loss	   in	  culture.	  Moreover,	  this	  finding	  
could	   suggest	   a	   possible	   damaging	   characteristic	   of	  ADMSC	   interaction	  with	  myofibres	   in	   vivo.	   For	  
example,	  an	  infiltration	  of	  fat	  tissue	  into	  muscle	   is	  believed	  to	  occur	  during	  DMD	  as	  well	  as	  ageing,	  
and	  has	  been	  implicated	  in	  reduced	  SC	  function	  (Taaffe	  et	  al.	  2009;	  Kragstrup	  et	  al.	  2011;	  Hamrick	  et	  
al.	  2016).	  However,	  the	  findings	  of	  the	  present	  study	  suggest	  a	  more	  direct	  feature	  of	  ADMSCs	  that	  
could	  lead	  to	  myofibre	  damage,	  that	  they	  can	  induce	  hypercontraction	  through	  myofibre	  contact	  as	  
elongated	  morphologies.	   In	   fact,	   there	  were	  no	  healthy	   intact	  myofibres	   remaining	   following	   three	  
days	   of	   ADMSC	   co-­‐culture.	  Moreover,	   it	  was	   noted	   that	  myofibres	   co-­‐cultured	  with	  AFS	   and	  MDA	  
cells	  remained	  viable	  for	  a	  minimum	  of	  10	  days.	  To	  further	  examine	  the	  proposed	  injurious	  feature	  of	  
ADMSC	  cells	   to	   the	  myofibre,	  staining	   for	   the	   localisation	  of	  non-­‐muscle	  myosin	   (II)	  organisation	   in	  
transplanted	   cells	   could	   give	   an	   indication	   as	   the	   tension	   applied	   to	   the	  myofibre	   surface	   through	  
lamellipodia	   extension	   (Vicente-­‐Manzanares	   et	   al.	   2009).	   Additionally,	   recent	   studies	   have	  
established	  myosin	  II	  as	  an	  essential	  cellular	  component	  necessary	  for	  ECM	  remodelling	  and	  matrix	  
stiffening	   (Hindman	   et	   al.	   2015;	   Engler	   et	   al.	   2006).	   Therefore,	   this	   finding	   could	   suggest	   that	  
transplanted	   ADMSCs	   exerted	   non-­‐muscle	   myosin	   II-­‐mediated	   tension,	   further	   remodelling	   the	  
myofibre	   surface,	   causing	   overall	   stiffening,	   which	   in	   turn,	   induced	   ADMSCs	   to	   adapt	   to	   a	   more	  
elongated	  morphology,	  eventually	  causing	  the	  myofibre	  to	  hypercontract.	  
The	  most	  remarkable	  finding	  of	  this	  series	  of	  experiments	  was	  that	  AFS	  and	  MDA	  cells,	  following	  10	  
days	  of	  co-­‐culture	  on	  the	  surface	  of	  myofibres,	  adopted	  not	  only	  myogenic	  features	  of	  cell	  migration,	  
but	   also	   a	   myogenic	   fate,	   as	   evident	   by	   MyoD	   expression	   (Morash	   et	   al.	   2017).	   Furthermore,	  
strikingly,	   AFS	   cells	   then	   subsequently,	   following	  dissociation	   from	  myofibres,	   fused	   to	   form	  MHC+	  
myotubes.	   Importantly,	   it	  was	  demonstrated	   that	   this	   state	  developed	  without	   first	   initiating	  Pax7	  
expression.	  Significantly,	  it	  is	  therefore	  surmised	  that	  these	  cell	  types	  are	  not	  utilising	  the	  molecular	  
programme	   associated	   with	   normal	   myogenic	   development	   (Amthor	   et	   al.	   1998).	   Instead,	   the	  
expression	   of	  MyoD	   alone,	   in	   the	   absence	   of	   Pax7,	   in	   adult	   SCs,	   indicates	   that	   the	   only	   option	   is	  
terminal	  differentiation	  and	  therefore,	  the	  potential	  of	  reverting	  to	  a	  stem	  cell	  state	  is	  lost	  (Zammit	  
et	   al.	   2004;	   Nagata	   et	   al.	   2006;	   Yablonka-­‐Reuveni	   &	   Rivera	   1994).	   This	   feature	   suggests	   that,	   for	  
future	   research	  and	  exploitation	  of	   these	   findings,	  AFS	   cells	   could	  only	  possibly	  be	  used	   to	   initiate	  
repair	   of	   damaged	   tissue,	   rather	   than	   being	   able	   to	   rely	   of	   these	   cells	   in	   forming	   a	   reservoir,	   or	  
replenishing	  exhausted	  SC	   stem	  cell	   pools,	   for	   future	   cycles	  of	  muscle	   regeneration.	  Overall,	   these	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findings	   suggest	   that	   an	   alternative	   stem	   cell	   type	   (AFS),	   as	   well	   as	   a	   non-­‐stem	   cell	   (MDA)	  
demonstrated	   myogenic	   lineage	   commitment,	   evident	   through	   robust	   MyoD	   expression,	   at	   a	  
relatively	   high	   frequency.	   These	   findings	   therefore	   imply	   that	   cells	   do	   not	   necessarily	   need	   to	   be	  
stem	  cells	   to	  be	   induced	   towards	   a	  myogenic	   lineage.	   Thus,	   this	  work	   can	  be	  extended	   to	  explore	  
other	  non-­‐muscle,	  non-­‐stem	  types	  that	  maintain	  a	  similar	  capacity	  to	  generate	  muscle	  cells	  for	  whole	  
cell-­‐based	  therapies	  in	  ageing,	  injury	  and	  disease.	  This	  would	  be	  beneficial,	  as	  current	  work	  into	  the	  
therapeutic	  potential	  of	  alternative	  non-­‐satellite	  cell	  types	  in	  trauma-­‐induced	  muscle	  regeneration	  so	  
far	  has	  shown	  varying	  success	   (Yin	  et	  al.	  2013).	  However,	  one	  route	  currently	  being	   investigated	   is	  
the	  use	  of	   embryonic	   stem	   (ES)	   cells	   and	   induced	  pluripotent	   stem	   (IPS)	   cell	   types,	   in	  determining	  
their	   capacity	   to	   incorporate	   into	   the	   SC	   niche,	   express	   Pax7,	   undergo	   extensive	   self-­‐renewal	   and	  
engraft	  successfully	  into	  injured	  muscle	  (Chang	  et	  al.	  2009;	  Mizuno	  et	  al.	  2010).	  Although,	  the	  use	  of	  
these	   cells	   is	   associated	   with	   issues	   related	   to	   both	   ethics	   and	   specialised	   isolation	   and	   culture	  
techniques	   (Condic	   &	   Rao	   2010;	   Medvedev	   et	   al.	   2010).	   Therefore,	   achieving	   a	   similar	   effect	   of	  
culturing	   alternative	   cell	   types	   and	   utilising	   the	   tissue	   matrix	   to	   almost	   ‘re-­‐programme’	   the	   cells	  
towards	  a	  myogenic	  fate,	  would	  be	  of	  great	  clinical	  value	  and	  merits	  further	  research.	  	  
Remarkably,	   these	   findings	   also	   revealed	   that	   AFS	   cells,	   but	   not	   the	   non-­‐stem	   cell	   (MDA),	   were	  
directed	   through	   contact	   with	   the	   muscle	   microenvironment	   to	   fuse	   and	   form	   MHC+	   myotubes,	  
reinforcing	   the	   potential	   therapeutic	   value	   of	   AFS	   cells.	   In	   conclusion,	   the	   findings	   indicate	   the	  
profound	  influence	  that	  the	  microenvironment	  or	  matrix	  has	  on	  regenerative	  processes,	  such	  as	  cell	  
differentiation	   and	   fusion	   (Morash	   et	   al.	   2017).	   Furthermore,	   this	   supports	   previous	   findings,	   that	  
alterations	  to	  the	  microenvironment	  or	  niche	  with	  age,	  or	  during	  damage	  or	  disease,	  can	  have	  major	  
implications	   in	   the	  regulation	  of	  cell	  behaviour	  during	  tissue	  repair,	  maintenance	  and	  homeostasis.	  
Moreover,	  whole	  stem	  cell-­‐based	  therapeutic	  approaches	  aimed	  to	  enhance	  tissue	  regeneration,	  can	  
be	  better	  optimised	  with	   the	  physical	   features	  of	   the	  host	  microenvironment,	  matrix	  elasticity	  and	  
cell	   to	  ECM	  interactions	  considered.	  For	  example,	  artificially	  engineered	  scaffolds	  and	  substrates	   in	  
vitro,	  that	  mimic	  the	  physiological	  characteristics	  of	  damaged,	  diseased,	  fibrotic	  or	  aged	  tissues	  could	  
be	   used	   to	   prime	   cultured	   cell	   populations	   prior	   to	   introduction	   into	   the	   host	   tissues.	   Numerous	  
studies	   are	   currently	   exploring	   the	   use	   of	   animal-­‐based,	   or	   completely	   artificial	   materials	   and	  
scaffolds	  in	  the	  treatment	  of	  muscle	  pathologies.	  For	  example,	  studies	  utilising	  human	  decellularised	  
skeletal	  muscle	  scaffolds	  that	  have	  been	  shown	  to	  maintain	  ECM	  architecture,	  are	  being	  conducted	  
to	  examine	  muscle	  cell	   implantation	  and	  colonisation	  (Porzionato	  et	  al.	  2015).	   In	  order	  to	  minimise	  
the	  use	  of	   large	  numbers	  of	  small	  animals,	   in	  scaled-­‐up	  experiments,	   larger	  scaffolds	  are	   therefore	  
required.	  However,	  (commercial)	  bovine	  sources,	  used	  as	  an	  alternative	  to	  human	  constructs,	  would	  
be	   more	   beneficial	   and	   ethical,	   in	   the	   generation	   of	   larger	   quantities	   of	   decellularised	   material.	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Furthermore,	   recent	   advances	   in	   the	   tissue	   engineering	   field	   are	   moving	   partially,	   or	   completely	  
away	  from	  the	  use	  of	  human/animal	  tissues	  and	  involve	  electrospun	  nanofibers	  or	  carbon	  nanotubes	  
for	   use	   in	   skeletal	   muscle-­‐based	   pathologies,	   where	   the	   potential	   for	   these	   scaffolds	   to	   promote	  
myogenesis,	  are	  assessed	  (Manchineella	  et	  al.	  2016;	  Kim	  et	  al.	  2016).	  However,	  these	  matrices	  have	  
yet	   to	   be	   investigated	   for	   their	   influence	   on	   the	   movement	   of	   SCs,	   to	   determine	   if	   cells	   adopt	  
amoeboid-­‐based	   migration,	   or	   whether	   the	   physical	   characteristics	   support	   myogenic	   lineage	  
specification	  in	  non-­‐muscle	  cells.	  Furthermore,	  the	  findings	  of	  the	  current	  study	  highlights	  the	  need	  
for	   extended	   examination	   into	   the	   influence	   of	   decellularised	   muscle	   and	   artificial	   muscle-­‐like	  
materials	   on	  migratory	   and	  differentiation	  mechanisms.	  Much	   research	   in	   this	   field	   is	   focussed	  on	  
developing	  an	  appropriate	  maximal	  decelluarisation	  technique,	  usually	  using	  detergents	  or	  enzymes,	  
as	  source	  tissues	  are	  typically	  allogeneic	  or	  xenogeneic	  (Crapo	  et	  al.	  2011).	  However,	  Perniconi	  and	  
colleagues	   developed	   acellular	   murine	   TA	   scaffolds	   that	   preserved	   biochemical	   features	   including	  
collagen,	   laminin	   and	   fibronectin	   and	   once	   implanted	   in	   vivo,	   to	   replace	   the	   whole	   host	   muscle,	  
resulted	   in	   a	   pro-­‐myogenic	   environment	   being	   established	   (Perniconi	   et	   al.	   2011).	   Additionally,	  
further	   characterisation	   of	   the	   key	   properties	   underpinning	   the	  myogenic	   specification	   of	   AFS	   and	  
MDA	  cells,	  by	   the	  myofibre	  co-­‐culture	  method	  utilised	   in	   the	  present	  study,	   is	   required.	  Lastly,	   the	  
additional	   hypothesis	   that	   these	   cells	   can	   subsequently	   be	   used	   to	   promote	   muscle	   tissue	  
regeneration,	   remains	   to	   be	   addressed.	   This	   could	   be	   examined	   through	   the	   development	   of	  
GFP+/MyoD+	   AFS	   and	  MDA	   cells,	   using	   the	   co-­‐culture	   technique	   described	   and	   injecting	   them	   into	  
immunocompromised	   mice	   following	   cardiotoxin-­‐induced	   muscle	   injury.	   Successful	   muscle	  
regeneration	  would	  be	  evident	  in	  the	  supposed	  development	  of	  GFP+	  myofibres.	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The	  main	   aim	  of	   this	   research	  project	  was	   to	   investigate	   the	  potential	   therapeutic	   effects	   of	   stem	  
cell-­‐derived	  conditioned	  media	  on	  the	  progression	  of	  sarcopenia.	  An	  experimental	  programme	  was	  
conducted	  in	  order	  to	  address	  the	  following:	  (A)	  An	  extensive	  naturally-­‐aged	  skeletal	  muscle	  profile,	  
examining	  a	  broad	  range	  of	  parameters	  at	  molecular,	  cellular,	  tissue	  and	  whole	  organism	  levels	  was	  
generated,	   to	   provide	   a	   basis	   for	   subsequent	   experimentation.	   (B)	   Features	   of	   skeletal	   muscle	  
composition,	   function	  and	   regeneration	  were	   characterised	   in	   the	  novel	  use	  of	   the	  Ercc1d/-­‐	  murine	  
model	  of	  progeria.	  The	  Ercc1d/-­‐	  skeletal	  muscle	  profile	  was	  subsequently	  examined	  in	  the	  capacity	  to	  
mimic	  aspects	  of	  decline	  associated	  with	  sarcopenia	  in	  natural	  ageing.	  (C)	  The	  therapeutic	  potential	  
of	   conditioned	   media	   (CM)	   treatment,	   generated	   from	   adipose-­‐derived	   mesenchymal	   stem	   cells	  
(ADMSC),	  was	   investigated	  in	  both	  naturally-­‐aged	  and	  progeric	  skeletal	  muscle.	  (D)	  The	  importance	  
of	  the	  skeletal	  muscle	  myofibre	  matrix	  in	  defining	  satellite	  cell	  (SC)	  regenerative	  function,	  as	  well	  as	  
the	  influence	  of	  the	  myogenic	  microenvironment	  on	  the	  behaviour	  and	  fate	  of	  non-­‐muscle	  cells,	  was	  
explored.	  
Development	  of	  an	  ageing	  skeletal	  muscle	  profile	  and	  the	  therapeutic	  effects	  of	  
conditioned	  media	  
The	   central	   hypothesis	   of	   this	   work	   was	   that	   conditioned	   media	   (CM)	   generated	   from	   adipose-­‐
derived	  mesenchymal	  stem	  cells	   (ADMSC),	  maintains	  regulatory	  properties	  that	  attenuate,	  delay	  or	  
even	   prevent	   age-­‐associated	   alterations	   in	   skeletal	   muscle	   composition	   and	   function.	   It	   has	   been	  
well-­‐established	   that	   skeletal	   muscle,	   along	   with	   all	   other	   tissues,	   undergoes	   time-­‐dependent,	  
progressive	  declines	  in	  genomic	  and	  cellular	  integrity	  and	  function	  (López-­‐otín	  et	  al.	  2013).	  This	  age-­‐
related	  deterioration	  of	  skeletal	  muscle	  is	  defined	  as	  sarcopenia,	  which	  broadly	  encompasses	  the	  loss	  
of	  muscle	  mass,	   strength,	   quality	   and	   function	   (Demontis	   et	   al.	   2013;	  Burton	  &	   Sumukadas	  2010).	  
Numerous	  other	  physiological,	  histochemical	  and	  biochemical	  alterations,	  have	  also	  been	  extensively	  
reported	   in	   ageing	   human	   and	   animal	   studies.	   Additionally,	   comparisons	  made	   to	   assess	   the	  well-­‐
defined	   intrinsic	   and	   extrinsic	   alterations	   that	   occur	   in	   skeletal	   muscle	   between	   both	   human	   and	  
rodents,	   indicate	  that	  mice	  and	  rats	  are	  close	  models	  of	  human	  sarcopenia	  (Demontis	  et	  al.	  2013).	  
For	   example,	   skeletal	  muscle	   is	   known	   to	   experience	   a	   loss	   of	   force-­‐generating	   capacity,	  myofibre	  
atrophy	  and	  a	  switch	   in	  myofibre	  composition,	  to	  comprise	  a	   larger	  proportion	  of	  those	  more	  slow	  
twitch	  and	  oxidative	  in	  nature,	  among	  others,	  in	  both	  humans	  and	  rodents	  (Degens	  2007;	  Larsson	  &	  
Edström	  1986;	  Ansved	  &	  Larsson	  1989;	  Lexell	  et	  al.	  1988;	  Alnaqeeb	  &	  Goldspink	  1987;	  Rowan	  et	  al.	  
2011).	  	  
It	  was	  established	  that	  sarcopenia	  was	  evident,	  primarily	  at	  a	  geriatric	  age,	  in	  the	  naturally-­‐aged	  mice	  
of	   the	   current	   study,	   by	   the	   observed	   loss	   of	   muscle	   mass	   and	   reduced	   grip	   strength.	   Key	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phenotypical	  characteristics,	   in	  keeping	  with	  what	   is	  established	   in	  the	   literature,	   included	  reduced	  
total	   myofibre	   number,	   increased	   metabolic	   dysfunction,	   greater	   O2-­‐	   ROS	   production,	   reduced	  
oxidative	  capacity	  (Soleus)	  and	  evidence	  of	  a	  fast	  to	  slow	  MHC	  switch	  (Soleus).	  However,	  a	  decline	  in	  
myofibre	  CSA,	  which	  is	  the	  general	  agreement,	  but	  highly	  variable	  among	  naturally-­‐aged	  human	  and	  
animal	  studies,	  was	  not	  noted	   in	  the	  present	  study	  (Klitgaard	  et	  al.	  1989;	  Degens,	  Veerkamp,	  et	  al.	  
1993;	  Lexell	  et	  al.	  1988).	  Furthermore,	  a	  switch	  in	  the	  reverse	  direction,	  instead	  from	  fast	  to	  an	  even	  
faster	   type,	   was	   observed	   in	   the	   ageing	   EDL.	   The	   ageing	   skeletal	  muscle	   profile	   developed	   in	   the	  
current	   study	   samples	   only	   a	   subset	   of	   key	   parameters	   in	   such	   as	   vast	   research	   field,	   in	   order	   to	  
provide	   a	   broad	  basis	   for	   subsequent	   novel	   examination	  of	   the	   therapeutic	   ‘anti-­‐ageing’	   paracrine	  
potential	   of	   ADMSC	   CM.	   Furthermore,	   these	   are	   the	   first	   reports,	   to	   our	   knowledge,	   of	   a	   broad	  
assessment	   of	   the	   influence	   of	   (ADMSC-­‐generated)	   CM,	   on	   the	   well-­‐defined	   skeletal	   muscle	  
characteristics,	  reported	  during	  the	  progression	  of	  sarcopenia.	  
As	  an	  alternative	   therapeutic	   approach	   to	  whole	   cell-­‐based	   treatments	   in	   injury	  and	  disease,	   stem	  
cell-­‐derived	   CM	   is	   currently	   being	   explored.	   It	   has	   been	   established	   that	   key	   regulatory	   growth	  
factors,	  such	  as	  VEGF,	  bFGF,	  TGF-­‐β	  and	  HGF,	  as	  well	  as	  antioxidants,	  are	  among	  the	  released	  factors	  
maintained	  by	  ADMSC	  CM	  that	  have	  shown	  beneficial	  effects	  in	  regeneration	  of	  dermal	  wounds	  (Kim	  
et	  al.	  2007;	  Kim	  et	  al.	  2009).	  Furthermore,	  CM	  generated	  from	  AFS	  cells,	  utilising	  the	  same	  isolation	  
method	   as	   the	   one	   used	   in	   the	   current	   study,	   produced	   a	   clinically-­‐compliant	   CM	   rich	   in	   secreted	  
factors,	  released	  under	  stressed	  conditions	  (Mellows	  et	  al.	  2017).	  The	  AFS	  CM	  was	  also	  free	  from	  all	  
other	  exogenous	  molecules	  and	  demonstrated	  enhanced	  muscular	  regenerative	  properties.	  Crucially,	  
circulating	   secretory	   factors	   released	   from	   young/healthy	   donor	   cellular	   sources,	   saw	   rejuvenating	  
effects	  once	  introduced	  into	  an	  aged	  microenvironment,	  impacting	  on	  the	  underlying	  mechanisms	  of	  
muscle	  regeneration,	  to	  improve	  SC	  proliferation	  and	  differentiation	  (Conboy	  et	  al.	  2005;	  Lavasani	  et	  
al.	  2012).	  	  
The	   findings	   at	   a	   tissue	   level,	   in	   the	   current	   project,	   indicated	   that	   firstly,	   the	   Soleus	   muscle	   was	  
affected	  to	  a	  greater	  degree	  by	  the	  ageing	  process,	  compared	  to	  the	  EDL.	  This	  could	  potentially	  be	  
explained	  by	  the	  slower	  twitch	  oxidative	  nature	  of	  the	  Soleus	  and	  that	  a	  switch	  to	  a	  slow	  phenotype	  
characteristic	  of	  ageing,	  may	  be	  more	  readily	  ‘achievable’	  in	  an	  already	  slow	  muscle	  (IIA	  to	  I),	  instead	  
of	  a	  faster,	  more	  glycolytic	  muscle,	  EDL	  (IIB	  to	  IIX	  to	  IIA	  to	  I)	  (Schiaffino	  &	  Reggiani	  2011).	  Secondly,	  
the	   findings	   demonstrate	   that	   while	   CM	   treatment	   in	   aged	   animals	   did	   not	   appear	   to	   influence	  
features	  of	  overall	  myofibre	  composition,	   such	  as	  myofibre	  number,	   size	  or	   types,	   there	  was	  some	  
evidence	   for	   potential	   modification	   of	   signalling	   pathways	   involved	   in	   angiogenesis,	   oxidative	  
metabolism,	  mitochondrial	  function,	  reduced	  ROS	  production/enhanced	  antioxidant	  activity,	  as	  well	  
as	   ECM	   collagen	   organisation.	   Therefore,	   it	   could	   be	   hypothesised	   that	   growth	   factors	   promoting	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angiogenesis,	  such	  as	  VEGF	  or	  bFGF,	  and	  collagen	  synthesis	  (procollagen	  I)	  in	  local	  dermal	  fibroblasts,	  
previously	   observed	   to	   enhance	   skin	   regeneration	   after	   treatment	   with	   ADMSC	   CM,	   may	   be	  
functioning	   similarly	   in	   ageing	   muscle	   in	   the	   present	   study	   (Kim	   et	   al.	   2007;	   Kim	   et	   al.	   2011).	  
However,	   features	  of	  myofibre	  composition	  such	  as	  hypertrophy,	  a	  highly	  orchestrated	  mechanism	  
driven	  by	  growth	  factor-­‐mediated	  protein	  synthesis	  signalling,	  were	  not	  altered	  significantly	  by	  CM	  
treatment.	  This	   is	  despite	  a	  proportion	  of	  CM	  content	  believed	   to	  be	  comprised	  of	   trophic	   factors,	  
alongside	  the	  mRNA	  (lesser	  amounts)	  and	  miRNA	  (more	  abundant).	  This	  suggests	  that	  the	  regulation	  
required	  to	  bring	  about	  these	  arguably	  quite	  major	  alterations	  to	  myofibre	  composition	  could	  be	  the	  
result	  of	  more	  sustained	  modulation,	  as	  with	  repeated	  exercise.	  Whereas,	  CM	  may	  be	  sufficient	   to	  
adapt	   cell	   to	   cell	   and	   cell	   to	   ECM	   communications,	   to	   bring	   about	   alterations	   to	   vascularisation,	  
collagen	   synthesis/deposition,	  mitochondrial	   biogenesis	   and	   function,	   in	   a	  more	   transient	  manner.	  
Whether	  an	   increased	  CM	  administration	  programme	  would	  be	  sufficient	  to	  alter	  these	  features	  of	  
overall	  myofibre	  composition	  and	  muscle	  strength,	  therefore,	  remains	  unknown.	  	  
As	   noted	   by	   Mellows	   and	   colleagues,	   miRNA	   contents	   that	   target	   the	   cellular	   mechanisms	   that	  
regulate	  vascularisation,	  may	  also	  be	  harboured	  by	  the	  CM	  generated	  in	  this	  project	  (Mellows	  et	  al.	  
2017).	  Moreover,	  the	  vast	  majority	  of	  the	  secreted	  miRNA	  from	  AFS	  CM,	  were	  established	  to	  target	  
signalling	  pathways	  associated	  with	  metabolic	  processes.	  Therefore,	  it	  is	  reasonably	  postulated	  that	  
ADMSC	   CM	   treatment	   could	   act	   similarly	   to	   drive	   changes	   in	   the	   regulation	   of	   mitochondrial	  
biogenesis,	  abundance	  and	  function	  and	  enhancing	  antioxidant	  activity	  (Mellows	  et	  al.	  2017).	  Thus,	  
this	  pin-­‐points	  two	  key	  areas	  to	  continue	  to	  explore	  further	  with	  ADMSC	  CM,	  the	  signalling	  pathways	  
involved	  in	  the	  formation	  of	  new	  vasculature,	  as	  well	  as	  those	  relating	  to	  metabolism.	  	  
Despite	   observing	   an	   increase	   in	   (oxidative)	   type	   I	   myofibres	   in	   the	   aged	   Soleus,	   the	   oxidative	  
capacity	   (SDH	   activity),	   was	   reduced	   in	   advanced	   old	   age	   which	   indicated	   potential	   metabolic	  
dysfunction	  or	   impaired	  oxygen	  delivery.	   It	  has	  been	  established	   that	   there	   is	  overall	   capillary	   loss	  
with	  age	   (Degens,	  Turek,	  et	  al.	  1993).	  However,	   it	  was	  determined	   that	   there	  was	  no	  evidence	   for	  
capillary	   loss	   with	   age	   in	   the	   present	   study.	   Although,	   this	   is	   just	   one	   aspect	   that	   could	   indicate	  
impaired	  oxygen	  delivery,	  so	  it	  cannot	  be	  ruled	  out	  completely.	  It	  would	  be	  of	  interest	  to	  probe	  this	  
line	  of	  enquiry	  further	  and	  assess	  features	  such	  as	  myoglobin	  or	  hypoxia	  inducible	  factor	  –	  1	  (HIF-­‐1)	  
expression,	  which	  would	  give	  a	  better	  understanding	  of	  the	  oxygen	  status,	  in	  future	  experimentation	  
(Fitts	  et	  al.	  1974;	  Ordway	  2004).	  	  
Although	  there	  was	  no	   loss	  of	  capillaries	  observed,	  CM	  demonstrated	  pro-­‐angiogenic	  effects	   in	  the	  
aged	  Soleus.	  VEGFa165	  mRNA	  expression	  was	  increased	  with	  CM	  in	  the	  aged	  Soleus,	  when	  compared	  
to	  a	  geriatric	  age	  only	  (it	  was	  unchanged	  to	  the	  old	  age	  control).	  This	  invites	  further	  investigation	  into	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the	  explanation	  of	  overall	  increased	  capillary	  density	  observed	  with	  CM	  treatment.	  For	  example,	  the	  
VEGF	   protein	   levels,	   VEGF	   receptors	   (VEGFR1	   and	   VEGFR2),	   or	   the	   alternative	   growth	   factors	   that	  
influence	   angiogenesis,	   such	   as	   FGF,	   as	  well	   as	   the	   VEGF	   content	   of	   the	   CM	   itself,	   have	   yet	   to	   be	  
investigated	  in	  the	  present	  study	  (Cross	  &	  Claesson-­‐Welsh	  2001).	  Croley	  and	  colleagues	  showed	  that	  
VEGF	   mRNA	   exercise-­‐induced	   expression	   was	   50%	   lower	   in	   aged	   Vastus	   lateralis	   muscle	   biopsies	  
from	  women,	  compared	  to	  a	  young	  age	  (Croley	  et	  al.	  2005).	  The	  VEGF	  protein	  was	  35%	  lower	  at	  rest	  
but	  there	  were	  no	  age-­‐related	  differences	  in	  VEGFR	  expression.	  A	  similar	  mRNA	  and	  protein	  trend	  for	  
VEGF,	   was	   then	   shown	   in	   aged	   men,	   although	   exercise	   increased	   VEGF	   mRNA	   and	   protein,	  
independent	   of	   age	   group	   (Ryan	   et	   al.	   2006).	   The	   laboratory	   mice	   in	   the	   present	   study	   remain	  
relatively	   sedentary	   in	   their	   cages,	   so	   it	   can	  be	   reasoned	   that	  VEGF	  mRNA	   remains	   low,	  with	   very	  
little	  fluctuation	  due	  to	  inactivity,	  with	  age	  as	  the	  main	  contributing	  factor	  to	  any	  changes.	  It	  would	  
therefore,	   be	   of	   interest	   to	   test	   the	   VEGF	   response	   at	   mRNA	   and	   protein	   levels	   in	   aged	   mice,	  
subjected	   to	   regular	   treadmill	   or	   running	  wheel	   exercises,	  with	  and	  without	  CM	   treatment.	  Wheel	  
running	  exercise	   in	  mice	   for	  example,	   induced	  VEGF	  mRNA	  expression	  and	  protected	  VEGF	  protein	  
levels	   against	   age-­‐related	   decline	   skeletal	   muscle	   and	   this	   activity	   was	   mediated	   by	   PGC-­‐1α	   and	  
downstream	  AMPK	  activation	  (Leick	  et	  al.	  2009).	  Additionally,	  treadmill	  exercise	  in	  mice	  was	  shown	  
to	  induce	  brain	  mitochondrial	  biogenesis	  via	  PGC-­‐1α,	  and	  neurogenesis	  via	  VEGF	  in	  the	  hippocampus,	  
thereby	   exercise	   initiates	   angiogenesis	   systemically,	   benefitting	   the	   function	   of	   further	  
compartments	   than	   just	   skeletal	  muscle	   (E	   et	   al.	   2014).	   Future	  work	  will	   explore	   the	   angiogenesis	  
signalling	  further,	  by	  examining	  other	  VEGF	  isoforms	  at	  protein	  and	  mRNA	  levels,	  VEGFR	  abundance,	  
as	   well	   as	   FGF,	   as	   an	   alternative	   growth	   factor	   influence	   on	   vascularisation,	   in	   the	   aged	   Soleus.	  
Interestingly,	  capillary	  densities	  were	  not	  affected	  in	  the	  aged	  EDL,	  this	  may	  not	  be	  overtly	  surprising	  
considering	  the	  more	  glycolytic	  nature	  of	  the	  EDL	  and	  unaltered	  oxidative	  capacity,	  noted	  with	  age	  in	  
this	  study.	  
Moreover,	  mitochondrial	  dysfunction	  is	  a	  defined	  hallmark	  of	  ageing	  and	  it	  was	  postulated	  that	  this	  
feature	  could	  contribute	  to	  the	  mis-­‐match	  between	  the	  increased	  type	  I	  myofibres	  and	  a	  decreased	  
oxidative	   capacity,	   observed	   in	   the	   current	   research	   project	   (López-­‐otín	   et	   al.	   2013;	   Pieczenik	   &	  
Neustadt	   2007).	   This	   was	   further	   supported	   by	   an	   increased	   ROS	   production	   (DHE	   analysis)	   at	  
geriatric	  ages.	  This	  finding	   in	  turn,	   lead	  to	  the	  examination	  of	  antioxidant	  SOD2	  expression	  analysis	  
which	  was	  unchanged	  with	  age.	  However	  importantly,	  this	  does	  not	  rule	  out	  insufficient	  antioxidant	  
activity	   as	   a	   contributing	   factor	   to	   this	   finding,	   as	   further	   types	   of	   antioxidant	   would	   require	  
exploration,	  at	  both	  mRNA	  and	  protein	  levels.	  	  
CM	   treatment	   reversed	   the	   decrease	   in	   oxidative	   capacity	   in	   aged	  Soleus	  muscles	   to	   levels	   higher	  
than	  younger	   controls.	   This	  also	  could	  explain	   the	   requirement	   for	  an	   increased	  blood	  supply	  with	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CM	   in	  old	  age,	  which	  seems	   to	  accompany	   this	   trend.	   It	  was	  established	   that	  CM	  reduced	  O2-­‐	  ROS	  
production	   (DHE)	   in	  old	  age	  and	  along	  with	  an	  unchanged	  SOD2	  antioxidant	  expression,	   this	   raises	  
questions	   regarding	   the	  mitochondrial	   function	   that	   are	   currently	   unidentified.	   Therefore,	   further	  
study	  into	  the	  mechanisms	  that	  underpin	  mitochondrial	  biogenesis,	  abundance	  and	  overall	  function	  
are	   required.	   For	   example,	   mitochondrial	   homeostasis	   is	   reportedly	   controlled	   by	   nuclear	  
transcription	   regulators	   such	   as	   p53,	   PGC-­‐1α,	   HIF1α,	   FOXO	   and	   SIRT1,	   SIRT6	   and	   SIRT7	   signalling	  
pathways,	   as	  well	   as	   NAD+	   availability,	   which	   is	   known	   to	   be	   depleted	   in	   ageing	   (Gibson	  &	   Kraus	  
2012;	  Fang	  et	  al.	  2016).	  Future	  work	  will	  be	  to	  analyse	  these	  key	  mitochondrial	  regulators	  using	  qPCR	  
analysis	   and	   also	  western	   blot	   protocols	   to	   get	   an	   overview	  of	   activity	   both	   at	   a	  molecular	  mRNA	  
level	  but	  also	  post-­‐translationally,	  to	  analyse	  protein	  function.	  
Additionally,	  O2-­‐	  is	  just	  one	  of	  the	  ROS	  that	  can	  play	  a	  role	  in	  overall	  damage	  of	  DNA,	  mtDNA,	  lipids,	  
proteins,	   oxidative	   phosphorylation	   enzymes	   for	   example,	   there	   are	   also	  many	   other	   free	   radicals	  
that	   can	   do	   just	   as	   much	   damage	   if	   levels	   are	   not	   maintained	   by	   the	   range	   of	   antioxidant	  
mechanisms.	  For	  example,	  initial	  superoxide	  damage	  has	  been	  shown	  to	  damage	  the	  active	  site	  of	  an	  
enzyme	   involved	   in	   the	   Kreb’s	   (TCA)	   cycle,	   exposing	   iron	  which	   then	   reacts	  with	   H2O2	   to	   produce	  
hydroxyl	   free	   radicals	   via	   Fenton’s	   reactions	   (Vásquez-­‐Vivar	   et	   al.	   2000).	   Furthermore,	   glutathione	  
peroxidase	  (GPX),	  an	  antioxidant	  enzyme	  that	  functions	  downstream	  of	  SOD2,	  is	  responsible	  for	  the	  
detoxification	  of	  H2O2	  to	  water	  (Pieczenik	  &	  Neustadt	  2007).	  GPX	  and	  catalase,	  a	  further	  antioxidant,	  
are	   known	   to	   increase	   with	   ageing	   and	   training	   in	   rat	   Vastus	   lateralis	   and	   Soleus	   muscles	  
(Leeuwenburgh	  et	  al.	  1994).	  These	  features	  and	  other	  free	  radicals,	  damage	  biological	  molecules	  and	  
it	   is	   almost	   impossible	   to	   distinguish	   a	   specific	   damage	   to	   a	   specific	   oxidant	   (Vásquez-­‐Vivar	   et	   al.	  
2000).	  Thus,	  it	  is	  reasoned	  that	  damage	  is	  dependent	  on	  the	  cell	  type,	  the	  biological	  target,	  as	  well	  as	  
interactions	  with	  other	  free	  radicals	  and	  these	  may	  act	  in	  conjunction	  with	  other	  cytotoxic	  processes	  
(Vásquez-­‐Vivar	  et	  al.	  2000;	  Olanow	  1992).	  This	  taken	  together	  suggests	  that	  investigation	  conducted	  
at	  a	  protein	   level,	  determining	   the	  activity	  of	   SOD2	  and	   its	   key	   regulators,	   such	  as	  NF-­‐κB	  and	  p53,	  
would	  provide	  a	  better	  understanding	  of	  antioxidant	  function	  in	  aged	  Soleus	  and	  EDL	  muscles,	  with	  
and	  without	  CM	  treatment.	  Moreover,	  analysis	  of	  the	  abundance	  and	  activity	  of	  other	  antioxidants,	  
such	  as	  GPX,	  could	  also	  establish	  a	  more	  comprehensive	  view	  of	  which	  components	  associated	  with	  
detoxification	  step,	  are	  potentially	  the	  most	  impaired.	  Therefore,	  this	  could	  aid	  in	  the	  identification	  
of	   where	   the	   largest	   sources	   of	   free	   radical	   accumulation	   lie,	   which	   lead	   to	   the	   overall	   increased	  
oxidative	   stress	   reported	   with	   age	   progression.	   Thus,	   potentially	   highlighting	   components	   most	  
susceptible,	  reflected	  in	  the	  natural	  ageing	  process	  that	  could	  be	  therapeutically	  targeted.	  	  
Collagen	  IV	  thickness	  was	  shown	  to	  increase	  with	  age	  in	  the	  Soleus	  which	  is	  in	  keeping	  with	  what	  is	  
reported	   in	   the	   literature	   (Marshall	   et	   al.	   1989).	   A	   corresponding	   downregulation	   of	   collagen	   IV	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mRNA	  expression	  with	  increasing	  age,	  indicated	  that	  at	  the	  molecular	  level,	  the	  thickening	  appeared	  
to	   be	   modulated.	   However,	   this	   does	   also	   suggest	   that	   despite	   this	   downregulation,	   post-­‐
translational	  modifications	   appear	   to	   be	   having	   a	  more	   predominant	   effect,	   resulting	   in	   increased	  
collagen	  deposition	  and/or	  a	   lack	  of	  degradation	  as	  an	  overall	  outcome,	  potentially	  highlighting	  an	  
area	  of	  collagen	  signalling	  dysfunction	  with	  age.	   Interestingly,	  CM	  treatment	   in	  old	  age	  maintained	  
collagen	  density	  at	  a	  thickness	  displayed	  in	  the	  adult	  muscle,	  thereby,	  attenuating	  the	  proposed	  post-­‐
translational	   dysfunction.	   As	   discussed,	   the	  AFS	   CM	   showed	   a	   large	   portion	   of	   the	  miRNA	  present	  
targeted	  ECM	  organisation	  which	  may	  indicate	  the	  underlying	  regulatory	  mechanisms	  we	  can	  expect	  
to	  identify	  in	  the	  ADMSC	  CM	  analyses	  (Mellows	  et	  al.	  2017).	  Therefore,	  signalling	  pathways	  targeted	  
may	   include	   those	   regulating	   collagen	   synthesis	   and	   degradation.	   Taken	   with	   the	   findings	   of	   a	  
reduction	  in	  collagen	  thickness	  with	  CM	  treatment	  in	  the	  aged	  Soleus,	  it	  can	  be	  hypothesised	  that	  the	  
signalling	  pathways	  targeted	  by	  CM	  components	  could	  include:	  downregulated	  Wnt-­‐,	  TGF-­‐β-­‐	  and	  IGF-­‐
1-­‐mediated	   collagen	   synthesis	   and	   deposition,	   reduced	   post-­‐translational	   collagen	   and	   advanced	  
glycation	  end-­‐product	   (AGE)	  cross-­‐linking	  and/or	   increased	  MMP-­‐2	  and	  MMP-­‐9	  activity	   (Kjær	  et	  al.	  
2009;	  Zimmerman	  et	  al.	  1993;	  Haus	  et	  al.	  2007;	  Bani	  et	  al.	  2008).	  
Overall,	   the	   vast	   majority	   of	   key	   phenotypical	   features	   examined	   in	   the	   present	   study,	   were	   in	  
agreement	  with	  what	  has	  already	  been	  established	   in	   the	   literature	  and	   therefore,	  were	  used	  as	  a	  
basis	   for	   subsequent	   experimentation.	   ADMSC	   CM	   treatment	   in	   these	   naturally-­‐aged	   animals	   saw	  
beneficial	  regulatory	  effects	  of	  the	  vasculature,	  oxidative	  metabolism	  and	  collagen	  organisation	  and	  
features	   of	   overall	   functionality,	   mass	   and	   composition	   were	   maintained	   into	   old	   age.	   Therefore,	  
these	   findings	   indicate	   that	   CM	   attenuates	   the	   progression	   of	   some	   of	   the	   hallmarks	   of	   ageing	  
mechanisms	  underlying	  decline,	  for	  example,	  mitochondrial	  dysfunction.	  
Characterisation	  of	  the	  skeletal	  muscle	  phenotype	  in	  the	  Ercc1d/-­‐	  murine	  model	  
of	  progeria	  
The	   main	   objectives	   of	   this	   body	   of	   work	   aimed	   to	   (A)	   Characterise	   the	   phenotypical	   aspects	   of	  
skeletal	  muscle	  in	  the	  Ercc1d/-­‐	  murine	  model	  of	  accelerated	  ageing	  (progeria).	  (B)	  As	  carried	  out	  in	  the	  
previous	   series	   of	   naturally-­‐aged	   experimentation,	   assessment	   of	   the	   therapeutic	   potential	   of	  
ADMSC	  CM	  treatment	  was	  extended	  into	  this	  severe	  model	  of	  systemic	  DNA	  damage	  accumulation.	  
(C)	   It	   was	   important	   to	   establish	   the	   suitability	   of	   this	   model,	   in	   mimicking	   those	   characteristic	  
alterations	   that	   are	   well-­‐defined	   in	   naturally-­‐aged	   skeletal	   muscle	   with	   the	   progression	   of	  
sarcopenia.	   It	  has	  been	  established	  that	  there	   is	  a	  requirement	  for	  a	  suitable	  mammalian	  model	  of	  
accelerated	   ageing,	   in	   order	   to	   examine	   potential	   intervention	   approaches,	   in	   the	   amelioration	   of	  
age-­‐related	   symptoms	  of	   sarcopenia	  and	  other	  pathologies,	  observed	   in	  both	  animals	  and	  humans	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(Demontis	   et	   al.	   2013;	  De	  Waard	  et	   al.	   2010;	   Lavasani	   et	   al.	   2012).	   The	  main	   criticisms	  of	  utilising	  
naturally-­‐aged	   rodents	   for	   this	   purpose,	   is	   that	   there	   is	   an	   inability	   to	   perform	   large-­‐scale	   genetic	  
screens	  in	  vivo,	  as	  carried	  out	  in	  simple	  model	  organisms	  and	  due	  to	  the	  2-­‐3	  year	  lifespan,	  efficiencies	  
of	  intervention	  programmes	  are	  low	  and	  uneconomical,	  as	  rodent	  housing	  costs	  are	  high	  (Demontis	  
et	  al.	  2013).	  	  
It	  is	  well-­‐known	  that	  in	  early	  (post-­‐natal)	  growth	  phases,	  body	  mass	  increases	  rapidly	  and	  continues	  
into	   adulthood	   and	  muscle	   hypertrophy,	   rather	   than	   hyperplasia,	   contributes	   the	  majority	   of	   this	  
increase	  (Gokhin	  et	  al.	  2008;	  White	  et	  al.	  2010;	  Stickland	  1981).	  The	  findings	  in	  the	  current	  series	  of	  
experiments	   however,	   in	   keeping	   with	   what	   is	   known	   about	   the	   Ercc1d/-­‐	   mutant,	   indicated	   that	  
progeric	   animals	   did	   not	   undergo	   this	   rapid	   growth	   and	   instead,	   displayed	   a	   small	   appearance	  
(Weeda	   et	   al.	   1997;	   De	  Waard	   et	   al.	   2010;	   Dollé	   et	   al.	   2006).	   Ercc1d/-­‐	   also	   displayed	  much	   lower	  
hindlimb	  muscle	  weights	  and	  grip	  strength,	  indicative	  of	  an	  extreme	  model	  of	  dysfunction,	  both	  are	  
key	  defining	  characteristics	  of	  sarcopenia.	  
It	  was	  shown	  that	  the	  Ercc1d/-­‐	  mice	  were	  severely	  stunted	  in	  their	  growth,	  which	  is	  attributed	  to	  the	  
rapid	  DNA	  damage	  accumulation	  and	  further	   indicates	  a	  switch	  away	  from	  growth,	  where	  genomic	  
and	  cellular	  maintenance	  is	  the	  priority	  (Weeda	  et	  al.	  1997;	  De	  Waard	  et	  al.	  2010;	  Niedernhofer	  et	  al.	  
2006;	  Garinis	  et	  al.	  2008).	  Furthermore,	  this	  shift	  must	  happen	  early	  on	  in	  their	  post-­‐natal	  growth,	  as	  
muscles	  were	  half	   the	  weight	  of	   the	  controls.	  This	   finding	   therefore	   raises	  questions	   regarding	   the	  
signalling	  pathways	  involved	  in	  this	  shift	  to	  maintenance,	  where	  it	  would	  be	  of	  interest	  to	  carry	  out	  
qPCR	   analysis	   of	   the	   following	   in	   the	   musculature	   of	   the	   Ercc1d/-­‐	   mice,	   to	   determine	   AMPK	  
expression,	   in	   response	   to	  metabolic	   stress	   and	  energy	  deprivation	   and	   the	  expected	  downstream	  
downregulation	   of	   mTORC1,	   4E-­‐BP2,	   eIF2	   and	   P70S6K1	   via	   the	   TSC1/TSC2	   complex	   (Baar	   2006).	  
Additionally,	   IGF-­‐1	  activity	  would	  also	  be	  expected	  to	  be	  downregulated,	   limiting	  protein	  synthesis,	  
which	  also	  acts	  on	  downstream	  mTORC2	  and	  AKT	  to	  activate	  FOXO	  (1	  and	  3),	  Atrogin-­‐1	  and	  MuRF1	  
(Milman	  et	  al.	  2014;	  Bartke	  2005;	  Niedernhofer	  et	  al.	  2006;	  Garinis	  et	  al.	  2008).	  
Myofibre	   loss	  was	  also	  evident	   in	   the	  Ercc1d/-­‐	   Soleus	   and	  as	  a	  diminished	   force-­‐generating	  capacity	  
with	  age,	  can	  be	  attributed	  to	  declines	  in	  myofibre	  number	  and/or	  myofibre	  size,	  it	  is	  suggested	  that	  
grip	   strength	   was	   decreased,	   due	   to	   these	   reductions	   in	   the	   Ercc1d/-­‐	  mice	   (Alnaqeeb	   &	   Goldspink	  
1987;	  Larsson	  &	  Edström	  1986).	  It	  was	  previously	  established	  that	  Ercc1d/-­‐	  animals	  experience	  motor	  
neuron	  degeneration	  and	  a	  progressive	   loss	  of	  neuromuscular	  connectivity	  (De	  Waard	  et	  al.	  2010).	  
Therefore,	  this	  would	  support	  the	  reduction	  in	  myofibre	  number,	  as	  a	  result	  of	  denervation-­‐induced	  
atrophy.	  Importantly,	  it	  has	  been	  previously	  established	  that	  initial	  development	  of	  Ercc1d/-­‐	  mice	  was	  
reportedly	  normal	  and	   it	  was	  noted	  that	  after	  this	   time,	  rapid	  DNA	  damage	  accumulation	  occurred	  
225	  
Taryn	  Morash	  
(Dollé	   et	   al.	   2006).	   This	   indicates	   that	   early	   muscle	   development	   was	   unaffected	   and	   therefore,	  
Ercc1d/-­‐	  muscles	  are	  believed	  to	  comprise	  a	  full	  complement	  of	  myofibres	  at	  birth,	  and	  as	  in	  natural	  
ageing,	   further	   implicating	   myofibre	   atrophy	   as	   a	   main	   contributing	   feature	   to	   reduced	   myofibre	  
numbers	  (Glass	  2005;	  Alnaqeeb	  &	  Goldspink	  1987;	  Rowe	  &	  Goldspink	  1969).	  
Furthermore,	  taken	  with	  the	  marked	  motor	  neuron	  degeneration	  known	  to	  take	  place	  in	  the	  Ercc1d/-­‐	  
mice,	   a	   lack	   of	   myofibre	   transition,	   suggests	   that	   the	   ability	   for	   surviving	   motor	   neurons	   to	  
successfully	   re-­‐innervate	   those	   denervated	   myofibres,	   may	   have	   also	   been	   affected,	   leading	   to	  
further	  wide-­‐spread,	  non-­‐specific	  myofibre	  loss	  (Degens	  2007;	  Lexell	  et	  al.	  1986;	  Larsson	  et	  al.	  1991).	  
However,	   loss	   of	   contractile	   ability	   is	   not	   solely	   attributable	   to	   reduced	   myofibre	   number,	  
composition	   and	   size.	   Other	   structural	   characteristics,	   such	   as	   collagen	   and	   AGE	   cross-­‐linking,	   fat	  
infiltration	  and	  ECM	  alterations,	  disrupted	  mechano-­‐sensing,	  dysregulated	  protein	  homeostasis	  and	  
post-­‐translational	   modifications,	   for	   example	   impacting	   on	   myosin	   structure	   and	   cross-­‐linking	  
activity,	  among	  multiple	  others,	   lead	   to	  overall	  muscle	  weakening	   (Degens	  2007;	  Lowe	  et	  al.	  2001;	  
Marshall	  et	  al.	  1989;	  Haus	  et	  al.	  2007;	  Hamrick	  et	  al.	  2016).	  
Moreover,	  the	  findings	  of	  the	  study	  currently	  suggest,	  that	  along	  with	  the	  overall	  smaller	  size	  of	  the	  
Ercc1d/-­‐	  mice	   having	   a	   profound	   effect	   of	   muscle	   mass,	   myofibre	   atrophy	   may	   be	   the	   only	   other	  
predominant	   cause	   of	   the	   dramatically	   reduced	   muscle	   mass.	   As	   further	   histological	   examination	  
revealed	  that	  unexpectedly,	  the	  muscle	  composition,	  regarding	  characteristics	  of	  myofibre	  number,	  
type,	  size	  and	  collagen	  density,	  were	  largely	  unchanged	  in	  the	  Ercc1d/-­‐	  animals,	  relative	  to	  their	  young	  
littermate	   controls.	   Skeletal	  muscle	   is	   known	   to	  be	   a	   large	   reservoir	   for	   amino	   acid	   storage	   in	   the	  
body,	  with	  a	   large	  protein	   synthesis/degradation	   turnover,	  which	  also	   sustains	  protein	   synthesis	   in	  
other	   tissues,	  while	   limited	  muscle	  mass	   is	  often	  associated	  with	   impaired	   responses	   to	   stress	  and	  
chronic	  illness	  (Wolfe	  2006).	  Therefore,	  it	  may	  be	  that	  this	  balance	  is	  tipped	  more	  strongly	  towards	  
degradation,	  in	  Ercc1d/-­‐	  animals	  where	  DNA	  damage	  accumulation	  will	  be	  leading	  to	  its	  chronic	  state	  
of	  cellular	  stress	   (McWhir	  et	  al.	  1993).	   In	  turn,	   this	  could	   	   impact	  on	  myofibrillar	  and	  other	  protein	  
content	   degradation,	   potentially	   having	   a	   profound	   impact	   on	   the	   overall	   weight.	   This	   is	   further	  
evidence	  for	  the	  notion	  that	  Ercc1d/-­‐	  animals	  experience	  a	  default	  survival	  response,	  as	  well	  as	  this,	  
loss	  of	  proteostasis	  is	  a	  well-­‐defined	  hallmark	  of	  ageing	  which	  may	  further	  exacerbate	  the	  observed	  
deterioration,	  of	  which	  future	  work	  will	  aim	  to	  determine,	  primarily	  utilising	  qPCR	  and	  western	  blot	  
techniques	  (López-­‐otín	  et	  al.	  2013;	  García-­‐Prat	  et	  al.	  2016;	  McWhir	  et	  al.	  1993).	  	  
A	  discrepancy	  remains	  however,	  as	   it	  was	  established	  that	  only	  the	  faster	  myofibre	  types,	  of	  which	  
there	   are	   very	   few,	   as	   this	   analysis	   was	   carried	   out	   in	   the	   Soleus,	   appeared	   to	   showed	   a	   trend	  
towards	   reduced	  CSAs.	  This	   result	   is	  more	  akin	   to	   that	   reported	   in	   the	  aged	   rat	  Plantaris	   (Degens,	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Turek,	  et	  al.	  1993).	  Myofibre	  CSA	  was	  unchanged	  in	  the	  slower	  type	  I	  and	  IIA	  myofibres.	  This	  finding	  
however	  is	  in	  agreement	  with	  the	  trends	  noted	  previously	  in	  the	  naturally-­‐aged	  series	  of	  experiments	  
but	   overall,	   is	   not	   in	   keeping	   with	   the	   general	   agreement	   of	   a	   reduced	   CSA	   in	   natural	   ageing	  
(Klitgaard	   et	   al.	   1989;	   Lexell	   et	   al.	   1988;	  Degens	   et	   al.	   1993).	  However,	   Chai	   and	   colleagues	   saw	  a	  
similar	  trend	  in	  geriatric	  (29	  month	  old)	  Soleus	  muscles,	  where	  CSA	  was	  not	  significantly	  different	  to	  
those	  at	  3	  months	  (Chai	  et	  al.	  2011).	  Which	  arguably,	  is	  a	  more	  age-­‐matched	  study	  to	  the	  naturally-­‐
aged	  geriatric	  mice	  of	  the	  present	  study,	  which	  experienced	  some	  of	  the	  most	  detrimental	  decline,	  
such	   as	   reduced	   oxidative	   capacity	   and	   a	   dramatically	   increased	   ROS	   production	   in	   the	   Soleus.	  
Additionally,	   there	  were	  no	  observed	  changes	   in	   collagen	   IV	   thickness	  measured	  histologically,	  nor	  
collagen	  I	  mRNA	  expression	  suggesting	  that	  the	  decreased	  grip	  strength	  may	  not	  be	  attributable	  to	  
altered	   collagen	   thickness.	   However,	   this	   does	   not	   take	   into	   account	   the	   potential	   impaired	  
contractility,	  associated	  with	  collagen	  cross-­‐linking,	  nor	  other	  ECM	  component	  stiffening	  such	  as	  AGE	  
cross	  links	  (Zimmerman	  et	  al.	  1993;	  Arnesen	  &	  Lawson	  2006;	  Haus	  et	  al.	  2007).	  	  
It	  was	  established	   that	   capillary	  density	  was	   reduced	   in	   the	  Ercc1d/-­‐	   Soleus,	   suggesting	   that	  oxygen	  
delivery	  may	  not	  be	  as	  efficient.	  This	  feature	  is	  in	  keeping	  with	  the	  loss	  of	  capillaries	  associated	  with	  
natural	  ageing,	  but	  was	  not	  observed	  in	  the	  naturally-­‐aged	  muscles	  of	  the	  current	  project	  (Degens	  et	  
al.	  1993).	  However,	  the	  reduction	  in	  capillary	  density	  did	  not	  impact	  on	  the	  overall	  oxidative	  capacity	  
in	   the	   Ercc1d/-­‐	   Soleus.	   It	   was	   also	   established	   that	   mitochondrial	   ROS	   production	   was	   slightly	  
increased	   and	   SOD2	   expression	   levels	   slightly	   decreased,	   somewhat	   indicating	   mitochondrial	  
dysfunction,	   however	   these	   differences	   were	   not	   significant.	   Moreover,	   these	   findings	   seem	  
surprising	   in	   a	  model	   that	   experiences	  high	   levels	  of	  oxidative	   stress,	  which	  would	  be	  expected	   to	  
further	  exacerbate	  DNA	  and	  mtDNA	  damage	  and	  further	  compromise	  genomic	  integrity	  (McWhir	  et	  
al.	  1993;	  Pieczenik	  &	  Neustadt	  2007).	  
An	   increased	   level	  of	  oxidative	  stress	  has	  been	  previously	  reported	   in	  the	   liver,	  kidney	  and	  brain	   in	  
the	   ERCC1-­‐deficient	   model	   (McWhir	   et	   al.	   1993).	   Therefore,	   due	   to	   the	   nature	   of	   the	   model	   of	  
insufficient	   NER,	   subsequent	   DNA	   damage	   accumulation	   and	   compromised	   nuclear	   and	  
mitochondrial	  DNA	   integrity,	   it	   is	   suspected	   that	  other	   characteristics	  of	  mitochondrial	  dysfunction	  
would	  also	  be	  evident,	  in	  addition	  to	  ROS	  and	  other	  free	  radical	  production.	  Moreover,	  regulation	  of	  
numerous	  other	  components	  and	  processes	  are	  key	  to	  maintaining	  mitochondrial	  functionality,	  such	  
as	  regulation	  of	  mitochondrial	  quantity	  and	  morphology,	  through	  efficient	  organelle	  biogenesis	  and	  
fusion-­‐	  and	  fission-­‐mediated	  renewal	  (Terman	  &	  Brunk	  2004;	  Frank	  et	  al.	  2001;	  Powers	  et	  al.	  2012).	  
Emerging	   findings	   from	   our	   research	   group,	   currently	   indicate	   decreased	  mitochondrial	   density	   in	  
Ercc1d/-­‐	   muscles,	   both	   within	   the	   intermyofibrillar	   space,	   responsible	   for	   contractile	   energy	  
production,	  as	  well	  as	  those	  lying	  just	  beneath	  the	  sarcolemma,	  implicated	  in	  ATP-­‐dependent	  events	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occurring	   at	   the	   membrane.	   Both	   sub-­‐populations	   are	   reportedly	   compromised	   during	   muscle	  
atrophy.	  The	  subsarcolemmal	  mitochondria	  are	  lost	  more	  readily	  during	  extended	  inactivity	  and	  also	  
produce	  higher	  levels	  of	  ROS,	  whereas,	  those	  located	  more	  centralised	  within	  the	  myofibre	  are	  more	  
susceptible	   to	   apoptotic	   stimuli	   induced	   by	   inactivity	   (Powers	   et	   al.	   2012).	   Additionally,	   emerging	  
evidence	   of	   mitochondrial	   swelling	   in	   Ercc1d/-­‐	   muscle	   would	   also	   suggest	   dysfunction	   in	   those	  
processes	   of	   morphological	   regulation	   of	   mitochondria	   during	   fusion	   and	   fission.	   Furthermore,	  
increased	  mitochondrial	   fission,	   orchestrated	   via	   dynamin-­‐related	   protein-­‐1	   (Drp1)	   for	   example,	   is	  
elevated	  in	  myofibre	  atrophy	  and	  equally,	  fusion	  is	  also	  required	  for	  maintaining	  mtDNA	  stability	  and	  
integrity.	  An	  imbalance	  or	  dysfunction	  in	  this	  process	  leads	  to	  abnormal	  mitochondrial	  morphologies	  
as	   well	   as	   swelling	   and	   is	   highly	   linked	   to	   contractile	   deficit	   and	   denervation-­‐induced	   myofibre	  
atrophy	  (Powers	  et	  al.	  2012).	  These	  features,	  among	  others	  discussed,	  are	  therefore	  postulated	  to	  be	  
main	   contributing	   factors	   in	   the	   overall	   declines	   observed	   in	   the	   Ercc1d/-­‐	   muscle.	   Although,	  
interestingly,	  it	  was	  CM	  treatment	  that	  seemingly	  exacerbated	  ROS	  production	  in	  the	  Ercc1d/-­‐	  Soleus,	  
whereas,	  this	  provides	  a	  possible	  underlying	  cause.	  As	  mitochondrial	  dysfunction	  was	  also	  evident	  in	  
the	   naturally-­‐aged	   Soleus	   and	   EDL,	   these	   mechanisms	   of	   mitochondrial	   homeostasis	   and	   ‘health’,	  
merit	  further	  investigation	  in	  both	  ageing	  and	  progeria,	  along	  with	  the	  assessment	  of	  any	  effects	  of	  
CM	  treatment	  on	  these	  processes.	  
CM	  treatment	  in	  the	  Ercc1d/-­‐	  Soleus	  
It	  was	  shown	  that	  with	  ADMSC	  CM	  treatment	  in	  the	  Ercc1d/-­‐	  Soleus,	  as	  with	  the	  naturally-­‐aged	  series	  
of	   experiments,	   whole	   organism	   parameters	   such	   as	   body	   weight,	   grip	   strength	   and	   rotarod	  
performance,	  as	  well	  as	  muscle	  weights	  and	  myofibre	  composition,	  CSA	  and	  oxidative	  capacity	  were	  
not	  influenced.	  However,	  CM	  increased	  the	  proportion	  of	  type	  IIA	  myofibres,	  which	  could	  potentially	  
indicate	  that	  CM	  prevented	  atrophy,	  or	  caused	  a	  myofibre	  switch	  to	  this	   faster,	  oxidative	  myofibre	  
type.	  In	  both	  of	  these	  scenarios,	  alterations	  to	  motor	  neuron	  activity	  are	  inferred,	  as	  a	  prevention	  of	  
myofibre	  loss	  in	  this	  myofibre	  type,	  would	  suggest	  that	  motor	  neuron	  degeneration	  may	  be	  reduced.	  
Although	   possibly	   not	   sufficiently	   enough	   to	   maintain	   a	   full	   complement	   of	   myofibres,	   as	   total	  
myofibre	  numbers	  were	  not	  significantly	  greater	  with	  CM	  treatment.	  Alternatively,	  a	  myofibre	  switch	  
could	   indicate	   more	   successful	   re-­‐innervation.	   However	   the	   reason	   for	   the	   switch	   to	   a	   faster	  
phenotype	   remains	   unclear,	   as	   this	   kind	   of	   transition	   is	   often	   associated	   with	   disuse	   or	   muscle	  
unloading.	  A	  recent	  study	  previously	  utilised	  an	   immunocytochemical	  protocol	   for	  bungarotoxin,	  to	  
assess	   neuromuscular	   junction	   (NMJ)	   connectivity	   and	   showed	   that	   in	   naturally-­‐aged	   geriatric	  
animals,	  the	  percentage	  of	  fully	  denervated	  myofibres	  was	  drastically	  increased,	  in	  the	  EDL,	  but	  not	  
in	  the	  Soleus	  (Chai	  et	  al.	  2011).	  Interestingly,	  however,	  this	  could	  be	  a	  potential	  method	  to	  determine	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the	   degree	   that	   motor	   neuron	   innervation	   is	   firstly	   diminished	   in	   Ercc1d/-­‐	  muscles	   and	   potentially	  
enhanced	  by	  CM	  treatment,	  if	  at	  all.	  	  
The	  other	  feature	  in	  the	  Ercc1d/-­‐	  Soleus	  that	  appeared	  to	  be	  altered	  by	  ADMSC	  CM	  treatment,	  was	  an	  
increased	   DHE	   intensity	   which	   indicated	   a	   higher	   level	   of	   O2-­‐	   ROS	   production.	   This,	   as	   previously	  
discussed,	  is	  seemingly	  counterintuitive	  for	  a	  potential	  therapy	  in	  a	  model	  of	  progeria,	  which	  would	  
only	  exacerbate	  the	  damage	  through	  increased	  levels	  of	  oxidative	  stress.	  However,	  it	  is	  reasoned	  that	  
CM	  treatment	  enhanced	  the	  rate	  of	  metabolism,	  using	  the	  ‘faulty’	  machinery	   in	  the	  Ercc1d/-­‐	  muscle	  
and	   inadvertently,	   also	   increased	   O2-­‐	   ROS	   generation,	   as	   a	   by-­‐product	   of	   dysfunctional	   oxidative	  
metabolism.	  Thus,	  as	  in	  the	  naturally-­‐aged	  experimentation,	  ADMSC	  CM	  demonstrated	  that	  contents	  
harboured	   could	   bring	   about	   alterations	   to	   features	   surrounding	   mitochondrial	   function,	   in	  
agreement	  with	  the	  vast	  majority	  of	  targets	  identified	  in	  AFS	  CM	  (Mellows	  et	  al.	  2017).	  
It	   was	   established	   that,	   despite	   the	   reduced	   muscle	   size	   and	   overall	   decreased	   grip	   strength	  
reflecting	   features	   of	   sarcopenia,	   at	   this	   histological	   level,	   most	   other	   characteristics	   of	   myofibre	  
composition,	  were	  not	  as	  dramatically	  affected	  in	  the	  Ercc1d/-­‐	  Soleus.	  This	  however,	  is	  unexpected	  in	  
a	  model	  of	  severe	  and	  rapid	  systemic	  decline.	  Although,	  as	  discussed,	  this	  could	  provide	  evidence	  for	  
the	   initiation	   of	   a	   strong	   survival	   response,	   where	   resources	   are	   conserved	   to	   support	   protein	  
maintenance.	   Therefore,	   it	   would	   be	   of	   great	   interest	   to	   explore	   the	   regulatory	   mechanisms	   of	  
protein	   synthesis	   (IGF-­‐1/PI3K/AKT/4E-­‐BP)	   and	   degradation	   (FOXO/MuRF1/Atrogin-­‐1),	   using	   both	  
qPCR	  and	  western	  blot	  analysis,	  to	  provide	  a	  better	  understanding	  of	  this	  proposed	  shift.	  
It	  was	   found	  that	  the	  Ercc1d/-­‐	  animals	  displayed	  characteristic	  parallels	   to	  the	  naturally-­‐aged	  Soleus	  
and	  these	  included	  oxidative	  capacity,	  ROS	  production	  and	  antioxidant	  activity,	  all	  features	  measured	  
that	  reflect	  the	  metabolic	  status	  of	  the	  muscle.	  In	  contrast,	  those	  features	  that	  appeared	  to	  occur	  to	  
a	   more	   extreme	   extent	   in	   the	   Ercc1d/-­‐	   progeric	   Soleus,	   relative	   to	   natural	   ageing,	   encompassed	   a	  
greater	  degree	  of	  myofibre	  atrophy,	  a	  dramatically	   reduced	  muscle	  weight,	  myofibre	  CSA,	  capillary	  
density,	   collagen	   thickness	   and	   dystrophin	   expression.	   Therefore,	   the	   characteristics	   implicate	  
altered	   myofibre	   composition	   and	   ECM	   components.	   Alternatively,	   it	   was	   established	   that	   the	  
Ercc1d/-­‐	   Soleus	   displayed	   an	   altogether	   distinctive	   MHC	   myofibre	   type	   composition,	   exhibiting	   an	  
overall	  faster	  phenotype.	  While	  the	  Ercc1d/-­‐	  Soleus	  was	  still	  a	  predominantly	  slow	  oxidative	  muscle,	  it	  
contained	   significantly	   more	   type	   IIX	   and	   IIB	   myofibres	   than	   in	   natural	   ageing.	   As	   previously	  
discussed,	  a	  transition	  in	  this	  direction,	  from	  slow	  to	  fast,	  is	  typically	  indicative	  of	  a	  more	  sedentary	  
lifestyle	  through	  disuse.	  Measurements	  of	  rodent	  activity	  are	  frequently	  recorded	  utilising	  open	  field	  
activity	   cage	  monitoring.	   For	  example,	   studies	   conducted	   in	  mice,	  have	  explored	   the	  effect	  of	  pre-­‐
clinical	   drugs	   in	   the	   mdx	   (DMD)	   mouse	   model	   on	   their	   activity,	   as	   well	   as	   in	   transgenic	   mice	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modelling	   human	   inflammatory	   myopathies,	   such	   as	   autoimmune	   myositis	   (Spurney	   et	   al.	   2009;	  
Nagaraju	  et	  al.	  2000).	  Therefore,	  activity	  cage	  monitoring	  would	  be	  a	  useful	  tool	  in	  determining	  the	  
overall	  mobility	  of	  Ercc1d/-­‐	  animals,	  compared	  to	  young	  control	  animals,	  as	  well	  as	  to	  naturally-­‐aged	  
activity.	  This	  provides	  general	  information	  regarding	  overall	  motility,	  distance	  travelled,	  high	  and	  low	  
speed	   movement,	   rearing	   counts,	   among	   numerous	   other	   analyses.	   It	   is	   postulated	   that	   CM	  
treatment	  improves	  overall	  mobility	  of	  the	  aged	  and	  progeric	  animals.	  
It	   was	   established	   that	   capillary	   density,	   collagen	   thickness	   and	   dystrophin	   expression	   were	   all	  
reduced	   in	   the	   Ercc1d/-­‐	   Soleus,	   however,	   this	   is	   unsurprising	   when	   the	   overall	   remarkably	   smaller	  
muscle	  size	  is	  considered.	  Capillary	  density,	  collagen	  synthesis	  and	  structural	  membrane	  components	  
are	  reportedly	  increased	  with	  compensatory	  hypertrophy,	  induced	  by	  exercise	  for	  example,	  in	  order	  
to	  better	  serve	  the	  larger	  myofibre	  (Degens,	  Turek,	  et	  al.	  1992;	  Yasuda	  et	  al.	  1996;	  Yang	  et	  al.	  1997;	  
Kjær	   et	   al.	   2009).	   Therefore,	   it	   is	   reasoned	   that	   smaller	   myofibres	   require	   a	   lower	   blood	   supply,	  
basement	  membrane	  collagen	   IV	  and	  dystrophin	  content,	   ‘scaled-­‐down’	  proportionately	   to	  Ercc1d/-­‐	  
myofibre	  size.	  	  
In	  conclusion,	  the	  Soleus	  muscle	  profile,	  examining	  characteristics	  measured	  at	  a	  whole	  tissue	  level,	  
reflects	   a	   number	   of	   features	   of	   sarcopenia	   observed	   in	   natural	   ageing.	   In	   contrast,	   however,	   the	  
extreme	  nature	  of	   the	  Ercc1d/-­‐	  mutant	   in	   the	   rapid	   accumulation	  of	   systemic	  DNA	  damage	  overall,	  
results	   in	   some	   arguably	   amplified	   characteristics	   of	   decline.	   It	   is	   postulated	   that	   levels	   of	  
deterioration	   in	   the	   Ercc1d/-­‐	  mouse	  model	   would	   far	   exceed	   those	   of	   even	   the	  most	  moribund	   of	  
naturally-­‐aged	  animals,	  if	  enabled	  to	  survive	  to	  end-­‐of-­‐life.	  These	  findings	  show	  that,	  from	  an	  ageing	  
skeletal	  muscle	   prospective,	   the	   amplified	   characteristics	   displayed	   as	  well	   as	   the	   strong	   switch	   to	  
maintenance,	   establishes	   the	   Ercc1d/-­‐	   mouse,	   as	   a	   ‘super-­‐ageing’	   model.	   Taken	   together,	   these	  
findings	   potentially	   indicate	   that	   CM	   treatment	   efficacy	   may	   be	   distinctly	   different	   in	   progeria,	  
compared	   to	   natural	   ageing,	   where	   seemingly	   beneficial	   alterations	   to	   the	   underlying	   regulatory	  
mechanisms	   were	   observed	   and	   brought	   about	   pro-­‐angiogenic,	   antioxidant	   and	   modified	   ECM	  
effects	   in	  naturally-­‐aged	  muscle.	  Whereas,	  comparatively,	  CM	  has	  had	  relatively	   little	   impact	   in	  the	  
severe	  model	  of	  premature	  ‘super-­‐ageing’.	  
Investigation	  into	  the	  therapeutic	  effects	  of	  conditioned	  media	  on	  satellite	  cell	  
number	  and	  mechanisms	  of	  function	  during	  natural	  ageing	  and	  in	  the	  Ercc1d/-­‐	  
model	  of	  progeria	  
The	  principle	  objective	  of	  this	  series	  of	  experimentation,	  extends	  the	  work	  carried	  out	  in	  the	  previous	  
two	  chapters,	   to	  examine	   the	  potential	  beneficial	  paracrine-­‐mediated	   regulatory	  effects	  of	  ADMSC	  
CM	   on	   ageing	   skeletal	   muscle	   regenerative	   function.	   Subsequently,	   this	   experimental	   programme	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was	  also	  carried	  out	  in	  the	  Ercc1d/-­‐	  progeric	  model	  to	  further	  explore	  its	  suitability	  as	  a	  natural	  ageing	  
model	  at	  a	  cellular	  level.	  Importantly,	  therefore,	  investigation	  was	  conducted	  in	  order	  to	  assess	  the	  
effects	   of	   ageing,	   with	   and	   without	   CM	   treatment,	   on	   the	   characteristics	   of	   the	   underlying	  
mechanisms	  both	  intrinsic	  to	  the	  cell,	  as	  well	  as	  extrinsic	  interactions	  with	  the	  myofibre	  matrix.	  
It	   is	  well-­‐established	  that	  the	  SC	  population	  experiences	  a	  decline	  in	  number	  and	  function	  with	  age	  
and	  features	  of	  this	  trend	  are	  arguably	  attributable	  to	  changes	  in	  the	  intrinsic	  regulation	  of	  the	  cell	  
itself	  or	  alternatively,	  alterations	  to	  the	  ageing	  skeletal	  muscle	  microenvironment	  or	  ‘niche’,	  or	  more	  
likely,	  a	  combination	  of	  the	  two	  (Collins	  et	  al.	  2007;	  Yin	  et	  al.	  2013).	  Intrinsic	  features	  to	  the	  cell	  lead	  
to	  a	  degree	  of	  heterogeneity	  in	  the	  population	  and	  these	  underpin	  the	  self-­‐renewal,	  proliferative	  or	  
myogenic	   differentiation	   potential	   of	   SCs.	   However,	   extrinsic	   signalling	   from	   numerous	   regulatory	  
factors	  of	  the	  local	  myofibre	  and	  ECM	  niche,	  direct	  SCs	  to	  activate,	  emerge,	  migrate,	  proliferate	  and	  
differentiate	   in	   response	   to	   muscle	   activity/exercise	   and	   crucially,	   following	   myofibre	   damage	   or	  
injury.	  	  
In	   ageing	  muscle,	   SCs	   have	   been	   shown	   to	   activate	   and	   emerge	   in	   a	   delayed	  manner,	   as	   well	   as	  
migrate	  via	  amoeboid-­‐based	  motility,	  at	  a	  slower	  rate	  compared	  to	  young	  SCs	  (Collins-­‐Hooper	  et	  al.	  
2012).	  However,	  the	  findings	  of	  the	  current	  study	  do	  not	  reflect	  these	  previously	  reported	  aspects	  of	  
function,	  despite	  utilising	  the	  same	  analysis	  techniques	  and	  age-­‐matched	  animals.	  Naturally-­‐aged	  SCs	  
in	  the	  present	  study	  alternatively,	  emerged	  at	  a	  seemingly	  advanced	  rate.	  However,	  young	  controls	  
also	  did	  not	   reflect	  what	  has	  previously	  been	  reported,	  as	  young	  SCs	  showed	  an	  opposing	  delayed	  
emergence.	  Furthermore,	  aged	  SCs	  in	  the	  current	  study	  did	  not	  parallel	  the	  delayed	  migration	  speed,	  
previously	   reported	   by	   Collins-­‐Hooper	   and	   colleagues	   (Collins-­‐Hooper	   et	   al.	   2012).	   It	   has	   been	  
previously	   established	   that	   aged	   SCs	   demonstrated	   abnormal	   bleb	   dynamics,	   with	   a	   prolonged	  
extension/retraction	  duration,	  which	  is	  believed	  to	  have	  had	  a	  detrimental	  effect	  on	  the	  rate	  of	  aged	  
SC	  movement	  (Collins-­‐Hooper	  et	  al.	  2012).	  Thus,	  as	  migration	  speeds	  in	  aged	  SCs	  in	  the	  present	  study	  
were	   unchanged	   to	   the	   young	   SCs,	   bleb	   dynamic	   measurements	   would	   provide	   a	   better	  
understanding	   of	   this	   finding,	   as	   it	   could	   be	   hypothesised	   that	   bleb	   dynamics	   would	   appear	  
statistically	  no	  different	  from	  the	  young	  controls.	  	  
Aged	  SCs	  did	  however,	  show	  a	  reduced	  proliferative	  capacity,	  which	  is	  in	  keeping	  with	  what	  has	  been	  
reported	  extensively	   (Schultz	  &	   Lipton	  1982;	  Collins	   et	   al.	   2007;	  Collins-­‐Hooper	  et	   al.	   2012;	   Sousa-­‐
Victor	  et	  al.	   2014;	  García-­‐Prat	  et	  al.	   2016).	   Therefore,	   these	  discrepancies	   suggest	   that	   intrinsically	  
the	  underlying	  regulatory	  mechanisms	  of	  SC	  activity,	  particularly	  those	  that	  mediate	  emergence	  and	  
migration,	   remain	   somewhat	   functional	   into	   old	   age.	   Perhaps	   with	   the	   exception	   of	   proliferative	  
capacity,	   which	   infers	   greater	   intrinsic	   dysregulation	   with	   age	   and	   potentially,	   differentiation	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capacity,	   which	   was	   untested	   in	   natural	   ageing,	   in	   the	   current	   series	   of	   experiments,	   but	   is	  
extensively	   reported	   to	   diminish	   in	   aged	   SC	   populations.	   Moreover,	   this	   suggests	   that	   extrinsic	  
signalling	  components	  may	  vary	  within	  our	  single	  myofibre	  experimental	  set-­‐ups	  or	  depending	  on	  the	  
dissection	   and	   single	  myofibre	   isolation,	   variation	   could	   be	   introduced.	   It	   is	   postulated	   that	   some	  
components	   of	   the	   single	   myofibre	   culture	   media	   are	   ill	   defined.	   For	   example,	   varying	   levels	   of	  
growth	  factors	  present	  in	  chick	  embryo	  extract	  as	  a	  media	  supplement.	  Indeed,	  any	  slight	  variability	  
in	   culture	   conditions,	   could	   produce	   slightly	   different	   results,	   although	   in	   general,	   the	  method	   for	  
single	  myofibre	  culture	  appears	  highly	   reproducible,	   so	   reasons	  behind	   these	  discrepancies	   remain	  
unclear	  (Bischoff	  1986b;	  Rosenblatt	  et	  al.	  1995;	  Zammit	  2002;	  Otto	  et	  al.	  2011).	  	  
It	  was	   further	  established	   that	  ADMSC	  CM	   (in	   vivo)	   treatment,	  had	   seemingly	  beneficial	  effects	  on	  
naturally-­‐aged	   SC	   migration	   speeds	   as	   compared	   to	   all	   other	   age	   groups,	   rate	   of	   motility	   was	  
drastically	  enhanced.	  Taken	  with	  what	  is	  known	  about	  the	  amoeboid/bleb-­‐based	  migration	  method,	  
continuation	  of	  this	  work	  will	  measure	  the	  CM	  effect	  on	  aged	  SC	  bleb	  dynamics	  (Collins-­‐Hooper	  et	  al.	  
2012).	  As	  a	  prolonged	  bleb	  lifecycle	  was	  associated	  with	  a	  slower	  SC	  rate	  of	  movement,	   it	  could	  be	  
postulated	  that	  the	  finding	  of	  a	  faster	  migration	  speed	  in	  aged	  SCs,	  would	  be	  supported	  by	  a	  more	  
rapid	  bleb	  lifecycle.	  Furthermore,	  it	  has	  been	  shown	  that	  AFS	  CM	  harboured	  miRNA	  that	  are	  known	  
to	  target	  and	  regulate	  cell	  motility	  (Mellows	  et	  al.	  2017).	  Therefore,	  future	  work	  into	  elucidating	  the	  
properties	   maintained	   by	   ADMSC	   CM	   utilised	   in	   the	   current	   study,	   may	   reveal	   similar	   regulatory	  
components.	  However,	  it	  is	  reasoned	  that	  a	  faster	  migratory	  speed	  may	  not	  prove	  to	  be	  a	  beneficial	  
property	   overall,	   if	   other	   aspects	   of	   motility	   are	   compromised,	   for	   example,	   directionality	   and	  
appropriate	  response	  to	  stimuli	  (chemotaxis).	  Therefore,	  it	  would	  be	  of	  interest	  to	  test	  these	  features	  
as	  future	  CM	  work,	  as	  directionality	  was	  demonstrated	  to	  be	  altered	  in	  aged	  SCs,	  using	  mathematical	  
modelling,	  to	  show	  SCs	  adopted	  a	  ‘memoryless’	  form	  of	  motility,	  which	  is	  believed	  to	  impact	  on	  the	  
speed	  cells	  arrive	  at	  a	   lesion	  site	   for	   repair	   (Collins-­‐Hooper	  et	  al.	  2012).	  Continued	  work	  therefore,	  
utilising	  mathematical	  modelling,	  could	  indicate	  if	  CM	  treatment	  is	  able	  to	  restore	  this	  defect	  in	  aged	  
SCs.	  Additionally,	  Bischoff	  used	  a	  form	  of	  ‘checkerboard’	  analysis,	  to	  create	  an	   in	  vitro	  gradient	  of	  a	  
variety	  of	  growth	  factors	  and	  saw	  that	  SCs	  responded	  with	  positive	  chemotactic	  activity	  to	  HGF	  and	  
TGF-­‐β	  (Bischoff	  1997).	  Furthermore,	  Johnstone	  and	  colleagues	  reported	  positive	  chemotactic	  activity	  
in	  myoblasts	  treated	  with	  angiotensin	  II	  (Ang	  II),	  believed	  to	  function	  through	  actin	  organisation	  and	  
MMP	   to	   initiate	   motility	   (Johnston	   et	   al.	   2010).	   Therefore,	   future	   work	   investigating	   aged	   SCs	  
response	  to	  stimuli	  to	  evoke	  motility	  (chemotaxis),	  would	  be	  of	   interest	  and	  these	  studies	  highlight	  
potential	  factors	  and	  an	  analysis	  method	  that	  could	  be	  utilised.	  
Moreover,	  CM	  did	  not	  alter	  the	  other	  aspects	  of	  SC	  function	  in	  naturally-­‐aged	  SCs,	  thus,	  emergence,	  
morphologies	   and	   proliferation,	   were	   all	   shown	   to	   be	   largely	   unchanged	   by	   CM	   treatment.	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Moreover,	  this	  could	  further	  suggest	  that	  the	  migratory	  feature	  of	  SC	  activity	  in	  old	  age,	  is	  reversible	  
and	  more	  readily	  altered	  by	  extrinsic	  factor	  treatment.	   In	  contrast	  to	  the	  self-­‐renewal,	  proliferative	  
capacity	  which	  appears	  to	  be	  governed	  more	  strongly	  by	  the	  altered	  intrinsic	  properties	  that	  arise	  in	  
aged	   SCs.	   Additionally,	   as	   this	   feature	   was	   restored	   in	   the	   studies	   conducted	   by	   Conboy	   and	  
colleagues,	   but	  was	   not	   affected	   by	   the	   paracrine	   factors	   in	   CM	   in	   the	   present	   study,	   it	   could	   be	  
postulated	  that	  the	  more	  constant	  delivery	  of	  rejuvenating	  factors	  in	  the	  serum	  via	  direct	  circulatory	  
coupling	  was	  more	  influential	   in	  altering	  proliferative	  capacity,	  relative	  to	  the	  8-­‐week	  course	  of	  CM	  
administration,	  once	  every	  2	  weeks.	  Therefore,	  more	  regular	  CM	  treatment	  may	  continue	  to	  observe	  
potentially	  therapeutic	  effects	  on	  these	  currently	  unchanged	  SC	  processes.	  
In	   the	   Ercc1d/-­‐	   SC	   populations	   however,	   along	   with	   a	   reduced	   proliferative	   capacity,	   in	   agreement	  
with	  natural	   ageing	   trends,	  Ercc1d/-­‐	  SCs	  migrated	  at	   a	   significantly	   increased	   rate,	   compared	   to	   the	  
control	   SCs.	  As	   discussed	  previously,	   the	   ability	   to	  migrate	   at	   an	   advanced	   rate,	   to	   the	   lesion	   site,	  
could	  be	  correlated	  with	  an	  expected	   faster	   rate	  of	   repair.	  However,	   it	   is	   reasoned	  that	   this	  would	  
result	   in	   successful	   myofibre	   repair,	   only	   if	   firstly,	   the	   superficially	   positive	   effect	   on	   increased	  
migration	   speed	   also	   comprises	   functional	   directionality	   and	   a	   response	   to	   damage	   stimuli	   and	  
secondly,	   the	   subsequent	   SC	   mechanisms	   are	   fully	   functional	   (proliferation	   and	   differentiation).	  
Therefore,	  additionally,	  it	  would	  be	  beneficial	  to	  also	  assess	  these	  features	  of	  migratory	  directionality	  
in	   the	   Ercc1d/-­‐	  SC	  population.	  Ercc1d/-­‐	  SC	  morphologies	  were	  unchanged	   compared	   to	   controls.	   This	  
indicated	  that	  both	  Ercc1d/-­‐	  SC	  populations	  and	  the	  control	  SCs,	  were	  migrating	  using	  the	  amoeboid-­‐
based	   mechanism	   of	   motility,	   which	   is	   established	   as	   the	   preferred	   method	   adopted	   by	   SCs	   on	  
myofibres	  (Otto	  et	  al.	  2011).	  Surprisingly,	  however,	  the	  differentiation	  programme	  was	  not	  altered	  in	  
the	  Ercc1d/-­‐	  SCs.	  This	  does	  not	  reflect	  the	  findings	  of	  Lavasani	  and	  colleagues,	  who	  found	  that	  Ercc1d/-­‐	  
SC/progenitor	  cells	  exhibited	  reduced	  proliferative	  and	  differentiation	  capacity,	  both	   in	  vitro	  and	   in	  
vivo	   (Lavasani	   et	   al.	   2012).	   The	   reasons	   for	   this	   discrepancy	   are	   unknown,	   although	   it	   could	   be	  
postulated	  that	  the	  in	  vitro	  system	  utilised	  in	  the	  current	  study,	  analyses	  SC	  function	  on	  the	  isolated	  
single	  myofibre,	  as	  opposed	   to	   tissue	  culture	  plates	  used	  by	  Lavasani	  and	  colleagues.	  Thus,	  as	   it	   is	  
known	  that	   the	  physical	  properties	  of	   the	  myofibre	  substrate,	  as	  well	  as	   the	  vast	  array	  of	   released	  
signalling	  components,	  function	  to	  bring	  about	  alterations	  in	  regulation	  and	  subsequent	  behaviour	  of	  
SCs,	   it	  can	  be	  suggested	  that	  the	  two	  culture	  methods	  would	  create	  variable	  results.	  However,	  this	  
does	  not	  account	  for	  the	  reduced	  regenerative	  (proliferation	  and	  differentiation)	  effects	  seen	  in	  the	  
Ercc1d/-­‐	  muscles	  in	  vivo.	  
CM	  treatment	  in	  the	  Ercc1d/-­‐	  animals	  resulted	  in	  a	  greater	  effect	  on	  the	  underlying	  mechanisms	  of	  SC	  
function,	   compared	   to	   those	   underpinning	   the	   parameters	  measured	   at	   a	   tissue	   level,	   previously.	  
Firstly,	   it	   was	   established	   that	   Ercc1d/-­‐	   SCs	   were	   driven	   towards	   an	   advanced	   rate	   of	   emergence,	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which	  is	  reasoned	  would	  be	  overall	  beneficial	  providing	  that	  as	  mentioned	  previously,	  the	  following	  
SC	  processes	  function	  successfully	  to	  bring	  about	  repair.	  Interestingly,	  the	  decreased	  migration	  speed	  
with	   CM	   treatment	   could	   indicate	   that	   indeed,	   the	   faster	   speed	   noted	   in	  Ercc1d/-­‐	   control	   SCs	  may	  
have	  been	  overall	  dysfunctional	  and	  CM	  treatment	  appears	  to	  have	  normalised	  this	  feature	  to	  those	  
in	   the	   (+/+)	   control	   SCs.	   Further	   exploration	   into	   the	   directionality	   as	   well	   as	   bleb	  
extension/retraction	   times,	   as	   previously	  mentioned	  would	   provide	   a	   better	   understanding	   of	   this	  
finding.	   It	   is	   hypothesised	   that	   Ercc1d/-­‐	   SCs,	   similarly	   to	   naturally-­‐aged	   SCs,	   experience	   altered	  
directionality	  and	  bleb	  dynamics	  leading	  to	  the	  findings	  of	  altered	  migration	  speeds,	  in	  this	  series	  of	  
experiments.	   Moreover,	   as	   seen	   in	   the	   naturally-­‐aged	   SCs,	   CM	   failed	   to	   increase	   proliferative	  
capacity.	  This	   further	   implicates	   intrinsic	  mechanistic	  dysfunction	   impacting	   to	  a	  greater	  degree	  on	  
this	   characteristic	  of	   SC	  activity.	   Furthermore,	   this	  provides	   further	  evidence	   that	   a	   strong	   survival	  
response,	  driving	  regulation	  away	  from	  proliferation	  and	  growth,	  is	  evident	  at	  this	  cellular	  level	  in	  the	  
Ercc1d/-­‐	   model,	   thus	   sharing	   this	   feature	   with	   naturally-­‐aged	   SCs.	   Moreover,	   it	   suggests	   that	   this	  
intrinsic	   dysregulation	   may	   not	   be	   so	   easily	   overridden	   by	   CM	   treatment.	   Lastly,	   myogenic	  
differentiation	  was	  shown	  to	  be	  delayed	  with	  CM	  treatment	  in	  both	  Ercc1d/-­‐	  and	  the	  control	  SCs,	  with	  
a	  larger	  proportion	  of	  cells	  maintaining	  Pax7,	  the	  maker	  of	  quiescence.	  It	  is	  reasoned	  that	  this	  would	  
overall	   negatively	   impact	   regenerative	   ability,	   as	   a	   smaller	   proportion	   of	   the	   SC	   population	  
progressed	  to	  express	  myogenin,	  towards	  terminal	  differentiation.	  However,	  as	  stem	  cell	  exhaustion	  
is	   a	   key	   feature	   of	   ageing	   and	   the	   SC	   pool	   is	   known	   to	   become	  depleted	  with	   advancing	   age,	   this	  
delay	  could	  indicate	  a	  proportion	  of	  the	  SC	  population	  that	  are	  down-­‐regulating	  MyoD	  between	  T48	  
and	  72	  to	  revert	  back	  to	  a	  state	  of	  quiescence	  (Shefer	  et	  al.	  2006;	  Nagata	  et	  al.	  2006).	  	  
Overall,	   the	  underlying	   features	  of	   SC	  activity	  were	  observed	   to	  be	  variable	   in	  both	  natural	   ageing	  
and	   progeric	   myofibre	   cultures,	   with	   a	   diminished	   proliferative	   capacity,	   common	   to	   both,	   as	  
evidence	  of	  dysfunction.	  However,	  these	  findings	  provide	  a	  platform	  for	  further	  investigation	  into	  the	  
effects	   of	   CM	   in	   vivo	   for	   example,	   in	   an	   acute	   injury	  model	   (cardiotoxin)	   and	  will	   determine	   how	  
these	   alterations	   noted	   in	   the	   present	   study,	   impact	   on	   overall	   regenerative	   function	   in	   natural	  
ageing	  and	  progeria.	  	  
Skeletal	  muscle	  myofibres	  promote	  non-­‐muscle	  stem	  cells	  and	  non-­‐stem	  cells	  
to	  adopt	  myogenic	  characteristics	  
The	   hypotheses	   for	   this	   work	   focused	   on	   the	   central	   role	   of	   the	   myofibre	   microenvironment	   in	  
determining	  the	  key	  features	  underlying	  SC	  function.	  It	  has	  been	  established	  that	  SCs	  migrate	  along	  
myofibres	  utilising	  a	  distinctive	  amoeboid-­‐based	  mechanism	  (Otto	  et	  al.	  2011;	  Collins-­‐Hooper	  et	  al.	  
2012).	   It	  was	  also	  postulated	  that	  the	  amoeboid-­‐based	  mechanism	  of	  motility	   is	  a	  migratory	  option	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available	   to	   all	   stem	   cells,	   not	   just	   SCs	   and	   that	   this	   characteristic	   is	   induced	   by	   contact	  with	   the	  
myofibre	  surface.	  	  
Firstly,	   it	   was	   established	   that	   non-­‐muscle	   stem	   cells	   (ADMSC,	   AFS	   and	   DP)	   and	   a	   non-­‐stem	   cell	  
(MDA)	  adopted	  a	   rounded	  morphology	  and	  migrated	  by	   the	  amoeboid-­‐based	   form	  of	  motility	   and	  
exhibited	   cell	   surface	  blebs.	   This	   finding	  demonstrates	   that	   these	   characteristics	   are	  not	  unique	   to	  
the	  SC	  but	  instead,	  directed	  by	  the	  myofibre	  surface	  (Morash	  et	  al.	  2017).	  Non-­‐muscle	  myosin	  II	  has	  
been	  established	  as	  a	  key	  component	  that	  exerts	  force	  through	  focal	  adhesion	  contacts,	  in	  order	  to	  
sense	  matrix	  elasticity	   (Engler	  et	  al.	  2006).	  Therefore,	  this	  could	  provide	  a	  mechanism	  in	  which	  the	  
transplanted	   cell	   types	   are	   able	   to	   sense	   the	  myofibre	   elasticity	   and	   respond,	   by	   altering	   intrinsic	  
regulation	   of	   cell	   motility.	   Furthermore,	   it	   was	   established	   that	   the	   key	   regulatory	   mechanisms	  
directing	   methods	   of	   cell	   motility,	   Rac	   and	   Rho	   GTPase	   signalling	   were	   responsible	   for	   directing	  
morphology	   in	   both	   SCs	   and	   non-­‐muscle	   cells,	   indicating	   that	   this	   pathway	   is	   conserved	   in	   the	  
differing	   cell	   types.	   Importantly,	   it	  was	   shown	   that	   despite	   all	   cells	   adopting	   the	   blebbing	   form	  of	  
motility,	   it	   was	   not	   always	   accompanied	   by	   a	   faster	   migration	   speed	   (Morash	   et	   al.	   2017).	   Bleb	  
dynamics	  measurements	  have	  shown	  that	  aged	  SCs	  experience	  a	  prolonged	  bleb	  lifecycle	  and	  this	  is	  
believed	   to	   be	   one	   of	   the	   contributing	   factors	   to	   an	   overall	   decreased	   migration	   speed	   (Collins-­‐
Hooper	   et	   al.	   2012).	   Therefore,	   bleb	   dynamics	   measurements	   in	   the	   non-­‐muscle	   cell	   types	   could	  
provide	  a	  better	  understanding	  of	   this	   induced	  form	  of	  motility	  and	  the	  effect	  on	  the	  different	  cell	  
speeds.	   It	  was	   also	   suggested	   that	   assembly	   and	  disassembly	  of	   focal	   adhesion	   contact	   apparatus,	  
could	  also	  influence	  the	  speed	  at	  which	  these	  different	  cells	  travel	  (Nagano	  et	  al.	  2012;	  Tozluoğlu	  et	  
al.	   2013;	   Charras	  &	  Paluch	  2008).	   Furthermore,	   it	   is	   reported	   that	   the	  majority	   of	   the	   cell	   to	   ECM	  
contact	   is	  maintained	  via	  the	   interaction	  of	  myofibre	  transmembrane	  receptors,	  as	  well	  as	   laminin,	  
which	   is	   the	   predominant	   cell-­‐adhesive	   protein	   found	   in	   the	   basement	   membrane	   (Mayer	   2003).	  
Staining	   the	   myofibre/non-­‐muscle	   cell	   co-­‐cultures	   for	   antibodies	   against	   laminin	   and	   integrin	  
isoforms,	  could	   indicate	  how	  these	  cells	  are	  forming	  attachments	  with	  the	  myofibre	  and	  migrating.	  
α7β1	  integrin	  is	  the	  major	  integrin	  receptor	  located	  in	  skeletal	  muscle	  (α5β1	  α6β1	  are	  also	  present)	  
which	  binds	  to	  laminin,	  facilitating	  SC	  motility,	  however	  there	  a	  multiple	  isoform	  variations	  (18	  α	  and	  
8	  β,	  with	  24	  different	  dimers)	  which	  results	  in	  variable	  substrate	  affinities	  (Mayer	  2003;	  Siegel	  et	  al.	  
2009).	   It	   is	  known	  that	  SCs	   remodel	   their	  niche,	   in	  order	   to	  emerge	  and	  migrate	   to	   the	   lesion	  site.	  
This	   is	   mediated	   mainly	   through	   the	   synthesis	   and	   secretion	   of	   MMP-­‐2	   and	  MMP-­‐9	   by	   SCs,	   that	  
target	   collagen	   IV	   and	   laminin	   (Guérin	  &	  Holland	   1995).	  With	   four	   differing	   cell	   types	   used	   in	   the	  
present	   study,	   it	   could	   be	   reasoned	   that	   some	   cell	   types	   would	   have	   a	   higher	   affinity	   with	   the	  
myofibre	  and	  remodel	  the	  ECM	  more	  effectively,	  relative	  to	  others.	  Additionally,	  future	  work	  would	  
evaluate	   these	   adhesion	   and	   cell	   to	   ECM	   interactions	   to	   further	   understand	   the	  differences	   in	   the	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different	   cell	   type	   response	   in	   speed,	   to	   the	  myofibre	   substrate,	   in	  both	  young	  and	  aged	  myofibre	  
cultures.	  
A	  further	  finding	  was	  that	  similarly	  to	  observations	  on	  young	  myofibres,	  all	  cell	  types	  adopted	  a	  more	  
rounded	  morphology	   on	   aged	  myofibres	   (Morash	   et	   al.	   2017).	   This	   could	   indicate	   therefore,	   that	  
despite	   the	  myofibre	   stiffening	  with	   age	   and	   the	   cells	   sensing	   this	   change	   in	   elasticity,	   it	   was	   not	  
sufficient	   to	   affect	   the	   rounded	   morphology	   adopted,	   in	   any	   of	   the	   conditions.	   Importantly,	   SC	  
morphologies	  nor	  migration	  speed,	  were	  altered	  on	  the	  aged	  myofibre,	  which	  could	  indicate	  a	  higher	  
adaptability	   in	   the	  resident	  niche,	  compared	  to	  the	  non-­‐muscle	  cells,	  all	  of	  which	  were	  affected	  by	  
the	  age	  of	  the	  myofibre,	  in	  either	  the	  morphology	  adopted	  or	  migration	  speed,	  or	  both.	  Interestingly,	  
all	  of	  the	  non-­‐muscle	  cell	  types,	  but	  not	  the	  SC,	  showed	  evidence	  of	  regulatory	  effects	  of	  in	  vitro	  CM	  
on	  morphology	  or	  migration,	  or	  both	  which	  further	  supports	  the	  higher	  plasticity	  of	  SC	  to	  cope	  with	  
alterations	   in	   their	   own	   niche.	   It	   would	   be	   of	   interest	   to	   explore	   this	   plasticity	   in	   reverse	   by	  
transplanting	   freshly	   isolated	   SCs	   into	   a	   non-­‐muscle	   microenvironment,	   in	   order	   to	   examine	  
migration,	   proliferation	   and	   differentiation	   potential.	   This	   could	   be	   achieved	   by	   utilising	   explant	  
cultures,	   for	   those	  similar	   in	  origin	  of	   the	  cell	   types	  used	   in	   the	  current	  study.	  For	  example,	  dentin	  
and	  umbilical	  cord	  matrix,	  which	  are	  both	  known	  to	  be	  a	  source	  of	  growth	  factors,	  similar	  to	  skeletal	  
muscle	  including,	  FGF,	  IGF,	  TGF-­‐β	  and	  VEGF,	  among	  others	  (Sloan	  et	  al.	  2000;	  La	  Rocca	  et	  al.	  2009).	  
Although,	   there	  would	  be	   some	   technical	   concerns	   to	  address	  as	   far	   as	   visualising	   transplanted	  SC	  
migration	  using	  a	  time-­‐lapse	  microscope	  as	  a	  denser	  explant	  tissue	  for	  example,	  would	  not	  be	  easily	  
viewable.	   As	   what	   makes	   single	   myofibre	   culture	   so	   feasible,	   is	   due	   to	   the	   translucency	   of	   the	  
myofibres	   enables	   tracking	   of	   single	   cells.	   However,	   GFP+	   tracking	   using	   fluorescent	   time-­‐lapse	  
confocal	  microscopy	  could	  circumvent	  the	  issue.	  
Taken	   together,	   the	   findings	   of	   this	   study,	   highlight	   the	   importance	   of	   the	   myofibre	  
microenvironment	   in	   regulating	   features	   of	   SC	   function,	   as	  well	   as	   the	   influence	  on	   the	  behaviour	  
and	  fate	  of	  non-­‐muscle	  cells.	  This	  series	  of	  experiments	  also	  indicates	  that	  SCs	  demonstrate	  a	  level	  of	  
plasticity	   in	   response	   to	   changes	   within	   their	   niche	   and	   by	   taking	   physical	   features	   of	   the	  
microenvironment	   into	   account,	   in	   ageing,	   injury	   and	  disease	   for	   example,	   stem	  cell	   therapies	   can	  
potentially	  be	  better	  tailored	  to	  the	  host	  tissue	  for	  greater	  engraftment	  success.	  This	  work	  provides	  a	  




Single	  myofibre	  experimentation	  
It	  would	  be	  of	   interest	   to	   the	   current	   study	   to	   continue	   this	   line	  of	  work	  by	   collecting	   the	   culture	  
media	  and	  characterising	  the	  properties	  released	  from	  the	  myofibres	  in	  our	  single	  myofibre	  culture,	  
from	   young	   and	   old	   ages,	   as	   well	   as	   that	   secreted	   from	   Ercc1d/-­‐	   progeric	   myofibres.	   It	   has	   been	  
established	  that	  numerous	  growth	  factors	  are	  released	  from	  the	  SCs,	  as	  well	  as	  the	  myofibre	  ECM,	  
that	  direct	  not	  only	  SC	  activity,	  but	  also	  many	  other	  interstitial	  cells,	   including	  fibroblasts,	  cells	  that	  
constitute	  the	  vasculature	  and	  immune	  system,	  motor	  neurons,	  as	  well	  as	  adipocytes,	  for	  example.	  
Common	   regulatory	   factors	   include	   HGF,	   bFGF,	   VEGF,	   IGF,	   Nitric	   oxide	   (NO),	   Delta/Jagged	   (Notch	  
signalling)	  and	  it	  is	  widely-­‐reported	  that	  changes	  in	  the	  regulation	  via	  these	  components	  alters	  with	  
age	  (Yin	  et	  al.	  2013).	  For	  example,	  Notch	  signalling	  has	  shown	  to	  be	  diminished	  in	  aged	  muscle	  which	  
directly	  impacts	  on	  regenerative	  function	  as	  SC	  proliferation	  and	  cell	  fate	  determination,	  are	  reduced	  
(Conboy	  et	  al.	  2003;	  Brack	  et	  al.	  2007).	  However,	  Conboy	  and	  colleagues	  subsequently,	  showed	  that	  
exposure	   to	   circulatory	   factors	   in	   young	   serum,	   restored	   Notch	   signalling	   in	   aged	   animals	   and	  
enhanced	   SC	   regenerative	   function	   (Conboy	   et	   al.	   2003;	   Conboy	   et	   al.	   2005).	   Importantly,	   this	  
indicates	   that	   dysfunctional	   reparative	   regulation	   in	   aged	   SCs	   is	   reversible.	  Additionally,	   this	   raises	  
further	  questions	  concerning	  the	  target	  of	  the	  rejuvenating	  factors	  present	  in	  young	  serum,	  whether	  
alterations	   in	   underlying	  mechanisms	   are	   achieved	   by	   targeting	   the	   SCs,	   or	   the	  myofibre	   ECM,	   or	  
both.	   Further	   experimentation	   therefore,	   could	   include	   the	   generation	   of	   conditioned	  media	   from	  
myofibre	   cultures,	   as	   well	   as	   isolated	   SC	   cultures	   from	   young	   and	   old	   animals	   and	   test	   the	  
regenerative	  potential,	  via	  a	  paracrine	  effect.	  Firstly,	  by	   treating	  an	  acute	   (Naja	  pallida)	  cardiotoxin	  
(CTX)	  injury	  model	   in	  vivo,	   in	  the	  Tibialis	  anterior	  (TA)	  and	  analysing	  the	  percentage	  of	  regenerative	  
myofibres	  within	  3	  and	  6	  days	  post-­‐injury,	  as	  well	  as	  the	  pro-­‐angiogenic	  and	  macrophage	  infiltration	  
activity,	   with	   each	   developed	   CM,	   as	   previously	   observed	   with	   AFS	   CM	   (Mellows	   et	   al.	   2017).	  
Secondly,	   the	   different	   CM	   could	   be	   used	   along	   with	   the	   senescence	   assay,	   utilised	   to	   test	   the	  
efficacy	   of	   the	   ADMSC	   CM	   in	   the	   present	   study,	   to	   assess	   the	   potential	   of	   myofibre/SC-­‐released	  
paracrine	   effects	   in	   the	   protection	   against	   senescence.	   Other	   in	   vitro	   assays	   are	   currently	   being	  
developed	   to	   test	   CM	   by	   colleagues	   and	   include	   a	   fibroblast	   migration/wound	   closure	   assay,	   to	  
examine	  regulatory	  impact	  on	  migration,	  as	  well	  as	  differentiation	  assays	  to	  examine	  adipo-­‐,	  osteo-­‐	  
and	  chondrogenic	  lineage	  specification.	  	  
Moreover,	   it	   is	   established	   that	   the	   skeletal	   muscle	   myofibre	   substrate	   and	   surrounding	   ECM	  
becomes	   stiffer	  with	   age	   and	   this	   has	   been	   attributed	   to	   the	   increased	   deposition	   and	   enzymatic	  
cross-­‐linking	   of	   ECM	   components	   by	   interstitial	   cells	   such	   as	   fibroblasts	   (Marshall	   et	   al.	   1989;	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Zimmerman	  et	  al.	  1993;	  Haus	  et	  al.	  2007).	  This	  not	  only	  impacts	  on	  overall	  muscle	  contractility,	  but	  is	  
also	  believed	  to	  alter	  SC	  to	  ECM	  interactions	  (Garg	  &	  Boppart	  2016;	  Lacraz	  et	  al.	  2015).	  The	  work	  in	  
this	  chapter	  studied	  the	  features	  of	  resident	  SC	  function	  and	  behaviour	  in	  young	  and	  old	  conditions.	  
It	  would	  therefore	  be	  of	   interest	  to	  further	  clarify	  whether	  these	  alterations	   in	  SC	  activity	  originate	  
predominantly	  with	   the	   age-­‐related	   changes	   in	   the	   SC,	   or	   the	   ageing	  myofibre	  microenvironment.	  
This	   could	   be	   achieved	   through	   the	   separate	   dissociation	   of	   the	   resident	   young	   and	   aged	   SC	  
populations	  from	  their	  myofibres	  and	  subsequently	  heterochronically	  co-­‐culture	  young	  SCs	  with	  old	  
myofibre	  and	  old	   SCs	  with	   young	  myofibres	   and	   repeat	   SC	  analyses	   as	   carried	  out	   in	   this	   series	  of	  
experimentation.	   Although,	   it	   has	   been	   established	   that	   the	  myofibre	   is	   able	   to	   heavily	   influence	  
non-­‐muscle	  cells	  to	  adopt	  SC	  characteristics	  (ADMSC,	  AFS,	  DP,	  MDA)	  and	  direct	  towards	  a	  myogenic	  
lineage	  and	  fuse	  to	   form	  myotubes	   (AFS)	   (Morash	  et	  al.	  2017).	  Thus,	   this	   finding	   indicates	   that	   the	  
physical	  properties	  of	  the	  myofibre	  surface	  are	  able	  to	  elicit	  remarkable	  alterations	   in	  transplanted	  
cells	  and	  therefore	  provides	  evidence	  that	  the	  myofibre	  plays	  a	  defining	  role	  in	  cellular	  activity.	  
Further	   investigations	   into	   the	  ECM	  could	  explain	   the	  observation	  of	   reduced	  grip	  strength	   in	  both	  
naturally-­‐aged	   and	   progeric	   animals.	   As	   glycation-­‐related	   cross-­‐linking	   of	   intramuscular	   connective	  
tissue,	  has	  been	  implicated	  in	  altered	  force-­‐generating	  capacity	  with	  age.	   It	  would	  be	  of	   interest	  to	  
investigate	  this	  feature	  further	  in	  both	  naturally-­‐aged	  and	  Ercc1d/-­‐	  muscle.	  Ramamurthy	  and	  Larsson	  
used	   an	   anti-­‐AGE	   immunofluorescence	   confocal	   microscopy	   protocol	   to	   identify	   intracellular	   and	  
sarcolemmal	   protein	   glycation	   (Ramamurthy	   &	   Larsson	   2013).	   It	   was	   found	   that	   myosin	   is	   also	  
glycated,	   in	   both	   type	   I	   and	   type	   II	   myofibres,	   of	   young	   and	   aged	   rat	   Soleus	   and	   EDL	   muscles.	  
Additionally,	   the	   greatest	   concentration	   of	   AGEs	   were	   located	   intracellularly	   in	   the	   aged	   Soleus.	  
Moreover,	  generation	  of	   irreversible	  AGEs,	   is	  believed	   to	  be	  mediated	  by	   free	   radical	  oxidation,	  of	  
which	  production	  is	  well-­‐defined	  in	  mitochondrial	  dysfunction	  with	  age	  (Avigad	  et	  al.	  1996;	  Pieczenik	  
&	  Neustadt	  2007).	  Continued	  work	  in	  the	  current	  study	  will	  examine	  the	  accumulation	  of	  AGEs	  in	  the	  
Soleus	  and	  EDL	  muscles	  of	  naturally-­‐aged	  and	  Ercc1d/-­‐	  animals,	  with	  and	  without	   in	  vivo	  ADMSC	  CM	  
treatment.	  It	  is	  postulated	  that	  CM	  will	  prevent	  the	  build-­‐up	  of	  age-­‐associated	  AGEs.	  
Ercc1d/-­‐	  progeric	  and	  natural	  ageing	  experimentation	  	  
In	  order	   to	  use	   the	   findings	  of	   the	   current	   study	   and	  extend	  both	   the	  naturally-­‐aged	   and	  progeric	  
experimentation	   forward,	   it	   will	   be	   essential	   to	   examine	   the	   overall	   regenerative	   capacity	   of	   the	  
Ercc1d/-­‐	  model	  at	  a	  tissue	  level,	  utilising	  the	  CTX	  induced-­‐injury	  model,	  comparatively	  the	  same	  will	  be	  
carried	  out	   in	   naturally-­‐aged	   animals.	   Following	   the	   same	  protocol	   as	   that	   carried	  out	   by	  Mellows	  
and	   colleagues,	   the	   ability	   of	   Ercc1d/-­‐	   SCs	   to	   carry	   out	   the	   renewal	   of	   whole,	   fully	   functional,	  
innervated	  and	  vascularised	  contractile	  myofibres	  will	  be	  assessed	  and	  compared	  to	  that	  of	  naturally-­‐
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aged	   tissue.	   Histologically,	   CD31	   analysis,	   as	   carried	   out	   in	   previous	   chapters	   will	   identify	  
capillarisation.	   F4/80	   staining	   for	  macrophages,	   responsible	   for	   the	  phagocytosis	   of	   dead	  myofibre	  
contents	   and	   cellular	   debris,	   will	   indicate	   the	   initiation	   and	   extent	   of	   an	   inflammatory	   response.	  
Embryonic	  myosin	  (MHC-­‐3)	  staining	  along	  with	  the	  presence	  of	  centrally-­‐located	  nuclei	  will	   identify	  
those	  myofibres	   that	  are	  undergoing	   regeneration	   (Mellows	  et	  al.	  2017).	  A	   further	  hypothesis	   that	  
will	   in	  turn,	  be	   investigated	   is	  that	  ADMSC	  CM	  treatment	  will	  enhance	  the	  regenerative	  capacity	  of	  
the	  Ercc1d/-­‐	  and	  naturally-­‐aged	  muscle	  following	  CTX	  injury.	  In	  this	  experimentation,	  TA	  muscles	  will	  
be	  primed	  with	  ADMSC	  CM,	  administered	  via	  the	  tail	  vein,	  prior	  to	  intramuscular	  (IM)	  CTX	  injections	  
(Mellows	  et	  al.	  2017).	  
Furthermore,	   extended	   investigations	   in	   both	   the	   naturally-­‐aged	   and	   Ercc1d/-­‐	   progeric	  
experimentation,	   would	   include	  more	   comprehensive	   functional	   testing.	   It	   is	   essential	   that	   force-­‐
generating	   capacity	   be	   assessed	   for	   comparison	   between	   natural	   ageing	   and	   progeria.	   It	   is	  
hypothesised	  that	  the	  ‘super-­‐ageing’	  features	  of	  the	  Ercc1d/-­‐	  mice	  would	  lead	  to	  a	  reduced	  maximal	  
isometric	  tetanic	  force	  compared	  to	  young	  controls	  and	  naturally-­‐aged	  muscles.	  A	  second	  hypothesis	  
would	   be	   that	   ADMSC	   CM	   enhances	  maximal	   tetanic	   force	   in	   naturally-­‐aged	   and	  Ercc1d/-­‐	  muscles.	  
This	   could	  be	  achieved	  by	  measuring	   the	  maximal	   isometric	   tetanic	   force	  of	   limb	  musculature	  and	  
recording	   this	   relative	   to	   muscle	   weight	   and	   CSA,	   using	   an	   isometric	   force	   transducer	   (Degens	   &	  
Alway	  2003).	  Similarly,	  muscle	  fatigue	  could	  also	  be	  measured	  in	  this	  way	  and	  these	  features	  would	  
provide	  a	  more	  detailed	  understanding	  of	  whether	   the	   strength	  exerted	  by	   the	  Ercc1d/-­‐	  muscles,	   is	  
proportionate	  to	  its	  reduced	  size.	  It	  has	  been	  established	  that	  in	  naturally-­‐aged	  rat	  Plantaris	  muscles,	  
following	   compensatory	   hypertrophy,	   the	   lowest	   tetanic	   force	   was	   that	   exerted	   by	   25-­‐month	   old	  
muscles	   and	  was	   highest	   in	   those	   at	   13-­‐months	   old	   (Degens	   et	   al.	   1993).	   Similarly,	   the	  mass	   and	  
maximal	   tetanic	   force	   diminished	   by	   approximately	   30%	   between	   the	   ages	   of	   9	   and	   26	   months	  
(Degens	  &	  Alway	  2003).	  Further	  investigation	  could	  measure	  the	  maximal	  tetanic	  force	  and	  fatigue	  of	  
treadmill-­‐trained	   Ercc1d/-­‐	   and	   naturally-­‐aged	   muscles	   in	   order	   to	   characterise	   and	   compare	   the	  
hypertrophic	   response	   to	   endurance	   training	   in	   the	   Ercc1d/-­‐	   model.	   These	   experiments	   can	   also	  
encompass	  cohorts	  treated	  with	  ADMSC	  CM	   in	  vivo	  as	   in	  the	  current	  study,	  to	  test	  any	  therapeutic	  
effects	  of	  CM	  on	  functionality	  with	  age	  and	  in	  progeria.	  
As	  the	  Ercc1d/-­‐	  model	  has	  demonstrated	  a	  severely	  reduced	  muscle	  mass,	   it	  would	  be	  of	   interest	  to	  
test	  not	  only	  the	  ability	  of	  the	  Ercc1d/-­‐	  musculature	  to	  undergo	  hypertrophy	  ‘naturally’,	  following	  high	  
levels	  of	  exercise	  training,	  or	  surgically,	  to	  induce	  compensatory	  hypertrophy,	  but	  pharmacologically.	  
This	   can	   be	   achieved	   through	   the	   inhibition	   of	   the	   negative	   regulators	   of	   skeletal	  muscle	   growth,	  
including	  myostatin,	  by	  using	  a	  soluble	  form	  of	  the	  Activin	  type	  IIB	  receptor	  (sActRIIB).	  Treatment	  of	  
normal	   and	  mdx	   mice	   has	   demonstrated	   rapid	  muscle	   growth	   and	   increases	   in	   absolute	  maximal	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force,	   of	   the	   EDL	   and	   Soleus	   and	   therefore,	   the	   myostatin/activin	   signalling	   pathway	   has	   been	  
identified	  as	  a	  potential	  therapeutic	  target	  in	  combating	  sarcopenia	  in	  old	  age	  (Relizani	  et	  al.	  2014).	  
Properties	  of	  conditioned	  media	  	  
Although,	  the	  current	  study	  demonstrates	  that	  ADMSC	  CM	  harbours	  properties	  impacting	  on	  various	  
characteristics	  of	  ageing	  skeletal	  muscle,	   the	   focus	  of	   these	  analyses	  was	  not	   to	  determine	  specific	  
regulatory	  components.	  However,	  by	  characterising	  the	  features	  that	  are	  altered	  by	  CM	  treatment,	  
in	   the	   current	   study,	   the	   first	   insights	   into	   its	   therapeutic	   potential	   in	   ageing	   and	   progeria,	   are	  
assessed.	   Therefore,	   the	   most	   immediate	   future	   work	   for	   the	   continuation	   of	   project	   will	   be	   to	  
determine	   the	   specific	   content	   of	  ADMSC	  CM,	  defining	   the	   signalling	  mechanisms	   and	   their	   broad	  
cellular	   process	   targets.	   Microarray	   analysis,	   as	   carried	   out	   by	   colleagues	   with	   the	   AFS	   CM,	   to	  
determine	  the	  mechanistic	  properties	  of	  the	  ADMSC	  CM	  would	  begin	  with	  isolating	  the	  extracellular	  
vesicle	  (EV)	  fraction,	  forming	  the	  two	  distinct	  types	  of	  CM,	  the	  whole	  CM	  (as	  used	  in	  this	  study)	  and	  
just	  the	  isolated	  EV	  fraction,	  through	  ultracentrifugation.	  This	  is	  because	  colleagues	  and	  others	  have	  
observed	  distinct	  differences	   in	   the	   contents	  of	   each	   fraction	   (Mellows	  et	   al.	   2017;	   Le	  Bihan	  et	   al.	  
2012).	   Alternatively	   to	   qPCR	   and	   western	   blot	   analysis,	   of	   specific	   pathway	   components,	   global	  
analyses	  of	  interest	  to	  determine	  the	  properties	  of	  ADMSC	  CM	  would	  include	  Luminex	  multi-­‐analyte	  
profiling	   (MAP)	  technology	  to	  screen	  CM	  for	  cytokines	  and	  growth	  factors	   (Oliver	  et	  al.	  1998).	  Gel-­‐
free	   nano-­‐flow	   LC-­‐MS/MS	   analysis	   and	   2-­‐dimensional	   gel	   electrophoresis	   (2DGE)	   and	   LC-­‐MS/MS	  
analysis.	  Additionally,	  computational	  sieving	  following	  RNA	  or	  protein	   identification	  can	  be	  a	  useful	  
tool	  to	  predict	  reliable	  subcellular	  localisation	  of	  protein	  content,	  as	  well	  as	  bioinformatics	  approach	  
in	  the	  evaluation	  of	  specific	  functional	  profiles	  of	  secreted	  factors	  (Le	  Bihan	  et	  al.	  2012).	  Additionally,	  
as	  EVs	  are	  membrane-­‐bound	  vesicles,	  these	  can	  be	  stained	  using	  a	  fluorescent	  cell	  linker	  (PKH26)	  and	  
used	  in	  a	  cell	  culture	  assay,	  to	  visualise	  the	  cellular	  uptake	  of	  ADMSC	  EVs	  (Mellows	  et	  al.	  2017).	  
Cell	  transplantation	  future	  experimentation	  
Based	   on	   the	   findings	   of	   the	   non-­‐muscle	   cell	   transplantation	   series	   of	   experimentation,	   a	   future	  
investigation	   would	   involve	   the	   transplantation	   of	   the	   non-­‐muscle	   cells	   types	   onto	   the	   single	  
myofibres	  of	   the	  Ercc1d/-­‐	  progeric	  mouse,	   in	  order	  to	  assess	  the	  extrinsic	  and	  physical	  properties	  of	  
the	   progeric	   ‘super-­‐ageing’	   model,	   with	   and	   without	   CM	   treatment,	   to	   compare	   to	   both	   the	  
naturally-­‐aged	  cell	  transplantation	  experiment,	  as	  well	  as	  young	  findings.	  Taken	  with	  the	  findings	  of	  
the	  previous	  experimentation,	  it	  is	  postulated	  that	  the	  physical	  myofibre	  environment	  will	  be	  further	  
altered	  in	  the	  Ercc1d/-­‐	  muscle	  and	  therefore,	  cell	  to	  ECM	  communications	  will	  be	  further	  affected,	  in	  
turn,	   impacting	   on	   observed	   cell	   behaviour.	   Furthermore,	   it	   is	   hypothesised	   that	   the	   Ercc1d/-­‐	  
myofibres	   matrix,	   may	   not	   elicit	   the	   same	   proliferative	   capacity	   and	   myogenic	   specification	   of	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transplanted	  cells	  as	  these	  characteristics	  were	  most	  affected	  in	  resident	  SC	  populations,	  observed	  in	  
this	  study.	  
One	  of	  the	  most	  remarkable	  findings	  of	  the	  current	  study	  was	  that	  a	  non-­‐muscle	  stem	  cell	  (AFS)	  and	  
a	  non-­‐stem	  cell	  (MDA)	  were	  induced	  towards	  a	  myogenic	  lineage	  (MyoD+)	  through	  contact	  with	  the	  
myofibre	   surface	   and	   strikingly,	   the	   AFS	   cells	   went	   on	   to	   fuse	   to	   produce	   MHC+	   myotubes.	  
Importantly,	   this	   finding	  opens	  up	   further	   avenues	  of	   experimentation,	   particularly	   in	   the	   fields	   of	  
stem	  cell	   therapy	  and	  tissue	  engineering	  for	  the	  treatment	  of	  human	   injury	  and	  disease,	  as	  well	  as	  
age-­‐related	   decline.	   Additionally,	   this	   highlights	   the	   clinical	   potential	   of	   AFS	   cells	   to	   be	   more	  
extensively	   researched	   for	   these	   applications	   but	   does	   not	   rule	   out	   the	   continuation	   to	   test	  more	  
non-­‐muscle	  cell	  types	  for	  similar	  properties	  in	  a	  myofibre	  set-­‐up.	  	  
Firstly,	  these	  findings	  indicate	  that	  cells	  can	  be	  more	  successfully	  cultured	  in	  vitro	  by	  initially	  priming	  
them	  to	  the	  relevant	  physiological	  elasticities,	  prior	  to	  administration	  into	  damaged	  tissues	  (Engler	  et	  
al.	  2004).	  It	  was	  shown	  that	  introduction	  of	  mesenchymal	  stem	  cells	  into	  a	  stiffening	  fibrotic	  infarct	  
region	  in	  the	  heart	  resulted	  in	  cellular	  expression	  of	  myocyte	  markers.	  However,	  differentiation	  was	  
halted	   and	   cells	   failed	   to	   assemble	   functional	   contractile	   apparatuses	   (Shake	   et	   al.	   2002).	  
Additionally,	   myoblast	   cultures	   are	   known	   to	   undergo	   fusion	   to	   form	   myotubes	   which	   can	   be	  
observed	   in	   vitro	   (Bischoff	   &	   Holtzer	   1970).	   However,	   contractile	   actin/myosin	   striations	   were	  
evident	   only	   in	   the	   myotube	   cultures	   mimicking	   the	   passive	   stiffness	   typical	   of	   normal	   muscle	  
(Young’s	   modulus,	   E	   ~12	   kPa)	   (Engler	   et	   al.	   2004).	   On	   substrates	   with	   much	   softer	   or	   stiffer	  
elasticities,	  for	  example	  on	  surfaces	  akin	  to	  soft	  fibroblast	  cell	  layers	  or	  those	  representing	  stiffened	  
dystrophic	  muscle,	  myotubes	  did	  not	  become	  striated.	  Thus,	   these	   findings	   indicate	   that	   there	   is	  a	  
seemingly	   narrow	   window	   of	   optimum	   substrate	   elasticity	   that	   will	   therefore	   support	   successful,	  
functional	   myogenic	   differentiation	   (Engler	   et	   al.	   2004).	   Therefore,	   in	   understanding	   the	   specific	  
physiological	  state	  and	  elasticity	  of	  the	  tissue	  matrix	  in	  vivo,	  culture	  conditions	  can	  be	  customised	  to	  
that	  specific	  tissue,	  whilst	  taking	  into	  account	  features	  such	  as	  fibrosis	  or	  differences	  in	  age,	  so	  that	  
stem	  cell	  introduction	  and	  processes	  of	  repair	  are	  more	  successful.	  However,	  further	  work	  would	  be	  
required	  in	  order	  to	  assess	  the	  effects	  of	  the	  well-­‐defined	  complications	  of	  a	  lack	  of	  diffuse	  migration	  
away	  from	  the	  point	  of	  administration	  and	  high	  levels	  of	  rapid	  cell	  death	  (Briggs	  &	  Morgan	  2013;	  Yin	  
et	   al.	   2013;	   Péault	   et	   al.	   2007).	   Although,	   with	   the	   cells	   having	   first	   been	   primed	   to	   the	   tissue	  
conditions,	   the	   expectation	   would	   be	   that	   the	   occurrence	   of	   these	   complications	   would	   be	   less.	  
Alternatively,	   3-­‐dimensional	   (3D)	   scaffold	   matrices	   either	   allogeneic,	   xenogeneic	   in	   origin	   or	  
artificially-­‐generated	   from	   biomaterials	   or	   moving	   away	   from	   these	   approaches	   to	   used	   synthetic	  
constructs	   (Perniconi	   et	   al.	   2011;	   Crapo	   et	   al.	   2011;	   Porzionato	   et	   al.	   2015;	   Carnio	   et	   al.	   2011;	  
Manchineella	  et	  al.	  2016).	  Carnio	  and	  colleagues	  created	  a	  3D	  collagen	  porous	  scaffold	  seeded	  with	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WT	  myogenic	  precursor	  cells	  and	  implanted	  this	  into	  the	  TA	  muscles	  of	  normal	  and	  mdx	  mice.	  It	  was	  
shown	  that	  scaffold-­‐delivered	  precursors	  exhibited	  lower	  apoptosis,	  higher	  proliferation	  and	  yielded	  
better	  dystrophin	  restoration	  that	  contralateral	  intramuscular	  injections	  of	  precursor	  cells	  (Carnio	  et	  
al.	  2011).	  Future	  work	  could	  examine	  the	  engraftment	  potential	  of	  AFS	  and	  other	  stem	  cells,	  primed	  
in	   vitro	   to	   the	   physiological	   elasticity	   of	   muscle	   (~12	   kPa),	   using	   decellularisation	   techniques	   on	  
myofibre	   or	   whole	   tissue	   scaffolds.	   Similarly,	   taken	   with	   the	   other	   findings	   of	   this	   work,	   the	  
importance	   of	   the	   microenvironment	   on	   cellular	   reparative	   function	   and	   the	   evidence	   that	   CM	  
treatment	   can	   alter	   features	   of	   the	   ECM	   having	   a	   predominant	   effect	   over	   suspected	   intrinsic	  
regulation.	  Primed	  whole	  stem	  cell-­‐based	  approaches,	  along	  with	  ADMSC	  or	  AFS-­‐generated	  CM	  as	  a	  
combination	  treatment,	  could	  act	  to	  also	  prime	  the	  microenvironment	  of	  the	  injury/disease	  site.	  This	  
is	   reasoned	   through	   the	   recent	   findings	   that	  AFS	  CM	  harboured	  miRNA	  and	  other	  molecules,	   that	  
were	  found	  to	  function	  on	  the	  already	  existing	  signalling	  machinery,	  in	  not	  just	  the	  resident	  stem	  cell	  
populations	   to	   carry	   out	   regeneration	   within	   the	   tissue,	   but	   on	   the	   cells	   of	   the	   supporting	   tissue	  
(Mellows	  et	  al.	  2017).	  
Key	  to	  the	  contractility	  of	  muscle	  cells	  is	  excitation-­‐contraction	  (EC)	  coupling.	  This	  is	  the	  physiological	  
mechanism	  which	   involves	   the	  transformation	  of	  an	  electrical	  signal	  sensed	  by	  the	  dihydropyridine	  
receptor	  (DHPR)	  located	  on	  the	  transverse	  tubules	  (T	  tubules),	  into	  a	  chemical	  gradient,	  through	  Ca2+	  
increase	  by	   activation	  of	   the	   ryanodine	   receptor	   (RyR)	   located	  on	   the	   sarcoplasmic	   reticulum	   (SR).	  
Investigation	   into	   the	   ultrastructural,	   biochemical	   and	   cellular	   properties	   of	   EC	   has	   been	   studied	  
using	   isolated	   single	   myofibres	   however,	   more	   recent	   success	   has	   arisen	   from	   the	   use	   of	  
immortalised	  myoblast	  cultures	  from	  human	  muscle	  biopsies	  (Ravenscroft	  et	  al.	  2007;	  Calderón	  et	  al.	  
2009;	   Rokach	   et	   al.	   2013).	   Rokach	   and	   colleagues	   have	   characterised	   the	   EC	   machinery	   using	   an	  
immortalised	   human	  muscle	   cell	   line	   to	   demonstrate	   that	   the	   cells	   retain	   expression	   of	   essential	  
mRNA	  and	  protein	   components	  of	   EC	  apparatus	   including	  CSQ,	   SERCA	   (1	   and	  2),	   Cav1.1,	  RyR1	  and	  
DHPR	   (Rokach	   et	   al.	   2013).	   Next,	   they	   determined	   the	   cellular	   localisation,	   using	   super	   resolution	  
structured	   illumination	   microscopy	   (3D-­‐SIM),	   of	   these	   proteins,	   as	   EC	   functionality	   is	   highly-­‐
dependent	   on	   the	   organisation	   in	   the	   T	   tubules	   (DHPR)	   and	   terminal	   cisternae	   of	   the	   SR	   (RyR).	  
Finally,	  they	  confirmed	  that	  these	  human	  myoblast	  cells	  displayed	  a	  normal	  response	  to	  membrane	  
de-­‐polarisation	   using	   voltage/patch-­‐clamping	   to	   measure	   Ca2+	   release.	   This	   work	   presents	   the	  
methodology	   key	   to	   examining	   the	   physiological	   mechanism	   of	   EC,	   which	   defines	   functional	  
differentiation	  of	  an	   immortalised	  cell	   line	   into	  myotubes.	  This	  methodology	  will	  be	  used	   in	   future	  
experimentation	   of	   the	   present	   study,	   to	   apply	   to	   the	   MHC+	   AFS	   myotube	   cultures	   following	   co-­‐
culture	   on	   the	   myofibre	   surface.	   This	   can	   be	   used	   to	   determine	   the	   presence	   of	   the	   vital	   EC	  
component	  organisation	  and	  Ca2+	  release,	   in	  AFS	  myotube	  cultures	  and	  thereby,	  will	  potentially	  re-­‐
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define	  these	  originally	  non-­‐muscle	  cells,	  as	  ‘functional’	  muscle	  cells.	  A	  further	  extension	  to	  this	  work	  
would	   then	   follow	  to	   test	   the	   regenerative	  and	  engraftment	  potential	  of	   the	  AFS	  cells,	  directed	  by	  
the	  myofibre	  to	  a	  myogenic	  lineage.	  This	  can	  be	  achieved	  with	  transplantation	  into	  immunodeficient	  
mice	  lacking	  competition	  from	  resident	  SCs/myoblasts,	  which	  is	  also	  a	  common	  method	  carried	  out	  
to	   test	   novel	   immortal	   SC	   lines	   and	   in	  myoblast	   transplantation	   experiments	   using	  mdx	   null	  mice	  




This	  is	  the	  first	  report,	  to	  my	  knowledge,	  that	  characterises	  the	  skeletal	  muscle	  phenotype	  in	  a	  novel	  
use	  of	  the	  Ercc1d/-­‐	  mutant	  model	  of	  progeria.	  I	  show	  that	  the	  growth	  of	  Ercc1d/-­‐	  hindlimb	  musculature	  
is	   stunted	  and	   the	  muscles	  are	   supported	  by	   fewer	  capillaries	  per	  myofibre,	  while	  almost	  all	  other	  
parameters	  analysed,	  remained	  proportionate	  and	  unchanged	  to	  the	  control.	  Furthermore,	  with	  the	  
novel	  use	  of	  CM	  treatment	   in	  the	  Ercc1d/-­‐	  animals	  however,	  unlike	   in	  the	  naturally-­‐aged	  Soleus,	  CM	  
had	  very	  little	  effect,	  indicating	  a	  slight	  shift	  to	  a	  faster	  myofibre	  phenotype,	  with	  an	  increase	  in	  type	  
IIA	   myofibres.	   I	   report	   here	   that	   rather	   counterintuitively,	   for	   a	   potential	   treatment	   against	   age-­‐
related	   decline,	   an	   increase	   in	   O2-­‐	   ROS	   production	   was	   further	   exacerbated	   by	   CM	   treatment.	   I	  
reason	   that	   this	   may	   be	   indicative	   of	   an	   enhanced	   rate	   of	   oxidative	   metabolism	   targeted	   by	   CM	  
properties,	   in	   a	  model	   where	  metabolic	  machinery	   is	   ‘faulty’.	   Importantly,	   these	   findings	   indicate	  
that	  CM	  treatment	  has	  a	  lower	  efficacy	  in	  altering	  myofibre	  composition	  and	  function	  in	  the	  Ercc1d/-­‐	  
Soleus	  muscle,	  compared	  to	  natural	  ageing.	  This	  suggests	  that	  in	  this	  model	  of	  severe	  DNA	  damage	  
accumulation,	   CM	   may	   not	   be	   a	   beneficial	   therapeutic	   approach.	   However,	   these	   findings	   also	  
provide	   a	   platform	   for	   future	   studies	   into	   alternative	   CM	   approaches,	   for	   example,	   investigating	  
more	   frequent	  CM	  delivery,	   alternative	   stem	  cell	   sources	  of	  CM,	  or	   the	  exploration	  of	  engineering	  
EVs	   to	   be	   used	   as	   a	   therapeutic	   drug-­‐delivery	   system.	   Alternative	   research	   focused	   on	   preventing	  
muscle	  wasting,	  could	  for	  example,	  involve	  the	  inhibition	  of	  Myostatin	  using	  a	  soluble	  activin	  type	  IIB	  
receptor,	   to	   induce	  muscle	   growth	   in	   the	  Ercc1d/-­‐	   determine	   their	   capacity	   for	  muscle	  hypertrophy	  
and	  examine	  the	  effects	  on	  composition	  and	  contractile	  function.	  
At	  a	  cellular	  level,	  in	  naturally-­‐aged	  SC	  populations	  I	  report	  that	  seemingly	  beneficial	  effects	  of	  CM	  on	  
rate	   of	   motility,	   as	   an	   underlying	   mechanism	   of	   SC	   regenerative	   function	   and	   cellular	   turnover.	  
Suggesting	   that	   the	  migratory	  characteristic	  of	  SC	  activity	  may	  be	  more	   readily	  altered	  by	  extrinsic	  
factor	  treatment,	  than	  the	  other	  aspects	  of	  function.	  I	  show	  that	  Ercc1d/-­‐	  SC	  populations,	  migrated	  at	  
a	   faster	   rate	  whereas	  CM	   treatment	  normalised	   this	   faster	  migration	   speed.	   I	   reason	   that	   a	   faster	  
rate	  may	   not	   necessarily	   be	   indicative	   of	   improved	   regenerative	   function	   in	   this	  model	   or	   even	   in	  
natural	  ageing,	  as	  other	  components	  such	  as	  bleb	  dynamics,	  ECM	  communication	  and	  SC	  measures	  
of	   directionality	   could	   also	   be	   influencing	   this	   behaviour.	   In	   naturally-­‐aged	   and	   Ercc1d/-­‐	   SC	  
populations,	  proliferative	  capacity	  is	  reduced,	  akin	  with	  previous	  studies	  and	  I	  show	  that	  ADMSC	  CM	  
(in	  vivo)	  treatment,	  was	  not	  able	  to	  restore	  this	  function.	  Furthermore,	  unlike	  the	  general	  agreement	  
of	   previous	   studies	   in	   natural	   ageing,	   I	   report	   that	   Ercc1d/-­‐	   SC	   differentiation	   potential	   is	   normal.	  
Whereas,	   I	   show	   that	   CM	   treatment	   resulted	   in	   the	   maintenance	   of	   Pax7	   expression	   in	   a	   large	  
proportion	  of	  SCs,	  thereby	  delaying	  or	  reducing	  the	  progression	  to	  terminal	  differentiation.	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I	  report	  a	  comparison	  between	  the	  underlying	  mechanisms	  of	  function	  in	  both	  Ercc1d/-­‐	  and	  naturally-­‐
aged	  SCs.	  I	  show	  that	  the	  Ercc1d/-­‐	  SC	  emergence	  trend	  is	  much	  more	  indicative	  of	  that	  which	  occurs	  in	  
young	  healthy	  SCs,	  as	  there	  was	  a	  discrepancy	  in	  the	  (advancement	  of)	  emergence	  in	  aged	  SCs	  in	  the	  
present	   study,	   compared	   to	   others	   where	   this	   feature	   was	   delayed.	   I	   report	   that	   the	   increase	   in	  
Ercc1d/-­‐	  SC	  migration	  is	  significantly	  greater	  than	  old	  SCs	  but	  not	  geriatric	  SCs.	  Furthermore,	  I	  report	  
that	  SC	   Ercc1d/-­‐	  morphology	  and	  proliferation	  mimicked	  natural	  ageing.	  These	   findings	   suggest	   that	  
Ercc1d/-­‐	   and	   naturally-­‐aged	   SC	   behaviour	   is	   variable	   when	   directly	   compared	   and	   further	   work	   is	  
required	   to	   understand	   the	   discrepancies	   between	   the	   opposing	   effects	   of	   CM	   on	   SC	   migration.	  
Although,	  it	  should	  be	  noted	  that	  there	  are	  both	  intrinsic	  and	  extrinsic	  components	  governing	  these	  
results	  and	  further	  work	  is	  required	  to	  study	  the	  differences	  in	  physical	  properties	  of	  the	  Ercc1d/-­‐	  and	  
naturally-­‐aged	  myofibre,	  as	  well	  as	   the	   local	   signalling	  components	  of	  each.	  However,	   importantly,	  
for	  SC	  self-­‐renewal	  and	  proliferation,	  both	  Ercc1d/-­‐	  and	  naturally-­‐aged	  SCs	  show	  a	  reduced	  potential,	  
thus,	  the	  Ercc1d/-­‐	  model	  does	  hold	  some	  potential	  for	  further	  work	  into	  enhancing	  this	  aspect	  of	  SC	  
function.	  Overall,	  I	  reason	  that	  while	  the	  impacts	  on	  SC	  function	  in	  both	  natural	  ageing	  and	  progeria	  
appeared	  variable,	  dysfunction	  of	  one	  or	  more	  of	  the	  underlying	  mechanisms	  would	  lead	  to	  altered	  
regenerative	  effects.	  However,	  this	  work	  provides	  a	  basis	  for	  further	  studies	  examining	  Ercc1d/-­‐	  and	  
aged	   SC	   function	   as	   well	   as	   CM	   treatment,	   in	   vivo	   using	   an	   induced	   injury	   model,	   for	   example,	  
cardiotoxin.	   This	   will	   provide	   a	   better	   understanding	   of	   how	   the	   alterations	   to	   the	   mechanisms	  
shown	  here,	  are	  impacting	  overall	  regenerative	  function.	  
Furthermore,	  the	  importance	  of	  the	  skeletal	  muscle	  myofibre	  microenvironment	  in	  determining	  key	  
features	   underlying	   SC	   function,	   was	   established.	   I	   show	   here	   that	   it	   is	   the	  myofibre	   surface	   that	  
directs	  SC	  amoeboid-­‐based	  form	  of	  motility.	  Furthermore,	  all	  non-­‐muscle	  cell	  types,	  once	  in	  contact	  
with	  the	  myofibre,	  adopt	  a	  rounded	  morphology	  and	  migrated	  by	  the	  bleb-­‐based	  mechanism.	  Thus,	  
demonstrating	   that	   these	   features	  are	  not	  unique	   intrinsic	   characteristics	  of	   SCs	  and	  are	  mediated	  
through	  contact	  with	  the	  myofibre	  and	  are	  not	  always	  accompanied	  by	  an	  increase	  in	  velocity.	  	  
It	  is	  shown	  that	  while	  all	  cell	  types	  adopted	  a	  rounded	  morphology	  on	  aged	  myofibres,	  resident	  SCs	  
demonstrated	   a	   higher	   level	   of	   adaptability	   to	   the	   aged	   environment	   than	   the	   transplanted	   non-­‐
muscle	   cells.	   Additionally,	   SC	  morphology	   and	  migration	   speeds	  were	   not	   affected	   by	   age	   nor	   CM	  
treatment.	  Whereas,	  all	  non-­‐muscle	  cells	  indicated	  variations	  in	  morphology	  and	  speed	  with	  age	  and	  
or	  CM.	  This	  indicates	  that	  there	  may	  be	  intrinsic	  differences	  between	  the	  SCs	  and	  non-­‐muscle	  cells,	  
within	   the	   myofibre	   microenvironment,	   that	   determines	   their	   response	   to	   the	   combination	   of	  
physical	   properties	   of	   the	  matrix,	   as	  well	   as	   exogenous	   signalling,	   for	   example,	  mediated	  by	   a	   CM	  
paracrine	  effect.	  I	  also	  show	  that	  there	  could	  be	  more	  potent	  effects	  of	  in	  vivo	  administration	  of	  CM	  
treatment	   in	   comparison	   to	   its	   addition	   to	  myofibre	   cultures	   in	   vitro,	   an	   important	   feature	   for	   the	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development	   of	   CM	   as	   a	   therapeutic	   treatment.	   Furthermore,	   I	   show	   that	   the	   same	   underlying	  
molecular	  pathways	  are	  responsible	  for	  directing	  the	  cell	  morphologies	  of	  both	  SCs	  and	  non-­‐muscle	  
cells	  on	  myofibres.	  
Most	  remarkably,	  I	  show	  that	  a	  non-­‐muscle	  stem	  cell	  (AFS)	  and	  a	  non-­‐stem	  cell	  (MDA),	  following	  10	  
days	  co-­‐culture	  on	  the	  surface	  of	  myofibres,	  adopted	  a	  myogenic	  fate.	  Importantly,	  I	  also	  show	  that	  
AFS	   cells,	   but	   not	   the	   non-­‐stem	   cell	   (MDA),	   were	   directed	   through	   contact	   with	   the	   muscle	  
microenvironment,	   to	   fuse	   and	   form	  MHC+	  myotubes.	   This	   reinforces	   the	   therapeutic	   potential	   of	  
AFS	  cells	  and	  highlights	  the	  importance	  of	  the	  tissue	  matrix	  in	  the	  success	  of	  whole	  stem	  cell-­‐based	  
and	   tissue	   engineering-­‐based	   therapies.	   Further	   work	   will	   aim	   to	   determine	   whether	   co-­‐cultured	  
myogenic	   AFS	   cells	   present	   aspects	   of	   functional	   excitation-­‐contraction	   coupling,	   challenging	   the	  
current	  thinking	  of	  what	  can	  broadly	  be	  defined	  as	  muscle.	  
This	   study	   has	   provided	   an	   extensive	   investigation	   into	   the	   effects	   of	   ADMSC	   CM	   on	   key	  
physiological,	   histochemical,	   morphometric	   and	   biochemical	   alterations	   associated	   with	   the	   onset	  
and	   progression	   of	   sarcopenia	   in	   naturally-­‐aged	   and	   progeric	   mice.	   I	   show	   here	   that,	   at	   a	   whole	  
organism	  and	   tissue	   level,	  while	  CM	  treatment	   in	  aged	  animals	  did	  not	  appear	   to	   influence	  overall	  
characteristic	   alterations	   to	   muscle	   function,	   as	   measured	   by	   grip	   strength	   and	   myofibre	  
composition,	  such	  as	  myofibre	  number,	  size	  or	  MHC	  types,	  well-­‐defined	  in	  sarcopenia,	  in	  neither	  the	  
Soleus,	   nor	   the	   EDL.	   CM	   treatment	   did,	   however,	   demonstrate	   beneficial	   regulatory	   effects	   in	  
mediating	  the	  signalling	   involved	  with	  the	  enhancement	  of	  angiogenesis	  and	  oxidative	  metabolism,	  
while	  reducing	  O2-­‐	  ROS	  production	  and	  collagen	  thickness,	  which	  importantly,	  appears	  to	  attenuate	  
any	  further	  decline.	  These	  alterations	  observed	  can	  instead	  be	  considered	  as	  key	  to	  the	  support	  and	  
maintenance	   of	   healthy	   ageing	   skeletal	   muscle	   and	   the	   slowing	   down	   of	   age-­‐associated	  
deterioration.	  This	  could	  also	  facilitate	  improved	  overall	  fitness	  and	  health	  as	  the	  observed	  beneficial	  
effects	   are	   unlikely	   to	   impact	   on	   skeletal	  muscle	   alone,	   but	   are	   hypothesised	   to	   improve	   function	  
tissue-­‐wide	  due	   to	   the	   systemic	   administration	  of	   CM.	   For	   example,	   increased	   angiogenesis	   in	   the	  
brain,	  would	  result	  in	  enhanced	  neurotrophic	  factor	  networks	  therefore,	  maintaining	  neuron	  health	  
and	  cognitive	   function	   into	  old	  age.	  Thus,	   these	  global	  benefits	  of	  CM	   in	  ageing	   individuals	   involve	  
the	  systemic	  regulation	  of	  mechanisms	  underpinning	  the	  nine	  hallmarks	  of	  ageing,	  such	  as	  mediation	  
of	  mitochondrial	  function	  and	  oxidative	  stress,	  energy	  and	  nutrient	  sensing	  and	  delivery,	  prevention	  
of	   cellular	   senescence	   and	   stem	   cell	   exhaustion,	   enhanced	   cell	   to	   cell	   and	   cell	   to	   ECM	  
communication,	  into	  advancing	  age,	  postulated	  to	  delay	  overall	  deterioration.	  
Furthermore,	   I	   report	   a	   comparison	   between	   both	   Ercc1d/-­‐	   and	   naturally-­‐aged	   Soleus	   muscle	  
phenotypes.	   Indicative	   of	   a	   strong	   shift	   of	   resources	   away	   from	   growth	   and	   protein	   synthesis,	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towards	  maintenance	   and	   preservation	   of	   genomic	   and	   cellular	   integrity.	   I	   show	   that	   the	   Ercc1d/-­‐	  
model	  is	  one	  of	  ‘super-­‐ageing’.	  Thus,	  far	  exceeding	  levels	  of	  deterioration	  reached	  in	  ‘normal’	  ageing,	  
such	  as	  a	  greatly	  reduced	  muscle	  mass,	  myofibre	  atrophy,	  myofibre	  CSA,	  capillary	  density,	  collagen	  IV	  
thickness	  and	  dystrophin	  expression.	  However,	   in	  such	  an	  acute	  model	  of	  tissue-­‐wide	  DNA	  damage	  
accumulation,	   these	  mice	   demonstrate	   that	   remarkably,	   through	   this	   switch	   to	  maintenance,	   they	  
have	   initiated	   a	   programme	   of	   slowing	   down	   the	   progression	   of	   deterioration,	   concerned	   with	  
preserving	  survival	  as	  a	  priority.	  Therefore,	  the	  ‘super-­‐ageing’	  description	  encompasses	  the	  ability	  of	  
the	   Ercc1d/-­‐	   mice	   to	   launch	   this	   survival	   programme,	   functioning	   above	   and	   delaying	   the	   natural	  
progression	  of	  age-­‐associated	  decline.	  This	  model	  therefore,	  can	  be	  used	  to	  provide	  insights	  into	  the	  
regulation	  behind	  this	  ‘super-­‐ageing’	  maintenance	  programme,	  including	  those	  pathways	  associated	  
with	   prolonged	   longevity,	   such	   as	   IGF-­‐1,	   to	   investigate	   further	   in	   human	   ageing.	   For	   example,	   the	  
genetic	   and	   stochastic	   events	   that	   lead	   to	   overall	   natural	   systemic	   deterioration	   in	   humans,	   also	  
appears	  to	  be	  mediated	  more	  successfully	  in	  a	  subset	  of	  the	  elderly	  population	  that	  live	  a	  prolonged	  
lifespan,	   including	   centenarians	   (over	   100	   years	   old)	   and	   supercentenarians	   (over	   110	   years	   old).	  
Thus,	  it	  could	  be	  reasoned	  that	  these	  extremely	  aged	  individuals	  maintain	  the	  ability,	  through	  factors	  
relating	   to	   genetics	   and/or	   lifestyle,	   to	   deploy	   a	   similar	   survival	   response,	   enabling	   the	   systemic	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Appendix	  1	  -­‐	  Materials	  
Mouse	  lines	  
The	  animals	  used	  were	  healthy	  wild-­‐type	  mice	  (Strain:	  C57BL/6JOla/Hsd),	  young	  (3-­‐4	  month	  old),	  
adult	  (6	  month	  old),	  old	  (24	  month	  old)	  and	  geriatric	  (27-­‐30	  month	  old).	  Young	  and	  adult	  mice	  were	  
obtained	  from	  Charles	  River.	  The	  naturally-­‐aged	  (24	  month	  old)	  and	  geriatric	  (27-­‐30	  month	  old)	  mice	  
and	  muscle	  tissues	  were	  generously	  provided	  by	  Dr.	  Paul	  Potter	  of	  the	  Medical	  Research	  Council	  
(MRC)	  Harwell,	  Oxford,	  United	  Kingdom,	  as	  part	  of	  the	  Shared	  Ageing	  Research	  Models	  (ShARM)	  
facility.	  Small	  breeding	  populations	  of	  heterozygous	  ERCC1	  knockout	  mice	  (+/-­‐)	  as	  well	  as	  ERCC1	  
delta	  mutants	  (d/+)	  on	  FVB	  and	  C57BL/6	  backgrounds	  were	  generously	  provided	  by	  Professor	  Jan	  
Hoeijmakers	  of	  the	  Department	  of	  Genetics,	  Erasmus	  University	  Medical	  Centre,	  Rotterdam,	  the	  
Netherlands.	  
Cell	  lines	  
Human	  adipose-­‐derived	  stem	  cells	  (hADMSC	  or	  ADMSC)	  
StemPro®	  Human	  Adipose−Derived	  Stem	  Cells	  (Life	  Technologies	  510070),	  lot	  number	  2117	  obtained	  
from	  a	  49	  year-­‐old	  female	  donor.	  
Human	  amniotic	  fluid	  stem	  cells	  (AFS)	  
Amniotic	  fluid	  stem	  cells,	  lentivirus-­‐transduced	  with	  GFP,	  were	  generously	  provided	  by	  Professor	  
Paolo	  De	  Coppi,	  Centre	  for	  Stem	  Cells	  and	  Regenerative	  Medicine,	  Institute	  for	  Child	  Health,	  
University	  College	  London	  (UCL),	  United	  Kingdom.	  These	  cells	  were	  obtained	  from	  second	  trimester	  
amniotic	  fluid,	  are	  human	  in	  origin	  and	  selected	  by	  FACS	  for	  c-­‐Kit	  (CD117)	  expression.	  
Rat	  dental	  pulp	  stem	  cells	  (DP)	  
DP	  cells	  (GFP)	  were	  isolated	  in-­‐house	  from	  SD-­‐Tg(CAG-­‐EGFP)CZ-­‐004OS6	  rats.	  
MDA-­‐MB-­‐231	  breast	  adenocarcinoma	  cell	  line	  (MDA)	  
MDA-­‐MB-­‐231	  adenocarcinoma	  cells	  were	  kindly	  gifted	  by	  Professor	  Philip	  Dash,	  University	  of	  
Reading,	  United	  Kingdom.	  MDA-­‐MB-­‐231	  cells	  had	  been	  permanently	  transfected	  using	  a	  PB	  CAG	  myr	  
GFP	  transposon	  and	  a	  PB	  HYPBASE	  transposase,	  to	  overexpress	  a	  membrane-­‐tagged	  GFP.	  The	  
original	  sample	  having	  been	  obtained	  from	  an	  adenocarcinoma,	  pleural	  effusion	  metastatic	  site	  in	  a	  
51	  year	  old	  female	  with	  breast	  cancer.	  
Human	  Foetal	  Lung	  Fibroblast	  Cells	  (IMR-­‐90)	  	  
Human	  foetal	  lung	  IMR-­‐90	  fibroblast	  cells	  were	  generously	  donated	  from	  Dr.	  Debacq-­‐Chainiaux,	  





2mg/mL	  type-­‐1	  collagenase	  solution	  (Sigma	  C0130),	  Dulbecco	  modified	  Eagle	  medium	  (DMEM)	  
(Gibco,	  Thermo	  Fisher	  Scientific	  31966-­‐021).	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Single	  fibre	  culture	  medium	  (SFCM)	  	  
Dulbecco	  modified	  Eagle	  medium	  (DMEM)	  (Gibco,	  Thermo	  Fisher	  Scientific	  31966-­‐021),	  10%	  horse	  
serum	  (Gibco,	  Thermo	  Fisher	  Scientific	  16050-­‐122),	  0.5%	  chick	  embryo	  extract	  (in-­‐house	  
preparation),	  1%	  penicillin	  streptomycin	  (100X)	  (Invitrogen,	  Thermo	  Fisher	  Scientific	  15240-­‐062).	  
Single	  fibre	  culture	  medium	  adapted	  for	  long-­‐term	  culture	  (LT-­‐SFCM)	  	  
Dulbecco	  modified	  Eagle	  medium	  (DMEM)	  (Gibco,	  Thermo	  Fisher	  Scientific	  31966-­‐021),	  10%	  horse	  
serum	  (Gibco,	  Thermo	  Fisher	  Scientific	  16050-­‐122),	  5%	  chick	  embryo	  extract	  (in-­‐house	  preparation),	  
1%	  penicillin	  streptomycin	  (100X)	  (Invitrogen,	  Thermo	  Fisher	  Scientific	  15240-­‐062).	  
Amniotic	  fluid	  stem	  (AFS)	  cell	  media	  
Minimum	  Essential	  Medium,	  alpha	  modifications	  (α-­‐MEM)	  (Gibco,	  Thermo	  Fisher	  Scientific	  32561-­‐
037),	  20%	  Chang	  B/C	  media	  supplement	  (Irvine	  Scientific	  T101-­‐019),	  15%	  foetal	  bovine	  serum	  (FBS)	  
(Gibco,	  Thermo	  Fisher	  Scientific	  10270-­‐106),	  1%	  L-­‐glutamine	  supplement	  (Invitrogen,	  Thermo	  Fisher	  
Scientific	  25030-­‐024),	  1%	  penicillin	  streptomycin	  (100X)	  (Invitrogen,	  Thermo	  Fisher	  Scientific	  15240-­‐
062).	  
Adipose-­‐derived	  mesenchymal	  stem	  cell	  (ADMSC)	  media	  
MesenPro	  RS™	  medium	  (Gibco,	  Thermo	  Fisher	  Scientific	  12746-­‐012)	  supplemented	  with	  1%	  penicillin	  
streptomycin	  (100X)	  (Invitrogen,	  Thermo	  Fisher	  Scientific	  15240-­‐062)	  
MDA-­‐MB-­‐231	  (MDA	  breast	  cancer	  cell	  line)	  media	  	  
DMEM	  (Gibco	  31966-­‐021),	  10%	  FBS	  (Gibco,	  Thermo	  Fisher	  Scientific	  10270-­‐106),	  1%	  L-­‐glutamine	  
(Invitrogen,	  Thermo	  Fisher	  Scientific	  25030-­‐024),	  1%	  penicillin	  streptomycin	  (100X)	  (Invitrogen,	  
Thermo	  Fisher	  Scientific	  15240-­‐062).	  
Dental	  pulp	  (DP)	  stem	  cell	  media	  
Minimum	  Essential	  Medium,	  alpha	  modifications	  (α-­‐MEM)	  (Gibco,	  Thermo	  Fisher	  Scientific	  32561-­‐
037),	  20%	  FBS	  (Gibco,	  Thermo	  Fisher	  Scientific	  10270-­‐106),	  1%	  L-­‐glutamine	  (Invitrogen,	  Thermo	  
Fisher	  Scientific	  25030-­‐024),	  1%	  penicillin-­‐streptomycin	  (100X)	  (Invitrogen,	  Thermo	  Fisher	  Scientific	  
15240-­‐062),	  100mM	  L-­‐ascorbic	  acid	  (Sigma-­‐Aldrich	  A8960).	  
IMR-­‐90	  lung	  fibroblast	  media	  
Minimum	  Essential	  Medium,	  alpha	  modifications	  (α-­‐MEM)	  (Gibco,	  Thermo	  Fisher	  Scientific	  32561-­‐
037),	  10%	  FBS	  (Gibco,	  Thermo	  Fisher	  Scientific	  10270-­‐106),	  1%	  penicillin-­‐streptomycin	  (100X)	  
(Invitrogen,	  Thermo	  Fisher	  Scientific	  15240-­‐062)	  
Myogenic	  differentiation	  media	  
DMEM	  (Gibco,	  Thermo	  Fisher	  Scientific	  31966-­‐021),	  2%	  horse	  serum	  (Gibco,	  Thermo	  Fisher	  Scientific	  
16050-­‐122),	  1%	  penicillin-­‐streptomycin	  (100X)	  (Invitrogen,	  Thermo	  Fisher	  Scientific	  15240-­‐062).	  
Mesenchymal	  Stem	  Cell	  Chondrogenic	  Differentiation	  Media	  	  
StemPro®	  Osteocyte/Chondrocyte	  basal	  medium	  (Life	  Technologies,	  Thermo	  Fisher	  Scientific	  
A10069-­‐01),	  StemPro®	  Chondrogenesis	  Supplement	  (Life	  Technologies,	  Thermo	  Fisher	  Scientific	  
A10064-­‐01).	  
Mesenchymal	  Stem	  Cell	  Osteogenic	  Differentiation	  Media	  	  
279	  
Taryn	  Morash	  
StemPro®	  Osteocyte/Chondrocyte	  basal	  medium	  (Life	  Technologies,	  Thermo	  Fisher	  Scientific	  
A10069-­‐01),	  StemPro®	  Osteogenesis	  Supplement	  (Life	  Technologies,	  Thermo	  Fisher	  Scientific	  
A10066-­‐01).	  
Mesenchymal	  Stem	  Cell	  Adipogenic	  Differentiation	  Media	  	  
StemPro®	  Adipogenesis	  basal	  medium	  (Life	  Technologies,	  Thermo	  Fisher	  Scientific	  A10410-­‐01),	  
StemPro®	  Adipogenesis	  Supplement	  (Life	  Technologies,	  Thermo	  Fisher	  Scientific	  A10065-­‐01).	  
Freezing	  media	  
90%	  FBS	  (Gibco,	  Thermo	  Fisher	  Scientific	  10270-­‐106),	  10%	  Dimethyl	  sulfoxide	  (DMSO)	  (BDH	  
Chemicals	  103234L).	  
1	  x	  PBS	  solution	  for	  cell	  culture	  	  
1	  PBS	  tablet	  (Oxoid	  BR0014G)	  per	  100mL	  distilled	  water.	  
Fixation	  medium	  
Fixation	  medium	  (Universal)	  	  
4%	  paraformaldehyde	  (w/v)	  (Sigma	  Aldrich	  P6148)	  in	  1	  x	  PBS	  solution.	  
Fixation	  medium	  for	  stress-­‐induced	  cellular	  senescence	  assay	  	  
0.2%	  glutaraldehyde	  (Sigma	  Aldrich	  G5882),	  2%	  paraformaldehyde	  (Sigma	  Aldrich	  P6148)	  in	  1	  x	  PBS	  
solution.	  
Histological	  staining	  
Stress	  induced	  cellular	  senescence	  staining	  solution	  	  
5mM	  sodium	  phosphate	  solution	  pH	  6.0,	  5mM	  potassium	  ferricyanide,	  5mM	  potassium	  ferrocyanide,	  
125mM	  sodium	  chloride,	  50mM	  magnesium	  chloride,	  2.5mg/mL	  X-­‐gal.	  
NBT	  stock	  solution	  
100mM	  phosphate	  buffer	  pH	  7.6,	  6.5ng/mL	  potassium	  cyanide	  (Thermo	  Fisher	  Scientific	  1059938),	  
0.185mg/mL	  EDTA	  (Sigma	  Aldrich	  E5134),	  1mg/mL	  nitroblue	  tetrazolium	  (Sigma	  Aldrich	  74032).	  
SDH	  incubation	  medium	  
500mM	  sodium	  succinate	  stock	  (Sigma	  Aldrich	  S2378)	  (0.1mL/1mL	  NBT	  stock),	  phenazine	  
methosulphate	  (Sigma	  Aldrich	  P9625)	  (0.35mg/1mL	  NBT	  stock).	  
DHE	  incubation	  medium	  
Dihydroethidium	  (DHE)	  (Sigma-­‐Aldrich	  D7008)	  20mg/mL	  made	  up	  in	  DMSO	  stock,	  used	  at	  1:2000	  
dilution	  in	  wash	  buffer.	  
Histology	  acidic	  alcohol	  solution	  	  
0.1%	  hydrochloric	  acid	  in	  70%	  ethanol	  	  
Oil	  Red	  O	  stock	  solution	  	  
0.5g	  Oil	  Red	  O	  (Sigma	  Aldrich	  0O625),	  200mL	  isopropyl	  alcohol,	  incubated	  at	  56°C	  for	  1	  hour,	  cooled	  
for	  20	  minutes	  at	  room	  temperature.	  Stable	  for	  6	  months.	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Oil	  Red	  O	  working	  solution	  	  
4	  parts	  water	  to	  6	  parts	  oil	  red	  O	  stock	  solution,	  incubated	  for	  10	  minutes	  at	  room	  temperature	  and	  
filtered	  through	  a	  0.2µM	  filter.	  Stable	  for	  2	  hours.	  	  
Alizarin	  Red	  S	  working	  solution	  	  
1mg/mL	  Alizarin	  Red	  S	  stain	  (Sigma-­‐Aldrich	  A5533)	  made	  up	  in	  dH2O,	  adjusted	  to	  pH	  5.5	  with	  
ammonium	  hydroxide	  (Sigma-­‐Aldrich	  320145).	  	  
Alcian	  blue	  working	  solution	  	  
0.1mg/mL	  Alcian	  blue	  (Sigma-­‐Aldrich	  A5268)	  made	  up	  in	  ethanol/acetic	  acid	  (6:4).	  
Immunocytochemistry	  
Permeability	  buffer	  	  
20mM	  Hepes,	  300mM	  sucrose,	  50mM	  NaCl,	  0.5%	  Triton	  X100,	  3mM	  MgCl2,	  0.05%	  sodium	  azide.	  
Wash	  buffer	  	  
5%	  FBS	  (Gibco,	  Thermo	  Fisher	  Scientific	  10270-­‐106),	  200mg	  sodium	  azide,	  0.05%	  Triton	  X-­‐100,	  500mL	  
phosphate	  buffered	  saline	  (PBS)	  (in-­‐house	  preparation).	  
Fluorescent	  mounting	  media	  
Mounting	  media	  containing	  2.5μg/mL	  4’,6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI)	  (DakoCytomation;	  DAKO	  
Corp,	  Carpinteria,	  Calif).	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Source	   Working	  
dilution	  
Supplier	   Catalogue	  
No.	  
Pan	  MHC	  A4.1025	   Mouse	   Neat	   Developmental	  Studies	  
Hybridoma	  Bank	  (DSHB)	  
-­‐	  
MHC	  isoform	  Type	  I	  
A4.840	  IgM	  
Mouse	   Neat	   Developmental	  Studies	  
Hybridoma	  Bank	  (DSHB)	  
-­‐	  
MHC	  isoform	  Type	  IIA	  
A4.74	  IgG	  
Mouse	   Neat	   Developmental	  Studies	  
Hybridoma	  Bank	  (DSHB)	  
-­‐	  
MHC	  isoform	  Type	  IIB	  	  
BF-­‐F3	  IgM	  
Mouse	   Neat	   Developmental	  Studies	  
Hybridoma	  Bank	  (DSHB)	  
-­‐	  
Pax7	   Mouse	   1:1	   Developmental	  Studies	  
Hybridoma	  Bank	  (DSHB)	  
-­‐	  
MyoD	  M-­‐318	   Rabbit	   1:200	   Santa	  Cruz	  Biotechnology	   SC-­‐760	  	  
	  
Myogenin	   Rabbit	   1:200	   Santa	  Cruz	  Biotechnology	   SC-­‐576	  	  
Laminin	   Rabbit	   1:100	   Sigma-­‐Aldrich	   L9393	  	  
	  
(Alpha)	  Smooth	  Muscle	  
Actin	  (SMA)	  




Protein	  (GFP)	  (Biotin)	  
Goat	   1:200	   Abcam	  
	  
AB6658	  
CD31	   Rat	   1:150	   Bio-­‐Rad	   MCA2388	  






Source	   Working	  
dilution	  
Supplier	   Catalogue	  
No.	  
Alexa	  fluor	  488	  IgG	  
(anti-­‐mouse)	  
Goat	   1:200	   Invitrogen	   A-­‐11029	  
Alexa	  fluor	  488	  IgG	  
(anti-­‐rabbit)	  
Goat	   1:200	   Invitrogen	   A-­‐11034	  
Alexa	  fluor	  594	  IgG	  	  
(anti-­‐mouse)	  
Goat	   1:200	   Invitrogen	   A-­‐11032	  
Alexa	  fluor	  594	  IgG	  
(anti-­‐rabbit)	  
Goat	   1:200	   Invitrogen	   A-­‐11037	  
Alexa	  fluor	  488	  
Streptavidin	  
Goat	   1:200	   Invitrogen	   S-­‐11223	  
Alexa	  fluor	  633	  IgM	  
(anti-­‐mouse)	  
Goat	   1:200	   Invitrogen	   A-­‐21046	  




Appendix	  3	  –	  Primers	  and	  PCR	  reagents	  
ERCC1	  genotyping	  polymerase	  chain	  reaction	  (PCR)	  primers	  
Primer	   Sequence	  
ERCC1d	  exon7	   AGCCGACCTCCTTATGGAAA	  (forward	  for	  mutant	  allele)	  
ERCC1d	  intron7	   ACAGATGCTGAGGGCAGACT	  (reverse	  for	  mutant	  allele)	  
ERCC1d	  neo	   TCGCCTTCTTGACGAGTTCT	  
ERCC1d	  3’utr	   CTAGGTGGCAGCAGGTCATC	  
ERCC1	  genotyping	  PCR	  reagents	  
Taq	  DNA	  Polymerase	  with	  Standard	  Taq	  Buffer	  (New	  England	  Biolabs	  M0273).	  Deoxynucleotide	  
Triphosphates	  (dNTPs)	  (Promega,	  dATP	  U1205,	  dCTP	  U1225,	  dGTP	  U1215,	  dTTP	  U1235).	  100bp	  DNA	  
ladder	  (Promega	  G2101).	  SYBR™	  Safe	  DNA	  Gel	  Stain	  (Thermo	  Fisher	  Scientific	  S33102)	  
Quantitative	  real-­‐time	  polymerase	  chain	  reaction	  (qPCR)	  primers	  
Primer	   Forward	  3’	   Reverse	  5’	  
Beta	  sarcoglycan	   GGACCGGCTCCATAAGACTG	   GATGACGGCCAGGATAAACAG	  
Collagen	  Ia	   TAAGGGTCCCCAATGGTGAGA	   GGGTCCCTCGACTCCTACAT	  
Collagen	  IVa	   GGCCCCAAAGGTGTTGATG	   CAGGTAAGCCGTTAAATCCAGG	  
Dystrophin	   ACTCAGCCACCCAAAGACTG	   TGTCTGGATAAGTGGTAGCAACA	  
HPRT	   GCTCGAGATGTCATGAAGGAGAT	   AAAGAACTTATAGCCCCCCTTGA	  
SOD2	   AGGAGAGTTGCTGGAGGCTA	   CTGTAAGCGACCTTGCTCCT	  
VEGFa	  165	   TGC	  AGG	  CTG	  CTG	  TAA	  CGA	  TG	   GAA	  CAA	  GGC	  TCA	  CAG	  TGA	  TTT	  TCT	  
Quantitative	  polymerase	  chain	  reaction	  (qPCR)	  kits	  and	  reagents	  
RNeasy®	  Mini	  Kit	  (Qiagen	  74104).	  RNase-­‐Free	  DNase	  Set	  (Qiagen	  79254).	  RevertAid	  H	  Minus	  First	  
Strand	  cDNA	  Synthesis	  Kit	  (Thermo	  Fisher	  Scientific	  K1631).	  SYBR®	  Green	  PCR	  Master	  Mix	  (Thermo	  
Fisher	  Scientific	  4309155).	  
	   	  
283	  
Taryn	  Morash	  
Appendix	  4	  –	  Publication	  
fibers
Article
Mammalian Skeletal Muscle Fibres Promote
Non-Muscle Stem Cells and Non-Stem Cells to
Adopt Myogenic Characteristics
Taryn Morash 1, Henry Collins-Hooper 1, Robert Mitchell 1 and Ketan Patel 1,2,*
1 School of Biological Sciences, University of Reading, Reading RG5 4EW, UK;
t.m.morash@pgr.reading.ac.uk (T.M.); henry.collins-hooper@uk.lockton.com (H.C.-H.);
r.mitchell@reading.ac.uk (R.M.)
2 Freiburg Institute for Advanced Studies (FRIAS), University of Freiburg, Freiburg 79104, Germany
* Correspondence: ketan.patel@reading.ac.uk; Tel.: +44-118-378-8079
Academic Editor: Stephen C. Bondy
Received: 15 December 2016; Accepted: 17 January 2017; Published: 23 January 2017
Abstract: Skeletal muscle fibres are unique cells in large animals, often composed of thousands
of post-mitotic nuclei. Following skeletal muscle damage, resident stem cells, called satellite cells,
commit to myogenic differentiation and migrate to carry out repair. Satellite stem cells migrate
on muscle fibres through amoeboid movement, which relies on dynamic cell membrane extension
and retraction (blebbing). It is not known whether blebbing is due to the intrinsic properties of
satellite cells, or induced by features of the myofibre surface. Here, we determined the influence
of the muscle fibre matrix on two important features of muscle regeneration: the ability to migrate
and to differentiate down a myogenic lineage. We show that the muscle fibre is able to induce
amoeboid movement in non-muscle stem cells and non-stem cells. Secondly, we show that prolonged
co-culture on myofibres caused amniotic fluid stem cells and breast cancer cells to express MyoD,
a key myogenic determinant. Finally, we show that amniotic fluid stem cells co-cultured on myofibres
are able to fuse and make myotubes that express Myosin Heavy Chain.
Keywords: stem cell; muscle; myofibre; adipose-derived stem cell; dental pulp; amniotic fluid stem
cells; reprogramming; migration; amoeboid
1. Introduction
Skeletal muscle is imbued with a stem cell resident population called satellite cells (SC), which
have a huge capacity to regenerate damaged tissue [1]. Transplantation of a single muscle fibre
containing a few SC is able to generate tens of thousands of cells in a matter of weeks [1]. SC also
have remarkable migratory properties, demonstrated by their ability to move from undamaged
muscles, into areas that require repair [2,3]. However, in a disease context, the ability of SC to
promote repair is severely hampered, for a number of reasons. Firstly, it is believed that repeated
rounds of degeneration/regeneration, leads to an exhaustion of the stem cell pool [4]. Secondly,
the development of a fibrotic and adipogenic environment impacts on not only SC differentiation,
but also on their ability to migrate [5]. A number of studies have demonstrated the importance of
migration in the muscle repair process. Clinical interventions based on myoblast injections have failed,
since cells are rarely dispersed more than 200 µm from the site of application [6–8]. Therefore, there is
an unmet need to generate cells with the appropriate ability to migrate, thus facilitating clinical skeletal
muscle generation.
We have previously shown that skeletal muscle fibres promote SC to migrate, using a distinctive
amoeboid-based mechanism in which cells extend and retract numerous membrane protrusions,
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often one tenth of the diameter of the cells, within a couple of minutes [9,10]. Amoeboid-based
migration is thought to develop simple focal adhesions (reviewed by [11]), and is believed to generate
traction through multiple blebs, all of which generate small amounts of pull [12]. The matrix appears
to be the defining factor governing how SC migrate, since placing them on plastic surfaces results in
the formation of lamellipodia [10].
The surface matrix not only governs the mechanism of migration, but also directs the fate of
stem cells. Engler and colleagues showed that the matrix elasticity directed the specification of stem
cells into either neural, myogenic, or osteogenic lineages [13]. They demonstrated that the stiffness,
over two orders of magnitude (ranging from 1 to 100 kPa), regulated the differentiation of human
mesenchymal stem cells, into either neurons, skeletal muscle, or bone [13]. Subsequent work showed
that changes in tissue stiffness (induced, for example, through fibrosis) had a major impact on the
self-renewing properties of SC [14].
Our previous work has shown that SC adopted amoeboid-based migration when positioned on
muscle fibres. However, it is not known whether this property is solely due to features of SC, or those
of the muscle fibre. Secondly, it is not known whether the amoeboid-based migration is an option
available to all stem cells, or even somatic cells, when they encounter the muscle fibre matrix. Lastly,
it remains to be determined whether the surface of a muscle fibre could influence the fate of, not only
stem cells, but also non-stem cells.
In this study, we examined the impact of the muscle fibre matrix on, firstly, the migratory
properties and, secondly, the ability to promote a myogenic fate on three well-defined stem cell
populations, as well as one non-stem cell line. We chose adipose-derived mesenchymal stem cells
(ADMSC), dental pulp stem cells (DP), and amniotic fluid stem cells (AFS) for our investigation,
as these have been extensively characterised for multi-potency, are relatively easy to culture, and are in
advanced stages of development as therapeutic agents for human diseases [15–19]. The MDA-MB-231
breast cancer line (MDA) was chosen as a non-stem cell source as it is extremely easy to propagate
and is well characterised. Here, we show that all three of the stem cell lines and the one non-stem
cell line, migrated by the mesenchymal mechanism on plastic. However, once they were seeded on
mouse muscle fibres, they adopted amoeboid-based migration. We also show that all of the cells
which adopted amoeboid-based migration were underpinned by the same molecular mechanisms;
ROCK (Rho-associated protein kinase) activity promoted blebbing, whereas Arp2/3 inhibited blebbing.
Most remarkably, we show that simple contact of AFS and MDA at the surface of a muscle fibre was
sufficient for cells to induce the expression of the key myogenic determinant, MyoD. Finally, we show
that AFS cells grown on myofibres are able to form myotubes.
2. Material and Methods
2.1. Ethical Approval
The experiments were performed under a project license from the United Kingdom (UK) Home
Office, in agreement with the Animals (Scientific Procedures) Act 1986.
2.2. Animal Maintenance
Healthy male wild-type C57BL/6 mice (3–5 month-old) were maintained in accordance with the
Animals (Scientific Procedures) Act 1986 (UK), and were approved by the University of Reading in
the Biological Resource Unit of Reading University. Mice were housed under standard environmental
conditions (20–22 ◦C, 12–12 h light–dark cycle), and were provided with food (standard pelleted diet)
and water ad libitum.
2.3. Cell Lines and Cultures
Cells transplanted onto mouse myofibres were identified using GFP-labelled cells. Human
adipose-derived mesenchymal stem cells (ADMSC) (Life Technologies 510070, Carlsbad, CA, USA)
were grown in MesenPro RS™ medium, supplemented with 1% penicillin streptomycin (Thermo Fisher
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Scientific, Carlsbad, CA, USA). Human amniotic fluid stem cells (AFS) (GFP+) (Gift from
Prof. Paolo De Coppi, University College London) were grown in Minimum Essential Medium (alpha
modification) (α-MEM), 15% foetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin streptomycin
(Thermo Fisher Scientific) supplemented with 20% Chang B/C media (Irvine Scientific, Santa Ana, CA,
USA). Rat dental pulp stem cells (DP) (GFP+; Isolated from SD-Tg(CAG-EGFP)CZ-004OS6 rats)
(Gift from Professor Bing Song, Cardiff, UK) [20] were cultivated in α-MEM, 20% FBS, 1% L-glutamine,
1% penicillin-streptomycin (Thermo Fisher Scientific), and 100 mM L-ascorbic acid (Sigma-Aldrich,
Saint Louis, MO, USA). A MDA-MB-231 (GFP+) breast adenocarcinoma cell line (MDA) (Gift from
Prof. P. Dash, University of Reading) was cultivated in DMEM containing GlutaMAX, supplemented
with 10% FBS, 1% L-glutamine, and 1% penicillin streptomycin (Thermo Fisher Scientific).
2.4. Single Myofibre Isolation and Culture
Animals were humanely sacrificed via Schedule 1 killing and myofibres were isolated from
the Extensor digitorum longus (EDL) muscle of the hindlimb, as previously described [21,22]. Briefly,
the EDL was carefully dissected and myofibres were dissociated with 0.2% type I collagenase in
Dulbecco’s modified Eagle medium (DMEM) at 37 ◦C in 5% CO2. Using tapered glass pipettes,
individual myofibres were liberated and placed into a suspension culture with single fibre culture
medium (SFCM) consisting of DMEM containing GlutaMAXm supplemented with 10% horse
serum, 1% penicillin/streptomycin, and 5% chick embryo extract, and were incubated at 37 ◦C
in 5% CO2. Cultures consisted of myofibres which had been isolated from three to nine animals, and
were combined in order to maintain consistency and homogeneity among experimental conditions.
Experimental time-zero (T0) began at the point of myofibre isolation. A total of 250,000 cells of each
cell type were seeded into separate single myofibre suspension cultures for 2 h (T0–T2), at 37 ◦C in
5% CO2, allowing for cell-myofibre adherence. At T2, myofibres (with non-muscle cells attached) were
transferred to new culture wells with fresh SFCM.
2.5. Cytoskeletal Inhibitor Preparation
The ROCK inhibitor Y-27632 (Abcam 120129, Cambridge, UK) was used at a concentration
of 10 µg/mL. The Arp2/3 inhibitor CK666 (Abcam 141231) was used at 150 µM. The required
concentrations of inhibitors were made up in SFCM.
2.6. Time-Lapse Microscopy
Myofibre cultures were examined using phase-contrast microscopy with time-lapse capabilities,
as previously described [9], but with the following differences: time-lapse video was captured at
10× magnification, at a rate of one frame per 15 min over a 12-h period (T2–T14), prior to endogenous
satellite stem cell emergence and proliferation [23].
2.7. Myotube Formation
Myofibres were cultured with or without transplanted non-muscle cell types, at 37 ◦C in 5% CO2
for up to 10 days (T240), and the fresh media (SFCM) was changed every three days. Cells were
dissociated from myofibres with TrypLE™ Select Enzyme (Thermo Fisher Scientific), seeded onto
cell culture-treated glass cover slips, and grown in cell-specific (AFS or MDA) growth medium (GM).
Once confluent, GM was exchanged for a myogenic differentiation medium consisting of DMEM with
GlutaMAX, containing 2% horse serum and 1% penicillin/streptomycin (Thermo Fisher Scientific),
and this was cultured for up to 14 days before fixation in 4% paraformaldehyde (PFA) in phosphate
buffered saline (PBS) for 15 min, after which it was stored in PBS.
2.8. Immunocytochemistry
Immunocytochemistry protocols for examining resident and transplanted non-muscle cells on
single myofibres were carried out as described previously [23]. Briefly, myofibres (or cell/ myotube
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cultures) were fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) (PFA) for 10 min,
and were washed three times in PBS before permeabilisation in a buffer solution, consisting of
20 mM HEPES, 300 mM sucrose, 50 mM NaCl, 3 mM MgCl2, 0.5% Triton X-100, and 0.05% sodium
azide (pH 7), at 4 ◦C for 15 min. Following this, non-specific binding was blocked using a wash
buffer with 5% FBS, in PBS containing 0.01% Triton X-100 and 200 mg sodium azide, for 30 min at
room temperature. The primary antibodies used in this study included: polyclonal rabbit anti-MyoD
(Santa Cruz Biotechnology, Dallas, TX, USA), sc-760, 1:200), monoclonal mouse anti-actin (alpha smooth
muscle) (Sigma-Aldrich, A2547, 1:200), polyclonal goat anti-green fluorescent protein (GFP) (biotin)
(Abcam, ab6658, 1:200), and monoclonal mouse anti-Myosin Heavy Chain (MHC) (Developmental
Studies Hybridoma Bank (DSHB) clone A4.1025, 1:1). Primary antibodies were visualised using the
following secondary antibodies: Alexa Fluor goat anti-mouse 488 (Invitrogen, Carlsbad, CA, USA,
A11029), Alexa Fluor goat anti-mouse 594 (Invitrogen, A11032), Alexa Fluor goat anti-rabbit 594
(Invitrogen, A11037), and Alexa Fluor 488 Streptavidin (Molecular Probes, Carlsbad, CA, USA,
S-11223). Secondary antibodies were used at a scale of 1:200. To visualise non-GFP hADMSCs,
a PKH26 red fluorescent membrane labelling kit was used, according to the manufacturer’s instructions
(Sigma-Aldrich, PKH26GL). Myofibres were mounted in fluorescent mounting medium (DAKO)
containing 5 µg/mL 4′,6-diamidino-2-phenylindole-(DAPI) for nuclear visualisation.
2.9. Fluorescence Microscopy
Mounted myofibres were visualised using a Zeiss AxioImager fluorescent microscope and images
were captured using an Axiocam digital camera system, before being analysed using Axiovision image
analysis software (version 4.9.1) (Carl Zeiss AG, Oberkochen, Germany).
2.10. Scanning Electron Microscopy
Scanning electron microscopy (SEM) of single myofibres was carried out as previously
described [9]. Briefly, single myofibres were fixed in 4% PFA/PBS for 10 min and dehydrated through
a series of 15-min ethanol incubations (30%, 50%, 70%, 80%, 90%, and 100% ethanol solutions).
Following this, myofibres were transferred to a critical point drier (Balzers CPD 030) (Oerlikon Balzers,
Balzers, Liechtenstein) and further dehydrated using liquid carbon dioxide. Using micro forceps,
dried myofibres were transferred to SEM sample stubs, and were gold-coated using an Edwards S150B
sputter-coater (HHV, Crawley, UK), before being visualised using an FEI 600F SEM (FEI, Hillsboro,
OR, USA) and supporting analysis software for image generation.
2.11. Image and Movie Analysis
All image analysis was carried out using the freeware package ImageJ (version 1.4.3) (Bethesda,
MA, USA). Individual resident and non-muscle cells were manually tracked using the MTrackJ plugin.
Bleb numbers and dimensions were quantified manually on SEM images of cells, using the cell counter
and length measurement tools. Blebs were counted across the visible extent of the cell surface in each
SEM image [9]. Measurements consisted of the bleb height from the individual point of protrusion,
outwards from the cell surface to the boundary of each single bleb, as well as the measurement across
each bleb to obtain the width. Cell morphology analysis of resident satellite cells and non-muscle
cell types on myofibres, as well as an investigation into the effects of differing inhibitor treatments
and the capacity for myogenic differentiation of non-muscle cells into myotubes, were all manually
assessed using quantification of live images through the Zeiss Axio Imager microscope (Carl Zeiss AG,
Oberkochen, Germany)and Axiovision digital camera system (Carl Zeiss AG, Oberkochen, Germany).
The percentage of myotubes produced by non-muscle cells, was quantified as the number of nuclei
located within myosin-positive cell structures, as a proportion of the total nuclei.
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2.12. Statistical Analysis
Statistical analysis was performed using Student’s t-tests, unless otherwise indicated, with
significance levels of * p < 0.05, ** p < 0.01, and *** p < 0.001, using GraphPad Prism statistical
software (Version 6) (La Jolla, CA, USA). All data are presented as mean ± standard error of the mean.
3. Results
Skeletal muscle stem cells display three interesting properties when examined on muscle fibres,
their native surface: (1) cells are round in shape rather than flat, with a broad leading edge; (2) migrate
at very high speeds; and (3) readily activate along the skeletal muscle differentiation pathway. Here,
we examined whether these properties are due to a feature of the muscle fibre, or intrinsic to the SC.
Firstly, we characterised the influence of the matrix on the mechanisms used for cell migration.
To that end, we compared the cell morphology of the differing cells on plastic versus muscle fibres.
Our results show that, like most SC, ADMSC, AFS, and DP stem cells on plastic, took on a flattened
elongated form (mesenchymal) (Figure 1(A, C1–C3)). In contrast to this, the majority of MDA cells were
rounded (Figure 1(A, C4)). We then compared this profile to the same cells on the surface of a muscle
fibre. As previously described, we found that all SC assumed a rounded morphology (Figure 1B) [10].
Surprisingly, there was a significant increase in the proportion of rounded morphologies in all of the
other cell types examined, when they were juxtapositioned on muscle fibres (Figure 1(B, C5–C8)). These
results show that the rounded morphology adopted by muscle stem cells, are not a unique intrinsic
feature. Instead, all cells tested, either stem or non-stem, assume this form when they encounter the
surface of a muscle fibre.
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Figure 1. The skeletal myofibre matrix influences non-muscle cellular morphologies. (A) Frequencies
of morphologies adopted by satellite cells (SC, n = 21 cells examined), adipose-derived mesenchymal
stem cells (ADMSC, n = 52), amniotic fluid stem cells (AFS, n = 32), dental pulp stem cells (DP, n = 26)
and MDA-MB-231 breast cancer cells (MDA, n = 31), on plastic; (B) Cell morphologies displayed by
SC (n = 45 myofibres examined), ADMSC (n = 34), AFS (n = 35), DP (n = 26), and MDA (n = 43),
on myofibres; (C) Representative m rphologies of non-muscle cells observed on plastic (1–4) and on
myofibres (5–8). Scale 50 µm. Individual Student’s t-tests showed statistical significance between
‘Round’ and ‘Elongated’ morphologies in each cell type, ** p < 0.01, *** p < 0.001.
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Next, we examined the influence of the matrix on cell migration speed, having previously
shown that SC on muscle fibres travelled at high velocities, when compared to their movement on
plastic [9,10]. In this study, we demonstrated that SC on myofibres moved at a higher speed than on
plastic, thus reproducing our previous findings (Figure 2A) [10]. The ability of the myofibre surface to
support faster movement than that of a plastic surface, was also found with DP and MDA (Figure 2A).
In contrast, ADMSC and AFS cells showed a significant decrease in migration speed on muscle fibres,
when compared to plastic (Figure 2A). Next, we examined the migration speeds of the differing cell
morphologies on muscle fibres. We found that for ADMSC, DP, and MDA cells, migration speed was
not influenced by the structure of the cell (Figure 2B). Surprisingly, we found that rounded AFS cells
on muscle fibres moved slower than those with elongated characteristics (Figure 2B).
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Figure 2. The skeletal muscle myofibre impacts on the migration speed of co-cultured non-muscle
cells. (A) Cell migration speed comparison between plastic and myofibre substrates; (B) Migration
speeds of differing morphologies of resident and non-muscle cells on myofibres. In all conditions
n ≥ 15 myofibres examined. Individual Student’s t-tests, ** p < 0.01, *** p < 0.001.
We have previously shown that the activity of ROCK was a key determinant of the
rounded/blebbing satellite cell morphology, when placed on muscle fibres [9,10]. In contrast, much
work has shown that the leading edge of mesenchymal cells required the activity of Arp2/3, in order
to promote the formation of lamellipodia [24]. Here, we examined the consequences of inhibiting
ROCK and Arp2/3 with their specific inhibitors, Y-27632 and CK666, respectively, on cell migration
velocity and morphology [25,26]. We found that inhibi ing ROCK decreased the migratory speed of all
cells examined, whe compared to mock treated e ls (solvent only) (Figure 3A). In contrast, inhibiting
Arp2/3 activity only decreased the migration speed of ADMSCs (Figure 3A). We also examined the
influence of the inhibitors on cell morphology. For all cell types, we found that inhibition of ROCK
promoted the abundance of elongated cells, whereas CK666 increased the proportion of rounded cells
(Figure 3B). These results show that molecular mechanisms regulating migration, are conserved in a
diverse group of cells.
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(B) Effect of inhibiting ROCK (Y-27632) and Arp2/3 (CK666) on cell morphology frequencies. In all
conditions n ≥ 15 myofibres examined. One-way ANOVA (A), individual Student’s t-tests (B),
* p < 0.05, ** p < 0.01, *** p < 0.001. In (B) statistical differences indicated between proportion of rounded
and elongated cell numbers.
Next, we examined non-muscle stem cells f r the pres nce of blebs, a key feature of amoeboid
migration. We have previou ly s own that SC on myofibres use the oeboid mechanism for cell
movement, w ich manifes s as a huge number of hi hly dynamic plasma membrane protru io s [10].
We found that, in all cell types examined, decreasing the Arp2/3 activity resulted in an increase in the
number of blebs on t surface of cells located on muscle fibres (Figure 4A, C–F and K–N). How ver,
the dimensions of the blebs in terms of their heights and widths, were not affected to any great degree,
with Arp2/3 inhibition increasing only the width of blebs on the surface of MDA cells (Figure 4B).
As previously demonstrated, inhibiting ROCK resulted in elongated cells that did not contain any
blebs (Figure 4A,G–J).
These results show that the mechanisms underpinning blebbing are highly conserved, with ROCK
activity responsible for maintaining a rounded profile and Arp2/3 controlling lamellipodia formation.
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(A) Quantification of bleb numbers on non-muscle cells following ROCK (Y-27632) and Arp2/3 (CK666)
inhibition; (B) Bleb dimensions. Scanning electron microscopy (SEM) images of the transplanted cell
types treated with solvent only (C–F), ROCK inhibitor (G–J) and Arp2/3 inhibitor (K–N). Scale 5 µm.
6 cells examined per condition. One-way ANOVA (A), individual Student’s t-tests (B), * p < 0.05,
** p < 0.01, *** p < 0.001.
Finally, we examined whether the myofibre surface encourages cells to adopt a myogenic fate.
To that end, we seeded GFP+ non-muscle stem cells, as well as GFP+ MDA cells, onto freshly isolated
muscle fibres, and profiled the expression of markers for muscle precursors (Pax7), committed muscle
cells (MyoD), and differentiating muscle cells (Myogenin) [23]. Resident SC (non-GFP) expressed
Pax7 on freshly isolated cells and continued to do so until 48 h, after which i s presence gradually
decreased, which is in agreement with previous studies [23,27]. MyoD is not express d n freshly
isolated SC, but is known to become detectable 24 h after activation [23]. Our data, in concordance with
the literature, showed that MyoD was present in over 80% of cases after 24 h of culture (Figure 5A).
Between 48 and 120 h of culture, all SC on myofibres expressed MyoD, which then decreased by 240 h,
which has previously been shown to be replaced by the expression of Myogenin (Figure 5A) [23].
None of the non-muscle cells expressed Pax7 at any time point up to 240 h of culture. Non-muscle
stem cells initially adopted rounded morphologies, up to approximately 48 h after seeding on freshly
isolated fibres, but then took on one of two morphologies. ADMSC and DP cells gradually elongated,
especially around the circumferenc of he fibres, and thereafter caused constrictions (Figure 5B,C).
By 72 h, there were no normal elongated fibres in the presence of ADMSC and DP cells, with the vast
majority either curled into balls or hyper-contracted, both of which signify myofibre damage.
In contrast, AFS and MDA maintained a rounded morphology and proliferated profusely
(Figure 5D,E). Of significance was the finding that by 240 h, approximately 50% of AFS and MDA cells
robustly expressed MyoD.
To investigate further, the myogenic differentiation potential of the non-muscle cells, as observed
with dissociated SC in previous studies [23], and their ability to form myotube structures following
enzymatic dissociation from the myofibres, was determined. Our results showed that AFS cells that had
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been dissociated from myofibres, fused to create elongated myotubes, indicated by myotube formation
with the co-expression of GFP+ and MHC, a key to the contractile protein of muscle (Figure 5F).
However, MDA cells that had also been detached from myofibres after 240 h of culture, failed to
express MHC, and showed no fusion events. Instead, they proliferated, producing multiple cell layers
(Figure 5H). Approximately 8% of all the AFS cells expressed MHC (Figure 5H) and formed cells with
1.5 nuclei (Figure 5I). Notably, no myogenic differentiation characteristics were observed in MDA or
AFS cells, which had not previously been in contact with myofibres.
These results show that the myofibre surface is unable to promote the expression of a marker of
muscle precursor cells (Pax7). However, prolonged culture of one stem cell (AFS) and remarkably, one
somatic cancer cell (MDA), resulted in the robust expression of a marker of committed muscle cells,
MyoD. Additionally, AFS cells cultured for prolonged periods with isolated myofibres, are able to
form myotubes.
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Figure 5. Induction of MyoD expression in AFS and MDA cells after prolonged culture on mouse
myofibres. (A) Temporal profiling of non-resident cells on myofibres for MyoD expression; (B) ADMSC
identified by GFP expression, constricting myofibre at T24; (C) DP cell distorting myofibre at T24;
(D) AFS cell at T240 showing nuclear expression of MyoD co-localising with DAPI (indicated by
magent arrow); (E) MDA cell at T240 showing nuclear expressi f yoD co-localising with
DAPI (indicated by magenta ar ow); (F) AFS cells, i ifi FP expre sion, co-localising with
myosin, fused to form elongated myotube str ct eads); (G) MDA cells co-cultured with
myofibres failed to initiate myosin expression; (H) Quantification of GFP+ cells expressing myosin;
(I) Number of nuclei per cell GFP+ expressing myosin. Scale 10 µm (B–E), and 100 µm (F, H). In (A–E),
n ≥ 12 myofibres examined.
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4. Discussion
The development of a source of muscle cells has huge clinical implications. Muscle is lost in a
large number of diseases such as Duchenne Muscular Dystrophy and Spinal Muscular Atrophy, but
is also a societal problem, as wasting occurs in a large proportion of the elderly who suffer from a
condition called sarcopenia [28]. Therefore, any means of generating muscle would potentially be of
great therapeutic value.
Previous work has shown that matrix elasticity has profound effects on cell fate, with stiff surfaces
promoting the formation of bone, medium stiffness inducing muscle, and soft surfaces allowing
the formation of neural tissues [13]. Here, we investigated the effect of the muscle fibre surface on
stem cell migration and differentiation. We have previously shown that the muscle fibre supports
a distinct form of movement, called amoeboid-based migration. Here, we show that three stem cell
types, and one non-stem cell line, adopted amoeboid-based migration when seeded onto muscle fibres.
Furthermore, they developed blebs, which made them essentially indistinguishable from resident stem
cells. However, it is noteworthy that an adoption of amoeboid-based migration for non-muscle cells
was not always accompanied by an increase in migration speed. It was previously proposed that rapid
movement based on bleb-based migration, was partly due to the simplicity of the focal adhesions
between the cells and the matrix, with less time being needed to assemble and disassemble these
structures [29]. However, our results show that blebbing does not always result in increased migration,
possibly due to a mis-match in the molecules needed for effective focal adhesion formation. We suggest
that non-muscle cells and satellite cells form different focal adhesions with the muscle fibre, possibly
linked to their developmental history. The concept of developmental history regulating cell behaviour
is well mapped in muscle, where it even segregates the properties of muscle stem cells [29]. Despite
differing profiles of migration speeds, we show that the cell morphology adopted by non-muscle cells
on fibres is regulated by the same molecular pathways. Elegant work by the Marshall lab have shown
that blebbing and lamellipodia-based mechanisms, act in an antagonistic fashion with Rho, through
ROCK supporting the former, and Rac, via WAVE2, promoting the latter [30]. Here, we show that this
relationship was conserved in the three differing stem cells and the one non-stem cell.
Our work sheds new light on a possible injurious role of ADMSC in chronic muscle
degeneration/regeneration. Accumulation of fat tissue is a key feature of this condition, for example,
in Duchenne Muscular Dystrophy, and is believed to hinder the activity of SC. [31,32]. However,
our work reveals a more direct property of ADMSC that would contribute to muscle pathology, based
on our finding that they induce fibre hyper-contraction. We were unable to find any live muscle fibres
that had been co-cultured with ADMSC after three days in culture. In contrast, the fibres with the
presence of other cells (e.g., AFS) are viable for a minimum of 10 days. Therefore, unregulated activity
of ADMSC may contribute to muscle pathology by inducing myofibre death.
The most intriguing aspect of our work is the finding that AFS and MDA cells adopted a myogenic
fate, as assessed by MyoD expression, and that AFS cells tfuse into MHC+ myotubes. Importantly,
we found that they developed this state without having first induced the expression of Pax7. This is
significant, as it implies that the cells are not deploying a molecular programme that is used during
normal development [33]. The expression of MyoD, but not Pax7, in adult cells has been interpreted to
indicate a state in which the only option is terminal differentiation, without a possibility of reverting
to a stem cell state [23]. This has major implications for future exploitation of our findings, as they
could only be used to carry out immediate repair of damaged tissue, but the cells themselves could
not be a reservoir for future rounds of muscle regeneration.
One major outcome of our work is that it shows that there is no necessity for using stem cells in
order to generate muscle cells. Stem cells are associated with issues related to ethics and specialised
isolation techniques [34]. However, we have shown that a rapidly growing non-muscle stem cell can
be converted at relatively highly frequency into cells that express MyoD. Importantly, as an extension
to this key finding, further investigation into the myogenic differentiation potential revealed that AFS
cells, but not the non-stem cell, were directed through the exposure to the muscle environment, to form
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myotube structures, reinforcing the potential therapeutic value of AFS cells. Therefore, we have further
established the influence that the microenvironment or matrix has on regenerative processes, such as
cell differentiation and fusion.
There are two major issues that we will resolve in future experiments, to determine the full
potential of our finding. Firstly, it would be ideal to minimise the use of a large number of small
animals for scale-up as a source of muscle matrix. To that end, we envisage using de-cellularised
muscle from bigger (commercial) species (bovine), which can be generated in large quantities [35].
A number of advances have recently been made in creating materials often involving electrospinning,
that direct either a partial or complete move away from man/animal tissues for use in muscle-based
pathologies [36]. Many of the artificial materials support the differentiation and fusion of muscle stem
cells, into ordered myotubes [37]. However, none, to our knowledge, have investigated the movement
of SC in these matrixes, nor whether they occur in an amoeboid manner, let alone if their physical
properties support myogenic conversion of non-muscle cells. Investigating migratory mechanisms
and myogenic reprogramming by de-cellularised muscle and artificial muscle-like materials, will be
the focus of our future investigations.
Secondly, it will be essential to characterise the key properties of myogenic cells induced by the
co-culture method deployed here. To that end, it will be necessary to determine whether these cells can
promote muscle regeneration. We will address this line of investigation by developing GFP-labelled
MyoD+ cells from both AFS and MDA, and injecting them into immunocompromised mice which
have undergone cardiotoxin-induced muscle degeneration, before assessing the development of GFP+
muscle fibres [38].
5. Conclusions
We show that the muscle fibre matrix is able to promote non-muscle cell movement based
on amoeboid-based migration. Both non-muscle stem cells and non-stem cells are amenable
to myofibre-based reprogramming of migration mechanisms. We also show that cell fate is
reprogrammable by the muscle fibre matrix, resulting in a robust expression of the myogenic marker
MyoD, in both AFS and MDA cells. Moreover, we demonstrate a greater myogenic differentiation
capability of AFS cells, following dissociation from the myofibre matrix, leading to myosin expression
and myotube formation.
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